"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2004/0006390 A1,001-835-226-214-434,2004-01-08,2004,US 18930902 A,2002-07-02,US 18930902 A,2002-07-02,INTERVERTEBRAL SUPPORT DEVICE AND RELATED METHODS,"
   An intervertebral support device may include a body having opposing first and second end faces, opposing top and bottom-faces extending between the first and second end faces, and opposing side faces extending between the first and second end faces. A first diagonal direction may be defined between a first vertical corner at the first end face and a diagonally opposite second vertical corner at the second end face, and a second diagonal direction defined between a second vertical corner at the first end face and a diagonally opposite first vertical corner at the second end face. The body may have a tapering height decreasing from the first end face to the second end face, and while also tapering more quickly in the first diagonal direction than the second diagonal direction to provide a corrected angle of spinal curvature upon positioning between adjacent vertebral bodies in a human spine. 
",DUARTE LUIS,DUARTE LUIS,,https://lens.org/001-835-226-214-434,Patent Application,yes,0,10,2,2,0,A61F2/447;;A61F2/447;;A61F2/28;;A61F2/28;;A61F2/30965;;A61F2/30965;;A61F2002/30266;;A61F2002/30266;;A61F2002/30281;;A61F2002/30281;;A61F2002/30593;;A61F2002/30593;;A61F2002/30772;;A61F2002/30772;;A61F2002/30841;;A61F2002/30841;;A61F2002/30904;;A61F2002/30904;;A61F2230/0082;;A61F2230/0082;;A61F2230/0086;;A61F2230/0086;;A61F2310/00011;;A61F2310/00011;;A61F2310/00359;;A61F2310/00359;;Y10S606/907;;Y10S606/907,A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44,623/17.11,0,0,,,,EXPIRED
2,US,B1,US 6682564 B1,051-348-620-986-884,2004-01-27,2004,US 18930902 A,2002-07-02,US 18930902 A,2002-07-02,Intervertebral support device and related methods,"
    An intervertebral support device may include a body having opposing first and second end faces, opposing top and bottom faces extending between the first and second end faces, and opposing side faces extending between the first and second end faces. A first diagonal direction may be defined between a first vertical corner at the first end face and a diagonally opposite second vertical corner at the second end face, and a second diagonal direction defined between a second vertical corner at the first end face and a diagonally opposite first vertical corner at the second end face. The body may have a tapering height decreasing from the first end face to the second end face, and while also tapering more quickly in the first diagonal direction than the second diagonal direction to provide a corrected angle of spinal curvature upon positioning between adjacent vertebral bodies in a human spine. 
",DUARTE LUIS,DUARTE LUIS,,https://lens.org/051-348-620-986-884,Granted Patent,yes,25,27,2,2,0,A61F2/447;;A61F2/447;;A61F2/28;;A61F2/28;;A61F2/30965;;A61F2/30965;;A61F2002/30266;;A61F2002/30266;;A61F2002/30281;;A61F2002/30281;;A61F2002/30593;;A61F2002/30593;;A61F2002/30772;;A61F2002/30772;;A61F2002/30841;;A61F2002/30841;;A61F2002/30904;;A61F2002/30904;;A61F2230/0082;;A61F2230/0082;;A61F2230/0086;;A61F2230/0086;;A61F2310/00011;;A61F2310/00011;;A61F2310/00359;;A61F2310/00359;;Y10S606/907;;Y10S606/907,A61F2/00;;A61F2/28;;A61F2/30;;A61F2/44,623/17.16;;623/17.11;;606/61,0,0,,,,EXPIRED
3,US,A1,US 2021/0093456 A1,015-304-130-729-690,2021-04-01,2021,US 202017120811 A,2020-12-14,US 202017120811 A;;US 201715720126 A,2017-09-29,BONE CAGE INCLUDING OFFSET SETS OF PROTRUSIONS WITHIN A BONE INGROWTH CAVITY AND RELATED METHODS,"A bone cage may include first and second spaced apart frames defining a bone ingrowth cavity therebetween, a plurality of first protrusions each having a proximal end coupled to the first frame and a distal end extending into the cavity toward the second frame but not contacting the second frame, and a plurality of second protrusions each having a proximal end coupled to the second frame and a distal end extending into the cavity toward the first frame but not contacting the first frame. Furthermore, the distal ends of the first protrusions may be laterally offset from the distal ends of the second protrusions.",DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/015-304-130-729-690,Patent Application,yes,18,0,5,5,0,A61F2/4455;;A61F2/447;;A61F2002/30772;;A61F2002/30879;;A61F2002/30881;;A61F2002/30884;;A61F2002/30891;;A61F2/30771;;A61F2/4465;;A61F2002/30892;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161;;A61F2002/30011;;A61F2/447;;A61F2/4455;;A61F2002/30881;;A61F2002/30884;;A61F2002/30879;;A61F2002/30772;;A61F2002/30891;;A61F2002/30011;;A61F2/30771;;A61F2/4465;;A61F2002/30593;;A61F2002/30622;;A61F2002/30754;;A61F2002/30892;;A61F2002/30894;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161,A61F2/30;;A61F2/44,,0,0,,,,ACTIVE
4,IT,A0,IT 8520289 A0,106-150-704-990-16X,1985-04-10,1985,IT 2028985 A,1985-04-10,ES 278800 U,1984-04-13,SISTEMA DI CONNESSIONE MULTIPLA PER CONDOTTI DI CIRCUITI DI FLUIDI.,,VULCA IND SA,DUARTE LUIS PUYUELO,,https://lens.org/106-150-704-990-16X,Patent Application,no,0,0,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,B29C45/00;;F16L13/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,,0,0,,,,EXPIRED
5,BR,U,BR 7402418 U,144-109-203-678-809,1997-04-01,1997,BR 7402418 U,1994-12-16,BR 7402418 U,1994-12-16,Escova de dentes com fio dental,,DUARTE CHEQUETTI JOSE LUIS;;DUARTE CHEQUETTI LUIS HENRIQUE,DUARTE CHEQUETTI JOSE LUIS;;DUARTE CHEQUETTI LUIS HENRIQUE,,https://lens.org/144-109-203-678-809,Patent Application,no,0,0,1,1,0,,A46B9/04;;A61C15/04,,0,0,,,,DISCONTINUED
6,FR,A1,FR 2562986 A1,097-976-735-650-754,1985-10-18,1985,FR 8505555 A,1985-04-12,ES 278800 U,1984-04-13,SYSTEME DE RACCORDEMENT MULTIPLE POUR CONDUITS DE CIRCUITS DE FLUIDES,"<P>SYSTEME 1 DE RACCORDEMENT MULTIPLE POUR CONDUITS DE CIRCUITS DE FLUIDES, AVEC APPLICATION PARTICULIERE AUX CIRCUITS D'ECHANGE DE CHALEUR DANS DES VEHICULES AUTOMOBILES. LE SYSTEME COMPREND UN RACCORD 4 TUBULAIRE ET RIGIDE MUNI D'UNE SERIE DE TUBULURES 6, 7 DONT LES TRONCONS D'EXTREMITE 6A, 7A S'INSERENT PAR PRESSION DANS LES CONDUITS 2, 3 A RACCORDER, LE RACCORD 4 ET UNE PARTIE D'EXTREMITE 21 DES CONDUITS 2, 3 ETANT RECOUVERTS, AU MOINS PARTIELLEMENT, PAR UNE ENVELOPPE 5 MOULEE EN CAOUTCHOUC OU EN RESINE SYNTHETIQUE.</P>",VULCA IND SA,DUARTE LUIS PUYUELO,,https://lens.org/097-976-735-650-754,Patent Application,no,5,1,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,B29C45/00;;B29C70/74;;F16L31/02;;F16L13/00;;F16L41/08;;F16L55/07,,0,0,,,,DISCONTINUED
7,US,B2,US 8105362 B2,013-019-269-244-377,2012-01-31,2012,US 49370909 A,2009-06-29,US 49370909 A;;US 7674708 P,2008-06-30,Percutaneous spinal rod insertion system and related methods,"A spinal rod implantation system may be used with pedicle screws to be secured to respective pedicles of a patient's spine, each pedicle screw having a spinal rod channel therethrough. The system may include extenders each including an inner member having a distal end, and an outer member surrounding the inner member and being slidable relative thereto to permit removable coupling of the distal end to a respective pedicle screw. The inner and outer members may include respective features defining a first joint permitting at least partial relative rotation to provide a first degree of rotational freedom. The system may further include extender heads each pivotally coupled to a proximal end of a respective outer member to define a second joint providing a second degree of rotational freedom. A spinal rod insertion assembly may be coupled to the extender heads for guiding the spinal rod through the spinal rod channels.",DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/013-019-269-244-377,Granted Patent,yes,17,20,2,2,0,A61B17/7011;;A61B17/7032;;A61B17/7089;;A61B17/7089;;A61B17/7032;;A61B17/7011,A61B17/70;;A61B17/58;;A61B17/88,606/264;;606/279;;606/301,0,0,,,,INACTIVE
8,ES,U,ES 1000493 U,156-379-455-610-144,1988-03-01,1988,ES 8600861 U,1986-10-21,ES 8600861 U,1986-10-21,"Making provision for derivation of a fluid circulation tube (Machine-translation by Google Translate, not legally binding)","Arrangement for taking bypass tube for circulation of fluids type in the wall (6) tube (2) is clamped between an expansion annular end (12) of an insert (8) tubular rigid through said wall ( 6) and outer washer (22), wherein the entire periphery of a cross-zone (30) tube (2) in which is the insert (8) and a portion emerging (32) of the same insert (8) he is covered with a layer (28) rubber or synthetic resins, contributed by molding and welding set, said layer (28) overlaying full washer (22). (Machine-translation by Google Translate, not legally binding)",INDUSTRIAS VULCA S.A.,PUYUELO DUARTE LUIS,THE GATES RUBBER COMPANY (1994-01-01),https://lens.org/156-379-455-610-144,Patent Application,no,0,0,2,2,0,,F16L47/00,,0,0,,,,EXPIRED
9,US,A1,US 2009/0326586 A1,014-401-022-395-820,2009-12-31,2009,US 49370909 A,2009-06-29,US 49370909 A;;US 7674708 P,2008-06-30,PERCUTANEOUS SPINAL ROD INSERTION SYSTEM AND RELATED METHODS,"A spinal rod implantation system may be used with pedicle screws to be secured to respective pedicles of a patient's spine, each pedicle screw having a spinal rod channel therethrough. The system may include extenders each including an inner member having a distal end, and an outer member surrounding the inner member and being slidable relative thereto to permit removable coupling of the distal end to a respective pedicle screw. The inner and outer members may include respective features defining a first joint permitting at least partial relative rotation to provide a first degree of rotational freedom. The system may further include extender heads each pivotally coupled to a proximal end of a respective outer member to define a second joint providing a second degree of rotational freedom. A spinal rod insertion assembly may be coupled to the extender heads for guiding the spinal rod through the spinal rod channels.",DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/014-401-022-395-820,Patent Application,yes,17,64,2,2,0,A61B17/7011;;A61B17/7032;;A61B17/7089;;A61B17/7089;;A61B17/7032;;A61B17/7011,A61B17/58;;A61B17/70;;A61B17/88,606/264;;X606 86  A;;606/301;;606/279,0,0,,,,INACTIVE
10,US,A1,US 2006/0076024 A1,135-289-468-041-349,2006-04-13,2006,US 24226505 A,2005-10-03,US 24226505 A;;US 61535004 P,2004-10-01,Surgical draping system for a patient on an operating table and an adjacent movable medical tool and related methods,A surgical draping method for a patient on an operating table and an adjacent movable medical tool may include positioning a patient drape having a surgical access opening in a medial portion thereof over the patient on the operating table so that the surgical access opening exposes a surgical site on the patient. Opposing medial side portions of the patient drape may be fastened together underneath the operating table to provide a pathway thereunder for passage of at least one portion of the medical tool therethrough. An equipment drape may be positioned adjacent a side of the operating table aligned with the pathway to cover the at least one portion of the medical tool when moved through the pathway.,DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/135-289-468-041-349,Patent Application,yes,16,29,2,2,0,A61B46/10;;A61B46/10;;A61B46/00;;A61B46/00,A61B19/00;;A61F5/37,128/849,0,0,,,,INACTIVE
11,WO,A1,WO 2019/068113 A1,074-144-831-440-099,2019-04-04,2019,US 2018/0060769 W,2018-11-13,US 201715720126 A,2017-09-29,BONE CAGE INCLUDING OFFSET SETS OF PROTRUSIONS WITHIN A BONE INGROWTH CAVITY,"A bone cage may include first and second spaced apart frames defining a bone ingrowth cavity therebetween, a plurality of first protrusions each having a proximal end coupled to the first frame and a distal end extending into the cavity toward the second frame but not contacting the second frame, and a plurality of second protrusions each having a proximal end coupled to the second frame and a distal end extending into the cavity toward the first frame but not contacting the first frame. Furthermore, the distal ends of the first protrusions may be laterally offset from the distal ends of the second protrusions.",DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/074-144-831-440-099,Patent Application,yes,5,0,5,5,0,A61F2/4455;;A61F2/447;;A61F2002/30772;;A61F2002/30879;;A61F2002/30881;;A61F2002/30884;;A61F2002/30891;;A61F2/30771;;A61F2/4465;;A61F2002/30892;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161;;A61F2002/30011;;A61F2/447;;A61F2/4455;;A61F2002/30881;;A61F2002/30884;;A61F2002/30879;;A61F2002/30772;;A61F2002/30891;;A61F2002/30011;;A61F2/30771;;A61F2/4465;;A61F2002/30593;;A61F2002/30622;;A61F2002/30754;;A61F2002/30892;;A61F2002/30894;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161,A61F2/44;;A61F2/30,,0,0,,,,PENDING
12,US,B2,US 11596518 B2,147-160-327-622-965,2023-03-07,2023,US 202017120811 A,2020-12-14,US 202017120811 A;;US 201715720126 A,2017-09-29,Bone cage including offset sets of protrusions within a bone ingrowth cavity and related methods,"A bone cage may include first and second spaced apart frames defining a bone ingrowth cavity therebetween, a plurality of first protrusions each having a proximal end coupled to the first frame and a distal end extending into the cavity toward the second frame but not contacting the second frame, and a plurality of second protrusions each having a proximal end coupled to the second frame and a distal end extending into the cavity toward the first frame but not contacting the first frame. Furthermore, the distal ends of the first protrusions may be laterally offset from the distal ends of the second protrusions.",DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/147-160-327-622-965,Granted Patent,yes,33,0,5,5,0,A61F2/4455;;A61F2/447;;A61F2002/30772;;A61F2002/30879;;A61F2002/30881;;A61F2002/30884;;A61F2002/30891;;A61F2/30771;;A61F2/4465;;A61F2002/30892;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161;;A61F2002/30011;;A61F2/447;;A61F2/4455;;A61F2002/30881;;A61F2002/30884;;A61F2002/30879;;A61F2002/30772;;A61F2002/30891;;A61F2002/30011;;A61F2/30771;;A61F2/4465;;A61F2002/30593;;A61F2002/30622;;A61F2002/30754;;A61F2002/30892;;A61F2002/30894;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161,A61F2/44;;A61B17/70;;A61B17/86;;A61F2/30;;A61F2/46,,0,0,,,,ACTIVE
13,DE,C3,DE 3512410 C3,092-671-057-058-356,1999-11-25,1999,DE 3512410 A,1985-04-04,ES 278800 U,1984-04-13,Verfahren zur Herstellung von Leitungsverbindungen und Verbindungselement für Fluidleitungen,,GATES RUBBER CO,PUYUELO DUARTE LUIS,"THE GATES RUBBER CO., DENVER, COL., US (1993-11-25)",https://lens.org/092-671-057-058-356,Granted Patent,no,16,0,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,F16L13/00;;B29C45/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,,0,0,,,,EXPIRED
14,US,B2,US 10893945 B2,145-364-422-667-338,2021-01-19,2021,US 201715720126 A,2017-09-29,US 201715720126 A,2017-09-29,Bone cage including offset sets of protrusions within a bone ingrowth cavity and related methods,"A bone cage may include first and second spaced apart frames defining a bone ingrowth cavity therebetween, a plurality of first protrusions each having a proximal end coupled to the first frame and a distal end extending into the cavity toward the second frame but not contacting the second frame, and a plurality of second protrusions each having a proximal end coupled to the second frame and a distal end extending into the cavity toward the first frame but not contacting the first frame. Furthermore, the distal ends of the first protrusions may be laterally offset from the distal ends of the second protrusions.",DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/145-364-422-667-338,Granted Patent,yes,17,0,5,5,0,A61F2/4455;;A61F2/447;;A61F2002/30772;;A61F2002/30879;;A61F2002/30881;;A61F2002/30884;;A61F2002/30891;;A61F2/30771;;A61F2/4465;;A61F2002/30892;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161;;A61F2002/30011;;A61F2/447;;A61F2/4455;;A61F2002/30881;;A61F2002/30884;;A61F2002/30879;;A61F2002/30772;;A61F2002/30891;;A61F2002/30011;;A61F2/30771;;A61F2/4465;;A61F2002/30593;;A61F2002/30622;;A61F2002/30754;;A61F2002/30892;;A61F2002/30894;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161,A61F2/44;;A61F2/30,,0,0,,,,ACTIVE
15,US,A1,US 2019/0099274 A1,168-972-590-586-637,2019-04-04,2019,US 201715720126 A,2017-09-29,US 201715720126 A,2017-09-29,BONE CAGE INCLUDING OFFSET SETS OF PROTRUSIONS WITHIN A BONE INGROWTH CAVITY AND RELATED METHODS,"A bone cage may include first and second spaced apart frames defining a bone ingrowth cavity therebetween, a plurality of first protrusions each having a proximal end coupled to the first frame and a distal end extending into the cavity toward the second frame but not contacting the second frame, and a plurality of second protrusions each having a proximal end coupled to the second frame and a distal end extending into the cavity toward the first frame but not contacting the first frame. Furthermore, the distal ends of the first protrusions may be laterally offset from the distal ends of the second protrusions.",DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/168-972-590-586-637,Patent Application,yes,4,4,5,5,0,A61F2/4455;;A61F2/447;;A61F2002/30772;;A61F2002/30879;;A61F2002/30881;;A61F2002/30884;;A61F2002/30891;;A61F2/30771;;A61F2/4465;;A61F2002/30892;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161;;A61F2002/30011;;A61F2/447;;A61F2/4455;;A61F2002/30881;;A61F2002/30884;;A61F2002/30879;;A61F2002/30772;;A61F2002/30891;;A61F2002/30011;;A61F2/30771;;A61F2/4465;;A61F2002/30593;;A61F2002/30622;;A61F2002/30754;;A61F2002/30892;;A61F2002/30894;;A61F2002/3093;;A61F2310/00023;;A61F2310/00161,A61F2/30;;A61F2/44,,0,0,,,,ACTIVE
16,BR,A,BR 9504882 A,010-066-613-104-019,1997-09-02,1997,BR 9504882 A,1995-10-26,BR 9504882 A,1995-10-26,Dispositivo inabilitador do pluge de caso de alimentação elétrica,,PERISSE DUARTE LUIS,PERISSE DUARTE LUIS,,https://lens.org/010-066-613-104-019,Patent Application,no,0,0,1,1,0,,H01R13/44,,0,0,,,,DISCONTINUED
17,IT,B,IT 1184411 B,142-020-708-302-467,1987-10-28,1987,IT 2028985 A,1985-04-10,ES 278800 U,1984-04-13,SISTEMA DI CONNESSIONE MULTIPLA PER CONDOTTI DI CIRCUITI DI FLUIDI,,VULCA IND SA,DUARTE LUIS PUYUELO,,https://lens.org/142-020-708-302-467,Granted Patent,no,0,0,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,B29C45/00;;F16L13/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,,0,0,,,,EXPIRED
18,ES,Y,ES 1000493 Y,148-428-341-910-163,1989-10-01,1989,ES 8600861 U,1986-10-21,ES 8600861 U,1986-10-21,DISPOSICION PARA TOMA DE DERIVACION DE UN TUBO PARA CIRCULACION DE FLUIDOS,,INDUSTRIAS VULCA S.A.,PUYUELO DUARTE LUIS,THE GATES RUBBER COMPANY (1994-01-01),https://lens.org/148-428-341-910-163,Limited Patent,no,0,0,2,2,0,,F16L47/00,,0,0,,,,EXPIRED
19,GB,B,GB 2157386 B,196-660-627-458-421,1987-07-29,1987,GB 8507404 A,1985-03-21,ES 278800 U,1984-04-13,MULTIPLE FLUID CIRCUIT CONNECTOR,,VULCA IND SA,DUARTE LUIS PUYUELO,,https://lens.org/196-660-627-458-421,Granted Patent,no,0,0,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,B29C45/00;;F16L13/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,B5A1R314C3;;B5A1R322;;B5A1R429B;;B5A1R429X;;B5A20T14;;B5AB2;;F2G18D;;F2G1E;;U1S1968;;U1SF2G,0,0,,,,EXPIRED
20,CN,U,CN 207307140 U,003-693-501-113-390,2018-05-04,2018,CN 201720567724 U,2017-05-19,CN 201720567724 U,2017-05-19,Single foot skating shoe,"The utility model provides a single foot skating shoe, at least, including a framework, a plurality of wheels, a kick support piece, a lateral wall and a running -board, each wheel pivot is located these framework both sides and is just rotated for in pairs, this foot support piece is used for supporting user's a first foot, the protruding top of locating this foot support piece of this lateral wall, this running -board is used for supporting user's a second foot from this lateral wall extension, this running -board contains from a first component of this foot support piece rear extension setting, and extend a second component that sets up from this foot support piece side, this second foot of user can be be simultaneously supported by this first component and this second component of thisrunning -board jointly.",DUARTE LUIS MIGUEL,DUARTE LUIS MIGUEL,,https://lens.org/003-693-501-113-390,Limited Patent,no,0,0,1,1,0,,A63C17/02;;A63C17/14;;A63C17/26,,0,0,,,,INACTIVE
21,GB,A,GB 2157386 A,023-716-881-141-135,1985-10-23,1985,GB 8507404 A,1985-03-21,ES 278800 U,1984-04-13,Multiple fluid circuit connector,"A multiple connection system for fluid circuit conduits, particularly applicable to heat exchange circuits in motor vehicles, comprises a rigid tubular insert 4 having a plurality of nozzles, 6, 7 the end portions of which are a press fit into the conduits 2a, 2b, 3 to be connected, the insert and an end portion of the conduits, being covered at least in part by a moulded rubber or synthetic resin casing 5. <IMAGE>",VULCA IND SA,DUARTE LUIS PUYUELO,,https://lens.org/023-716-881-141-135,Patent Application,no,6,23,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,B29C45/00;;F16L13/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,B5A AB18          AB18P;;B5A AB2           AB2;;B5A A1R314C3      AB18P;;B5A A1R314C3      AB2;;B5A A1R322        AB18P;;B5A A1R322        AB2;;B5A A1R429B       AB18P;;B5A A1R429B       AB2;;B5A A1R429X       AB18P;;B5A A1R429X       AB2;;B5A A20T14        AB18P;;B5A A20T14        AB2;;F2G G1            G1;;F2G G1E           G1;;F2G G18           G18D;;F2G G18D          G18D;;U1S S1968,0,0,,,,EXPIRED
22,PT,B,PT 80200 B,029-794-500-567-557,1987-05-29,1987,PT 8020085 A,1985-04-01,ES 278800 U,1984-04-13,SISTEMA DE LIGACAO MULTIPLA PARA CONDUTAS DE CIRCUITOS DE FLUIDOS,,VULCA IND SA,DUARTE LUIS PUYUELO,,https://lens.org/029-794-500-567-557,Granted Patent,no,0,0,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,B29C45/00;;F16L13/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,,0,0,,,,EXPIRED
23,DE,A1,DE 3512410 A1,177-714-190-734-05X,1985-11-28,1985,DE 3512410 A,1985-04-04,ES 278800 U,1984-04-13,MEHRFACHVERBINDUNGSSYSTEM FUER FLUIDLEITUNGEN,,VULCA IND SA,PUYUELO DUARTE LUIS,"THE GATES RUBBER CO., DENVER, COL., US (1993-11-25)",https://lens.org/177-714-190-734-05X,Patent Application,no,16,6,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,F16L13/00;;B29C45/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,,0,0,,,,EXPIRED
24,CA,A1,CA 2569421 A1,040-307-997-407-424,2008-02-14,2008,CA 2569421 A,2006-11-15,US 83722306 P,2006-08-14,THE ROCKIT-SINGLE FOOT SKATE/SCOOTER,,DUARTE LUIS M,DUARTE LUIS M,,https://lens.org/040-307-997-407-424,Patent Application,no,0,0,4,4,0,A63C17/01;;A63C17/015;;A63C17/26;;A63C2201/02;;A63C17/262;;A63C17/26;;A63C17/01;;A63C17/015;;A63C2201/02;;A63C17/262;;A63C17/1436,A63C17/02;;A63C17/01;;B62K17/00,,0,0,,,,DISCONTINUED
25,US,B2,US 7717117 B2,157-653-503-365-434,2010-05-18,2010,US 24226505 A,2005-10-03,US 24226505 A;;US 61535004 P,2004-10-01,Surgical draping system for a patient on an operating table and an adjacent movable medical tool and related methods,A surgical draping method for a patient on an operating table and an adjacent movable medical tool may include positioning a patient drape having a surgical access opening in a medial portion thereof over the patient on the operating table so that the surgical access opening exposes a surgical site on the patient. Opposing medial side portions of the patient drape may be fastened together underneath the operating table to provide a pathway thereunder for passage of at least one portion of the medical tool therethrough. An equipment drape may be positioned adjacent a side of the operating table aligned with the pathway to cover the at least one portion of the medical tool when moved through the pathway.,DUARTE LUIS E,DUARTE LUIS E,,https://lens.org/157-653-503-365-434,Granted Patent,yes,16,14,2,2,0,A61B46/10;;A61B46/10;;A61B46/00;;A61B46/00,A61B19/00,128/849;;128/853,0,0,,,,INACTIVE
26,BR,A,BR 8205835 A,101-919-361-841-071,1984-06-12,1984,BR 8205835 A,1982-10-05,BR 8205835 A,1982-10-05,MINI-BAR MODULAR,,LUIS CARLOS SANTOS DUARTE,DUARTE LUIS CARLOS SANTOS,,https://lens.org/101-919-361-841-071,Patent Application,no,0,0,1,1,0,,E04H1/12,,0,0,,,,DISCONTINUED
27,WO,A2,WO 2010/079115 A2,131-012-171-011-651,2010-07-15,2010,EP 2009068040 W,2009-12-30,CH 222009 A,2009-01-08,HEATING POSITIVE-DISPLACEMENT PUMP FOR LIQUIDS,"The invention relates to a liquid pump comprising: a cylinder (2); a valve (4) for taking liquid into the cylinder; a valve (5) for discharging the liquid out of the cylinder; a piston (2) sliding in said cylinder so as to draw the liquid into the cylinder and to expel the liquid out of the cylinder; a cylinder-heating electric circuit (7) with at least one resistor (70, 71) for electrically heating the liquid in the cylinder; a temperature sensor (11) for measuring the liquid temperature in the cylinder; and a control circuit (8) for reducing the electric current in said heating electric circuit and for starting the discharge of the liquid out of the cylinder as soon as the liquid temperature has reached a predetermined setpoint value.",GOTEC SA;;GRENON VINCENT;;DUARTE LUIS,GRENON VINCENT;;DUARTE LUIS,,https://lens.org/131-012-171-011-651,Patent Application,yes,6,0,2,2,0,F04B39/122;;F04B53/08;;F04B53/162;;F04B2205/11;;F24H1/142,F24H1/12;;F24H9/20,,0,0,,,,PENDING
28,WO,A3,WO 2010/079115 A3,005-872-597-558-023,2012-08-30,2012,EP 2009068040 W,2009-12-30,CH 222009 A,2009-01-08,HEATING POSITIVE-DISPLACEMENT PUMP FOR LIQUIDS,"The invention relates to a liquid pump comprising: a cylinder (2); a valve (4) for taking liquid into the cylinder; a valve (5) for discharging the liquid out of the cylinder; a piston (2) sliding in said cylinder so as to draw the liquid into the cylinder and to expel the liquid out of the cylinder; a cylinder-heating electric circuit (7) with at least one resistor (70, 71) for electrically heating the liquid in the cylinder; a temperature sensor (11) for measuring the liquid temperature in the cylinder; and a control circuit (8) for reducing the electric current in said heating electric circuit and for starting the discharge of the liquid out of the cylinder as soon as the liquid temperature has reached a predetermined setpoint value.",GOTEC SA;;GRENON VINCENT;;DUARTE LUIS,GRENON VINCENT;;DUARTE LUIS,,https://lens.org/005-872-597-558-023,Search Report,yes,3,0,2,2,0,F04B39/122;;F04B53/08;;F04B53/162;;F04B2205/11;;F24H1/142,F24H1/14;;F04B39/12;;F04B53/08;;F04B53/16;;F24H9/20,,0,0,,,,PENDING
29,BR,A,BR 8400091 A,018-056-816-528-331,1985-08-13,1985,BR 8400091 A,1984-01-10,BR 8400091 A,1984-01-10,SALA DE PROJECAO MODULAR TRANSPORTAVEL,,LUIS CARLOS SANTOS DUARTE,DUARTE LUIS CARLOS SANTOS,,https://lens.org/018-056-816-528-331,Patent Application,no,0,0,1,1,0,,B60P3/32;;E04H3/30,,0,0,,,,DISCONTINUED
30,PT,A,PT 103228 A,167-088-375-609-396,2006-07-31,2006,PT 10322805 A,2005-01-25,PT 10322805 A,2005-01-25,SISTEMA REMOTO DE SEGURANCA,,DUARTE LUIS AUGUSTO NEVES,DUARTE LUIS AUGUSTO NEVES,,https://lens.org/167-088-375-609-396,Patent Application,no,0,0,4,4,0,H01H9/285;;H01H2300/03;;H01H2300/032;;H01R13/7037;;H01R13/7038;;H01R13/713;;Y04S20/14;;Y04S40/124;;Y04S40/126;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005;;Y02B90/20;;Y04S20/00;;H01H9/285;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005,H04L9/08,,0,0,,,,INACTIVE
31,BR,A,BR 8206327 A,083-493-174-943-738,1984-06-05,1984,BR 8206327 A,1982-10-29,BR 8206327 A,1982-10-29,ARMARIO PARA MAQUINA POST-MIX,,LUIS CARLOS SANTOS DUARTE,DUARTE LUIS CARLOS SANTOS,,https://lens.org/083-493-174-943-738,Patent Application,no,0,0,1,1,0,,A47F10/00,,0,0,,,,DISCONTINUED
32,CH,A2,CH 700233 A2,080-396-115-577-287,2010-07-15,2010,CH 232009 A,2009-01-08,CH 232009 A,2009-01-08,Procédé pour délivrer un volume de boisson chaude.,"Procédé pour délivrer un volume de boisson chaude, comportant les étapes suivantes: a) Ouverture d’une soupape d’admission (4) de liquide afin de permettre à un liquide de pénétrer dans un cylindre chauffant (2). b) Déplacement longitudinal dans un premier sens d’un piston (3) dans ledit cylindre (2), de manière à aspirer ledit volume déterminé de liquide dans ledit cylindre chauffant (2). c) Fermeture de ladite soupape d’admission (4), et ouverture d’une soupape d’expulsion (5). d) Déplacement longitudinal dans un deuxième sens opposé audit premier sens dudit piston (3) dans ledit cylindre (2), de manière à expulser au moins une partie du liquide chauffé hors dudit cylindre et à humecter une poudre. e) Attente pendant une durée prédéterminée. f) Déplacement longitudinal dans ledit premier sens dudit piston (3) dans ledit cylindre (2), de manière à réduire la pression du liquide dans la poudre. g) Déplacement longitudinal dans ledit deuxième sens dudit piston (3) dans ledit cylindre (2), de manière à expulser le liquide à travers ladite poudre et à délivrer ledit volume de boisson chaude.",GOTEC SA,GRENON VINCENT;;DUARTE LUIS,GOTEC SA (2011-04-15),https://lens.org/080-396-115-577-287,Patent Application,no,0,0,3,3,0,A47J31/002;;A47J31/002;;A47J31/461;;A47J31/461,A47J31/40,,0,0,,,,ACTIVE
33,CH,A2,CH 698340 A2,170-319-942-115-186,2009-07-15,2009,CH 222009 A,2009-01-08,CH 252008 A;;CH 222009 A,2008-01-09,Pompe volumétrique chauffante pour liquides.,"Pompe à liquide comportant: <br />- un cylindre (2);<br />- une soupape d'admission (4) de liquide dans le cylindre;<br />- une soupape d'expulsion (5) dudit liquide hors du cylindre;<br />- un piston (2) coulissant dans ledit cylindre de manière à aspirer ledit liquide dans le cylindre, puis à l'expulser hors du cylindre;<br />- un circuit électrique (7) de chauffage du cylindre avec au moins une résistance afin de chauffer électriquement le liquide dans le cylindre,<br />- une sonde de température pour mesurer la température du liquide dans le cylindre,<br />et un circuit de régulation agencé pour réduire le courant électrique dans ledit circuit électrique de chauffage et pour commencer l'expulsion du liquide hors du cylindre dès que la température du liquide a atteint une valeur de consigne prédéterminée. La pompe est en particulier destinée à étre utilisée dans un distributeur de boissons chaudes, p.ex. de cafés.",GOTEC SA,GRENON VINCENT;;DUARTE LUIS,GOTEC SA (2011-04-15),https://lens.org/170-319-942-115-186,Patent Application,no,0,0,9,9,0,A47J31/402;;A47J31/402;;A47J31/468;;A47J31/468;;A47J31/542;;A47J31/542;;F04B53/08;;F04B53/08;;F04B53/162;;F04B53/162;;H05B3/78;;H05B3/78,F04B15/04;;A47J31/36,,0,0,,,,ACTIVE
34,CH,B1,CH 698340 B1,036-578-312-558-116,2014-02-28,2014,CH 222009 A,2009-01-08,CH 252008 A;;CH 222009 A,2008-01-09,Pompe volumétrique chauffante pour liquides.,"L’invention concerne une pompe pour délivrer un volume déterminé de liquide chauffé comportant – un cylindre (2); – une soupape d’admission (4) de liquide dans le cylindre; – une soupape d’expulsion (5) dudit liquide hors du cylindre; – un piston (3) coulissant dans ledit cylindre de manière à aspirer ledit liquide dans le cylindre, puis à l’expulser hors du cylindre; – un circuit électrique (7) de chauffage du cylindre avec au moins une résistance afin de chauffer électriquement le liquide dans le cylindre, – une sonde de température pour mesurer la température du liquide dans le cylindre, et un circuit de régulation agencé pour réduire ou interrompre le courant électrique dans ledit circuit électrique de chauffage et pour commencer l’expulsion du liquide hors du cylindre dès que la température du liquide a atteint une valeur de consigne prédéterminée. La pompe est en particulier destinée à être utilisée dans un distributeur de boissons chaudes, par exemple de cafés.",GOTEC SA,GRENON VINCENT;;DUARTE LUIS,GOTEC SA (2011-04-15),https://lens.org/036-578-312-558-116,Granted Patent,no,0,0,9,9,0,A47J31/402;;A47J31/402;;A47J31/468;;A47J31/468;;A47J31/542;;A47J31/542;;F04B53/08;;F04B53/08;;F04B53/162;;F04B53/162;;H05B3/78;;H05B3/78,F04B15/04;;A47J31/36,,0,0,,,,ACTIVE
35,WO,A1,WO 2010/079116 A1,107-169-042-505-36X,2010-07-15,2010,EP 2009068041 W,2009-12-30,CH 232009 A,2009-01-08,METHOD FOR SUPPLYING A VOLUME OF A HOT BEVERAGE,"The invention relates to a method for supplying a volume of a hot beverage, comprising the following steps: a) opening a liquid intake valve (4) for enabling a liquid to enter a heating cylinder (2); b) longitudinally moving a piston (3) in a first direction in said cylinder (2) in order to draw the predetermined liquid volume into the heating cylinder (2) through said intake valve (4); c) closing said intake valve (4) and opening a discharge valve (5); d) longitudinally moving said piston (3) in a second direction opposite to the first one in the cylinder (2) in order to expel through said discharge valve (5) at least a portion of the heated liquid out of the cylinder and to wet a powder; e) waiting for a predetermined duration; f) longitudinally moving the piston (3) in the first direction in said cylinder (2) so as to reduce the liquid pressure in the powder; g) longitudinally moving said piston (3) in the second direction in said cylinder (2) in order to expel the liquid through said discharge valve (5) and through the powder in order to provide said volume of hot beverage.",GOTEC SA;;GRENON VINCENT;;DUARTE LUIS,GRENON VINCENT;;DUARTE LUIS,,https://lens.org/107-169-042-505-36X,Patent Application,yes,9,0,3,3,0,A47J31/002;;A47J31/002;;A47J31/461;;A47J31/461,A47J31/00;;A47J31/46,,0,0,,,,PENDING
36,WO,A3,WO 2006/080863 A3,031-056-012-572-08X,2006-09-08,2006,PT 2006000004 W,2006-01-25,PT 10322805 A,2005-01-25,REMOTE SAFETY SYSTEM,"The Remote Safety System is an electronic system that avoids the peril of electrocutions in high-tension electrical grids. It is characterized in that each switch has a lock with a safety key, which is blocked/unblocked by a remote unit (fig. 1) , and in that it exists a remote unit (fig. 2) for every point of the electrical grid needing repairs. The remote unit has set of working cards (17) that are distributed to workers, which are returned after the repairs have finished. When the safety key is blocked inside the central unit, the working cards (17) are unblocked inside the remote unit, and vice versa. The safety key is never unblocked at the same time of the working cards . Each central unit communicates with every remote unit using modems, or transceivers, or mobile phones.",NEVES DUARTE LUIS AUGUSTO,NEVES DUARTE LUIS AUGUSTO,,https://lens.org/031-056-012-572-08X,Search Report,no,6,0,4,4,0,H01H9/285;;H01H2300/03;;H01H2300/032;;H01R13/7037;;H01R13/7038;;H01R13/713;;Y04S20/14;;Y04S40/124;;Y04S40/126;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005;;Y02B90/20;;Y04S20/00;;H01H9/285;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005,H02J13/00;;G06Q10/00;;H04L9/08;;H01R13/70,,0,0,,,,PENDING
37,BR,A,BR 8205836 A,081-195-247-631-674,1984-05-08,1984,BR 8205836 A,1982-10-05,BR 8205836 A,1982-10-05,CARRINHO PORTATIL PRE-MIX,,LUIS CARLOS SANTOS DUARTE,DUARTE LUIS CARLOS SANTOS,,https://lens.org/081-195-247-631-674,Patent Application,no,0,0,1,1,0,,B67D1/04,,0,0,,,,DISCONTINUED
38,BR,U,BR 7802785 U,092-733-312-849-106,2000-06-06,2000,BR 7802785 U,1998-08-31,BR 7802785 U,1998-08-31,Sistema de vedação e centragem de vávula borboleta,"PATENTE DE MODêLO DE UTILIDADE DE ""SISTEMA DE VEDAçãO E CENTRAGEM DE VáLVULA BORBOLETA"" Refere-se o presente a um sistema de vedação e centragem de válvula borboleta, afim de se obter uma vida útil mais longa do equipamento e conseguir um custo final mais baixo, apesar de se usar mais componentes. Para centragem usam-se rolamentos de centro e para obtenção de vedação, usam-se uma bucha central, gaxetas, buchas estabilizadoras, separadora e anéis CRing. E, finalmente para a centragem de conexões que à válvula venham a se unir, frizos em baixo relêvo nos flanges laterais do corpo central bipartido.",METALURGICA WIGG LTDA,NASCIMENTO GERALDO LUIS DUARTE,,https://lens.org/092-733-312-849-106,Patent Application,no,0,0,1,1,0,,F16K1/16,,0,0,,,,DISCONTINUED
39,WO,A2,WO 2006/080863 A2,020-615-416-468-843,2006-08-03,2006,PT 2006000004 W,2006-01-25,PT 10322805 A,2005-01-25,REMOTE SAFETY SYSTEM,"The Remote Safety System is an electronic system that avoids the peril of electrocutions in high-tension electrical grids. It is characterized in that each switch has a lock with a safety key, which is blocked/unblocked by a remote unit (fig. 1) , and in that it exists a remote unit (fig. 2) for every point of the electrical grid needing repairs. The remote unit has set of working cards (17) that are distributed to workers, which are returned after the repairs have finished. When the safety key is blocked inside the central unit, the working cards (17) are unblocked inside the remote unit, and vice versa. The safety key is never unblocked at the same time of the working cards . Each central unit communicates with every remote unit using modems, or transceivers, or mobile phones.",NEVES DUARTE LUIS AUGUSTO,NEVES DUARTE LUIS AUGUSTO,,https://lens.org/020-615-416-468-843,Patent Application,yes,0,7,4,4,0,H01H9/285;;H01H2300/03;;H01H2300/032;;H01R13/7037;;H01R13/7038;;H01R13/713;;Y04S20/14;;Y04S40/124;;Y04S40/126;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005;;Y02B90/20;;Y04S20/00;;H01H9/285;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005,H02J13/00;;G06Q10/00;;H04L9/08;;H01R13/70,,0,0,,,,PENDING
40,PT,B,PT 103228 B,140-934-749-393-906,2006-12-29,2006,PT 10322805 A,2005-01-25,PT 10322805 A,2005-01-25,SISTEMA REMOTO DE SEGURANÇA,"O SISTEMA REMOTO DE SEGURANÇA É UM SISTEMA ELECTRÓNICO QUE EVITA O PERIGO DE ELECTROCUSSÕES EM REDES ELÉCTRICAS DE ALTA TENSÃO. CARACTERIZA-SE POR CADA INTERRUPTOR TER UMA FECHADURA COM UMA CHAVE DE SEGURANÇA, A QUAL É BLOQUEADA/DESBLOQUEADA POR UMA UNIDADE CENTRAL (FIG. 1), E POR EXISTIR UMA UNIDADE REMOTA (FIG. 2) EM CADA PONTO DA REDE ELÉCTRICA A REPARAR. A UNIDADE REMOTA TEM UM CONJUNTO DE CARTÕES DE TRABALHO (17) QUE SÃO DISTRIBUÍDOS AOS TRABALHADORES, OS QUAIS SÃO DEVOLVIDOS FINDAS AS REPARAÇÕES. QUANDO A CHAVE DE SEGURANÇA ESTÁ BLOQUEADA NA UNIDADE CENTRAL, OS CARTÕES DE TRABALHO (17) ESTÃO DESBLOQUEADOS NA UNIDADE REMOTA, E VICE VERSA. NUNCA A CHAVE DE SEGURANÇA ESTÁ DESBLOQUEADA AO MESMO TEMPO QUE OS CARTÕES DE TRABALHO. CADA UNIDADE CENTRAL COMUNICA COM CADA UMA DAS UNIDADES REMOTAS ATRAVÉS DE MODEMS, OU RÁDIOS EMISSORES-RECEPTORES, OU TELEMÓVEIS.",NEVES DUARTE LUIS AUGUSTO,NEVES DUARTE LUIS AUGUSTO,,https://lens.org/140-934-749-393-906,Granted Patent,no,0,0,4,4,0,H01H9/285;;H01H2300/03;;H01H2300/032;;H01R13/7037;;H01R13/7038;;H01R13/713;;Y04S20/14;;Y04S40/124;;Y04S40/126;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005;;Y02B90/20;;Y04S20/00;;H01H9/285;;H02J13/00016;;H02J13/00024;;H02J13/00036;;H02J13/0005,H04L9/08,,0,0,,,,INACTIVE
41,CH,B1,CH 700233 B1,070-283-472-159-004,2013-01-15,2013,CH 232009 A,2009-01-08,CH 232009 A,2009-01-08,Procédé et pompe volumétrique pour délivrer un volume de boisson chaude.,"Procédé pour délivrer un volume de boisson chaude, comportant les étapes suivantes: a) Ouverture d’une soupape d’admission (4) de liquide afin de permettre à un liquide de pénétrer dans un cylindre chauffant (2), b) Déplacement longitudinal dans un premier sens d’un piston (3) dans ledit cylindre (2), de manière à aspirer ledit volume déterminé de liquide dans ledit cylindre chauffant (2), c) Fermeture de ladite soupape d’admission (4), et ouverture d’une soupape d’expulsion (5), d) Déplacement longitudinal dans un deuxième sens opposé audit premier sens dudit piston (3) dans ledit cylindre (2), de manière à expulser au moins une partie du liquide chauffé hors dudit cylindre et à humecter une poudre, e) Attente pendant une durée prédéterminée, f) Déplacement longitudinal dans ledit premier sens dudit piston (3) dans ledit cylindre (2), de manière à réduire la pression du liquide dans la poudre, g) Déplacement longitudinal dans ledit deuxième sens dudit piston (3) dans ledit cylindre (2), de manière à expulser le liquide à travers ladite poudre et à délivrer ledit volume de boisson chaude. L’invention concerne également une pompe volumétrique pour mettre en œuvre le procédé ci-dessus.",GOTEC SA,GRENON VINCENT;;DUARTE LUIS,GOTEC SA (2011-04-15),https://lens.org/070-283-472-159-004,Granted Patent,no,0,0,3,3,0,A47J31/002;;A47J31/002;;A47J31/461;;A47J31/461,A47J31/41;;A47J31/46,,0,0,,,,ACTIVE
42,EP,B1,EP 2019001 B1,033-634-592-059-550,2012-06-13,2012,EP 07381054 A,2007-07-27,EP 07381054 A,2007-07-27,Dual chamber airbag module with anti-return difuser.,,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE,,https://lens.org/033-634-592-059-550,Granted Patent,yes,7,0,3,3,0,B60R21/233;;B60R21/2346;;B60R21/233;;B60R21/2346,B60R21/233;;B60R21/2346,,0,0,,,,ACTIVE
43,EP,A1,EP 2019001 A1,036-640-869-951-155,2009-01-28,2009,EP 07381054 A,2007-07-27,EP 07381054 A,2007-07-27,Dual chamber airbag module with anti-return difuser.,"Airbag module for a car that consists of a bag (11) consisting of at least two chambers (13, 15) inflatable with gas produced by a generator (21) and providing to each one of them via outlets from a distributor conduit (23) connected to the generator (21); the outlets would be configured to provide varying gas pressure in such chambers (13, 15) that also include a diffuser (31, 33, 35, 37) associated to said distribution conduit 823) in order to prevent the passage of gas between the chambers (13, 15) through such distribution conduit (23) after finishing the gas supply from the generator (21) in order to maintain different pressure levels in both chambers (13, 15) during the entire interaction period with the occupant.
",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE,,https://lens.org/036-640-869-951-155,Patent Application,yes,7,2,3,3,0,B60R21/233;;B60R21/2346;;B60R21/233;;B60R21/2346,B60R21/233;;B60R21/2346,,0,0,,,,ACTIVE
44,US,A1,US 2010/0289230 A1,179-871-605-890-495,2010-11-18,2010,US 59581307 A,2007-08-14,US 59581307 A;;CA 2569421 A;;US 83722306 P;;CA 2007001395 W,2006-08-14,SINGLE FOOT SKATE,"A skate comprising a frame, a plurality of wheels rotatably coupled to the frame and configured to effect rolling motion of the skate across a reaction surface; a foot support coupled to the frame, and including an operative foot support surface configured for supporting a skater's first foot, wherein the operative foot support surface includes a longitudinal axis, a foot coupling unit coupled to the frame, and configured for coupling a skater's first foot to the operative foot support surface, and a foot rest extending from the frame, and including an operative foot rest support surface configured for supporting the skater's second foot when the skater's first foot is supported by and coupled to the operative foot support surface; wherein the operative foot rest support surface includes a minimum linear width of at least 30 millimetres and also includes a maximum linear width of less than 45 millimetres, and wherein each of the minimum width and the maximum width is measured along a plane to which the longitudinal axis is normal.",DUARTE LUIS MIGUEL;;KARMAZYN DANIEL DAVID,DUARTE LUIS MIGUEL;;KARMAZYN DANIEL DAVID,DUARTE LUIS MIGUEL (2007-10-23),https://lens.org/179-871-605-890-495,Patent Application,yes,20,6,4,4,0,A63C17/01;;A63C17/015;;A63C17/26;;A63C2201/02;;A63C17/262;;A63C17/26;;A63C17/01;;A63C17/015;;A63C2201/02;;A63C17/262;;A63C17/1436,A63C17/14;;A63C17/00,280/11.204;;280/11.19,0,0,,,,ACTIVE
45,BR,A2,BR PI0900037 A2,018-381-520-232-303,2010-10-19,2010,BR PI0900037 A,2009-01-08,BR PI0900037 A,2009-01-08,processo para purificação de óleos,"PROCESSO PARA PURIFICAçãO DE óLEOS. A presente invenção está relacionada a um processo para purificação de óleos compreendendo etapas como filtração, aquecimento e centrifugação, de forma a produzir um óleo compatível com normas internacionais.",ALFA CENTRI MANUTENCAO DE MAQU,DIAS JOSE LUIS DUARTE;;ZANETTI LUCIANO,,https://lens.org/018-381-520-232-303,Patent Application,no,0,0,1,1,0,,B01D17/00,,0,0,,,,DISCONTINUED
46,US,A1,US 2017/0312089 A1,090-147-520-628-629,2017-11-02,2017,US 201615142160 A,2016-04-29,US 201615142160 A,2016-04-29,BONE GROWTH ENHANCING IMPLANT,An implant device having a non-conductive base structure with at least two exposed or exterior surfaces wherein at least one of the exposed or exterior surfaces has attained electrical conductivity on at least portions of the surface by an energy exposure wherein portions of the exposed or exterior surfaces are transformed by the energy exposure to attain the electrical conductivity.,VIVEX BIOMEDICAL INC,DUARTE LUIS E;;RADCLIFFE JEFFREY SCOTT,BONE PHARM LLC (2020-10-01);;VIVEX BIOLOGICS GROUP INC (2019-07-31);;GANEY TIMOTHY (2020-05-19),https://lens.org/090-147-520-628-629,Patent Application,yes,10,10,2,2,0,A61F2002/2835;;A61F2/30771;;A61F2002/3093;;A61F2002/30805;;A61F2002/3092;;A61F2002/30904;;A61F2/4455;;A61F2/442;;A61F2002/30593,A61F2/44,,0,0,,,,ACTIVE
47,PT,A,PT 103087 A,139-264-977-433-791,2005-09-30,2005,PT 10308704 A,2004-03-04,PT 10308704 A,2004-03-04,GRELHA MISTA DE TURBINAS,,DUARTE LUIS AUGUSTO DE PEDRO C,DUARTE LUIS AUGUSTO DE PEDRO C,,https://lens.org/139-264-977-433-791,Patent Application,no,0,0,1,1,0,,H02K7/18,,0,0,,,,DISCONTINUED
48,US,B2,US 10383740 B2,171-007-155-595-495,2019-08-20,2019,US 201615142160 A,2016-04-29,US 201615142160 A,2016-04-29,Bone growth enhancing implant,An implant device having a non-conductive base structure with at least two exposed or exterior surfaces wherein at least one of the exposed or exterior surfaces has attained electrical conductivity on at least portions of the surface by an energy exposure wherein portions of the exposed or exterior surfaces are transformed by the energy exposure to attain the electrical conductivity.,VIVEX BIOMEDICAL INC,DUARTE LUIS E;;RADCLIFFE JEFFREY SCOTT,BONE PHARM LLC (2020-10-01);;VIVEX BIOLOGICS GROUP INC (2019-07-31);;GANEY TIMOTHY (2020-05-19),https://lens.org/171-007-155-595-495,Granted Patent,yes,12,0,2,2,0,A61F2002/2835;;A61F2/30771;;A61F2002/3093;;A61F2002/30805;;A61F2002/3092;;A61F2002/30904;;A61F2/4455;;A61F2/442;;A61F2002/30593,A61F2/44,,0,0,,,,ACTIVE
49,DE,C2,DE 3512410 C2,080-998-771-616-289,1992-12-10,1992,DE 3512410 A,1985-04-04,ES 278800 U,1984-04-13,DE 3512410 C2,,"INDUSTRIAS VULCA S.A., SANT JUST DESVERN, ES","PUYUELO DUARTE, LUIS, CASTELLDEFELS, BARCELONA, ES","THE GATES RUBBER CO., DENVER, COL., US (1993-11-25)",https://lens.org/080-998-771-616-289,Granted Patent,no,1,0,18,18,0,B29C45/00;;B29C70/74;;B29L2031/246;;F16L31/02;;F16L55/07,F16L13/00;;B29C45/00;;B29C70/74;;F16L31/02;;F16L41/08;;F16L55/07,,0,0,,,,EXPIRED
50,WO,A1,WO 2008/019482 A1,172-874-719-062-582,2008-02-21,2008,CA 2007001395 W,2007-08-14,US 83722306 P;;CA 2569421 A,2006-08-14,SINGLE FOOT SKATE,"A skate comprising a frame, a plurality of wheels rotatably coupled to the frame and configured to effect rolling motion of the skate across a reaction surface; a foot support coupled to the frame, and including an operative foot support surface configured for supporting a skater's first foot, wherein the operative foot support surface includes a longitudinal axis, a foot coupling unit coupled to the frame, and configured for coupling a skater's first foot to the operative foot support surface, and a foot rest extending from the frame, and including an operative foot rest support surface configured for supporting the skater's second foot when the skater's first foot is supported by and coupled to the operative foot support surface; wherein the operative foot rest support surface includes a minimum linear width of at least 30 millimetres and also includes a maximum linear width of less than 45 millimetres, and wherein each of the minimum width and the maximum width is measured along a plane to which the longitudinal axis is normal.",DUARTE LUIS MIGUEL;;KARMAZYN DANIEL DAVID,DUARTE LUIS MIGUEL;;KARMAZYN DANIEL DAVID,,https://lens.org/172-874-719-062-582,Patent Application,yes,4,16,4,4,0,A63C17/01;;A63C17/015;;A63C17/26;;A63C2201/02;;A63C17/262;;A63C17/26;;A63C17/01;;A63C17/015;;A63C2201/02;;A63C17/262;;A63C17/1436,A63C17/02;;A63C17/00;;A63C17/01,,0,0,,,,PENDING
51,US,B2,US 8573614 B2,153-154-003-369-568,2013-11-05,2013,US 59581307 A,2007-08-14,US 59581307 A;;CA 2569421 A;;US 83722306 P;;CA 2007001395 W,2006-08-14,Single foot skate,"A skate including a main body, a plurality of wheels, a primary foot support, a sidewall, and a foot rest. The plurality of wheels are rotatably coupled to the main body. The primary foot support is configured to support a skater's first foot. The sidewall projects above the primary foot support. The foot rest extends from the sidewall to support a skater's second foot. The foot rest includes a first portion extending rearward relative to the primary foot support, and a second portion extending laterally relative to the primary foot support. The skater's second foot can be positioned upon and simultaneously supported by both the first portion and the second portion of the foot rest.",DUARTE LUIS MIGUEL;;KARMAZYN DANIEL DAVID,DUARTE LUIS MIGUEL;;KARMAZYN DANIEL DAVID,DUARTE LUIS MIGUEL (2007-10-23),https://lens.org/153-154-003-369-568,Granted Patent,yes,21,2,4,4,0,A63C17/01;;A63C17/015;;A63C17/26;;A63C2201/02;;A63C17/262;;A63C17/26;;A63C17/01;;A63C17/015;;A63C2201/02;;A63C17/262;;A63C17/1436,A63C17/00;;A63C17/14;;A63C17/26,280/87.041;;280/11.208;;280/607,0,0,,,,ACTIVE
52,BR,A2,BR 112012026005 A2,046-794-068-025-885,2015-09-08,2015,BR 112012026005 A,2011-04-13,IB 2011001292 W;;US 32378810 P,2010-04-13,composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados,"composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados. a presente invenção refere-se a métodos e composições para tratar diabetes do tipo ii. esta invenção revela uma formulação farmacêutica oralmente administrável, como terapia conveniente para reduzir os níveis de glicose no sangue, impedir o desenvolvimento de diabetes e uma exaustão precose do pâncreas. em certas modalidades, a invenção fornece combinação das formulações farmacêuticass oralmente administráveis, compreendendo pelo menos um sensibilizador de insulina (por exemplo, uma glitazona tal como pioglitazona ou rosiglitazona), pelo menos uma sulfonilureia (por exemplo, glimepirida), e pelo menos uma biguanida (por exemplo, metformina ou um sal ou éster farmaceuticamente aceitável da mesma, tal como hci de metformina). a presente invenção também fornece métodos de tratar diabetes do tipo ii e distúrbios relacionados em um mamífero, adequadamente um humano, administrando a um mamífero em necessidade do mesmo uma ou mais das composições da presente invenção.",NUCITEC SA DE CV,ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,,https://lens.org/046-794-068-025-885,Patent Application,no,0,0,7,7,0,A61K31/155;;A61K31/44;;A61K45/06;;A61P3/10;;A61K31/155;;A61K45/06;;A61K31/44,A01N33/02,,0,0,,,,DISCONTINUED
53,US,B2,US 7938438 B2,013-890-053-214-790,2011-05-10,2011,US 15719708 A,2008-06-06,EP 07380196 A,2007-06-29,Three-chamber adaptive side airbag,"The invention relates to a side airbag module for an automotive vehicle which includes an inflatable bag ( 11 ) configured to be deployed between an occupant and the vehicle body upon being filled with the gas produced by a generator, which bag comprises a front panel ( 21 ) intended to make contact with the occupant, a rear panel ( 23 ) and at least one inner panel ( 25 ) forming a first chamber ( 13 ) with the rear panel ( 23 ) and a second chamber ( 15 ) with the front panel ( 21 ), having a vent hole ( 19 ), the inner panel ( 25 ) including a duct ( 39 ) allowing the passage of gas from the first chamber ( 13 ) to the second chamber ( 15 ) and which is located in a position allowing it to be blocked upon the front panel ( 21 ) moving closer to the inner panel ( 25 ) during the contact of the bag ( 11 ) with the occupant.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2008-07-29),https://lens.org/013-890-053-214-790,Granted Patent,yes,31,7,4,4,0,B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23324;;B60R2021/23382;;B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23382;;B60R2021/23324,B60R21/231;;B60R21/233;;B60R21/2338,280/730.2;;280/742;;280/729,0,0,,,,INACTIVE
54,US,A1,US 2009/0001692 A1,193-062-824-385-795,2009-01-01,2009,US 15719708 A,2008-06-06,EP 07380196 A,2007-06-29,Three-chamber adaptive side airbag,"The invention relates to a side airbag module for an automotive vehicle which includes an inflatable bag ( 11 ) configured to be deployed between an occupant and the vehicle body upon being filled with the gas produced by a generator, which bag comprises a front panel ( 21 ) intended to make contact with the occupant, a rear panel ( 23 ) and at least one inner panel ( 25 ) forming a first chamber ( 13 ) with the rear panel ( 23 ) and a second chamber ( 15 ) with the front panel ( 21 ), having a vent hole ( 19 ), the inner panel ( 25 ) including a duct ( 39 ) allowing the passage of gas from the first chamber ( 13 ) to the second chamber ( 15 ) and which is located in a position allowing it to be blocked upon the front panel ( 21 ) moving closer to the inner panel ( 25 ) during the contact of the bag ( 11 ) with the occupant.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2008-07-29),https://lens.org/193-062-824-385-795,Patent Application,yes,31,7,4,4,0,B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23324;;B60R2021/23382;;B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23382;;B60R2021/23324,B60R21/231;;B60R21/2338,280/728.3,0,0,,,,INACTIVE
55,EP,B1,EP 1990242 B1,018-540-394-960-70X,2010-08-04,2010,EP 07381038 A,2007-05-10,EP 07381038 A,2007-05-10,Airbag with a venting regulation device,"The present invention relates to an airbag for automotive vehicles with a gas venting regulation device assembled around a venting opening (11) comprising a first part (15) joined to the inflatable cushion (13) covering the venting opening (11), formed by an elastic area (31) and a non-elastic area (33) with a plurality of openings (17, 19) for the passage of gas; a second rigid part (21) joined to the inflatable cushion (13) and to said first part (15), with a projecting neck (23) forming a gas outlet mouth; and in eihich at least one part of said non-elastic area (33) is arranged such that when the first part (15) is deformed as a result of the internal pressure in the inflatable cushion during its deployment, the passage of gas through said openings (17) is completely or partially sealed by said projecting neck (23.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,,https://lens.org/018-540-394-960-70X,Granted Patent,yes,4,0,6,6,0,B60R21/239;;B60R21/239,B60R21/16,,0,0,,,,ACTIVE
56,DE,D1,DE 602007008207 D1,173-783-101-610-121,2010-09-16,2010,DE 602007008207 T,2007-05-10,EP 07381038 A,2007-05-10,Airbag mit einer Belüftungsregulierungsvorrichtung,"The present invention relates to an airbag for automotive vehicles with a gas venting regulation device assembled around a venting opening (11) comprising a first part (15) joined to the inflatable cushion (13) covering the venting opening (11), formed by an elastic area (31) and a non-elastic area (33) with a plurality of openings (17, 19) for the passage of gas; a second rigid part (21) joined to the inflatable cushion (13) and to said first part (15), with a projecting neck (23) forming a gas outlet mouth; and in eihich at least one part of said non-elastic area (33) is arranged such that when the first part (15) is deformed as a result of the internal pressure in the inflatable cushion during its deployment, the passage of gas through said openings (17) is completely or partially sealed by said projecting neck (23.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,,https://lens.org/173-783-101-610-121,Granted Patent,no,0,0,6,6,0,B60R21/239;;B60R21/239,B60R21/16,,0,0,,,,ACTIVE
57,EP,A1,EP 1990242 A1,193-636-621-457-891,2008-11-12,2008,EP 07381038 A,2007-05-10,EP 07381038 A,2007-05-10,Airbag with a venting regulation device,"The present invention relates to an airbag for automotive vehicles with a gas venting regulation device assembled around a venting opening (11) comprising a first part (15) joined to the inflatable cushion (13) covering the venting opening (11), formed by an elastic area (31) and a non-elastic area (33) with a plurality of openings (17, 19) for the passage of gas; a second rigid part (21) joined to the inflatable cushion (13) and to said first part (15), with a projecting neck (23) forming a gas outlet mouth; and in eihich at least one part of said non-elastic area (33) is arranged such that when the first part (15) is deformed as a result of the internal pressure in the inflatable cushion during its deployment, the passage of gas through said openings (17) is completely or partially sealed by said projecting neck (23.
",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,,https://lens.org/193-636-621-457-891,Patent Application,yes,4,2,6,6,0,B60R21/239;;B60R21/239,B60R21/16,,0,0,,,,ACTIVE
58,CL,A1,CL 2012002823 A1,027-222-545-227-242,2013-02-08,2013,CL 2012002823 A,2012-10-09,US 32378810 P,2010-04-13,"Composición farmacéutica para el tratamiento de la diabetes y los trastornos relacionados, que comprende un sensibilizador de insulina seleccionado entre pioglitazona y rosiglitazona, glimepirida y metmorfina; formulación farmacéutica oral que la comprende; kit para tratar diabetes tipo ii; y uso de dicha formulación para tratar diabetes.","Composición farmacéutica para el tratamiento de la diabetes y los trastornos relacionados, que comprende un sensibilizador de insulina seleccionado entre pioglitazona y rosiglitazona, glimepirida y metmorfina; formulación farmacéutica oral que la comprende; kit para tratar diabetes tipo II; y uso de dicha formulación para tratar diabetes.",NUCITEC SA DE CV,ROSADO JORGE LUIS;;DUARTE VASQUEZ MIGUEL ANGEL,,https://lens.org/027-222-545-227-242,Patent Application,no,0,0,7,7,0,A61K31/155;;A61K31/44;;A61K45/06;;A61P3/10;;A61K31/155;;A61K45/06;;A61K31/44,A61K31/4439;;A61K31/55;;A61P3/10,,0,0,,,,PENDING
59,EP,B1,EP 2025563 B1,068-265-750-184-592,2009-12-30,2009,EP 07381056 A,2007-08-07,EP 07381056 A,2007-08-07,Airbag module for automotive vehicles with a foldable container,,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RUEDA ROBERTO,,https://lens.org/068-265-750-184-592,Granted Patent,yes,11,0,5,5,0,B60R21/2176;;B60R21/2176,B60R21/20,,0,0,,,,ACTIVE
60,EP,A1,EP 1990248 A1,107-317-068-727-94X,2008-11-12,2008,EP 07381037 A,2007-05-09,EP 07381037 A,2007-05-09,Side airbag with an adaptive venting device,"The present invention relates to a side airbag for an automotive vehicle comprising a venting regulation device formed by a part made of a flexible material (21) joined to the inflatable cushion (11) such that it can completely or partially close or free the venting opening (17), and a tension belt (23) joined by one part to said part made of a flexible material (21) and by another part to the inflatable cushion (11), the geometric configurations of said tension belt (23) and said part made of a flexible material (21) being determined such that the degree of closing/freeing of the venting opening (17) varies according to the width of the inflatable cushion (11) during its different deployment phases during the collision, being closed in the initial and end phases and freed in the intermediate phase.
",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,,https://lens.org/107-317-068-727-94X,Patent Application,yes,10,1,7,7,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R21/239;;B60R21/2338;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
61,BR,A,BR 8801100 A,118-399-628-906-040,1989-10-03,1989,BR 8801100 A,1988-03-11,BR 8801100 A,1988-03-11,BLOCO REFRATARIO DENSO PARA INJECAO DE GASES EM METAIS E LIGAS EM ESTADO DE FUSAO,,MAGNESITA S A,DUARTE ALAMAR KAZAN;;OLIVEIRA WALTER LUIS DE,,https://lens.org/118-399-628-906-040,Patent Application,no,0,0,1,1,0,,C21C5/48,,0,0,,,,DISCONTINUED
62,EP,A1,EP 2025563 A1,133-101-957-283-525,2009-02-18,2009,EP 07381056 A,2007-08-07,EP 07381056 A,2007-08-07,Airbag module for automotive vehicles with a foldable container,"The invention relates to an airbag module for automotive vehicles, comprising a gas generator (15) and an inflatable cushion (13) which are housed in a container (11) which is prismatic in shape and formed by folding a flat sheet of suitable material in which its large sides (31, 33), its back side (35) and, as extensions of the sides of said large sides (31), flaps (37, 37', 37"") corresponding to the sides of the closing surface of the container (11), are defined by means of pre-cut lines, said flaps (37, 37', 37"") and the large side (33) they are separated from including cooperating means (41, 43, 45) defined by means of pre-cut lines, which allow closing the container (11). The container (11) additionally includes means (51, 53) defined by means of pre-cut lines intended for aiding in positioning and fixing the airbag module in the vehicle.
",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RUEDA ROBERTO,,https://lens.org/133-101-957-283-525,Patent Application,yes,11,0,5,5,0,B60R21/2176;;B60R21/2176,B60R21/20,,0,0,,,,ACTIVE
63,EP,B1,EP 1990248 B1,124-893-041-732-767,2010-10-27,2010,EP 07381037 A,2007-05-09,EP 07381037 A,2007-05-09,Side airbag with an adaptive venting device,"The present invention relates to a side airbag for an automotive vehicle comprising a venting regulation device formed by a part made of a flexible material (21) joined to the inflatable cushion (11) such that it can completely or partially close or free the venting opening (17), and a tension belt (23) joined by one part to said part made of a flexible material (21) and by another part to the inflatable cushion (11), the geometric configurations of said tension belt (23) and said part made of a flexible material (21) being determined such that the degree of closing/freeing of the venting opening (17) varies according to the width of the inflatable cushion (11) during its different deployment phases during the collision, being closed in the initial and end phases and freed in the intermediate phase.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,,https://lens.org/124-893-041-732-767,Granted Patent,yes,3,0,7,7,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R21/239;;B60R21/2338;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
64,EP,A1,EP 2008879 A1,015-428-984-388-732,2008-12-31,2008,EP 07380196 A,2007-06-29,EP 07380196 A,2007-06-29,Three-chamber adaptive side airbag,"The invention relates to a side airbag module for an automotive vehicle which includes an inflatable bag (11) configured to be deployed between an occupant and the vehicle body upon being filled with the gas produced by a generator, which bag comprises a front panel (21) intended to make contact with the occupant, a rear panel (23) and at least one inner panel (25) forming a first chamber (13) with the rear panel (23) and a second chamber (15) with the front panel (21), having a vent hole (19), the inner panel (25) including a duct (39) allowing the passage of gas from the first chamber (13) to the second chamber (15) and which is located in a position allowing it to be blocked upon the front panel (21) moving closer to the inner panel (25) during the contact of the bag (11) with the occupant.
",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;DENYS ISABELLE,,https://lens.org/015-428-984-388-732,Patent Application,yes,7,9,4,4,0,B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23324;;B60R2021/23382;;B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23382;;B60R2021/23324,B60R21/231;;B60R21/233;;B60R21/2338;;B60R21/239,,0,0,,,,ACTIVE
65,US,A1,US 2014/0012384 A1,049-297-324-640-740,2014-01-09,2014,US 201314020374 A,2013-09-06,US 201314020374 A;;US 201113135675 A;;US 201113200911 A;;US 201261697795 P,2011-07-12,INTERBODY FUSION DEVICE AND ASSOCIATED METHODS,"A method and apparatus is provided for use in spinal fusion procedures. An interbody fusion device has a first piece that is a load bearing device designed to bear the axial loading from the end plates of adjacent vertebrae. A second piece of the interbody fusion device is a retention component whose primary functions are to prevent migration of the load bearing device and loss or migration of graft material from within the load bearing device. A secondary function of the retention component is to address fixation of fasteners when the surgeon is confronted with a challenging access to adequate boney structures due to excessive curvature/angulation of the vertebrae column, minimal invasive surgery techniques, danger to surrounding vascular or neurological tissues, poor bone quality, or similar surgical complications. A tertiary function of the retention component is to provide better alignment and stabilization of misaligned vertebrae when spondylolisthesis is a significant factor. One or more fasteners secure the retention component to each of the vertebrae above and below the load bearing device. The fasteners cause the end plates of the vertebrae to compress the end plates to the load bearing device to facilitate proper fusion.",SPINESMITH PARTNERS LP,KANA RICHARD J;;DUARTE LUIS;;GUNDANNA MUKUND,SPINESMITH PARTNERS L.P (2013-09-19),https://lens.org/049-297-324-640-740,Patent Application,yes,5,32,2,6,0,A61F2/4465;;A61F2/4465;;A61B17/8033;;A61B17/8033;;A61B17/8042;;A61F2/30744;;A61F2/30744;;A61F2/4455;;A61F2/4455;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/3008;;A61F2002/3008;;A61F2002/30131;;A61F2002/30131;;A61F2002/30171;;A61F2002/30171;;A61F2002/30331;;A61F2002/30331;;A61F2002/30354;;A61F2002/30354;;A61F2002/305;;A61F2002/305;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30607;;A61F2002/30607;;A61F2002/30616;;A61F2002/30616;;A61F2002/30774;;A61F2002/30774;;A61F2002/30782;;A61F2002/30782;;A61F2002/30904;;A61F2002/30904;;A61F2310/00011;;A61F2310/00011;;A61L27/18;;A61L27/18;;A61L2430/38;;A61L2430/38,A61F2/44,623/17.16,0,0,,,,ACTIVE
66,US,B2,US 7810839 B2,093-845-678-024-494,2010-10-12,2010,US 15173708 A,2008-05-08,EP 07381037 A,2007-05-09,Side airbag with an adaptive venting device,"The present invention relates to a side airbag for an automotive vehicle comprising a venting regulation device formed by a part made of a flexible material ( 21 ) joined to the inflatable cushion ( 11 ) such that it can completely or partially close or free the venting opening ( 17 ), and a tension belt ( 23 ) joined by one part to said part made of a flexible material ( 21 ) and by another part to the inflatable cushion ( 11 ), the geometric configurations of said tension belt ( 23 ) and said part made of a flexible material ( 21 ) being determined such that the degree of closing/freeing of the venting opening ( 17 ) varies according to the width of the inflatable cushion ( 11 ) during its different deployment phases during the collision, being closed in the initial and end phases and freed in the intermediate phase.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2008-06-23),https://lens.org/093-845-678-024-494,Granted Patent,yes,3,9,7,7,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R21/239;;B60R21/2338;;B60R2021/23382,B60R21/2338;;B60R21/239,280/739;;280/730.2;;280/743.2,0,0,,,,ACTIVE
67,BR,A,BR 9801114 A,178-350-236-844-687,1999-12-07,1999,BR 9801114 A,1998-03-06,BR 9801114 A,1998-03-06,Sistema para condicionamento de animais,"Patente de Invenção: <B>""SISTEMA PARA CONDICIONAMENTO DE ANIMAIS""<D>. A presente invenção refere se a um sistema para condicionamento de animais e, mais particularmente, a um dispositivo elétrico capaz de gerar pulsos elétricos semelhantes a uma descarga de eletricidade. O objetivo da presente invenção é de oferecer um sistema que auxilie o treinamento de animais domésticos, sendo tal objetivo alcançado através de um sistema para condicionamento de animais compreendendo um circuito elétrico (10) capaz de gerar pulsos de tensão elétrica e pelo menos um conector elétrico (20).",PAULO ROGERIO CAVALINS NOVAS,NOVAS PAULO ROGERIO CAVALINS;;DUARTE LUIS ANTONIO,,https://lens.org/178-350-236-844-687,Patent Application,no,0,0,1,1,0,,H05C1/04,,0,0,,,,DISCONTINUED
68,US,A1,US 2008/0277912 A1,013-613-760-611-220,2008-11-13,2008,US 15173808 A,2008-05-08,EP 07381038 A,2007-05-10,Airbag with a venting regulation device,"The present invention relates to an airbag for automotive vehicles with a gas venting regulation device assembled around a venting opening ( 11 ) comprising a first part ( 15 ) joined to the inflatable cushion ( 13 ) covering the venting opening ( 11 ), formed by an elastic area ( 31 ) and a non-elastic area ( 33 ) with a plurality of openings ( 17, 19 ) for the passage of gas; a second rigid part ( 21 ) joined to the inflatable cushion ( 13 ) and to said first part ( 15 ), with a projecting neck ( 23 ) forming a gas outlet mouth; and in which at least one part of said non-elastic area ( 33 ) is arranged such that when the first part ( 15 ) is deformed as a result of the internal pressure in the inflatable cushion during its deployment, the passage of gas through said openings ( 17 ) is completely or partially sealed by said projecting neck ( 23.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2008-06-12),https://lens.org/013-613-760-611-220,Patent Application,yes,6,10,6,6,0,B60R21/239;;B60R21/239,B60R21/239,280/739,0,0,,,,INACTIVE
69,WO,A3,WO 2011/128782 A3,049-057-865-223-269,2012-01-19,2012,IB 2011001292 W,2011-04-13,US 32378810 P,2010-04-13,COMPOSITIONS AND METHODS FOR TREATING TYPE II DIABETES AND RELATED DISORDERS,"The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.",ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,,https://lens.org/049-057-865-223-269,Search Report,yes,3,0,7,7,0,A61K31/155;;A61K31/44;;A61K45/06;;A61P3/10;;A61K31/155;;A61K45/06;;A61K31/44,A01N33/02,,1,0,,,"LAKSHMI ET AL.: ""T. Rajesh et al. Development and Validation of Liquid Chromatographic and UV Derivative Spectrophotometric Methods for the Determination of Metformin, Pioglitazone and Glimepiride in Pharmaceutical Formulations."", DER PHARMA CHEMICA, vol. 1, no. 1, 2009, pages 238 - 246",PENDING
70,US,A1,US 2009/0091106 A1,061-936-783-819-144,2009-04-09,2009,US 15173708 A,2008-05-08,EP 07381037 A,2007-05-09,Side airbag with an adaptive venting device,"The present invention relates to a side airbag for an automotive vehicle comprising a venting regulation device formed by a part made of a flexible material ( 21 ) joined to the inflatable cushion ( 11 ) such that it can completely or partially close or free the venting opening ( 17 ), and a tension belt ( 23 ) joined by one part to said part made of a flexible material ( 21 ) and by another part to the inflatable cushion ( 11 ), the geometric configurations of said tension belt ( 23 ) and said part made of a flexible material ( 21 ) being determined such that the degree of closing/freeing of the venting opening ( 17 ) varies according to the width of the inflatable cushion ( 11 ) during its different deployment phases during the collision, being closed in the initial and end phases and freed in the intermediate phase.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2008-06-23),https://lens.org/061-936-783-819-144,Patent Application,yes,3,5,7,7,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R21/239;;B60R21/2338;;B60R2021/23382,B60R21/2338;;B60R21/239,280/730.2;;280/740;;280/737,0,0,,,,ACTIVE
71,AT,T1,AT E476326 T1,114-866-604-178-282,2010-08-15,2010,AT 07381038 T,2007-05-10,EP 07381038 A,2007-05-10,AIRBAG MIT EINER BELÜFTUNGSREGULIERUNGSVORRICHTUNG,"The present invention relates to an airbag for automotive vehicles with a gas venting regulation device assembled around a venting opening (11) comprising a first part (15) joined to the inflatable cushion (13) covering the venting opening (11), formed by an elastic area (31) and a non-elastic area (33) with a plurality of openings (17, 19) for the passage of gas; a second rigid part (21) joined to the inflatable cushion (13) and to said first part (15), with a projecting neck (23) forming a gas outlet mouth; and in eihich at least one part of said non-elastic area (33) is arranged such that when the first part (15) is deformed as a result of the internal pressure in the inflatable cushion during its deployment, the passage of gas through said openings (17) is completely or partially sealed by said projecting neck (23.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,,https://lens.org/114-866-604-178-282,Granted Patent,no,0,0,6,6,0,B60R21/239;;B60R21/239,,,0,0,,,,INACTIVE
72,DE,D1,DE 602007004108 D1,005-290-397-479-347,2010-02-11,2010,DE 602007004108 T,2007-08-07,EP 07381056 A,2007-08-07,Airbagmodul mit faltbarem Behälter für Kraftfahrzeuge,,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RUEDA ROBERTO,,https://lens.org/005-290-397-479-347,Granted Patent,no,0,0,5,5,0,B60R21/2176;;B60R21/2176,B60R21/20,,0,0,,,,ACTIVE
73,WO,A2,WO 2011/128782 A2,075-407-762-073-253,2011-10-20,2011,IB 2011001292 W,2011-04-13,US 32378810 P,2010-04-13,COMPOSITIONS AND METHODS FOR TREATING TYPE II DIABETES AND RELATED DISORDERS,"The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.",ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,,https://lens.org/075-407-762-073-253,Patent Application,yes,0,5,7,7,0,A61K31/155;;A61K31/44;;A61K45/06;;A61P3/10;;A61K31/155;;A61K45/06;;A61K31/44,A61K31/155,,0,0,,,,PENDING
74,US,A1,US 2012/0095059 A1,138-016-458-393-004,2012-04-19,2012,US 201113086213 A,2011-04-13,US 201113086213 A;;US 32378810 P,2010-04-13,Compositions and Methods for Treating Type II Diabetes and Related Disorders,"The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.",ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,,https://lens.org/138-016-458-393-004,Patent Application,yes,4,2,7,7,0,A61K31/155;;A61K31/44;;A61K45/06;;A61P3/10;;A61K31/155;;A61K45/06;;A61K31/44,A61K31/4439;;A61P3/10,514/342,2,1,016-856-436-439-786,10.1016/j.clinthera.2005.10.017;;16330290,"Roberts et al. (Clinical Therapeutics, 27(10):1535-1547, 2005);;Description of Amaryl� (Glimepiride Tablet, May, 2009).",DISCONTINUED
75,US,B2,US 9161841 B2,184-729-490-751-359,2015-10-20,2015,US 201314020374 A,2013-09-06,US 201314020374 A;;US 201113135675 A;;US 201113200911 A;;US 201261697795 P,2011-07-12,Interbody fusion device and associated methods,"A method and apparatus is provided for use in spinal fusion procedures. An interbody fusion device has a first piece that is a load bearing device designed to bear the axial loading from the end plates of adjacent vertebrae. A second piece of the interbody fusion device is a retention component whose primary functions are to prevent migration of the load bearing device and loss or migration of graft material from within the load bearing device. A secondary function of the retention component is to address fixation of fasteners when the surgeon is confronted with a challenging access to adequate boney structures due to excessive curvature/angulation of the vertebrae column, minimal invasive surgery techniques, danger to surrounding vascular or neurological tissues, poor bone quality, or similar surgical complications. A tertiary function of the retention component is to provide better alignment and stabilization of misaligned vertebrae when spondylolisthesis is a significant factor. One or more fasteners secure the retention component to each of the vertebrae above and below the load bearing device. The fasteners cause the end plates of the vertebrae to compress the end plates to the load bearing device to facilitate proper fusion.",SPINESMITH PARTNERS LP,KANA RICHARD J;;DUARTE LUIS;;GUNDANNA MUKUND,SPINESMITH PARTNERS L.P (2013-09-19),https://lens.org/184-729-490-751-359,Granted Patent,yes,5,26,2,6,0,A61F2/4465;;A61F2/4465;;A61B17/8033;;A61B17/8033;;A61B17/8042;;A61F2/30744;;A61F2/30744;;A61F2/4455;;A61F2/4455;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/3008;;A61F2002/3008;;A61F2002/30131;;A61F2002/30131;;A61F2002/30171;;A61F2002/30171;;A61F2002/30331;;A61F2002/30331;;A61F2002/30354;;A61F2002/30354;;A61F2002/305;;A61F2002/305;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30607;;A61F2002/30607;;A61F2002/30616;;A61F2002/30616;;A61F2002/30774;;A61F2002/30774;;A61F2002/30782;;A61F2002/30782;;A61F2002/30904;;A61F2002/30904;;A61F2310/00011;;A61F2310/00011;;A61L27/18;;A61L27/18;;A61L2430/38;;A61L2430/38,A61F2/44;;A61B17/80;;A61F2/28;;A61F2/30;;A61L27/18,,0,0,,,,ACTIVE
76,DE,D1,DE 602007010105 D1,196-180-958-324-767,2010-12-09,2010,DE 602007010105 T,2007-05-09,EP 07381037 A,2007-05-09,Seitenairbag mit adaptiver Entlüftungsvorrichtung,"The present invention relates to a side airbag for an automotive vehicle comprising a venting regulation device formed by a part made of a flexible material (21) joined to the inflatable cushion (11) such that it can completely or partially close or free the venting opening (17), and a tension belt (23) joined by one part to said part made of a flexible material (21) and by another part to the inflatable cushion (11), the geometric configurations of said tension belt (23) and said part made of a flexible material (21) being determined such that the degree of closing/freeing of the venting opening (17) varies according to the width of the inflatable cushion (11) during its different deployment phases during the collision, being closed in the initial and end phases and freed in the intermediate phase.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,,https://lens.org/196-180-958-324-767,Granted Patent,no,0,0,7,7,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R21/239;;B60R21/2338;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
77,AT,T1,AT E453548 T1,010-595-959-949-004,2010-01-15,2010,AT 07381056 T,2007-08-07,EP 07381056 A,2007-08-07,AIRBAGMODUL MIT FALTBAREM BEHÄLTER FÜR KRAFTFAHRZEUGE,,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RUEDA ROBERTO,,https://lens.org/010-595-959-949-004,Granted Patent,no,0,0,5,5,0,B60R21/2176;;B60R21/2176,,,0,0,,,,INACTIVE
78,US,B2,US 7810840 B2,011-836-792-614-448,2010-10-12,2010,US 15173808 A,2008-05-08,EP 07381038 A,2007-05-10,Airbag with a venting regulation device,"An airbag for automotive vehicles with a gas venting regulation device assembled around a venting opening ( 11 ) comprising a first part ( 15 ) joined to the inflatable cushion ( 13 ) covering the venting opening ( 11 ), formed by an elastic area ( 31 ) and a non-elastic area ( 33 ) with a plurality of openings ( 17, 19 ) for the passage of gas; a second rigid part ( 21 ) joined to the inflatable cushion ( 13 ) and to the first part ( 15 ), with a projecting neck ( 23 ) forming a gas outlet mouth; and in which at least one part of the non-elastic area ( 33 ) is arranged such that when the first part ( 15 ) is deformed as a result of the internal pressure in the inflatable cushion during its deployment, the passage of gas through the openings ( 17 ) is completely or partially sealed by the projecting neck ( 23 ).",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2008-06-12),https://lens.org/011-836-792-614-448,Granted Patent,yes,9,5,6,6,0,B60R21/239;;B60R21/239,B60R21/239,280/739;;280/742;;280/743.1,1,0,,,"English Abstract of ES2,182,629, Mar. 1, 2003.",INACTIVE
79,EP,B1,EP 2008879 B1,162-133-209-468-581,2012-06-27,2012,EP 07380196 A,2007-06-29,EP 07380196 A,2007-06-29,Three-chamber adaptive side airbag,,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;DENYS ISABELLE,,https://lens.org/162-133-209-468-581,Granted Patent,yes,5,3,4,4,0,B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23324;;B60R2021/23382;;B60R21/23138;;B60R21/233;;B60R21/239;;B60R2021/23382;;B60R2021/23324,B60R21/231;;B60R21/233;;B60R21/2338;;B60R21/239,,0,0,,,,ACTIVE
80,WO,A4,WO 2011/128782 A4,083-764-580-140-756,2012-03-15,2012,IB 2011001292 W,2011-04-13,US 32378810 P,2010-04-13,COMPOSITIONS AND METHODS FOR TREATING TYPE II DIABETES AND RELATED DISORDERS,"The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.",ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,ROSADO JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,,https://lens.org/083-764-580-140-756,Patent Application,yes,0,0,7,7,0,A61K31/155;;A61K31/44;;A61K45/06;;A61P3/10;;A61K31/155;;A61K45/06;;A61K31/44,A01N33/02,,0,0,,,,PENDING
81,CO,A2,CO 6420389 A2,018-961-250-755-534,2012-04-16,2012,CO 11123616 A,2011-09-21,US 16011009 P,2009-03-13,COMPOSICIONES Y MÉTODOS PARA EL TRATAMIENTO Y PREVENCIÓN DE LA ENFERMEDAD CARDIOVASCULAR,"La presente invención está en el campo de la medicina, los productos farmacéuticos, nutracéuticos y cardiología. En un aspecto, la invención proporciona composiciones que comprenden enalapril y simvastatina para el uso en métodos para el tratamiento y/o prevención de enfermedades cardiovasculares, y el uso de dichas composiciones en la fabricación de productos para el tratamiento yo prevención. En otro aspecto, la invención proporciona métodos para el tratamiento y o prevención de enfermedades cardiovasculares utilizando composiciones que comprenden simvastatina enalapril y ácido acetilsalicílico. Las composiciones y los métodos de la invención son útiles en el tratamiento y prevención de la enfermedad cardiovascular en una variedad de animales, particularmente los humanos.",NUCITEC SA DE CV,DUARTE VASQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/018-961-250-755-534,Patent Application,no,0,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A01N37/02,,0,0,,,,DISCONTINUED
82,WO,A1,WO 2010/103384 A1,084-732-900-558-124,2010-09-16,2010,IB 2010000506 W,2010-03-10,US 16011009 P,2009-03-13,COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE,"The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.",NUCITEC SA DE CV;;DUARTE-VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,DUARTE-VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/084-732-900-558-124,Patent Application,yes,1,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A01N37/02,,1,0,,,See also references of EP 2405747A4,PENDING
83,WO,A1,WO 2006/033568 A1,158-802-935-956-222,2006-03-30,2006,MX 2005000057 W,2005-07-18,MX PA04009236 A,2004-09-23,SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DIABETES AND THE COMORBIDITES THEREOF,"The invention relates to the pharmaceutical industry in general and to the industry involved in the manufacture of pharmaceutical products for the treatment of diabetes and the comorbidites thereof. The invention is advantageous over prior art compositions in that it enables long-term management of diabetic symptoms in order to maintain adequate glycaemic control, such as to produce a more powerful effect in relation to hyperglycaemia, thereby enabling a reduction in doses and, consequently, the individual collateral effects of the drugs utilised. In addition, the inventive composition improves insulin sensitivity of pancreatic beta receptors, simultaneously correcting insulin secretion disorders, and stimulates lipid metabolism, thereby improving the profile of same in the blood plasma. The composition is formed by a hypoglycaemic agent, glimepiride, and an anti-hypoglycaemic agent, pioglitazone. The composition contains between 5 and 2,500 mg pioglitazone and between 1 and 250 mg glimepiride.",ROSADO LORIA JORGE LUIS;;DUARTE VASQUEZ MIGUEL ANGEL,ROSADO LORIA JORGE LUIS;;DUARTE VASQUEZ MIGUEL ANGEL,,https://lens.org/158-802-935-956-222,Patent Application,yes,2,0,2,2,0,A61K31/4439;;A61K31/64;;A61P3/10,A61K31/64;;A61K31/4439;;A61P3/10,,1,1,006-474-805-273-333,14693980;;10.2337/diacare.27.1.141,"HANEFELD M. ET AL: ""One-year glysemic conrol with a sulfonylurea plus pioglitozone versus a sulfonylurea plus metformin inpatients with type 2 diabetes"", DIABETES CARE, vol. 27, no. 1, 2004, pages 141 - 147",PENDING
84,US,A1,US 2013/0189398 A1,021-610-635-445-506,2013-07-25,2013,US 201213559195 A,2012-07-26,MX 2011007872 A,2011-07-26,"Nutritional Composition for Children with Reflux, Colic and/or Constipation","The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.",ROSADO LORIA JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL;;NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,NUCITEC S.A. DE C.V (2012-08-24),https://lens.org/021-610-635-445-506,Patent Application,yes,5,26,8,8,0,A23L33/40;;A23L33/40;;A23L33/40,A23L33/00,426/71;;426/590;;426/580;;426/72;;426/73;;426/74;;426/588,4,3,081-435-827-020-52X;;035-974-149-419-535;;085-583-199-088-186,10.1038/sj.ejcn.1602848;;17657228;;16254515;;10.1097/01.mpg.0000187817.38836.42;;10.1097/00005176-200402000-00013;;14734879,"Davis et al. ""Alpha-Lactalbumin-rich infant formula fed to healthy term infants in a nulticenter study: plasma essential amino acids and gastrointestinal tolerance"" in Europena Journal of Clinical Nutrition (2008), 62, p. 1294-1301.;;Brizee (""Summary of Formulas used for Nutritional Support of Infants"" - www. courses.washington.edu/nutri526/news/Infant_Formulas_05.doc, updated June 2004).;;Koletzko et al. ""Global Standards for the Composition of Infant Formula: Recommendations of an ESPGHAN Coordinated International Expert Group"" - in Journal of Pediatric Gastroenterology and Nutrition, Vol. 41, No. 5, November 2005, p. 584-599.;;Lien et al. ""Growth and Safety in Term Infants Fed Reduced-Protein Formula with Added Bovine alpha-Lactalbumin"" in Journal of Pediatric Gastroenterology and Nutrition (2004), 38, p. 170-176",ACTIVE
85,CL,A1,CL 2015000599 A1,105-021-811-465-443,2015-11-27,2015,CL 2015000599 A,2015-03-11,MX 2012010488 A,2012-09-11,"Fórmula infantil para el óptimo crecimiento, protección gastrointestinal y protección inmunológica de infantes.",,NUCITEC SA DE CV,DUARTE VASQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/105-021-811-465-443,Patent Application,no,0,0,4,4,0,A61K31/702;;A61K31/702;;A23L33/10;;A23L33/10;;A23L33/12;;A23L33/12;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/155;;A23L33/155;;A23L33/16;;A23L33/16;;A23L33/175;;A23L33/175;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2200/30;;A23V2200/30;;A61K31/047;;A61K31/047;;A61K31/07;;A61K31/07;;A61K31/122;;A61K31/122;;A61K31/14;;A61K31/14;;A61K31/185;;A61K31/185;;A61K31/197;;A61K31/197;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/205;;A61K31/205;;A61K31/355;;A61K31/355;;A61K31/375;;A61K31/375;;A61K31/4415;;A61K31/4415;;A61K31/455;;A61K31/455;;A61K31/51;;A61K31/51;;A61K31/525;;A61K31/525;;A61K31/7016;;A61K31/7016;;A61K31/7068;;A61K31/7068;;A61K31/7072;;A61K31/7072;;A61K31/7076;;A61K31/7076;;A61K31/708;;A61K31/708;;A61K31/714;;A61K31/714;;A61K38/018;;A61K38/018;;A61K38/1709;;A61K38/1709;;A61K38/38;;A61K38/38;;A61K45/06;;A61K45/06,A23C21/06;;A23C9/00;;A23C9/152;;A23C9/16;;A23L33/00;;A23L33/15;;A23L33/155,,0,0,,,,PENDING
86,WO,A1,WO 2014/042504 A1,103-288-726-918-778,2014-03-20,2014,MX 2013000058 W,2013-05-02,MX 2012010487 A,2012-09-11,COMPOSITION OF NUTRIENTS AND BIOACTIVE SUBSTANCES WHICH PROMOTE GROWTH AND REDUCE INTOLERANCE AND SIDE EFFECTS IN PREMATURE INFANTS,"The invention relates to the production of a nutritional formula intended to be fed to preterm infants. The formula comprises a mixture of casein; whey protein; alpha-lactalbumin; A2 beta-casein protein, lactose; palmitic acid in the beta position; indigestible oligosaccharides; long-chain polyunsaturated fatty acid (LC PUFAS); nucleotides; vitamins and minerals; inositol, choline, taurine and carnitine in sufficient concentrations to satisfy the nutritional requirements of premature infants, as well as being better tolerated.",NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL,,https://lens.org/103-288-726-918-778,Patent Application,yes,5,2,4,4,0,A23L5/00;;A23L5/00;;A23L29/30;;A23L29/30;;A23L33/10;;A23L33/10;;A23L33/115;;A23L33/115;;A23L33/12;;A23L33/12;;A23L33/125;;A23L33/125;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00;;A23V2200/00;;A23V2200/00,A23C9/00;;A23C9/152;;A23C9/16;;A23C21/06;;A23L1/30;;A23L33/00;;A23L33/15;;A23L33/155,,0,0,,,,PENDING
87,US,A1,US 2010/0234442 A1,077-811-734-628-490,2010-09-16,2010,US 72325210 A,2010-03-12,US 72325210 A;;US 16011009 P,2009-03-13,Compositions and Methods for Treatment and Prevention of Cardiovascular Disease,"The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.",NUCITEC SA DE CV,DUARTE-VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/077-811-734-628-490,Patent Application,yes,25,13,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A61K31/40;;A61P9/00,514/423,0,0,,,,DISCONTINUED
88,MX,A,MX 2014015971 A,151-256-281-395-250,2016-06-20,2016,MX 2014015971 A,2014-12-19,MX 2014015971 A,2014-12-19,LIPID ENCAPSULATION PROCESS BY SPRAY DRYING FOR USE IN CHILDREN SPECIALIZED FORMULATIONS.,"The present disclosure is related to the food industry in general, and to the manufacturing of food formulations for infants with special requirements. The advantages of the present invention with respect of state-of-the-art compositions, lies in that the present invention allows having lipid micro and nano-capsules of interest in infant nutrition with increased stability; furthermore, since the present invention is a protein-free formulation, it is useful in the development of specialized infant formulations such as those used for feeding infants showing cow's milk protein allergy or multiple food allergy. The capsules are formed by a wall and a core material (lipid). The wall material is formed by a combination of maltodextrin / modified starch in a ratio of 1:1. The preferred wall material-core material ratio is 1:3 and the micro and the nano-capsules are obtained by spay drying.",GENECORP S A DE C V,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/151-256-281-395-250,Patent Application,no,0,0,1,1,0,,A23P10/35;;A23P20/00,,0,0,,,,PENDING
89,WO,A1,WO 2006/046847 A1,185-585-076-830-859,2006-05-04,2006,MX 2005000058 W,2005-07-18,MX PA04010692 A,2004-10-28,COMPOSITION FOR THE TREATMENT OF OBESITY AND HYPERLIPIDAEMIA,"The invention relates to the pharmaceutical industry and, more specifically, the industry involved in the manufacture of pharmaceutical products used to reduce weight and to treat hyperlipidaemia. The invention is advantageous over similar existing compositions in that it eliminates the collateral effects normally caused by ingestion of a lipase inhibitor. According to the invention, both the lipase inhibitor component and the fat-trapper are optimised, using a suitable composition for, and very small quantities of each of the components. The invention relates to a composition for the treatment of obesity and hyperlipidaemia, which is characterised in that it combines a lipase inhibitor and a fat-trapper compound.",ROSADO LORIA JORGE LUIS;;DUARTE VASQUEZ MIGUEL ANGEL,ROSADO LORIA JORGE LUIS;;DUARTE VASQUEZ MIGUEL ANGEL,,https://lens.org/185-585-076-830-859,Patent Application,yes,2,1,5,5,0,A61K31/722;;A61K38/17;;A61P3/04;;A61P3/06;;A61K38/17;;A61K31/722,A61K31/722;;A61K38/00,,0,0,,,,PENDING
90,PE,A1,PE 20120647 A1,143-014-788-257-859,2012-05-31,2012,PE 2011001641 A,2010-03-10,US 16011009 P,2009-03-13,COMPOSICIONES Y METODOS PARA EL TRATAMIENTO Y PREVENCION DE LA ENFERMEDAD CARDIOVASCULAR,"REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) AGENTE REDUCTOR DE COLESTEROL TAL COMO SIMVASTATINA ENTRE 5-140mg; B) UN INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA TAL COMO ENALAPRIL DE 1-80 mg; C) UN ANTIAGREGANTE PLAQUETARIO TAL COMO ACIDO ACETILSALICILICO DE 20-50 mg. DICHA COMPOSICION FARMACEUTICA ES DE ADMINISTRACION ORAL EN FORMA DE CAPSULA, TABLETA, POLVO DISPERSABLE EN AGUA O BEBIDAS Y ES UTIL EN LA PREVENCION DE ENFERMEDADES CARDIOVASULARES",NUCITEC SA DE CV,DUARTE-VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/143-014-788-257-859,Patent Application,no,0,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A01N37/02,,0,0,,,,DISCONTINUED
91,MX,A,MX 2012010487 A,159-298-422-013-444,2014-03-26,2014,MX 2012010487 A,2012-09-11,MX 2012010487 A,2012-09-11,COMPOSITION OF NUTRIENTS AND BIOACTIVE SUBSTANCES WHICH PROMOTE GROWTH AND REDUCE INTOLERANCE AND SIDE EFFECTS IN PREMATURE INFANTS.,"The invention relates to the production of a nutritional formula intended to be fed to preterm infants. The formula comprises a mixture of casein; whey protein; alpha-lactalbumin; A2 beta-casein protein, lactose; palmitic acid in the beta position; indigestible oligosaccharides; long-chain polyunsaturated fatty acid (LC PUFAS); nucleotides; vitamins and minerals; inositol, choline, taurine and carnitine in sufficient concentrations to satisfy the nutritional requirements of premature infants, as well as being better tolerated.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VÁZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/159-298-422-013-444,Patent Application,no,0,0,4,4,0,A23L5/00;;A23L5/00;;A23L29/30;;A23L29/30;;A23L33/10;;A23L33/10;;A23L33/115;;A23L33/115;;A23L33/12;;A23L33/12;;A23L33/125;;A23L33/125;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00;;A23V2200/00;;A23V2200/00,A23L1/00;;A23L33/00;;A23L33/15;;A23L33/155,,0,0,,,,PENDING
92,MX,A,MX 2012010488 A,165-677-135-122-821,2014-03-26,2014,MX 2012010488 A,2012-09-11,MX 2012010488 A,2012-09-11,"INFANT FORMULA FOR OPTIMAL GROWTH, GASTROINTESTINAL PROTECTION AND IMMUNOLOGICAL PROTECTION OF INFANTS.","The invention relates to formula for children of between 0 and 36 months, for reducing intolerance problems associated to the consumption of the state-of-the-art infant formulas.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VÁZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/165-677-135-122-821,Patent Application,no,0,1,4,4,0,A61K31/702;;A61K31/702;;A23L33/10;;A23L33/10;;A23L33/12;;A23L33/12;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/155;;A23L33/155;;A23L33/16;;A23L33/16;;A23L33/175;;A23L33/175;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2200/30;;A23V2200/30;;A61K31/047;;A61K31/047;;A61K31/07;;A61K31/07;;A61K31/122;;A61K31/122;;A61K31/14;;A61K31/14;;A61K31/185;;A61K31/185;;A61K31/197;;A61K31/197;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/205;;A61K31/205;;A61K31/355;;A61K31/355;;A61K31/375;;A61K31/375;;A61K31/4415;;A61K31/4415;;A61K31/455;;A61K31/455;;A61K31/51;;A61K31/51;;A61K31/525;;A61K31/525;;A61K31/7016;;A61K31/7016;;A61K31/7068;;A61K31/7068;;A61K31/7072;;A61K31/7072;;A61K31/7076;;A61K31/7076;;A61K31/708;;A61K31/708;;A61K31/714;;A61K31/714;;A61K38/018;;A61K38/018;;A61K38/1709;;A61K38/1709;;A61K38/38;;A61K38/38;;A61K45/06;;A61K45/06,A23L1/00;;A23L33/00;;A23L33/15;;A23L33/155,,0,0,,,,DISCONTINUED
93,MX,A,MX 2011009587 A,053-366-720-480-567,2011-10-13,2011,MX 2011009587 A,2010-03-10,US 16011009 P;;IB 2010000506 W,2009-03-13,COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE.,"The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/053-366-720-480-567,Patent Application,no,0,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A01N37/02,,0,0,,,,ACTIVE
94,BR,A,BR PI0516889 A,097-002-297-934-013,2008-09-23,2008,BR PI0516889 A,2005-07-18,MX PA04010692 A;;MX 2005000058 W,2004-10-28,composição para o tratamento da obesidade e hiperlipidemia,"COMPOSIçãO PARA O TRATAMENTO DA OBESIDADE E HIPERLIPIDEMIA. Onde a composição farmacêutica da presente invenção reduz a absorção de gordura proveniente da dieta através da inibição da enzima lipase gastrintestinal. Os inibidores utilizados são a polilisina e a protamina, ambas moléculas carregadas positivamente e têm a capacidade de interagir com o substrato emulsificado e impedir a absorção da enzima na interfase inibindo desta forma sua atividade. A combinação do inibidor de lipase com o polímero coletor de gordura (quitosano), aumenta o efeito inibidor da absorção de gordura, tal efeito sinérgico é atribuído à aceleração do trânsito gastrintestinal do alimento produzido pelo polímero insolúvel.",LORIA JORGE LUIS ROSADO,LORIA JORGE LUIS ROSADO;;VASQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/097-002-297-934-013,Patent Application,no,0,0,5,5,0,A61K31/722;;A61K38/17;;A61P3/04;;A61P3/06;;A61K38/17;;A61K31/722,A61K31/722;;A61K38/00,,0,0,,,,DISCONTINUED
95,MX,A,MX 2016017077 A,095-857-572-658-799,2018-06-18,2018,MX 2016017077 A,2016-12-19,MX 2016017077 A,2016-12-19,PROCESS FOR THE PREPARATION OF AN IS-UDMA BIOBASED MONOMER AND ITS USE IN THE DEVELOPMENT OF DENTAL FORMULATIONS BASED ON IS-UDMA AND BIS-GMA WITH ANTI-SHRINK AND LOW MICROFILTRATION PROPERTIES FOR APPLICATION IN DENTAL RESTORATIONS.,"The present invention relates to the process of preparation and use of the urethane dimethyl acrylate monomer of isosorbide (Is-UDMA) in a copolymer formed by two acrylic monomers that are Is-UDMA and Bis-GMA, for obtaining properties with synergistic effect for the development of new dental formulations. The Is-UDMA monomer is prepared in situ, by two synthesis phases and characterized by FTIR spectroscopy and proton nuclear magnetic resonance (+ HRMN) techniques. The dental formulations are prepared from different concentrations were used in weight percentage of the copolymer Is-UDMA / Bis-GMA (0/100) (25/75) (50/50) (75/75) and (100/0) respectively. The efficiency of the Is-UDMA / Bis-GMA copolymer as an organic matrix in the dental formulation is evaluated by conversion of double bonds (DC) by real-time photo-polymerization kinetics (RT-FTIR) by FTIR spectroscopy, viscoelastic properties, shrinkage or contraction and microfiltration in vitro, using premolar teeth. Some combination s achieve making the use of the two acrylic monomers more efficient since they proved to increase the final properties in the evaluated dental resins. Furthermore, in vitro microfiltration tests with dental organs showed that the formulations possess high synergistic potential as dental restorative materials.",CENTRO DE INVESTIGACION EN QUIM APLICADA,MARIA LYDIA BERLANGA DUARTE;;LUIS ALBERTO REYNA MEDINA,,https://lens.org/095-857-572-658-799,Patent Application,no,0,0,1,1,0,,A61K6/083;;A61K6/00,,0,0,,,,ACTIVE
96,US,A1,US 2011/0241713 A1,098-724-266-457-913,2011-10-06,2011,US 74962110 A,2010-03-30,US 74962110 A,2010-03-30,TEST STRUCTURE ACTIVATED BY PROBE NEEDLE,"A test structure ( 200 ) in an integrated circuit ( 100 ) includes a probe pad ( 210 ) disposed at a surface of a die ( 102 ) of the integrated circuit, a transmission gate ( 202 ) for connecting portions of an electronic circuit within the integrated circuit in response to a momentary signal applied to the probe pad, a first inverter ( 221 ) having an input coupled to the probe pad and having an output coupled to a control input of the transmission gate, and a second inverter ( 222 ) having an input coupled to an output of the first inverter and having an output coupled to another control input of the transmission gate. The output of the second inverter is coupled to the input of the first inverter. Upon power-up, the transmission gate is open. After the momentary signal is applied to the probe pad, the transmission gate closes and remains closed until power is disconnected.",FREESCALE SEMICONDUCTOR INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS,FREESCALE SEMICONDUCTOR INC (2010-03-29);;NXP USA INC (2016-11-07),https://lens.org/098-724-266-457-913,Patent Application,yes,2,15,4,4,0,G01R31/2884;;G01R31/2884;;G01R31/2896,G01R31/02;;G01R1/067;;G01R31/26,324/755.01;;324/762.02,0,0,,,,ACTIVE
97,US,A1,US 2015/0237902 A1,185-023-387-414-76X,2015-08-27,2015,US 201314427379 A,2013-05-02,MX 2012010488 A;;MX 2013000057 W,2012-09-11,"INFANT FORMULA FOR OPTIMAL GROWTH, GASTROINTESTINAL PROTECTION AND IMMUNOLOGICAL PROTECTION OF INFANTS","An infant formula specially designed for covering nutrition necessities of infants between 0 and 36 months of life is described, which reduces the intolerance problems related to the consumption of infant formulas currently found in the art.",NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE VÁZQUEZ MIGUEL ANGEL,NUCITEC S.A. DE C.V (2015-11-08),https://lens.org/185-023-387-414-76X,Patent Application,yes,1,37,4,4,0,A61K31/702;;A61K31/702;;A23L33/10;;A23L33/10;;A23L33/12;;A23L33/12;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/155;;A23L33/155;;A23L33/16;;A23L33/16;;A23L33/175;;A23L33/175;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2200/30;;A23V2200/30;;A61K31/047;;A61K31/047;;A61K31/07;;A61K31/07;;A61K31/122;;A61K31/122;;A61K31/14;;A61K31/14;;A61K31/185;;A61K31/185;;A61K31/197;;A61K31/197;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/205;;A61K31/205;;A61K31/355;;A61K31/355;;A61K31/375;;A61K31/375;;A61K31/4415;;A61K31/4415;;A61K31/455;;A61K31/455;;A61K31/51;;A61K31/51;;A61K31/525;;A61K31/525;;A61K31/7016;;A61K31/7016;;A61K31/7068;;A61K31/7068;;A61K31/7072;;A61K31/7072;;A61K31/7076;;A61K31/7076;;A61K31/708;;A61K31/708;;A61K31/714;;A61K31/714;;A61K38/018;;A61K38/018;;A61K38/1709;;A61K38/1709;;A61K38/38;;A61K38/38;;A61K45/06;;A61K45/06,A23L1/30;;A23L1/304;;A23L1/305;;A23L33/00;;A23L33/15;;A23L33/155;;A61K31/047;;A61K31/14;;A61K31/185;;A61K31/20;;A61K31/202;;A61K31/205;;A61K31/7016;;A61K31/702;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61K38/17;;A61K38/38;;A61K45/06,,6,4,038-501-245-371-913;;035-974-149-419-535;;011-949-502-854-656;;036-906-218-064-822,12032520;;10.1067/mpd.2002.123282;;16254515;;10.1097/01.mpg.0000187817.38836.42;;17255839;;10.1097/01.mpg.0000243435.54958.68;;10.1111/j.1541-4337.2007.00020.x,"Innis et al. (âDocosahexanoic acid and arachidonic acid enhance growth with no adverse effects in preterm infants fed formulaâ The Journal of Pediatrics 2002;140:547-54).;;Koletzko et al. (âGlobal Standard for the Composition of Infant Formula: Recommendations of an ESPGHAN Coordinated International Expert Group"" Journal of Pediatric Gastroenterology and Nutrition; 2005 41: 584-599).;;Lein et al. (""Infant formula with increased concentrationso of Î±-lactalbumin"" Am J Clin Nutr 2003:77(suppl):1555S-8S);;King et al. (Journal of Pediatric Gastroenterology and nutrition 2007, Vol. 44:245-251).;;Beate (US Whey products and child nutrition: US Dairy Export council, 2002);;Thompkinson et al. (""Aspects of Infant Formulation"" Comprehensive Reviews in Food Science and Food Safety; Vol. 6, 2007, p. 79).",DISCONTINUED
98,CA,A1,CA 2755543 A1,051-980-913-481-432,2010-09-16,2010,CA 2755543 A,2010-03-10,US 16011009 P;;IB 2010000506 W,2009-03-13,COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE,"The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or preven-tion. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compo-sitions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.",NUCITEC SA DE CV,DUARTE-VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/051-980-913-481-432,Patent Application,no,0,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A01N37/02,,0,0,,,,DISCONTINUED
99,EP,A1,EP 2405747 A1,199-799-247-662-186,2012-01-18,2012,EP 10750431 A,2010-03-10,IB 2010000506 W;;US 16011009 P,2009-03-13,COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE,,NUCITEC SA DE CV,DUARTE-VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/199-799-247-662-186,Patent Application,yes,0,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A01N37/02;;A61K31/366;;A61K31/40;;A61K31/616;;A61K45/06;;A61P9/00;;A61P9/12,,0,0,,,,DISCONTINUED
100,US,B2,US 9645196 B2,022-769-318-618-654,2017-05-09,2017,US 201213684840 A,2012-11-26,US 201213684840 A;;US 74962110 A,2010-03-30,Test structure activated by probe needle,"A test structure ( 200 ) in an integrated circuit ( 100 ) includes a probe pad ( 210 ) disposed at a surface of a die ( 102 ) of the integrated circuit, a transmission gate ( 202 ) for connecting portions of an electronic circuit within the integrated circuit in response to a momentary signal applied to the probe pad, a first inverter ( 221 ) having an input coupled to the probe pad and having an output coupled to a control input of the transmission gate, and a second inverter ( 222 ) having an input coupled to an output of the first inverter and having an output coupled to another control input of the transmission gate. The output of the second inverter is coupled to the input of the first inverter. Upon power-up, the transmission gate is open. After the momentary signal is applied to the probe pad, the transmission gate closes and remains closed until power is disconnected.",FREESCALE SEMICONDUCTOR INC;;NXP USA INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS,NXP USA INC (2012-11-21),https://lens.org/022-769-318-618-654,Granted Patent,yes,9,0,4,4,0,G01R31/2884;;G01R31/2884;;G01R31/2896,G01R31/26;;G01R31/28,,0,0,,,,ACTIVE
101,CL,A1,CL 2015000598 A1,020-366-223-892-07X,2015-11-27,2015,CL 2015000598 A,2015-03-11,MX 2012010487 A,2012-09-11,Composición de nutrimentos y sustancias bioactivas que favorecen el crecimiento y que disminuyen la intolerancia y los efectos adversos en infantes prematuros.,,NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL,,https://lens.org/020-366-223-892-07X,Patent Application,no,0,0,4,4,0,A23L5/00;;A23L5/00;;A23L29/30;;A23L29/30;;A23L33/10;;A23L33/10;;A23L33/115;;A23L33/115;;A23L33/12;;A23L33/12;;A23L33/125;;A23L33/125;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00;;A23V2200/00;;A23V2200/00,A23C21/06;;A23C9/00;;A23C9/152;;A23C9/16;;A23L33/00;;A23L33/15;;A23L33/155,,0,0,,,,PENDING
102,MX,A,MX 2019000483 A,025-236-084-014-440,2020-07-13,2020,MX 2019000483 A,2019-01-11,MX 2019000483 A,2019-01-11,METHOD FOR SELECTING BOVINE CATTLE FOR THE PRODUCTION OF COW'S MILK FREE OF BETACASEIN A1 AND ITS USE IN THE PREPARATION OF FOODS THAT STIMULATE MUSCLE RECOVERY IN ATHLETES.,"The present invention relates to the biotechnology industry and the specialized food manufacturing industry. It possesses the advantages of its ability to genotype cattle based on the CSN2 gene to identify and select the bulls and cows that carry the CSN2 A2/A2 genotype, to breed them, raise dairy cattle capable of producing BCAS A2 compound milk, and free from BCAS A1. Said milk is useful in the manufacture of supplements to promote muscle regeneration in athletes. The method includes the insertion of a point mutation in the codon, where the polymorphism of bovine BCAS A1 and BCAS A2 occurs, using a modified oligonucleotide. The CSR PCR product, which results from the amplification of CSN2 A2, has a restriction site for a specific endonuclease, which does not occur with the CSR PCR product of CSN2 A1. After amplification, the CSR PCR products are digested with the specific endonuclease and the restriction fragments are analyzed on a 1% agarose gel. The genotype of the animals is defi ned based on the pattern of the bands of the fragments, which result from the restriction enzymatic digestion.",NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE VÁZQUEZ MIGUEL ANGEL,,https://lens.org/025-236-084-014-440,Patent Application,no,0,0,1,1,0,,C12Q1/68;;A23C9/00;;A23C19/00;;A61P21/00;;C12Q1/683,,0,0,,,,PENDING
103,EP,A4,EP 2405747 A4,162-985-657-925-408,2013-01-16,2013,EP 10750431 A,2010-03-10,IB 2010000506 W;;US 16011009 P,2009-03-13,COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE,,NUCITEC SA DE CV,DUARTE-VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/162-985-657-925-408,Search Report,no,1,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A01N37/02;;A61K31/366;;A61K31/40;;A61K31/616;;A61K45/06;;A61P9/00;;A61P9/12,,3,1,004-693-374-687-565,10.1038/ncpcardio1419;;19104519,"ANONYMOUS: ""Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases"", 13 August 2008 (2008-08-13), XP002688782, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00734123/2008_08_13> [retrieved on 20121206];;GINÉS SANZ ET AL: ""Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population"", NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, vol. 6, no. 2, 23 December 2008 (2008-12-23), pages 101 - 110, XP055046981, ISSN: 1743-4297, DOI: 10.1038/ncpcardio1419;;See also references of WO 2010103384A1",DISCONTINUED
104,AR,A1,AR 087333 A1,112-764-979-669-870,2014-03-19,2014,AR P120102713 A,2012-07-26,MX 2011007872 A,2011-07-26,"COMPOSICION NUTRIMENTAL PARA NIÑOS QUE PRESENTAN REFLUJO, COLICO Y/O ESTREÑIMIENTO","Una fórmula infantil especialmente diseñada para disminuir los episodios de regurgitación, cólico y estreñimiento, que se presentan en infantes alimentados con fórmulas lácteas sustitutas de la leche materna.Reivindicación 2: La composición de la reivindicación 1, caracterizada porque comprende caseína; proteína de suero de leche; a-lactoalbúmina. proteína b-caseina A1 y A2, lactosa; un agente espesante seleccionado de entre, almidón de maíz, almidón de papa, goma xantana, goma de algarrobo, carboximetilcelulosa, entre otros; ácido palmítico; oligosacáridos no digeribles; ácido grasos poliinsaturado de cadena larga (LC PUFAS); nucleótidos; vitaminas y minerales; inositol; colina, taurina; y carnitina.",NUCITEC SA DE CV,DUARTE VAZQUEZ MIGUEL ANGEL;;ROSADO LORIA JORGE LUIS,,https://lens.org/112-764-979-669-870,Patent Application,no,0,0,8,8,0,A23L33/40;;A23L33/40;;A23L33/40,A23C9/00;;A23L1/30;;A23L33/00,,0,0,,,,ACTIVE
105,MX,A,MX 2014015970 A,123-636-838-478-176,2016-06-20,2016,MX 2014015970 A,2014-12-19,MX 2014015970 A,2014-12-19,SYNERGISTIC COMPOSITION OF AN ANTIDIABETIC AGENT AND AN ANTIOXIDANT FOR THE TREATMENT OF DIABETES AND MICRO AND MACRO-VASCULAR COMPLICATIONS THEREOF.,"The present disclosure is related to the pharmaceutical industry in general and the pharmaceutical manufacturing industry for the treatment of diabetes and its complications. The advantages of the present invention with respect to state-of-the-art compositions, lies in that the present invention allows reducing both glycemia and micro and macro-vascular complications of the disease which are responsible in most cases of premature deaths from diabetes. The composition is formed by an antidiabetic and an antioxidant agent. The antidiabetic agent is metformin, while the antioxidant agent is Resveratrol. The metformin is present in the composition in an amount between 500 - 3000 mg, while resveratrol in an amount between 100 - 3000 mg. The combination may have any physical or pharmaceutical form.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/123-636-838-478-176,Patent Application,no,0,0,1,1,0,,A61K31/155;;A61K31/045;;A61K31/05;;A61P3/10,,0,0,,,,PENDING
106,MX,A,MX 2011001866 A,138-256-670-431-701,2012-08-29,2012,MX 2011001866 A,2011-02-18,MX 2011001866 A,2011-02-18,APPETITE SUPPRESSANT COMPOSITION FOR TREATING OBESITY AND REDUCING THE RISK OF CARDIOVASCULAR DISEASE.,"Described is a food formula used as a partial substitute of food in obese or overweight subjects. It is a food supplement added with 26 vitamins and minerals, designed specially for people who require losing or maintaining a healthy weight. The supplement provides nutriments that have been identified with deficit in obese or overweight populations, which inclusion in the diet is beneficial and avoids fat deposition. In addition, the invention contains antioxidants that reduce the oxidation of serum lipoproteins and a soluble fibre which helps to reduce the levels of triglycerides and lipoproteins of high density, thus improving the cardiovascular health. Some additional benefits include the reduction of the plasmatic homocysteine due to the addition of folic acid. The composition comprises a natural appetite suppressor, which helps to avoid the consumption of food between meals. The composition may be used in control weight programs, also providing additional benefits in diseases clos ely related to obesity such as diabetes, insulin resistance, dyslipidemia and cardiovascular disease.",LORIA JORGE LUIS ROSADO,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/138-256-670-431-701,Patent Application,no,0,0,1,1,0,,A23L1/308;;A23L1/30;;A23L1/304;;A23L33/00;;A23L33/15;;A23L33/20,,0,0,,,,PENDING
107,BR,U,BR 7903031 U,163-114-068-674-092,2001-07-31,2001,BR 7903031 U,1999-12-24,BR 7903031 U,1999-12-24,Amplificador de forças,"<B>AMPLIFICADOR DE FORçAS<D> é descrito um amplificador de forças acoplável a um equipamento de ensaios mecânicos (dinamómetro). Mais especificamente, a presente invenção refere-se a um equipamento para magnificar a força num sistema de pistões através da aplicação do princípio de Pascal de modo que a força aplicada no pistão primário (menor diâmetro) é multiplicada no pistão secundário (maior diâmetro) através da pressão transmitida por um fluido hidráulico.",OPP PETROQUIMICA S A;;UNIV FED DO RIO GRANDE DO SUL,TOKUMOTO SHINICHI;;SAMIOS DIMITRIOS;;BRAGANCA ANTONIO LUIS DUARTE,UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL (BR/RS) (2006-11-14),https://lens.org/163-114-068-674-092,Patent Application,no,0,1,2,2,0,,G01L3/00,,0,0,,,,EXPIRED
108,CL,A1,CL 2011002265 A1,169-576-583-053-930,2012-07-06,2012,CL 2011002265 A,2011-09-13,US 16011009 P,2009-03-13,"Composicion farmaceutica que comprende simvastatina, enalapril y acido acetilsalicilico; uso para prevenir y tratar enfermedades cardiovasculares.",Composición farmacéutica que comprende simvastatina en alapril y ácido acetilsalicílico; uso de la composición farmacéutica para tratar o prevenir enfermedades cardiovasculares tales como hipercolesterolemia o hipertensión.,NUCITEC SA DE CV,DUARTE VAZQUEZ MIGUEL ANGEL ROSADO LORIA JORGE LUIS,,https://lens.org/169-576-583-053-930,Patent Application,no,0,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A61K9/08;;A61K9/10;;A61K9/20;;A61K9/48;;A61P9/10;;A61P9/12,,0,0,,,,PENDING
109,US,B2,US 9591872 B2,032-255-496-900-534,2017-03-14,2017,US 201213559195 A,2012-07-26,MX 2011007872 A,2011-07-26,"Nutritional composition for children with reflux, colic and/or constipation","The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.",ROSADO LORIA JORGE LUIS;;DUARTE-VÁZQUEZ MIGUEL ANGEL;;NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE-VÁZQUEZ MIGUEL ANGEL,NUCITEC S.A. DE C.V (2012-08-24),https://lens.org/032-255-496-900-534,Granted Patent,yes,14,6,8,8,0,A23L33/40;;A23L33/40;;A23L33/40,A23L33/10;;A23L33/00,,14,13,081-435-827-020-52X;;035-974-149-419-535;;085-583-199-088-186;;115-036-118-516-374;;077-713-808-894-371;;034-937-692-057-610;;063-152-579-347-263;;008-290-442-310-858;;005-856-878-522-49X;;016-641-650-718-825;;010-240-897-401-98X;;078-476-853-361-670;;127-804-547-164-703,10.1038/sj.ejcn.1602848;;17657228;;16254515;;10.1097/01.mpg.0000187817.38836.42;;10.1097/00005176-200402000-00013;;14734879;;3575022;;10.1016/j.jpeds.2007.06.014;;18035136;;10.1542/peds.2005-1543;;16390920;;10634302;;10.1097/00005176-200001001-00011;;2288394;;10.1111/j.1398-9995.1990.tb00944.x;;10.1080/080352500750028997;;10677051;;11099588;;10.1542/peds.106.6.1349;;16736065;;10.1038/sj.ejcn.1602457;;10.1007/bf01955238;;8404966;;10.1016/s0016-5085(01)80241-9,"Davis et al. ""Alpha-Lactalbumin-rich infant formula fed to healthy term infants in a nulticenter study: plasma essential amino acids and gastrointestinal tolerance"" in Europena Journal of Clinical Nutrition (2008), 62, p. 1294-1301.;;Brizee (""Summary of Formulas used for Nutritional Support of Infants""-www.courses.washington.edu/nutri526/news/Infant-Formulas-05.doc, updated Jun. 2004).;;Koletzko et al. ""Global Standards for the Composition of Infant Formula: Recommendations of an ESPGHAN Coordinated International Expert Group""-in Journal of Pediatric Gastroenterology and Nutrition, vol. 41, No. 5, Nov. 2005, p. 584-599.;;Lien et al. ""Growth and Safety in Term Infants Fed Reduced-Protein Formula with Added Bovine alpha-Lactalbumin"" in Journal of Pediatric Gastroenterology and Nutrition (2004), 38, p. 170-176.;;Bock, ""Prospective Appraisal of Complaints of Adverse Reactions to Foods in Children During the First 3 Years of Life,"" Pediatrics 79(5):683-688, American Academy of Pediatrics, United States (1987).;;Corvaglia, L., et al., ""The Effect of Body Positioning on Gastroesophageal Reflux in Premature Infants: Evaluation by Combined Impedance and pH Monitoring,""J Pediatr 151: 591-596, Mosby Inc., United States (2007).;;Guillet, R., et al., ""Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,"" Pediatrics 117(2):e137-e142, American Academy of Pediatrics, United States (2006).;;Hill, D.J. and Hosking, C.S., ""Infantile Colic and Food Hypersensitivity,"" Journal of Pediatric Gastroenterology and Nutrition 30:S67-S76, Lippincott Williams & Wilkins, Inc., United States (2000).;;Høst, A. and Halken, S., ""A prospective study of cow milk allergy in Danish infants during the first 3 years of life,"" Allergy 45:587-596, Wiley-Blackwell, Denmark (1990).;;Jakobsson, I., et al., ""Effectiveness of casein hydrolysate feedings in infants with colic,"" Acta Pædiatr 89:18-21, Scandinavian University Press, Norway (2000).;;Lucassen, P.L.B.J., et al., ""Infantile Colic: Crying Time Reduction With a Whey Hydrolysate: A Double-Blind, Randomized, Placebo-Controlled Trial,"" Pediatrics 106(6):1349-1354, American Academy of Pediatrics, United States (2000).;;Savino, F., et al., ""Reduction of crying episodes owing to infantile colic: a randomized controlled study on the efficacy of a new infant formula,"" European Journal of Clinical Nutrition 60:1304-1310, Nature Publishing Group, England (2006).;;Schrander, J.J.P., et al., ""Cow's milk protein intolerance in infants under 1 year of age: a prospective epidemiological study,"" Eur J Pediatr 152:640-644, Springer-Verlag, Germany (1993).;;Shalaby, T.M. and Orenstein, S.R., ""Efficacy of Conservative Therapy in Infants with Gastroesophageal Reflux Disease Referred by Pediatricians to Pediatric Gastroenterologists,"" Gastroenterology 120(5), Supplement 1:A49, 254, Elsevier Inc., United States (2001).",ACTIVE
110,AR,A1,AR 088069 A1,094-516-001-958-307,2014-05-07,2014,AR P120103580 A,2012-09-27,MX 2011010299 A,2011-09-29,FORMULA INFANTIL A BASE DE PROTEINA DE ARROZ EXTENSAMENTE HIDROLIZADA PARA SU USO EN LA ALIMENTACION DE INFANTES CON ALERGIA ALIMENTICIA,"Se desarrolló una fórmula infantil especialmente diseñada para infantes con antecedentes de alergia a las proteínas de la leche de vaca, que se presenta en infantes que se alimentan con fórmulas lácteas sustitutos de la leche materna. Además por su composición es más efectiva para atender el problema de alergia a las proteínas, contiene sustancias que sustentan un adecuado desarrollo físico y mental del infante. Reivindicación 2: La composición de la reivindicación 1, caracterizada porque comprende proteína de arroz extensamente hidrolizada; azúcar, almidón de maíz, almidón de arroz, maltodextrina, oligosacáridos no digeribles; ácido grasos poliinsaturado de cadena larga (LC PUFAS); nucleótidos; vitaminas y minerales; inositol; colina, taurina; y carnitina.",NUCITEC SA DE CV,JORGE LUIS ROSADO LORIA;;MIGUEL ANGEL DUARTE VAZQUEZ,,https://lens.org/094-516-001-958-307,Patent Application,no,0,0,4,4,0,A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00,A23L33/00,,0,0,,,,PENDING
111,BR,A2,BR 102020003036 A2,178-501-070-465-446,2021-08-03,2021,BR 102020003036 A,2020-02-13,BR 102020003036 A,2020-02-13,aperfeiçoamentos em perfil condutor de água de infiltrações de túneis subterrâneos e respectivo método de aplicação,"aperfeiçoamentos em perfil condutor de água de infiltrações de túneis subterrâneos e respectivo método de aplicação. trata-se de um perfil condutor (10) do tipo aplicado em construções como galerias, túneis (t) e outros para condução da água derivada de infiltrações (if) do lençol freático ou similar e que recepciona camadas de material (cm) para impermeabilização da superfície (t1) no qual foi instalado os perfis (10); bem como, os aperfeiçoamentos são baseados em método de aplicação (30) do tipo que contempla sequência de aplicação (sa) compreendida por: (s1) limpeza da superfície do terreno do túnel ou outra área de instalação similar, já providos de primeira camada de concreto projetado (32) aplicado sobre a pedra (31); (s2) instalação dos drenos e (s4) aplicação de concreto projetado; dito perfil (10) compreende um formato de dreno (20) para captação e condução da água (ag) derivada da infiltração (if) por canais verticais (22c) e prevê método de aplicação (30) de camada de argamassa polimérica (33) sobre os drenos (20) e demais áreas da superfície de aplicação.",CASSIO LUIS ABEID MOURA;;JOAO DUARTE GUIMARAES FILHO,CASSIO LUIS ABEID MOURA;;JOÃO DUARTE GUIMARÃES FILHO,,https://lens.org/178-501-070-465-446,Patent Application,no,0,0,1,1,0,E21F16/02;;E21D11/38,E21D11/38;;E21F16/02,,0,0,,,,DISCONTINUED
112,MX,A,MX 2011010299 A,035-901-457-616-437,2013-03-29,2013,MX 2011010299 A,2011-09-29,MX 2011010299 A,2011-09-29,EXTENSIVELY HYDROLYZED RICE PROTEIN-BASED INFANT FORMULA AND USE IN FEEDING INFANTS WITH FOOD ALLERGIES.,"An infant formula was developed. This formula was specially designed for infants with history of allergy to cow's milk proteins, which normally occurs in infants fed with infant formula. The invention represents a novelty, because in addition to its unique composition, the formula of the invention is more effective than the formulas commonly used to address the problem of protein allergy, and also it contains substances that support a proper physical and mental development of the infant.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/035-901-457-616-437,Patent Application,no,0,0,4,4,0,A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00,A23L1/00;;A23L33/00,,0,0,,,,DISCONTINUED
113,US,A1,US 2013/0082726 A1,121-170-879-267-063,2013-04-04,2013,US 201213684840 A,2012-11-26,US 201213684840 A;;US 74962110 A,2010-03-30,TEST STRUCTURE ACTIVATED BY PROBE NEEDLE,"A test structure ( 200 ) in an integrated circuit ( 100 ) includes a probe pad ( 210 ) disposed at a surface of a die ( 102 ) of the integrated circuit, a transmission gate ( 202 ) for connecting portions of an electronic circuit within the integrated circuit in response to a momentary signal applied to the probe pad, a first inverter ( 221 ) having an input coupled to the probe pad and having an output coupled to a control input of the transmission gate, and a second inverter ( 222 ) having an input coupled to an output of the first inverter and having an output coupled to another control input of the transmission gate. The output of the second inverter is coupled to the input of the first inverter. Upon power-up, the transmission gate is open. After the momentary signal is applied to the probe pad, the transmission gate closes and remains closed until power is disconnected.",FREESCALE SEMICONDUCTOR INC;;FREESCALE SEMICONDUCTOR INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS,NXP USA INC (2012-11-21),https://lens.org/121-170-879-267-063,Patent Application,yes,2,0,4,4,0,G01R31/2884;;G01R31/2884;;G01R31/2896,G01R31/28,324/750.3,0,0,,,,ACTIVE
114,ES,T3,ES 2351860 T3,097-988-832-488-881,2011-02-11,2011,ES 07381037 T,2007-05-09,EP 07381037 A,2007-05-09,AIRBAG LATERAL CON UN DISPOSITIVO DE VENTILACION ADAPTATIVO.,"The present invention relates to a side airbag for an automotive vehicle comprising a venting regulation device formed by a part made of a flexible material (21) joined to the inflatable cushion (11) such that it can completely or partially close or free the venting opening (17), and a tension belt (23) joined by one part to said part made of a flexible material (21) and by another part to the inflatable cushion (11), the geometric configurations of said tension belt (23) and said part made of a flexible material (21) being determined such that the degree of closing/freeing of the venting opening (17) varies according to the width of the inflatable cushion (11) during its different deployment phases during the collision, being closed in the initial and end phases and freed in the intermediate phase.",DALPHI METAL ESPANA SA,DENYS ISABELLE;;DUARTE DE AREZ LUIS JOSE OEC,,https://lens.org/097-988-832-488-881,Granted Patent,no,0,0,7,7,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R21/239;;B60R21/2338;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
115,US,A1,US 2013/0115336 A1,141-362-935-340-344,2013-05-09,2013,US 201213630911 A,2012-09-28,MX 2011010299 A,2011-09-29,Extensively Hydrolyzed Rice Protein-Based Infant Formula and Use in Feeding Infants with Food Allergies,"An infant formula was developed. This formula was specially designed for infants with history of allergy to cow's milk proteins, Which normally occurs in infants fed with infant formula. The invention represents a novelty, because in addition to its unique composition, the formula of the invention is more effective than the formulas commonly used to address the problem of protein allergy, and also it contains substances that support a proper physical and mental development of the infant.",ROSADO LORIA JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL;;NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE-VAZQUEZ MIGUEL ANGEL,NUCITEC S.A. DE C.V (2013-01-08),https://lens.org/141-362-935-340-344,Patent Application,yes,2,6,4,4,0,A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00,A23L33/00,426/71;;426/590;;426/72;;426/598;;426/73,1,1,067-613-250-318-170,10.1111/j.1399-3038.2010.00991.x;;pmc2904490;;20337976,"Reche, M. et al. 2010 ""The effect of a partially hydrolysed formula based on rice protein in the treatment of infants with cow's milk protein allergy"", pages 1-10. Pediatr Allergy Immunol. 2010 June;21(4p1):577-585. http://www.ncbi.nlm.hih.gov/pmc/articles/PMC2904490/.",DISCONTINUED
116,US,B2,US 8339152 B2,012-462-767-941-132,2012-12-25,2012,US 74962110 A,2010-03-30,US 74962110 A,2010-03-30,Test structure activated by probe needle,"A test structure ( 200 ) in an integrated circuit ( 100 ) includes a probe pad ( 210 ) disposed at a surface of a die ( 102 ) of the integrated circuit, a transmission gate ( 202 ) for connecting portions of an electronic circuit within the integrated circuit in response to a momentary signal applied to the probe pad, a first inverter ( 221 ) having an input coupled to the probe pad and having an output coupled to a control input of the transmission gate, and a second inverter ( 222 ) having an input coupled to an output of the first inverter and having an output coupled to another control input of the transmission gate. The output of the second inverter is coupled to the input of the first inverter. Upon power-up, the transmission gate is open. After the momentary signal is applied to the probe pad, the transmission gate closes and remains closed until power is disconnected.",DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS;;FREESCALE SEMICONDUCTOR INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS,FREESCALE SEMICONDUCTOR INC (2010-03-29);;NXP USA INC (2016-11-07),https://lens.org/012-462-767-941-132,Granted Patent,yes,7,2,4,4,0,G01R31/2884;;G01R31/2884;;G01R31/2896,G01R31/26,324/762.03;;324/750.3;;324/756.01,0,0,,,,ACTIVE
117,BR,A2,BR 102012024845 A2,016-532-857-745-641,2013-10-29,2013,BR 102012024845 A,2012-09-28,MX 2011010299 A,2011-09-29,FÓRMULA INFANTIL BASEADA EM PROTEÍNA DE ARROZ EXTENSAMENTE HIDROLISADA PARA ALIMENTAÇÃO DE CRIANÇAS COM ALERGIAS ALIMENTARES,"FÓRMULA INFABTIL BASEADA EM PROTEÍNA DE ARROZ EXTENSAMENTE HIDROLISADA PARA ALIMENTAÇÃO DE CRIANÇAS COM ALERGIAS ALIMENTARES A presente invenção se refere a uma fórmula infantil especialmente desenvolvida para crianças com histórico de alergia às proteínas do leite de vaca, que ocorre em lactantes alimentados com fórmulas lácteas que substituem o leite materno. A presente invenção é nova porque além da sua composição única ser mais eficaz para resolver o problema da alergia à proteína, contém substâncias que propiciam um bom desenvolvimento físico e mental da criança.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;DUARTE VAZQUEZ MIGUEL ANGEL,,https://lens.org/016-532-857-745-641,Patent Application,no,0,0,4,4,0,A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00,A23L33/00,,0,0,,,,DISCONTINUED
118,US,A1,US 2017/0332690 A1,092-377-510-345-883,2017-11-23,2017,US 201715450935 A,2017-03-06,US 201715450935 A;;MX 2011007872 A;;US 201213559195 A,2011-07-26,"NUTRITIONAL COMPOSITION FOR CHILDREN WITH REFLUX, COLIC AND/OR CONSTIPATION","The present invention is directed to an infant formula specially designed to reduce episodes of regurgitation, colic and constipation that occur in infants fed on infant formula. The composition represents a needed improvement to the art because it contains in a single composition substances that simultaneously addresses these three problems.",NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE-VÁZQUEZ MIGUEL ANGEL,NUCITEC S.A. DE C.V (2012-08-24),https://lens.org/092-377-510-345-883,Patent Application,yes,0,2,8,8,0,A23L33/40;;A23L33/40;;A23L33/40,A23L33/00,,0,0,,,,DISCONTINUED
119,MX,B,MX 357919 B,004-556-003-467-490,2018-07-25,2018,MX 2011009587 A,2010-03-10,US 16011009 P;;IB 2010000506 W,2009-03-13,COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE.,"The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.",NUCITEC SA DE CV,JORGE LUIS ROSADO LORIA;;MIGUEL ANGEL DUARTE VÁZQUEZ,,https://lens.org/004-556-003-467-490,Granted Patent,no,0,0,10,10,0,A61K45/06;;A61K45/06;;A61K9/2054;;A61K9/2054;;A61K9/2846;;A61K9/2846;;A61K31/366;;A61K31/366;;A61K31/40;;A61K31/40;;A61K31/616;;A61K31/616;;A61P9/00;;A61P9/10;;A61P9/12,A61K31/366;;A01N37/02;;A61K31/40;;A61K31/616,,0,0,,,,ACTIVE
120,MX,A,MX 2017013706 A,060-563-601-412-648,2019-04-26,2019,MX 2017013706 A,2017-10-25,MX 2017013706 A,2017-10-25,"FORMULATIONS FOR DENTAL APPLICATION WITH A LOW LEVEL OF SHRINKAGE, MICROFILTRATION, AND TOXICITY BY THE USE OF AN ACRYLIC MONOMER ORTHOS-PYROCARBONATE AND BIS-GMA.","The present invention relates to the process of preparation and use of ortho-pyrocarbonate urethane dimethyl acrylate monomer (SOF-IF-DMA) as a dental restorative material, which possesses mainly anti-shrinkage, microfiltration, toxicity, high conversion, and good mechanical properties. It aims to provide dental formulations from SOC-IF-DMA and Bis-GMA at different percentages by weight, (0/100) (25/75) (50/50) (75/25) and (100/0) respectively. The efficiency of the novel formulations based on SOC-IF-DMA/Bis-GMA is evaluated by conversion of double bonds (CDE) by the kinetics of photo polymerization in real time (RT-FTIR) where conversion values ??of up to 71%. The viscoelastic properties values ??of up to 10189MPa and for the flexural strength modules of up to 7161MPa. Said formulations in contraction tests and in vitro microfiltration using premolar teeth can reduce shrinkage and microfiltration of up to 51%. Further, combinations between SOC-IF-DMA/Bis-GMA manage to make the use of the two acrylic monomers more efficient since they proved to increase the final properties in the evaluated dental resins. Likewise, the cytotoxicity tests of the novel formulations showed that those based on SOC-IF-DMA turn out to be non-toxic when they contain more than 50% by weight of Bis-GMA.",CENTRO DE INVESTIGACION EN QUIM APLICADA,MARIA LYDIA BERLANGA DUARTE;;LUIS ALBERTO REYNA MEDINA,,https://lens.org/060-563-601-412-648,Patent Application,no,0,0,1,1,0,,C07C67/27;;C07D471/04;;C07D471/14,,0,0,,,,PENDING
121,MX,A,MX 2015017115 A,100-548-057-661-205,2016-05-05,2016,MX 2015017115 A,2015-12-11,MX 2015017115 A,2015-12-11,INFANT FORMULA WITH HIGH IMMUNOLOGICAL VALUE COMPRISING A MIXTURE OF BOVINE COLOSTRUM AND OTHER COMPONENTS NORMALLY FOUND IN BREAST MILK.,"The present invention discloses a formula with high immunological value comprising bovine colostrum enriched with other components normally found in breast milk, which is especially useful for feeding the newborn infant during the first days. The formula is especially designed with highly digestible substances according to the immaturity of the digestive system in newborns, in addition to providing defensive substances which allow for the first immunization. The invention represents a novelty in that the nutritional components present in the colostrum have been modified so as to make it as similar as possible to breast milk, thereby reducing adverse effects produced by the consumption of an infant formula in the short and long term, and guaranteeing an optimum growth.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VÁZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/100-548-057-661-205,Patent Application,no,0,1,1,1,0,,A23L33/10;;A23C9/20,,0,0,,,,PENDING
122,MX,A,MX 2011007872 A,089-124-194-340-410,2013-01-29,2013,MX 2011007872 A,2011-07-26,MX 2011007872 A,2011-07-26,"NUTRITIONAL COMPOSITION FOR CHILDREN WITH REFLUX, COLIC AND/OR CONSTIPATION.","Developed is an infant formula specially designed for reducing the episodes of regurgitation, colic and constipation present in infants being fed milk formula instead of breast milk. The invention represents a novelty as it contains substances that solve simultaneously three problems in a single composition.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/089-124-194-340-410,Patent Application,no,0,2,8,8,0,A23L33/40;;A23L33/40;;A23L33/40,A23C9/00;;A23L33/00,,0,0,,,,PENDING
123,MX,A,MX 2012005998 A,112-733-897-030-510,2013-06-18,2013,MX 2012005998 A,2011-04-13,US 32378810 P;;IB 2011001292 W,2010-04-13,COMPOSITIONS AND METHODS FOR TREATING TYPE II DIABETES AND RELATED DISORDERS.,"The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/112-733-897-030-510,Patent Application,no,0,0,7,7,0,A61K31/155;;A61K31/44;;A61K45/06;;A61P3/10;;A61K31/155;;A61K45/06;;A61K31/44,A01N33/02,,0,0,,,,PENDING
124,WO,A1,WO 2014/042503 A1,117-685-637-736-742,2014-03-20,2014,MX 2013000057 W,2013-05-02,MX 2012010488 A,2012-09-11,"INFANT FORMULA FOR OPTIMAL GROWTH, GASTROINTESTINAL PROTECTION AND IMMUNOLOGICAL PROTECTION OF INFANTS","The invention relates to formula for children of between 0 and 36 months, comprising per 100 g: 5 - 15 g protein, 40 - 70 g carbohydrates, and 15 - 40 g fat. The proteins contain a high concentration of alpha-lactalbumin and A2 beta-casein. The formula also contains palmitic acid, oligosaccharides, long-chain fatty acids, nucleotides and vitamins. The formula can take the form of a powder or be mixed with a liquid when it is to serve as food.",NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL,,https://lens.org/117-685-637-736-742,Patent Application,yes,5,5,4,4,0,A61K31/702;;A61K31/702;;A23L33/10;;A23L33/10;;A23L33/12;;A23L33/12;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/155;;A23L33/155;;A23L33/16;;A23L33/16;;A23L33/175;;A23L33/175;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2200/30;;A23V2200/30;;A61K31/047;;A61K31/047;;A61K31/07;;A61K31/07;;A61K31/122;;A61K31/122;;A61K31/14;;A61K31/14;;A61K31/185;;A61K31/185;;A61K31/197;;A61K31/197;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/205;;A61K31/205;;A61K31/355;;A61K31/355;;A61K31/375;;A61K31/375;;A61K31/4415;;A61K31/4415;;A61K31/455;;A61K31/455;;A61K31/51;;A61K31/51;;A61K31/525;;A61K31/525;;A61K31/7016;;A61K31/7016;;A61K31/7068;;A61K31/7068;;A61K31/7072;;A61K31/7072;;A61K31/7076;;A61K31/7076;;A61K31/708;;A61K31/708;;A61K31/714;;A61K31/714;;A61K38/018;;A61K38/018;;A61K38/1709;;A61K38/1709;;A61K38/38;;A61K38/38;;A61K45/06;;A61K45/06,A23C9/00;;A23C9/152;;A23C9/16;;A23C21/06;;A23L1/30;;A23L33/00;;A23L33/15;;A23L33/155,,0,0,,,,PENDING
125,US,A1,US 2015/0245644 A1,181-748-960-712-595,2015-09-03,2015,US 201314427376 A,2013-05-02,MX 2012010487 A;;MX 2013000058 W,2012-09-11,COMPOSITION OF NUTRIENTS AND BIOACTIVE SUBSTANCES WHICH PROMOTE GROWTH AND REDUCE INTOLERANCE AND SIDE EFFECTS IN PREMATURE INFANTS,"The present disclosure is related to the obtaining of a nutritional formula for the feeding of preterm born infants. The formula comprises a mixture of casein; whey milk protein; alphalactalbumin; beta casein A2 protein, lactose; palmitic acid in beta position; non digestible oligosaccharides; long chain polyunsaturated fatty acids (LC PUFAS); nucleotides; vitamins and minerals; inositol, choline, taurine and carnitine in concentrations sufficient enough to satisfy nutritional requirements of premature children, besides being better-tolerated.",NUCITEC SA DE CV,ROSADO LORIA JORGE LUIS;;DUARTE VÁZQUEZ MIGUEL ANGEL,NUCITEC S.A. DE C.V (2015-07-20),https://lens.org/181-748-960-712-595,Patent Application,yes,1,5,4,4,0,A23L5/00;;A23L5/00;;A23L29/30;;A23L29/30;;A23L33/10;;A23L33/10;;A23L33/115;;A23L33/115;;A23L33/12;;A23L33/12;;A23L33/125;;A23L33/125;;A23L33/13;;A23L33/13;;A23L33/15;;A23L33/15;;A23L33/19;;A23L33/19;;A23L33/40;;A23L33/40;;A23V2002/00;;A23V2002/00;;A23V2200/00;;A23V2200/00,A23L1/304;;A23L33/00;;A23L33/15;;A23L33/155,,4,3,056-445-462-657-810;;031-494-060-906-478;;104-631-006-453-695,8985844;;10.1097/00005176-199612000-00007;;17666771;;10.1007/bf03195213;;10.1542/peds.2009-2609;;20837597,"Virgilio et al.,""Structural Position and Amount of Palmitic Acid in Infant Formulas: Effects on Fat, Fatty Acid, and Mineral Balance"" - Journal of Pediatric Gastroenterology & Nutrition, December 1996, Volume 23, Issue 5, pp. 553-560.;;KamiÅski et al.,""Polymorphism of bovine beta-casein and its potential effect on human health"" - J Appl Genet,48(3), 2007, pp. 189-198.;;Raiten et al., ""Executive Summary for the Report: Assessment of Nutrient Requirements for Infant Formulas"" published as supplement to The Journal of Nutrition, volume 128, no. 11S; 1998, 2059S-2294S- http://jn.nutrition.org/content/128/11/suppl/DC1.;;Singhal et al., ""Dietary Nucleotides and Early Growth in Formula-Fed Infants: A Randomized Controlled Trial"" - Pediatrics, October 2010, volume 126/Issue 4, pp. 1-13, http://pediatrics.aappublications.org/content/126/4/e946.",DISCONTINUED
126,BR,A2,BR PI1000630 A2,047-602-120-593-597,2012-01-17,2012,BR PI1000630 A,2010-02-12,BR PI1000630 A,2010-02-12,processo de fabricação de caixa para instrumentos cirúrgicos,"PROCESSO DE FABRICAçãO DE CAIXA PARA INSTRUMENTOS CIRúRGICOS. Trata a presente invenção, afeta ao setor dos materiais plásticos, de processo de fabricação de uma caixa para instrumentação cirúrgica, leve, inquebrável, colorida e transparente, totalmente produzida com polímeros de alta performance, resistentes à esterilização por autoclave, e atendendo a todas as especificações internacionais para produtos médicos.",SPERB MARCELO,SPERB MARCELO;;DOS SANTOS EDMUNDO LUIS;;DUARTE ROBERTO LOPES,,https://lens.org/047-602-120-593-597,Patent Application,no,0,0,1,1,0,,B29C45/02;;C08L81/06,,0,0,,,,DISCONTINUED
127,EP,A1,EP 3046546 A1,085-319-383-025-49X,2016-07-27,2016,EP 14772421 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS,,HOVIONE INT LTD,DUARTE IRIS;;PEREIRA MARIA JOSÉ;;PADRELA LUIS;;TEMTEM MÁRCIO,HOVIONE HOLDING LIMITED (2018-12-26),https://lens.org/085-319-383-025-49X,Patent Application,yes,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00,,0,0,,,,ACTIVE
128,US,A1,US 2016/0228373 A1,081-831-179-092-190,2016-08-11,2016,US 201415022429 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,Synthesis and Particle Engineering of Cocrystals,"The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particles. The invention also provides the use of cocrystals made according to the method of the invention in the formulation of a pharmaceutical composition. The invention also provides cocrystals obtainable or obtained by the method of the present invention, in particular cocrystals in the form of particles. Also provided is a pharmaceutical composition comprising cocrystals made according to the method of the invention, in particular, a pharmaceutical composition comprising cocrystals in the form of particles made according to the method of the invention.",HOVIONE INT LTD,DUARTE IRIS;;PEREIRA MARIA JOSE;;PADRELA LUIS;;TEMTEM MARCIO,HOVIONE HOLDING LIMITED (2016-08-22);;HOVIONE INTERNATIONAL LTD (2016-05-25),https://lens.org/081-831-179-092-190,Patent Application,yes,2,1,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,,6,6,138-320-065-640-680;;043-028-207-104-478;;015-241-500-051-43X;;097-204-188-873-456;;063-842-798-930-473;;018-676-942-833-481,10.1021/cg100451q;;10.1007/s11095-010-0273-9;;20872053;;10.1016/j.ejpb.2007.09.011;;17962005;;10.1016/j.ijpharm.2006.03.028;;16697539;;10.1080/07373937.2011.633251;;2014208;;10.1023/a:1015874121860,"Velaga et al.; “Formation of Cocrystals from Stoichiometric Solutions of Incongruently Saturating Systems by Spray Drying,” ACS, 2010; Crystal Growth & Design, Vol. 10, No. 8, pp. 3302-3305. (Year: 2010);;Dhumal et al.; “Cocrystalization and Simultaneous Agglomeration Using Hot Melt Extrusion,” 2010, SPRINGER; Pharm. Res. Vol. 27, pp. 2725-2733. (Year: 2010);;Albertini et al.; “New spray congealing atomizer for the microencapsulation of highly concentrated solid and liquid substances,” 2008, ELSEVIER; European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, pp. 348-357. (Year: 2008);;Passerini et al.; “Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel,” 2006; ELSEVIER; International Journal of Pharmaceutics, Vol. 318, pp. 92-102. (Year: 2006);;Martins et al.; “Spray Congealing of Pharmaceuticals: Study on Production of Solid Dispersions Using Box-Behnken Design,” 2012, Taylor & Francis; Drying Technology, Vol. 30, pp. 935-945. (Year: 2012);;Eldem et al.; ""Optimization of Spray-Dried and -Congealed Lipid Microparticles and Characterization of Their Surface Morphology by Scanning Electron Microscopy,"" 1991; Plenum Publishing; Pharmaceutical Research, Vol. 8, No. 1, pp. 47-54. (Year: 1991)",DISCONTINUED
129,HU,T2,HU E042518 T2,094-946-501-819-813,2019-07-29,2019,HU E14772421 A,2014-09-16,PT 10716613 A,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS,,HOVIONE HOLDING LTD,DUARTE IRIS;;PEREIRA MARIA JOSE;;PADRELA LUIS;;TEMTEM MARCIO,,https://lens.org/094-946-501-819-813,Amended Patent,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00;;C30B11/02;;C30B29/54,,0,0,,,,PENDING
130,ES,T3,ES 2717754 T3,090-297-752-339-061,2019-06-25,2019,ES 14772421 T,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,Síntesis e ingeniería de partículas de cocristales,,HOVIONE HOLDING LTD,DUARTE IRIS;;PEREIRA MARIA JOSÉ;;PADRELA LUIS;;TEMTEM MÁRCIO,,https://lens.org/090-297-752-339-061,Granted Patent,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00;;C30B11/02;;C30B29/54,,0,0,,,,ACTIVE
131,CA,A1,CA 2923529 A1,130-399-089-210-46X,2015-03-19,2015,CA 2923529 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS,"The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particles. The invention also provides the use of cocrystals made according to the method of the invention in the formulation of a pharmaceutical composition. The invention also provides cocrystals obtainable or obtained by the method of the present invention, in particular cocrystals in the form of particles. Also provided is a pharmaceutical composition comprising cocrystals made according to the method of the invention, in particular, a pharmaceutical composition comprising cocrystals in the form of particles made according to the method of the invention.",HOVIONE INT LTD,DUARTE IRIS;;PEREIRA MARIA JOSE;;PADRELA LUIS;;TEMTEM MARCIO,,https://lens.org/130-399-089-210-46X,Patent Application,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,B01D9/00;;A61K9/16,,0,0,,,,ACTIVE
132,CA,C,CA 2923529 C,082-102-516-781-154,2021-07-27,2021,CA 2923529 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS,"The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particles. The invention also provides the use of cocrystals made according to the method of the invention in the formulation of a pharmaceutical composition. The invention also provides cocrystals obtainable or obtained by the method of the present invention, in particular cocrystals in the form of particles. Also provided is a pharmaceutical composition comprising cocrystals made according to the method of the invention, in particular, a pharmaceutical composition comprising cocrystals in the form of particles made according to the method of the invention.",HOVIONE INT LTD,DUARTE IRIS;;PEREIRA MARIA JOSE;;PADRELA LUIS;;TEMTEM MARCIO,,https://lens.org/082-102-516-781-154,Granted Patent,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00,,0,0,,,,ACTIVE
133,MX,A,MX 2016003212 A,193-904-311-538-141,2016-08-08,2016,MX 2016003212 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS.,"The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particles. The invention also provides the use of cocrystals made according to the method of the invention in the formulation of a pharmaceutical composition. The invention also provides cocrystals obtainable or obtained by the method of the present invention, in particular cocrystals in the form of particles. Also provided is a pharmaceutical composition comprising cocrystals made according to the method of the invention, in particular, a pharmaceutical composition comprising cocrystals in the form of particles made according to the method of the invention.",HOVIONE INT LTD,IRIS DUARTE;;MARÍA JOSÉ PEREIRA;;LUIS PADRELA;;MÁRCIO TEMTEM,,https://lens.org/193-904-311-538-141,Patent Application,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,B01D9/00;;A61K9/16,,0,0,,,,PENDING
134,WO,A1,WO 2015/036799 A1,196-418-982-938-045,2015-03-19,2015,GB 2014052799 W,2014-09-16,PT 10716613 A,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS,"The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particles. The invention also provides the use of cocrystals made according to the method of the invention in the formulation of a pharmaceutical composition. The invention also provides cocrystals obtainable or obtained by the method of the present invention, in particular cocrystals in the form of particles. Also provided is a pharmaceutical composition comprising cocrystals made according to the method of the invention, in particular, a pharmaceutical composition comprising cocrystals in the form of particles made according to the method of the invention.",HOVIONE INT LTD;;KING LAWRENCE,DUARTE IRIS;;PEREIRA MARIA JOSÉ;;PADRELA LUIS;;TEMTEM MÁRCIO,,https://lens.org/196-418-982-938-045,Patent Application,yes,3,4,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00,,7,7,095-348-708-872-984;;010-886-977-131-660;;048-831-305-633-423;;138-320-065-640-680;;001-276-718-090-812;;016-012-863-206-768;;083-580-115-147-526,19446625;;10.1016/j.ijpharm.2009.05.011;;10.1016/s0168-3659(03)00009-9;;12628333;;10.1007/s11095-011-0605-4;;22009589;;10.1021/cg100451q;;pmc3581642;;23297166;;10.1208/s12249-012-9883-3;;23618970;;10.1016/j.ijpharm.2013.04.042;;21827842;;10.1016/j.ijpharm.2011.07.037,"ILIC I ET AL: ""Microparticle size control and glimepiride microencapsulation using spray congealing technology"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 381, no. 2, 3 November 2009 (2009-11-03), pages 176 - 183, XP026643523, ISSN: 0378-5173, [retrieved on 20090514], DOI: 10.1016/J.IJPHARM.2009.05.011;;PASSERINI N ET AL: ""Controlled release of verapamil hydrochloride from waxy microparticles prepared by spray congealing"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 88, no. 2, 7 March 2003 (2003-03-07), pages 263 - 275, XP004412759, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(03)00009-9;;XU LIU ET AL: ""Improving the Chemical Stability of Amorphous Solid Dispersion with Cocrystal Technique by Hot Melt Extrusion"", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 29, no. 3, 19 October 2011 (2011-10-19), pages 806 - 817, XP035016527, ISSN: 1573-904X, DOI: 10.1007/S11095-011-0605-4;;ALHALAWEH A ET AL: ""Formation of cocrystals from stoichiometric solutions of incongruently saturating systems by spray drying"", CRYSTAL GROWTH AND DESIGN 20100804 AMERICAN CHEMICAL SOCIETY USA, vol. 10, no. 8, 4 August 2010 (2010-08-04), pages 3302 - 3305, XP009181241, DOI: 10.1021/CG100451Q;;AMJAD ALHALAWEH ET AL: ""Theophylline Cocrystals Prepared by Spray Drying: Physicochemical Properties and Aerosolization Performance"", AAPS PHARMSCITECH, vol. 14, no. 1, 8 January 2013 (2013-01-08), pages 265 - 276, XP055152173, DOI: 10.1208/s12249-012-9883-3;;KEEN JUSTIN M ET AL: ""Enhancing bioavailability through thermal processing"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 450, no. 1, 22 April 2013 (2013-04-22), pages 185 - 196, XP028554182, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2013.04.042;;NING QIAO ET AL: ""Pharmaceutical cocrystals: An overview"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 419, no. 1, 23 July 2011 (2011-07-23), pages 1 - 11, XP028306606, ISSN: 0378-5173, [retrieved on 20110802], DOI: 10.1016/J.IJPHARM.2011.07.037",PENDING
135,DK,T3,DK 3046546 T3,116-848-828-501-601,2019-05-06,2019,DK 14772421 T,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,Syntese og partikelmanipulation af co-krystaller,,HOVIONE HOLDING LTD,DUARTE IRIS;;PEREIRA MARIA JOSÉ;;PADRELA LUIS;;TEMTEM MÁRCIO,,https://lens.org/116-848-828-501-601,Granted Patent,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00;;C30B11/02;;C30B29/54,,0,0,,,,ACTIVE
136,EP,A1,EP 3184892 A1,162-933-279-760-559,2017-06-28,2017,EP 16201595 A,2016-12-01,PT 10904815 A,2015-12-22,BURNER DEVICE,"Die Erfindung geht aus von einer Brennervorrichtung (10) mit zumindest einem Strukturelement (12), welches eine Vielzahl von Durchlassausnehmungen (26) für ein Verbrennungsfluid aufweist und welches zumindest eine Verbrennungsoberfläche (14) bereitstellt. Es wird vorgeschlagen, dass die Brennervorrichtung (10) zumindest ein Sekundärstrukturelement (16) umfasst, welches eine Vielzahl von Durchlassausnehmungen (28) für das Verbrennungsfluid aufweist, welches zumindest eine zweite Verbrennungsoberfläche (18) bereitstellt und welches, entlang einer Hauptströmungsrichtung (20) des Verbrennungsfluids betrachtet, beabstandet zu dem Strukturelement (12) angeordnet ist.
",BOSCH TERMOTECNOLOGIA SA,PACHECO MONTEIRO LUIS MIGUEL;;DUARTE NUNO FERNANDES GARCIA LIMA,,https://lens.org/162-933-279-760-559,Patent Application,yes,3,1,2,2,0,F23C6/045;;F23D14/08;;F23D14/82;;F23D2203/1023;;F23D2203/104;;F23D2209/10;;F24H9/18,F23C6/04;;F23D14/08;;F23D14/82,,0,0,,,,DISCONTINUED
137,PT,A,PT 109048 A,129-706-769-380-544,2017-06-22,2017,PT 10904815 A,2015-12-22,PT 10904815 A,2015-12-22,DISPOSITIVO DE QUEIMADOR,"A PRESENTE INVENÇÃO REFERE-SE A UM DISPOSITIVO DE QUEIMADOR (10) COM PELO MENOS UM ELEMENTO ESTRUTURAL (12), QUE APRESENTA UMA PLURALIDADE DE ORIFÍCIOS DE PASSAGEM (26) PARA UM FLUIDO DE COMBUSTÃO E QUE DISPONIBILIZA PELO MENOS UMA SUPERFÍCIE DE COMBUSTÃO (14).É SUGERIDO QUE O DISPOSITIVO DE QUEIMADOR (10) COMPREENDA PELO MENOS UM ELEMENTO ESTRUTURAL SECUNDÁRIO (16), QUE APRESENTA UMA PLURALIDADE DE ORIFÍCIOS DE PASSAGEM (28) PARA O FLUIDO DE COMBUSTÃO, QUE DISPONIBILIZA PELO MENOS UMA SEGUNDA SUPERFÍCIE DE COMBUSTÃO (18) E QUE, OBSERVADO AO LONGO DE UMA DIREÇÃO DE FLUXO PRINCIPAL (20) DO FLUIDO DE COMBUSTÃO, ESTÁ DISPOSTO DE FORMA ESPAÇADA EM RELAÇÃO AO ELEMENTO ESTRUTURAL (12).",BOSCH TERMOTECNOLOGIA SA,LUIS MIGUEL PACHECO MONTEIRO;;DUARTE NUNO FERNANDES GARCIA LIMA,,https://lens.org/129-706-769-380-544,Patent Application,no,0,0,2,2,0,F23C6/045;;F24H9/18;;F23D14/08;;F23D14/82;;F23D2203/1023;;F23D2203/104;;F23D2209/10,F24H9/18,,0,0,,,,PENDING
138,CN,A,CN 105682644 A,009-558-557-901-368,2016-06-15,2016,CN 201480050929 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,Synthesis and particle engineering of cocrystals,"The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particles. The invention also provides the use of cocrystals made according to the method of the invention in the formulation of a pharmaceutical composition. The invention also provides cocrystals obtainable or obtained by the method of the present invention, in particular cocrystals in the form of particles. Also provided is a pharmaceutical composition comprising cocrystals made according to the method of the invention, in particular, a pharmaceutical composition comprising cocrystals in the form of particles made according to the method of the invention.",HOVIONE INT LTD,DUARTE IRIS;;PEREIRA MARIA JOSE;;PADRELA LUIS;;TEMTEM MARCIO,,https://lens.org/009-558-557-901-368,Patent Application,no,3,4,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00,,1,0,,,"刘广文: ""《喷雾干燥实用技术大全》"", 31 October 2001, 中国轻工业出版社",ACTIVE
139,AT,T1,AT E485976 T1,076-401-079-952-172,2010-11-15,2010,AT 07381037 T,2007-05-09,EP 07381037 A,2007-05-09,SEITENAIRBAG MIT ADAPTIVER ENTLÜFTUNGSVORRICHTUNG,"The present invention relates to a side airbag for an automotive vehicle comprising a venting regulation device formed by a part made of a flexible material (21) joined to the inflatable cushion (11) such that it can completely or partially close or free the venting opening (17), and a tension belt (23) joined by one part to said part made of a flexible material (21) and by another part to the inflatable cushion (11), the geometric configurations of said tension belt (23) and said part made of a flexible material (21) being determined such that the degree of closing/freeing of the venting opening (17) varies according to the width of the inflatable cushion (11) during its different deployment phases during the collision, being closed in the initial and end phases and freed in the intermediate phase.",DALPHI METAL ESPANA SA,DENYS ISABELLE PARQUE;;DUARTE DE AREZ LUIS JOSE PARQUE,,https://lens.org/076-401-079-952-172,Granted Patent,no,0,0,7,7,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R21/239;;B60R21/2338;;B60R2021/23382,B60R21/2338,,0,0,,,,INACTIVE
140,BR,U2,BR MU9000272 U2,077-312-554-607-311,2011-09-27,2011,BR MU9000272 U,2010-02-12,BR MU9000272 U,2010-02-12,disposição construtiva em tampa e bandeja para caixa de instrumentos cirúrgicos,"DISPOSIçãO CONSTRUTIVA EM TAMPA E BANDEJA PARA CAIXA DE INSTRUMENTOS CIRúRGICOS. Refere-se o presente modelo, afeto a área dos materiais plásticos (polímeros) a uma tampa e uma bandeja interna para caixa de instrumentos ciurúrgicos, totalmente confeccionadas em polimeros que atendem a todas as normas internacionais para material médico, esterilizável por autoclave, transparentes e coloridas, resistente a quedas, amassados e quebras.",SPERB MARCELO,SPERB MARCELO;;DOS SANTOS EDMUNDO LUIS;;LOPES DUARTE ROBERTO,,https://lens.org/077-312-554-607-311,Patent Application,no,0,0,1,1,0,,A61B50/30,,0,0,,,,DISCONTINUED
141,EP,A1,EP 1580237 A1,029-677-000-090-470,2005-09-28,2005,EP 05075514 A,2005-03-02,BR PI0400842 A,2004-03-03,Process for the production of packages using thermoplastic biodegradable cassava bagasse agglomerate,"The present invention refers to a process for obtaining thermoplastic biodegradable cassava bagasse-based material agglutinated with cassava starch, intended for the production of 100% non-toxic biodegradable packages that, after use, may be incorporated to animal food. The process basically consists in agglomerating cassava bagasse agglutinated using a cassava starch paste  in natura  (whether pregelatinized or not) that, in the presence of a solvent and subject to a source of heat, causes an expansion associated to agglutination among the cassava bagasse particles.",LAZZARO EVASIO;;NEVES JUAREZ TEODORO;;MONTANARI LUIS ANTONIO DUARTE,LAZZARO EVASIO;;NEVES JUAREZ TEODORO;;MONTANARI LUIS ANTONIO DUARTE,,https://lens.org/029-677-000-090-470,Patent Application,yes,3,3,2,2,0,B29C67/24;;B29K2003/00;;C08L97/02,B29C67/24;;B65D65/46;;C08L3/00;;C08L97/02,,0,0,,,,DISCONTINUED
142,EP,B1,EP 3046546 B1,060-966-957-938-428,2019-01-02,2019,EP 14772421 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS,,HOVIONE HOLDING LTD,DUARTE IRIS;;PEREIRA MARIA JOSÉ;;PADRELA LUIS;;TEMTEM MÁRCIO,HOVIONE HOLDING LIMITED (2018-12-26),https://lens.org/060-966-957-938-428,Granted Patent,yes,1,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00;;C30B11/02;;C30B29/54,,1,1,101-423-046-579-035,18651749;;10.1021/mp800050q,"CHERI A. BARTA ET AL: ""Effects of Monoglycerides on P-Glycoprotein: Modulation of the Activity and Expression in Caco-2 Cell Monolayers"", MOLECULAR PHARMACEUTICS, vol. 5, no. 5, 6 October 2008 (2008-10-06), US, pages 863 - 875, XP055361691, ISSN: 1543-8384, DOI: 10.1021/mp800050q",ACTIVE
143,AU,A1,AU 2014/320095 A1,013-833-947-794-949,2016-03-24,2016,AU 2014/320095 A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,Synthesis and particle engineering of cocrystals,"The present invention discloses a scalable and solvent-free method to produce cocrystals in a particulate form. A method of making cocrystals comprises the steps of: a) feeding a molten mixture of at least a first substance and a second substance which are able to form cocrystals to an atomizer; b) atomizing the molten mixture to droplets; c) solidifying the droplets to particles; d) collecting the said particles. The invention also provides the use of cocrystals made according to the method of the invention in the formulation of a pharmaceutical composition. The invention also provides cocrystals obtainable or obtained by the method of the present invention, in particular cocrystals in the form of particles. Also provided is a pharmaceutical composition comprising cocrystals made according to the method of the invention, in particular, a pharmaceutical composition comprising cocrystals in the form of particles made according to the method of the invention.",HOVIONE INT LTD,DUARTE IRIS;;PEREIRA MARIA JOSE;;PADRELA LUIS;;TEMTEM MARCIO,,https://lens.org/013-833-947-794-949,Patent Application,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,A61K9/16;;B01D9/00,,0,0,,,,DISCONTINUED
144,SG,A,SG 11201601811Y A,103-458-870-555-915,2016-04-28,2016,SG 11201601811Y A,2014-09-16,PT 10716613 A;;GB 2014052799 W,2013-09-16,SYNTHESIS AND PARTICLE ENGINEERING OF COCRYSTALS,,HOVIONE INT LTD,DUARTE IRIS;;PEREIRA MARIA JOSÉ;;PADRELA LUIS;;TEMTEM MÁRCIO,,https://lens.org/103-458-870-555-915,Unknown,no,0,0,19,19,0,A61K9/1617;;B01D9/0009;;B01D9/0063;;A61K9/1688;;A61K9/1617;;B01D9/0063;;B01D9/0009;;A61K9/1688;;A61K31/194;;A61K31/455;;A61K31/522;;A61K31/55;;A61K31/60;;C30B11/02;;C30B29/54,B01D9/00;;A61K9/16,,0,0,,,,PENDING
145,EP,A1,EP 3527439 A1,083-141-379-488-717,2019-08-21,2019,EP 19155670 A,2019-02-06,DE 202018100871 U,2018-02-16,AIRBAG MODULE AND MODULE HOUSING OF AN AIRBAG MODULE AND VEHICLE SEAT WITH SUCH A MODULE,"Die Erfindung betrifft ein Modulgehäuse (20) eines Gassackmoduls (14), mit einer Gehäusewand (24), die im geschlossenen Zustand des Modulgehäuses (20) ein Gehäuseinneres von einer Gehäuseumgebung trennt, wobei die Gehäusewand (24) einen Gehäusevorsprung (30) aufweist, welcher von der Gehäusewand (24) in Richtung zur Gehäuseumgebung vorsteht, wobei der Gehäusevorsprung (30) wenigstens eine Kante (32) mit einem Kantenradius von weniger als 3,5 mm aufweist, und wobei benachbart zu dieser wenigstens einen Kante (32) ein einstückig mit der Gehäusewand (24) ausgebildeter Wandfortsatz (34) vorgesehen ist, welcher ausschließlich Kanten mit einem Kantenradius von mehr als 3,2 mm aufweist und von der Gehäusewand (24) wenigstens so weit in Richtung zur Gehäuseumgebung (28) vorsteht wie der Gehäusevorsprung (30). Ferner betrifft die Erfindung auch ein Gassackmodul (14) mit einem solchen Modulgehäuse (20) sowie einen Fahrzeugsitz mit einem entsprechenden Gassackmodul (14).
",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSÉ;;PEREZ DIEGO;;MIRANDA CARLOS,,https://lens.org/083-141-379-488-717,Patent Application,yes,3,0,3,3,0,B60R21/217;;B60R21/207,B60R21/217;;B60R21/207,,0,0,,,,ACTIVE
146,BR,U2,BR MU9000273 U2,116-935-150-882-185,2011-10-04,2011,BR MU9000273 U,2010-02-12,BR MU9000273 U,2010-02-12,disposição construtiva em caixa para instrumentos cirúrgicos,"DISPOSIçãO CONSTRUTIVA EM CAIXA PARA INSTRUMENTOS CIRúRGICOS. Refere-se o presente modelo, afeto a área dos materiais plásticos (polímeros) a uma caixa para instrumentos cirúrgicos, totalmente confeccionada em polímeros que atendem a todas as normas internacionais para material médico, esterilizável por autoclave, com lados transparentes e coloridos, com peso extremamente baixo em relação às caixas metálicas convencionais, resistente a quedas, amassados e quebras.",SPERB MARCELO,SPERB MARCELO;;DOS SANTOS EDMUNDO LUIS;;DUARTE ROBERTO LOPES,,https://lens.org/116-935-150-882-185,Patent Application,no,0,0,1,1,0,,A61B50/34,,0,0,,,,DISCONTINUED
147,EP,B1,EP 3527439 B1,147-023-336-702-368,2020-08-19,2020,EP 19155670 A,2019-02-06,DE 202018100871 U,2018-02-16,AIRBAG MODULE AND MODULE HOUSING OF AN AIRBAG MODULE AND VEHICLE SEAT WITH SUCH A MODULE,,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSÉ;;PEREZ DIEGO;;MIRANDA CARLOS,,https://lens.org/147-023-336-702-368,Granted Patent,yes,3,0,3,3,0,B60R21/207;;B60R21/217,B60R21/217;;B60R21/207,,0,0,,,,ACTIVE
148,PT,U,PT 11938 U,161-000-785-379-290,2021-02-18,2021,PT 1193820 U,2020-03-18,PT 1193820 U,2020-03-18,SISTEMA DE MONITORIZAÇÃO E CONTROLO DO CONSUMO DE UM LÍQUIDO,"A PRESENTE INVENÇÃO REFERE-SE A UM EQUIPAMENTO PARA MONITORIZAÇÃO E CONTROLO DO CONSUMO DE UM LÍQUIDO. PODE SER INSTALADA EM RESIDÊNCIAS, GINÁSIOS, HOSPITAIS, DUCHES COLETIVOS OU EM QUALQUER LOCAL EM QUE SE PRETENDA TER UM CONTROLO, QUE PODE SER PERSONALIZADO, NO CONSUMO DE UM LÍQUIDO. O SISTEMA DA INVENÇÃO INCORPORA DUAS ELECTROVÁLVULAS (1), UM MISTURADOR (2), UM MEDIDOR DE FLUXO COM MEDIÇÃO DE TEMPERATURA (3), UM HIDRO GERADOR (4) E UM MÓDULO DE CONTROLO COM LEITURA BIOMÉTRICA (5). A CONFIGURAÇÃO DOS PARÂMETROS PERSONALIZADOS É FEITA ATRAVÉS DE UMA APLICAÇÃO WEB SENDO QUE OS PARÂMETROS PODEM SER O TEMPO DE CONSUMO DO LÍQUIDO E A TEMPERATURA DO LÍQUIDO, ENTRE OUTROS. A INVENÇÃO TEM UMA APLICAÇÃO PARTICULARMENTE VANTAJOSA NO CONTROLO E MONITORIZAÇÃO DO CONSUMO DE ÁGUA NO DUCHE, PERMITINDO REDUZIR AS FATURAS DA ÁGUA E DOS SISTEMAS QUE SUPORTAM O AQUECIMENTO DAS ÁGUAS SANITÁRIAS. O SISTEMA É UNIVERSAL E PODE SER INSTALADO SUBSTITUINDO AS TONEIRAS DE DUCHE EXISTENTES, OU NO CASO DE OBRA SER INSTALADO DE FORMA ENCASTRADA E EM VEZ DAS TORNEIRAS.",LUIS MANUEL DOMINGOS NOVELA;;MANUEL LUIS QUEIJEIRA DUARTE;;PAULO JORGE PIDWELL E SILVA DABOIM,LUIS MANUEL DOMINGOS NOVELA;;MANUEL LUIS QUEIJEIRA DUARTE;;PAULO JORGE PIDWELL E SILVA D'ABOIM,,https://lens.org/161-000-785-379-290,Limited Patent,no,0,0,1,1,0,G05D23/19;;G05D7/06,G05D23/19;;G05D7/06,,0,0,,,,ACTIVE
149,PT,U,PT 11933 U,083-435-095-862-715,2020-08-21,2020,PT 1193320 U,2020-02-21,PT 1193320 U,2020-02-21,SISTEMA DE MONITORIZAÇÃO DA QUANTIDADE DE FLUIDO NUM CONTENTOR,"A PRESENTE INVENÇÃO REFERE-SE A UM EQUIPAMENTO PARA MONITORIZAÇÃO, CONTROLO, MEDIÇÃO E COMUNICAÇÃO DE UMA GRANDEZA FÍSICA, MAIS ESPECIFICAMENTE A UM SISTEMA QUE PODE SER INSTALADO EM QUALQUER INSTALAÇÃO DOMÉSTICA, INDUSTRIAL OU COMERCIAL QUE ESTEJA EQUIPADA COM UM CONTENTOR QUE CONTENHA UM FLUIDO SOB PRESSÃO. O SISTEMA DA INVENÇÃO INCORPORA UM CONTENTOR (1), MEDIDOR DE FLUXO (2), UMA ELETROVÁLVULA (3) DE REARME AUTOMÁTICO, UM DETETOR DE FUGAS (4) QUE CORTA O FORNECIMENTO AUTOMATICAMENTE QUANDO UMA FUGA É DETETADA E UMA UNIDADE DE CONTROLO LÓGICO PROGRAMÁVEL (5) (PLC). A INVENÇÃO TEM UMA APLICAÇÃO PARTICULARMENTE VANTAJOSA NA MONITORIZAÇÃO DA QUANTIDADE DE GÁS RESTANTE NUMA GARRAFA DE GÁS LIQUEFEITO (GPL), POIS AO PODER SER QUANTIFICADA A QUANTIDADE DE GÁS RESTANTE NUMA GARRAFA DE GÁS, QUANDO ESTA É TROCADA POR OUTRA, É POSSÍVEL O CONSUMIDOR SER RESSARCIDO DO VALOR DESSE GÁS.",LUIS MANUEL DOMINGOS NOVELA;;MANUEL LUIS QUEIJEIRA DUARTE;;PAULO JORGE PIDWELL E SILVA ABOIM,LUIS MANUEL DOMINGOS NOVELA;;MANUEL LUIS QUEIJEIRA DUARTE;;PAULO JORGE PIDWELL E SILVA ABOIM,,https://lens.org/083-435-095-862-715,Limited Patent,no,0,0,2,2,0,G06Q50/06,G06Q50/06,,0,0,,,,ACTIVE
150,PT,Y,PT 11933 Y,120-583-250-749-275,2021-03-29,2021,PT 1193320 U,2020-02-21,PT 1193320 U,2020-02-21,SISTEMA DE MONITORIZAÇÃO DA QUANTIDADE DE FLUIDO NUM CONTENTOR,"A PRESENTE INVENÇÃO REFERE-SE A UM EQUIPAMENTO PARA MONITORIZAÇÃO, CONTROLO, MEDIÇÃO E COMUNICAÇÃO DE UMA GRANDEZA FÍSICA, MAIS ESPECIFICAMENTE A UM SISTEMA QUE PODE SER INSTALADO EM QUALQUER INSTALAÇÃO DOMÉSTICA, INDUSTRIAL OU COMERCIAL QUE ESTEJA EQUIPADA COM UM CONTENTOR QUE CONTENHA UM FLUIDO SOB PRESSÃO. O SISTEMA DA INVENÇÃO INCORPORA UM CONTENTOR (1), MEDIDOR DE FLUXO (2), UMA ELETROVÁLVULA (3) DE REARME AUTOMÁTICO, UM DETETOR DE FUGAS (4) QUE CORTA O FORNECIMENTO AUTOMATICAMENTE QUANDO UMA FUGA É DETETADA E UMA UNIDADE DE CONTROLO LÓGICO PROGRAMÁVEL (5) (PLC). A INVENÇÃO TEM UMA APLICAÇÃO PARTICULARMENTE VANTAJOSA NA MONITORIZAÇÃO DA QUANTIDADE DE GÁS RESTANTE NUMA GARRAFA DE GÁS LIQUEFEITO (GPL), POIS AO PODER SER QUANTIFICADA A QUANTIDADE DE GÁS RESTANTE NUMA GARRAFA DE GÁS, QUANDO ESTA É TROCADA POR OUTRA, É POSSÍVEL O CONSUMIDOR SER RESSARCIDO DO VALOR DESSE GÁS.",LUIS MANUEL DOMINGOS NOVELA;;MANUEL LUIS QUEIJEIRA DUARTE;;PAULO JORGE PIDWELL E SILVA ABOIM,LUIS MANUEL DOMINGOS NOVELA;;MANUEL LUIS QUEIJEIRA DUARTE;;PAULO JORGE PIDWELL E SILVA ABOIM,,https://lens.org/120-583-250-749-275,Limited Patent,no,0,0,2,2,0,G06Q50/06,G06Q50/06,,0,0,,,,ACTIVE
151,DK,T3,DK 0884054 T3,014-050-748-406-187,2003-07-21,2003,DK 98500119 T,1998-05-12,ES 9701017 A,1997-05-13,Fastdosiskombination af en angiotensin-omdannende enzyminhibitor og en calsiumkanalantagonist til behandling af cardiovaskulære sygdomme,,VITA LAB,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN ANTO;;CANOVAS PEDRO,,https://lens.org/014-050-748-406-187,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
152,EP,B9,EP 0884054 B9,092-530-332-172-315,2007-02-14,2007,EP 98500119 A,1998-05-12,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses,,PROCTER & GAMBLE PHARMA,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN ANTO;;CANOVAS PEDRO,"LABORATORIOS VITA, S.A. (2003-08-01);;S.A. *LABORATORIOS VITA (2003-04-09);;FERRER INTERNACIONAL, S.A. (2009-03-11);;PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L. (2005-05-02);;S.A. *LABORATORIOS VITAAVDA. DE BARCELONA 69, 0897 (2003-04-09)",https://lens.org/092-530-332-172-315,Amended Patent,yes,6,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/40;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,3,0,,,"SWEET, C. S. ET AL: ""Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers"" J. CARDIOVASC. PHARMACOL. ( 1986 ), 8(SUPPL. 1), S15-S19 , XP002140850;;STAESSEN J.A. ET AL: ""Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action."" HYPERTENSION, (1996) 27/3 I (414-420). , XP000921342;;BAUER, FRöMMING, FüHRER: ""Lehrbuch der Pharmazeutischen Technologie"", 1999, WISSENACHAFTLICHE VERLAGSGESELLSCHAFT MBH STUTTGART, STUTTGART",EXPIRED
153,EP,A3,EP 0884054 A3,095-717-564-388-19X,2000-08-23,2000,EP 98500119 A,1998-05-12,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses,"Comprises a dose of (a) enalapril or a pharmaceutically acceptable salt thereof and another dose of (b) nitrendipine or a pharmaceutically acceptable salt thereof and in that it is administered in single-dose gallenic form. The method comprises: (a) dissolving enalapril maleate in water with an inorganic salt; (b) mixing the micronized nitrendipine with a fraction of the disintegrating excipients, the wetting agent, the fragmentary diluting agent, the agglutinating agent, and the plastic diluting agent, previously sieved; (c) granulating the products homogenized in section (b) with the solution obtained in section (a); (d) drying the granulated mass; (e) incorporating the lubricating agent, and the remaining fraction of the disintegrating excipients and homogenizing the calibrated granulate; (f) compressing the granulate. Use of said association for the manufacture of a medicament for the treatment of illnesses of the cardiovascular system.",VITA INVEST SA,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAGUIN ANTO;;CANOVAS PEDRO,"LABORATORIOS VITA, S.A. (2003-08-01);;S.A. *LABORATORIOS VITA (2003-04-09);;FERRER INTERNACIONAL, S.A. (2009-03-11);;PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L. (2005-05-02);;S.A. *LABORATORIOS VITAAVDA. DE BARCELONA 69, 0897 (2003-04-09)",https://lens.org/095-717-564-388-19X,Search Report,yes,6,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/40;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,2,2,097-468-989-374-648;;008-212-960-071-486,10.1097/00005344-198600081-00004;;2422487;;8698447;;10.1161/01.hyp.27.3.414,"SWEET, C. S. ET AL: ""Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers"", J. CARDIOVASC. PHARMACOL. ( 1986 ), 8(SUPPL. 1), S15-S19, XP002140850;;STAESSEN J.A. ET AL: ""Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action."", HYPERTENSION, (1996) 27/3 I (414-420)., XP000921342",EXPIRED
154,CN,A,CN 108604978 A,180-712-599-905-095,2018-09-28,2018,CN 201680080274 A,2016-01-26,EP 2016051504 W,2016-01-26,Apparatus and method for managing full-duplex communication between base station and plurality of user equipment,"The invention relates to an apparatus (301) for managing full-duplex communication between a base station (BS0) and a set of user equipments (101a,b), the base station (BS0) comprising a plurality oftransmitter antennas, the plurality of transmitter antennas being associated with a downlink communication channel H between the base station (BS0) and the set of user equipments (101a,b) and a plurality of interference channels Gi between the base station (BS0) and a plurality of neighboring base stations (BSi), the apparatus (301) comprising: a determiner (303) configured to determine an aggregate interference channel G on the basis of the plurality of interference channels Gi , a modifier (305) configured to modify the aggregate interference channel G to obtain a modified aggregate interference channel F under the constraint that a performance measure depending on the downlink communication channel H and the modified aggregate interference channel F meets a performance measure criterion, wherein the modified aggregate interference channel F spans a subspace of the space spanned by the aggregate interference channel G, and a precoder (307) configured to precode signals to be transmitted by the plurality of transmitter antennas on the basis of a precoder matrix W, wherein the precoder matrix W depends on the modified aggregate interference channel F.",HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;DEBBAH MEROUANE;;GUILLAUD MAXIME,,https://lens.org/180-712-599-905-095,Patent Application,no,7,0,7,7,0,H04B7/0456;;H04L5/143;;H04L5/0073;;H04B7/0456;;H04L5/143;;H04B17/345;;H04L5/0073;;H04L5/14,H04L5/14;;H04B7/0456,,1,0,,,"BEI YIN等: ""Full-Duplex in Large-Scale Wireless Systems"", 《2013 ASILOMAR CONFERENCE ON SIGNALS, SYSTEMS AND COMPUTERS》",ACTIVE
155,EP,A1,EP 3403364 A1,185-974-128-108-868,2018-11-21,2018,EP 16701746 A,2016-01-26,EP 2016051504 W,2016-01-26,AN APPARATUS AND A METHOD FOR MANAGING FULL-DUPLEX COMMUNICATION BETWEEN A BASE STATION AND A PLURALITY OF USER EQUIPMENTS,,HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;DEBBAH MEROUANE;;GUILLAUD MAXIME,,https://lens.org/185-974-128-108-868,Patent Application,yes,0,0,7,7,0,H04B7/0456;;H04L5/143;;H04L5/0073;;H04B7/0456;;H04L5/143;;H04B17/345;;H04L5/0073;;H04L5/14,H04L5/14;;H04B7/04,,0,0,,,,ACTIVE
156,US,A1,US 2018/0359076 A1,017-007-785-362-852,2018-12-13,2018,US 201816045340 A,2018-07-25,EP 2016051504 W,2016-01-26,APPARATUS AND A METHOD FOR MANAGING FULL-DUPLEX COMMUNICATION BETWEEN A BASE STATION AND A PLURALITY OF USER EQUIPMENTS,"The invention relates to an apparatus ( 301 ) for managing full-duplex communication between a base station (BS 0 ) and a set of user equipments ( 101 a,b ), the base station (BS 0 ) comprising a plurality of transmitter antennas, the plurality of transmitter antennas being associated with a downlink communication channel H between the base station (BS 0 ) and the set of user equipments ( 101 a,b ) and a plurality of interference channels G i between the base station (BS 0 ) and a plurality of neighboring base stations (BS i ).",HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;DEBBAH MEROUANE;;GUILLAUD MAXIME,HUAWEI TECHNOLOGIES CO. LTD (2019-03-04),https://lens.org/017-007-785-362-852,Patent Application,yes,0,2,7,7,0,H04B7/0456;;H04L5/143;;H04L5/0073;;H04B7/0456;;H04L5/143;;H04B17/345;;H04L5/0073;;H04L5/14,H04L5/14;;H04B7/0456;;H04B17/345;;H04L5/00,,0,0,,,,ACTIVE
157,NZ,A,NZ 330447 A,032-840-643-947-832,1998-12-23,1998,NZ 33044798 A,1998-05-13,ES 9701017 A,1997-05-13,"ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, ENALAPRIL, AND THE CALCIUM CHANNEL ANTAGONIST, NITRENDIPINE, IN A FIXED DOSE ASSOCIATION FOR THE TREATMENT OF ARTERIAL HYPERTENSION AND OTHER CARDIOVASCULAR ILLNESSES",,VITA INVEST SA,CANOVAS SOLER PEDRO;;DELGADILLO DUARTE JOAQUIN;;MICHETO ESCUDER LUIS MANUEL,"LABORATORIOS VITA, ES (2003-05-30);;PROCTER AND GAMBLE PHARMACEUTICALS S.A.R.L., CH (2005-07-29);;FERRER INTERNACIONAL S.A, ES (2010-09-30)",https://lens.org/032-840-643-947-832,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/40;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,DISCONTINUED
158,NO,D0,NO 982112 D0,142-812-015-546-245,1998-05-08,1998,NO 982112 A,1998-05-08,ES 9701017 A,1997-05-13,"Fiksert-dosesammensetning av en angiotensinkonverterende enzyminhibitor og en kalsiumkanalantagonist, fremgangsmÕte for dens fremstilling og anvendelse derav i behandling av kardiovaskulµre sykdommer",,VITA INVEST SA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/142-812-015-546-245,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K31/40;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
159,US,B2,US 10216452 B2,148-508-148-066-546,2019-02-26,2019,US 201615210567 A,2016-07-14,US 201615210567 A,2016-07-14,Breach detection in integrated circuits,"An apparatus embodiment includes an integrated circuit (IC) and breach-detection circuitry. The IC includes data storage circuitry, a power grid configured to distribute power to the data storage circuitry, and a plurality of nodes distributed over at least one sensitive region of the IC. The breach-detection circuitry monitors power grid integrity at the at least one sensitive region of the IC and detects an event indicative of a breach by an external probe at a portion of the at least one sensitive region in response to floating node detection or a change in voltage at one of the plurality of nodes.",FREESCALE SEMICONDUCTOR INC;;NXP USA INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS;;GODOI GUILHERME,NXP USA INC (2016-07-14),https://lens.org/148-508-148-066-546,Granted Patent,yes,8,0,4,4,0,G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F3/0623;;G06F3/064;;G06F3/0652;;G06F3/0679;;H01L23/57,G06F3/06;;G06F21/86;;H01L23/00,,0,0,,,,ACTIVE
160,EP,A1,EP 3270323 A1,148-263-092-405-736,2018-01-17,2018,EP 17178495 A,2017-06-28,US 201615210567 A,2016-07-14,BREACH DETECTION IN INTEGRATED CIRCUITS,"An apparatus embodiment includes an integrated circuit (IC) and breach-detection circuitry. The IC includes data storage circuitry, a power grid configured to distribute power to the data storage circuitry, and a plurality of nodes distributed over at least one sensitive region of the IC. The breach-detection circuitry monitors power grid integrity at the at least one sensitive region of the IC and detects an event indicative of a breach by an external probe at a portion of the at least one sensitive region in response to floating node detection or a change in voltage at one of the plurality of nodes.
 
",NXP USA INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS;;GODOI GUILHERME,,https://lens.org/148-263-092-405-736,Patent Application,yes,1,0,4,4,0,G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F3/0623;;G06F3/064;;G06F3/0652;;G06F3/0679;;H01L23/57,G06F21/86;;H01L23/00,,0,0,,,,ACTIVE
161,AU,A,AU 1998/065973 A,050-195-655-804-541,1998-11-19,1998,AU 1998/065973 A,1998-05-13,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist,,FERRER INT,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,"LABORATORIOS VITA, S.A. (2003-06-26);;PROCTER AND GAMBLE PHARMACEUTICALS S.A.R.L. (2004-10-28)",https://lens.org/050-195-655-804-541,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
162,DE,T2,DE 69813083 T2,057-789-402-800-414,2004-05-27,2004,DE 69813083 T,1998-05-12,ES 9701017 A,1997-05-13,Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen,,VITA LAB,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN ANTO;;CANOVAS PEDRO,"LABORATORIOS VITA, S.A., SANT JOAN DESPI, BARCELON (2004-01-29);;PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L., PETIT-L (2005-06-16)",https://lens.org/057-789-402-800-414,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K31/40;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
163,AT,T1,AT E236653 T1,111-879-803-339-10X,2003-04-15,2003,AT 98500119 T,1998-05-12,ES 9701017 A,1997-05-13,KOMBINATION IN FESTE DOSIERMENGE VON ANGIOTENSIN- CONVERTING-ENZYME-HEMMERN MIT CALCIUM-KANAL ANTAGONISTEN ZUR BEHANDLUNG VON HERZ- KREISLAUFERKRANKUNGEN,,VITA INVEST SA,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN ANTO;;CANOVAS PEDRO,,https://lens.org/111-879-803-339-10X,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,PENDING
164,HU,D0,HU 9801075 D0,102-631-976-351-259,1998-07-28,1998,HU P9801075 A,1998-05-12,ES 9701017 A,1997-05-13,"FIXED-DOSE ASSOCIATION OF AN ANGIOTENSINCONVERTING ENZYME INHIBITOR AND OF A CALCIUM CHANNEL ANTAGONIST, METHOD FOR PREPARATION AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR ILLNESSES",,VITA INVEST SA,CANOVAS SOLER PERDO;;DELGADILLO DUARTE JOAQUIN;;MICHETO ESCUDER LUIS MANUEL,"FERRER INTERNACIONAL, S.A., ES (2010-12-28)",https://lens.org/102-631-976-351-259,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,PENDING
165,PL,B1,PL 192117 B1,176-200-012-813-340,2006-09-29,2006,PL 32624698 A,1998-05-12,ES 9701017 A,1997-05-13,"Composition applied at predeterminated dosis and consisting of a combination pf abiogestin enzyme transforming inhibitor and of calcium channel antagonist, method of preparing such composition and application thereof in treating cardiovascular diseases",,PROCTER & GAMBLE PHARMA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/176-200-012-813-340,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K31/4422;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
166,NO,B1,NO 315545 B1,059-276-822-774-282,2003-09-22,2003,NO 982112 A,1998-05-08,ES 9701017 A,1997-05-13,"Blanding med bestemt dose, av en angiotensinkonverterende enzyminhibitor ogav en kalsiumkanal antagonist, fremgangsmåte for fremstilling oganvendelse derav ved behandling av kardiovaskul¶re sykdommer",,VITA LAB,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/059-276-822-774-282,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/40;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
167,WO,A1,WO 2017/129227 A1,063-014-607-198-491,2017-08-03,2017,EP 2016051504 W,2016-01-26,EP 2016051504 W,2016-01-26,AN APPARATUS AND A METHOD FOR MANAGING FULL-DUPLEX COMMUNICATION BETWEEN A BASE STATION AND A PLURALITY OF USER EQUIPMENTS,"The invention relates to an apparatus (301) for managing full-duplex communication between a base station (BS 0 ) and a set of user equipments (101a,b), the base station (BS 0 ) comprising a plurality of transmitter antennas, the plurality of transmitter antennas being associated with a downlink communication channel H between the base station (BS 0 ) and the set of user equipments (101a,b) and a plurality of interference channels G i between the base station (BS 0 ) and a plurality of neighboring base stations (BS i ), the apparatus (301) comprising: a determiner (303) configured to determine an aggregate interference channel G on the basis of the plurality of interference channels G i , a modifier (305) configured to [modify the aggregate interference channel G to obtain a modified aggregate interference channel F under the constraint that a performance measure depending on the downlink communication channel H and the modified aggregate interference channel F meets a performance measure criterion, wherein the modified aggregate interference channel F spans a subspace of the space spanned by the aggregate interference channel G , and a precoder (307) configured to precode signals to be transmitted by the plurality of transmitter antennas on the basis of a precoder matrix W , wherein the precoder matrix W depends on the modified aggregate interference channel F .",HUAWEI TECH CO LTD;;GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;DEBBAH MEROUANE;;GUILLAUD MAXIME,GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;DEBBAH MEROUANE;;GUILLAUD MAXIME,,https://lens.org/063-014-607-198-491,Patent Application,yes,2,2,7,7,0,H04B7/0456;;H04L5/143;;H04L5/0073;;H04B7/0456;;H04L5/143;;H04B17/345;;H04L5/0073;;H04L5/14,H04L5/14;;H04B7/04,,13,12,048-258-990-971-877;;009-202-158-548-758;;125-926-536-179-144;;068-062-674-738-580;;101-625-570-556-142;;026-879-062-415-206;;111-952-104-230-04X;;038-630-896-931-241;;031-873-460-592-877;;038-105-302-659-514;;063-497-212-541-856;;015-638-893-092-27X,10.1109/mcom.2012.6353682;;10.1109/mcom.2015.7105650;;10.1109/twc.2013.101713.121152;;10.1109/vtcfall.2012.6399106;;10.1109/glocom.2010.5683973;;10.1109/acssc.2013.6810573;;10.1109/jsac.2014.2330091;;10.1109/msp.2011.2178495;;10.1109/mcom.2014.6736761;;10.1109/vetecf.2011.6093291;;10.1109/iswcs.2012.6328480;;10.1002/bltj.21602,"YIN BEI ET AL: ""Full-duplex in large-scale wireless systems"", 2013 ASILOMAR CONFERENCE ON SIGNALS, SYSTEMS AND COMPUTERS, IEEE, 3 November 2013 (2013-11-03), pages 1623 - 1627, XP032593086, DOI: 10.1109/ACSSC.2013.6810573;;Z. SHEN; A. KHORYAEV; E. ERIKSSON; X. PAN: ""Dynamic uplink-downlink configuration and interference management in TD-LTE"", IEEE COMMUNICATIONS MAGAZINE, November 2012 (2012-11-01);;S. GOYAL; P. LIU; S. S PANWAR; R. A. DIFAZIO; R. YANG; E. BALA: ""Full duplex cellular systems: Will doubling interference prevent doubling capacity?"", IEEE COMMUNICATIONS MAGAZINE, May 2015 (2015-05-01);;Y. S. CHOI; H. SHIRANI-MEHR: ""Simultaneous Transmission and Reception: Algorithm, Design and System Level Performance"", IEEE TRANSACTIONS ON WIRELESS COMMUNICATIONS, December 2013 (2013-12-01);;K. . PEDERSEN; Y. WANG; B. SORET; F. FREDERIKSEN: ""eICIC functionality and performance for LTE HetNet co-channel deployments"", PROC. IEEE VEHICULAR TECHNOLOGY CONFERENCE FALL, 2012;;T. NOVLAN; J. G. ANDREWS; SOHN; R. K. GANTI; A. GHOSH: ""Comparison of fractional frequency reuse approaches in the OFDMA cellular downlink"", PROC. IEEE GLOBAL TELECOMMUNICATION CONFERENCE, 2010;;B. YIN; M. STUDER; J. R. CAVALLARO; J. LILLEBERG: ""Full-duplex in large-scale wireless systems"", PROC. ASILOMAR CONFERENCE ON SIGNAL SYSTEMS AND COMPUTERS, November 2013 (2013-11-01);;H. Q. NGO; H. A. SURAWERA; M. MATTHAIOU; E. G. LARSSON, MULTIPAIR FULL-DUPLEX RELAYING WITH MASSIVE ARRAYS AND LINEAR PROCESSING, Retrieved from the Internet <URL:http://arxiv.org/abs/1405.1063>;;F. RUSEK; D. PERSSON; B. K. LAU; E. G. LARSSON; T. L. MARZETTA; O. EDFORS; F. TUFVESSON: ""Scaling up MIMO: Opportunities and challenges with very large arrays"", IEEE SIGNAL PROCESSING MAGAZINE, January 2013 (2013-01-01);;E. G. LARSSON; F. TUFVESSON; O. EDFORS; T. L. MARZETTA: ""Massive MIMO for Next Generation Wireless Systems"", IEEE COMMUNICATIONS MAGAZINE, February 2014 (2014-02-01);;XIANG GAO; EDFORS, O.; RUSEK, F.; TUFVESSON, F.: ""Linear Pre-Coding Performance in Measured Very-Large MIMO Channels"", VEHICULAR TECHNOLOGY CONFERENCE (VTC FALL), 2011 IEEE, 5 September 2011 (2011-09-05), pages 1 - 5, XP032029775, DOI: doi:10.1109/VETECF.2011.6093291;;HOYDIS, J.; HOEK, C.; WILD, T.; TEN BRINK, S.: ""Channel measurements for large antenna arrays,'' in Wireless Communication Systems (ISWCS"", 2012 INTERNATIONAL SYMPOSIUM, 28 August 2012 (2012-08-28), pages 811 - 815;;J. HOYDIS; K. HOSSENI; S. T. BRINK; M. DEBBAH: ""Making smart use of excess antennas: Massive MIMO, small cells, and TDD"", BELL LABS TECHNICAL JOURNAL, vol. 18, no. 2, 2013, pages 5 - 21, XP011569588, DOI: doi:10.1002/bltj.21602",PENDING
168,EP,A2,EP 0884054 A2,069-659-906-776-454,1998-12-16,1998,EP 98500119 A,1998-05-12,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses,"Comprises a dose of (a) enalapril or a pharmaceutically acceptable salt thereof and another dose of (b) nitrendipine or a pharmaceutically acceptable salt thereof and in that it is administered in single-dose gallenic form. The method comprises: (a) dissolving enalapril maleate in water with an inorganic salt; (b) mixing the micronized nitrendipine with a fraction of the disintegrating excipients, the wetting agent, the fragmentary diluting agent, the agglutinating agent, and the plastic diluting agent, previously sieved; (c) granulating the products homogenized in section (b) with the solution obtained in section (a); (d) drying the granulated mass; (e) incorporating the lubricating agent, and the remaining fraction of the disintegrating excipients and homogenizing the calibrated granulate; (f) compressing the granulate. Use of said association for the manufacture of a medicament for the treatment of illnesses of the cardiovascular system.",VITA INVEST SA,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAGUIN ANTO;;CANOVAS PEDRO,"LABORATORIOS VITA, S.A. (2003-08-01);;S.A. *LABORATORIOS VITA (2003-04-09);;FERRER INTERNACIONAL, S.A. (2009-03-11);;PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L. (2005-05-02);;S.A. *LABORATORIOS VITAAVDA. DE BARCELONA 69, 0897 (2003-04-09)",https://lens.org/069-659-906-776-454,Patent Application,yes,0,5,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/40;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
169,EP,B1,EP 3403364 B1,074-594-337-120-274,2019-10-02,2019,EP 16701746 A,2016-01-26,EP 2016051504 W,2016-01-26,AN APPARATUS AND A METHOD FOR MANAGING FULL-DUPLEX COMMUNICATION BETWEEN A BASE STATION AND A PLURALITY OF USER EQUIPMENTS,,HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;DEBBAH MEROUANE;;GUILLAUD MAXIME,,https://lens.org/074-594-337-120-274,Granted Patent,yes,2,0,7,7,0,H04B7/0456;;H04L5/143;;H04L5/0073;;H04B7/0456;;H04L5/143;;H04B17/345;;H04L5/0073;;H04L5/14,H04L5/14;;H04B7/04,,1,0,,,"YIN BEI ET AL: ""Full-duplex in large-scale wireless systems"", 2013 ASILOMAR CONFERENCE ON SIGNALS, SYSTEMS AND COMPUTERS, IEEE, 3 November 2013 (2013-11-03), pages 1623-1627, XP032593086, DOI: 10.1109/ACSSC.2013.6810573 [retrieved on 2014-05-05] cited in the application",ACTIVE
170,US,A1,US 2016/0045332 A1,009-795-199-283-748,2016-02-18,2016,US 201514645272 A,2015-03-11,US 201514645272 A;;US 201461951351 P,2014-03-11,COLLAPSIBLE TWO-PIECE OLIF IMPLANT,"The invention is directed to an interbody fusion device comprises a load bearing component and a retention component and further comprises two bone screws that pass through the retention device and into the vertebral bodies. When implanted, the construct is flush with the anterior face of the vertebras and provides support and temporary fixation for the ultimate fusion of the vertebral bodies.",SPINESMITH PARTNERS LP,KANA RICHARD J;;DUNWORTH KEVIN;;ROSSMAN JOHN B;;DUARTE LUIS,SPINESMITH PARTNERS L.P (2015-11-04),https://lens.org/009-795-199-283-748,Patent Application,yes,3,5,2,2,0,A61F2/4455;;A61F2/4455;;A61F2002/30471;;A61F2002/30471;;A61F2002/30578;;A61F2002/30578;;A61F2002/30579;;A61F2002/30579,A61F2/44,,0,0,,,,ACTIVE
171,CA,A1,CA 2234899 A1,057-762-958-963-753,1998-11-13,1998,CA 2234899 A,1998-05-12,ES 9701017 A,1997-05-13,"FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND OF A CALCIUM CHANNEL ANTAGONIST, METHOD FOR PREPARATION AND USETHEREOF IN THE TREATMENT OF CARDIOVASCULARILLNESSES","FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND OF A CALCIUM CHANNEL ANTAGONIST, METHOD FOR PREPARATION AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR ILLNESSES Comprises a dose of (a) enalapril or a pharmaceutically acceptable salt thereof and another dose of (b) nitrendipine or a pharmaceutically acceptable salt thereof and in that it is administered in single-dose gallenic form. The method comprises: (a) dissolving enalapril maleate in water with an inorganic salt; (b) mixing the micronized nitrendipine with a fraction of he disintegrating excipients, the wetting agent, the fragmentary diluting agent, the agglutinating agent, and the plastic diluting agent, previously sieved; (c) granulating the products homogenized in section (b) with the solution obtained in section (a); (d) drying the granulated mass; (e) incorporating the lubricating agent, and the remaining fraction of the disintegrating excipients and homogenizing the calibrated granulate; (f) compressing the granulate. Use of said association for the manufacture of a medicament for the treatment of illnesses of the cardiovascular system.",VITA INVEST SA,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN;;CANOVAS SOLER PEDRO,,https://lens.org/057-762-958-963-753,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
172,ZA,B,ZA 983806 B,019-034-489-017-495,1999-02-19,1999,ZA 983806 A,1998-05-06,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist method for preparation and use thereof in the treatment of cardiovascular illnesses,,VITA INVEST SA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/019-034-489-017-495,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
173,US,B2,US 10058434 B2,033-597-341-654-208,2018-08-28,2018,US 201514645272 A,2015-03-11,US 201514645272 A;;US 201461951351 P,2014-03-11,Collapsible two-piece olif implant,"The invention is directed to an interbody fusion device comprises a load bearing component and a retention component and further comprises two bone screws that pass through the retention device and into the vertebral bodies. When implanted, the construct is flush with the anterior face of the vertebras and provides support and temporary fixation for the ultimate fusion of the vertebral bodies.",SPINESMITH PARTNERS LP,KANA RICHARD J;;DUNWORTH KEVIN;;ROSSMAN JOHN B;;DUARTE LUIS,SPINESMITH PARTNERS L.P (2015-11-04),https://lens.org/033-597-341-654-208,Granted Patent,yes,3,0,2,2,0,A61F2/4455;;A61F2/4455;;A61F2002/30471;;A61F2002/30471;;A61F2002/30578;;A61F2002/30578;;A61F2002/30579;;A61F2002/30579,A61F2/44;;A61F2/30,,0,0,,,,ACTIVE
174,HU,A2,HU P9801075 A2,065-928-143-805-823,1999-01-28,1999,HU P9801075 A,1998-05-12,ES 9701017 A,1997-05-13,"FIXED-DOSE ASSOCIATION OF AN ANGIOTENSINCONVERTING ENZYME INHIBITOR AND OF A CALCIUM CHANNEL ANTAGONIST, METHOD FOR PREPARATION AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR ILLNESSES","A találmány egy angiőtenzin kőnvertáló enzim inhibitőr és egykalciűmcsatőrna-antagőnista meghatárőzőtt dózisú kőmbinációja, azzaljelemezve, hőgy a) enalapril vagy gyógyászatilag alkalmazható sójánakegy dózisát és b) nitrendipin vagy gyógyászatilag alkalmazható sójánakegy másik dózisát tartalmazza, és a kőmbináció egyszeri dózisúgalenűsi készítmény főrmájában alkalmazandó. A találmány tárgyát képezi a fenti kőmbinációt tartalmazó gyógyászatikészítmények, tővábbá annak előállítására szőlgáló eljárás. ŕ",VITA INVEST SA,CANOVAS SOLER PERDO;;DELGADILLO DUARTE JOAQUIN;;MICHETO ESCUDER LUIS MANUEL,"FERRER INTERNACIONAL, S.A., ES (2010-12-28)",https://lens.org/065-928-143-805-823,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/40;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,PENDING
175,BR,A8,BR 102018068920 A8,108-022-247-989-548,2023-05-09,2023,BR 102018068920 A,2018-09-18,BR 102018068920 A,2018-09-18,CATALISADORES QUÍMICOS HETEROGÊNEOS À BASE DE AREIA MONAZÍTICA PARA A REAÇÃO DE TRANSESTERIFICAÇÃO DE TRIACILGLICERÓIS DE BIO-ÓLEOS COM ALCOÓIS DE CADEIAS MOLECULARES CURTAS PARA A PRODUÇÃO DE MONOÉSTERES DE ÁCIDOS GRAXOS (BIODIESEL),"CATALISADORES QUÍMICOS HETEROGÊNEOS À BASE DE AREIA MONAZÍTICA PARA A REAÇÃO DE TRANSESTERIFICAÇÃO DE TRIACILGLICERÓIS DE BIO-ÓLEOS COM ALCOÓIS DE CADEIAS MOLECULARES CURTAS PARA A PRODUÇÃO DE MONOÉSTERES DE ÁCIDOS GRAXOS (BIODIESEL) A presente invenção trata do processo para produção de biodiesel, uma mistura de ésteres de ácidos graxos, obtido por transesterificação de triacilgliceróis com alcoóis de cadeia molecular relativamente curta, por uso de catalisadores heterogêneos derivados de um minério de terras raras, diferentes dos tradicionalmente encontrados no estado da técnica: o catalisador consiste da fração pesada de areia monazítica, proveniente da mineração de terras raras, misturada com óxido de cálcio e submetida à calcinação.",UNIV FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI;;FUND AMPARO PESQUISA ESTADO MINAS GERAIS FAPEMIG;;FUNDACAO UNIV FEDERAL DO PIAUI UFPI,BÁRBARA GONÇALVES ROCHA;;JOSÉ DOMINGOS FABRIS;;LUIS CARLOS DUARTE CAVALCANTE,,https://lens.org/108-022-247-989-548,Patent Application,no,0,0,2,2,0,C07C67/02;;C10G3/48;;C10G3/40;;B01J23/10;;C01B25/16;;C01B25/08;;C10L1/02;;C10L2270/026;;C08K2003/2206;;B01J35/33;;Y02P30/20;;Y02E50/10,B01J23/10;;B01J23/02;;C07C67/03;;C10G3/00;;C10L1/02,,0,0,,,,DISCONTINUED
176,BR,A2,BR 102018014137 A2,197-540-294-861-289,2020-02-04,2020,BR 102018014137 A,2018-07-11,BR 102018014137 A,2018-07-11,modelo experimental para treinamento de reversão de vasectomia,"modelo experimental para treinamento de reversão de vasectomia a presente invenção tem como intuito promover o ganho de habilidades em microcirurgia e permitir o treinamento de uma reversão de vasectomia, sem a necessidade da utilização de animais de laboratório. o modelo experimental proposto é constituído de uma pequena caixa e 2 tubos de silicone, com revestimento de polivinil acetato (pva), da cor branca. a invenção consegue simular de forma bastante equivalente o campo operatório de uma reversão de vasectomia, no momento que os cotos dos ductos deferentes são isolados das outras estruturas do cordão espermático. destaca-se pela praticidade, sendo de fácil transporte e manuseio, permitindo várias sessões de treinamento de reversão de vasectomia com mesmo modelo, bastando possuir instrumentais básicos de microcirurgia (microscópio, lupas, pinças e fio apropriado).",UNIV DO ESTADO DO PARA,HERICK PAMPOLHA HUET DE BACELAR;;LUIS OTÁVIO AMARAL DUARTE PINTO,,https://lens.org/197-540-294-861-289,Patent Application,no,0,0,1,1,0,A61B17/12;;G09B23/28,G09B23/28;;A61B17/12,,0,0,,,,DISCONTINUED
177,DE,D1,DE 69813083 D1,065-531-142-646-407,2003-05-15,2003,DE 69813083 T,1998-05-12,ES 9701017 A,1997-05-13,Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen,,VITA INVEST SA,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN ANTO;;CANOVAS PEDRO,"LABORATORIOS VITA, S.A., SANT JOAN DESPI, BARCELON (2004-01-29);;PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L., PETIT-L (2005-06-16)",https://lens.org/065-531-142-646-407,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K31/40;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
178,ES,T3,ES 2197443 T3,140-839-265-793-393,2004-01-01,2004,ES 98500119 T,1998-05-12,EP 98500119 A;;ES 9701017 A,1997-05-13,ASOCIACION A DOSIS FIJAS DE UN INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DE LOS CANALES DE CALCIO PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES.,"SE INCLUYE UNA DOSIS DE (A) ENALAPRIL O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, Y OTRA DOSIS DE (B) NITRENDIPINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, Y SE ADMINISTRA EN UNA FORMA GALENICA DE DOSIS UNICA. EL PROCEDIMIENTO INCLUYE: (A) DISOLVER EL MALEATO DE ENALAPRIL EN AGUA CON UNA SAL INORGANICA; (B) MEZCLAR LA NITRENDIPINA MICRONIZADA CON UNA FRACCION DE LOS EXCIPIENTES DISGREGANTES, EL AGENTE HUMECTANTE, EL AGENTE DILUYENTE FRAGMENTARIO, EL AGENTE AGLUTINANTE Y EL AGENTE DILUYENTE PLASTICO, PREVIAMENTE TAMIZADOS; (C) GRANULAR LOS PRODUCTOS HOMOGENEIZADOS EN LA SECCION (B) CON LA SOLUCION OBTENIDA EN LA SECCION (A); (D) SECAR LA MASA GRANULADA; (E) INCORPORAR EL AGENTE LUBRICANTE Y EL RESTO DE LA FRACCION DE LOS EXCIPIENTES DISGREGANTES Y HOMOGENEIZAR EL GRANULADO CALIBRADO; (F) COMPRIMIR EL GRANULADO. SE DESCRIBE EL USO DE DICHA ASOCIACION PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA CARDIOVASCULAR.",VITA LAB,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN ANTO;;CANOVAS PEDRO,,https://lens.org/140-839-265-793-393,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/40;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
179,BR,A2,BR 102018068920 A2,187-998-167-009-140,2020-03-31,2020,BR 102018068920 A,2018-09-18,BR 102018068920 A,2018-09-18,catalisadores químicos heterogêneos à base de areia monazítica para a reação de transesterificação de triacilgliceróis de bio-óleos com alcoóis de cadeias moleculares curtas para a produção de monoésteres de ácidos graxos (biodiesel),"catalisadores químicos heterogêneos à base de areia monazítica para a reação de transesterificação de triacilgliceróis de bio-óleos com alcoóis de cadeias moleculares curtas para a produção de monoésteres de ácidos graxos (biodiesel) a presente invenção trata do processo para produção de biodiesel, uma mistura de ésteres de ácidos graxos, obtido por transesterificação de triacilgliceróis com alcoóis de cadeia molecular relativamente curta, por uso de catalisadores heterogêneos derivados de um minério de terras raras, diferentes dos tradicionalmente encontrados no estado da técnica: o catalisador consiste da fração pesada de areia monazítica, proveniente da mineração de terras raras, misturada com óxido de cálcio e submetida à calcinação.",FUND AMPARO PESQUISA ESTADO MINAS GERAIS FAPEMIG;;FUNDACAO UNIV FEDERAL DO PIAUI UFPI;;UNIV FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI,BÁRBARA GONÇALVES ROCHA;;JOSÉ DOMINGOS FABRIS;;LUIS CARLOS DUARTE CAVALCANTE,,https://lens.org/187-998-167-009-140,Patent Application,no,0,0,2,2,0,C07C67/02;;C10G3/48;;C10G3/40;;B01J23/10;;C01B25/16;;C01B25/08;;C10L1/02;;C10L2270/026;;C08K2003/2206;;B01J35/33;;Y02P30/20;;Y02E50/10,B01J23/10;;B01J35/00;;C01B25/08;;C01B25/16;;C01F17/00;;C07C67/02;;C08K3/22;;C10G3/00;;C10L1/02,,0,0,,,,DISCONTINUED
180,US,B2,US 10715303 B2,185-798-223-272-607,2020-07-14,2020,US 201816045340 A,2018-07-25,EP 2016051504 W,2016-01-26,Apparatus and a method for managing full-duplex communication between a base station and a plurality of user equipments,"The invention relates to an apparatus ( 301 ) for managing full-duplex communication between a base station (BS 0 ) and a set of user equipments ( 101 a,b ), the base station (BS 0 ) comprising a plurality of transmitter antennas, the plurality of transmitter antennas being associated with a downlink communication channel H between the base station (BS 0 ) and the set of user equipments ( 101 a,b ) and a plurality of interference channels G i between the base station (BS 0 ) and a plurality of neighboring base stations (BS i ).",HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;DEBBAH MEROUANE;;GUILLAUD MAXIME,HUAWEI TECHNOLOGIES CO. LTD (2019-03-04),https://lens.org/185-798-223-272-607,Granted Patent,yes,15,0,7,7,0,H04B7/0456;;H04L5/143;;H04L5/0073;;H04B7/0456;;H04L5/143;;H04B17/345;;H04L5/0073;;H04L5/14,H04L5/14;;H04B7/0456;;H04B17/345;;H04L5/00,,22,11,026-879-062-415-206;;048-258-990-971-877;;009-202-158-548-758;;125-926-536-179-144;;068-062-674-738-580;;101-625-570-556-142;;038-630-896-931-241;;031-873-460-592-877;;038-105-302-659-514;;063-497-212-541-856;;015-638-893-092-27X,10.1109/acssc.2013.6810573;;10.1109/mcom.2012.6353682;;10.1109/mcom.2015.7105650;;10.1109/twc.2013.101713.121152;;10.1109/vtcfall.2012.6399106;;10.1109/glocom.2010.5683973;;10.1109/msp.2011.2178495;;10.1109/mcom.2014.6736761;;10.1109/vetecf.2011.6093291;;10.1109/iswcs.2012.6328480;;10.1002/bltj.21602,"YIN BEI; WU MICHAEL; STUDER CHRISTOPH; CAVALLARO JOSEPH R.; LILLEBERG JORMA: ""Full-duplex in large-scale wireless systems"", 2013 ASILOMAR CONFERENCE ON SIGNALS, SYSTEMS AND COMPUTERS, IEEE, 3 November 2013 (2013-11-03), pages 1623 - 1627, XP032593086, DOI: 10.1109/ACSSC.2013.6810573;;Z. Shen et al., “Dynamic Uplink-Downlink Configuration and Interference Management in TD-LTE,” IEEE Communications Magazine, Nov. 2012, pp. 51-59.;;S. Goyal et al., “Full Duplex Cellular Systems: Will Doubling Interference Prevent Doubling Capacity?,” IEEE Communications Magazine, May 2015, pp. 121-127.;;Y. S. Choi et al., “Simultaneous Transmission and Reception: Algorithm, Design and System Level Performance,” IEEE Transactions on Wireless Communications, vol. 12, No. 12, Dec. 2013, pp. 5992-6010.;;K. I. Pedersen et al., “eICIC Functionality and Performance for LTE HetNet Co-Channel Deployments,” 2012 IEEE (5 pp.).;;T. Novlan et al., “Comparison of Fractional Frequency Reuse Approaches in the OFDMA Cellular Downlink,” 2010 IEEE (5 pp.).;;H. Q. Ngo et al., “Multipair Full-Duplex Relaying with Massive Arrays and Linear Processing,” May 5, 2014, IEEE International Conference on Communications (15 pp.).;;F. Rusek et al., “Scaling up MIMO: Opportunities and challenges with very large arrays,” IEEE Signal Processing Magazine, Jan. 2013, pp. 40-60.;;E. G. Larsson et al., “Massive MIMO for Next Generation Wireless Systems”, IEEE Communications Magazine, Feb. 2014, pp. 186-195.;;Xiang Gao et al., “Linear pre-coding performance in measured very-large MIMO channels,” 2011 IEEE (5 pp.).;;Jakob Hoydis et al., “Channel Measurements for Large Antenna Arrays,” 2012 IEEE, pp. 811-815.;;Jakob Hoydis et al., “Making Smart Use of Excess Antennas: Massive MIMO, Small Cells, and TDD,” Bell Labs Technical Journal 18(2), 2013, pp. 5-21.;;A. Sabharwal, et al., “In-Band Full-Duplex Wireless: Challenges and Opportunities,” May 20, 2014, pp. 1-22.;;4G Americas, “4G Americas' Recommendations on 5G Requirements and Solutions,” Oct. 2014 (40 pp.).;;3GPP, “Evolved Universal Terrestrial Radio Access (E-UTRA) and Evolved Universal Terrestrial Radio Access Network (E-UTRAN); Overall Description; Stage 2 (3GPP TS 36.300 version 10.4.0 Release 10),” ETSI TS 136 300 V10.4.0, Jun. 2011. pp. 1-207.;;Huawei, “Further Analysis of Soft Frequency Reuse Scheme,” 3GPP TSG RAN WG1#42, R1-050841, London, UK, Aug. 29-Sep. 2, 2005 (6 pp.).;;E. Everett et al., “Passive Self-Interference Suppression for Full-Duplex Infrastructure Nodes,” Dec. 17, 2013, pp. 1-16.;;E. Everett et al., “Measurement-driven Evaluation of All-digital Many-antenna Full-duplex Communication,” Aug. 15, 2015, pp. 1-15.;;3GPP, 3rd Generation Partnership Project; Technical Specification Group Radio Access Network; Evolved Universal Terrestrial Radio Access (E-UTRA); Further enhancements to LTE Time Division Duplex (TDD) for Downlink-Uplink (DL-UL) interference management and traffic adaptation (Release 11), 3GPP TR 36.828 V11.0.0 (Jun. 2012), pp. 1-109.;;International Search Report, dated Sep. 26, 2016, in International Application No. PCT/EP2016/051504 (6 pp.).;;Written Opinion of the International Searching Authority, dated Sep. 26, 2016, in International Application No. PCT/EP2016/051504 (7 pp.).;;International Search Report dated Sep. 26, 2016 in corresponding International Patent Application No. PCT/EP2016/051504.",ACTIVE
181,TW,B,TW 562679 B,194-981-984-600-70X,2003-11-21,2003,TW 87107210 A,1998-05-11,ES 9701017 A,1997-05-13,"A pharmaceutical composition for fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist, method for preparation and a pharmaceutical composition for the treatment of cardiovascular illnesses","Use of said association for the manufacture of a medicament for the treatment of illnesses of the cardiovascular system comprises a dose of (a) enalapril or a pharmaceutically acceptable salt thereof and another dose of (b) nitrendipine or a pharmaceutically acceptable salt thereof and in that it is administered in single-dose gallenic form. The method comprises: (a) dissolving enalapril maleate in water with an inorganic salt; (b) mixing the micronized nitrendipine with a fraction of the disintegrating excipients, the wetting agent, the fragmentary diluting agent, the agglutinating agent, and the plastic diluting agent, previously sieved; (c) granulating the products homogenized in section (b) with the solution obtained in section (a); (d) drying the granulated mass; (e) incorporating the lubricating agent, and the remaining fraction of the disintegrating excipients and homogenizing the calibrated granulate; (f) compressing the granulate.",VITA INVEST SA,CANOVAS PEDRO SOLER;;DELGADILLO DUARTE JOAGUIN;;MICHETO ESCUDER LUIS MANUEL,,https://lens.org/194-981-984-600-70X,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
182,CZ,B6,CZ 292616 B6,132-583-022-848-752,2003-11-12,2003,CZ 138198 A,1998-05-05,ES 9701017 A,1997-05-13,"Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist, use thereof, pharmaceutical composition based thereon and process of its preparation","In the present invention, there is disclosed a fixed-dose combination of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist, the combination comprising in single-dose galenic form a dose of (a) enalapril in the form of its sodium salt and another dose of (b) micronized nitrendipine, wherein said enalapril dose amount is within the range 2.5 to 20 mg and said nitrendipine dose amount ranges within 5 to 20 mg. Disclosed is also a pharmaceutical composition containing the above described combination and further also plastic diluting agent, a fragmentary diluting agent, a disintegrating agent, an agglutinating agent, a wetting agent, and a lubricating agent. Claimed is also the use of the above-indicated combination for the manufacture of a medicament for the treatment cardiovascular system diseases, in particular arterial hypertension.",VITA LAB,CANOVAS SOLER PEDRO;;DELGADILLO DUARTE JOAQUIN;;MICHETO ESCUDER LUIS MANUEL,,https://lens.org/132-583-022-848-752,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
183,PT,E,PT 884054 E,139-984-622-479-50X,2003-08-29,2003,PT 98500119 T,1998-05-12,ES 9701017 A,1997-05-13,ASSOCIACAO DE DOSE FIXA COMPREENDENDO UM INIBIDOR DO ENZIMA CONVERSOR DA ANGIOTENSINA E DE UM ANTAGONISTA DOS CANAIS DE CALCIO PARA O TRATAMENTO DE DOENCAS CARDIOVASCULARES,,VITA LAB,ESCUDE LUIS MANUEL MICHETO;;DUARTE JOAQUIN ANTONIO DELGADI;;CANOVAS PEDRO,,https://lens.org/139-984-622-479-50X,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K31/40;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
184,US,A1,US 2018/0018125 A1,162-934-504-420-222,2018-01-18,2018,US 201615210567 A,2016-07-14,US 201615210567 A,2016-07-14,BREACH DETECTION IN INTEGRATED CIRCUITS,"An apparatus embodiment includes an integrated circuit (IC) and breach-detection circuitry. The IC includes data storage circuitry, a power grid configured to distribute power to the data storage circuitry, and a plurality of nodes distributed over at least one sensitive region of the IC. The breach-detection circuitry monitors power grid integrity at the at least one sensitive region of the IC and detects an event indicative of a breach by an external probe at a portion of the at least one sensitive region in response to floating node detection or a change in voltage at one of the plurality of nodes.",FREESCALE SEMICONDUCTOR INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS;;GODOI GUILHERME,NXP USA INC (2016-07-14),https://lens.org/162-934-504-420-222,Patent Application,yes,6,0,4,4,0,G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F3/0623;;G06F3/064;;G06F3/0652;;G06F3/0679;;H01L23/57,G06F3/06,,0,0,,,,ACTIVE
185,NO,L,NO 982112 L,183-371-169-999-219,1998-11-16,1998,NO 982112 A,1998-05-08,ES 9701017 A,1997-05-13,"Blanding med bestemt dose, av en angiotensinkonverterende enzyminhibitor og en kalsiumkanal antagonist, fremgangsmÕte for fremstilling og anvendelse derav i behandling av kardiovaskulµre sykdommer",,VITA INVEST SA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/183-371-169-999-219,Abstract,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
186,US,B2,US 9056134 B2,171-973-824-545-954,2015-06-16,2015,US 201113188265 A,2011-07-21,US 201113188265 A;;US 36639510 P,2010-07-21,Single daily dosage form for prevention and treatment of metabolic syndrome,"The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and/or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and/or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and/or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.",DUARTE-VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA;;ROSADO JORGE LUIS;;NUCITEC SA DE CV,DUARTE-VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA;;ROSADO JORGE LUIS,NUCITEC S.A. DE C.V (2011-01-13),https://lens.org/171-973-824-545-954,Granted Patent,yes,3,16,6,6,0,A61K45/06;;A61K45/06;;A61K9/4808;;A61K9/4808;;A61K31/155;;A61K31/155;;A61K31/40;;A61K31/40;;A61K31/403;;A61K31/403;;A61K31/41;;A61K31/41;;A61K31/60;;A61K31/60;;A61P3/00,A61K9/48;;A61K31/155;;A61K31/40;;A61K31/403;;A61K31/41;;A61K31/60;;A61K45/06,,0,0,,,,INACTIVE
187,JP,A,JP H11124330 A,110-251-973-620-746,1999-05-11,1999,JP 13059098 A,1998-05-13,ES 9701017 A,1997-05-13,"FIXED DOSE COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND CALCIUM CHANNEL ANTAGONIST, ITS PRODUCTION AND ITS USE FOR TREATMENT OF CARDIOVASCULAR DISEASE","PROBLEM TO BE SOLVED: To provide a fixed dose combination of an angiotensin converting enzyme inhibitor and a calcium channel antagonist, its production process and its use for the treatment of cardiovascular diseases. SOLUTION: This preparation contains (a) a dose of enalapril or its pharmacologically permissible salt and (b) a dose of nitrendipine or its pharmacologically permissible salt and is administered in the form of a single dose preparation. The process for the production of the preparation comprises (a) the dissolution of enalapril maleate and an inorganic salt into water, (b) the mixing of pulverized nitrendipine with preparatorily sieved components composed of a part of disintegration excipient, a wetting agent, a fragment diluent, a coagulant and a plastic diluent, (c) the granulation of the product homogenized in the step (b) together with the solution produced by the step (a), (d) the drying of the granulated product, (e) the compounding of a lubricant and the remaining part of the disintegration excipient followed by the homogenization of the weighed granule and (f) the pressing of the granule.",VITA INVEST SA,SOLER PEDRO CANOVAS;;DELGADILLO DUARTE JOAGUIN;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/110-251-973-620-746,Patent Application,no,0,4,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
188,CA,C,CA 2234899 C,145-677-853-789-967,2004-08-10,2004,CA 2234899 A,1998-05-12,ES 9701017 A,1997-05-13,"FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND OF A CALCIUM CHANNEL ANTAGONIST, METHOD FOR PREPARATION AND USETHEREOF IN THE TREATMENT OF CARDIOVASCULARILLNESSES","FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND OF A CALCIUM CHANNEL ANTAGONIST, METHOD FOR PREPARATION AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR ILLNESSES Comprises a dose of (a) enalapril or a pharmaceutically acceptable salt thereof and another dose of (b) nitrendipine or a pharmaceutically acceptable salt thereof and in that it is administered in single-dose gallenic form. The method comprises: (a) dissolving enalapril maleate in water with an inorganic salt; (b) mixing the micronized nitrendipine with a fraction of she disintegrating excipients, the wetting agent, the fragmentary diluting agent, the agglutinating agent, and the plastic diluting agent, previously sieved; (c) granulating- the products homogenized in section (b) with the solution obtained in section (a); (d) drying the granulated mass; (e) incorporating the lubricating agent, and the remaining fraction of the disintegrating excipients and homogenizing the calibrated granulate; (f) compressing the granulate. Use of said association for the manufacture of a medicament for the treatment of illnesses of the cardiovascular system.",VITA INVEST SA,CANOVAS SOLER PEDRO;;DELGADILLO DUARTE JOAQUIN;;MICHETO ESCUDE LUIS MANUEL,,https://lens.org/145-677-853-789-967,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
189,AU,B2,AU 735404 B2,156-801-678-416-657,2001-07-05,2001,AU 1998/065973 A,1998-05-13,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist,,VITA INVEST SA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,"LABORATORIOS VITA, S.A. (2003-06-26);;PROCTER AND GAMBLE PHARMACEUTICALS S.A.R.L. (2004-10-28)",https://lens.org/156-801-678-416-657,Granted Patent,no,3,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
190,EP,B1,EP 0884054 B1,194-694-945-685-358,2003-04-09,2003,EP 98500119 A,1998-05-12,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses,,VITA INVEST SA,MICHETO ESCUDE LUIS MANUEL;;DELGADILLO DUARTE JOAQUIN ANTO;;CANOVAS PEDRO,"LABORATORIOS VITA, S.A. (2003-08-01);;S.A. *LABORATORIOS VITA (2003-04-09);;FERRER INTERNACIONAL, S.A. (2009-03-11);;PROCTER & GAMBLE PHARMACEUTICALS S.A.R.L. (2005-05-02);;S.A. *LABORATORIOS VITAAVDA. DE BARCELONA 69, 0897 (2003-04-09)",https://lens.org/194-694-945-685-358,Granted Patent,yes,0,1,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/40;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,1,0,,,"BAUER, FRÖMMING, FÜHRER: ""Lehrbuch der Pharmazeutischen Technologie"", 1999, WISSENACHAFTLICHE VERLAGSGESELLSCHAFT MBH STUTTGART, STUTTGART",EXPIRED
191,BR,A,BR 9805597 A,152-561-719-270-071,2000-04-11,2000,BR 9805597 A,1998-05-13,ES 9701017 A,1997-05-13,"Associação em dose fixa de um inibidor da enzima conversora da angiotensina e de um antagonista dos canais de cálcio, procedimento para sua preparação e sua utilização para o tratamento de enfermidades cardiovasculares.","Patente de Invenção: <B>""ASSOCIAçãO EM DOSE FIXA DE UM INIBIDOR DA ENZIMA CONVERSORA DA ANGIOTENSINA E DE UM ANTAGONISTA DOS CANAIS DE CáLCIO, PROCEDIMENTO PARA SUA PREPARAçãO E SUA UTILIZAçãO PARA O TRATAMENTO DE ENFERMIDADES CARDIOVASCULARES""<D>.Compreende (a) enalapirl ou um sal farmaceuticamente aceitável do mesmo e (b) nitrendipino ou um sal farmaceuticamente aceitável do mesmo, que se administra em forma galênica de dose unitária. O processo compreende: (a) dissolver enalapril em água com um sal inorgânico; b) misturar o nitrendipino com uma fração dos excipiente desagregantes, agente umidificante, diluente fragmentário, agente aglutinante e diluente plástico, previamente tamisados; c) granular a mistura do item (b) com a solução obtida no item (a); d) seca a massa granulada; e) incorporar o agente lubrificante e a fração restante de excipientes e homogeneizar o granulado calibrado; f) comprimir o granulado. Utilização da dita associação para a fabricação de um medicamento para tratamento de enfermidades do sistema cardiovascular.",VITA INVEST SA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDE LUIS MANUEL MICHETO,PROCTER AND GAMBLE PHARMACEUTICALS SARL (CH) (2006-05-16),https://lens.org/152-561-719-270-071,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,DISCONTINUED
192,PL,A1,PL 326246 A1,194-206-877-983-71X,1998-11-23,1998,PL 32624698 A,1998-05-12,ES 9701017 A,1997-05-13,"COMPOSITION APPLIED AT PREDETERMINATED DOSIS AND CONSISTING OF A COMBINATION PF ABIOGESTIN ENZYME TRANSFORMING INHIBITOR AND OF CALCIUM CHANNEL ANTAGONIST, METHOD OF PREPARING SUCH COMPOSITION AND APPLICATION THEREOF IN TREATING CARDIOVASCULAR DISEASES",,VITA INVEST SA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN DELGADILLO;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/194-206-877-983-71X,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
193,BR,B1,BR 102016004487 B1,087-896-920-996-930,2023-03-14,2023,BR 102016004487 A,2016-02-29,BR 102016004487 A,2016-02-29,PROCESSO DE BENEFICIAMENTO DE MATERIAL GEMOLÓGICO ATRAVÉS DA GRAVAÇÃO POR LASER CO2,"PROCESSO DE BENEFICIAMENTO DE MATERIAL GEMOLÓGICO ATRAVÉS DA GRAVAÇÃO POR LASER CO2. A presente invenção descreve um processo de beneficiamento de material gemológico, através da gravação de desenhos por meio do uso de laser CO2, com parâmetros de equipamento tais como potência, velocidade, ajuste vertical para foco, configurações de exportação de arquivos, otimizados para a reprodução de formas simples e/ou complexas, compostas por linhas e/ou curvas, contornadas e/ou preenchidas. A presente invenção se situa nos campos de design, joalheria, materiais, gemologia e engenharia.",UNIV FEDERAL RIO GRANDE SUL,MARIANA KUHL CIDADE;;LAUREN DA CUNHA DUARTE;;FELIPE LUIS PALOMBINI,,https://lens.org/087-896-920-996-930,Granted Patent,no,0,0,2,2,0,,B44B7/00;;A44C17/00;;A44C27/00,,0,0,,,,ACTIVE
194,EP,B1,EP 3270323 B1,131-170-211-008-902,2021-03-24,2021,EP 17178495 A,2017-06-28,US 201615210567 A,2016-07-14,BREACH DETECTION IN INTEGRATED CIRCUITS,,NXP USA INC,DUARTE DE MARTIN FABIO;;VILAS BOAS ANDRE LUIS;;GODOI GUILHERME,,https://lens.org/131-170-211-008-902,Granted Patent,yes,1,0,4,4,0,G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F21/86;;H01L23/5286;;H01L23/576;;Y04S40/20;;G06F3/0623;;G06F3/064;;G06F3/0652;;G06F3/0679;;H01L23/57,G06F21/86;;H01L23/00;;H01L23/528,,0,0,,,,ACTIVE
195,SK,B6,SK 284337 B6,107-925-436-996-254,2005-02-04,2005,SK 61698 A,1998-05-11,ES 9701017 A,1997-05-13,"Fixed-dose combination of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist, use thereof, pharmaceutical composition based thereon and process of its preparation","Fixed-dose combination of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist comprising in single-dose galenic form a dose of (a) enalapril in the form of its sodium salt and another dose of (b) micronized nitrendipine, wherein said enalapril dose amount is within the range 2.5 to 20 mg and said nitrendipine dose amount ranges within 5 to 20 mg. Disclosed is also a pharmaceutical composition containing the above described combination and further also plastic diluting agent, a fragmentary diluting agent, a disintegrating agent, an agglutinating agent, a wetting agent, and a lubricating agent and the process of its preparation. Claimed is also the use of the above-indicated combination for the manufacture of a medicament for the treatment cardiovascular system diseases, in particular arterial hypertension.",PROCTER & GAMBLE PHARMA,CANOVAS SOLER PEDRO;;DELGADILLO DUARTE JOAQUIN;;MICHETO ESCUDER LUIS MANUEL,"FERRER INTERNACIONAL, S.A., BARCELONA, ES (2008-04-30)",https://lens.org/107-925-436-996-254,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
196,BR,U2,BR MU9000940 U2,129-088-050-417-646,2012-04-24,2012,BR MU9000940 U,2010-06-24,BR MU9000940 U,2010-06-24,arranjo de vedação para o êmbolo de uma bomba de alta pressão,"ARRANJO DE VEDAçãO PAPA O EMBOLO DE UMA BOMBA DE ALTA PRESSãO. A bomba de alta pressão compreende: uma luva (30) cendo um furo axial passante (31) , um alojamento anelar (32) e um furo axial alargado (33) , aberto para o alojamento anelar (32) e para um extremo (30a) da luva (30) ; um cabeçote (20) fixado ao dito extremo (30a) da luva (130) e definindo uma câmara de compressão (C); um êmbolo (ILO) a ser deslocado no interior do furo axial passante (31), do alojamento anelar (32), do furo axial alargado (33) e da câmara de compressão (a) ; e uma gaxeta (40) , montada no alojamento anelar (32) O arranjo compreende: uma bucha (50) cujo corpo tubular (51) é encaixado, de modo justo, no furo axial alargado (33), definindo reduzida folga radial com o êmbolo (10) e incorporando um flange extremo externo (52) a ser assentado contra o extremo (30a) da luva (30) Um anel de vedação (60) é disposto ent.re o cabeçote (20) e o referido extremo (30a) da luva (30).",SCHULZ SA,ALVES DENCKER FABIANO;;DUARTE MARTINS KARINE CRISTINA;;LUSSOLLI JOAO LUIS,,https://lens.org/129-088-050-417-646,Patent Application,no,0,0,1,1,0,,F04B53/00,,0,0,,,,DISCONTINUED
197,CZ,A3,CZ 138198 A3,159-805-233-684-365,1998-12-16,1998,CZ 138198 A,1998-05-05,ES 9701017 A,1997-05-13,"CONNECTION OF FIXED DOSE OF ENZYME-CONVERTING ANGIOTENSIN INHIBITOR AND CALCIUM PASSAGE ANTAGONIST, PROCESS OF THEIR PREPARATION AND USE FOR TREATING CARDIOVASCULAR DISEASES",,VITA INVEST SA,CANOVAS SOLER PEDRO;;DELGADILLO DUARTE JOAQUIN;;MICHETO ESCUDER LUIS MANUEL,,https://lens.org/159-805-233-684-365,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K31/40;;A61K9/14;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
198,US,A1,US 2012/0021049 A1,184-127-318-557-978,2012-01-26,2012,US 201113188265 A,2011-07-21,US 201113188265 A;;US 36639510 P,2010-07-21,Single Daily Dosage Form for Prevention and Treatment of Metabolic Syndrome,"The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and/or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and/or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and/or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.",DUARTE-VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA;;ROSADO JORGE LUIS;;NUCITEC SA DE CV,DUARTE-VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA;;ROSADO JORGE LUIS,NUCITEC S.A. DE C.V (2011-01-13),https://lens.org/184-127-318-557-978,Patent Application,yes,3,4,6,6,0,A61K45/06;;A61K45/06;;A61K9/4808;;A61K9/4808;;A61K31/155;;A61K31/155;;A61K31/40;;A61K31/40;;A61K31/403;;A61K31/403;;A61K31/41;;A61K31/41;;A61K31/60;;A61K31/60;;A61P3/00,A61K9/48;;A61K31/155;;A61K31/40;;A61K31/403;;A61K31/41;;A61K31/60;;A61P3/00,424/451;;514/423;;514/412;;514/381;;514/161;;514/635,0,0,,,,INACTIVE
199,BR,A2,BR 102018073447 A2,123-430-207-197-972,2020-05-26,2020,BR 102018073447 A,2018-11-13,BR 102018073447 A,2018-11-13,película biocompatível para cicatrização de feridas,"película biocompatível para cicatrização de feridas, invenção pertence ao campo dos produtos de tratamento da pele, setor farmacêutico, o produto em questão pode efetivamente recuperar e tratar feridas aumentando o número de fibras de colágeno e sua qualidade, tendo a vantagem de ser reabsorvida não havendo assim a necessidade de troca ou retirada do curativo, ele foi desenvolvido a partir de uma matriz polimérica, tendo como base quitosa e polivinilalcool, a qual apresenta alta biossegurança e não tem efeitos colaterais ou tóxicos nas células humanas; além disso, a quitosana fonece um material excelente em maciez e alta em respirabilidade, nesta matriz são carreados o óleo de bocaiúva e as nanoparticulas de selênio que apresentam propriedade de acelerar o processo de reparo celular com qualidade de fibras de colágeno.",UNIV FEDERAL DA GRANDE DOURADOS,LETÍCIA CASTELLANI DUARTE;;NELSON LUIS DE CAMPOS DOMINGUES;;SUSANA ELISA MORENO,,https://lens.org/123-430-207-197-972,Patent Application,no,0,0,1,1,0,A61L15/18;;A61L15/28;;A61L15/40;;A61L15/64,A61L15/18;;A61L15/28;;A61L15/40;;A61L15/64,,0,0,,,,PENDING
200,US,A1,US 2020/0325742 A1,171-001-293-809-079,2020-10-15,2020,US 201816492742 A,2018-03-12,US 201816492742 A;;US 201762469827 P;;US 2018/0021913 W,2017-03-10,AUTOMATED CHOKE CONTROL APPARATUS AND METHODS,"Automated choke control apparatus and methods are disclosed herein. An apparatus for automatically controlling a choke valve comprises a controller. The controller is to control a choke position of the choke valve via a first control loop in response to selection of a first one of a plurality of operation modes being detected. The controller is further to control a wellhead pressure of a wellhead via a second control loop in response to selection of a second one of the plurality of operation modes being detected, the wellhead being operatively coupled to the choke valve.",SCHLUMBERGER TECHNOLOGY CORP,ASTUDILLO LUIS;;ALBRECHT DE FREITAS TIAGO;;DUARTE MOSER HENRIQUE;;AZEM WASIM,SCHLUMBERGER TECHNOLOGY CORPORATION (2018-06-20),https://lens.org/171-001-293-809-079,Patent Application,yes,0,10,8,8,0,E21B34/16;;E21B21/08;;E21B21/08;;E21B34/02;;E21B34/16;;E21B34/025;;E21B21/08;;E21B21/106;;E21B34/16;;E21B47/06,E21B21/08;;E21B21/10;;E21B34/02;;E21B47/06,,0,0,,,,ACTIVE
201,RU,C2,RU 2182002 C2,110-956-903-569-236,2002-05-10,2002,RU 98109345 A,1998-05-12,ES 9701017 A,1997-05-13,COMPOSITION CONTAINING FIXED DOSE OF ANGIOTENSIN-TRANSFORMING ENZYME AND CALCIUM CANAL ANTAGONIST AND METHOD FOR PRODUCING THE COMPOSITION AND TREATING CARDIOVASCULAR DISEASES,"medicine. SUBSTANCE: composition has Enalapryl dose or its pharmaceutically permissible salt and different dose of Nitrenedipine or its pharmaceutically permissible salt. The composition is administered in single dose as galenic preparation. Method involves a) dissolving Enalapryl maleate in water with organic salt; b) mixing microionized Nitrenedipine with loosening fillers fraction, moistening agents, fragmental diluting agent, gluing agent and plastic diluting agent preliminarily sieved; c) granulating products homogenized at (b) stage with solution produced at (a); d) drying the granulated mass; e) introducing lubricating agent and the rest of the loosening fillers fraction and homogenizing the calibrated granulate; f) pressing the granulate. EFFECT: enhanced effectiveness of treatment; reduced risk of adverse side effects. 10 cl, 3 dwg, 8 tbl",VITA INVEST SA,KANOVAS SOLER PEDRO;;DELGADIL O DUARTE KHOAKVIN;;MICHETO EHSKUDER LUIS MANUEHL,,https://lens.org/110-956-903-569-236,Granted Patent,no,0,1,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K9/48;;A61K31/40;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
202,US,A1,US 2009/0197831 A1,146-019-425-290-766,2009-08-06,2009,US 71804605 A,2005-07-18,MX PA04010692 A;;MX 2005000058 W,2004-10-28,Composition for the Treatment of Obesity and Hyperlipidemia,"Current invention is related to the pharmaceutical industry in general and to the industry of the manufacture of pharmaceutical products for weight reduction and hyperlipidemia treatment. The advantages of the current invention respect of the similar of the state of the art are that in the present invention side effects normally produced by the consumption of lipase inhibitors are eliminated; optimizing both the lipase inhibitor component and the fat-trapping; with the adequate composition of each one of the components and with very small amounts of each one. The invention consists of a composition for the treatment of the obesity and hyperlipidemia, characterized by comprising in combination a lipase inhibitor and a fat-trapping component.",ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA,ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA,NUCITEC S.A. DE C.V (2008-01-21),https://lens.org/146-019-425-290-766,Patent Application,yes,1,3,5,5,0,A61K31/722;;A61K38/17;;A61P3/04;;A61P3/06;;A61K38/17;;A61K31/722,A61K31/722;;A61P3/04;;A61P3/06,514/55,0,0,,,,INACTIVE
203,BR,A2,BR 102018010131 A2,002-781-123-959-375,2019-11-26,2019,BR 102018010131 A,2018-05-18,BR 102018010131 A,2018-05-18,película biocompatível para cicatrização de feridas,"película biocompatível para cicatrização de feridas é uma invenção pertence ao campo dos produtos de tratamento da pele, setor farmacêutico, o produto em questão pode efetivamente recuperar e tratar feridas aumentando o número de fibras de colágeno e sua qualidade, tendo a vantagem de ser reabsorvida não havendo assim a necessidade de troca ou retirada do curativo, ele foi desenvolvido a partir de uma matriz polimérica, tendo como base quitosa e polivinilalcool, a qual apresenta alta biossegurança e não tem efeitos colaterais ou tóxicos nas células humanas; além disso, a quitosana fonece um material excelente em maciez e alta em respirabilidade, nesta matriz são carreados o óleo de bocaiúva e as nanoparticulas de selênio que apresentam propriedade de acelerar o processo de reparo celular com qualidade de fibras de colágeno.",UNIV FEDERAL DA GRANDE DOURADOS,LETÍCIA CASTELLANI DUARTE;;NELSON LUIS DE CAMPOS DOMINGUES;;SUSANA ELISA MORENO,,https://lens.org/002-781-123-959-375,Patent Application,no,0,0,1,1,0,,A61L15/20;;A61L15/28;;A61L15/34;;A61L15/64,,0,0,,,,DISCONTINUED
204,US,B2,US 8324185 B2,008-961-636-177-746,2012-12-04,2012,US 71804605 A,2005-07-18,MX PA04010692 A;;MX 2005000058 W,2004-10-28,Composition for the treatment of obesity and hyperlipidemia,"Current invention is related to the pharmaceutical industry in general and to the industry of the manufacture of pharmaceutical products for weight reduction and hyperlipidemia treatment. The advantages of the current invention respect of the similar of the state of the art are that in the present invention side effects normally produced by the consumption of lipase inhibitors are eliminated; optimizing both the lipase inhibitor component and the fat-trapping; with the adequate composition of each one of the components and with very small amounts of each one. The invention consists of a composition for the treatment of the obesity and hyperlipidemia, characterized by comprising in combination a lipase inhibitor and a fat-trapping component.",ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA;;NUCITEC S A DF C V,ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL;;PADILLA SANDRA GARCIA,NUCITEC S.A. DE C.V (2008-01-21),https://lens.org/008-961-636-177-746,Granted Patent,yes,1,0,5,5,0,A61K31/722;;A61K38/17;;A61P3/04;;A61P3/06;;A61K38/17;;A61K31/722,A01N43/04,514/55;;514/23;;514/54,1,1,033-502-857-390-069,10.1021/bm025661y;;12625721,"Shenoy et al. Biomacromolecules (2003), vol. 4, pp. 265-272.",INACTIVE
205,MX,A,MX PA06007962 A,029-787-896-699-509,2007-03-28,2007,MX PA06007962 A,2006-07-12,MX PA06007962 A,2006-07-12,COMPOSITION FOR TREATING DYSLIPIDAEMIA AND PROTECTING DIABETIC PATIENTS FROM CARDIOVASCULAR RISKS.,"The present invention is related to the pharmaceutical industry in general, and to the industry for manufacturing pharmaceutical products intended to prevent diabetic patients from cardiovascular risks. The advantages of the present composition compared to further drugs are that it reduces collateral effects caused by drugs for controlling both pathologies; it reduces cardiovascular risks, as well as side effects caused by the formula components; it achieves other synergystics effects by combining an antidiabetic agent along with a dyslipidaemic agent. The inventive composition consists in the combination of (i) a hypoglycemic agent, (ii) a hypolipemiant agent and (iii) a vitamin. ?? ?? ?? ??.",LORIA JORGE LUIS ROSADO,LORIA JORGE LUIS ROSADO;;PADILLA SANDRA GARCIA;;VAZQUEZ MIGUEL ANGEL DUARTE,,https://lens.org/029-787-896-699-509,Patent Application,no,0,0,1,1,0,,A61K31/00;;C07D417/12,,0,0,,,,ACTIVE
206,MX,A,MX 2013015302 A,062-016-238-147-252,2015-06-18,2015,MX 2013015302 A,2013-12-19,MX 2013015302 A,2013-12-19,TILTABLE DRAWER.,"A refrigerated cabinet having a cabinet, thermal insulation, cover or liner, which help it form a cavity which can house objects to be refrigerated with at least one shelf and one door comprising a vegetable drawer which itself on its lateral and opposite walls having an appendage integrated by a head, an upper crossbar, a lower crossbar, a skate, a hump; which runs within a rail comprising a channel formed by a barrier, a lower bay, a neck in C with a straight which is inclined, a gulf and a stump; with the peculiarity that when the vegetable drawer is found in its resting or closed position, the front wall of said vegetable drawer is in close proximity to the vertical; the head (32) is coupled within the neck in C, the skate is in contact with the upper face of the lower bay, and the barrier is in contact with a portion of the lower face of the lower crossbar; and that when the vegetable drawer is extracted in its final runner position, the vegetable drawer has an a inclination with relation to the horizontal; wherein the head (32) is coupled unto the gulf of the rail, and the barrier is in contact with a lateral face of the skate, as well as with a portion of the lower face of the lower crossbar.",MABE SA DE CV,SOLÍS LUIS FRANCÍSCO CASTRO;;ROBLES LÁZARO DUARTE DE;;GONZÁLEZ JUAN SÚAREZ,,https://lens.org/062-016-238-147-252,Patent Application,no,0,1,6,6,0,F25D25/025;;F25D25/025;;F25D25/025;;F25D2500/02;;F25D2500/02;;F25D2500/02,F25D23/04,,0,0,,,,ACTIVE
207,ES,A1,ES 2125198 A1,008-544-606-842-242,1999-02-16,1999,ES 9701017 A,1997-05-13,ES 9701017 A,1997-05-13,Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses,"Comprises a dose of (a) enalapril or a pharmaceutically acceptable salt thereof and another dose of (b) nitrendipine or a pharmaceutically acceptable salt thereof and in that it is administered in single-dose gallenic form. The method comprises: (a) dissolving enalapril maleate in water with an inorganic salt (b) mixing the micronized nitrendipine with a fraction of the disintegrating excipients, the wetting agent, the fragmentary diluting agent, the agglutinating agent, and the plastic diluting agent, previously sieved (c) granulating the products homogenized in section (b) with the solution obtained in section (a) (d) drying the granulated mass (e) incorporating the lubricating agent, and the remaining fraction of the disintegrating excipients and homogenizing the calibrated granulate (f) compressing the granulate. Use of said association for the manufacture of a medicament for the treatment of illnesses of the cardiovascular system.",VITA INVEST SA,CANOVAS SOLER PEDRO;;DELGADILLO DUARTE JOAQUIN ANTO;;MICHETO ESCUDE LUIS MANUEL,"FERRER INTERNACIONAL, S.A. (2011-05-25)",https://lens.org/008-544-606-842-242,Patent Application,no,1,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,3,3,004-580-521-481-532;;021-843-132-425-105;;023-074-988-210-709,10.3109/10641968409044064;;6094050;;2468881;;10.1097/00005344-198806124-00016;;1691399;;10.1097/00005344-199004000-00021,"CHEMICAL ABSTRACTS, Vol. 102, Nr. 1, 7-Enero-1985, pagina 35, resumen 372X, Columbus, Ohio, US; M.E. VINCENT y col. ""Hemodynamic and humoral responses to enalapril and nifedipine in the rat"" & CLIN. EXP. HYPERTENS., PART A 1984, A6 (8), 1485-1497;;J. CARDIOVASC. PHARMACOL. Vol. 12 (Suppl. 4), 1988; A. ZANCHETTI; ""Nitrendipine und ACE Inhibitors"".;;J. CARDIOVASC. PHARMACOL. Vol. 15, No 4, 1990; E. SCALBERT y col.; ""Systemic and Regional Hemodynamic Interactions of Perindopril and Nitrendipine in the Spontaneously Hypertensive rat""",EXPIRED
208,EP,A1,EP 3592941 A1,132-683-132-412-907,2020-01-15,2020,EP 18764140 A,2018-03-12,US 201762469827 P;;US 2018/0021913 W,2017-03-10,AUTOMATED CHOKE CONTROL APPARATUS AND METHODS,,SERVICES PETROLIERS SCHLUMBERGER;;SCHLUMBERGER TECHNOLOGY BV,ASTUDILLO LUIS;;ALBRECHT DE FREITAS TIAGO;;DUARTE MOSER HENRIQUE;;AZEM WASIM,,https://lens.org/132-683-132-412-907,Patent Application,yes,0,0,8,8,0,E21B34/16;;E21B21/08;;E21B21/08;;E21B34/02;;E21B34/16;;E21B34/025;;E21B21/08;;E21B21/106;;E21B34/16;;E21B47/06,E21B34/16;;E21B33/03;;E21B34/02,,0,0,,,,DISCONTINUED
209,BR,U,BR 6300151 U,026-058-099-269-638,1984-02-28,1984,BR 6300151 U,1983-02-11,BR 6300151 U,1983-02-11,COFRE FOTOGRAFICO,,LUIS ALFONSO ESCANDON SANCHES;;RAIMUNDO FRANCISCO NASCIMENTO;;DOMINGOS DUARTE DA SILVA,SANCHES LUIS ALFONSO ESCANDON;;NASCIMENTO RAIMUNDO FRANCISCO;;SILVA DOMINGOS DUARTE DA,,https://lens.org/026-058-099-269-638,Patent Application,no,0,0,1,1,0,,A45C1/12,,0,0,,,,DISCONTINUED
210,MX,A,MX 2007002752 A,048-425-951-973-234,2009-03-06,2009,MX 2007002752 A,2007-03-07,MX 2007002752 A,2007-03-07,"ORALLY ADMINISTERED COMPOSITION BASED ON ALPHA KETO ANALOGUE AMINO ACIDS HAVING A SHORT RELEASE TIME, AND PROCESS FOR THE OBTENTION THEREOF.","Described is a composition based on alpha keto analogue amino acids having a shorter release time, the invention also comprising a process for the manufacture of said compositions, which are useful for manufacturing drugs for treating renal insufficiency.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE;;OCHOA LORENA OLVERA,,https://lens.org/048-425-951-973-234,Patent Application,no,0,0,1,1,0,,A61K9/32;;A61K31/198;;A61P13/12,,0,0,,,,ACTIVE
211,WO,A1,WO 2018/165643 A1,095-684-509-007-827,2018-09-13,2018,US 2018/0021913 W,2018-03-12,US 201762469827 P,2017-03-10,AUTOMATED CHOKE CONTROL APPARATUS AND METHODS,"Automated choke control apparatus and methods are disclosed herein. An apparatus for automatically controlling a choke valve comprises a controller. The controller is to control a choke position of the choke valve via a first control loop in response to selection of a first one of a plurality of operation modes being detected. The controller is further to control a wellhead pressure of a wellhead via a second control loop in response to selection of a second one of the plurality of operation modes being detected, the wellhead being operatively coupled to the choke valve.",SCHLUMBERGER TECHNOLOGY CORP;;SCHLUMBERGER CA LTD;;SERVICES PETROLIERS SCHLUMBERGER;;SCHLUMBERGER TECHNOLOGY BV,ASTUDILLO LUIS;;DE FREITAS TIAGO ALBRECHT;;DUARTE MOSER HENRIQUE;;AZEM WASIM,,https://lens.org/095-684-509-007-827,Patent Application,yes,5,0,8,8,0,E21B34/16;;E21B21/08;;E21B21/08;;E21B34/02;;E21B34/16;;E21B34/025;;E21B21/08;;E21B21/106;;E21B34/16;;E21B47/06,E21B34/16;;E21B33/03;;E21B34/02,,1,0,,,See also references of EP 3592941A4,PENDING
212,EP,A4,EP 3592941 A4,077-242-720-487-685,2020-12-02,2020,EP 18764140 A,2018-03-12,US 201762469827 P;;US 2018/0021913 W,2017-03-10,AUTOMATED CHOKE CONTROL APPARATUS AND METHODS,,SERVICES PETROLIERS SCHLUMBERGER;;SCHLUMBERGER TECHNOLOGY BV,AZEM WASIM;;ASTUDILLO LUIS;;ALBRECHT DE FREITAS TIAGO;;DUARTE MOSER HENRIQUE,,https://lens.org/077-242-720-487-685,Search Report,no,5,0,8,8,0,E21B34/16;;E21B21/08;;E21B21/08;;E21B34/02;;E21B34/16;;E21B34/025;;E21B21/08;;E21B21/106;;E21B34/16;;E21B47/06,E21B34/16;;E21B21/08;;E21B33/03;;E21B34/02,,1,0,,,See also references of WO 2018165643A1,DISCONTINUED
213,RU,C2,RU 2765904 C2,156-275-732-469-075,2022-02-04,2022,RU 2019131156 A,2018-03-12,US 201762469827 P;;US 2018/0021913 W,2017-03-10,DEVICE AND METHODS FOR AUTOMATED CONTROL OF FITTING,"FIELD: controlling devices.SUBSTANCE: group of inventions relates to a device and methods for automated control of a fitting. The device for automatic control of a fitting valve contains a controller. The controller is made with the possibility of controlling a position of the fitting of the fitting valve by means of the first control circuit in response to the choice of the first of a set of detectable operating modes. The controller is also made with the possibility of controlling the wellhead pressure by means of the second control circuit in response to the choice of the second of the set of detectable operating modes. The wellhead is functionally connected to the fitting valve. A method for automatic control of the fitting valve and a machine-readable carrier are claimed.EFFECT: reduction in the degree of human intervention necessary to maintain the wellhead pressure and the position of the valve fitting within required values.20 cl, 5 dwg",SCHLUMBERGER TECHNOLOGY BV,ASTUDILLO LUIS;;ALBRECHT DE FREITAS TIAGO;;DUARTE MOSER HENRIQUE;;AZEM WASIM,,https://lens.org/156-275-732-469-075,Granted Patent,no,8,0,8,8,0,E21B34/16;;E21B21/08;;E21B21/08;;E21B34/02;;E21B34/16;;E21B34/025;;E21B21/08;;E21B21/106;;E21B34/16;;E21B47/06,E21B21/08;;E21B34/02;;E21B34/16,,0,0,,,,ACTIVE
214,US,B2,US 11091968 B2,164-339-355-265-64X,2021-08-17,2021,US 201816492742 A,2018-03-12,US 201816492742 A;;US 201762469827 P;;US 2018/0021913 W,2017-03-10,Automated choke control apparatus and methods,"Automated choke control apparatus and methods are disclosed herein. An apparatus for automatically controlling a choke valve comprises a controller. The controller is to control a choke position of the choke valve via a first control loop in response to selection of a first one of a plurality of operation modes being detected. The controller is further to control a wellhead pressure of a wellhead via a second control loop in response to selection of a second one of the plurality of operation modes being detected, the wellhead being operatively coupled to the choke valve.",SCHLUMBERGER TECHNOLOGY CORP,ASTUDILLO LUIS;;ALBRECHT DE FREITAS TIAGO;;DUARTE MOSER HENRIQUE;;AZEM WASIM,SCHLUMBERGER TECHNOLOGY CORPORATION (2018-06-20),https://lens.org/164-339-355-265-64X,Granted Patent,yes,19,0,8,8,0,E21B34/16;;E21B21/08;;E21B21/08;;E21B34/02;;E21B34/16;;E21B34/025;;E21B21/08;;E21B21/106;;E21B34/16;;E21B47/06,E21B34/02;;E21B21/08;;E21B21/10;;E21B34/16;;E21B47/06,,3,0,,,"Extended Search Report issued in the EP Application 18764140.2, dated Nov. 4, 2020 (7 pages).;;International Preliminary Report on Patentability issued in the related PCT Application PCT/US2018/021913, dated Sep. 19, 2019 (14 pages).;;International Search Report and Written Opinion issued in the related PCT Application PCT/US2018/021913, dated Jun. 26, 2018 (15 pages).",ACTIVE
215,MX,A,MX 2007002751 A,040-585-348-722-678,2009-02-25,2009,MX 2007002751 A,2007-03-07,MX 2007002751 A,2007-03-07,"PROCESS FOR THE MANUFACTURE OF COMPOSITIONS INCLUDING METFORMIN HYDROCHLORIDE, FENOFIBRATE AND FOLIC ACID.","Described is a process for the manufacture of a pharmaceutical composition that comprises as active principles a hypoglycaemic agent of the metformin type, a lipid reducing agent such as derivatives of fibric acid and folic acid for treating dyslipidemia associated or not with non-insulin dependent diabetes mellitus type 2, wherein the bioavailability of the active principles is substantially increased.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE;;CORONA BRISIA VILLALON,,https://lens.org/040-585-348-722-678,Patent Application,no,0,0,1,1,0,,A61P3/10;;A61K31/192;;A61K31/195;;A61K31/215,,0,0,,,,ACTIVE
216,DE,A1,DE 102018122037 A1,168-078-936-127-256,2020-03-12,2020,DE 102018122037 A,2018-09-10,DE 102018122037 A,2018-09-10,"VORRICHTUNG, ANORDNUNG UND VERFAHREN ZUM TESTEN EINES INSASSENRÜCKHALTESYSTEMS","Die Erfindung betrifft eine Vorrichtung zum Testen eines Insassenrückhaltesystems (2), insbesondere eines Seitenairbags, wobei das Insassenrückhaltesystem (2) Teil eines Fahrzeugsitzes (4) ist, aufweisend einen Test-Dummy zum Anordnen auf dem Fahrzeugsitz (4); eine Aufnahmeplattform (8) zum Aufnehmen und Befestigen des Fahrzeugsitzes (4); einen Stoßkörper (10) zum Anordnen seitlich am Fahrzeugsitz (4) und zum Übertragen eines Stoßes auf den Fahrzeugsitz (4) und/oder auf den Test-Dummy (6); und eine Aufpralleinheit (12) zum Anordnen an der dem Stoßkörper (10) gegenüberliegenden Seite des Fahrzeugsitzes (4) und zum Abdämpfen einer Stoßbewegung des Test-Dummys (6) beim Stoß durch den Stoßkörper (10). Die Erfindung betrifft ebenfalls eine Anordnung umfassend die obengenannte Vorrichtung und den Fahrzeugsitz (4) sowie ein Verfahren zum Testen eines Insassenrückhaltesystems (2).",DALPHI METAL ESPANA SA,VIZAN MARIA CRESPO;;DUARTE DE AREZ LUIS JOSÉ;;ORTEGA PEDRO MARTINEZ,,https://lens.org/168-078-936-127-256,Patent Application,no,7,2,1,1,0,G01M7/08;;G01M17/0078,G01M7/08;;G01M17/00,,0,0,,,,PENDING
217,BR,A2,BR 102014029415 A2,148-363-116-218-539,2016-08-16,2016,BR 102014029415 A,2014-11-25,MX 2013015302 A,2013-12-19,gaveta inclinável,"gaveta inclinável um armário refrigerado que possui um gabinete (10), isola ento térmico, cobertura ou revestimento (11), o que o ajuda a formar uma cavidade[ 14) que pode abrigar objetos a serem refrigerados com pelo menos uma prateleira (15) e uma porta consistindo de uma gaveta de verduras (20) a qual ela própria em suas p redes laterais e opostas tem um apêndice (31) integrado por uma cabeça, uma barra tran versa} superior, uma barra transversal inferior, um patim (33), uma protuberância; que corre dentro de um trilho (43) consistindo de uma canal formado por uma barreira, a baia inferior, um pescoço em c (53),com uma linha reta que é inclinada, um vão e ~m toco; com a peculiaridade de que quando a gaveta de verduras (20) se encontra enf sua posição de repouso ou fechada, a parede frontal da citada gaveta de verduras !(20) está muito próxima à vertical; a cabeça (32) está acoplada dentro do pescoço em c (53), o patim (33) está em contato com a face superior da baia inferior, e a barreira (54) está em contato com uma porção da face inferior da barra transversal inferior/ e que quando a gaveta de verduras (20) é extraída em sua posição final de corrida, a gaveta de verduras 1 (20) tem uma inclinação a em relação à horizontal; em que a cabeça (12) é acoplada ao vão do trilho, e a barreira (54) está em contato com uma face lateral do patim (33), 1 assim como com uma porção da face inferior da barra transversal infer · or.",MABE SA DE CV,GONZALEZ JUAN SUAREZ;;SOLIS LUIS FRANCISCO CASTRO;;ROBLES LÁZARO DUARTE DE,,https://lens.org/148-363-116-218-539,Patent Application,no,0,0,6,6,0,F25D25/025;;F25D25/025;;F25D25/025;;F25D2500/02;;F25D2500/02;;F25D2500/02,F25D25/02,,0,0,,,,DISCONTINUED
218,US,B2,US 9328955 B2,183-029-471-867-256,2016-05-03,2016,US 201414560560 A,2014-12-04,MX 2013015302 A,2013-12-19,Tiltable drawer,"A refrigerated cabinet having a cabinet, thermal insulation, cover or liner, which help it form a cavity which can house objects to be refrigerated with at least one shelf and one door comprising a vegetable drawer which itself on its lateral and opposite walls having an appendage integrated by a head, an upper crossbar, a lower crossbar, a skate, a hump; which runs within a rail comprising a channel formed by a barrier, a lower bay, a neck in C with a straight which is inclined, a gulf and a stump; with the peculiarity that when the vegetable drawer is found in its resting or closed position, the front wall of said vegetable drawer is in close proximity to the vertical; the head ( 32 ) is coupled within the neck in C, the skate is in contact with the upper face of the lower bay, and the barrier is in contact with a portion of the lower face of the lower crossbar; and that when the vegetable drawer is extracted in its final runner position, the vegetable drawer has an α inclination with relation to the horizontal; wherein the head ( 32 ) is coupled unto the gulf of the rail, and the barrier is in contact with a lateral face of the skate, as well as with a portion of the lower face of the lower crossbar.",MABE SA DE CV,CASTRO SOLIS LUIS FRANCISCO;;DUARTE DE ROBLES LAZARO;;SUAREZ GONZALEZ JUAN,MABE S.A. DE C.V (2014-09-22),https://lens.org/183-029-471-867-256,Granted Patent,yes,38,25,6,6,0,F25D25/025;;F25D25/025;;F25D25/025;;F25D2500/02;;F25D2500/02;;F25D2500/02,F25D25/00;;F25D25/02,,0,0,,,,ACTIVE
219,US,A1,US 2010/0327893 A1,012-004-821-293-888,2010-12-30,2010,US 49253109 A,2009-06-26,US 49253109 A,2009-06-26,Probing Structure for Evaluation of Slow Slew-Rate Square Wave Signals in Low Power Circuits,"An integrated circuit probing structure ( 40 ) is provided for evaluating functional circuitry ( 42 ), such as a slow slew-rate square wave signal from a low power circuit, where the probing structure includes two or more probe pads ( 48, 49 ) for testing the functional circuitry which are formed to be electrically separate from one another, and a probe test circuit ( 46 ) connected to the functional circuitry ( 42 ) for conveying a signal from the functional circuitry to a probe needle ( 47 ) only when the probe needle ( 47 ) electrically connects the two or more probe pads ( 48, 49 ).",VILAS BOAS ANDRE LUIS L;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO,VILAS BOAS ANDRE LUIS L;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO,FREESCALE SEMICONDUCTOR INC (2009-05-29);;NXP USA INC (2016-11-07),https://lens.org/012-004-821-293-888,Patent Application,yes,15,10,2,2,0,G01R31/2884;;G01R31/2884;;G01R31/2855;;G01R31/31701;;G01R31/31926,G01R31/02,324/754.07;;324/762.03;;324/756.05,0,0,,,,ACTIVE
220,TR,A2,TR 199800847 A2,144-054-694-884-790,1999-10-21,1999,TR 9800847 A,1998-05-13,ES 9701017 A,1997-05-13,Bir anjiyotensin dönüstürücü enzim inhibitörünün sabit doz bilesimi.,"Bilesim (a) bir enalapril veya bunun bir farmakolojik kabul edilebilir bir tuzunun bir dozunu ve bir baska (b) nitrendipin veya bunun farmakolojik kabul edilebilir bir tuzunun dozunu içermektedir ve bilesim tek doz galenik formda kullanilmaktadir. Yöntem su islem asamalari kapsamaktadir: (a) enalapril maleat su içinde bir inorganik tuz ile çözülmekte; (b) mikronize nitrendipin bir çözücü yardimci maddenin, islatma maddesinin, fragmanlastirici seyreltme maddesinin, aglutinat maddesinin ve daha önce elekten geçirilen plastik seyreltme maddesinin fraksiyonu ile karistirilmakta; (c) (b) asamasinda homojenize edilen ürünler (a) asamasinda elde edilen solüsyon ile granüle edilmekte; (e) yaglama maddesinin ve çözücü yardimci maddenin kalan fraksiyonunun birlestirilmesi ve kalibre edilen granülatin homojenlestirilmesi; (f) granüllerin preslenmesi.",VITA INVEST SA,SOLER PEDRO CANOVAS;;DUARTE JOAQUIN ANTONIO DELGADI;;ESCUDER LUIS MANUEL MICHETO,,https://lens.org/144-054-694-884-790,Patent Application,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K31/40;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,PENDING
221,US,A1,US 2015/0176887 A1,013-762-643-558-837,2015-06-25,2015,US 201414560560 A,2014-12-04,MX 2013015302 A,2013-12-19,TILTABLE DRAWER,"A refrigerated cabinet having a cabinet, thermal insulation, cover or liner, which help it form a cavity which can house objects to be refrigerated with at least one shelf and one door comprising a vegetable drawer which itself on its lateral and opposite walls having an appendage integrated by a head, an upper crossbar, a lower crossbar, a skate, a hump; which runs within a rail comprising a channel formed by a barrier, a lower bay, a neck in C with a straight which is inclined, a gulf and a stump; with the peculiarity that when the vegetable drawer is found in its resting or closed position, the front wall of said vegetable drawer is in close proximity to the vertical; the head ( 32 ) is coupled within the neck in C, the skate is in contact with the upper face of the lower bay, and the barrier is in contact with a portion of the lower face of the lower crossbar; and that when the vegetable drawer is extracted in its final runner position, the vegetable drawer has an a inclination with relation to the horizontal; wherein the head ( 32 ) is coupled unto the gulf of the rail, and the barrier is in contact with a lateral face of the skate, as well as with a portion of the lower face of the lower crossbar.",MABE SA DE CV,CASTRO SOLIS LUIS FRANCISCO;;DUARTE DE ROBLES LAZARO;;SUAREZ GONZALEZ JUAN,MABE S.A. DE C.V (2014-09-22),https://lens.org/013-762-643-558-837,Patent Application,yes,13,20,6,6,0,F25D25/025;;F25D25/025;;F25D25/025;;F25D2500/02;;F25D2500/02;;F25D2500/02,F25D23/04;;F25D23/02;;F25D25/02,,0,0,,,,ACTIVE
222,MX,B,MX 343169 B,083-497-205-021-217,2016-10-26,2016,MX 2013015302 A,2013-12-19,MX 2013015302 A,2013-12-19,TILTABLE DRAWER.,"A refrigerated cabinet having a cabinet, thermal insulation, cover or liner, which help it form a cavity which can house objects to be refrigerated with at least one shelf and one door comprising a vegetable drawer which itself on its lateral and opposite walls having an appendage integrated by a head, an upper crossbar, a lower crossbar, a skate, a hump; which runs within a rail comprising a channel formed by a barrier, a lower bay, a neck in C with a straight which is inclined, a gulf and a stump; with the peculiarity that when the vegetable drawer is found in its resting or closed position, the front wall of said vegetable drawer is in close proximity to the vertical; the head (32) is coupled within the neck in C, the skate is in contact with the upper face of the lower bay, and the barrier is in contact with a portion of the lower face of the lower crossbar; and that when the vegetable drawer is extracted in its final runner position, the vegetable drawer has an a inclination with relation to the horizontal; wherein the head (32) is coupled unto the gulf of the rail, and the barrier is in contact with a lateral face of the skate, as well as with a portion of the lower face of the lower crossbar.",MABE SA DE CV,LUIS FRANCÍSCO CASTRO SOLÍS;;LÁZARO DUARTE DE ROBLES;;JUAN SÚAREZ GONZÁLEZ,,https://lens.org/083-497-205-021-217,Granted Patent,no,0,0,6,6,0,F25D25/025;;F25D25/025;;F25D25/025;;F25D2500/02;;F25D2500/02;;F25D2500/02,F25D23/04;;F25D23/06;;F25D25/00;;F25D25/02,,0,0,,,,ACTIVE
223,SA,B1,SA 98190540 B1,030-495-741-899-857,2006-04-04,2006,SA 98190540 A,1998-09-14,SA 98190540 A,1998-09-14,جرعة مشتركة ثابتة تحتوي على مثبط لأنزيم تحويل الأنجيوتنسين وعلى عامل مضاد لقناة الكالسيوم لعلاج الأمراض القلبية الوعائية,الملخص: يتعلق الاختراع بجرعة تحتوي على (أ) إنالابريل enalapril أو ملح مقبول صيدلانيا منهوجرعة أخرى (ب) تحتوي على نيترينديبينnitrendipine أو ملح مقبول صيدلانيا منه حيث يتم تناولهما معا في صورة جرعة متبلرة واحدة. تشتمل الطريقة على: (أ) إذابة مالبيات الإنالابريل enalapril maleate في ماء مع ملح غير عضوي؛ (ب) مزج النيترينديبين nitrendipine الذي سبق طحنه إلى جسيمات دقيقة مع جزء سبق غربلته من سواغات التفكيك disintegrating excipients ، والعامل المرطب، والعامل المخفف المؤلف من شظايا، وعامل التلازن، وعامل التخفيف اللدن؛ (ج) طحن المنتجات المتجانسة التي سبق الحصول عليها من الفقرة (ب) لتكوين حبيبات دقيقة باستخدام المحلول الذي تم الحصول عليه في الفقرة (أ)، (د) تجفيف الكتلة الحبيبية؛ (ه) إضافة عامل التزليق والجزء الباقي من سواغات التفكيك disintegrating excipients والعمل على تجانس الكتلة الحبيبية المعايرة؛ (و) ضغط الكتلة الحبيبية. كما يتعلق الاختراع باستخدام الجرعة المشتركة المذكورة في تصنيع دواء لعلاج أمراض الجهاز القلبي الوعائي.cardiovascular system,LABOURITORIOZ VITA S A,DUARTE JOAZUIN ANTONIO DELGADILLO;;ESCUDER LUIS MANUEL MICHETO;;SOLER PEDRO CANOVAS,,https://lens.org/030-495-741-899-857,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
224,CA,A1,CA 2870772 A1,090-399-536-166-976,2015-06-19,2015,CA 2870772 A,2014-11-13,MX 2013015302 A,2013-12-19,TILTABLE DRAWER,"A refrigerated cabinet having a cabinet, thermal insulation, cover or liner, which help it form a cavity which can house objects to be refrigerated with at least one shelf and one door comprising a vegetable drawer which itself on its lateral and opposite walls having an appendage integrated by a head, an upper crossbar, a lower crossbar, a skate, a hump; which runs within a rail comprising a channel formed by a barrier, a lower bay, a neck in C with a straight which is inclined, a gulf and a stump; with the peculiarity that when the vegetable drawer is found in its resting or closed position, the front wall of said vegetable drawer is in close proximity to the vertical; the head (32) is coupled within the neck in C, the skate is in contact with the upper face of the lower bay, and the barrier is in contact with a portion of the lower face of the lower crossbar; and that when the vegetable drawer is extracted in its final runner position, the vegetable drawer has an a inclination with relation to the horizontal; wherein the head (32) is coupled unto the gulf of the rail, and the barrier is in contact with a lateral face of the skate, as well as with a portion of the lower face of the lower crossbar.",MABE SA DE CV,CASTRO SOLIS LUIS FRANCISCO;;DUARTE DE ROBLES LAZARO;;SUAREZ GONZALEZ JUAN,,https://lens.org/090-399-536-166-976,Patent Application,no,0,0,6,6,0,F25D25/025;;F25D25/025;;F25D25/025;;F25D2500/02;;F25D2500/02;;F25D2500/02,F25D25/00;;F25D23/08,,0,0,,,,DISCONTINUED
225,TR,A3,TR 199800847 A3,150-177-509-397-868,1999-10-21,1999,TR 9800847 A,1998-05-13,ES 9701017 A,1997-05-13,Bir anjiyotensin dönüstürücü enzim inhibitörünün sabit doz bilesimi.,,"VITA-INVEST, S.A.",PEDRO CANOVAS SOLER;;JOAQUIN ANTONIO DELGADILLO DUARTE;;LUIS MANUEL MICHETO ESCUDER,,https://lens.org/150-177-509-397-868,Search Report,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K31/40;;A61K9/16;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,PENDING
226,ES,B1,ES 2125198 B1,007-404-405-282-129,1999-11-16,1999,ES 9701017 A,1997-05-13,ES 9701017 A,1997-05-13,"ASOCIACION A DOSIS FIJA DE UN INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DE LOS CANALES DE CALCIO, PROCEDIMIENTO PARA SU PREPARACION Y SU UTILIZACION PARA EL TRATAMIENTO DE ENFERMEES CARDIOVASCULARES.","Asociación a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparación y su utilización para el tratamiento de enfermedades cardiovasculares. Comprende (a) enalapril o una sal farmacéuticamente aceptable del mismo y (b) nitrendipino o una sal farmacéuticamente aceptable del mismo, que se administra en forma galénica de dosis unitaria. El procedimiento comprende: a) disolver enalapril en agua con una sal inorgánico, b) mezclar el nitrendipino con una fracción de los excipientes disgregantes, agente mojante, diluyente fragmentario, agente aglutinante y diluyente plástico, previamente tamizados, c) granular la mezcla del apartado (b) con la solución obtenida en el apartado (a); (d) secar la masa granulada, (e) incorporar el agente lubricante y la fracción restante de excipientes y homogeneizar el granulado calibrado; (f) comprimir el granulado. Utilización de dicha asociación para la fabricación de un medicamento para el tratamiento de enfermedades del sistema cardiovascular.",VITA INVEST SA,CANOVAS SOLER PEDRO;;DELGADILLO DUARTE JOAQUIN ANTO;;MICHETO ESCUDE LUIS MANUEL,"FERRER INTERNACIONAL, S.A. (2011-05-25)",https://lens.org/007-404-405-282-129,Granted Patent,no,0,0,41,41,0,A61K38/556;;A61P43/00;;A61P9/00;;A61P9/12,A61K9/14;;A61K9/16;;A61K31/40;;A61K9/48;;A61K31/401;;A61K31/44;;A61K31/4422;;A61K31/455;;A61K38/00;;A61K38/55;;A61K47/12;;A61K47/26;;A61K47/32;;A61K47/38;;A61P9/00;;A61P9/12;;A61P43/00,,0,0,,,,EXPIRED
227,US,B2,US 8779790 B2,040-486-135-897-796,2014-07-15,2014,US 49253109 A,2009-06-26,US 49253109 A,2009-06-26,Probing structure for evaluation of slow slew-rate square wave signals in low power circuits,"An integrated circuit probing structure ( 40 ) is provided for evaluating functional circuitry ( 42 ), such as a slow slew-rate square wave signal from a low power circuit, where the probing structure includes two or more probe pads ( 48, 49 ) for testing the functional circuitry which are formed to be electrically separate from one another, and a probe test circuit ( 46 ) connected to the functional circuitry ( 42 ) for conveying a signal from the functional circuitry to a probe needle ( 47 ) only when the probe needle ( 47 ) electrically connects the two or more probe pads ( 48, 49 ).",VILAS BOAS ANDRE LUIS L;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO;;FREESCALE SEMICONDUCTOR INC,VILAS BOAS ANDRE LUIS L;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO,FREESCALE SEMICONDUCTOR INC (2009-05-29);;NXP USA INC (2016-11-07),https://lens.org/040-486-135-897-796,Granted Patent,yes,14,2,2,2,0,G01R31/2884;;G01R31/2884;;G01R31/2855;;G01R31/31701;;G01R31/31926,G01R31/02;;G01R31/28;;G01R31/317;;G01R31/319,324/754.07;;714/724,0,0,,,,ACTIVE
228,CO,A1,CO 4340666 A1,196-535-281-303-47X,1996-07-30,1996,CO 95005382 A,1995-02-13,CO 95005382 A,1995-02-13,"SISTEMA PARA POSICIONAR Y ASENTAR RESTAURACIONES ODONTOLOGI- CAS EN DIENTES POSTERIORES, Y APARATO QUE HACE POSIBLE EL SISTEMA","REIVINDICACION NUMERO UN SISTEMA PARA POSICIONAR Y ASENTAR RESTAURACIO- NES ODONTOLOGICAS EN LOS DIENTES POSTERIORES, CA- RACTERIZADO POR LLEVAR LA RESTAURACION AGARRADA Y ASEGURADA EN LAS PUNTAS SUFICIENTEMENTE DELGADAS DE UNA PINZA DE ACCION INVERSA QUE NO SATURAN EL ESPACIO BUCAL, PERMITIENDO OBSERVAR VISUALMENTE EL SITIO DE COLOCACION DE LA RESTAURACION, LLEVAR SIMULTANEAMENTE UN ASENTADOR DE CAUCHO O MORDIDA, COLOCADO EN UNA BARRA PORTA-ASENTADOR LATERALMENTE ESCUALIZABLE QUE ATRAVIESA EL ASENTADOR HOLGADA- MENTE, PARA LOCALIZAR DICHO ASENTADOR O MORDIDA POR DEBAJO O POR ENCIMA DE LA RESTAURACION, Y PER- MITIR QUE EL PACIENTE MUERDA DICHO ASENTADOR EJER- CIENDO PRESION SOBRE LA RESTAURACION PARA FIJARLA EN SU SITIO, AFLOJAR LA PRESION MANUAL SOBRE LA PINZA PARA SOLTAR LA RESTAURACION, Y RETIRAR DICHA PINZA JUNTO CON LA BARRA PORTA-ASENTADOR DE LA BO- CA DEL PACIENTE, DEJANDO EL ASENTADOR O MORDIDA ENTRE LA BOCA DEL PACIENTE, HASTA QUE SE EFECTUA LA REACCION DE ENDURECIMIENTO DEL CEMENTO EL MEDIO DE FIJACION DE LA RESTAURACION, Y EXTRAER LUEGO MANUALMENTE EL ASENTADOR DESPUES DE QUE HAYA FRA- GUADO AL MEDIO DE FIJACION"".",ARIZA GERMAN ALBERTO;;HERNANDEZ ESCOBAR CARLOS MARIO;;PEDRAZA DUARTE LUIS ENRIQUE,ARIZA GERMAN ALBERTO;;HERNANDEZ ESCOBAR CARLOS MARIO;;PEDRAZA DUARTE LUIS ENRIQUE,,https://lens.org/196-535-281-303-47X,Patent Application,no,0,0,1,1,0,,A61C13/20,,0,0,,,,PENDING
229,US,B2,US 10018528 B2,180-445-122-554-095,2018-07-10,2018,US 201515112418 A,2015-01-16,PT 10740814 A;;PT 2015000004 W,2014-01-17,Method and device for testing the tightness of cork stoppers,"The present invention relates to a process and a device ( 1 ) to test the sealing of cork stoppers (R). The device ( 1 ) comprises a partitioning mechanism dividing a chamber in two compartments ( 8 a, 8 b ). The partitioning mechanism comprises: an adjustable insulator ( 9 ) configured to hermetically seal a central part of the stopper (R) from the outside environment and simultaneously to arrange each end of the stopper (R) in one of the compartments ( 8 a, 8 b ); and an insulator actuation member ( 10 ) to arrange the insulator ( 9 ) on the central part of the stopper (R). The device farther comprises a block ( 11 a ) for closing the compartment ( 8 a ); an inlet ( 12 ) connected to a test fluid source, the source arranged in the block ( 11 a ), and a detection member ( 13 ) connected to the same block ( 11 a ). The present invention finds application in the field of cork stopper production and in the cork industry in general.",AMORIM CORK RES & SERVICES LDA,MACHADO DA SILVA LUIS FILIPE PEIXOTO;;AMADOR NUNO DUARTE DE FIGUEIREDO SEABRA,AMORIM CORK RESEARCH & SERVICES LDA (2016-04-03),https://lens.org/180-445-122-554-095,Granted Patent,yes,3,0,10,10,0,G01N21/952;;G01M3/26;;G01N21/952;;G01M3/26,G01M3/26,,1,0,,,"David P. Faria, et al. “Permeability of Cork to Gases”, Journal of Agriculture and Food Chemistry, American Chemical Society, US., vol. 59, No. 8, Aug. 1, 2011.",ACTIVE
230,US,A1,US 2016/0334299 A1,038-756-622-951-695,2016-11-17,2016,US 201515112418 A,2015-01-16,PT 10740814 A;;PT 2015000004 W,2014-01-17,METHOD AND DEVICE FOR TESTING THE TIGHTNESS OF CORK STOPPERS,"The present invention relates to a process and a device ( 1 ) to test the sealing of cork stoppers (R). The device ( 1 ) comprises a partitioning mechanism dividing a chamber in two compartments ( 8 a, 8 b ). The partitioning mechanism comprises: an adjustable insulator ( 9 ) configured to hermetically seal a central part of the stopper (R) from the outside environment and simultaneously to arrange each end of the stopper (R) in one of the compartments ( 8 a, 8 b ); and an insulator actuation member ( 10 ) to arrange the insulator ( 9 ) on the central part of the stopper (R). The device farther comprises a block ( 11 a ) for closing the compartment ( 8 a ); an inlet ( 12 ) connected to a test fluid source, the source arranged in the block ( 11 a ), and a detection member ( 13 ) connected to the same block ( 11 a ). The present invention finds application in the field of cork stopper production and in the cork industry in general.",AMORIM CORK RES & SERVICES LDA,MACHADO DA SILVA LUIS FILIPE PEIXOTO;;AMADOR NUNO DUARTE DE FIGUEIREDO SEABRA,AMORIM CORK RESEARCH & SERVICES LDA (2016-04-03),https://lens.org/038-756-622-951-695,Patent Application,yes,3,1,10,10,0,G01N21/952;;G01M3/26;;G01N21/952;;G01M3/26,G01M3/26,,0,0,,,,ACTIVE
231,ES,T1,ES 2924900 T1,004-455-416-060-311,2022-10-11,2022,ES 15703116 T,2015-01-16,PT 10740814 A;;PT 2015000004 W,2014-01-17,Método y dispositivo para probar la hermeticidad de tapones de corcho,"La presente invención se refiere a un proceso y un dispositivo (1) para probar el sellado de tapones de corcho (R). El dispositivo (1) comprende un mecanismo de partición que divide una cámara en dos compartimentos (8a, 8b). El mecanismo divisorio comprende: un aislador ajustable (9) configurado para sellar herméticamente una parte central del tapón (R) del ambiente exterior y simultáneamente disponer cada extremo del tapón (R) en uno de los compartimentos (8a, 8b) ; y un elemento de accionamiento del aislador (10) para disponer el aislador (9) sobre la parte central del tapón (R). El dispositivo comprende además un bloque (11a) de cierre del compartimento (8a); una entrada (12) conectada a una fuente de fluido de prueba, dispuesta la fuente en el bloque (11a), y un miembro de detección (13) conectado al mismo bloque (11a). La presente invención encuentra aplicación en el campo de la producción de tapones de corcho y en la industria del corcho en general. (Traducción automática con Google Translate, sin valor legal)",AMORIM CORK RES & SERVICES LDA,MACHADO DA SILVA LUIS FILIPE PEIXOTO;;AMADOR NUNO DUARTE DE FIGUEIREDO SEABRA,,https://lens.org/004-455-416-060-311,Patent Application,no,0,0,10,10,0,G01N21/952;;G01M3/26;;G01N21/952;;G01M3/26,G01M3/26,,0,0,,,,ACTIVE
232,WO,A1,WO 2022/122155 A1,030-626-521-285-500,2022-06-16,2022,EP 2020085491 W,2020-12-10,EP 2020085491 W,2020-12-10,FULL-DUPLEX TRANSCEIVER AND METHOD FOR OPERATING THE SAME,"The present disclosure relates to a Full-Duplex (FD) transceiver configured to cope with the problem of Signal-of-Interest (SoI) degradation caused by a Self-Interference (SI), as well as to a method for operating the FD transceiver. This problem is addressed by using a modulo- based analog-to-digital converter (ADC) in the FD transceiver. A digital signal obtained by the modulo-based ADC is a folded and quantized representation of a received analog signal. The SI in the digital signal is estimated based on one or more reference signals. The digital representation of the SoI is obtained based on the digital signal and the estimated SI. By so doing, it is possible to provide efficient SI estimation and cancellation. Moreover, since the SI estimation and cancellation are performed in the digital domain, the state-of-the-art analog SI cancellation and/or isolation techniques are not required at all.",HUAWEI TECH CO LTD;;GARCIA ORDONEZ LUIS,GARCIA ORDONEZ LUIS;;DUARTE GELVEZ MELISSA;;FERRAND PAUL;;GUILLAUD MAXIME;;YANG GANGHUA,,https://lens.org/030-626-521-285-500,Patent Application,yes,3,1,3,3,0,H04B1/40;;H04B1/525,H04B1/40;;H04B1/525,,0,0,,,,PENDING
233,BR,A,BR 9606281 A,028-007-110-572-113,1998-09-15,1998,BR 9606281 A,1996-12-27,BR 9606281 A,1996-12-27,Processo de obtenção de fibras curtas de carbono ativadas a partir de piche de alcatrão vegetal,,ACOS ESPECIAIS ITABIRA ACESITA,REZENDE LUIS CLAUDIO;;PASA VANYA MARCIA DUARTE;;POLIDORO HEITOR AGUIAR;;OTANI CHOYU,ACESITA S.A. (BR/MG) (2006-09-19),https://lens.org/028-007-110-572-113,Patent Application,no,0,0,1,1,0,,C10C3/10,,0,0,,,,DISCONTINUED
234,WO,A2,WO 2012/148500 A2,104-613-454-060-765,2012-11-01,2012,US 2012/0000224 W,2012-04-27,US 201161517877 P,2011-04-27,INTERBODY FUSION DEVICE WITH LIPPED ANTERIOR PLATE AND ASSOCIATED METHODS,"A method and apparatus is provided for use in spinal fusion procedures. An interbody fusion device has a first piece that is a load bearing device designed to bear the axial loading from the end plates of adjacent vertebrae. A second piece of the interbody fusion device is a retention device whose function is to prevent migration of the load bearing device. One or more fasteners secure the retention device to the vertebrae above and below the load bearing device. The fasteners cause the end plates of the vertebrae to compress the end plates to the load bearing device to facilitate proper fusion. The second piece can be configured to include lips that abut the apothyseal rings during, with the plate including bores angled such that fasteners penetrate the apothyseal rings.",SPINESMITH PARTNERS LP;;KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN,KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN,,https://lens.org/104-613-454-060-765,Patent Application,yes,0,4,4,4,0,A61F2/4455;;A61F2/4455;;A61B17/8042;;A61B17/8042;;A61B17/86;;A61B17/86;;A61F2/30744;;A61F2/30744;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2/4611;;A61F2/4611;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30131;;A61F2002/30131;;A61F2002/302;;A61F2002/302;;A61F2002/30349;;A61F2002/30349;;A61F2002/30352;;A61F2002/30352;;A61F2002/30355;;A61F2002/30355;;A61F2002/30372;;A61F2002/30372;;A61F2002/30373;;A61F2002/30373;;A61F2002/30383;;A61F2002/30383;;A61F2002/30387;;A61F2002/30387;;A61F2002/30397;;A61F2002/30397;;A61F2002/30482;;A61F2002/30482;;A61F2002/30507;;A61F2002/30507;;A61F2002/30517;;A61F2002/30517;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30604;;A61F2002/30604;;A61F2002/30607;;A61F2002/30607;;A61F2002/30616;;A61F2002/30616;;A61F2002/30774;;A61F2002/30774;;A61F2002/30782;;A61F2002/30782;;A61F2002/30904;;A61F2002/30904,A61F2/44,,0,0,,,,PENDING
235,ES,T3,ES 2362442 T3,117-726-823-010-409,2011-07-05,2011,ES 07381069 T,2007-10-09,EP 07381069 A,2007-10-09,AIRBAG FRONTAL CON UN DISPOSITIVO DE VENTILACION ADAPTATIVO.,"The invention relates to a front airbag module for an automotive vehicle comprising an inflatable cushion (11) that can be inflated with the gas produced by a generator, including at least one venting opening (17) and a venting regulation device formed by a flexible material part (21) joined to the inflatable cushion (11) on the periphery or near zones of said venting opening (17) such that it can completely or partially close or uncover it, preventing or allowing the output of gas, and a stress member (23) joined at one of its ends to said flexible material part (21) and at the other end to the inflatable cushion (11), the geometric configurations of said stress member (23) and of said flexible material part (21) being established such that the opening degree of the venting opening (17) is determined by the stress level in the stress member (23) during cushion (11) deployment.",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RAMOS RAMON;;DENYS ISABELLE;;CORE ALMARZA EMILIANO,,https://lens.org/117-726-823-010-409,Granted Patent,no,0,0,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
236,AT,T1,AT E500095 T1,183-913-303-812-771,2011-03-15,2011,AT 07381069 T,2007-10-09,EP 07381069 A,2007-10-09,FRONTAIRBAG MIT ADAPTIVER ENTLÜFTUNGSVORRICHTUNG,"The invention relates to a front airbag module for an automotive vehicle comprising an inflatable cushion (11) that can be inflated with the gas produced by a generator, including at least one venting opening (17) and a venting regulation device formed by a flexible material part (21) joined to the inflatable cushion (11) on the periphery or near zones of said venting opening (17) such that it can completely or partially close or uncover it, preventing or allowing the output of gas, and a stress member (23) joined at one of its ends to said flexible material part (21) and at the other end to the inflatable cushion (11), the geometric configurations of said stress member (23) and of said flexible material part (21) being established such that the opening degree of the venting opening (17) is determined by the stress level in the stress member (23) during cushion (11) deployment.",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RAMOS RAMON;;DENYS ISABELLE;;CORE ALMARZA EMILIANO,,https://lens.org/183-913-303-812-771,Granted Patent,no,0,0,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/2338,,0,0,,,,INACTIVE
237,MX,A,MX 2017008445 A,048-959-303-483-903,2019-02-08,2019,MX 2017008445 A,2017-06-22,MX 2017008445 A,2017-06-22,PROCESS FOR GENOTYPIFICATION AND SELECTION OF BOVINE CATTLE FOR THE PRODUCTION OF BETA-CASEINE A1 FREE COW MILK AND ITS USE IN THE PREPARATION OF FOOD FOR CHILDREN'S NUTRITION.,"The present disclosure is related to the biotechnological industry and the specialized food manufacturing industry. The advantage of the present invention with respect to the compositions of the state of the art, lies in its ability to genotype cattle according to the CSN2 gene to identify and select bulls and cows that bear the genotype CSN2 A2 / A2. To reproduce and raise dairy cattle that have the capacity to produce milk composed of BCAS A2 and that is free of BCAS A1. Cow's milk with the aforementioned characteristics can be used for manufacturing specialized products for infant feeding. The present method involves the insertion of a point mutation in the codon, where the bovine polymorphism of the BCAS A1 and the BCAS A2 occurs, using a modified oligonucleotide at its 5' end. The product of the CSR PCR, which results from the amplification of CSN2 A2, presenting a restriction site for a specific endonuclease, which does not occur with the product of the CSR PCR of CSN2 A1. After the amplification, the products of the CSR PCR are digested with the specific endonuclease and the restriction fragments are analyzed on a 1% of agarose gel. The genotype of the animals is defined according to the pattern of the fragment bands, which result from the restriction enzymatic digestion.",ECOLOGICO TIERRA VIVA S P R DE R L DE C V,JORGE LUIS ROSADO LORIA;;CARLOS RAÚL GARCÍA UGALDE;;MIGUEL ANGEL DUARTE VÁZQUEZ,,https://lens.org/048-959-303-483-903,Patent Application,no,0,0,1,1,0,,C12Q1/68;;A23C9/00;;A23C19/00,,0,0,,,,PENDING
238,DE,D1,DE 602007012889 D1,015-844-573-532-405,2011-04-14,2011,DE 602007012889 T,2007-10-09,EP 07381069 A,2007-10-09,Frontairbag mit adaptiver Entlüftungsvorrichtung,"The invention relates to a front airbag module for an automotive vehicle comprising an inflatable cushion (11) that can be inflated with the gas produced by a generator, including at least one venting opening (17) and a venting regulation device formed by a flexible material part (21) joined to the inflatable cushion (11) on the periphery or near zones of said venting opening (17) such that it can completely or partially close or uncover it, preventing or allowing the output of gas, and a stress member (23) joined at one of its ends to said flexible material part (21) and at the other end to the inflatable cushion (11), the geometric configurations of said stress member (23) and of said flexible material part (21) being established such that the opening degree of the venting opening (17) is determined by the stress level in the stress member (23) during cushion (11) deployment.",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RAMOS RAMON;;DENYS ISABELLE;;CORE ALMARZA EMILIANO,,https://lens.org/015-844-573-532-405,Granted Patent,no,0,0,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
239,DE,A1,DE 102021106051 A1,028-277-006-256-065,2022-09-15,2022,DE 102021106051 A,2021-03-12,DE 102021106051 A,2021-03-12,"GASSACKGEWEBE, GASSACK SOWIE VERFAHREN ZUM ZUSAMMENLEGEN EINES GASSACKS","Ein Gassack (10) eines Fahrzeuginsassenrückhaltesystems ist aus einem Gassackgewebe gefertigt, das Gewebe-Kettfäden, Gewebe-Schussfäden sowie zusätzliche elektrisch leitfähige Fäden umfasst, die in das Gassackgewebe (12) eingebracht sind. Eine Vorrichtung (20) zum Zusammenlegen des Gassacks (10) weist eine elektrische Stromversorgung (22) und wenigstens einen Kontaktbereich (26') auf, der so ausgelegt ist, dass ein Stromfluss durch die elektrisch leitfähigen Fäden des Gassacks (10) erzeugt werden kann, um das Gassackgewebe (12) zu erwärmen. Um den Gassack (10) zusammenzulegen, wird das Gassackgewebe (12) erwärmt, indem ein Stromfluss in den elektrisch leitfähigen Fäden (18) des Gassackgewebes (12) erzeugt und der Gassack (10) in einer gewünschten Form zu einem Gassackpaket (36) zusammengelegt wird, bevor das Gassackpaket abkühlt.",DALPHI METAL ESPANA SA;;SAFELIFE IND DE COMPONENTES DE SEGURANCA AUTOMOVEL S A,SILVA JOÃO PEDRO MATIAS;;CORREIA LUIS;;FRANCO BARTOLOMEU;;AMORIM CORREIA JOÃO DUARTE,,https://lens.org/028-277-006-256-065,Patent Application,no,0,0,2,2,0,B60R2021/2375;;B60R2021/23542;;B60R21/237;;B60R21/235,B60R21/235;;B60R21/237,,0,0,,,,PENDING
240,ES,T3,ES 2924900 T3,101-413-237-309-899,2024-01-26,2024,ES 15703116 T,2015-01-16,PT 10740814 A;;PT 2015000004 W,2014-01-17,Proceso y dispositivo para comprobar el sellado de tapones de corcho,"La presente invención se refiere a un proceso y un dispositivo (1) para probar el sellado de tapones de corcho (R). El dispositivo (1) comprende un mecanismo de partición que divide una cámara en dos compartimentos (8a, 8b). El mecanismo divisorio comprende: un aislador ajustable (9) configurado para sellar herméticamente una parte central del tapón (R) del ambiente exterior y simultáneamente disponer cada extremo del tapón (R) en uno de los compartimentos (8a, 8b) ; y un elemento de accionamiento del aislador (10) para disponer el aislador (9) sobre la parte central del tapón (R). El dispositivo comprende además un bloque (11a) de cierre del compartimento (8a); una entrada (12) conectada a una fuente de fluido de prueba, dispuesta la fuente en el bloque (11a), y un miembro de detección (13) conectado al mismo bloque (11a). La presente invención encuentra aplicación en el campo de la producción de tapones de corcho y en la industria del corcho en general. (Traducción automática con Google Translate, sin valor legal)",AMORIM CORK RES & SERVICES LDA,MACHADO DA SILVA LUIS FILIPE PEIXOTO;;AMADOR NUNO DUARTE DE FIGUEIREDO SEABRA,,https://lens.org/101-413-237-309-899,Granted Patent,no,0,0,10,10,0,G01N21/952;;G01M3/26;;G01N21/952;;G01M3/26,G01M3/26,,0,0,,,,ACTIVE
241,US,B2,US 10034764 B2,148-906-195-516-910,2018-07-31,2018,US 201213506566 A,2012-04-27,US 201213506566 A;;US 1870308 A;;US 75921907 A;;US 201161517877 P;;US 98141407 P,2007-06-06,Interbody fusion device with lipped anterior plate and associated methods,"A method and apparatus is provided for use in spinal fusion procedures. An interbody fusion device has a first piece that is a load bearing device designed to bear the axial loading from the end plates of adjacent vertebrae. A second piece of the interbody fusion device is a retention device whose function is to prevent migration of the load bearing device. One or more fasteners secure the retention device to the vertebrae above and below the load bearing device. The fasteners cause the end plates of the vertebrae to compress the end plates to the load bearing device to facilitate proper fusion. The second piece can be configured to include lips that abut the apothyseal rings during, with the plate including bores angled such that fasteners penetrate the apothyseal rings.",KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN;;SPINESMITH PARTNERS LP,KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN,SPINESMITH PARTNERS L.P (2012-05-10),https://lens.org/148-906-195-516-910,Granted Patent,yes,12,1,4,4,0,A61F2/4455;;A61F2/4455;;A61B17/8042;;A61B17/8042;;A61B17/86;;A61B17/86;;A61F2/30744;;A61F2/30744;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2/4611;;A61F2/4611;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30131;;A61F2002/30131;;A61F2002/302;;A61F2002/302;;A61F2002/30349;;A61F2002/30349;;A61F2002/30352;;A61F2002/30352;;A61F2002/30355;;A61F2002/30355;;A61F2002/30372;;A61F2002/30372;;A61F2002/30373;;A61F2002/30373;;A61F2002/30383;;A61F2002/30383;;A61F2002/30387;;A61F2002/30387;;A61F2002/30397;;A61F2002/30397;;A61F2002/30482;;A61F2002/30482;;A61F2002/30507;;A61F2002/30507;;A61F2002/30517;;A61F2002/30517;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30604;;A61F2002/30604;;A61F2002/30607;;A61F2002/30607;;A61F2002/30616;;A61F2002/30616;;A61F2002/30774;;A61F2002/30774;;A61F2002/30782;;A61F2002/30782;;A61F2002/30904;;A61F2002/30904,A61F2/44;;A61B17/80;;A61B17/86;;A61F2/28;;A61F2/30;;A61F2/46,,0,0,,,,ACTIVE
242,EP,A1,EP 4208949 A1,177-948-412-876-232,2023-07-12,2023,EP 20824208 A,2020-12-10,EP 2020085491 W,2020-12-10,FULL-DUPLEX TRANSCEIVER AND METHOD FOR OPERATING THE SAME,,HUAWEI TECH CO LTD,DUARTE GELVEZ MELISSA;;FERRAND PAUL;;GUILLAUD MAXIME;;YANG GANGHUA;;GARCIA ORDONEZ LUIS,,https://lens.org/177-948-412-876-232,Patent Application,yes,0,0,3,3,0,H04B1/40;;H04B1/525,H04B1/40;;H04B1/525,,0,0,,,,PENDING
243,EP,A1,EP 2048041 A1,122-005-957-555-86X,2009-04-15,2009,EP 07381069 A,2007-10-09,EP 07381069 A,2007-10-09,Front airbag with an adaptive venting device,"The invention relates to a front airbag module for an automotive vehicle comprising an inflatable cushion (11) that can be inflated with the gas produced by a generator, including at least one venting opening (17) and a venting regulation device formed by a flexible material part (21) joined to the inflatable cushion (11) on the periphery or near zones of said venting opening (17) such that it can completely or partially close or uncover it, preventing or allowing the output of gas, and a stress member (23) joined at one of its ends to said flexible material part (21) and at the other end to the inflatable cushion (11), the geometric configurations of said stress member (23) and of said flexible material part (21) being established such that the opening degree of the venting opening (17) is determined by the stress level in the stress member (23) during cushion (11) deployment.
",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RAMOS RAMON;;DENYS ISABELLE;;CORE ALMARZA EMILIANO,,https://lens.org/122-005-957-555-86X,Patent Application,yes,11,1,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
244,EP,A1,EP 3106854 A1,112-178-092-081-628,2016-12-21,2016,EP 15703116 A,2015-01-16,PT 10740814 A;;PT 2015000004 W,2014-01-17,METHOD AND DEVICE FOR TESTING THE TIGHTNESS OF CORK STOPPERS,"The present invention relates to a process and a device (1) to test the sealing of cork stoppers (R). The device (1) comprises a partitioning mechanism dividing a chamber in two compartments (8a, 8b). The partitioning mechanism comprises: an adjustable insulator (9) configured to hermetically seal a central part of the stopper (R) from the outside environment and simultaneously to arrange each end of the stopper (R) in one of the compartments (8a, 8b); and an insulator actuation member (10) to arrange the insulator (9) on the central part of the stopper (R). The device further comprises a block (11a) for closing the compartment (8a); an inlet (12) connected to a test fluid source, the source arranged in the block (11a), and a detection member (13) connected to the same block (11a). The present invention finds application in the field of cork stopper production and in the cork industry in general.",AMORIM CORK RES & SERVICES LDA,MACHADO DA SILVA LUIS FILIPE PEIXOTO;;AMADOR NUNO DUARTE DE FIGUEIREDO SEABRA,,https://lens.org/112-178-092-081-628,Patent Application,yes,0,0,10,10,0,G01N21/952;;G01M3/26;;G01N21/952;;G01M3/26,G01M3/26,,0,0,,,,ACTIVE
245,EP,B1,EP 3106854 B1,101-452-911-871-894,2023-06-28,2023,EP 15703116 A,2015-01-16,PT 10740814 A;;PT 2015000004 W,2014-01-17,PROCESS AND DEVICE FOR CHECKING THE SEALLING OF CORK STOPPERS,,AMORIM CORK RES & SERVICES LDA,MACHADO DA SILVA LUIS FILIPE PEIXOTO;;AMADOR NUNO DUARTE DE FIGUEIREDO SEABRA,,https://lens.org/101-452-911-871-894,Granted Patent,yes,1,0,10,10,0,G01N21/952;;G01M3/26;;G01N21/952;;G01M3/26,G01M3/26,,0,0,,,,ACTIVE
246,US,A1,US 2012/0277873 A1,139-673-694-021-751,2012-11-01,2012,US 201213506566 A,2012-04-27,US 201213506566 A;;US 1870308 A;;US 75921907 A;;US 201161517877 P;;US 98141407 P,2007-06-06,Interbody fusion device with lipped anterior plate and associated methods,"A method and apparatus is provided for use in spinal fusion procedures. An interbody fusion device has a first piece that is a load bearing device designed to bear the axial loading from the end plates of adjacent vertebrae. A second piece of the interbody fusion device is a retention device whose function is to prevent migration of the load bearing device. One or more fasteners secure the retention device to the vertebrae above and below the load bearing device. The fasteners cause the end plates of the vertebrae to compress the end plates to the load bearing device to facilitate proper fusion. The second piece can be configured to include lips that abut the apothyseal rings during, with the plate including bores angled such that fasteners penetrate the apothyseal rings.",KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN,KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN,SPINESMITH PARTNERS L.P (2012-05-10),https://lens.org/139-673-694-021-751,Patent Application,yes,12,65,4,4,0,A61F2/4455;;A61F2/4455;;A61B17/8042;;A61B17/8042;;A61B17/86;;A61B17/86;;A61F2/30744;;A61F2/30744;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2/4611;;A61F2/4611;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30131;;A61F2002/30131;;A61F2002/302;;A61F2002/302;;A61F2002/30349;;A61F2002/30349;;A61F2002/30352;;A61F2002/30352;;A61F2002/30355;;A61F2002/30355;;A61F2002/30372;;A61F2002/30372;;A61F2002/30373;;A61F2002/30373;;A61F2002/30383;;A61F2002/30383;;A61F2002/30387;;A61F2002/30387;;A61F2002/30397;;A61F2002/30397;;A61F2002/30482;;A61F2002/30482;;A61F2002/30507;;A61F2002/30507;;A61F2002/30517;;A61F2002/30517;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30604;;A61F2002/30604;;A61F2002/30607;;A61F2002/30607;;A61F2002/30616;;A61F2002/30616;;A61F2002/30774;;A61F2002/30774;;A61F2002/30782;;A61F2002/30782;;A61F2002/30904;;A61F2002/30904,A61F2/44,623/17.16,0,0,,,,ACTIVE
247,EP,B1,EP 2048041 B1,117-675-473-674-282,2011-03-02,2011,EP 07381069 A,2007-10-09,EP 07381069 A,2007-10-09,Front airbag with an adaptive venting device,"The invention relates to a front airbag module for an automotive vehicle comprising an inflatable cushion (11) that can be inflated with the gas produced by a generator, including at least one venting opening (17) and a venting regulation device formed by a flexible material part (21) joined to the inflatable cushion (11) on the periphery or near zones of said venting opening (17) such that it can completely or partially close or uncover it, preventing or allowing the output of gas, and a stress member (23) joined at one of its ends to said flexible material part (21) and at the other end to the inflatable cushion (11), the geometric configurations of said stress member (23) and of said flexible material part (21) being established such that the opening degree of the venting opening (17) is determined by the stress level in the stress member (23) during cushion (11) deployment.",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;RAMOS RAMON;;DENYS ISABELLE;;CORE ALMARZA EMILIANO,,https://lens.org/117-675-473-674-282,Granted Patent,yes,4,0,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/239;;B60R21/2338,,0,0,,,,ACTIVE
248,CN,A,CN 116547913 A,118-819-745-850-101,2023-08-04,2023,CN 202080107726 A,2020-12-10,EP 2020085491 W,2020-12-10,Full duplex transceiver and operating method thereof,"The present disclosure relates to a full duplex (FD) transceiver for coping with a signal of interest (SoI) degradation problem caused by self-interference (SI), and a method for operating the FD transceiver. This problem is solved by using a mode-based analog-to-digital converter (ADC) in the FD transceiver. The digital signal obtained by the mode-based ADC is a folded and quantized representation of the received analog signal. The SI in the digital signal is estimated based on one or more reference signals. A digital representation of the SoI is obtained based on the digital signal and the estimated SI. By doing so, efficient SI estimation and cancellation may be provided. Furthermore, since the SI estimation and cancellation are performed in the digital domain, there is no need for existing analog SI cancellation and/or isolation techniques at all.",HUAWEI TECH CO LTD,GARCIA ORDONIZ LUIS;;DUARTE GALVEZ MELISSA;;FERRAND PAUL;;GUIRAUD MAXIME;;YANG GANGHUA,,https://lens.org/118-819-745-850-101,Patent Application,no,0,0,3,3,0,H04B1/40;;H04B1/525,H04B1/525,,0,0,,,,PENDING
249,CN,A,CN 101407202 A,148-018-031-271-376,2009-04-15,2009,CN 200810169926 A,2008-10-09,EP 07381069 A,2007-10-09,Front airbag with an adaptive venting device,"The invention relates to a front airbag module for an automotive vehicle comprising an inflatable cushion (11) that can be inflated with the gas produced by a generator, including at least one venting opening (17) and a venting regulation device formed by a flexible material part (21) joined to the inflatable cushion (11) on the periphery or near zones of said venting opening (17) such that it can completely or partially close or uncover it, preventing or allowing the output of gas, and a stress member (23) joined at one of its ends to said flexible material part (21) and at the other end to the inflatable cushion (11), the geometric configurations of said stress member (23) and of said flexible material part (21) being established such that the opening degree of the venting opening (17) is determined by the stress level in the stress member (23) during cushion (11) deployment.",DALPHI METAL ESPANA SA,JOSE DUARTE DE AREZ LUIS;;RAMON RAMOS;;ISABELLE DENYS;;EMILIANO CORE ALMARZA,,https://lens.org/148-018-031-271-376,Patent Application,no,0,1,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/16;;B60R21/2338;;B60R21/239,,0,0,,,,DISCONTINUED
250,WO,A3,WO 2012/148500 A3,015-361-756-424-988,2012-12-27,2012,US 2012/0000224 W,2012-04-27,US 201161517877 P,2011-04-27,INTERBODY FUSION DEVICE WITH LIPPED ANTERIOR PLATE AND ASSOCIATED METHODS,"A method and apparatus is provided for use in spinal fusion procedures. An interbody fusion device has a first piece that is a load bearing device designed to bear the axial loading from the end plates of adjacent vertebrae. A second piece of the interbody fusion device is a retention device whose function is to prevent migration of the load bearing device. One or more fasteners secure the retention device to the vertebrae above and below the load bearing device. The fasteners cause the end plates of the vertebrae to compress the end plates to the load bearing device to facilitate proper fusion. The second piece can be configured to include lips that abut the apothyseal rings during, with the plate including bores angled such that fasteners penetrate the apothyseal rings.",SPINESMITH PARTNERS LP;;KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN,KANA RICHARD;;DUNWORTH KEVIN;;DUARTE LUIS;;BURKINSHAW BRIAN;;GUNDANNA MUKUND;;MEDEMA RYAN,,https://lens.org/015-361-756-424-988,Search Report,yes,7,0,4,4,0,A61F2/4455;;A61F2/4455;;A61B17/8042;;A61B17/8042;;A61B17/86;;A61B17/86;;A61F2/30744;;A61F2/30744;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2/4611;;A61F2/4611;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30131;;A61F2002/30131;;A61F2002/302;;A61F2002/302;;A61F2002/30349;;A61F2002/30349;;A61F2002/30352;;A61F2002/30352;;A61F2002/30355;;A61F2002/30355;;A61F2002/30372;;A61F2002/30372;;A61F2002/30373;;A61F2002/30373;;A61F2002/30383;;A61F2002/30383;;A61F2002/30387;;A61F2002/30387;;A61F2002/30397;;A61F2002/30397;;A61F2002/30482;;A61F2002/30482;;A61F2002/30507;;A61F2002/30507;;A61F2002/30517;;A61F2002/30517;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30604;;A61F2002/30604;;A61F2002/30607;;A61F2002/30607;;A61F2002/30616;;A61F2002/30616;;A61F2002/30774;;A61F2002/30774;;A61F2002/30782;;A61F2002/30782;;A61F2002/30904;;A61F2002/30904,A61B17/70;;A61B17/80,,2,1,039-185-786-719-518,10.1007/s11999-010-1597-9;;pmc3032850;;20882376,"SCHOLZ, MD, M ET AL.: ""A New Zero-Profile Implant For Stand-Alone Anterior Cervical Interbody Fusion"", CLIN ORTHOP RELAT RES., vol. 469, 30 September 2010 (2010-09-30), pages 666 - 673;;""Zero-P Instruments and Implants: Zero-Profile Anterior Cervical Interbody Fusion (ACIF) Device: Technique Guide"", SYNTHES SPINE: INSTRUMENTS AND IMPLANTS APPROVED BY THE AO FOUNDATION, April 2010 (2010-04-01)",PENDING
251,WO,A1,WO 2015/108431 A1,091-047-432-109-501,2015-07-23,2015,PT 2015000004 W,2015-01-16,PT 10740814 A,2014-01-17,METHOD AND DEVICE FOR TESTING THE TIGHTNESS OF CORK STOPPERS,"The present invention relates to a method and device (1) for testing the tightness of cork stoppers (R). The device (1) comprises a partitioning mechanism that divides a chamber into two compartments (8a, 8b). The partitioning mechanism comprises: an adjustable insulator (9) designed to seal a central part of the stopper (R) hermetically from the outside and, at the same time, arrange each end of the stopper (R) in one of the compartments (8a, 8b); and an insulator actuator (10) to place the insulator (9) in the central part of the cork (R). The device further comprises a closing block (11a) for the compartment (8a); an inlet (12) arranged in the block (11a) and connected to a test fluid source, and a detection element (13) connected to the same block (11a). The present invention pertains to the field of cork stopper manufacture and of the cork industry in general.",AMORIM CORK RES & SERVICES LDA,MACHADO DA SILVA LUIS FILIPE PEIXOTO;;AMADOR NUNO DUARTE DE FIGUEIREDO SEABRA,,https://lens.org/091-047-432-109-501,Patent Application,yes,3,0,10,10,0,G01N21/952;;G01M3/26;;G01N21/952;;G01M3/26,G01M3/26,,1,1,028-364-007-887-294,10.1021/jf200491t;;21434693,"DAVID P FARIA ET AL: ""permeability of cork to gases"", vol. 59, no. 8, 1 August 2011 (2011-08-01), pages 3590 - 3597, XP002677208, ISSN: 0021-8561, Retrieved from the Internet <URL:http://pubs.acs.org/doi/abs/10.1021/jf200491t> [retrieved on 20110324], DOI: 10.1021/JF200491T",PENDING
252,MX,A,MX 2015004679 A,122-942-200-211-789,2016-10-12,2016,MX 2015004679 A,2015-04-13,MX 2015004679 A,2015-04-13,PROCESS FOR PRRODUCING RECOMBINANT BOVINE BETA-CASEINE A2 PROTEIN APPLIED TO FOOD.,"The present invention refers to a process for the production of a pure functional recombinant bovine BCN A2 protein, which is used in the manufacture of safe, specialized food with a high added value, which overpasses the disadvantages and adverse effects related to the consumption of cow milk.",NUCITEC SA DE CV,JORGE LUIS ROSADO LORIA;;MIGUEL ANGEL DUARTE VAZQUEZ;;CARLOS RAÚL GARCÍA UGALDE,,https://lens.org/122-942-200-211-789,Patent Application,no,0,0,1,1,0,,C12N15/62;;C12P21/00,,0,0,,,,PENDING
253,BR,A2,BR 102022008126 A2,186-332-257-728-811,2023-11-07,2023,BR 102022008126 A,2022-04-28,BR 102022008126 A,2022-04-28,Mesa de trabalho ergométrica com regulagem de altura,"mesa de trabalho ergométrica com regulagem de altura. a presente invenção diz respeito a uma mesa ergométrica com o intuito de elevar verticalmente uma mesa de trabalho para que seja possível regular diversas alturas que irão possibilitar ao usuário várias posições de trabalho. em essência, busca-se com o invento a caracterização de uma nova concepção nos sistemas de elevação das atuais mesas disponíveis no mercado. o foco da invenção consiste em um sistema de elevação que utiliza um sistema de cremalheira e engrenagem acionado por um motor elétrico. com cada cremalheira sendo acionada independente.",INST FEDERAL SUL RIO GRANDENSE,PINZON CASSIANO;;HENRIQUE DARON LORENZATO;;JIAN VIVIAN DE AZEVEDO;;JOÃO LUIS MARTINELLI DUARTE,,https://lens.org/186-332-257-728-811,Patent Application,no,0,0,1,1,0,,A47B9/06,,0,0,,,,PENDING
254,US,A1,US 2009/0091109 A1,051-449-356-672-757,2009-04-09,2009,US 24341408 A,2008-10-01,EP 07381069 A,2007-10-09,FRONT AIRBAG WITH AN ADAPTIVE VENTING DEVICE,"The invention relates to a front airbag module for an automotive vehicle comprising an inflatable cushion ( 11 ) that can be inflated with the gas produced by a generator, including at least one venting opening ( 17 ) and a venting regulation device formed by a flexible material part ( 21 ) joined to the inflatable cushion ( 11 ) on the periphery or near zones of said venting opening ( 17 ) such that it can completely or partially close or uncover it, preventing or allowing the output of gas, and a stress member ( 23 ) joined at one of its ends to said flexible material part ( 21 ) and at the other end to the inflatable cushion ( 11 ), the geometric configurations of said stress member ( 23 ) and of said flexible material part ( 21 ) being established such that the opening degree of the venting opening ( 17 ) is determined by the stress level in the stress member ( 23 ) during cushion ( 11 ) deployment.",DALPHI METAL ESPANA S L,DUARTE DE AREZ LUIS JOSE;;ALMARZA EMILIANO CORE;;DENYS ISABELLE;;RAMOS AGUSTIN RAMON,DALPHI METAL ESPANA S.A (2008-11-04),https://lens.org/051-449-356-672-757,Patent Application,yes,4,3,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/2338,280/736,0,0,,,,DISCONTINUED
255,PT,A,PT 104159 A,159-264-957-230-554,2010-02-11,2010,PT 10415908 A,2008-08-11,PT 10415908 A,2008-08-11,PROCESSO TECNOLÓGICO PARA O FABRICO DE RESERVATÓRIOS DE PAREDE FINA A PARTIR DE PRÉ-FORMAS TUBULARES E SUAS APLICAÇÕES,"O PRESENTE INVENTO É UMA EVOLUÇÃO DO PEDIDO DE PATENTE DE INVENÇÃO NACIONAL NO. 103953 E REFERE-SE A UM PROCESSO DE DEFORMAÇÃO PLÁSTICA DESTINADO AO FABRICO DE RESERVATÓRIOS DE PAREDE FINA (5) A PARTIR DE PRÉ-FORMAS TUBULARES (4) E (6) DE MATERIAIS METÁLICOS E NÃO-METÁLICOS. ESTA EVOLUÇÃO DO PROCESSO DE FABRICO PERMITE ALCANÇAR ABERTURAS POLARES DE MENORES DIMENSÕES, MELHORES ACABAMENTOS SUPERFICIAIS (INTERIORES E EXTERIORES), BOAS PRECISÕES GEOMÉTRICAS E DIMENSIONAIS E UMA ESPESSURA FINAL DA PAREDE UNIFORME E CONTROLADA AO LONGO DA DIRECÇÃO MERIDIONAL. O CONTROLO DE ESPESSURA AO LONGO DA DIRECÇÃO MERIDIONAL É CONSEGUIDO ATRAVÉS DA UTILIZAÇÃO DE UM MANDRIL FLEXÍVEL E DESCARTÁVEL (6), FEITO DE UM MATERIAL COM BOA ENFORMABILIDADE E MENOR RESISTÊNCIA MECÂNICA DO QUE O EXTERIOR (4) COMO POR EXEMPLO DE MATERIAL POLIMÉRICO, COLOCADO NO INTERIOR DA PRÉ-FORMA TUBULAR (4). A FORMA GEOMÉTRICA DA SUPERFÍCIE INTERNA DO MANDRIL (6) PERMITE CONTROLAR A EVOLUÇÃO DA ESPESSURA DESDE A ZONA EQUATORIAL ATÉ À ZONA POLAR DOS RESERVATÓRIOS. TAL COMO NO PEDIDO DE PATENTE DE INVENÇÃO NACIONAL NO. 103953 O PROCESSO DE FABRICO REALIZA-SE NUMA FERRAMENTA TIPO ''PUNÇÃO-MATRIZ'' QUE FAZ INTERVIR DUAS MATRIZES HEMISFÉRICAS (1) E (2) E UM ANEL EXTERIOR FLUTUANTE (3), DE CARACTERÍSTICAS INOVADORAS. A FERRAMENTA PODE SER INSTALADA NUMA MÁQUINA FERRAMENTA OU MECANISMO QUE POSSUA MOVIMENTO AXIAL ALTERNADO PERMITINDO ASSIM ALIMENTAR AS PRÉ-FORMAS TUBULARES E DEFORMÁ-LAS PARA A GEOMETRIA ESFÉRICA OU TUBULAR COM EXTREMIDADES EM FORMA DE CALOTE ESFÉRICA. OS COMPONENTES PRODUZIDOS ATRAVÉS DESTE PROCESSO DE FABRICO POSSUEM DUAS ABERTURAS NAS REGIÕES POLARES, QUE SÃO FUNÇÃO DA ALTURA INICIAL DA PRÉ-FORMA TUBULAR E DA FORMA E DIMENSÃO DO MANDRIL FLEXÍVEL E DESCARTÁVEL.",INST SUPERIOR TECNICO;;OMNIDEA LDA,PARDAL TIAGO DA COSTA DUARTE;;ALVES LUIS MANUEL MENDONCA;;MARTINS PAULO ANTONIO FIRME,,https://lens.org/159-264-957-230-554,Patent Application,no,0,0,1,6,0,,B21D51/02,,0,0,,,,INACTIVE
256,PT,A,PT 103953 A,066-844-060-720-929,2009-08-03,2009,PT 10395308 A,2008-02-01,PT 10395308 A,2008-02-01,PROCESSO TECNÓLOGICO PARA O FABRICO DE ESFERAS OCAS DE PAREDE FINA A PARTIR DE PRÉ-FORMAS TUBULARES,"O PRESENTE INVENTO REFERE-SE A UM PROCESSO DE DEFORMAÇÃO PLÁSTICA DESTINADO AO FABRICO DE ESFERAS OCAS DE PAREDE FINA A PARTIR DE PRÉ-FORMAS TUBULARES DE MATERIAIS METÁLICOS E NÃO-METÁLICOS. O PROCESSO DE FABRICO REALIZA-SE NUMA FERRAMENTA TIPO ''PUNÇÃO- MATRIZ'' QUE FAZ INTERVIR DUAS MATRIZES HEMISFÉRICAS (1 E 2) E UM ANEL EXTERIOR FLUTUANTE, DE CARACTERÍSTICAS INOVADORAS. A FERRAMENTA PODE SER INSTALADA NUMA PRENSA OU NUM MARTELO DE QUEDA E O SEU MOVIMENTO AXIAL ALTERNADO PERMITE ALIMENTAR AS PRÉ-FORMAS TUBULARES (4) E DEFORMÁ-LAS PARA A GEOMETRIA ESFÉRICA (5) PRETENDIDA. AS ESFERAS PRODUZIDAS ATRAVÉS DESTE PROCESSO DE FABRICO POSSUEM DOIS FUROS NAS REGIÕES POLARES, CUJA ABERTURA É FUNÇÃO DA ALTURA INICIAL DA PRÉ-FORMA TUBULAR, E SÃO CARACTERIZADAS POR UM BOM ACABAMENTO SUPERFICIAL, UMA BOA PRECISÃO GEOMÉTRICA E DIMENSIONAL E UMA ESPESSURA FINAL DE PAREDE APROXIMADAMENTE CONSTANTE AO LONGO DA DIRECÇÃO MERIDIONAL.",OMNIDEA LDA;;INST SUPERIOR TECNICO,PARDAL TIAGO DA COSTA DUARTE;;ALVES LUIS MANUEL MENDONCA;;MARTINS PAULO ANTONIO FIRME,,https://lens.org/066-844-060-720-929,Patent Application,no,0,0,1,6,0,,B21D51/08,,0,0,,,,DISCONTINUED
257,JP,A,JP 2009090976 A,036-533-360-212-92X,2009-04-30,2009,JP 2008261519 A,2008-10-08,EP 07381069 A,2007-10-09,FRONT AIRBAG WITH ADAPTIVE VENTING DEVICE,"<P>PROBLEM TO BE SOLVED: To provide an airbag module for an automobile capable of performing a self-adaptation to differences of the position of an occupant, the dimension of a body and the kind of impact, and of absorbing tolerance of other passive type safety system including a change of an expected position of the occupant. <P>SOLUTION: A cushion 11 includes at least one venting opening 17 and a regulating device regulating venting passing through the venting opening 17. The regulating device is formed by a flexible material part 21 connected to the inflatable cushion 11 at a peripheral edge part of the venting opening 17. The flexible material part 21 completely or partially closes or opens the venting opening 17 to prevent or allow outflow of gas. A stress member 23 has one end connected to the flexible material part 21 and the other end connected to the inflatable cushion 11. A geometric configuration of the stress member 23 and the flexible material part 21 is set so that an opening degree of the venting opening 17 may be determined by a stress level of the stress member 23 during deployment of the cushion 11. <P>COPYRIGHT: (C)2009,JPO&INPIT",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;CORE ALMARZA EMILIANO;;DENYS ISABELLE;;RAMOS AGUSTIN RAMON,,https://lens.org/036-533-360-212-92X,Patent Application,no,1,2,8,8,0,B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R21/2338;;B60R2021/2395;;B60R2021/23382,B60R21/2338;;B60R21/16,,0,0,,,,PENDING
258,BR,A,BR PI0502576 A,165-579-807-627-656,2007-02-27,2007,BR PI0502576 A,2005-07-06,BR PI0502576 A,2005-07-06,método para impregnar um fármaco ou uma composição de fármacos em artigos oftalmológicos,"""MéTODO PARA IMPREGNAR UM FáRMACO OU UMA COMPOSIçãO DE FáRMACOS EM ARTIGOS OFTALMOLóGICOS"". Esta invenção descreve um método de impregnação de um fármaco, ou de uma composição de fármacos, em artigos oftalmológicos com o objetivo de preparar sistemas de liberação controlada de fármacos, principalmente para o tratamento do glaucoma e de outras doenças do olho. Os artigos oftalmológicos podem ser, por exemplo, lentes de contato. O fármaco, ou composição de fármacos, é dissolvido num fluido comprimido, ou numa mistura de fluidos comprimidos, num estado líquido, lúquido sub-crítico, gasoso ou supercrítico e podem ser adicionados co-solventes, de forma a aumentar a solubilidade dos fármacos nos fluidos comprimidos. A mistura é posteriormente posta em contato com o artigo oftalmológico. Este processo pode ser efetuado num único passo ou em dois passos consecutivos. A impregnação pode ser realizada em artigos oftalmológicos acabados ou semi-acabados.",UNIV DE COIMBRA;;INST DE BIOLOG EX E TECNOLOGIC,SOUZA HERMINIO JOSE CIPRIANO D;;GIL MARIA HELENA MENDES;;DUARTE CATARINA MARIA MARTINS;;LEITE EUGENIO OSCAR LUIS BAPTI;;DUARTE ANA RITA CRUZ,,https://lens.org/165-579-807-627-656,Patent Application,no,0,0,1,1,0,,A61K9/08,,0,0,,,,DISCONTINUED
259,CA,A1,CA 2739787 A1,075-068-588-495-704,2010-04-15,2010,CA 2739787 A,2009-10-08,US 13684508 P;;IB 2009007234 W,2008-10-08,.BETA.-HYDROXY-.GAMMA.-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF,"The present invention provides ß-hydroxy-?-aminophosphonates, ß-amino-?- aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ß-hydroxy-?-aminophosphonates, ß-amino-?- aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",NUCITEC SA DE CV,VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,,https://lens.org/075-068-588-495-704,Patent Application,no,0,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A61K31/662;;A61P3/04;;A61P3/10;;A61P25/28;;C07F9/38,,0,0,,,,DISCONTINUED
260,WO,A2,WO 2010/041144 A2,171-854-065-494-946,2010-04-15,2010,IB 2009007234 W,2009-10-08,US 13684508 P,2008-10-08,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF,"The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ- aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ- aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",NUCITEC SA DE CV;;VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA;;LORIA JORGE LUIS ROSADO,VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,,https://lens.org/171-854-065-494-946,Patent Application,yes,0,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A61K31/662;;A61P3/04;;A61P3/10;;A61P25/28;;C07F9/38,,0,0,,,,PENDING
261,WO,A1,WO 2022/236695 A1,199-108-559-050-917,2022-11-17,2022,CN 2021093101 W,2021-05-11,CN 2021093101 W,2021-05-11,MODULO-BASED ANALOG-TO-DIGITAL CONVERSION APPARATUS AND METHOD,"A modulo-based analog-to-digital conversion, ADC, implementation relating to the field of signal processing is disclosured. The modulo-based ADC implementation disclosed herein involves converting an input analog signal into phases of other M periodic analog reference signals based on one or more transfer functions, wherein M≥2. The phase of each of the M reference signals comprises a folded signal corresponding to the input analog signal that is amplitude-folded to fall within a required amplitude range. This signal-to-phase conversion allows a modulo operation to be implemented over the input analog signal. Further, the M reference signals are used to obtain M discrete-time digital signals which, in turn, are used to obtain a digital representation of the input analog signal.",HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;GUILLAUD MAXIME;;YANG GANGHUA;;FERRAND PAUL;;DUARTE GELVEZ MELISSA;;LI XU,,https://lens.org/199-108-559-050-917,Patent Application,yes,4,0,3,3,0,H03M1/64,H03M1/00,,0,0,,,,PENDING
262,EP,A1,EP 3107768 A1,033-933-544-089-333,2016-12-28,2016,EP 15713644 A,2015-02-19,DE 202014001513 U;;EP 2015000367 W,2014-02-20,THORAX OCCUPANT PROTECTION DEVICE AND METHOD OF PROTECTING THE THORAX OF A VEHICLE OCCUPANT IN SIDE IMPACTS,,DALPHI METAL ESPAÑA S A,PÉREZ GARCIA AZUCENA;;CRESPO VIZÁN MARIA;;UGARTE ALBA OSCAR;;DUARTE DE AREZ LUIS JOSÉ,,https://lens.org/033-933-544-089-333,Patent Application,yes,0,0,7,7,0,B60R21/23138;;B60R21/23138;;B60R21/233;;B60R2021/0041;;B60R2021/0041;;B60R2021/23316,B60R21/231,,1,0,,,See references of WO 2015124299A1,ACTIVE
263,US,A1,US 2013/0079308 A1,194-175-887-071-803,2013-03-28,2013,US 201213427155 A,2012-03-22,US 201213427155 A;;US 57585609 A;;US 13684508 P,2008-10-08,Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof,"The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",DE LA CRUZ CORDERO RICARDO ABRAHAM;;VAZQUEZ MIGUEL AANGEL DUARTE;;LORIA JORGE LUIS ROSADO;;NUCITEC SA DE CV,DE LA CRUZ CORDERO RICARDO ABRAHAM;;VAZQUEZ MIGUEL AANGEL DUARTE;;LORIA JORGE LUIS ROSADO,,https://lens.org/194-175-887-071-803,Patent Application,yes,0,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,C07F9/40;;C07F9/38,514/114;;435/184,0,0,,,,INACTIVE
264,WO,A4,WO 2010/041144 A4,065-638-821-609-51X,2010-07-15,2010,IB 2009007234 W,2009-10-08,US 13684508 P,2008-10-08,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF,"The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ- aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ- aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",NUCITEC SA DE CV;;VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,,https://lens.org/065-638-821-609-51X,Patent Application,yes,0,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A01N57/18,,0,0,,,,PENDING
265,US,A1,US 2016/0355155 A1,092-535-175-739-623,2016-12-08,2016,US 201515117751 A,2015-02-19,DE 202014001513 U;;EP 2015000367 W,2014-02-20,THORAX OCCUPANT PROTECTION DEVICE AND METHOD OF PROTECTING THE THORAX OF A VEHICLE OCCUPANT IN SIDE IMPACTS,"The present invention relates to a thorax occupant protection device ( 10 ) comprising a side airbag ( 12 ), especially for being mounted in a door or the seat of ah automotive vehicle, which in the inflated and mounted state of the side airbag ( 12 ) at its upper end includes at least one occupant-side inflatable inner wing ( 22 ) for shifting the occupant's adjacent arm forward and at least one door-side inflatable outer wing ( 24 ) for protecting the thorax, wherein the inner and outer wings ( 22, 24 ) in the inflated state are juxtaposed at least in portions and are separated from each other by an indentation ( 26 ) of the airbag wall ( 13 ) extending from the upper end in the downward direction. The present invention further relates to a method of protecting the thorax of a vehicle occupant in the event of a side impact.",DALPHI METAL ESPANA SA,PEREZ GARCIA AZUCENA;;CRESPO VIZAN MARIA;;UGARTE ALBA OSCAR;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2016-08-25),https://lens.org/092-535-175-739-623,Patent Application,yes,1,3,7,7,0,B60R21/23138;;B60R21/23138;;B60R21/233;;B60R2021/0041;;B60R2021/0041;;B60R2021/23316,B60R21/231;;B60R21/233,,0,0,,,,ACTIVE
266,US,B2,US 10173631 B2,122-602-613-080-632,2019-01-08,2019,US 201515117751 A,2015-02-19,DE 202014001513 U;;EP 2015000367 W,2014-02-20,Thorax occupant protection device and method of protecting the thorax of a vehicle occupant in side impacts,"The present invention relates to a thorax occupant protection device ( 10 ) comprising a side airbag ( 12 ), especially for being mounted in a door or the seat of an automotive vehicle, which in the inflated and mounted state of the side airbag ( 12 ) at its upper end includes at least one occupant-side inflatable inner wing ( 22 ) for shifting the occupant's adjacent arm forward and at least one door-side inflatable outer wing ( 24 ) for protecting the thorax, wherein the inner and outer wings ( 22, 24 ) in the inflated state are juxtaposed at least in portions and are separated from each other by an indentation ( 26 ) of the airbag wall ( 13 ) extending from the upper end in the downward direction. The present invention further relates to a method of protecting the thorax of a vehicle occupant in the event of a side impact.",DALPHI METAL ESPANA SA;;DALPHI METAL ESPANA SA,PEREZ GARCIA AZUCENA;;CRESPO VIZAN MARIA;;UGARTE ALBA OSCAR;;DUARTE DE AREZ LUIS JOSE,DALPHI METAL ESPANA S.A (2016-08-25),https://lens.org/122-602-613-080-632,Granted Patent,yes,10,5,7,7,0,B60R21/23138;;B60R21/23138;;B60R21/233;;B60R2021/0041;;B60R2021/0041;;B60R2021/23316,B60R21/231;;B60R21/00;;B60R21/233,,0,0,,,,ACTIVE
267,EP,A1,EP 4324096 A1,040-975-774-787-099,2024-02-21,2024,EP 21941270 A,2021-05-11,CN 2021093101 W,2021-05-11,MODULO-BASED ANALOG-TO-DIGITAL CONVERSION APPARATUS AND METHOD,,HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;GUILLAUD MAXIME;;YANG GANGHUA;;FERRAND PAUL;;DUARTE GELVEZ MELISSA;;LI XU,,https://lens.org/040-975-774-787-099,Patent Application,yes,0,0,3,3,0,H03M1/64,H03M1/00,,0,0,,,,PENDING
268,MX,A,MX 2011003772 A,163-029-647-034-480,2011-08-12,2011,MX 2011003772 A,2009-10-08,US 13684508 P;;IB 2009007234 W,2008-10-08,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF.,"The present invention provides Î²-hydroxy-Î³-aminophosphonates, Î²-amino-Î³- aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these Î²-hydroxy-Î³-aminophosphonates, Î²-amino-Î³- aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VAZQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ,,https://lens.org/163-029-647-034-480,Patent Application,no,0,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A01N57/18,,0,0,,,,ACTIVE
269,EP,A4,EP 2348865 A4,165-136-690-938-158,2012-08-01,2012,EP 09818863 A,2009-10-08,IB 2009007234 W;;US 13684508 P,2008-10-08,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF,,NUCITEC SA DE CV,VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,,https://lens.org/165-136-690-938-158,Search Report,no,0,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A01N57/18,,1,1,010-865-109-364-023,10.1016/j.tet.2005.09.126,"YAMAGISHI T ET AL: ""Asymmetric synthesis of phosphonic acid analogues for acylcarnitine"", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 62, no. 1, 2 January 2006 (2006-01-02), pages 54 - 65, XP025002061, ISSN: 0040-4020, [retrieved on 20060102], DOI: 10.1016/J.TET.2005.09.126",ACTIVE
270,US,B2,US 8536362 B2,009-895-971-229-404,2013-09-17,2013,US 201213427155 A,2012-03-22,US 201213427155 A;;US 57585609 A;;US 13684508 P,2008-10-08,beta-hydroxy-gamma-aminophosphonates and methods for the preparation and use thereof,"The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",DE LA CRUZ CORDERO RICARDO ABRAHAM;;VAZQUEZ MIGUEL AANGEL DUARTE;;LORIA JORGE LUIS ROSADO;;NUCITEC SA DE CV,DE LA CRUZ CORDERO RICARDO ABRAHAM;;VAZQUEZ MIGUEL AANGEL DUARTE;;LORIA JORGE LUIS ROSADO,,https://lens.org/009-895-971-229-404,Granted Patent,yes,4,1,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,C07F9/40,558/169;;564/15,15,11,019-243-390-735-607;;056-910-887-742-122;;022-356-183-794-566;;001-881-714-575-017;;093-001-762-848-963;;031-918-874-072-771;;024-336-398-005-522;;018-321-853-529-039;;010-865-109-364-023;;027-811-946-271-194;;033-701-088-111-046,15530988;;10.1016/j.bioorg.2004.05.009;;19452263;;10.1007/s10545-009-1126-8;;10.1007/s00125-007-0605-4;;pmc5682624;;17310372;;10.3998/ark.5550190.0006.623;;12398518;;10.1021/jo020330x;;10.1016/j.tetasy.2006.12.001;;10.1039/b307638p;;14599018;;10.1002/1099-0690(200208)2002:16<2758::aid-ejoc2758>3.0.co;2-q;;10.1016/j.tet.2005.09.126;;9486313;;10.1152/ajpregu.1998.274.2.r524;;10.2337/diacare.15.6.773;;1600836,"Tadeusiak, 2004, Bioorganic Chemistry, vol. 32, p. 473-482.;;How to Prevent Diabetes, http://diabetes.webmd.com/guide/understanding-diabetes-prevention, accessed Oct. 27, 2011.;;Spiekerkoetter et al, 2009, J. Inherit Metab Dis, vol. 32, p. 498-505.;;Power et al, 2007, Diabetologia, vol. 50, p. 824-832.;;De la Cruz-Cordero, R. et al., ""Preparation of phosphostatine and phosphoepistatine from L-leucine via high diastereoselective reduction of 3-amino-2-ketophosphonates,"" ARKIVOC (vi):277-286, ARKAT USA, Inc. (2005).;;Mikolajczyk, M. et al., ""Chemoenzymatic Synthesis of Phosphocarnitine Enantiomers,"" J. Org. Chem. 67:7872-7875, American Chemical Society (2002).;;Ordonez, M. and Cativiela, C., ""Stereoselective synthesis of gamma-amino acids,"" Tetrahedron Asymmetry 18:3-99, Elsevier Ltd. (2007).;;Young, L.W., International Search Report and Written Opinion for International Patent Application No. PCT/IB09/07234, International Search Authority, U.S. Patent and Trademark Office, Alexandria, Virginia, mailed Mar. 19, 2010.;;Stahl, Handbook of Pharmaceutical Salts, 2002, Wiley-Ch, p. 1-7, 84, 161-173, 214-215, 310-311.;;Wang, ""Enzymatic Synthesis of Phosphocarnitine, Phosphogabob and Fosfomycin,"" 2003, Org. Biomol. Chem., vol. 1, p. 3564-3569, Royal Society of Chemistry.;;Wroblewski, ""An Efficient Synthesis of Enantiomeric (S)-Phosphocarnitine,"" 2002, Eur. J. Org. Chem., p. 2758-2763. Wiley-VCH.;;Yamagishi, ""Asymmetric Synthesis of Phosphonic Acid Analogues for Acylcarnitine,"" 2006, Tetrahedron, vol. 62, p. 54-65, Oxford: Pergamon Press.;;Deems, R.O. et al., ""Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys,"" Am. J. Physiol. Regul. Integr. Comp. Physiol. 274:R524-R528, American Physiological Society (1998).;;Foley, J.E., ""Rationale and Application Of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus,"" Diabetes Care 15:773-784, American Diabetes Association (1992).;;Office Action mailed Oct. 25, 2011, in U.S. Appl. No. 12/575,856, filed Oct. 8, 2009, inventors: de la Cruz Cordero et al., U.S. Patent and Trademark Office, Alexandria, VA.",INACTIVE
271,US,A1,US 2010/0087400 A1,090-861-654-329-905,2010-04-08,2010,US 57585609 A,2009-10-08,US 57585609 A;;US 13684508 P,2008-10-08,Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof,"The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",NUCITEC SA DE CV,DE LA CRUZ CORDERO RICARDO ABRAHAM;;VAZQUEZ MIGUEL ANGEL DUARTE;;LORIA JORGE LUIS ROSADO,NUCITEC S.A. DE C.V (2009-10-16),https://lens.org/090-861-654-329-905,Patent Application,yes,3,2,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A61K31/662;;A61P3/04;;A61P3/10;;A61P25/28;;C07F9/38,514/114;;564/15,0,0,,,,INACTIVE
272,WO,A3,WO 2010/041144 A3,140-633-710-151-812,2010-06-03,2010,IB 2009007234 W,2009-10-08,US 13684508 P,2008-10-08,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF,"The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ- aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ- aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",NUCITEC SA DE CV;;VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA;;LORIA JORGE LUIS ROSADO,VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,,https://lens.org/140-633-710-151-812,Search Report,yes,3,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A01N57/18,,3,3,093-001-762-848-963;;001-881-714-575-017;;031-918-874-072-771,12398518;;10.1021/jo020330x;;10.3998/ark.5550190.0006.623;;10.1016/j.tetasy.2006.12.001,"MIKOLAJCZYK ET AL.: ""the article,'Chemoenzymatic Synthesis of Phosphocarnitine Enantiomers'"", J. ORG. CHEM., vol. 67, 2002, pages 7872 - 7875, XP008147179;;DE LA CRUZ-CORDERO ET AL.: ""'Preparation of phosphostatine and phosphoepistatine from L- leucine via high diastereoselective reduction of 3-amino-2-ketophosphonates"", ARKIVOC 2005, pages 277 - 286, XP008147178;;ORDONEZ ET AL.: ""Stereoselective synthesis of gamma-amino acids"", TETRAHEDRON: ASYMMETRY, vol. 18, 2007, pages 3 - 99, XP005877872",PENDING
273,US,B1,US 8519780 B1,013-584-945-910-26X,2013-08-27,2013,US 201213368793 A,2012-02-08,US 201213368793 A,2012-02-08,Charge pump voltage regulator,A regulator ( 104 ) for a charge pump ( 102 ) includes a clock amplitude modulator ( 150 ) that changes voltage of a clock signal used in operation of the charge pump in response to changes in magnitude of output voltage of the change pump. The clock amplitude modulator is powered by an output of an auxiliary circuit ( 120 ). The output of the auxiliary circuit is at a higher voltage than an input voltage of the charge pump. A maximum amplitude of the voltage of the clock signal is higher than the input voltage of the charge pump.,VILAS BOAS ANDRE LUIS;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO;;MANSANO ANDRE L R;;FREESCALE SEMICONDUCTOR INC,VILAS BOAS ANDRE LUIS;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO;;MANSANO ANDRE L R,FREESCALE SEMICONDUCTOR INC (2012-02-08);;NXP USA INC (2016-11-07),https://lens.org/013-584-945-910-26X,Granted Patent,yes,9,14,2,2,0,H02M3/07;;H02M3/07;;H02M1/0003;;H02M1/0003,G05F1/10,327/536,1,1,143-650-289-882-446,10.1109/sbcci.2003.1232825,"Soldera, J., et al., ""A Low Ripple Fully Integrated Charge Pump Regulator"", Proceedings of the 16th Symposium on Integrated Circuits and Systems Design (2003), 0-07695-2009-X/03.",ACTIVE
274,CN,A,CN 117223224 A,027-348-369-825-588,2023-12-12,2023,CN 202180097558 A,2021-05-11,CN 2021093101 W,2021-05-11,Module-based analog-to-digital conversion device and method,"A mode-based analog-to-digital conversion (ADC) implementation relating to the field of signal processing is disclosed. Module-based ADC implementations disclosed herein relate to converting an input analog signal to phases of other M periodic analog reference signals based on one or more transfer functions, where M > = 2. The phase of each of the M reference signals includes a folded signal corresponding to an input analog signal that is amplitude folded to fall within a desired amplitude range. This signal-to-phase conversion allows modular operations to be implemented on an input analog signal. Further, the M reference signals are used to obtain M discrete time digital signals, which in turn are used to obtain a digital representation of the input analog signal.",HUAWEI TECH CO LTD,GARCIA ORDONEZ LUIS;;GUELADE MAXIME;;YANG GANGHUA;;FERRAND PAUL;;DUARTE GUELVEZ MELISSA;;LI XU,,https://lens.org/027-348-369-825-588,Patent Application,no,0,0,3,3,0,H03M1/64,H03M1/00,,0,0,,,,PENDING
275,WO,A1,WO 2015/124299 A1,080-798-386-394-185,2015-08-27,2015,EP 2015000367 W,2015-02-19,DE 202014001513 U,2014-02-20,THORAX OCCUPANT PROTECTION DEVICE AND METHOD OF PROTECTING THE THORAX OF A VEHICLE OCCUPANT IN SIDE IMPACTS,"The present invention relates to a thorax occupant protection device (10) comprising a side airbag (12), especially for being mounted in a door or the seat of ah automotive vehicle, which in the inflated and mounted state of the side airbag (12) at its upper end includes at least one occupant-side inflatable inner wing (22) for shifting the occupant's adjacent arm forward and at least one door-side inflatable outer wing (24) for protecting the thorax, wherein the inner and outer wings (22, 24) in the inflated state are juxtaposed at least in portions and are separated from each other by an indentation (26) of the airbag wall (13) extending from the upper end in the downward direction. The present invention further relates to a method of protecting the thorax of a vehicle occupant in the event of a side impact.",DALPHI METAL ESPANA SA,PÉREZ GARCIA AZUCENA;;CRESPO VIZÁN MARIA;;UGARTE ALBA OSCAR;;DUARTE DE AREZ LUIS JOSÉ,,https://lens.org/080-798-386-394-185,Patent Application,yes,4,0,7,7,0,B60R2021/0041;;B60R21/23138;;B60R2021/0041;;B60R21/23138;;B60R21/233;;B60R2021/23316,B60R21/231,,0,0,,,,PENDING
276,US,A1,US 2013/0200943 A1,101-664-082-072-271,2013-08-08,2013,US 201213368793 A,2012-02-08,US 201213368793 A,2012-02-08,CHARGE PUMP VOLTAGE REGULATOR,A regulator ( 104 ) for a charge pump ( 102 ) includes a clock amplitude modulator ( 150 ) that changes voltage of a clock signal used in operation of the charge pump in response to changes in magnitude of output voltage of the change pump. The clock amplitude modulator is powered by an output of an auxiliary circuit ( 120 ). The output of the auxiliary circuit is at a higher voltage than an input voltage of the charge pump. A maximum amplitude of the voltage of the clock signal is higher than the input voltage of the charge pump.,VILAS BOAS ANDRE LUIS;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO;;MANSANO ANDRE L R;;FREESCALE SEMICONDUCTOR INC,VILAS BOAS ANDRE LUIS;;DUARTE DE MARTIN FABIO;;OLMOS ALFREDO;;MANSANO ANDRE L R,FREESCALE SEMICONDUCTOR INC (2012-02-08);;NXP USA INC (2016-11-07),https://lens.org/101-664-082-072-271,Patent Application,yes,0,10,2,2,0,H02M3/07;;H02M3/07;;H02M1/0003;;H02M1/0003,G05F1/10,327/536;;323/234,0,0,,,,ACTIVE
277,EP,B1,EP 2348865 B1,136-644-356-188-098,2015-07-15,2015,EP 09818863 A,2009-10-08,IB 2009007234 W;;US 13684508 P,2008-10-08,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF,,NUCITEC SA DE CV,VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,,https://lens.org/136-644-356-188-098,Granted Patent,yes,3,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,C07F9/38;;A61P3/04;;A61P3/06;;C07F9/40,,4,0,,,"YAMAGISHI T ET AL: ""Asymmetric synthesis of phosphonic acid analogues for acylcarnitine"", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 62, no. 1, 2 January 2006 (2006-01-02), pages 54-65, XP025002061, ISSN: 0040-4020, DOI: 10.1016/J.TET.2005.09.126 [retrieved on 2006-01-02];;MIKOLAJCZYK ET AL.: 'the article,'Chemoenzymatic Synthesis of Phosphocarnitine Enantiomers'' J. ORG. CHEM. vol. 67, 2002, pages 7872 - 7875, XP008147179;;DE LA CRUZ-CORDERO ET AL.: ''Preparation of phosphostatine and phosphoepistatine from L- leucine via high diastereoselective reduction of 3-amino-2-ketophosphonates' ARKIVOC 2005 pages 277 - 286, XP008147178;;ORDONEZ ET AL.: 'Stereoselective synthesis of gamma-amino acids' TETRAHEDRON: ASYMMETRY vol. 18, 2007, pages 3 - 99, XP005877872",ACTIVE
278,EP,A2,EP 2348865 A2,172-175-610-678-655,2011-08-03,2011,EP 09818863 A,2009-10-08,IB 2009007234 W;;US 13684508 P,2008-10-08,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF,,NUCITEC SA DE CV,VASQUEZ MIGUEL ANGEL DUARTE;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;LORIA JORGE LUIS ROSADO,,https://lens.org/172-175-610-678-655,Patent Application,yes,0,0,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,C07F9/38;;A61P3/04;;A61P3/06;;C07F9/40,,0,0,,,,ACTIVE
279,EP,B1,EP 3107768 B1,187-432-713-569-653,2019-01-30,2019,EP 15713644 A,2015-02-19,DE 202014001513 U;;EP 2015000367 W,2014-02-20,THORAX OCCUPANT PROTECTION DEVICE AND METHOD OF PROTECTING THE THORAX OF A VEHICLE OCCUPANT IN SIDE IMPACTS,,DALPHI METAL ESPANA SA,PÉREZ GARCIA AZUCENA;;CRESPO VIZÁN MARIA;;UGARTE ALBA OSCAR;;DUARTE DE AREZ LUIS JOSÉ,,https://lens.org/187-432-713-569-653,Granted Patent,yes,4,0,7,7,0,B60R2021/0041;;B60R21/23138;;B60R2021/0041;;B60R21/23138;;B60R21/233;;B60R2021/23316,B60R21/231,,0,0,,,,ACTIVE
280,US,B2,US 8178515 B2,180-427-249-992-704,2012-05-15,2012,US 57585609 A,2009-10-08,US 57585609 A;;US 13684508 P,2008-10-08,β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof,"The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.",DE LA CRUZ CORDERO RICARDO ABRAHAM;;DUARTE-VAZQUEZ MIGUEL ANGEL;;LORIA JORGE LUIS ROSADO;;NUCITEC SA DE CV,DE LA CRUZ CORDERO RICARDO ABRAHAM;;DUARTE-VAZQUEZ MIGUEL ANGEL;;LORIA JORGE LUIS ROSADO,NUCITEC S.A. DE C.V (2009-10-16),https://lens.org/180-427-249-992-704,Granted Patent,yes,4,1,13,13,0,C07F9/3808;;A61P25/28;;A61P3/04;;A61P3/06;;A61P3/10;;C07F9/3808;;C07F9/4006,A61K31/662;;C07F9/40,514/114;;564/15,8,6,024-336-398-005-522;;018-321-853-529-039;;010-865-109-364-023;;001-881-714-575-017;;093-001-762-848-963;;031-918-874-072-771,10.1039/b307638p;;14599018;;10.1002/1099-0690(200208)2002:16<2758::aid-ejoc2758>3.0.co;2-q;;10.1016/j.tet.2005.09.126;;10.3998/ark.5550190.0006.623;;12398518;;10.1021/jo020330x;;10.1016/j.tetasy.2006.12.001,"Stahl, Handbook of Pharmaceutical Salts, 2002, Wiley-Ch, p. 1-7, 84, 161-173, 214-215, 310-311.;;Wang, Enzymatic synthesis of phosphocarnitine, phosphogabob and fosfomycin, 2003, Org. Biomol. Chem. vol. 1, p. 3564-3569.;;Wroblewski, An Efficient Synthesis of Enantiomeric (S)-Phosphocarnitine, 2002, Er. J. Org. Chem., p. 2758-2763.;;Yamagishi, Asymmetric synthesis of phosphonic acid analogues for acylcarnitine, 2006, Tetrahedron, vol. 62, p. 54-65.;;De la Cruz-Cordero, R. et al., ""Preparation of phosphostatine and phosphoepistatine from L-leucine via high diastereoselective reduction of 3-amino-2-ketophosphonates,"" ARKIVOC (vi):277-286, ARKAT USA, Inc. (2005).;;Mikolajczyk, M. et al., ""Chemoenzymatic Synthesis of Phosphocarnitine Enantiomers,"" J. Org. Chem. 67:7872-7875, American Chemical Society (2002).;;Ordonez, M. and Cativiela, C., ""Stereoselective synthesis of gamma-amino acids,"" Tetrahedron Asymmetry 18:3-99, Elsevier Ltd. (2007).;;Young, L.W., International Search Report and Written Opinion for International Patent Application No. PCT/IB09/07234, International Search Authority, U.S. Patent and Trademark Office, Alexandria, Virginia, mailed Mar. 19, 2010.",INACTIVE
281,BR,A2,BR 102015017662 A2,116-977-624-152-033,2017-01-31,2017,BR 102015017662 A,2015-07-23,BR 102015017662 A,2015-07-23,processo e dispositivo de pesagem dinâmica de um animal,"processo e dispositivo de pesagem dinâmica de um animal. a presente invenção pertence ao setor técnico da pesagem de animais. a invenção refere-se a um processo de pesagem dinâmica de um animal (6), que inclui uma etapa de passagem deste animal (6) sobre uma plataforma de pesagem (1), e que inclui ainda as seguintes etapas: - obter uma primeira (7) e uma segunda (8) curvas de peso em função do tempo; - calcular o primeiro e o segundo pesos médios, cada um a partir dos pesos da curva correspondente de peso que estão situados entre um pico (9, 12) e um ponto secundário (10, 11); - somar o primeiro peso médio e o segundo peso médio para obter o peso do animal (6). a presente invenção refere-se também a um dispositivo de pesagem dinâmica de um animal (6).",ROBERT BOSCH LTDA,LUIS FERNANDO RIBEIRO JUNIOR;;RENATA GHISLOTI DUARTE DE SOUZA GRANHA;;RICARDO KEIGO DE SALES ANDRADE,,https://lens.org/116-977-624-152-033,Patent Application,no,0,0,4,4,0,G01G17/08;;G01G23/12,A01K29/00;;G01G11/04;;G01G17/08;;G01G23/18,,0,0,,,,ACTIVE
282,BR,B1,BR 102015017662 B1,004-613-955-415-792,2021-07-06,2021,BR 102015017662 A,2015-07-23,BR 102015017662 A,2015-07-23,processo e dispositivo de pesagem dinâmica de um animal,"processo e dispositivo de pesagem dinâmica de um animal. a presente invenção pertence ao setor técnico da pesagem de animais. a invenção refere-se a um processo de pesagem dinâmica de um animal (6), que inclui uma etapa de passagem deste animal (6) sobre uma plataforma de pesagem (1), e que inclui ainda as seguintes etapas: - obter uma primeira (7) e uma segunda (8) curvas de peso em função do tempo; - calcular o primeiro e o segundo pesos médios, cada um a partir dos pesos da curva correspondente de peso que estão situados entre um pico (9, 12) e um ponto secundário (10, 11); - somar o primeiro peso médio e o segundo peso médio para obter o peso do animal (6). a presente invenção refere-se também a um dispositivo de pesagem dinâmica de um animal (6).",ROBERT BOSCH LTDA,LUIS FERNANDO RIBEIRO JUNIOR;;RENATA GHISLOTI DUARTE DE SOUZA GRANHA;;RICARDO KEIGO DE SALES ANDRADE,,https://lens.org/004-613-955-415-792,Granted Patent,no,0,0,4,4,0,G01G17/08;;G01G23/12,A01K29/00;;G01G11/04;;G01G17/08;;G01G23/18,,0,0,,,,ACTIVE
283,US,B2,US 9397969 B2,028-673-822-921-822,2016-07-19,2016,US 201213729257 A,2012-12-28,US 201213729257 A;;US 201161581554 P,2011-12-29,Electronic system and method for creation and management of media content,"An electronic system (and corresponding method) for creating and managing media content involves at least one content management system (CMS) and a service. The CMS is configured to interact with at least one first-type user in order to create and manage media content for publication. The service is configured to interact with a plurality of second-type users in order to submit media content items that are associated with media content managed by the CMS and to store such media content items. Both the CMS and the service include corresponding interfaces that allow for exchange of electronic messages therebetween via network communications over the Internet, wherein the electronic messages conform to a predefined protocol.",BUNNYFORCE INC,TORRENEGRA ALEX;;ZAPATA TANIA;;DUARTE-REY ABELARDO;;MOLINA LUIS;;CANASTERO-PRIETO HENRY;;RODRIGUEZ-LOZANO CARLOS,VOICE123 INC (2019-04-29);;TORRE TECHNOLOGIES CO (2016-05-19);;EMMA GROUP INC (2021-07-30),https://lens.org/028-673-822-921-822,Granted Patent,yes,5,4,2,2,0,H04L12/1836;;H04L51/52;;H04L51/046;;H04L12/1836;;H04L51/52,G06F3/048;;H04L12/18;;H04L12/58,,2,0,,,"VOICE123-The Voice Over Marketplace-Voice Overs, Voice Actors, and Talents, How it works for Buyers, available at voice123.com/doc/how-buyers.html, 2003-2013.;;VOICE123-The Voice Over Marketplace-Voice Overs, Voice Actors, and Talents, How it works for Talents, available at voice123.com/doc/how-talents.html, 2003-2013.",ACTIVE
284,US,A1,US 2021/0226940 A1,002-562-333-347-561,2021-07-22,2021,US 202016747792 A,2020-01-21,US 202016747792 A,2020-01-21,AUTOMATED RENEWAL OF CERTIFICATES ACROSS A DISTRIBUTED COMPUTING SECURITY SYSTEM,"A system for data processing, comprising a plurality of data processing systems, each associated with a user and having an anchor certificate, a proxy system operating on a processor and configured to determine whether an expiration associated with the anchor certificate for each data processing system is within a predetermined time of expiration and a certificate expiration monitor operating on the processor and configured to generate a certificate signing request in response to the determination that the expiration associated with the anchor certificate for each data processing system is within the predetermined time of expiration.",FORCEPOINT LLC,COUTO LUIS DIOGO MONTEIRO DUARTE;;DORNEY CIARÁN JAMES;;DEPPING RALPH HANS;;SMITH JORDAN;;O'MAHONY FINBAR,FORCEPOINT FEDERAL HOLDINGS LLC (2021-04-01),https://lens.org/002-562-333-347-561,Patent Application,yes,13,0,2,2,0,H04L9/3268;;H04L9/3247;;H04L9/006;;H04L9/3265;;H04L63/0281;;H04L63/0823;;H04L63/108;;H04L63/0823;;H04L9/3263;;H04L63/0281;;H04L63/108,H04L29/06;;H04L9/32,,4,4,097-582-446-583-717;;125-240-551-157-377;;006-490-840-423-982;;056-232-046-877-073,10.1145/2812428.2812446;;10.1145/3319535.3363192;;10.1145/2491185.2491199;;10.1109/hst.2011.5955006,"Jozef Filipek et al., Distributed Firewall Using PKI in Mobile Ad Hoc Networks, 25 June 2015, ACM, Pages: 292–298. (Year: 2015);;Josh Aas et al., Let’s Encrypt: An Automated Certificate Authority to Encrypt the Entire Web, 06 November 2019, ACM, Pages: 2473–2487. (Year: 2019);;Diego Kreutz et al., Towards Secure and Dependable Software-Defined Networks, 16 August 2013, ACM, Pages: 55–60. (Year: 2013);;Stephen Papa et al., Placement of Trust Anchors in Embedded Computer Systems, 14 July 2011, IEEE, Pages: 111-116. (Year: 2011)",ACTIVE
285,US,A1,US 2013/0174053 A1,097-702-357-777-599,2013-07-04,2013,US 201213729257 A,2012-12-28,US 201213729257 A;;US 201161581554 P,2011-12-29,Electronic System and Method For Creation and Management of Media Content,"An electronic system (and corresponding method) for creating and managing media content involves at least one content management system (CMS) and a service. The CMS is configured to interact with at least one first-type user in order to create and manage media content for publication. The service is configured to interact with a plurality of second-type users in order to submit media content items that are associated with media content managed by the CMS and to store such media content items. Both the CMS and the service include corresponding interfaces that allow for exchange of electronic messages therebetween via network communications over the Internet, wherein the electronic messages conform to a predefined protocol.",BUNNYFORCE INC;;BUNNYFORCE INC,TORRENEGRA ALEX;;ZAPATA TANIA;;DUARTE-REY ABELARDO;;MOLINA LUIS;;CANASTERO-PRIETO HENRY;;RODRIGUEZ-LOZANO CARLOS,VOICE123 INC (2019-04-29);;TORRE TECHNOLOGIES CO (2016-05-19);;EMMA GROUP INC (2021-07-30),https://lens.org/097-702-357-777-599,Patent Application,yes,2,14,2,2,0,H04L12/1836;;H04L51/52;;H04L51/046;;H04L12/1836;;H04L51/52,H04L12/58,715/752,0,0,,,,ACTIVE
286,WO,A1,WO 2017/011889 A1,107-767-050-531-904,2017-01-26,2017,BR 2016050167 W,2016-07-22,BR 102015017662 A,2015-07-23,DYNAMICAL WEIGHING PROCESS AND DEVICE FOR ANIMALS,"The present invention relates to the technical sector of animal weighing. The invention relates to a dynamic weighing process for weighing an animal (6), which includes the step of weighing this animal (6) on a weighing platform (1), and which further includes the following steps: - obtaining a first (7) and a second (8) curve of weight versus time; - calculating the first and the second average weights, each from the weights of the corresponding weight curve that are located between a peak (9, 12) and a secondary point (10, 11); - adding the first average weight and the second average weight to obtain the weight of the animal (6). The present invention also relates to a dynamic weighing device for weighing an animal (6).",ROBERT BOSCH LTDA,RIBEIRO JUNIOR LUIS FERNANDO;;GHISLOTI DUARTE DE SOUZA GRANHA RENATA;;KEIGO DE SALES ANDRADE RICARDO,,https://lens.org/107-767-050-531-904,Patent Application,yes,3,5,4,4,0,G01G17/08;;G01G23/12,G01G17/08;;G01G23/12,,0,0,,,,PENDING
287,EP,A1,EP 2019002 A1,119-479-456-591-447,2009-01-28,2009,EP 07381055 A,2007-07-27,EP 07381055 A,2007-07-27,Adaptive airbag with a tension retension band that shapes bag areas into a v,"Airbag module for protecting an occupant of car with a bag (11) that includes a main front panel (17) and main rear panel (19) connected by its ends and a retention band (21) connected to the panels in two opposite ends (31, 33), capable of withstanding maximum pressure during the unfolding of the bag (11) without breaking or disconnecting from said panels, and whose length L is less than the maximum distance D that would exist between said opposite areas (31, 33) during the unfolding of the bag should said retention band (21) not exist; the bag has a ventilation orifice (23) around one of the union areas (31, 33) that can be covered by the main front and rear panels (17, 19) when the bag (11) contacts the occupant (15).
 
",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;DENYS ISABELLE;;TAVARES DA SILVA VINHAS JOANA;;PEREZ GARCIA AZUCENA,,https://lens.org/119-479-456-591-447,Patent Application,yes,11,4,6,6,0,B60R21/233;;B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R2021/2395;;B60R21/233;;B60R21/2338;;B60R2021/23382,B60R21/233;;B60R21/239,,0,0,,,,ACTIVE
288,US,B2,US 11722477 B2,193-135-850-342-152,2023-08-08,2023,US 202016747792 A,2020-01-21,US 202016747792 A,2020-01-21,Automated renewal of certificates across a distributed computing security system,"A system for data processing, comprising a plurality of data processing systems, each associated with a user and having an anchor certificate, a proxy system operating on a processor and configured to determine whether an expiration associated with the anchor certificate for each data processing system is within a predetermined time of expiration and a certificate expiration monitor operating on the processor and configured to generate a certificate signing request in response to the determination that the expiration associated with the anchor certificate for each data processing system is within the predetermined time of expiration.",FORCEPOINT LLC,COUTO LUIS DIOGO MONTEIRO DUARTE;;DORNEY CIARÁN JAMES;;DEPPING RALPH HANS;;SMITH JORDAN;;O'MAHONY FINBAR,FORCEPOINT FEDERAL HOLDINGS LLC (2021-04-01),https://lens.org/193-135-850-342-152,Granted Patent,yes,25,0,2,2,0,H04L9/3268;;H04L9/3247;;H04L9/006;;H04L9/3265;;H04L63/0281;;H04L63/0823;;H04L63/108;;H04L63/0823;;H04L9/3263;;H04L63/0281;;H04L63/108,H04L9/32;;H04L9/40,,4,4,097-582-446-583-717;;125-240-551-157-377;;006-490-840-423-982;;056-232-046-877-073,10.1145/2812428.2812446;;10.1145/3319535.3363192;;10.1145/2491185.2491199;;10.1109/hst.2011.5955006,"Jozef Filipek et al., Distributed Firewall Using PKI in Mobile Ad Hoc Networks, Jun. 25, 2015, ACM, pp. 292-298. (Year: 2015).;;Josh Aas et al., Let's Encrypt: An Automated Certificate Authority to Encrypt the Entire Web, Nov. 6, 2019, ACM, pp. 2473-2487. (Year: 2019).;;Diego Kreutz et al., Towards Secure and Dependable Software-Defined Networks, Aug. 16, 2013, ACM, pp. 55-60. (Year: 2013).;;Stephen Papa et al., Placement of Trust Anchors in Embedded Computer Systems, Jul. 14, 2011, IEEE, pp. 111-116. (Year: 2011).",ACTIVE
289,ES,T3,ES 2362447 T3,078-535-388-328-716,2011-07-05,2011,ES 07381055 T,2007-07-27,EP 07381055 A,2007-07-27,AIRBAG ADAPTATIVO CON UNA BANDA DE RETENCION DE TENSION QUE CONFORMA ZONAS EN FORMA DE V EN EL SACO.,"Un módulo airbag para la protección del ocupante de un vehículo automóvil que comprende un saco inflable (11) con el gas producido por un generador cuando se produce una colisión, estando el saco (11) configurado para desplegarse entre el ocupante (15) y el vehículo y que comprende un panel principal delantero (17) destinado a entrar en contacto con el ocupante (15) y un panel principal trasero (19) unidos entre sí por sus bordes periféricos, tal que el saco (11) también comprende: a) al menos una banda de retención (21) unida por sus extremos a dichos paneles principales delantero y trasero (17, 19) en dos zonas opuestas (31, 33) de sus bordes periféricos, capaz de soportar la presión máxima prevista durante el despliegue del saco (11) sin romperse ni desunirse de dichos paneles principales delantero y trasero (17, 19), y cuya longitud (L) es menor que la máxima distancia (D) que existiría entre dichas zonas opuestas (31, 33) durante el despliegue del saco si no existiera dicha banda de retención (21), y b) al menos un orificio de ventilación (23) situado en uno de dichos paneles principales delantero y trasero (17, 19), en el entorno de al menos una de dichas zonas de unión (31, 33) de la banda de retención (21) con los paneles principales delantero y trasero (17, 19), caracterizado porque el orificio de ventilación (23) está configurado de tal modo que puede quedar taponado al acercarse entre sí los paneles principales delantero y trasero (17, 19) cuando el saco (11) entra en contacto con el ocupante (15).",DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;DENYS ISABELLE;;TAVARES DA SILVA VINHAS JOANA FRANCISCA;;PEREZ GARCIA AZUCENA,,https://lens.org/078-535-388-328-716,Granted Patent,no,0,0,6,6,0,B60R21/233;;B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R2021/2395;;B60R21/233;;B60R21/2338;;B60R2021/23382,B60R21/233;;B60R21/239,,0,0,,,,ACTIVE
290,US,B2,US 9996537 B2,124-731-343-809-502,2018-06-12,2018,US 201514742560 A,2015-06-17,US 201514742560 A;;US 201462014403 P,2014-06-19,Systems and methods for automatic narrative creation,"A clustering module in communication with a processor and a memory may be configured to receive a dataset comprising a plurality of media elements each comprising metadata and organize the plurality of media elements into a plurality of clusters based on the metadata, the plurality of clusters being organized into a clustering tree. A narrative module in communication with the processor and the memory may be configured to create a narrative comprising a plurality of the media elements arranged into a narrative sequence, the narrative sequence being structured according to the clustering tree and for a predetermined duration, thereby transforming media elements into a narrative.",NATIVO;;STORYMATIK SOFTWARE S A,FONSECA E COSTA MANUEL RICARDO;;LUIS DUARTE LEONEL FILIPE;;DE VASCONCELOS CARVALHO DA COSTA FILIPE MANUEL,STORYMATIK SOFTWARE S.A (2018-01-16),https://lens.org/124-731-343-809-502,Granted Patent,yes,9,0,2,2,0,G06F16/4393;;G06F16/4393,G06F17/30,,0,0,,,,ACTIVE
291,DE,D1,DE 602007012859 D1,086-519-302-714-991,2011-04-14,2011,DE 602007012859 T,2007-07-27,EP 07381055 A,2007-07-27,"Adaptiver Airbag mit einem Spannungsausgleichband, das Airbagbereiche zu einem V formt",,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;DENYS ISABELLE;;TAVARES DA SILVA VINHAS JOANA FRANCISCA;;PEREZ GARCIA AZUCENA,,https://lens.org/086-519-302-714-991,Granted Patent,no,0,0,6,6,0,B60R21/233;;B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R2021/2395;;B60R21/233;;B60R21/2338;;B60R2021/23382,B60R21/233;;B60R21/239,,0,0,,,,ACTIVE
292,ES,B1,ES 2335467 B1,116-574-620-753-329,2010-12-30,2010,ES 200802676 A,2008-09-22,ES 200802676 A,2008-09-22,SINTESIS DE PARTICULAS SUBNANOMETRICAS DE AU CATALITICAS SOPORTADAS EN SUPERFICIES CON GRUPOS AMINO,,CONSEJO SUPERIOR INVESTIGACION;;UNIV VIGO;;FUNDACIO PRIVADA INST CATALA DE NANOTECNOLOGIA,CORREA DUARTE MIGUEL ANGEL;;LIZ MARZAN LUIS;;SANLES SOBRIDO MARCOS;;LECHUGA GOMEZ LAURA;;MENDOZA GOMEZ ERNESTO,,https://lens.org/116-574-620-753-329,Granted Patent,no,0,0,3,3,0,B01J21/185;;B01J23/52;;B01J37/16;;B22F9/24;;B82Y30/00;;B01J35/393;;B01J35/23;;B01J23/52;;B82B1/00;;B82B3/00,B82B3/00;;B01J23/52;;B22F9/24;;B82B1/00,,0,0,,,,INACTIVE
293,ES,A1,ES 2335467 A1,178-665-812-100-464,2010-03-26,2010,ES 200802676 A,2008-09-22,ES 200802676 A,2008-09-22,SYNTHESIS OF CATALYTIC SUBNANOMETRIC AU PARTICLES SUPPORTED ON SURFACES HAVING AMINE GROUPS,The present invention refers to structures comprising particles of Au of subnanometric size (<3 nm) synthesized on a surface coated with molecules or polymers presenting amine groups. This invention moreover relates to a procedure for the obtainment of these structures and the use thereof as catalysts for industry.,CONSEJO SUPERIOR INVESTIGACION;;UNIV DE VIGO 50;;FUNDACIO PRIVADA INST CATALA D,LECHUGA GOMEZ LAURA;;MENDOZA GOMEZ ERNESTO;;CORREA DUARTE MIGUEL ANGEL;;LIZ MARZAN LUIS;;SANLES SOBRIDO MARCOS,,https://lens.org/178-665-812-100-464,Patent Application,no,1,0,3,3,0,B01J21/185;;B01J23/52;;B01J37/16;;B22F9/24;;B82Y30/00;;B01J35/393;;B01J35/23;;B01J23/52;;B82B1/00;;B82B3/00,B82B3/00;;B01J23/52;;B22F9/24;;B82B1/00,,4,3,027-383-150-615-635;;149-557-698-039-777;;108-419-725-001-684,10.1016/s0008-6223(03)00339-7;;10.1016/j.jcat.2005.12.014;;14719978;;10.1021/cr030698+,"JIANG, L. et al. Modified carbon nanotubes: an effective way to selective attachment of gold nanoparticles. Carbon 41 (2003), pág.2923-2929; introducción, experimental, figura 7.;;JIANG, L. et al. Selective attachment of gold nanoparticles to nitrogen-doped carbon nanotubes. Nano Letters (2003), Vol. 3, Nº. 3, páginas 275- 277; pág. 275, figura 2.;;SANTHOSH, P. et al. Gold nanoparticles dispersed polyaniline grafted multiwall carbon nanotubes as newer electrocatalysts: Preparation and performances for methanol oxidation. Journal of Catalysis 238 (2006), pág.177-185; resumen.;;DANIEL, M.C. et al. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size- related properties, and applications toward biology, catalysis, and nanotechnology. Chemical Reviews (2004), Vol. 104, páginas 293-346; pág. 296-309,325,329, figura 26.",INACTIVE
294,US,A1,US 2015/0370888 A1,135-544-860-897-18X,2015-12-24,2015,US 201514742560 A,2015-06-17,US 201514742560 A;;US 201462014403 P,2014-06-19,SYSTEMS AND METHODS FOR AUTOMATIC NARRATIVE CREATION,"A clustering module in communication with a processor and a memory may be configured to receive a dataset comprising a plurality of media elements each comprising metadata and organize the plurality of media elements into a plurality of clusters based on the metadata, the plurality of clusters being organized into a clustering tree. A narrative module in communication with the processor and the memory may be configured to create a narrative comprising a plurality of the media elements arranged into a narrative sequence, the narrative sequence being structured according to the clustering tree and for a predetermined duration, thereby transforming media elements into a narrative.",NATIVO,FONSECA E COSTA MANUEL RICARDO;;LUIS DUARTE LEONEL FILIPE;;DE VASCONCELOS CARVALHO DA COSTA FILIPE MANUEL,STORYMATIK SOFTWARE S.A (2018-01-16),https://lens.org/135-544-860-897-18X,Patent Application,yes,0,21,2,2,0,G06F16/4393;;G06F16/4393,G06F17/30;;G06F17/24;;G06K9/00,,0,0,,,,ACTIVE
295,CO,A1,CO 2020007371 A1,174-794-142-344-499,2020-12-21,2020,CO 2020007371 A,2020-06-17,CO 2020007371 A,2020-06-17,Dispositivo y método para comunicaciones con luz,"El presente invento divulga un dispositivo y un método para comunicaciones ópticas. El dispositivo se caracteriza por incluir: un dispositivo de acceso óptico OWAP; un dispositivo de interfaz de usuario óptico inalámbrico OWNIC, que comprende un receptor óptico y un transmisor óptico, conectado al punto de acceso óptico Inalámbrico OWAP; un transceptor óptico OWMT que comprende al menos un receptor óptico y un transmisor óptico, el transceptor óptico OWMT se conecta al punto de acceso óptico Inalámbrico OWAP en donde el receptor óptico es de baja potencia, en algunas realizaciones de la invención el receptor óptico integra un fotomultiplicador SiPM y no requiere filtros ópticos. El método para comunicaciones ópticas está caracterizado por las etapas de a) activar un dispositivo de interfaz de usuario óptica inalámbrica OWNIC; b) enviar trama de reconocimiento (un conjunto de bytes específico); c) detectar y validar la trama de reconocimiento por OWNIC y enviar una trama de confirmación, en caso de no detectar la trama de validación regresar a la etapa b; d) recibir trama de confirmación, si la trama es válida entonces activar la interfaz transparente Ethernet-UART e iniciar la comunicación a través del canal óptico del OWNIC de lo contrario regresar a la etapa b. Algunas realizaciones en las etapas c) y en la etapa d) el OWNIC se reemplaza por un punto de acceso óptico Inalámbrico OWAP.",UNIV ANTONIO NARINO,CASTAÑO FORERO JAVIER FERNANDO;;CASTAÑEDA MELO LUIS FERNANDO;;GUTIÉRREZ SALAMANCA RAFAEL MARÍA;;HERNÁNDEZ DUARTE ANDRES IGNACIO,,https://lens.org/174-794-142-344-499,Patent Application,no,0,0,1,1,0,,H04B10/00;;H04B10/25,,0,0,,,,PENDING
296,US,A1,US 2023/0202439 A1,056-028-922-837-269,2023-06-29,2023,US 202117564960 A,2021-12-29,US 202117564960 A,2021-12-29,VEHICLE WITH VALVE THAT ADJUSTS OUTPUT BRAKE PRESSURE ACCORDING TO A PLURALITY OF PRESSURE CURVES,"A vehicle includes: a brake pedal to produce vehicle brake pressure; a trailer brake valve to output a variable trailer brake pressure to a trailer brake of a trailer, the trailer brake valve configured to output the variable trailer brake pressure as a function of the vehicle brake pressure; and an electronic control unit operably coupled to the trailer brake valve and configured to: output a first valve signal to the trailer brake valve to output the trailer brake pressure according to a first vehicle brake pressure curve; and output a second valve signal to the trailer brake valve to output the trailer brake pressure according to a second vehicle brake pressure curve responsively to determining a curve adjustment condition exists. The first vehicle brake pressure curve and/or the second vehicle brake pressure curve is not a single straight line curve.",CNH IND AMERICA LLC,GAMA VINICIUS LUIS;;DILLON SHANE P;;MARTINHO DE OLIVEIRA MURILO;;CARDOSO DUARTE FILHO OTACILIO;;FREISLEBEN MICHAEL,CNH INDUSTRIAL AMERICA LLC (2022-01-07),https://lens.org/056-028-922-837-269,Patent Application,yes,6,0,3,3,0,B60T7/20;;B60T8/1708;;B60T7/20;;B60T13/662;;B60T8/323;;B60T8/1708;;B60T8/171;;B60T8/1837;;B60T8/1887;;B60T13/686;;B60T2250/02;;B60T2270/88,B60T8/18;;B60T8/17;;B60T8/171;;B60T13/68,,0,0,,,,PENDING
297,MX,A,MX 2018014724 A,042-069-527-392-338,2019-03-28,2019,MX 2018014724 A,2018-11-29,MX 2018014724 A,2018-11-29,EPOXY RESINS WITH MEMORY FORM OF REINFORCED WITH GRAPHENE OXIDE FUNCTIONALIZED WITH URETHANE AND ACRYLIC GROUPS.,"The present invention relates to the preparation of an isocyanate-acrylate-type compound (IPI-MA) from the monoacylation of isophorone diisocyanate, as well as the use of IPI-MA to chemically modify sheets of graphene oxide (GO). It characterizes by the Fourier Transform Infrared Spectroscopy (FT-IR) and Proton Nuclear Magnetic Resonance Spectroscopy (1H-NMR) techniques. Said graphene oxide is modified with urethane and acrylic groups (GOM) used as a filler in the preparation of polymeric Nano-compounds with memory form based on epoxy resins (SMPs). By the polymerization by thermo-curing of a commercial epoxy resin such as glycidyl ether of bisphenol A (BADGE) using a mixture of primary amines as a curing agent and polyethylene glycol (PEG) as a flexing agent, a Nano-compound SMP-GOM is obtained. The visco-elastic properties of the SMP-GOM, evaluated by Mechanical Dynamic Analysis (DMA) are higher without load. The improvement of the mechanical properties is due to the increase of t he chemical compatibility between the GOM and the epoxy resin. In addition, the presence of the GOM does not alter the memory form property of the nanocomposite.",CENTRO DE INVESTIGACION EN QUIM APLICADA,MARIA LYDIA BERLANGA DUARTE;;LUIS ALBERTO REYNA MEDINA;;MARIA ESTHER TREVIÑO MARTINEZ;;GABRIELA YOLOTZIN ROMERO ZUÑIGA,,https://lens.org/042-069-527-392-338,Patent Application,no,0,2,1,1,0,,C08L63/10;;C08K3/04,,0,0,,,,PENDING
298,EP,B1,EP 2019002 B1,041-817-843-791-36X,2011-03-02,2011,EP 07381055 A,2007-07-27,EP 07381055 A,2007-07-27,Adaptive airbag with a tension retension band that shapes bag areas into a v,,DALPHI METAL ESPANA SA,DUARTE DE AREZ LUIS JOSE;;DENYS ISABELLE;;TAVARES DA SILVA VINHAS JOANA FRANCISCA;;PEREZ GARCIA AZUCENA,,https://lens.org/041-817-843-791-36X,Granted Patent,yes,4,0,6,6,0,B60R21/233;;B60R21/2338;;B60R21/239;;B60R2021/23382;;B60R2021/2395;;B60R21/239;;B60R2021/2395;;B60R21/233;;B60R21/2338;;B60R2021/23382,B60R21/233;;B60R21/239,,0,0,,,,ACTIVE
299,EP,A1,EP 4206046 A1,095-232-449-058-691,2023-07-05,2023,EP 22216998 A,2022-12-28,US 202117564960 A,2021-12-29,VEHICLE WITH VALVE THAT ADJUSTS OUTPUT BRAKE PRESSURE ACCORDING TO A PLURALITY OF PRESSURE CURVES,"A vehicle (102) includes: a brake pedal (110) to produce vehicle brake pressure; a trailer brake valve (218) to output a variable trailer brake pressure to a trailer brake (220) of a trailer (104), the trailer brake valve (218) configured to output the variable trailer brake pressure as a function of the vehicle brake pressure; and an electronic control unit operably coupled to the trailer brake valve (218) and configured to: output a first valve signal to the trailer brake valve (218) to output the trailer brake pressure according to a first vehicle brake pressure curve; and output a second valve signal to the trailer brake valve (218) to output the trailer brake pressure according to a second vehicle brake pressure curve responsively to determining a curve adjustment condition exists. The first vehicle brake pressure curve and/or the second vehicle brake pressure curve is not a single straight line curve.
",CNH IND ITALIA SPA,GAMA VINICIUS LUIS;;DILLON SHANE P;;MARTINHO DE OLIVEIRA MURILO;;CARDOSO DUARTE FILHO OTACILIO;;FREISLEBEN MICHAEL,,https://lens.org/095-232-449-058-691,Patent Application,yes,7,0,3,3,0,B60T7/20;;B60T8/1708;;B60T7/20;;B60T13/662;;B60T8/323;;B60T8/1708;;B60T8/171;;B60T8/1837;;B60T8/1887;;B60T13/686;;B60T2250/02;;B60T2270/88,B60T7/20;;B60T8/32;;B60T13/66,,0,0,,,,PENDING
300,CO,A1,CO 2021013977 A1,182-257-418-143-02X,2021-11-19,2021,CO 2021013977 A,2021-11-03,CO 2021013977 A,2021-11-03,Dispositivo automatizado para la medición de la fuerza muscular isométrica,"La presente invención corresponde a un Dispositivo Automatizado de medición fuerza isométrica de los grupos musculares de la extremidad inferior. Este dispositivo puede ser usado en centros de alto rendimiento, universidades y centros de rehabilitación, con fines de establecer el rendimiento neuromuscular mediante la determinación del Pico de la Fuerza y el cálculo de la Tasa de Desarrollo de la Fuerza, asegurando una evaluación consistente y confiable del estado muscular.",UNIV DE PAMPLONA,PARDO GARCIA ALDO;;CONTRERAS DENNIS GREGORIO;;ORJUELA DUARTE AILIN;;NEIRA ROPERO LUIS ERNESTO;;ROJAS JAIMES DIEGO ALEJANDRO,,https://lens.org/182-257-418-143-02X,Patent Application,no,0,0,1,1,0,,A61B5/00;;A61B5/11,,0,0,,,,PENDING
301,WO,A1,WO 2022/047562 A1,139-665-014-815-25X,2022-03-10,2022,BR 2021050377 W,2021-09-02,BR 102020017972 A,2020-09-02,"HYDROPHOBIC STARCH POLYMER, PROCESS FOR OBTAINING SAME, COMPOSITION, PROCESS FOR OBTAINING THE COMPOSITION, COATING METHOD AND USE OF THE HYDROPHOBIC STARCH POLYMER","The present invention relates to a hydrophobic starch polymer in the form of a pre-gel, to the process for producing same and to uses for the purpose of increasing the shelf life of perishables. The present invention pertains to the fields of chemistry and engineering.",UFRGS UNIV FEDERAL DO RIO GRANDE DO SUL;;UNESPAR UNIV ESTADUAL DO PARANA,LERMEN FERNANDO HENRIQUE;;COELHO TANIA MARIA;;FILHO NABI ASSAD;;RIBEIRO JOSÉ LUIS DUARTE;;ECHEVESTE MÁRCIA ELISA SOARES,,https://lens.org/139-665-014-815-25X,Patent Application,yes,7,0,2,2,0,C08B31/00;;C08J5/18;;C08K5/07;;C08L3/00;;C08L3/04;;C08L2201/00;;B29C48/00;;B65D65/46;;C08B30/14;;C08J5/18;;C08K5/053;;C08L3/00;;C08L67/00;;D06M15/11;;D21H19/54;;Y02W90/10,C08L3/00;;B29C48/00;;B65D65/46;;C08B30/14;;C08J5/18;;C08K5/053;;C08L67/00;;D06M15/11;;D21H19/54,,3,3,014-003-391-251-212;;007-499-046-639-118;;016-447-558-748-774,34062678;;10.1016/j.msec.2012.05.035;;10.1016/j.jfoodeng.2011.08.006;;10.1111/ijfs.13805,"OLIVIA V. LOPE Z ET AL.: ""Starch films from a novel (Pachyrhizus ahipa) and conventional sources: Development and characterization"", MATERIALS SCIENCE AND ENGINEERING: C, vol. 32, no. 7, 2012, pages 1931 - 1940, XP028503982, ISSN: 0928-4931, Retrieved from the Internet <URL:https://www.seieneedireet.com/seience/artiGle/pii/SQ928493112QQ255X> DOI: https://doi.org/i0.1016/j.msec.2012.05.035;;P.D. MBOUGUENG ET AL.: ""Influence of acetylation on physicochemical, functional and thermal properties of potato and cassava starches"", JOURNAL OF FOOD ENGINEERING, vol. 108, no. 2, 2012, pages 320 - 326, XP028306805, ISSN: 0260-8774, Retrieved from the Internet <URL:rhttps:/7www.sciencedireet.com/science/article/pii/S0260877411004328> DOI: https://doi.org/10-1016/i.jfoodeng.2011.08.006;;WANG XINTIAN, WANG HONGWEI, SONG JIANING, ZHANG YANGYANG, ZHANG HUA: ""Understanding the structural characteristics, pasting and rheological behaviours of pregelatinised cassava starch"", INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD., GB, vol. 53, no. 9, 1 September 2018 (2018-09-01), GB , pages 2173 - 2180, XP055911760, ISSN: 0950-5423, DOI: 10.1111/ijfs.13805",PENDING
302,CO,A1,CO 2022004069 A1,159-407-531-710-820,2022-04-19,2022,CO 2022004069 A,2022-03-31,CO 2022004069 A,2022-03-31,Estructura fotovoltaica que presenta una configuración de tipo de árbol pitagórico fractal,"La presente solicitud hace referencia a una estructura fotovoltaica (100) para proporcionar áreas de incidencia favorable para la luz solar en las superficies exteriores de las celdas fotovoltaicas o solares, que comprende múltiples estructuras fractales (200), las cuales comprenden una pluralidad de paneles (110) con superficies exteriores inductoras (120) configurados para captar la luz solar que es incidente a las mismas; dicha pluralidad de paneles (110) con formas simétricamente idénticas y tamaños variables, ubicados en una distribución de árbol fractal pitagórica, , que comprenden distancias d1 y d2 definidas como (DE) ̅ y (DF) ̅ y que son las aristas de las caras correspondientes y están dispuestos entre sí en un ángulo α; en donde la pluralidad de paneles(110) en una modalidad de la invención, comprenden rebordes alrededor del perímetro de cada, en el que la cantidad de estructuras fractales (200) forman una o más ramificaciones que hacen parte de la configuración de la estructura fotovoltaica (100) en forma de árbol fractal pitagórico.",UNIV MILITAR NUEVA GRANADA,DOMÍNGUEZ CAJELI DARÍO MANUEL;;LLANO SANCHEZ LUIS EDUARDO;;MELO DE ALONSO MARTHA CECILIA;;QUIÑONEZ DUARTE JOAQUÍN ROBERTO,,https://lens.org/159-407-531-710-820,Patent Application,no,0,0,1,1,0,Y02E10/547,B82Y40/00;;C09J9/02;;C09J11/04;;C09J11/06;;C09K11/02;;H01L31/0236;;H01L31/042;;H01L31/048;;H01L31/052;;H01L31/056;;H01L31/077;;H02S20/30;;H02S20/32;;H02S30/00;;H02S50/10,,0,0,,,,PENDING
303,BR,A2,BR 102020017972 A2,084-688-004-629-806,2022-03-15,2022,BR 102020017972 A,2020-09-02,BR 102020017972 A,2020-09-02,"Polímero de amido hidrofóbico, processo para obtenção do mesmo, composição, processo para obtenção da composição, método de revestimento e uso do polímero de amido hidrofóbico","polímero de amido hidrofóbico, processo para obtenção do mesmo, composição, processo para obtenção da composição, método de revestimento e uso do polímero de amido hidrofóbico. a presente invenção apresenta um polímero de amido hidrofóbico, sua forma em pré-gel, seu processo de produção e usos com vistas a aumentar o tempo de vida útil de perecíveis. a presente invenção se situa nos campos da química e engenharia.",UNESPAR UNIV ESTADUAL DO PARANA;;UNIV FEDERAL RIO GRANDE SUL,FERNANDO HENRIQUE LERMEN;;JOSÉ LUIS DUARTE RIBEIRO;;MÁRCIA ELISA SOARES ECHEVESTE;;NABI ASSAD FILHO;;TÂNIA MARIA COELHO,,https://lens.org/084-688-004-629-806,Patent Application,no,0,0,2,2,0,C08B31/00;;C08J5/18;;C08K5/07;;C08L3/00;;C08L3/04;;C08L2201/00;;B29C48/00;;B65D65/46;;C08B30/14;;C08J5/18;;C08K5/053;;C08L3/00;;C08L67/00;;D06M15/11;;D21H19/54;;Y02W90/10,C08B31/00;;B29C48/00;;C08J5/18;;C08K5/07;;C08L3/00;;C08L3/04,,0,0,,,,PENDING
304,WO,A1,WO 2021/255083 A1,135-474-845-195-082,2021-12-23,2021,EP 2021066223 W,2021-06-16,PT 2020029793 A,2020-06-17,CALCIUM CARBONATE-CONTAINING MATERIAL,"The present invention refers to a calcium carbonate-containing material, wherein the calcium carbonate-containing material is prepared from an avian eggshell, wherein the calcium carbonate-containing material has a weight-median particle size d50 of from 0.5 to 10 µm, and/or a weight top cut particle size d98 of from 2.0 to 40 µm, and wherein the calcium carbonate-containing material comprises organic matter in an amount of below 1.5 wt.%, based on the total dry weight of the calcium carbonate-containing material, and wherein the calcium carbonate-containing material has i) a brightness from 90 to 100%, according to R457, and/or ii) L* from 95 to 100, according to DIN 6174. The present invention also relates to a process for preparing the inventive calcium carbonate-containing material, a paint comprising the inventive calcium carbonate-containing material, and to the use of the inventive calcium carbonate-containing material.",OMYA SA,PEDROSO LUIS;;CURADO CAROLINA;;FREIRE VIEIRA MARIA TERESA;;GOMES DE OLIVEIRA MANAIA ANA TERESA;;FREIRE DUARTE JOÃO PEDRO,,https://lens.org/135-474-845-195-082,Patent Application,yes,3,1,7,7,0,C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/16;;C01P2006/80;;C09C1/021;;C09D7/61;;C08K3/26;;C08K2003/265;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09D7/61;;C01F11/185;;C01P2004/03;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/16;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/022;;C09C3/006;;C09C3/041;;C09C3/06,C09C1/02,,4,3,016-833-196-771-779;;122-921-120-903-707;;016-030-752-507-33X,10.1016/j.jclepro.2012.09.045;;19665373;;10.1016/j.biortech.2009.06.112;;10.2741/3985,"OLIVEIRA D A ET AL: ""A literature review on adding value to solid residues: egg shells"", JOURNAL OF CLEANER PRODUCTION, ELSEVIER, AMSTERDAM, NL, vol. 46, 11 October 2012 (2012-10-11), pages 42 - 47, XP028593324, ISSN: 0959-6526, DOI: 10.1016/J.JCLEPRO.2012.09.045;;GAURANG GOLAKYA: ""EXTRACTION OF CALCIUM CARBONATE FROM WASTE EGGSHELLS AS FILLERS IN COMPOSITES"", 29 January 2020 (2020-01-29), pages 1 - 106, XP055847339, Retrieved from the Internet <URL:https://harvest.usask.ca/bitstream/handle/10388/12568/GOLAKIYA-THESIS-2020.pdf?sequence=1&isAllowed=y>;;YOO S ET AL: ""Utilization of calcium carbonate particles from eggshell waste as coating pigments for ink-jet printing paper"", BIORESOURCE TECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 100, no. 24, 1 December 2009 (2009-12-01), pages 6416 - 6421, XP026520490, ISSN: 0960-8524, [retrieved on 20090807], DOI: 10.1016/J.BIORTECH.2009.06.112;;HINCKE ET AL.: ""The eggshell: structure, composition and mineralization"", FRONTIERS IN BIOSCIENCE, vol. 17, pages 1266 - 1280",PENDING
305,PT,E,PT 1357805 E,143-319-598-522-815,2012-11-29,2012,PT 02715323 T,2002-01-09,BR 0100421 A,2001-01-12,IMPROVING REPRODUCTIVE PERFORMANCE IN MAMMALS,,FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAOLO,LANNA DANTE PAZZANESE DUARTE;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;OLIVEIRA DIMAS ESTRASULAS DE;;AROEIRA LUIS JANUARIO M,,https://lens.org/143-319-598-522-815,Granted Patent,no,0,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23K1/16;;A23K1/14;;A23K1/18;;A23K50/15,,0,0,,,,EXPIRED
306,EP,A1,EP 1357805 A1,166-510-538-099-744,2003-11-05,2003,EP 02715323 A,2002-01-09,BR 0200003 W;;BR 0100421 A,2001-01-12,IMPROVING REPRODUCTIVE PERFORMANCE IN MAMMALS,,FUNDACAO DE AMPARAO A PESQUISA,DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,,https://lens.org/166-510-538-099-744,Patent Application,yes,0,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23K1/14;;A23K1/16;;A23K1/18;;A23K50/15,,0,0,,,,EXPIRED
307,US,A1,US 2009/0017158 A1,065-510-312-186-384,2009-01-15,2009,US 17571608 A,2008-07-18,US 17571608 A;;BR 0100421 A;;US 48918604 A;;BR 0200003 W,2001-01-12,Nutritional Composition for Increasing Milk Protein in Mammals,"A process for obtaining an increase in the concentration and/or production of milk protein and/or improving reproductive performance. The process includes administering to a mammal a composition including at least one unsaturated fatty acid, or a derivative thereof, and at least one feed supplement, wherein the combination is administered in an amount such that the mammal absorbs 1 g to 95 g of the at least one unsaturated fatty acid, or the derivative thereof, per day.",FUNDACAO DE AMPARO A PESQUISA,DUARTE LANNA DANTE PAZZANESE;;MCGUIRE MARK A;;DE MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO,,https://lens.org/065-510-312-186-384,Patent Application,yes,4,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23J1/20;;A23K1/14;;A23K1/16;;A23K1/18;;A23K50/15,426/2,4,3,004-515-988-514-229;;018-539-645-061-779;;061-217-306-386-445,9565891;;10.3168/jds.s0022-0302(98)75644-9;;10958826;;10.1093/jn/130.9.2292;;10.1093/jn/124.12.2344;;16856314;;10.1093/jn/124.12.344,"Pieper et al. (Natural solutions for sexual enhancement: increase the energy in your sex life with alternatives to drug therapy. 1998);;Staples et al. (Symposium: Optimizing Energy Nutrition For Reproducing Dairy Cows. Influence of Supplemental Fats on Reproductive Tissues and Performance of Lactating Cows. J Dairy Sci. 1998. 81:856-871);;Bee (Dietary Conjugated Linoleic Acids Alter Adipose Tissue and Milk Lipids of Pregnant and Lactating Sows. J. Nutr. September 1, 2000 vol. 130 no. 9 2292-2298);;Chin et al. (Conjugated linoleic acid is a growth factor for rats as shown by enhanced weight gain and improved feed efficiency. J Nutr. 1994 Dec;124(12):2344-9)",EXPIRED
308,AU,A1,AU 2021/290975 A1,101-532-105-455-95X,2023-01-05,2023,AU 2021/290975 A,2021-06-16,PT 2020029793 A;;EP 2021066223 W,2020-06-17,Calcium carbonate-containing material,"The present invention refers to a calcium carbonate-containing material, wherein the calcium carbonate-containing material is prepared from an avian eggshell, wherein the calcium carbonate-containing material has a weight-median particle size d50 of from 0.5 to 10 µm, and/or a weight top cut particle size d98 of from 2.0 to 40 µm, and wherein the calcium carbonate-containing material comprises organic matter in an amount of below 1.5 wt.%, based on the total dry weight of the calcium carbonate-containing material, and wherein the calcium carbonate-containing material has i) a brightness from 90 to 100%, according to R457, and/or ii) L* from 95 to 100, according to DIN 6174. The present invention also relates to a process for preparing the inventive calcium carbonate-containing material, a paint comprising the inventive calcium carbonate-containing material, and to the use of the inventive calcium carbonate-containing material.",OMYA SA,PEDROSO LUIS;;CURADO CAROLINA;;FREIRE VIEIRA MARIA TERESA;;GOMES DE OLIVEIRA MANAIA ANA TERESA;;FREIRE DUARTE JOÃO PEDRO,,https://lens.org/101-532-105-455-95X,Patent Application,no,0,0,7,7,0,C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/16;;C01P2006/80;;C09C1/021;;C09D7/61;;C08K3/26;;C08K2003/265;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09D7/61;;C01F11/185;;C01P2004/03;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/16;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/022;;C09C3/006;;C09C3/041;;C09C3/06,C09C1/02,,0,0,,,,PENDING
309,WO,A1,WO 2002/054886 A1,141-694-797-969-689,2002-07-18,2002,BR 0200003 W,2002-01-09,BR 0100421 A,2001-01-12,NUTRITIONAL COMPOSITION FOR INCREASING MILK PROTEIN IN MAMMALS,"It is described a process to obtain increased milk production and/or greater milk protein concentration using supplements with a fatty acid mixture or through production of specific fatty acids within the animal. The process or the supplementation of the product described in this invention (supplements formulated with fatty acids mixtures and with adequate levels of metabolizable protein) allows greater efficiency and/or better quality and/or a healthier mammal with improved productivity. The process includes supplementation of specific types of fatty acids with or without ruminal protection to ruminants and, generally, a diet with metabolizable protein energy ratio greater than the one suggested by the state of the art. The process may include the production of the said compounds (conjugated fatty acids) on the animal itself from fat, certain compounds and microorganisms added to the diet capable of modifying the environment of the gut. The supplementation includes offering fatty acids capable of altering animal metabolism, as well as offering normal fatty acids (which do not change metabolism whitch, given some conditions in the rumen environment, can change their molecular structure and transform themselves in fatty acids capable of affecting tissue metabolism (including increasing protein content and yield). Both, the offering of the fatty acid with metabolic effects, as well as the production of these active fatty acids in the gut, make possible increases in the concentration and/or production of milk protein.",FUNDACAO DE AMPARO A PESQUISA;;DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,,https://lens.org/141-694-797-969-689,Patent Application,yes,2,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23K1/14;;A23K1/16;;A23K1/18;;A23K50/15,,5,5,021-019-845-781-294;;018-032-432-041-771;;025-462-381-686-783;;025-462-381-686-783;;010-055-979-970-188,9566998;;10.1093/jn/128.5.881;;9868189;;10.1093/jn/128.12.2411;;10.3168/jds.s0022-0302(94)76948-4;;8120192;;10.3168/jds.s0022-0302(94)76948-4;;8120192;;10.1530/ror.0.0050038;;10.1530/revreprod/5.1.38;;10711734,"KELLY M L ET AL: ""DIETARY FATTY ACID SOURCES AFFECT CONJUGATED LINOLEIC ACID CONCENTRATONS IN MILK FROM LACTATING DAIRY COWS"", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 128, no. 5, May 1998 (1998-05-01), pages 881 - 885, XP000884344, ISSN: 0022-3166;;LOOR J J ET AL: ""EXOGENOUS CONJUGATED LINOLEIC ACID ISOMERS REDUCE BOVINE MILK FAT CONCENTRATION AND YIELD BY INHIBITING DE NOVO FATTY ACID SYNTHESIS"", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 128, no. 12, 1998, pages 2411 - 2419, XP000973609, ISSN: 0022-3166;;TEH, T.H., TRUNG, L. T., JIA, Z. H., GIPSON, T. A., OGDEN, K. B., AND SWEENEY, T. F.: ""Varying amounts of rumen-inert fat for high producing goats in early lactation"", JOURNAL OF DAIRY SCIENCE, vol. 77, no. 1, 1994, pages 253 - 258, XP002198752;;TEH, T.H. ET AL., JOURNAL OF DAIRY SCIENCE, vol. 77, no. 1, 1994, pages 253 - 258;;RICARDO MATTOS ET AL., REVIEWS OF REPRODUCTION, vol. 5, 2000, pages 38 - 45",PENDING
310,US,A1,US 2023/0166978 A1,153-368-907-218-248,2023-06-01,2023,US 202117921712 A,2021-06-16,PT 2020029793 A;;EP 2021066223 W,2020-06-17,CALCIUM CARBONATE-CONTAINING MATERIAL,"A calcium carbonate-containing material and a process for preparing the inventive calcium carbonate-containing material, wherein a paint includes the inventive calcium carbonate-containing material, and to the use of the inventive calcium carbonate-containing material. The calcium carbonate-containing material is prepared from an avian eggshell, wherein the calcium carbonate-containing material has a weight-median particle size d50 of from 0.5 to 10 μm, and/or a weight top cut particle size d98 of from 2.0 to 40 μm, and wherein the calcium carbonate-containing material includes organic matter in an amount of below 1.5 wt. %, based on the total dry weight of the calcium carbonate-containing material, and wherein the calcium carbonate-containing material has i) a brightness from 90 to 100%, according to R457, and/or ii) L* from 95 to 100, according to DIN 6174.",OMYA SA,PEDROSO LUIS;;CURADO CAROLINA;;FREIRE VIEIRA MARIA TERESA;;GOMES DE OLIVEIRA MANAIA ANA TERESA;;FREIRE DUARTE JOÃO PEDRO,OMYA S.A (2020-06-05),https://lens.org/153-368-907-218-248,Patent Application,yes,0,0,7,7,0,C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/16;;C01P2006/80;;C09C1/021;;C09D7/61;;C08K3/26;;C08K2003/265;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09D7/61;;C01F11/185;;C01P2004/03;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/16;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/022;;C09C3/006;;C09C3/041;;C09C3/06,C01F11/18;;C09C1/02;;C09C3/00;;C09C3/04;;C09C3/06;;C09D7/61,,0,0,,,,PENDING
311,EP,B1,EP 1357805 B1,048-525-654-664-644,2012-08-15,2012,EP 02715323 A,2002-01-09,BR 0200003 W;;BR 0100421 A,2001-01-12,IMPROVING REPRODUCTIVE PERFORMANCE IN MAMMALS,,FUNDACAO DE AMPARO A PESQUISA,DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,,https://lens.org/048-525-654-664-644,Granted Patent,yes,0,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/16;;A23K1/10;;A23K1/14;;A23K1/18;;A23K50/15,,2,2,010-055-979-970-188;;010-055-979-970-188,10.1530/ror.0.0050038;;10.1530/revreprod/5.1.38;;10711734;;10.1530/ror.0.0050038;;10.1530/revreprod/5.1.38;;10711734,"MATTOS R ET AL: ""EFFECTS OF DIETARY FATTY ACIDS ON REPRODUCTION IN RUMINANTS"", REVIEWS OF REPRODUCTION, JOURNAL OF REPRODUCTION AND FERTILITY, CAMBRIDGE, GB LNKD- DOI:10.1530/ROR.0.0050038, vol. 5, no. 1, 1 January 2000 (2000-01-01), pages 38 - 45, XP008055454, ISSN: 1359-6004;;MATTOS ET AL.: ""EFFECTS OF DIETARY FATTY ACIDS ON REPRODUCTION IN RUMINANTS"", REVIEWS OF REPRODUCTION, vol. 5, 2000, pages 38 - 45, XP008055454, DOI: doi:10.1530/ror.0.0050038",EXPIRED
312,ES,T3,ES 2396052 T3,079-630-819-593-098,2013-02-18,2013,ES 02715323 T,2002-01-09,BR 0100421 A;;BR 0200003 W,2001-01-12,Mejora de la función reproductora en mamíferos,"Procedimiento de tratamiento no terapéutico de mamíferos para mejorar la función reproductora caracterizadopor alimentar o administrar a los mamíferos un compuesto seleccionado del grupo que consiste en ácido linoleicoconjugado (ALC), asociado o no con uno o más aceites vegetales o grasa animal, incluyendo posiblescombinaciones con uno o más alimentos y/o complementos alimenticios con diferentes proporciones de proteína :energía metabolizable y opcionalmente agentes aromatizantes, aditivos colorantes, vitaminas, minerales,acondicionadores, estabilizantes y otros aditivos conocidos por el experto en la materia.",FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAOLO,DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,,https://lens.org/079-630-819-593-098,Granted Patent,no,0,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/16;;A23K1/10;;A23K1/14;;A23K1/18;;A23K50/15,,0,0,,,,EXPIRED
313,EP,A1,EP 1268587 A1,120-106-463-373-409,2003-01-02,2003,EP 00993865 A,2000-12-29,BR 0000153 W;;BR 9906018 A;;BR 9906023 A,1999-12-30,PROCESS FOR PREPARING HIGH MELT STRENGTH POLYPROPYLENE AND CROSSLINKED POLYPROPYLENE PREPARED THEREWITH,,OPP PETROQUIMICA S A;;INST DE PESQUISAS ENERGETICAS,OJEDA TELMO MANFROM;;TOKUMOTO SHINICHI;;BRAGANCA ANTONIO LUIZ DUARTE;;CASSINELLI LUIS FERNANDO;;LUGAO ADEMAR BENEVOLO;;HUTZLER BEATRIZ WELTMAN,BRASKEM S.A. (2005-02-16);;OPP QUIMICA S.A. (2004-03-31);;INSTITUTO DE PESQUISAS ENERGETICAS E NUCLEARES (CN (2005-02-16),https://lens.org/120-106-463-373-409,Patent Application,yes,0,0,3,5,0,C08F2/54;;C08F255/02;;C08L51/06;;C08F2810/20;;C08J3/24;;C08J3/247;;C08J2323/10;;C08F8/00;;C08F255/02;;C08F2/54;;C08L51/06;;C08F2810/20;;C08J2323/10;;C08J3/24;;C08J3/247;;C08F8/00,C08F2/54;;C08F8/00;;C08F255/02;;C08L51/06,,0,0,,,,DISCONTINUED
314,AU,A1,AU 2002/224682 A1,199-945-362-864-042,2002-07-24,2002,AU 2002/224682 A,2002-01-09,BR 0100421 A,2001-01-12,Nutritional Composition for Increasing Milk Protein in Mammals,,FUNDACAO DE AMPARO A PESQUISA;;DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,,https://lens.org/199-945-362-864-042,Patent Application,no,0,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23K1/14;;A23K1/16;;A23K1/18;;A23K50/15,,0,0,,,,DISCONTINUED
315,US,A1,US 2004/0171712 A1,082-872-945-241-253,2004-09-02,2004,US 24053702 A,2002-12-02,BR 9906018 A;;BR 9906023 A;;BR 0000153 W,1999-12-30,Process for preparing high melt strength polypropylene and crosslinked prepared therewith,"
   A process for preparing polypropylene and its copolymers of high melt strength while is kept melt index suitable for processing is described, the polypropylene and its copolymers being modified by grafting with high molecular weight portions and crosslinking with free radicals, both modifications being promoted by high energy ionizing radiation used at low doses in the presence of an atmosphere that contains crosslinking promoting gases, the polypropylene and its copolymers optionally containing stabilizing substances dispersed in the amorphous phase. 
",OJEDA TELMO MANFROM;;TOKUMOTO SHINICHI;;BRACANCA ANTONIO LUIZ DUARTE;;CASSINELLI LUIS FERNANDO;;LUGAO ADEMAR BENEVOLO;;HUTZLER BEATRIZ WELTMAN,OJEDA TELMO MANFROM;;TOKUMOTO SHINICHI;;BRACANCA ANTONIO LUIZ DUARTE;;CASSINELLI LUIS FERNANDO;;LUGAO ADEMAR BENEVOLO;;HUTZLER BEATRIZ WELTMAN,BRASKEM S.A (2002-10-31);;INSTITUTO DE PESQUISAS ENERGETICAS E NUCLEARES (CNEN/IPEN) (2002-10-31),https://lens.org/082-872-945-241-253,Patent Application,yes,6,18,3,5,0,C08F2/54;;C08F255/02;;C08L51/06;;C08F2810/20;;C08J3/24;;C08J3/247;;C08J2323/10;;C08F8/00;;C08F255/02;;C08F2/54;;C08L51/06;;C08F2810/20;;C08J2323/10;;C08J3/24;;C08J3/247;;C08F8/00,C08F2/54;;C08F8/00;;C08F255/02;;C08L51/06,522/5;;522/134;;522/135,0,0,,,,DISCONTINUED
316,BR,A2,BR 112022021805 A2,180-862-587-697-958,2023-01-17,2023,BR 112022021805 A,2021-06-16,EP 2021066223 W;;PT 2020029793 A,2020-06-17,"MATERIAL CONTENDO CARBONATO DE CÁLCIO, PROCESSO PARA PREPARAR UM MATERIAL CONTENDO CARBONATO DE CÁLCIO, FORMULAÇÃO DE TINTA, E, USO DE UM MATERIAL CONTENDO CARBONATO DE CÁLCIO","MATERIAL CONTENDO CARBONATO DE CÁLCIO, PROCESSO PARA PREPARAR UM MATERIAL CONTENDO CARBONATO DE CÁLCIO, FORMULAÇÃO DE TINTA, E, USO DE UM MATERIAL CONTENDO CARBONATO DE CÁLCIO. A presente invenção refere-se a um material contendo carbonato de cálcio, em que o material contendo carbonato de cálcio é preparado a partir de casca de ovo de ave, em que o material contendo carbonato de cálcio tem um tamanho de partícula médio ponderal d50 de 0,5 a 10 µm, e/ou um tamanho de partícula máximo ponderal d98 de 2,0 a 40 µm, e em que o material contendo carbonato de cálcio compreende matéria orgânica em uma quantidade abaixo de 1,5% em peso, com base no peso seco total do material contendo carbonato de cálcio, e em que o material contendo carbonato de cálcio tem i) uma brancura de 90 a 100%, de acordo com a R457, e/ou ii) L* de 95 a 100, de acordo com a norma DIN 6174. A presente invenção também se refere a um processo para preparar o material contendo carbonato de cálcio da invenção, a uma tinta compreendendo o material contendo carbonato de cálcio da invenção e ao uso do material contendo carbonato de cálcio da invenção.",OMYA SA,LUIS PEDROSO;;CAROLINA CURADO;;MARIA TERESA FREIRE VIEIRA;;ANA TERESA GOMES DE OLIVEIRA MANAIA;;JOÃO PEDRO FREIRE DUARTE,,https://lens.org/180-862-587-697-958,Patent Application,no,0,0,7,7,0,C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/16;;C01P2006/80;;C09C1/021;;C09D7/61;;C08K3/26;;C08K2003/265;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09D7/61;;C01F11/185;;C01P2004/03;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/16;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/022;;C09C3/006;;C09C3/041;;C09C3/06,C09C1/02,,0,0,,,,PENDING
317,PT,A,PT 105141 A,167-761-902-622-339,2011-09-05,2011,PT 10514110 A,2010-05-26,PT 1053810 U;;PT 10514110 A,2010-03-05,ARTIGO ABSORVENTE BIODEGRADÁVEL PARA HIGIENE PESSOAL,"A PRESENTE INVENÇÃO CONSISTE NA APLICAÇÃO DE DOIS POLÍMEROS BIODEGRADÁVEIS DESIGNADOS POR ÁCIDO POLILÁCTICO (PLA) E POLICAPROLACTONA (PCL) NA PRODUÇÃO DE PRODUTOS DE HIGIENE PESSOAL, COMO FRALDAS, PENSOS HIGIÉNICOS, PROTECTORES DE CAMA E SIMILARES. OS PRODUTOS FINAIS QUE COMPREENDEM ESTES DOIS MATERIAIS TORNAM-SE BIODEGRADÁVEIS, REDUZINDO ASSIM OS PROBLEMAS AMBIENTAIS QUE OS PRODUTOS DE HIGIENE PRODUZEM, ASSIM COMO TÊM UMA BOA IMPERMEABILIDADE E BOAS RESPECTIVAS PROPRIEDADES MECÂNICAS. UM DOS PRODUTOS, UMA FRALDA DESCARTÁVEL BIODEGRADÁVEL, É CONSTITUÍDA POR UMA CAMADA EXTERIOR DE PCL (5), UMA CAMADA INTERMÉDIA DENOMINADA DE NÚCLEO ABSORVENTE (1) E UMA CAMADA INTERIOR DE NÃO-TECIDO DE PLA (4) O NÚCLEO COMPREENDE ALGODÃO HIDRÓFILO E/OU PASTA CELULOSE E POLÍMERO SUPERABSORVENTE. AS FRALDAS PARA ALÉM DE CONTEREM AS CAMADAS REFERIDAS POSSUEM MATERIAIS DE FECHO COMO ADESIVOS (3) E ELÁSTICOS (2).",VALINDO GESTAO DE IMOVEIS S A,AGUIAR ALIPIO PAULO DA CUNHA;;MAIA JOAO MANUEL LUIS LOPES;;DUARTE FERNANDO MOURA;;AZEVEDO ANA GABRIELA BARROSO DE,,https://lens.org/167-761-902-622-339,Patent Application,no,0,0,1,1,0,,A61L15/20,,0,0,,,,DISCONTINUED
318,US,A1,US 2020/0230299 A1,180-836-904-347-697,2020-07-23,2020,US 201716084059 A,2017-03-13,PT 10922916 A;;IB 2017051448 W,2016-03-11,"BIODEGRADABLE URETERAL STENTS, METHODS AND USES THEREOF","The present disclosure relates to biodegradable ureteral stents comprising an anti-cancer drug, and to a composition for use in medicine that may be used to ensure patency of a channel, namely a mammal ureter, for example, an obstructed ureter by a urinary stone, neoplasia or by a surgical procedure. The biodegradable ureteral stents (BUS) disclosed in the present disclosure unexpectedly allow a proper release of anti-cancer drugs, thus extending the duration of the treatment and increasing the efficacy of the treatment.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENG AND CELL BASED TECHNLOGIES & THERAPIES A4TEC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTONIO;;RODRIGUES DE LIMA ESTEVAO AUGUSTO,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES & THERAPIES (A4TEC) - ASSOCIAÇÃO (2018-08-28),https://lens.org/180-836-904-347-697,Patent Application,yes,3,0,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/14;;A61F2/04;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/04;;A61L31/16;;A61L31/18,,0,0,,,,PENDING
319,EP,A1,EP 4168494 A1,063-543-512-831-964,2023-04-26,2023,EP 21735195 A,2021-06-16,PT 12979320 A;;EP 2021066223 W,2020-06-17,CALCIUM CARBONATE-CONTAINING MATERIAL,,OMYA SA,PEDROSO LUIS;;CURADO CAROLINA;;FREIRE VIEIRA MARIA TERESA;;GOMES DE OLIVEIRA MANAIA ANA TERESA;;FREIRE DUARTE JOÃO PEDRO,,https://lens.org/063-543-512-831-964,Patent Application,yes,0,0,1,1,0,C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C08K3/26;;C08K2003/265;;C09C1/021;;C09D7/61,C09C1/02,,0,0,,,,PENDING
320,MX,A,MX 2022014986 A,030-661-884-928-37X,2023-02-09,2023,MX 2022014986 A,2021-06-16,PT 2020029793 A;;EP 2021066223 W,2020-06-17,CALCIUM CARBONATE-CONTAINING MATERIAL.,"The present invention refers to a calcium carbonate-containing material, wherein the calcium carbonate-containing material is prepared from an avian eggshell, wherein the calcium carbonate-containing material has a weight-median particle size d50 of from 0.5 to 10 Âµm, and/or a weight top cut particle size d98 of from 2.0 to 40 Âµm, and wherein the calcium carbonate-containing material comprises organic matter in an amount of below 1.5 wt.%, based on the total dry weight of the calcium carbonate-containing material, and wherein the calcium carbonate-containing material has i) a brightness from 90 to 100%, according to R457, and/or ii) L* from 95 to 100, according to DIN 6174. The present invention also relates to a process for preparing the inventive calcium carbonate-containing material, a paint comprising the inventive calcium carbonate-containing material, and to the use of the inventive calcium carbonate-containing material.",OMYA SA,PEDROSO LUIS;;CURADO CAROLINA;;FREIRE VIEIRA MARIA TERESA;;GOMES DE OLIVEIRA MANAIA ANA TERESA;;FREIRE DUARTE JOÃO PEDRO,,https://lens.org/030-661-884-928-37X,Patent Application,no,0,0,7,7,0,C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/16;;C01P2006/80;;C09C1/021;;C09D7/61;;C08K3/26;;C08K2003/265;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09D7/61;;C01F11/185;;C01P2004/03;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/16;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/022;;C09C3/006;;C09C3/041;;C09C3/06,C09C1/02,,0,0,,,,PENDING
321,CA,A1,CA 3175598 A1,086-081-463-577-170,2021-12-23,2021,CA 3175598 A,2021-06-16,PT 2020029793 A;;EP 2021066223 W,2020-06-17,CALCIUM CARBONATE-CONTAINING MATERIAL,"The present invention refers to a calcium carbonate-containing material, wherein the calcium carbonate-containing material is prepared from an avian eggshell, wherein the calcium carbonate-containing material has a weight-median particle size d50 of from 0.5 to 10 µm, and/or a weight top cut particle size d98 of from 2.0 to 40 µm, and wherein the calcium carbonate-containing material comprises organic matter in an amount of below 1.5 wt.%, based on the total dry weight of the calcium carbonate-containing material, and wherein the calcium carbonate-containing material has i) a brightness from 90 to 100%, according to R457, and/or ii) L* from 95 to 100, according to DIN 6174. The present invention also relates to a process for preparing the inventive calcium carbonate-containing material, a paint comprising the inventive calcium carbonate-containing material, and to the use of the inventive calcium carbonate-containing material.",OMYA SA,PEDROSO LUIS;;CURADO CAROLINA;;FREIRE VIEIRA MARIA TERESA;;GOMES DE OLIVEIRA MANAIA ANA TERESA;;FREIRE DUARTE JOAO PEDRO,,https://lens.org/086-081-463-577-170,Patent Application,no,0,0,7,7,0,C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/16;;C01P2006/80;;C09C1/021;;C09D7/61;;C08K3/26;;C08K2003/265;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09D7/61;;C01F11/185;;C01P2004/03;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/16;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/022;;C09C3/006;;C09C3/041;;C09C3/06,C09C1/02,,0,0,,,,PENDING
322,WO,A1,WO 2001/088001 A1,123-497-163-303-783,2001-11-22,2001,BR 0000153 W,2000-12-29,BR 9906018 A;;BR 9906023 A,1999-12-30,PROCESS FOR PREPARING HIGH MELT STRENGTH POLYPROPYLENE AND CROSSLINKED POLYPROPYLENE PREPARED THEREWITH,"A process for preparing polypropylene and its copolymers of high melt strength while is kept melt index suitable for processing is described, the polypropylene and its copolymers being modified by grafting with high molecular weight portions and crosslinking with free radicals, both modifications being promoted by high energy ionizing radiation used at low doses in the presence of an atmosphere that contains crosslinking promoting gases, the polypropylene and its copolymers optionally containing stabilizing substances dispersed in the amorphous phase.",OPP PETROQUIMICA S A;;INST DE PESQUISAS ENERGETICAS;;OJEDA TELMO MANFROM;;TOKUMOTO SHINICHI;;BRAGANCA ANTONIO LUIZ DUARTE;;CASSINELLI LUIS FERNANDO;;LUGAO ADEMAR BENEVOLO;;HUTZLER BEATRIZ WELTMAN,OJEDA TELMO MANFROM;;TOKUMOTO SHINICHI;;BRAGANCA ANTONIO LUIZ DUARTE;;CASSINELLI LUIS FERNANDO;;LUGAO ADEMAR BENEVOLO;;HUTZLER BEATRIZ WELTMAN,,https://lens.org/123-497-163-303-783,Patent Application,yes,2,4,3,5,0,C08F2/54;;C08F255/02;;C08L51/06;;C08F2810/20;;C08J3/24;;C08J3/247;;C08J2323/10;;C08F8/00;;C08F255/02;;C08F2/54;;C08L51/06;;C08F2810/20;;C08J2323/10;;C08J3/24;;C08J3/247;;C08F8/00,C08F2/54;;C08F8/00;;C08F255/02;;C08L51/06,,0,0,,,,PENDING
323,KR,A,KR 20230024903 A,124-192-362-882-166,2023-02-21,2023,KR 20227043880 A,2021-06-16,PT 2020029793 A;;EP 2021066223 W,2020-06-17,탄산칼슘-함유 물질,"본 발명은 탄산칼슘-함유 물질에 관한 것으로, 여기서 탄산칼슘-함유 물질이 조류 난각으로부터 제조되고, 여기서 탄산칼슘-함유 물질이 0.5 내지 10 μm의 중량-중앙 입자 크기 d50 및/또는 2.0 내지 40 μm의 중량 탑 컷 입자 크기 d98을 갖고, 여기서 탄산칼슘-함유 물질이 탄산칼슘-함유 물질의 전체 건조 중량을 기준으로 1.5 wt% 미만의 양으로 유기 물질을 포함하고, 여기서 탄산칼슘-함유 물질이 i) R457에 따른 휘도 90 내지 100% 및/또는 ii) DIN 6174에 따른 L* 95 내지 100을 갖는다. 본 발명은 또한 본 발명의 탄산칼슘-함유 물질을 제조하기 위한 방법, 본 발명의 탄산칼슘-함유 물질을 포함하는 페인트 및 본 발명의 탄산칼슘-함유 물질의 용도에 관한 것이다.",OMYA SA,PEDROSO LUIS;;CURADO CAROLINA;;FREIRE VIEIRA MARIA TERESA;;GOMES DE OLIVEIRA MANAIA ANA TERESA;;FREIRE DUARTE JOAO PEDRO,,https://lens.org/124-192-362-882-166,Patent Application,no,0,0,7,7,0,C09C1/021;;C01P2004/80;;C01P2004/82;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/16;;C01P2006/80;;C09C1/021;;C09D7/61;;C08K3/26;;C08K2003/265;;C01P2004/80;;C01P2004/82;;C01P2006/16;;C01P2006/60;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09D7/61;;C01F11/185;;C01P2004/03;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/16;;C01P2006/62;;C01P2006/64;;C01P2006/80;;C09C1/022;;C09C3/006;;C09C3/041;;C09C3/06,C09C1/02;;C08K3/26;;C09D7/61,,0,0,,,,PENDING
324,DK,T3,DK 1357805 T3,176-183-322-684-597,2012-12-03,2012,DK 02715323 T,2002-01-09,BR 0100421 A;;BR 0200003 W,2001-01-12,NUTRITIONAL COMPOSITION FOR INCREASING MILK PROTEIN IN MAMMALS,,FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAOLO,DANTE PAZZANESE DUARTE LANNA;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,,https://lens.org/176-183-322-684-597,Granted Patent,no,0,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23K1/16;;A23K1/14;;A23K1/18;;A23K50/15,,0,0,,,,EXPIRED
325,US,A1,US 2005/0031672 A1,174-930-205-099-528,2005-02-10,2005,US 48918604 A,2004-09-23,BR 0100421 A;;BR 0200003 W,2001-01-12,Nutritional composition for increasing milk protein in mammals,"It is described a process to obtain increased milk production and/or greater milk protein concentration using supplements with a fatty acid mixture or through production of specific fatty acids within the animal. The process or the supplementation of the product described in this invention (supplements formulated with fatty acids mixtures and with adequate levels of metabolizable protein) allows greater efficiency and/or better quality and/or a healthier mammal with improved productivity. The process includes supplementation of specific types of fatty acids with or without ruminal protection to ruminants and, generally, a diet with metabolizable protein energy ratio greater than the one suggested by the state of the art. The process may include the production of the said compounds (conjugated fatty acids) on the animal itself from fat, certain compounds and microorganisms added to the diet capable of modifying the environment of the gut. The supplementation includes offering fatty acids capable of altering animal metabolism, as well as offering normal fatty acids (which do not change metabolism which, given some conditions in the rumen environment, can change their molecular structure and transform themselves in fatty acids capable of affecting tissue metabolism (including increasing protein content and yield). Both, the offering of the fatty acid with metabolic effects, as well as the production of these active fatty acids in the gut, make possible increases in the concentration and/or production of milk protein.",DUARTE LANNA DANTE PAZZANESSE;;MCGUIRE MARK A.;;DE MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M.,DUARTE LANNA DANTE PAZZANESSE;;MCGUIRE MARK A;;DE MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (2004-03-03),https://lens.org/174-930-205-099-528,Patent Application,yes,3,2,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23K1/14;;A23K1/16;;A23K1/18;;A23K50/15,424/442;;424/757,0,0,,,,DISCONTINUED
326,PT,T,PT 10323 T,030-773-284-585-613,2008-12-15,2008,PT 1032308 U,2008-04-26,PT 1032308 U,2008-04-26,SISTEMA DE TRIGERAÇÃO COM CAPACIDADE DE UTILIZAÇÃO DE FONTES RENOVÁVEIS,"A PRESENTE INVENÇÃO REFERE A UM SISTEMA DE TRIGERAÇÃO, QUE CONTEM UMA CENTRAL TÉRMICA DE PEQUENAS DIMENSÕES (1), UTILIZADORA DE DIVERSOS TIPOS DE COMBUSTÍVEL, ONDE SE DESTACA A BIOMASSA SÓLIDA (2) PARA PRODUÇÃO ELÉCTRICA, ATRAVÉS DE QUALQUER TIPO DE EQUIPAMENTO QUE TRANSFORME ENERGIA TÉRMICA EM ENERGIA MECÂNICA (3), QUE SEGUIDAMENTE É TRANSFORMADA EM ENERGIA ELÉCTRICA (4). O CALOR ABSORVIDO NA FONTE FRIA DA CENTRAL TÉRMICA (5), PELO FLUIDO DE DISTRIBUIÇÃO DE AQUECIMENTO (12) DO FLUIDO TÉRMICO (11), QUE PODE CIRCULAR QUER NO ESTADO LÍQUIDO, QUER NO ESTADO GASOSO SERÁ APROVEITADO, PARA TRANSMISSÃO DE CALOR, QUER DIRECTAMENTE, QUER ATRAVÉS DE UM CHILLER DE ABSORÇÃO INDIRECTA OU ANÁLOGO (6). O FLUIDO DE DISTRIBUIÇÃO DE FRIO (13) AÍ OBTIDO PODE SER USADO EM SISTEMAS DE CLIMATIZAÇÃO (7) OU REFRIGERAÇÃO (8). AO PROCESSO, CASO AS NECESSIDADES O JUSTIFIQUEM, PODE ACOPLAR-SE UM DEPÓSITO DE ENERGIA TÉRMICA (9), QUE TEM COMO FINALIDADE ACUMULAR ENERGIA. A PRINCIPAL APLICAÇÕES DESTE ESQUEMA DE PRINCIPIO SERÃO EM ESTUFAS AGRÍCOLAS E AVIÁRIOS, EMBORA TAMBÉM POSSA TER OUTROS DESTINOS COMO POR EXEMPLO EDIFÍCIOS, ENTREPOSTOS FRIGORÍFICOS E PARQUES INDUSTRIAIS.",CARVALHO OSCAR JOSE GONCALVES DE;;SIMOES TIAGO AZEVEDO PEREIRA SERRAS,CARVALHO OSCAR JOSE GONCALVES DE;;COELHO LUIS MANUEL RODRIGUES;;SIMOES TIAGO AZEVEDO PEREIRA SERRAS;;GARCIA JOAO DUARTE NUNO PINTO,,https://lens.org/030-773-284-585-613,Patent Application,no,0,0,1,1,0,,F01K7/00;;F25B7/00;;F25B33/00,,0,0,,,,DISCONTINUED
327,EP,B1,EP 2149593 B1,094-663-555-949-787,2017-03-22,2017,EP 09251483 A,2009-06-04,BR PI0802431 A,2008-07-28,Process for removing silicon compounds from hydrocarbon streams,,PETROLEO BRASILEIRO SA,MENEGASSI DE ALMEIDA RAFAEL;;KLOTZ RABELLO CARLOS RENÉ;;VINICIUS EIFFLE DUARTE MARCUS;;MONTEIRO DE SOUZA GUILHERME LUIS;;XIAONDONG HU,,https://lens.org/094-663-555-949-787,Granted Patent,yes,3,0,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,C10G25/00;;C10G25/12,,0,0,,,,ACTIVE
328,US,B2,US 11147293 B2,037-015-696-410-838,2021-10-19,2021,US 17571608 A,2008-07-18,US 17571608 A;;BR 0100421 A;;US 48918604 A;;BR 0200003 W,2001-01-12,Nutritional composition for increasing milk protein in mammals,"A process for obtaining an increase in the concentration and/or production of milk protein and/or improving reproductive performance. The process includes administering to a mammal a composition including at least one unsaturated fatty acid, or a derivative thereof, and at least one feed supplement, wherein the combination is administered in an amount such that the mammal absorbs 1 g to 95 g of the at least one unsaturated fatty acid, or the derivative thereof, per day.",DUARTE LANNA DANTE PAZZANESE;;MCGUIRE MARK A;;DE MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M;;FUND DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO,DUARTE LANNA DANTE PAZZANESE;;MCGUIRE MARK A;;DE MEDEIROS SERGIO RAPOSO;;DE OLIVEIRA DIMAS ESTRASULAS;;AROEIRA LUIS JANUARIO M,,https://lens.org/037-015-696-410-838,Granted Patent,yes,6,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K50/10;;A23K1/10;;A23K1/14;;A23K1/16;;A23K1/18;;A23K20/158;;A23K50/15,,18,15,020-919-904-140-241;;024-716-752-022-996;;061-217-306-386-445;;004-515-988-514-229;;018-539-645-061-779;;061-217-306-386-445;;024-716-752-022-996;;021-019-845-781-294;;018-032-432-041-771;;020-919-904-140-241;;025-462-381-686-783;;008-617-625-736-036;;049-109-615-479-757;;008-608-702-535-912;;080-847-494-665-833,11015491;;10.1093/jn/130.10.2568;;987164;;10.1093/jn/106.10.1383;;10.1093/jn/124.12.2344;;16856314;;10.1093/jn/124.12.344;;9565891;;10.3168/jds.s0022-0302(98)75644-9;;10958826;;10.1093/jn/130.9.2292;;10.1093/jn/124.12.2344;;16856314;;10.1093/jn/124.12.344;;987164;;10.1093/jn/106.10.1383;;9566998;;10.1093/jn/128.5.881;;9868189;;10.1093/jn/128.12.2411;;11015491;;10.1093/jn/130.10.2568;;10.3168/jds.s0022-0302(94)76948-4;;8120192;;10644637;;10.1152/ajpregu.2000.278.1.r179;;11110851;;10.1093/jn/130.12.2943;;11412893;;10.1016/s0163-7827(01)00008-x;;12416815;;10.3168/jds.s0022-0302(02)74346-4,"Piperova, Liliana, et al, Mammary Lipogenic Enzyme Activity, trans Fatty Acids and Conjugated Linoleic Acids Are Altered in Lactating Dairy Cows Fed a Milk Fat-Depressing Diet, The Journal of Nutrition, vol. 130, pp. 2568-2574 (2000).;;Ackerson, Barbara, et al, Effects of Treatment of Whole Fat Soybeans or Soy Flour with Formaldehyde to Protect the Polyunsaturated Fatty Acids from Biohydration in the Rumen, The Journal of Nutrition, vol. 106, Issue 10, pp. 1383-1390 (1976).;;Chin et al. (Conjugated Linoleic Acid Is a Growth Factor for Rats as Shown by Enhanced Weight Gain and Improved Feed Efficiency. Biochemical and Molecular Roles of Nutrients.1994).;;Pieper et al. (Natural solutions for sexual enhancement: increase the energy in your sex life with alternatives to drug therapy. 1998).;;Staples et al. (Symposium: Optimizing Energy Nutrition For Reproducing Dairy Cows. Influence of Supplemental Fats on Reproductive Tissues and Performance of Lactating Cows. J Dairy Sci. 1998. 81:856-871).;;Bee (Dietary Conjugated Linoleic Acids Alter Adipose Tissue and Milk Lipids of Pregnant and Lactating Sows. J. Nutr. Sep. 1, 2000 vol. 130 No. 9 2292-2298).;;Chin et al. (Conjugated linoleic acid is a growth factor for rats as shown by enhanced weight gain and improved feed efficiency. J Nutr. Dec. 1994;124(12):2344-9).;;Ackerson et al., Effects of Treatment of Whole Fat Soybeans or Soy Flour with Formaldehyde to Protect the Polyunsaturated Fatty Acids from Biohydrogenation in the Rumen, Journal of Nutrition, 106:10 (1976), 1383-1390.;;Kelly et al., Dietary Fatty Acid Sources Affect Conjugated Linoleic Acid Concentrations in Milk from Lactating Dairy Cows, Journal of Nutrition, 128:5 (1998), 881-885.;;Loor et al., Exogenous Conjugated Linoleic Acid Isomers Reduce Bovine Milk Fat Concentration and Yield by Inhibiting De Novo Fatty Acid Synthesis, Journal of Nutrition, 128:12 (1998), 2411-2419.;;Piperova et al., Mammary Lipogenic Enzyme Activity, trans Fatty Acids and Conjugated Linoleic Acids Are Altered in Lactating Dairy Cows Fed a Milk Fat-Depressing Diet, Journal of Nutrition, 130 (2000), 2568-2574.;;Teh et al., Varying Amounts of Rumen-Inert Fat for High Producing Goats in Early Lactation, Journal of Dairy Science, 77:1 (1994), 253-258.;;Office Action of Apr. 17, 2007, in related U.S. Appl. No. 10/489,186.;;Office Action of Jan. 23, 2008, in related U.S. Appl. No. 10/489,186.;;Baumgard, L.H. et al., “Identification of the conjugated linoleic acid isomer that inhibits milk at synthesis,” Am. J. Physiol. Regulatory Integrative Comp. Physiol. (2000) 278:R179-R184.;;Blankson, H. et al., “Conjugated Linoleic Acid Reduces Body Fat Mass in Overweight and Obese Humans,” The Journal of Nutrition (2000) 2943-2948.;;Pariza, M.W. et al., “The biologically active isomers of conjugated linoleic acid,” Progress in Lipid Research (2001) 40:283-298.;;Perfield, J.W. et al., “Effects of Dietary Supplementation of Rumen-Protected Conjugated Linoleic Acid in Dairy Cows during Established Lactation,” J. Dairy Sci. (2002) 85:2609-2617.",ACTIVE
329,BR,A,BR 0100421 A,152-423-352-034-658,2002-09-10,2002,BR 0100421 A,2001-01-12,BR 0100421 A,2001-01-12,"Produto para alimentação de mamìferos visando aumentar o teor e/ou produção de proteìna no leite, processo de obtenção de aumento de produção e/ou teor de proteìna no leite e processo de obtenção de leite que propicia maior rendimento e/ou qualidade dos produtos lácteos produzidos a partir deste leite","""PRODUTO PARA ALIMENTAçãO DE MAMìFEROS VISANDO AUMENTAR O TEOR E/OU PRODUçãO DE PROTEìNA NO LEITE, PROCESSO DE OBTENçãO DE AUMENTO DE PRODUçãO E/OU TEOR DE PROTEìNA NO LEITE E PROCESSO DE OBTENçãO DE LEITE QUE PROPICIA MAIOR RENDIMENTO E/OU QUALIDADE DOS PRODUTOS LáCTEOS PRODUZIDOS A PARTIR DESTE LEITE"". Trata-se de processo de obtenção de aumento de produção de leite e/ou de aumento do teor de proteína do leite através do uso de uma mistura de ácidos graxos. O processo ou o fornecimento do produto descrito neste invento (rações formuladas com uma mistura de ácidos graxos e com teores adequados de proteína metabolizável são utilizados) permite melhor rendimento e/ou melhor qualidade e/ou melhor estado de saúde e produtividade de mamíferos. O processo envolve a suplementação de alguns tipos específicos de ácidos graxos com e/ou sem proteção ruminal para ruminantes e, geralmente, uma dieta com relação proteína metabolizável/energia superior às exigências indicadas pelo estado da arte. O processo também pode envolver a produção, no próprio animal, destes compostos (ácidos graxos conjugados) a partir de gorduras adicionados à dieta e de outros compostos modificadores do ambiente do trato gastrointestinal. Esta suplementação envolve o fornecimento de um ácido graxo com efeito de modificador do metabolismo animal, bem como o fornecimento de ácidos graxos inertes que em função das condições ruminais podem mudar sua forma molecular transformando-se em ácidos graxos com efeito modificador do metabolismo. Ambos, o fornecimento do ácido graxo com efeito metabólico como a produção desta ácido graxo no próprio trato digestivo possibilita grandes aumentos no teor e/ou produção de proteína do leite.",FUNDACAO DE AMPARO A PESQUISA,LANNA DANTE PAZZANESE DUARTE;;MCGUIRE MARK A;;MEDEIROS SERGIO RAPOSO DE;;OLIVEIRA DIMAS ESTRASULAS DE;;AROEIRA LUIS JANUARIO M,FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAU (2007-12-18),https://lens.org/152-423-352-034-658,Patent Application,no,0,0,12,12,0,A23K20/158;;A23K50/10;;A23K50/10;;A23K20/158,A23K1/10;;A23K1/14;;A23K1/16;;A23K1/18;;A23K50/15,,0,0,,,,DISCONTINUED
330,ES,A1,ES 2953842 A1,040-510-421-721-211,2023-11-16,2023,ES 202330605 A,2023-07-17,ES 202330605 A,2023-07-17,"DUST HUBCAPS (Machine-translation by Google Translate, not legally binding)","Dustproof hubcaps. The invention describes a dust-proof hubcap (2) for a vehicle wheel rim (4), which comprises air directors (10) arranged in a circle around a common central area, which extend towards the central area; a hollow-shaped filter (20), arranged in the central area so that the air directors (10) converge towards the lateral perimeter of the filter (20); and an air outlet (30), which is in communication with the interior cavity of the filter (20), the air outlet (30) being responsible for allowing the exit of filtered air to the outside of the hubcap (2); The hubcap (2) may be attachable to the rim (4), or it may be integrated at least partially into the rim (4). (Machine-translation by Google Translate, not legally binding)",NUADI EUROPE S L,ANAUT EZQUER BORJA;;BARBA ARESO ENEKO;;CELIZ DUARTE CAROL;;CIORDIA CORCUERA JOSE LUIS;;GONI FLORES AITOR;;LARUMBE FERRERES GUILLERMO,,https://lens.org/040-510-421-721-211,Patent Application,no,6,0,1,1,0,B60B7/0066;;B60B7/002;;F16D65/0031,B60B7/00;;F16D65/00,,0,0,,,,PENDING
331,BR,B1,BR PI0802431 B1,067-506-859-115-513,2017-02-07,2017,BR PI0802431 A,2008-07-28,BR PI0802431 A,2008-07-28,processo de remoção de compostos de silício de correntes de hidrocarbonetos,"processo de remoção de compostos de sílicio de correntes de hidrocarbonetos. a presente invenção se refere a um processo de remoção de compostos orgânicos de silício de correntes de hidrocarbonetos por contato com adsorvente e hidrogênio. o adsorvente é composto por hidrôxídos duplos lamelares e metal hidrogenante do grupo vi-b ou grupo viii. mais especificamente, o processo da presente invenção envolve etapa de ativação para formação do hidrôxido duplo lamelar, e manutenção da fase de hidróxido duplo lamelar pela adição de água.",PETRÓLEO BRASILEIRO S/A - PETROBRAS,CARLOS RENÉ KLOTZ RABELLO;;GUILHERME LUIS MONTEIRO DE SOUZA;;MARCUS VINÍCIUS EIFFLE DUARTE;;RAFAEL MENEGASSI DE ALMEIDA;;XIAONDONG HU,,https://lens.org/067-506-859-115-513,Granted Patent,no,0,0,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,B01J20/06;;B01D15/20;;C10G25/02,,0,0,,,,ACTIVE
332,BR,A2,BR PI0802431 A2,122-295-521-176-437,2010-03-23,2010,BR PI0802431 A,2008-07-28,BR PI0802431 A,2008-07-28,processo de remoÇço de compostos de silÍcio de correntes de hidrocarbonetos,"PROCESSO DE REMOÇçO DE COMPOSTOS DE SÍLICIO DE CORRENTES DE HIDROCARBONETOS. A presente invenção se refere a um processo de remoção de compostos orgânicos de silício de correntes de hidrocarbonetos por contato com adsorvente e hidrogênio. O adsorvente é composto por hidrôxídos duplos lamelares e metal hidrogenante do grupo VI-B ou grupo VIII. Mais especificamente, o processo da presente invenção envolve etapa de ativação para formação do hidrôxido duplo lamelar, e manutenção da fase de hidróxido duplo lamelar pela adição de água.",PETROLEO BRASILEIRO SA,ALMEIDA RAFAEL MENEGASSI DE;;RABELLO CARLOS RENE KLOTZ;;DUARTE MARCUS VINICIUS EIFFLE;;SOUZA GUILHERME LUIS MONTEIRO DE;;HU XIAONDONG,,https://lens.org/122-295-521-176-437,Patent Application,no,0,1,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,C10G25/02;;B01D15/20;;B01J20/06,,0,0,,,,ACTIVE
333,ES,T3,ES 2631202 T3,193-272-178-862-694,2017-08-29,2017,ES 09251483 T,2009-06-04,BR PI0802431 A,2008-07-28,Procedimiento para eliminar compuestos de silicio de corrientes de hidrocarburos,"Procedimiento para eliminar un compuesto de silicio de una corriente de hidrocarburo, en el que el proceso comprende las siguientes etapas: a) activar un adsorbente poniéndolo en contacto con H2O y CO2 a una temperatura de 80ºC a 360ºC, preferiblemente de 110ºC a 220ºC, más preferiblemente de 120ºC a 160ºC y presión de 0,05 a 5,0 MPag, preferiblemente de 0,05 a 2,0 MPag, más preferiblemente de 0,05 a 0,2 MPag, donde dicho adsorbente comprende una mezcla de: (I) un hidróxido doble laminar, preferiblemente hidrotalcita, típicamente obtenible mezclando óxidos de metales divalentes y trivalentes, preferiblemente MgO y Al2O3, y (II) un metal del grupo VI-B o del grupo VIII; b) poner en contacto una carga de hidrocarburo, que tiene típicamente un contenido de un compuesto de silicio, con el adsorbente a una temperatura de 80ºC a 360ºC, preferiblemente de 160ºC a 320ºC, más preferiblemente de 220ºC a 280ºC, a una presión en el intervalo de 0,5 a 5,0 MPag, preferiblemente de 1,5 a 3,0 MPag, y en el que las condiciones son, típicamente, mantenibles por o para una relación H2/carga de 10 a 1000 Nm3 de gas/m3 de carga, más preferiblemente de 50 a 500 Nm3 de gas/m3 de carga, y una velocidad espacial LHSV de 1 a 20h-1, preferiblemente de 2 a 5 h-1; c) mantener dicho adsorbente en estado de hidróxido mixto laminar, mediante adición continua de H2O, en el que el caudal de H2O es de 0,01% a 100%, preferiblemente de 0,1% a 20%, más preferiblemente de 0,1% a 10% del volumen de la carga de hidrocarburo que se está procesando; d) recuperar la corriente de hidrocarburo, que está libre de compuestos de silicio o tiene contenido de compuesto de silicio que es menor que el de la carga de hidrocarburo.",PETROLEO BRASILEIRO SA,MENEGASSI DE ALMEIDA RAFAEL;;KLOTZ RABELLO CARLOS RENÉ;;VINICIUS EIFFLE DUARTE MARCUS;;MONTEIRO DE SOUZA GUILHERME LUIS;;XIAONDONG HU,,https://lens.org/193-272-178-862-694,Granted Patent,no,0,0,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,C10G25/00;;C10G25/12,,0,0,,,,ACTIVE
334,AR,A1,AR 070789 A1,186-606-917-316-819,2010-05-05,2010,AR P090100767 A,2009-03-04,BR PI0802431 A,2008-07-28,PROCESO DE REMOCION DE COMPUESTOS DE SILICIO DE CORRIENTES DE HIDROCARBUROS,"La presente se refiere a un proceso de remocion de compuestos orgánicos de silicio de corrientes de hidrocarburos por contacto con adsorbente e hidrogeno. El adsorbente está compuesto por hidroxidos dobles laminares y metal hidrogenante del grupo VI-B o grupo VIII. Más específicamente, el proceso de la presente involucra una etapa de activacion para la formacion del hidroxido doble laminar, y mantenimiento de la fase de hidroxido laminar por adicion de agua.",PETROLEO BRASILEIRO SA,MONTEIRO DE SOUZA GUILHERME LUIS;;HU XIAONDONG;;KLOTZ RABELLO CARLOS RENE;;MENEGASSI DE ALMEIDA RAFAEL;;EIFFLE DUARTE MARCUS VINICIUS,,https://lens.org/186-606-917-316-819,Patent Application,no,0,0,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,,,0,0,,,,ACTIVE
335,PT,T,PT 2149593 T,017-650-294-461-517,2017-07-04,2017,PT 09251483 T,2009-06-04,BR PI0802431 A,2008-07-28,PROCESS FOR REMOVING SILICON COMPOUNDS FROM HYDROCARBON STREAMS,,PETROLEO BRASILEIRO SA,RAFAEL MENEGASSI DE ALMEIDA;;GUILHERME LUIS MONTEIRO DE SOUZA;;CARLOS RENÉ KLOTZ RABELLO;;MARCUS VINICIUS EIFFLE DUARTE;;HU XIAONDONG,,https://lens.org/017-650-294-461-517,Patent Application,no,0,0,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,C10G25/00;;C10G25/12,,0,0,,,,PENDING
336,AU,A2,AU 2006/273658 A2,058-632-544-301-70X,2008-04-03,2008,AU 2006/273658 A,2006-07-25,PT 10332605 A;;IB 2006052552 W,2005-07-27,Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies,,CARDADOR DOS SANTOS JOSE LUIS;;DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MARTINS DUARTE CATARINA MARIA;;MORGADO MARQUES NUNES ANA VITAL;;SEREJO GOULAO CRESPO JOAO PAULO,MATIAS ANA ALEXANDRA FIGUEIRED;;DUARTE CATARINA MARIA MARTINS;;PONTE MANUEL LUIS DE MAGALHAES;;CRESPO JOAO PAULO SEREJO GOULA;;SANTOS JOSE LUIS CARDADOR DOS;;NUNES ANA VITAL MORGADO MARQUE,,https://lens.org/058-632-544-301-70X,Patent Application,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C39/11;;A23L1/30;;A61K8/34;;A61K31/05;;A61Q19/02;;C07C37/00;;C07C37/68,,0,0,,,,DISCONTINUED
337,AU,A1,AU 2006/273658 A1,034-643-488-337-961,2007-02-01,2007,AU 2006/273658 A,2006-07-25,PT 10332605 A;;IB 2006052552 W,2005-07-27,Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies,,NUNES ANA VITAL MORGADO MARQUE;;CRESPO JOAO PAULO SEREJO GOULA;;JOSE CARDADOR DOS SANTOS;;ANA FIGUEIREDO MATIAS;;CATARINA MARTINS DUARTE;;MANUEL DE MAGALHAES NUNES DA P,MATIAS ANA ALEXANDRA FIGUEIRED;;DUARTE CATARINA MARIA MARTINS;;PONTE MANUEL LUIS DE MAGALHAES;;CRESPO JOAO PAULO SEREJO GOULA;;SANTOS JOSE LUIS CARDADOR DOS;;NUNES ANA VITAL MORGADO MARQUE,,https://lens.org/034-643-488-337-961,Patent Application,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C39/11;;A23L1/30;;A61K8/34;;A61K31/05;;A61Q19/02;;C07C37/00;;C07C37/68,,0,0,,,,DISCONTINUED
338,BR,A,BR 9503602 A,063-349-980-945-752,1997-09-16,1997,BR 9503602 A,1995-08-03,BR 9503602 A;;AU 1997/012542 A;;GB 9707574 A,1995-08-03,Cavalete auto-alinhante pneumático,,VALE DO RIO DOCE CO,NOLASCO ADAILSON JOSE;;DUARTE MARCELO AGUIAR;;RODRIGUES CARLOS AUGUSTO;;NEO DANIELLE NEVES;;DE FREITAS NETO FIDELIS LUIZ;;OLIVEIRA DIONE LUIS,,https://lens.org/063-349-980-945-752,Patent Application,no,0,0,4,6,0,B65G39/16,B65G39/16,,0,0,,,,EXPIRED
339,BR,A2,BR 102019024766 A2,072-338-869-421-638,2021-06-08,2021,BR 102019024766 A,2019-11-25,BR 102019024766 A,2019-11-25,compostos de ouro (i) com tiocarbamoilpirazolinas como agentes anticancerígenos,"compostos de ouro (i) com tiocarbamoilpirazolinas como agentes anticancerígenos. a presente invenção se refere ao processo de obtenção de uma nova família de compostos organometálicos caracterizados como possíveis metalofármacos inéditos baseados no metal de transição ouro(i) com estado de oxidação (+1) ligado quimicamente a ligantes da família das tiocarbamoilpirazolinas 1,3,5-trissubstituídas.compostos das classes [(ph)3pau(l)]x e [au(l)cl] onde (l = ligantes tiocarbamoilpirazolinas e x = ânions) mostraram-se potentes agentes anticancerígenos em ensaios conduzidos in vitro contra células 4t1-adenocarcinoma metastático de mama de camundongo e células bf16-f10-melanoma murino. visto este grande potencial de aplicação destas novas moléculas na produção de novos quimioterápicos para o tratamento de vários tipos de câncer, estamos protegendo 98 compostos inéditos bem como seu uso para quimioterapia frente ao câncer.",UNIV FEDERAL DA GRANDE DOURADOS UFGD;;UNIV FEDERAL DE MATO GROSSO DO SUL,AMILCAR MACHULEK JUNIOR;;GLEISON ANTONIO CASAGRANDE;;LETÍCIA BARBOSA DE OLIVEIRA;;LIS REGIANE VIZOLLI FAVARIN;;LUCAS PIZZUTI;;LUIS FERNANDO BARBOSA DUARTE,UNIVERSIDADE FEDERAL DE MATO GROSSO DO SUL (BR/MS) (2020-12-08);;UNIVERSIDADE FEDERAL DE MATO GROSSO DO SUL (BR/MS) ; UNIVERSIDADE FEDERAL DA GRANDE DOURADOS - UFGD (BR/MS) (2021-04-13),https://lens.org/072-338-869-421-638,Patent Application,no,0,0,1,1,0,A61K31/40;;C07D231/06;;C01G7/006,A61K31/40;;A61K33/242;;A61P35/00;;C01G7/00;;C07D231/06,,0,0,,,,PENDING
340,BR,B1,BR 102016028719 B1,197-708-809-704-482,2022-08-02,2022,BR 102016028719 A,2016-12-07,BR 102016028719 A,2016-12-07,EQUIPAMENTO E SISTEMA DE COLETA DE RESÍDUOS,"EQUIPAMENTO E SISTEMA DE COLETA DE RESÍDUOS. A presente invenção refere-se a um equipamento e a um sistema de coleta de resíduos que otimiza a coleta dos resíduos oriundos de um processo de manufatura fabril. O equipamento da presente invenção compreende pelo menos um módulo móvel de coleta (1) tendo uma estrutura que tem uma base substancialmente plana (2) configurada para receber um recipiente de resíduos cheio a partir de um módulo estático (20), e pelo menos um módulo móvel de reposição (4) tendo uma estrutura que tem uma base inclinada (5) configurada para transferir um recipiente de resíduos vazio para o módulo estático (20). Os módulos (1,4) são rebocados por um veículo tracionador, na forma de um trem de transporte, por uma trajetória adjacente ao módulo estático, pelo que inicialmente transfere-se um recipiente de resíduos carregado desde o módulo estático para o módulo de coleta e posteriormente, após um deslocamento relativo do trem de transporte, um recipiente de resíduos vazio é transferido desde o módulo de reposição para o módulo estático, as ditas transferências sendo realizadas exclusivamente por ação gravitacional.",FCA FIAT CHRYSLER AUTOMOVEIS BRASIL LTDA,LENADRO DE SOUZA DONATO;;JOSÉ RENATO LUCINDA PAGANO;;LUIS FELIPE PINTO DUARTE;;ALEXANDRE MARCELO LOPES GONÇALVES;;AGNALDO CORRÊA DA COSTA,,https://lens.org/197-708-809-704-482,Granted Patent,no,0,0,2,2,0,,B60P1/52;;B65F3/02,,0,0,,,,ACTIVE
341,BR,A8,BR 102017022103 A8,124-814-929-011-606,2022-08-09,2022,BR 102017022103 A,2017-10-13,BR 102017022103 A,2017-10-13,"SÍNTESE DE ÉSTERES METÍLICOS OU ETÍLICOS (BIODIESEL), OU DE ÁLCOOL SUPERIOR, DE ÁCIDOS GRAXOS, VIA REAÇÃO DE TRANSESTERIFICAÇÃO DE TRIACILGLICERÓIS EM BIO-ÓLEOS OU BIO-GORDURAS, PROMOVIDA POR CATALISADORES HETEROGÊNEOS BASEADOS EM REJEITOS MAGNÉTICOS DE MINERAÇÃO DE FOSFATO.","""SÍNTESE DE ÉSTERES METÍLICOS OU ETÍLICOS (BIODIESEL), OU DE ÁLCOOL SUPERIOR, DE ÁCIDOS GRAXOS, VIA REAÇÃO DE TRANSESTERIFICAÇÃO DE TRIACILGLICERÓIS EM BIO-ÓLEOS OU BIOGORDURAS, PROMOVIDA POR CATALISADORES HETEROGÊNEOS BASEADOS EM REJEITOS MAGNÉTICOS DE MINERAÇÃO DE FOSFATO."" A presente invenção está relacionada ao processo para produção de biodiesel através da transesterificação de triacilgliceróis, utilizando catalisadores heterogêneos derivados de rejeito mineral magnético rico em magnetita (Fe304), material, aqui, intitulado meramente ""magnetita"", da mineração de depósitos minerais de apatita. Especificamente, a presente invenção está relacionada a um processo para produção de biodiesel através da transesterificação de triacilgliceróis de bio-óleos ou bio-gorduras com álcool metílico, álcool etílico, ou qualquer outra formação similar de ésteres com alcoóis superiores, utilizando o catalisador heterogêneo diferente dos encontrados tradicionalmente no estado da técnica. O catalisador a que aqui se reivindica consiste em material de magnetita (Fe304), proveniente de rejeito da mineração de fosfato, misturado com óxido de cálcio; a mistura é calcinada a uma temperatura entre 100 °C e 1000 °C.",UNIV FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI UFVJM,BÁRBARA GONÇALVES ROCHA;;JOSÉ DOMINGOS FABRIS;;ALICE LOPES MACEDO;;BÁRBARA RODRIGUES FREITAS;;PRISCYLLA CAIRES DE ALMEIDA;;LUIS CARLOS DUARTE CAVALCANTE,,https://lens.org/124-814-929-011-606,Patent Application,no,0,0,2,2,0,C10L1/026;;C10L1/1233;;C07C67/03;;B01J23/745;;B01J37/342;;B01J2523/842;;B01J2523/23;;C10L2230/04;;C10L2230/22;;C10L2290/40;;C10L2290/141;;B01J35/33;;Y02E50/10,C07C67/03;;B01J23/78;;B01J35/00;;C10L1/02,,0,0,,,,DISCONTINUED
342,BR,A2,BR 102017022103 A2,039-365-261-552-354,2019-05-07,2019,BR 102017022103 A,2017-10-13,BR 102017022103 A,2017-10-13,"síntese de ésteres metílicos ou etílicos (biodiesel), ou de álcool superior, de ácidos graxos, via reação de transesterificação de triacilgliceróis em bio-óleos ou bio-gorduras, promovida por catalisadores heterogêneos baseados em rejeitos magnéticos de mineração de fosfato.","""síntese de ésteres metílicos ou etílicos (biodiesel), ou de álcool superior, de ácidos graxos, via reação de transesterificação de triacilgliceróis em bio-óleos ou biogorduras, promovida por catalisadores heterogêneos baseados em rejeitos magnéticos de mineração de fosfato."" a presente invenção está relacionada ao processo para produção de biodiesel através da transesterificação de triacilgliceróis, utilizando catalisadores heterogêneos derivados de rejeito mineral magnético rico em magnetita (fe304), material, aqui, intitulado meramente ""magnetita"", da mineração de depósitos minerais de apatita. especificamente, a presente invenção está relacionada a um processo para produção de biodiesel através da transesterificação de triacilgliceróis de bio-óleos ou bio-gorduras com álcool metílico, álcool etílico, ou qualquer outra formação similar de ésteres com alcoóis superiores, utilizando o catalisador heterogêneo diferente dos encontrados tradicionalmente no estado da técnica. o catalisador a que aqui se reivindica consiste em material de magnetita (fe304), proveniente de rejeito da mineração de fosfato, misturado com óxido de cálcio; a mistura é calcinada a uma temperatura entre 100 °c e 1000 °c.",UNIV FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI UFVJM,ALICE LOPES MACEDO;;BÁRBARA GONÇALVES ROCHA;;BÁRBARA RODRIGUES FREITAS;;JOSÉ DOMINGOS FABRIS;;LUIS CARLOS DUARTE CAVALCANTE;;PRISCYLLA CAIRES DE ALMEIDA,,https://lens.org/039-365-261-552-354,Patent Application,no,0,0,2,2,0,C10L1/026;;C10L1/1233;;C07C67/03;;B01J23/745;;B01J37/342;;B01J2523/842;;B01J2523/23;;C10L2230/04;;C10L2230/22;;C10L2290/40;;C10L2290/141;;B01J35/33;;Y02E50/10,B01J23/745;;B01J35/00;;B01J37/34;;C07C67/03;;C10L1/02;;C10L1/12,,0,0,,,,DISCONTINUED
343,BR,A2,BR 102016028719 A2,199-971-888-247-873,2018-06-19,2018,BR 102016028719 A,2016-12-07,BR 102016028719 A,2016-12-07,equipamento e sistema de coleta de resíduos,"a presente invenção refere-se a um equipamento e a um sistema de coleta de resíduos que otimiza a coleta dos resíduos oriundos de um processo de manufatura fabril. o equipamento da presente invenção compreende pelo menos um módulo móvel de coleta (1) tendo uma estrutura que tem uma base substancialmente plana (2) configurada para receber um recipiente de resíduos cheio a partir de um módulo estático (20), e pelo menos um módulo móvel de reposição (4) tendo uma estrutura que tem uma base inclinada (5) configurada para transferir um recipiente de resíduos vazio para o módulo estático (20). os módulos (1,4) são rebocados por um veículo tracionador, na forma de um trem de transporte, por uma trajetória adjacente ao módulo estático, pelo que inicialmente transfere-se um recipiente de resíduos carregado desde o módulo estático para o módulo de coleta e posteriormente, após um deslocamento relativo do trem de transporte, um recipiente de resíduos vazio é transferido desde o módulo de reposição para o módulo estático, as ditas transferências sendo realizadas exclusivamente por ação gravitacional.",FCA FIAT CHRYSLER AUTOMOVEIS BRASIL LTDA,AGNALDO CORRÊA DA COSTA;;ALEXANDRE MARCELO LOPES GONÇALVES;;JOSÉ RENATO LUCINDA PAGANO;;LENADRO DE SOUZA DONATO;;LUIS FELIPE PINTO DUARTE,,https://lens.org/199-971-888-247-873,Patent Application,no,0,0,2,2,0,,B60P1/52;;B65F3/02,,0,0,,,,ACTIVE
344,US,A1,US 2021/0188646 A1,120-052-409-921-944,2021-06-24,2021,US 202117194051 A,2021-03-05,US 202117194051 A;;PT 10938716 A;;US 201816300611 A;;PT 2017000007 W,2016-05-13,"PROCESS, REACTOR AND SYSTEM FOR FABRICATION OF FREE-STANDING TWO-DIMENSIONAL NANOSTRUCTURES USING PLASMA TECHNOLOGY","The present invention relates to a process, reactor and system to produce self-standing two-dimensional nanostructures, using a microwave-excited plasma environment. The process is based on injecting, into a reactor, a mixture of gases and precursors in stream regime. The stream is subjected to a surface wave electric field, excited by the use of microwave power which is introduced into a field applicator, generating high energy density plasmas, that break the precursors into its atomic and/or molecular constituents. The system comprises a plasma reactor with a surface wave launching zone, a transient zone with a progressively increasing cross-sectional area, and a nucleation zone. The plasma reactor together with an infrared radiation source provides a controlled adjustment of the spatial gradients, of the temperature and the gas stream velocity.",INST SUPERIOR TECNICO,TATAROVA ELANA STEFANOVA;;DOS SANTOS DUARTE VIEIRA HENRIQUES JULIO PAULO;;DA MOTA CAPITAO LEMOS ALVES LUIS PAULO;;SOARES GONCALVES BRUNO MIQUEL,,https://lens.org/120-052-409-921-944,Patent Application,yes,2,0,13,13,0,B82Y30/00;;B82Y40/00;;H05H1/46;;C01B32/184;;C01B32/186;;H05H1/4615;;B82Y40/00;;H05H1/46;;C01B32/184;;C01B32/186;;C01B32/184;;B01J12/002;;B82Y30/00;;B82Y40/00;;C01P2004/20;;C01P2004/64;;H05H1/46;;H05H1/4615;;B01J2219/0898;;B01J19/126;;B01J2219/1224;;B01J2219/1206,C01B32/184;;B01J12/00;;H05H1/46,,1,1,059-896-195-670-034,28860575;;10.1038/s41598-017-10810-3;;pmc5579263,"Tatarova, E., A. Dias, J. Henriques, M. Abrashev, N. Bundaleska, E. Kovacevic, N. Bundaleski et al. ""Towards large-scale in free-standing graphene and N-graphene sheets."" Scientific Reports 7 (2017): 10175. (Year: 2017)",PENDING
345,BR,B1,BR 102018016840 B1,115-732-779-704-902,2023-02-14,2023,BR 102018016840 A,2018-08-17,BR 102018016840 A,2018-08-17,"SÍNTESE DE UM COMPOSTO DA CLASSE DE FLUORÓFOROS, COMPOSTO OBTIDO E SEU USO, PROCESSO DE OBTENÇÃO DE DIODOS ORGÂNICOS EMISSORES DE LUZ BRANCA E DIODOS OBTIDOS","SÍNTESE DE UM COMPOSTO DA CLASSE DE FLUORÓFOROS, COMPOSTO OBTIDO E SEU USO, PROCESSO DE OBTENÇÃO DE DIODOS ORGÂNICOS EMISSORES DE LUZ BRANCA E DIODOS OBTIDOS. A presente invenção refere-se a uma síntese de uma classe de fluoróforos desenvolvido pela combinação das classes dos salicilidenos e benzazóis, bem como o composto obtido e sua aplicação tecnológica na forma de diodo emissor de luz (WOLED). A referida síntese obtém um composto que possui propriedades ópticas e eletrônicas diferenciadas e com grande potencial de aplicação em diodos emissores de luz. Assim, adicionalmente, a presente invenção refere-se um processo de obtenção de diodos orgânicos emissores de luz branca (WOLEDs) bem como os diodos obtidos.",UNIV ESTADUAL CAMPINAS UNICAMP;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,LUIS GUSTAVO TEIXEIRA ALVES DUARTE;;JÔNATAS FALEIRO BERBIGIER;;JOSÉ CARLOS GERMINO;;MARCELO MEIRA FALEIROS;;FABIANO SEVERO RODEMBUSCH;;TERESA DIB ZAMBON ATVARS,,https://lens.org/115-732-779-704-902,Granted Patent,no,0,0,3,3,0,C07D513/00;;C07D513/00;;C07D277/62;;C07D401/12;;C07D513/12,C07D513/00,,0,0,,,,ACTIVE
346,WO,A1,WO 2020/034022 A1,190-094-137-338-644,2020-02-20,2020,BR 2019050342 W,2019-08-16,BR 102018016840 A,2018-08-17,"SYNTHESIS OF A FLUOROPHORE-CLASS COMPOUND, COMPOUND PRODUCED AND USE THEREOF, PROCESS FOR PRODUCING WHITE ORGANIC LIGHT EMITTING DIODES AND DIODES PRODUCED","The present invention relates to the synthesis of a class of fluorophores developed by combining the salicylidene and benzazole classes, and to the compound produced and the technical use thereof in the form of a light emitting diode (WOLED). Said synthesis produces a compound which has advantageous optical and electronic properties and high potential for use in light emitting diodes. The present invention further relates to a process for producing white organic light emitting diodes (WOLEDs) as well as to the diodes produced.",UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS;;UNICAMP,TEIXEIRA ALVES DUARTE LUIS GUSTAVO;;SEVERO RODEMBUSCH FABIANO;;GERMINO JOSÉ CARLOS;;FALEREIRO BERBIGIER JÔNATAS;;DIB ZAMBON ATVARS TERESA;;MEIRA FALEIROS MARCELO,,https://lens.org/190-094-137-338-644,Patent Application,yes,4,0,3,3,0,C07D513/00;;C07D513/00;;C07D277/62;;C07D401/12;;C07D513/12,C07D277/62;;C07D401/12;;C07D513/12,,1,1,002-505-764-859-867,10.1039/c5cs00543d;;26506465,"PADALKAR ET AL.: ""Excited-state intramolecular proton-transfer (ESIPT)-inspired solid state emitters"", CHEMICAL SOCIETY REVIEWS, vol. 45, October 2015 (2015-10-01), pages 169 - 202, XP055686264",PENDING
347,US,A1,US 2010/0038287 A1,049-118-755-668-888,2010-02-18,2010,US 51037109 A,2009-07-28,BR PI0802431 A,2008-07-28,PROCESS FOR REMOVING SILICON COMPOUNDS FROM HYDROCARBON STREAMS,"The present invention relates to a process for removing organic silicon compounds from hydrocarbon streams by contact with an adsorbent and hydrogen. The adsorbent is composed of lamellar double hydroxides and group VI-B or group VIII hydrogenating metal. More specifically, the process of the present invention involves a stage of activation for formation of the lamellar double hydroxide, and maintaining the phase of lamellar double hydroxide by adding water.",PETROLEO BRASILEIRO SA,MENEGASSI DE ALMEIDA RAFAEL;;RABELLO CARLOS RENE KLOTZ;;DUARTE MARCUS VINICIUS EIFFLE;;MONTEIRO DE SOUZA GUILHERME LUIS;;LESLIE JOYCE;;HU XIAONDONG,PETROLEO BRASILEIRO S.A.-PETROBRAS (2009-05-12),https://lens.org/049-118-755-668-888,Patent Application,yes,11,5,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,C10G19/00,208/283,0,0,,,,ACTIVE
348,BR,A2,BR 102018016840 A2,121-326-218-098-790,2020-02-27,2020,BR 102018016840 A,2018-08-17,BR 102018016840 A,2018-08-17,"síntese de um composto da classe de fluoróforos, composto obtido e seu uso, processo de obtenção de diodos orgânicos emissores de luz branca e diodos obtidos","síntese de um composto da classe de fluoróforos, composto obtido e seu uso, processo de obtenção de diodos orgânicos emissores de luz branca e diodos obtidos. a presente invenção refere-se a uma síntese de uma classe de fluoróforos desenvolvido pela combinação das classes dos salicilidenos e benzazóis, bem como o composto obtido e sua aplicação tecnológica na forma de diodo emissor de luz (woled). a referida síntese obtém um composto que possui propriedades ópticas e eletrônicas diferenciadas e com grande potencial de aplicação em diodos emissores de luz. assim, adicionalmente, a presente invenção refere-se um processo de obtenção de diodos orgânicos emissores de luz branca (woleds) bem como os diodos obtidos.",UNIV ESTADUAL CAMPINAS UNICAMP;;UNIV FEDERAL DO RIO GRANDE DO SUL UFRGS,FABIANO SEVERO RODEMBUSCH;;JOSÉ CARLOS GERMINO;;JÔNATAS FALEIRO BERBIGIER;;LUIS GUSTAVO TEIXEIRA ALVES DUARTE;;MARCELO MEIRA FALEIROS;;TERESA DIB ZAMBON ATVARS,,https://lens.org/121-326-218-098-790,Patent Application,no,0,0,3,3,0,C07D513/00;;C07D513/00;;C07D277/62;;C07D401/12;;C07D513/12,C07D513/00,,0,0,,,,ACTIVE
349,US,B2,US 11254575 B2,066-216-504-274-505,2022-02-22,2022,US 201716300611 A,2017-05-11,PT 10938716 A;;PT 2017000007 W,2016-05-13,"Process, reactor and system for fabrication of free-standing two-dimensional nanostructures using plasma technology","The present invention relates to a process, reactor and system to produce self-standing two-dimensional nanostructures, using a microwave-excited plasma environment. The process is based on injecting, into a reactor, a mixture of gases and precursors in stream regime. The stream is subjected to a surface wave electric field, excited by the use of microwave power which is introduced into a field applicator, generating high energy density plasmas, that break the precursors into its atomic and/or molecular constituents. The system comprises a plasma reactor with a surface wave launching zone, a transient zone with a progressively increasing cross-sectional area, and a nucleation zone. The plasma reactor together with an infrared radiation source provides a controlled adjustment of the spatial gradients, of the temperature and the gas stream velocity.",INST SUPERIOR TECNICO,TATAROVA ELENA STEFANOVA;;DOS SANTOS DUARTE VIEIRA HENRIQUES JULIO PAULO;;DA MOTA CAPITAO LEMOS ALVES LUIS PAULO;;SOARES GONCALVES BRUNO MIGUEL,INSTITUTO SUPERIOR TÉCNICO (2020-03-02),https://lens.org/066-216-504-274-505,Granted Patent,yes,10,0,13,13,0,B82Y30/00;;B82Y40/00;;H05H1/46;;C01B32/184;;C01B32/186;;H05H1/4615;;B82Y40/00;;H05H1/46;;C01B32/184;;C01B32/186;;C01B32/184;;B01J12/002;;B82Y30/00;;B82Y40/00;;C01P2004/20;;C01P2004/64;;H05H1/46;;H05H1/4615;;B01J2219/0898;;B01J19/126;;B01J2219/1224;;B01J2219/1206,C01B32/184;;B01J12/00;;B82Y30/00;;B82Y40/00;;H05H1/46,,7,6,027-059-421-182-022;;058-972-690-292-902;;078-621-397-307-15X;;170-836-738-805-038;;057-226-406-701-473;;059-896-195-670-034,10.1088/0963-0252/25/1/015013;;10.1088/0022-3727/20/7/005;;10.1021/nl8011566;;18529034;;10.1063/1.4822178;;10.1088/0022-3727/47/38/385501;;28860575;;10.1038/s41598-017-10810-3;;pmc5579263,"Tsyganov, D., et al. “On the plasma-based growth of ‘flowing’graphene sheets at atmospheric pressure conditions.” Plasma Sources Science and Technology 25.1 (2015): 015013.;;Lamontagne, B., et al. “Large-area microwave plasma etching of polyimide.” Journal of Physics D: Applied Physics 20.7 (1987): 844.;;International Search Report, PCT/PT2017/000007, dated Dec. 18, 2017.;;Dato et al, “Substrate-Free Gas-Phase Synthesis of Graphene Sheets” 2008 Nano Letters 8 2012.;;E. Tatarova, J. Henriques, C.C. Luhrs, A. Dias, J. Phillips, M.V. Abrashev, C.M. Ferreira, “Microwave plasma based single step method for free standing graphene synthesis at atmospheric conditions” 2013 Appl. Phys. Lett. 103 134101-5.;;E. Tatarova, et al., “Microwave plasmas applied for the synthesis of free standing graphene sheets” 2014 J. Phys D: Appl. Phys. 47 385501-512.;;Tatarova et al., Towards large scale in free standing graphese and N-graphee sheets, Scientific Reports, 7, 1, Aug. 2017.",ACTIVE
350,MA,B1,MA 29748 B1,157-902-712-908-700,2008-09-01,2008,MA 30673 A,2008-02-22,PT 10332605 A,2005-07-27,PROCEDE PERMETTANT D'OBTENIR UN CONCENTRE RICHE EN HYDROXYTYROSOL NATUREL A PARTIER DE RESIDUS ET DE SOUS-PRODUITS D'OLIVIER UTILISANT DES TECHNOLOGIES PROPRES.,"PROCEDE PERMETTANT D'OBTENIR UN CONCENTRE RICHE EN HYDROXYTYROSOL NATUREL A PARTIR DE RESIDUS ET DE SOUS-PRODUITS D'OLIVIER UTILISANT DES TECHNOLOGIES PROPRES. La présente invention concerne un procédé pour l'obtention d'un concentré naturel, bioactf, riche en hydroxytyrosol, en partant de résidus d'oliviers et de sous-produits, en utilisant des technologies propres. Cettes technologies comprenent l'extraction par un fluide supercritique, la nanofiltration et l'osmose inverse, que sont utilisées seules ou selon un mode intégré. L'extrait naturel comprend une concentration minime de 15% (fraction em masse) en hydroxytyrosol et une concentration maxime de 98% (fraction em masse) en ce composé. Le concentré riche en hydroxytyrosol présente des activités antioxydante, antimicrobienne, anti-inflammatoire et anticarcinogène, qui sont plus importantes que les activités qu'on a noté pour l'hydroxytyrosol seule, dans une concentration équivalente. Le concentré riche en hydroxytyrosol peut être préparé sous la forme de particules solides, comme une solution dans l'eau, comme émulsion ou comme des nanoparticules à base lipidique. L'application industrielle comprend les industries alimentaire, pharmaceutique et cosmétique.",MAGALHAEES NUNES DA PONTE MANUEL LUIS DE;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,,https://lens.org/157-902-712-908-700,Granted Patent,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,,,0,0,,,,ACTIVE
351,CA,C,CA 2617002 C,188-600-123-039-309,2014-02-11,2014,CA 2617002 A,2006-07-25,PT 10332605 A;;IB 2006052552 W,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,"The present invention relates to a process of obtaining a natural, bioactive concentrate, rich on hydroxytyrosol, from olive tree residues and subproducts using clean technologies. These technologies comprise supercritical fluid extraction, nanofiltration and reverse osmosis which are used individually or in an integrated mode. The natural extract comprises a minimum concentration of 15% (mass fraction) in hydroxytirosol and a maximum concentration of 98% (mass fraction) in this compound. The hydroxytyrosol-rich concentrate exhibits anti-oxidant, anti-microbial, anti-inflammatory and anti-carcinogenic activities, which are superior to the activities observed for isolated hydroxytyrosol in equivalent concentration. The hydroxytyrosol-rich concentrate can be prepared in the form of solid particles, as an aqueous solution, in an emulsion or as lipidic based nanoparticles. Industrial application comprises the food, pharmaceutical and cosmetics industries.",DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,,https://lens.org/188-600-123-039-309,Granted Patent,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C39/11;;A23L1/30;;A61K8/34;;A61K31/05;;A61Q19/02;;C07C37/00;;C07C37/68,,0,0,,,,ACTIVE
352,BR,A2,BR 102012005272 A2,134-743-409-469-792,2013-11-26,2013,BR 102012005272 A,2012-03-09,BR 102012005272 A,2012-03-09,"SISTEMA PARA GERENCIAMENTO DE ENERGIA ELÉTRICA, INTEGRADO A SERVIÇOS DE ENTRETENIMENTO E INTERATIVIDADE","""SISTEMA PARA GERENCIAMENTO DE ENERGIA ELÉTRICA, INTEGRADO A SERVIÇOS DE ENTRETENIMENTO E INTERATIVIDADE"" A PRESENTE PATENTE DE INVENÇÃO REFERE-SE A SISTEMA PARA O GERENCIAMENTO À DISTÂNCIA DO CONSUMO DE ENERGIA, INTEGRADO A SERVIÇOS DE ENTRETENIMENTO E INTERATIVIDADE, DISPONIBILIZADOS POR UM SET-TOP-BOX (STB) QUE PROVÊ, ATRAVÉS DE UMA MESMA INTERFACE, AS FUNCIONALIDADES DE MONITORAÇÃO DA UTILIZAÇÃO DA ENERGIA, TV DIGITAL, ACESSO À INTERNET, VOIP, COMUNICAÇÃO POR VÍDEO, IPTV E SERVIÇOS DE E-COMMERCE. O PRESENTE SISTEMA É COSTITUIDO POR UMA REDE SEM FIO ATRAVÉS DA QUAL PODEM COMUNICAR-SE: CONJUNTO DE MEDIDORES REMOTOS CONECTADOS À REDE ELÉTRICA E CONJUNTO DE SET-TOP-BOXES, SITUADOS NOS DOMICÍLIOS DOS CONSUMIDORES, E COMPUTADOR CENTRAL PARA GERENCIAMENTO REMOTO. OS SET-TOP-BOXES ESTENDEM A FUNCIONALIDADE DE RECEPÇÃO DE SINAIS DE TV DIGITAL ABERTA DE TAL FORMA QUE ATUAM TAMBÉM COMO GATEWAY ENTRE A REDE DE MEDIDORES E A INTERNET, ATRAVÉS DA QUAL O GERENCIAMENTO REMOTO É OBTIDO POR PARTE DA CONCESSIONÁRIA DE ENERGIA. AS EXTENSÕES DE FUNCIONALIDADES SÃO OBTIDAS POR MÓDULOS DE HARDWARE E APLICATIVOS DE SOFTWARE EM TOTAL ACORDO COM O PADRÃO BRASILEIRO DE TV DIGITAL (GINGA).",CEMIG DISTRIBUIDORA S A;;SENERGY SIST S DE MEDICAO S A,CAMARGO CAPATI DE AQUINO LUIS FERNANDO;;CANCIAN WELLINGTON FAZZI;;MOURTHE DUARTE SERGIO HENRIQUE;;PIMENTA FALCAO RAFAEL JR;;FERREIRA DE SOUZA RONALDO,,https://lens.org/134-743-409-469-792,Patent Application,no,0,0,1,1,0,,H04W4/38;;H04N21/40,,0,0,,,,DISCONTINUED
353,US,A1,US 2020/0123010 A1,117-654-854-906-304,2020-04-23,2020,US 201716300611 A,2017-05-11,PT 10938716 A;;PT 2017000007 W,2016-05-13,"PROCESS, REACTOR AND SYSTEM FOR FABRICATION OF FREE-STANDING TWO-DIMENSIONAL NANOSTRUCTURES USING PLASMA TECHNOLOGY","The present invention relates to a process, reactor and system to produce self-standing two-dimensional nanostructures, using a microwave-excited plasma environment. The process is based on injecting, into a reactor, a mixture of gases and precursors in stream regime. The stream is subjected to a surface wave electric field, excited by the use of microwave power which is introduced into a field applicator, generating high energy density plasmas, that break the precursors into its atomic and/or molecular constituents. The system comprises a plasma reactor with a surface wave launching zone, a transient zone with a progressively increasing cross-sectional area, and a nucleation zone. The plasma reactor together with an infrared radiation source provides a controlled adjustment of the spatial gradients, of the temperature and the gas stream velocity.",INST SUPERIOR TECNICO,TATAROVA ELENA STEFANOVA;;DOS SANTOS DUARTE VIEIRA HENRIQUES JULIO PAULO;;DA MOTA CAPITAO LEMOS ALVES LUIS PAULO;;SOARES GONCALVES BRUNO MIGUEL,INSTITUTO SUPERIOR TÉCNICO (2020-03-02),https://lens.org/117-654-854-906-304,Patent Application,yes,0,1,13,13,0,B82Y30/00;;B82Y40/00;;H05H1/46;;C01B32/184;;C01B32/186;;H05H1/4615;;B82Y40/00;;H05H1/46;;C01B32/184;;C01B32/186;;C01B32/184;;B01J12/002;;B82Y30/00;;B82Y40/00;;C01P2004/20;;C01P2004/64;;H05H1/46;;H05H1/4615;;B01J2219/0898;;B01J19/126;;B01J2219/1224;;B01J2219/1206,C01B32/184;;B01J12/00;;H05H1/46,,0,0,,,,ACTIVE
354,ES,A6,ES 2028545 A6,107-562-638-106-141,1992-07-01,1992,ES 9002507 A,1990-10-03,ES 9002507 A,1990-10-03,Two-processor system for power analysis and quality monitoring in industrial electric installations,"The two-processor system for power analysis and quality monitoring in industrial electric installations manages said consumption in an optimum manner (for more rational use), reducing the billing level for the enterprise, on permitting (due to it being incorporated in an automatic control system) the connection or disconnection of apparatuses or subsystems with excessive consumption, in accordance with a preestablished programme, also providing alarms and indications regarding possibilities for manoeuvre should the consumption trend exceed the contracted electric power quota (functioning in this case as a quasi-intelligent maximeter). In addition, the quality of the energy which the electricity company provides to the user is analysed and monitored, whether private, nodes or substations between power stations of different national or international electricity companies.",CONSEJO SUPERIOR INVESTIGACION,PACHECO MANCHADO ANTONIO;;MOCHON MUNOZ JAVIER;;ANDRES SANZ MIGUEL P;;ENRIQUEZ BERCIANO JOSE LUIS;;GALAN MARTINEZ PEDRO;;GARCIA DUARTE JOSE E,,https://lens.org/107-562-638-106-141,Granted Patent,no,0,0,1,1,0,,G05F1/70,,0,0,,,,EXPIRED
355,PT,E,PT 1910257 E,023-155-222-321-776,2014-04-10,2014,PT 06780204 T,2006-07-25,PT 10332605 A,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,,PONTE MANUEL LUIS DE MAGALHAES NUNES DA;;SANTOS JOSE LUIS CARDADOR DOS;;MATIAS ANA ALEXANDRA FIGUEIREDO;;NUNES ANA VITAL MORGADO MARQUES;;DUARTE CATARINA MARIA MARTINS;;CRESPO JOAO PAULO SEREJO GOULAO,CRESPO JOAO PAULO SEREJO GOULAO;;PONTE MANUEL LUIS DE MAGALHAES NUNES DA;;SANTOS JOSE LUIS CARDADOR DOS;;MATIAS ANA ALEXANDRA FIGUEIREDO;;NUNES ANA VITAL MORGADO MARQUES;;DUARTE CATARINA MARIA MARTINS,,https://lens.org/023-155-222-321-776,Granted Patent,no,0,1,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,A61Q19/00;;A23L1/30;;A61K8/34;;A61K8/97;;A61Q17/00;;C07C37/00;;C07C39/11,,0,0,,,,ACTIVE
356,BR,A2,BR PI0614917 A2,102-387-357-262-837,2011-04-19,2011,BR PI0614917 A,2006-07-25,PT 10332605 A;;IB 2006052552 W,2005-07-27,"proceso para a obtenção de um concentrado natural, rico em hidroxitirosol, a partir de resìduos de oliveiras e de subprodutos, utilizando tecnologias limpas","PROCESSO PARA A OBTENçãO DE UM CONCENTRADO NATURAL, RICO EM HIDROXITIROSOL, A PARTIR DE RESìDUOS DE OLIVEIRAS E DE SUBPRODUTOS, UTILIZANDO TECNOLOGIAS LIMPAS. A presente invenção refere-se a um processo para a obtenção de um concentrado natural, bioativo, rico em hidroxitirosol, a partir de resíduos de oliveiras e de subprodutos, utilizando tecnologias limpas. Estas tecnologias compreendem a extração por um fluido supercrítico, a nanofiltração e a osmose inversa, que são utilizadas individualmente ou num modo integrado. O extrato natural compreende uma concentração mínima de 15% (fração mássica) de hidroxitirosol e uma concentração máxima de 98% (fração mássica) deste composto. O concentrado rico em hidroxitirosol exibe atividades antioxidante, anti- microbiana, anti-inflamatória e anticarcinogénica, que são superiores às atividades observadas para o hidroxitirosol isolado, em concentração equivalente, O concentrado rico em hidroxitirosol pode ser preparado na forma de partículas sólidas, como uma solução aquosa, em emulsão ou como nanopartículas de base lipídica. A aplicação industrial compreende as indústrias alimentar, farmacêutica e cosmética.",PONTE MANUEL LUIS DE MAGALHAES NUNES DA;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;VITAL MORGADO MARQUES NUNES ANA;;GOULAO CRESPO JOAO PAULO SEREJO;;MARTINS DUARTE CATARINA MARIA,FIGUEIREDO MATIAS ANA ALEXANDRA;;VITAL MORGADO MARQUES NUNES ANA;;GOULAO CRESPO JOAO PAULO SEREJO;;DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;MARTINS DUARTE CATARINA MARIA,,https://lens.org/102-387-357-262-837,Patent Application,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C39/11;;A23L1/30;;A61K8/34;;A61K31/05;;A61Q19/02;;C07C37/00;;C07C37/68,,0,0,,,,ACTIVE
357,PL,T3,PL 1910257 T3,032-586-137-807-019,2014-07-31,2014,PL 06780204 T,2006-07-25,PT 10332605 A;;EP 06780204 A;;IB 2006052552 W,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,,https://lens.org/032-586-137-807-019,Patent Application,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,A61Q19/00;;A23L1/30;;A61K8/34;;A61K8/97;;A61Q17/00;;C07C37/00;;C07C39/11,,0,0,,,,PENDING
358,US,B2,US 8066881 B2,063-512-468-930-727,2011-11-29,2011,US 2096008 A,2008-01-28,PT 10332605 A;;IB 2006052552 W,2005-07-27,Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies,"A process of obtaining a natural, bioactive concentrate, rich on hydroxytyrosol, from olive tree residues and subproducts using clean technologies is presented. These technologies comprise supercritical fluid extraction, nanofiltration and reverse osmosis which are used individually or in an integrated mode. The natural extract comprises hydroxytyrosol at a minimum concentration of 15% (mass fraction) and a maximum concentration of 98% (mass fraction). The hydroxytyrosol-rich concentrate exhibits anti-oxidant, anti-microbial, anti-inflammatory and anti-carcinogenic activities, which are superior to the activities observed for isolated hydroxytyrosol in equivalent concentration. The hydroxytyrosol-rich concentrate can be prepared in the form of solid particles, as an aqueous solution, in an emulsion or as lipidic based nanoparticles. Industrial application includes the food, pharmaceutical and cosmetics industries.",DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,,https://lens.org/063-512-468-930-727,Granted Patent,yes,4,1,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,A61K36/63;;A61K36/00;;C02F1/44,210/637;;210/652;;424/725,3,1,103-582-254-869-134,10.1002/app.11626,"Allouche et al., Phenolic compounds with antioxidant activity from olive mill wastewaters, Journal de la Societe Chimique de Tunisie (2004), 6 (1), 33-43.;;Chan et al, Preparation and characterization of nanofiltration membranes fabricated from poly (amidesulfonamide), and their application in water-oil separation (Journal of applied polymer science, 87: 1803-1810, 2003.;;Skaltsounis, L., et al., ""Minos Project Process development for an integrated olive mill waste management recovering natural antioxidants and producing organic fertilizer,"" Internet Citation [Online] Apr. 2004, Retrieved from the Internet: URL:http://www.pharm.uoa.gr/minos/manualeng.pdf> [retrieved on Nov. 16, 2005].",ACTIVE
359,ES,T3,ES 2455999 T3,101-093-863-169-600,2014-04-21,2014,ES 06780204 T,2006-07-25,PT 10332605 A;;IB 2006052552 W,2005-07-27,Procedimiento de obtención de un concentrado natural rico en hidroxitirosol a partir de residuos y subproductos de olivo que usa tecnologías limpias,"Un procedimiento para la obtención de un concentrado natural rico en hidroxitirosol a partir de residuos y subproductos del olivo, que consiste en la siguiente etapas: (a) procesar los residuos sólidos y semisólidos procedentes del olivo mediante una extracción con agua o con mezclas hidroalcohólicas, (b) bien suministrar el extracto que contiene el hidroxitirosol y otros compuestos bioactivos procedentes del olivo directamente a una unidad de nanofiltración con un peso molecular de corte menor de 300 Da, o bien mezclar el extracto obtenido en la etapa (a) con las aguas vegetales de las moliendas de la oliva y centrifugar con objeto de eliminar las partículas y otros sólidos suspendidos, y suministrar el sobrenadante obtenido de la centrífuga a dicha unidad de nanofiltración, en el que dicho hidroxitirosol y otros compuestos bioactivos de bajo peso molecular son recuperados en una corriente de permeado de dicha unidad de nanofiltración, y (c) suministrar la corriente de permeado de dicha unidad de nanofiltración al compartimento de suministro de una unidad de ósmosis inversa, en el que dicho hidroxitirosol y otros compuestos bioactivos son retenidos y concentrados en una corriente de retenido.",MAGALHAES NUNES DA PONTE MANUEL LUIS DE;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,,https://lens.org/101-093-863-169-600,Granted Patent,no,0,1,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,A61Q19/00;;A23L1/30;;A61K8/34;;A61K8/97;;A61Q17/00;;C07C37/00;;C07C39/11,,0,0,,,,ACTIVE
360,EP,B1,EP 1910257 B1,077-299-375-678-348,2014-01-01,2014,EP 06780204 A,2006-07-25,IB 2006052552 W;;PT 10332605 A,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,DE MAGALHAES NUNES DA PONTE MANUEL LUIS;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDRA;;MORGADO MARQUES NUNES ANA VITAL;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAULO,"ZEYTON NUTRACEUTICALS, LDA, PT (2015-01-07);;ZEYTON NUTRACEUTICALS, LDA. (2014-06-11)",https://lens.org/077-299-375-678-348,Granted Patent,yes,3,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,A61Q19/00;;A23L1/30;;A61K8/34;;A61K8/97;;A61Q17/00;;C07C37/00;;C07C39/11,,1,0,,,"SKALTSOUNIS L ET AL: ""MINOS PROJECT Process development for an integrated olive mill waste management recovering natural antioxidants and producing organic fertilizer"" INTERNET CITATION, [Online] April 2004 (2004-04), XP002354663 Retrieved from the Internet: URL:http://www.pharm.uoa.gr/minos/manualen g.pdf> [retrieved on 2005-11-16]",ACTIVE
361,ZA,B,ZA 200800880 B,104-357-801-617-16X,2009-01-28,2009,ZA 200800880 A,2008-01-29,PT 10332605 A,2005-07-27,Methods of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies,,VITAL MORGADO MARQUES NUNES AN;;PAULO SEREJO GOULAO CRESPO JOA;;MARIA MARTINS DUARTE CATARINA;;LUIS CARDADOR DOS SANTOS JOSE;;MAGALHAES NUNES DA PONTE MANUE;;ALEXANDRA FIGUEIREDO MATIAS AN,LUIS CARDADOR DOS SANTOS JOSE;;LUIS DE MAGALHAES NUNES DA PONTE MANUEL;;ALEXANDRA FIGUEIREDO MATIAS ANA;;VITAL MORGADO MARQUES NUNES ANA;;PAULO SEREJO GOULAO CRESPO JOAO;;MARIA MARTINS DUARTE CATARINA,,https://lens.org/104-357-801-617-16X,Granted Patent,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,A23L/;;A61K/;;A61Q/;;C07C/,,0,0,,,,ACTIVE
362,PT,A,PT 103637 A,055-276-786-454-55X,2008-07-31,2008,PT 10363707 A,2007-01-09,PT 10363707 A,2007-01-09,SECADOR DE MADEIRAS ENERGETICAMENTE EFICIENTE,"O PRESENTE INVENTO DIZ RESPEITO A UM SECADOR DE MADEIRAS ENERGETICAMENTE EFICIENTE QUE FUNCIONA COM BASE NO APROVEITAMENTO DE CONDIÇÕES NATURAIS FAVORÁVEIS, COMO UM SISTEMA DE CIRCULAÇÃO DO AR EXTERIOR E AQUECIMENTO COM ENERGIA SOLAR, QUE DEPOIS É FEITO CIRCULAR POR CONVECÇÃO E POR VENTILAÇÃO FORÇADA POR MEIO DE VENTILADORES ELÉCTRICOS QUE VÃO INJECTAR O AR QUENTE ATRAVÉS DA UMA PILHA DE MADEIRA, PROMOVENDO DESTE MODO A SUA SECAGEM, ATRAVÉS DA LIBERTAÇÃO DA HUMIDADE EXISTENTE NA MADEIRA VERDE.",INETI INST NAC DE ENGENHARIA T,SANTOS JOSE ANTONIO DOS;;MARTINS MARIA JOAO ALMEIDA;;COSTA ARNALDO JORGE CRUZ;;LOUREIRO DAVID PEREIRA;;NOGUEIRA ANTONIO JULIO DUARTE;;RAMALHO ALVARO FERREIRA;;DUARTE CARLOTA REDOL;;PESTANA LUIS COSTA DA CAMARA;;ENOCH SANDRA CRISTINA ROSARIO,,https://lens.org/055-276-786-454-55X,Patent Application,no,0,0,1,1,0,,F26B3/28,,0,0,,,,INACTIVE
363,PT,B,PT 105914 B,003-903-000-819-750,2013-10-28,2013,PT 10591411 A,2011-10-06,PT 10591411 A,2011-10-06,UTILIZAÇÃO DE UM EXTRACTO DE BAGAÇO DE AZEITONA INIBIDOR DA ENZIMA ACETILCOLINESTERASE NO TRATAMENTO DE PERTURBAÇÕES COLINÉRGICAS,"A PRESENTE INVENÇÃO DIZ RESPEITO À APLICAÇÃO DE UM EXTRACTO DE BAGAÇO DE AZEITONA MAIORITARIAMENTE COMPOSTO POR HIDROXITIROSOL, COM ACTIVIDADE INIBIDORA DA ENZIMA ACETILCOLINESTERASE (ACHEI), PARA SER UTILIZADO COMO INIBIDOR DESTA ENZIMA NA PREVENÇÃO / TRATAMENTO DE DOENÇAS NEUROEGENERATIVAS / PERTURBAÇÕES COLINÉRGICAS. ESTE COMPREENDE UM EXTRACTO NATURAL NÃO TÓXICO, DO BAGAÇO DE AZEITONA EXTRACTADO, MAIORITARIAMENTE CONSTITUÍDO PELO COMPOSTO FENÓLICO HIDROXITIROSOL, PODENDO CONTER TIROSOL E SEUS DERIVADOS E DERIVADOS DO HIDROXITIROSOL, ENTRE OUTROS COMPOSTOS FENÓLICOS, OBTIDO DO BAGAÇO DE AZEITONA, SUBPRODUTO DA INDÚSTRIA DE PRODUÇÃO DO AZEITE. O REFERIDO EXTRACTO COMPREENDE UMA ACTIVIDADE ANTI-ACETILCOLINESTERÁSICA SUPERIOR À ACTIVIDADE DO HIDROXITIROSOL ISOLADO E PURIFICADO (PADRÃO) NA MESMA CONCENTRAÇÃO. ESTE EXTRACTO NATURAL NÃO TÓXICO MAIORITARIAMENTE CONSTITUÍDO POR HIDROXITIROSOL PODE SER UTILIZADO EM FORMULAÇÕES INDUSTRIAIS, NOMEADAMENTE PARA AS INDÚSTRIAS ALIMENTAR E/OU FARMACÊUTICA.",UNIV LISBOA;;NAC DE EN E GEOL LAB,RAUTER AMELIA PILAR GRASES SANTOS SILVA;;LOURENCO PEDRO MIGUEL LOPES;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;FALE PEDRO LUIS VIEIRA;;ROSEIRO LUISA BIVAR;;SERRALHEIRO MARIA LUISA MOURATO DE OLIVEIRA MARQUE,"UNIVERSIDADE DE LISBOA, PT (2014-07-29);;FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBO, PT (2014-12-31);;LABORATORIO NACIONAL DE ENERGIA E GEOLOGIA, PT (2014-12-31)",https://lens.org/003-903-000-819-750,Granted Patent,no,2,0,2,2,0,,A61K31/045;;A61P25/28,,7,6,038-217-506-910-375;;041-396-220-671-529;;086-095-111-200-676;;102-892-385-043-057;;007-007-466-025-573;;085-803-224-545-433,10.1016/j.jep.2006.04.010;;16737790;;10.1016/j.fct.2006.01.008;;16530907;;10.1016/j.amjhyper.2007.01.012;;17586406;;10.1152/ajpheart.00755.2006;;17172277;;10.1016/j.foodchem.2007.01.037;;21333710;;10.1016/j.neuint.2011.02.010,"Araújo MEM, et al., The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal, Journal of Ethnopharmacology, 20060101;;KarimaChakroun, ChristianSchulze, EddaThies, Arjan Geerlings, Roland Martin Neuroprotective properties of hydroxytyrosol – A natural phenol from olive oil, ISNI, 20100101;;Soni MG, Burdock GA, Christian MS, Bitler CM, Crea R. Safety assessment of aqueous olive pulp extract as an antioxidant or antimicrobial agent in foods. Food Chem Toxicol., 20060101;;Rodriguez-Rodriguez R, Herrera MD, de Sotomayor MA, Ruiz-Gutierrez V. Pomace olive oil improves endothelial function in spontaneously hypertensive rats by increasing endothelial nitric oxide synthase expression. Am J Hypertens., 20070101;;Rietjens SJ, Bast A, de Vente J, Haenen GR. The olive oil antioxidant hydroxytyrosol efficiently protects against the oxidative stress-induced impairment of the NObullet response of isolated rat aorta. Am J Physiol Heart Circ Physiol., 20070101;;M. Savarese, E. De Marco and R. Sacchi, Characterization of phenolic extracts from olives (Olea europaea cv. Pisciottana) by electrospray ionization mass spectrometry Food Chemistry Volume, 01050101;;Daccache A, Lion C, Sibille N, Gerard M, Slomianny C, Lippens G, Cotelle P. Oleuropein and derivatives from olives as Tau aggregation inhibitors. Neurochem Int., 20110101",ACTIVE
364,WO,A1,WO 2024/023382 A1,002-892-246-684-860,2024-02-01,2024,ES 2023070450 W,2023-07-13,ES 202230701 A,2022-07-29,SILICA MESOPOROUS NANOPARTICLES AND USE THEREOF FOR CAPTURING IMMUNOGLOBULINS,"The present invention relates to a silica mesoporous nanoparticle comprising a covalently bound protein G' or protein A, the composition comprising said nanoparticle, the use thereof for capturing, purifying, eliminating and/or isolating immunoglobulins, preferably IgG, as well as a method for purifying an immunoglobulin, methods for pre-treating samples in order to subsequently diagnose allergies, infections and/or autoimmune diseases in a patient, and said diagnostic methods.",SERVICIO ANDALUZ DE SALUD;;UNIV MALAGA,PARIS FERNANDEZ DE LA PUENTE JUAN LUIS;;FERNÁNDEZ DUARTE TAHIA DIANA;;MONTAÑEZ VEGA MARÍA ISABEL;;MAYORGA MAYORGA CRISTOBALINA;;TORRES JAÉN MARÍA JOSÉ,,https://lens.org/002-892-246-684-860,Patent Application,yes,0,0,2,2,2,A61K9/51;;B82Y5/00;;C01B33/12,C01B33/12;;A61K9/51;;B82Y5/00,,4,0,,,"HUANG SI, CHENG SI-YUAN, ZHANG SHU-YUAN, YAN YI-LUN, CAI SONG-LIANG, LI XIN-LE, ZHENG SHENG-RUN, FAN JUN, ZHANG WEI-GUANG: ""Protein A-mesoporous silica composites for chromatographic purification of immunoglobulin G"", NEW JOURNAL OF CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 44, no. 19, 18 May 2020 (2020-05-18), GB , pages 7884 - 7890, XP093135752, ISSN: 1144-0546, DOI: 10.1039/D0NJ00337A;;SALIMI KOUROUSH, USTA DUYGU DENIZ, KOÇER İLKAY, ÇELIK EDA, TUNCEL ALI: ""Protein A and protein A/G coupled magnetic SiO2 microspheres for affinity purification of immunoglobulin G"", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 111, 1 May 2018 (2018-05-01), NL , pages 178 - 185, XP093135753, ISSN: 0141-8130, DOI: 10.1016/j.ijbiomac.2018.01.019;;WEN QI ET AL.: ""Intramesoporous silica structure differentiating protein loading density"", MATERIALS LETTERS, vol. 75, 29 January 2012 (2012-01-29), Amsterdam, Nl, pages 102 - 106, XP028473530, ISSN: 0167-577X, DOI: 10.1016/j.matlet. 2012.01.12 8;;SHIN HYE-SEON, HWANG YONG-KYUNG, HUH SEONG: ""Facile Preparation of Ultra-Large Pore Mesoporous Silica Nanoparticles and Their Application to the Encapsulation of Large Guest Molecules"", APPLIED MATERIALS & INTERFACES, AMERICAN CHEMICAL SOCIETY, US, vol. 6, no. 3, 12 February 2014 (2014-02-12), US , pages 1740 - 1746, XP093135754, ISSN: 1944-8244, DOI: 10.1021/am404709w",PENDING
365,KR,A,KR 20180124847 A,028-560-341-404-313,2018-11-21,2018,KR 20187022321 A,2017-03-13,PT 10922916 A;;IB 2017051448 W,2016-03-11,"생분해성 요관 스텐트, 방법 및 이의 용도","본 발명은 항암약물을 포함하는 생분해성 요도 스텐트에 관한 것이고, 또한 채널, 즉 포유 동물의 요관, 예를 들어 요로 결석, 종양 형성 또는 수술에 의해 막힌 요관의 개방성을 보장하기 위해 사용될 수 있는 의약용 조성물에 관한 것이다. 본 발명에 개시된 생분해성 요도 스텐트(BUS)는 예기치 않게 항암약물의 적절한 방출을 허용하여 치료 기간을 연장시키고 치료의 효능을 증가시킨다.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONCALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTONIO;;RODRIGUES DE LIMA ESTEVAO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRE,,https://lens.org/028-560-341-404-313,Patent Application,no,0,2,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/16;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/04;;A61L31/14;;A61L31/18;;C08L83/06,,0,0,,,,DISCONTINUED
366,ES,T3,ES 2157060 T3,133-791-038-766-674,2001-08-01,2001,ES 97901516 T,1997-01-17,CU 1996010 A,1996-01-17,SISTEMA DE EXPRESION DE ANTIGENOS HETEROLOGOS COMO PROTEINAS DE FUSION.,"LA PRESENTE INVENCION SE REFIERE A LA BIOTECNOLOGIA Y A LA INGENIERIA GENETICA, ESPECIALMENTE A LA EXPRESION DE PROTEINAS HETEROLOGAS EN MICROORGANISMOS A TRAVES DE SU FUSION MEDIANTE LA APLICACION DE LA TECNOLOGIA DEL ADN RECOMBINANTE A LOS PEPTIDOS BACTERIANOS. LA PRESENTE INVENCION PROPORCIONA UN PROCEDIMIENTO EFICAZ PARA LA EXPRESION EN ESCHERICHIA COLI DE PROTEINAS HETEROLOGAS COMO POLIPEPTIDOS DE FUSION CON EL OBJETIVO DE OBTENER ESTAS CON UN ALTO GRADO DE PUREZA, EN CANTIDADES COMERCIALMENTE UTILES Y EN UNA FORMA APROPIADA PARA SU INCLUSION EN PREPARACIONES DE VACUNAS PREVISTAS PARA USO HUMANO. PARA ELLO, LO QUE SE UTILIZA ESENCIALMENTE ES UNA SECUENCIA ESTABILIZANTE DERIVADA DE LOS 47 PRIMEROS AMINOACIDOS DEL ANTIGENO P64K DE NEISSERIA MENINGITIDIS B:4:P1.15. EN PARTICULAR, SE UTILIZA UN PLASMIDO RECOMBINANTE QUE CONTIENE DICHA SECUENCIA BAJO EL CONTROL DEL PROMOTOR DEL TRIPTOFANO DE E. COLI Y DEL TERMINADOR DE LA TRANSCRIPCION DEL FAGO T4, INCLUYENDO LOS SITIOS DE RESTRICCION, QUEPROPORCIONA LA CLONACION EN FASE DE FRAGMENTOS DE ADN QUE CODIFICAN PARA LOS POLIPEPTIDOS DE INTERES. EL PROCEDIMIENTO DE LA INVENCION ES APLICABLE A LA INDUSTRIA FARMACEUTICA PARA EL DESARROLLO DE SISTEMAS DIAGNOSTICOS, PREPARACIONES DE VACUNA Y EN CUALQUIER SITUACION DONDE SE REQUIERA PARA OBTENER ELEVADAS CANTIDADES DE PROTEINAS HETEROLOGAS COMO POLIPEPTIDOS DE FUSION EN E. COLI.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA,,https://lens.org/133-791-038-766-674,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
367,PT,A,PT 105914 A,063-767-146-667-756,2013-04-08,2013,PT 10591411 A,2011-10-06,PT 10591411 A,2011-10-06,UTILIZAÇÃO DE UM EXTRACTO DE BAGAÇO DE AZEITONA INIBIDOR DA ENZIMA ACETILCOLINESTERASE NO TRATAMENTO DE PERTURBAÇÕES COLINÉRGICAS,"A PRESENTE INVENÇÃO DIZ RESPEITO À APLICAÇÃO DE UM EXTRACTO DE BAGAÇO DE AZEITONA MAIORITARIAMENTE COMPOSTO POR HIDROXITIROSOL, COM ACTIVIDADE INIBIDORA DA ENZIMA ACETILCOLINESTERASE (ACHEI), PARA SER UTILIZADO COMO INIBIDOR DESTA ENZIMA NA PREVENÇÃO / TRATAMENTO DE DOENÇAS NEUROEGENERATIVAS / PERTURBAÇÕES COLINÉRGICAS. ESTE COMPREENDE UM EXTRACTO NATURAL NÃO TÓXICO, DO BAGAÇO DE AZEITONA EXTRACTADO, MAIORITARIAMENTE CONSTITUÍDO PELO COMPOSTO FENÓLICO HIDROXITIROSOL, PODENDO CONTER TIROSOL E SEUS DERIVADOS E DERIVADOS DO HIDROXITIROSOL, ENTRE OUTROS COMPOSTOS FENÓLICOS, OBTIDO DO BAGAÇO DE AZEITONA, SUBPRODUTO DA INDÚSTRIA DE PRODUÇÃO DO AZEITE. O REFERIDO EXTRACTO COMPREENDE UMA ACTIVIDADE ANTI-ACETILCOLINESTERÁSICA SUPERIOR À ACTIVIDADE DO HIDROXITIROSOL ISOLADO E PURIFICADO (PADRÃO) NA MESMA CONCENTRAÇÃO. ESTE EXTRACTO NATURAL NÃO TÓXICO MAIORITARIAMENTE CONSTITUÍDO POR HIDROXITIROSOL PODE SER UTILIZADO EM FORMULAÇÕES INDUSTRIAIS, NOMEADAMENTE PARA AS INDÚSTRIAS ALIMENTAR E/OU FARMACÊUTICA.",UNIV LISBOA;;NAC DE EN E GEOL LAB,RAUTER AMELIA PILAR GRASES SANTOS SILVA;;LOURENCO PEDRO MIGUEL LOPES;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;FALE PEDRO LUIS VIEIRA;;ROSEIRO LUISA BIVAR;;SERRALHEIRO MARIA LUISA MOURATO DE OLIVEIRA MARQUE,"UNIVERSIDADE DE LISBOA, PT (2014-07-29);;FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBO, PT (2014-12-31);;LABORATORIO NACIONAL DE ENERGIA E GEOLOGIA, PT (2014-12-31)",https://lens.org/063-767-146-667-756,Patent Application,no,0,2,2,2,0,,A61K31/045;;A61P25/28,,0,0,,,,ACTIVE
368,EP,C0,EP 3426314 C0,120-463-386-823-01X,2023-06-07,2023,EP 17716635 A,2017-03-13,PT 10922916 A;;IB 2017051448 W,2016-03-11,"BIODEGRADABLE URETERAL STENTS, METHODS AND USES THEREOF",,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEER (2019-04-24),https://lens.org/120-463-386-823-01X,Unknown,no,0,0,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/04;;A61L31/10;;A61L31/16;;A61L31/18,,0,0,,,,ACTIVE
369,ES,A1,ES 2959709 A1,130-851-004-618-035,2024-02-27,2024,ES 202230701 A,2022-07-29,ES 202230701 A,2022-07-29,Nanopartículas mesoporosas de sílice y su uso en la captación de inmunoglobulinas,,SERVICIO ANDALUZ DE SALUD;;UNIV MALAGA,PARIS FERNANDEZ DE LA PUENTE JUAN LUIS;;FERNANDEZ DUARTE TAHIA DIANA;;MONTANEZ VEGA MARIA ISABEL;;MAYORGA MAYORGA CRISTOBALINA;;TORRES JAEN MARIA JOSE,,https://lens.org/130-851-004-618-035,Patent Application,no,0,0,2,2,0,A61K9/51;;B82Y5/00;;C01B33/12,C01B33/12;;A61K9/51;;B82Y5/00,,4,0,,,"HUANG S ET AL. Protein A-mesoporous silica composites for chromatographic purification of immunoglobulin G. New Journal of Chemistry 20200521 Royal Society of Chemistry gbr. , 21/05/2020, Vol. 44, Páginas 7884 - 7890 ISSN 1144-0546 (print) ISSN 1369-9261 (electronic), (DOI: doi:10.1039/d0nj00337a) página 7885, columna izquierda, segundo párrafo, último párrafo; página, 7885, columna derecha, tercer párrafo; página 7886, columna izquierda, segundo párrafo; página7887, columna izquierda, segundo, tercer, último párrafos; página 7889, columna derecha, último párrafo; figura 1.;;SALIMI K ET AL. Protein A and protein A/G coupled magnetic SiO2 microspheres for affinity purification of immunoglobulin G. International Journal of Biological Macromolecules May 2018 Elsevier B.V. Netherlands. , 30/04/2018, Vol. 111, Páginas 178 - 185 ISSN 0141-8130 (print), (DOI: doi:10.1016/j.ijbiomac.2018.01.019) página 178, columna derecha, último párrafo- página 179, columna izquierda, primer párrafo; página 179, columna izquierda, tercer párrafo; página 179, columna derecha, segundo, último párrafo; página 184, columna derecha último párrafo.;;WEN QI ET AL. Intramesoporous silica structure differentiating protein loading density. Materials Letters, 20120129 ELSEVIER, AMSTERDAM, NL. , 29/01/2012, Vol. 75, Páginas 102 - 106 ISSN 0167-577X, (DOI: doi:10.1016/j.matlet.2012.01.128) página 102, columna izquierda, primer párrafo; página 102, columna derecha, primer párrafo y página 104, columna izquierda, segundo párrafo.;;SHIN H-S ET AL. Facile preparation of ultra-large pore mesoporous silica nanoparticles and their application to the encapsulation of large guest molecules. ACS Applied Materials and Interfaces 20140212 American Chemical Society usa. , 12/02/2014, Vol. 6, Páginas 1740 - 1746 ISSN 1944-8244 (print) ISSN 1944-8252 (electronic), (DOI: doi:10.1021/am404709w) página 1740, columna derecha, segundo párrafo; página 1741, columna izquierda, último párrafo; resumen.",PENDING
370,CN,A,CN 109069702 A,142-659-545-456-652,2018-12-21,2018,CN 201780013906 A,2017-03-13,PT 10922916 A;;IB 2017051448 W,2016-03-11,"BIODEGRADABLE URETERAL STENTS, METHODS AND USES THEREOF","The present disclosure relates to biodegradable ureteral stents comprising an anti-cancer drug, and to a composition for use in medicine that may be used to ensure patency of a channel, namely a mammal ureter, for example, an obstructed ureter by a urinary stone, neoplasia or by a surgical procedure. The biodegradable ureteral stents (BUS) disclosed in the present disclosure unexpectedly allow a proper release of anti-cancer drugs, thus extending the duration of the treatment and increasing the efficacy of the treatment.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH AND THERAPIES A4TEC,GONCALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTONIO;;RODRIGUES DE LIMA ESTEVAO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRE,,https://lens.org/142-659-545-456-652,Patent Application,no,2,1,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/04;;A61L31/10;;A61L31/16;;A61L31/18,,5,4,011-044-344-133-151;;001-591-775-469-466;;009-016-719-741-779;;066-724-404-458-295,26392243;;10.1016/j.ijpharm.2015.08.040;;10.1002/jbm.b.33237;;24965000;;23958902;;10.1016/j.jconrel.2013.08.010;;10.1038/nrurol.2014.340;;25534997,"LIHONG FAN ET AL.: ""Preparation and Characterization of Alginate/Gelatin Blend Fibers"", 《JOURNAL OF APPLIED POLYMER SCIENCE》;;ALEXANDRE A. BARROSA ET AL.: ""Ketoprofen-eluting biodegradable ureteral stents by CO2 impregnation:In vitro study"", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》;;ALEXANDRE A. BARROS ET AL.: ""Bioresorbable ureteral stents from natural origin polymers"", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B：APPLIED BIOMATERIALS》;;MOHSIN SHAIKH ET AL.: ""Non-vascular drug eluting stents as localized controlled drug delivery platform: Preclinical and clinical experience"", 《JOURNAL OF CONTROLLED RELEASE》;;DIRK LANGE ET AL.: ""Ureteral stent-associated complications-where we are and where we are going"", 《NATURE REVIEWS UROLOGY》",DISCONTINUED
371,WO,A1,WO 2017/153973 A1,071-415-736-345-408,2017-09-14,2017,IB 2017051448 W,2017-03-13,PT 10922916 A,2016-03-11,"BIODEGRADABLE URETERAL STENTS, METHODS AND USES THEREOF","The present disclosure relates to biodegradable ureteral stents comprising an anti-cancer drug, and to a composition for use in medicine that may be used to ensure patency of a channel, namely a mammal ureter, for example, an obstructed ureter by a urinary stone, neoplasia or by a surgical procedure. The biodegradable ureteral stents (BUS) disclosed in the present disclosure unexpectedly allow a proper release of anti-cancer drugs, thus extending the duration of the treatment and increasing the efficacy of the treatment.",ASS FOR THE ADVANCEMENT OF TISSUE ENG AND CELL BASED TECH AND THERAPIES - A4TEC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ,,https://lens.org/071-415-736-345-408,Patent Application,yes,2,0,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/04;;A61L31/10;;A61L31/16;;A61L31/18,,40,38,011-044-344-133-151;;009-016-719-741-779;;001-591-775-469-466;;066-724-404-458-295;;031-292-746-704-939;;045-835-523-103-163;;035-541-420-302-657;;069-523-146-059-141;;011-044-344-133-151;;001-591-775-469-466;;087-149-056-157-405;;068-675-343-065-598;;157-267-722-587-752;;092-527-104-610-355;;064-023-202-305-501;;013-526-081-457-094;;060-337-406-305-876;;015-819-742-902-08X;;045-042-573-552-688;;005-807-629-066-285;;105-571-226-655-517;;086-718-888-684-911;;017-963-868-860-54X;;006-555-449-698-312;;066-724-404-458-295;;039-812-918-159-410;;016-497-913-211-484;;005-131-933-206-759;;010-942-778-503-066;;109-060-146-180-292;;000-689-594-021-506;;077-058-028-041-476;;009-016-719-741-779;;070-818-972-537-153;;123-255-240-746-974;;085-891-707-245-091;;050-405-107-391-048;;036-688-755-259-462,26392243;;10.1016/j.ijpharm.2015.08.040;;23958902;;10.1016/j.jconrel.2013.08.010;;10.1002/jbm.b.33237;;24965000;;10.1038/nrurol.2014.340;;25534997;;26142248;;10.1016/j.ijpharm.2015.06.038;;23007718;;10.1007/s00345-012-0949-3;;10.1016/j.urolonc.2010.07.016;;20884249;;10.1016/j.eururo.2013.06.003;;23827737;;26392243;;10.1016/j.ijpharm.2015.08.040;;10.1002/jbm.b.33237;;24965000;;10.1002/app.1992.070460204;;23013232;;10.1021/mp300231d;;10.1039/c4tb00863d;;32261866;;10.1002/mame.201400369;;10.1039/a906486i;;10.1016/s1569-9056(14)60027-0;;15380633;;10.1016/j.jconrel.2004.06.020;;10.1111/j.1464-410x.2008.07571.x;;18384637;;10.1016/j.juro.2009.05.011;;19616245;;10.1016/s1004-9541(11)60159-6;;11790492;;10.1016/s0378-5173(01)00905-x;;10.1016/j.jconrel.2012.02.010;;22366546;;10.1007/978-94-011-3929-8_12;;10.1016/j.juro.2009.11.035;;20092835;;10.1038/nrurol.2014.340;;25534997;;10.1016/j.ejps.2015.03.006;;25772330;;10.1111/j.1464-410x.2011.10903.x;;22313688;;11025695;;10.1016/s0022-5347(05)67019-x;;10.1097/00005392-200011000-00014;;10.1016/j.jconrel.2010.07.005;;21529581;;10.1007/s13277-014-2190-8;;25833690;;11371932;;10.1097/00005392-200106000-00074;;10.1016/s0022-5347(05)66298-2;;22328315;;10.1002/pst.426;;23958902;;10.1016/j.jconrel.2013.08.010;;10.1021/je049551l;;10.1016/s0378-3812(97)00056-3;;10.1039/c1ra00070e;;10.1201/9780203021378;;10.1002/mabi.201400416;;25504255,"BARROS ALEXANDRE A ET AL: ""Ketoprofen-eluting biodegradable ureteral stents by CO2impregnation:In vitro study"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 495, no. 2, 21 September 2015 (2015-09-21), pages 651 - 659, XP029292185, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2015.08.040;;SHAIKH MOHSIN ET AL: ""Non-vascular drug eluting stents as localized controlled drug delivery platform: Preclinical and clinical experience"", JOURNAL OF CONTROLLED RELEASE, vol. 172, no. 1, 17 August 2013 (2013-08-17), pages 105 - 117, XP028772919, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2013.08.010;;ALEXANDRE A. BARROS ET AL: ""Bioresorbable ureteral stents from natural origin polymers"", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART B: APPLIED BIOMATERIALS, vol. 103, no. 3, 26 June 2014 (2014-06-26), US, pages 608 - 617, XP055223832, ISSN: 1552-4973, DOI: 10.1002/jbm.b.33237;;DIRK LANGE ET AL: ""Ureteral stent-associated complications?where we are and where we are going"", NATURE REVIEWS. UROLOGY, vol. 12, no. 1, 23 December 2014 (2014-12-23), US, pages 17 - 25, XP055383632, ISSN: 1759-4812, DOI: 10.1038/nrurol.2014.340;;AROSO, I.M; CRAVEIRO, R.; ROCHA, A.; DIONISIO, M.; BARREIROS, S.; REIS, R.L.; PAIVA, A.; DUARTE, A.R.C.: ""Design of controlled release systems for THEDES-Therapeutic deep eutectic solvents, using supercritical fluid technology"", INT. J. PHARM., vol. 492, 2015, pages 73 - 9, XP029258597, DOI: doi:10.1016/j.ijpharm.2015.06.038;;AUDENET, F.; TRAXER, O.; BENSALAH, K.; ROUPRET, M.: ""Upper urinary tract instillations in the treatment of urothelial carcinomas: A review of technical constraints and outcomes"", WORLD J. UROL, vol. 31, 2013, pages 45 - 52;;AUDENET, F.; YATES, D.R.; CUSSENOT, O.; ROUPRET, M.: ""The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC"", UROL. ONCOL., vol. 31, 2013, pages 407 - 13;;BABJUK, M.; BURGER, M.; ZIGEUNER, R.; SHARIAT, S.F.; VAN RHIJN, B.W.G.; COMPERAT, E.; SYLVESTER, R.J.; KAASINEN, E.; BOHLE, A.; PA: ""EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013"", EUR. UROL., vol. 64, 2013, pages 639 - 53;;BARROS, A.A.; OLIVEIRA, C.; REIS, R.L.; LIMA, E.; DUARTE, A.R.C.: ""Ketoprofen-eluting biodegradable ureteral stents by C02 impregnation: In vitro study"", INT. J. PHARM., vol. 495, 2015, pages 651 - 9, XP029292185, DOI: doi:10.1016/j.ijpharm.2015.08.040;;BARROS, A.A.; RITA, A.; DUARTE, C.; PIRES, R.A.; SAMPAIO-MARQUES, B.; LUDOVICO, P.; LIMA, E.; MANO, J.F.; REIS, R.L.: ""Bioresorbable ureteral stents from natural origin polymers"", J. BIOMED. MATER. RES. PART B APPL. BIOMATER., vol. 103, 2015, pages 608 - 617, XP055223832, DOI: doi:10.1002/jbm.b.33237;;BERENS, A.R; HUVARD, G.S.; KORSMEYER, R.W.; KUNIG, F.W.: ""Application of compressed carbon dioxide in the incorporation of additives into polymers"", J. APPL. POLYM. SCI., vol. 46, 1992, pages 231 - 242;;BROWNE, S.; FONTANA, G.; RODRIGUEZ, B.J.; PANDIT, A.: ""A protective extracellular matrix-based gene delivery reservoir fabricated by electrostatic charge manipulation"", MOL. PHARM., vol. 9, 2012, pages 3099 - 106;;BROWNE, S.; PANDIT, A.: ""Multi-modal delivery of therapeutics using biomaterial scaffolds"", J. MATER. CHEM. B, vol. 2, 2014, pages 6692 - 6707;;CHAMPEAU, M.; THOMASSIN, J.-M.; TASSAING, T.; JEROME, C.: ""Drug Loading of Sutures by Supercritical C02 Impregnation: Effect of Polymer"", DRUG INTERACTIONS AND THERMAL TRANSITIONS. MACROMOL. MATER. ENG., vol. 300, 2015, pages 596 - 610, XP055193663, DOI: doi:10.1002/mame.201400369;;COOPER, A.I.: ""Polymer synthesis and processing using supercritical carbon dioxide"", J. MATER. CHEM., vol. 10, 2000, pages 207 - 234, XP055112373, DOI: doi:10.1039/a906486i;;D.; L.; M.; M.; M.; K.; M.; S.: ""Hydrogel based drug retention system for the treatment of upper tract urothelial carcinoma"", EUR. UROL., vol. 13, 2014, pages E25 - E25A;;ELVIRA, C.; FANOVICH, A.; FERN??NDEZ, M.; FRAILE, J.; SAN ROM??N, J.; DOMINGO, C.: ""Evaluation of drug delivery characteristics of microspheres of PMMA-PCL-cholesterol obtained by supercritical-CO 2 impregnation and by dissolution-evaporation techniques"", J. CONTROL. RELEASE, vol. 99, 2004, pages 231 - 240, XP004569544, DOI: doi:10.1016/j.jconrel.2004.06.020;;HADASCHIK, B.A.; TER BORG, M.G.; JACKSON, J.; SOWERY, R.D.; SO, A.I.; BURT, H.M.; GLEAVE, M.E.: ""Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer"", BJU INT., vol. 101, 2008, pages 1347 - 1355;;HELLENTHAL, N.J.; SHARIAT, S.F.; MARGULIS, V.; KARAKIEWICZ, P.I.; ROSCIGNO, M.; BOLENZ, C.; REMZI, M.; WEIZER, A.; ZIGEUNER, R.; B: ""Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration"", J. UROL., vol. 182, 2009, pages 900 - 6, XP026447990;;JIAO, Z.; CHEN, Z.; WU, Y.; MA, S.: ""Determination of Paclitaxel Solubility in Carbon Dioxide Using Quartz Crystal Microbalance"", CHINESE J. CHEM. ENG., vol. 19, 2011, pages 227 - 231;;KAZARIAN, S.G.: ""Polymer Processing with Supercritical Fluids"", POLYM. SCI., vol. 42, 2000, pages 78 - 101, XP002739176;;KAZARIAN, S.G.; MARTIROSYAN, G.G.: ""Spectroscopy of polymer/drug formulations processed with supercritical fluids: in situ ATR-IR and Raman study of impregnation of ibuprofen into PVP"", INT. J. PHARM., vol. 232, 2002, pages 81 - 90, XP027429878, DOI: doi:10.1016/S0378-5173(01)00905-X;;KHAN, W.; FARAH, S.; DOMB, A.J.: ""Drug eluting stents: developments and current status"", J. CONTROL. RELEASE, vol. 161, 2012, pages 703 - 12, XP028492695, DOI: doi:10.1016/j.jconrel.2012.02.010;;KIKIC, I.; SIST, P.: ""Applications of Supercritical Fluids to Pharmaceuticals: Controlled Drug Release Systems BT - Supercritical Fluids: Fundamentals and Applications"", 2000, SPRINGER NETHERLANDS, pages: 291 - 306;;KIKIC, I.; VECCHIONE, F.: ""Supercritical impregnation of polymers"", CURR. OPIN. SOLID STATE MATER. SCI., vol. 7, 2003, pages 399 - 405, XP055131937, DOI: doi:10.1016/j.cossms.2003.09.001;;KRAMBECK, A.E.; WALSH, R.S.; DENSTEDT, J.D.; PREMINGER, G.M.; LI, J.; EVANS, J.C.; LINGEMAN, J.E.: ""A Novel Drug Eluting Ureteral Stent: A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of a Ketorolac Loaded Ureteral Stent"", J. UROL., vol. 183, 2010, pages 1037 - 1043, XP026938397, DOI: doi:10.1016/j.juro.2009.11.035;;LANGE, D.; BIDNUR, S.; HOAG, N.; CHEW, B.H.: ""Ureteral stent-associated complications[mdash]where we are and where we are going"", NAT REV UROL, vol. 12, 2015, pages 17 - 25, XP055383632, DOI: doi:10.1038/nrurol.2014.340;;LU, S.; NEOH, K.G.; KANG, E.-T.; MAHENDRAN, R.; CHIONG, E.: ""Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy"", EUR. J. PHARM. SCI., vol. 72, 2015, pages 57 - 68, XP029124475, DOI: doi:10.1016/j.ejps.2015.03.006;;MENDEZ-PROBST, C.E.; GONEAU, L.W.; MACDONALD, K.W.; NOTT, L.; SENEY, S.; ELWOOD, C.N.; LANGE, D.; CHEW, B.H.; DENSTEDT, J.D.; CADI: ""The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial"", BJU INT., vol. 110, 2012, pages 749 - 754, XP055370006, DOI: doi:10.1111/j.1464-410X.2011.10903.x;;MUNOZ, J.J.; ELLISON, L.M.: ""Upper tract urothelial neoplasms: incidence and survival during the last 2 decades"", J. UROL., vol. 164, 2000, pages 1523 - 1525, XP005553928, DOI: doi:10.1016/S0022-5347(05)67019-X;;NUNES, A. V; RODRIGUEZ-ROJO, S.; ALMEIDA, A.P.; MATIAS, A.A.; REGO, D.; SIMPLICIO, A.L.; BRONZE, M.R.; COCERO, M.J.; DUARTE, C.M.M: ""NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer"", J. CONTROL. RELEASE, vol. 148, 2010, pages ELL-2;;PAPADOPOULOS, E.; YOUSEF, G.; SCORILAS, A.: ""Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes"", TUMOR BIOL., vol. 36, 2015, pages 3197 - 3207, XP036218273, DOI: doi:10.1007/s13277-014-2190-8;;PU, Y.S.; CHEN, J.; HUANG, C.Y.; GUAN, J.Y.; LU, S.H.; HOUR, T.C.: ""Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells"", J. UROL., vol. 165, 2001, pages 2082 - 5, XP005544912, DOI: doi:10.1016/S0022-5347(05)66298-2;;SEBAUGH, J.L.: ""Guidelines for accurate EC50/IC50 estimation"", PHARM. STAT., vol. 10, 2011, pages 128 - 134, XP055254257, DOI: doi:10.1002/pst.426;;SHAIKH, M.; KICHENADASSE, G.; CHOUDHURY, N.R.; BUTLER, R.; GARG, S.: ""Non-vascular drug eluting stents as localized controlled drug delivery platform: preclinical and clinical experience"", J. CONTROL. RELEASE, vol. 172, 2013, pages 105 - 17, XP028772919, DOI: doi:10.1016/j.jconrel.2013.08.010;;SULEIMAN, D.; ANTONIO EST??VEZ, L.; PULIDO, J.C.; GARC??A, J.E.; MOJICA, C.: ""Solubility of anti-inflammatory, anti-cancer, and anti-HIV drugs in supercritical carbon dioxide"", J. CHEM. ENG. DATA, 2005;;VANDANA, V.; TEJA, A.S.: ""The solubility of paclitaxel in supercritical C02 and N20"", FLUID PHASE EQUILIB, vol. 135, 1997, pages 83 - 87;;YODA, S.; SATO, K.; OYAMA, H.T.: ""Impregnation of paclitaxel into poly(dl-lactic acid) using high pressure mixture of ethanol and carbon dioxide"", RSC ADV., vol. 1, 2011, pages 156 - 162;;YORK, P.; KOMPELLA, U.B.; SHEKUNOV, B.Y.: ""Drugs and the Pharmaceutical Sciences"", 2004, TAYLOR & FRANCIS, article ""Supercritical Fluid Technology for Drug Product Development"";;YU, Q.; ZHANG, J.; ZHANG, G.; GAN, Z.: ""Synthesis and Functions of Well-defined Polymer-drug Conjugates as Efficient Nanocarriers for Intravesical Chemotherapy of Bladder Cancera"", MACROMOL. BIOSCI., vol. 15, 2015, pages 509 - 520",PENDING
372,PT,A,PT 106174 A,160-455-430-643-421,2013-08-26,2013,PT 10617412 A,2012-02-24,PT 10617412 A,2012-02-24,ESTRUTURA TRIDIMENSIONAL POROSA QUE PERMITE A VASCULARIZAÇÃO SEGMENTAR PARA A ENGENHARIA DE TECIDOS COMPLEXOS E MÉTODOS DE PRODUÇÃO DA MESMA,"A PRESENTE INVENÇÃO REFERE-SE AO DESENVOLVIMENTO E MÉTODO(S) PARA A PRODUÇÃO DE ESTRUTURA(S) TRIDIMENSIONAL(AIS) POROSA(S) E IMPLANTÁVEL(EIS) QUE PERMITA(M) CONTROLAR O CRESCIMENTO CELULAR, A VASCULARIZAÇÃO SEGMENTAR E A INERVAÇÃO. A(S) ESTRUTURA(S) TRIDIMENSIONAL(AIS) POROSA(S) INCLUI(EM) A MATRIZ POLIMÉRICA POROSA DE SUPORTE E UM GEL OU HIDROGEL (EIS), SENDO QUE A GELIFICAÇÃO DO GEL (NA QUAL A GELIFICAÇÃO PODE OCORRER IN SITU POR MEIO IÓNICO E FOTO-RETICULAÇÃO). A(S) ESTRUTURA(S) TRIDIMENSIONAL(AIS) POROSA(S) PODE(M) SER UTILIZADA(S) COMO IMPLANTE. ADICIONALMENTE A PRESENTE INVENÇÃO DESCREVE O MÉTODO DE PROCESSAMENTO PARA O FABRICO DA (S) ESTRUTURA (S) DE SUPORTE IMPLANTÁVEL (EIS) E AS SUAS DIFERENTES APLICAÇÕES, INCLUINDO O FABRICO DE IMPLANTES PARCIAIS OU TOTAIS DO MENISCO PARA ENGENHARIA DE TECIDOS E COMO SUPORTES BI-OU MULTI-CAMADAS PARA O TRATAMENTO DE DEFEITOS OSTEOCONDRAIS. O(S) IMPLANTE(S) DESCRITO(S) SÃO PARTICULARMENTE ADEQUADOS PARA O TRATAMENTO DE DESORDENS DEGENERATIVAS OU LESÕES, EM QUE A RESPOSTA NATURAL DO PACIENTE NÃO PERMITE REPARAR O DEFEITO.",ASS FOR THE ADVANCEMENT OF TISSUE ENGINEERING CELL BASED TECHNOLOGIES & THERAPIES A4TEC ASSOCIACAO,REIS RUI LUIS GONCALVES DOS;;CORREIA JOANA CATARINA DA SILVA;;MENDES JOAO DUARTE COELHO DO SAMEIRO ESPREGUEIRA;;YAN LEPING;;OLIVEIRA ANA LEITE DE ALMEIDA MONTEIRO DE;;OLIVEIRA JOAQUIM MIGUEL ANTUNES DE;;PEREIRA HELDER MIGUEL DUARTE,,https://lens.org/160-455-430-643-421,Patent Application,no,1,0,2,2,0,,A61L27/52,,3,3,133-160-850-132-911;;113-405-751-074-928;;018-923-826-133-547,17482309;;10.1016/j.addr.2007.03.012;;21604382;;10.1002/term.363;;10.1016/j.actbio.2011.09.037;;22019518,"MALAFAYA, P ET AL, Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications, Advanced Drug Delivery Reviews, 59, 207-233, 20070406;;SILVA-CORREIA J, ET AL, Gellan gum-based hydrogels for intervertebral disc tissue-engineering applications, Journal of Tissue Engineering and Regenerative Medicine, 5, e97.e107, 20101229;;YAN L ET AL, Macro/microporous silk fibroin scaffolds with potential for articular cartilage and meniscus tissue engineering applications, Acta Biomaterialia, 00080101",ACTIVE
373,EP,B1,EP 3426314 B1,120-087-384-888-331,2023-06-07,2023,EP 17716635 A,2017-03-13,PT 10922916 A;;IB 2017051448 W,2016-03-11,"BIODEGRADABLE URETERAL STENTS, METHODS AND USES THEREOF",,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEER (2019-04-24),https://lens.org/120-087-384-888-331,Granted Patent,yes,2,0,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/04;;A61L31/10;;A61L31/16;;A61L31/18,,4,0,,,"BARROS ALEXANDRE A ET AL: ""Ketoprofen-eluting biodegradable ureteral stents by CO2impregnation:In vitro study"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 495, no. 2, 21 September 2015 (2015-09-21), pages 651-659, XP029292185, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2015.08.040 cited in the application;;SHAIKH MOHSIN ET AL: ""Non-vascular drug eluting stents as localized controlled drug delivery platform: Preclinical and clinical experience"", JOURNAL OF CONTROLLED RELEASE, vol. 172, no. 1, 17 August 2013 (2013-08-17), pages 105-117, XP028772919, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2013.08.010 cited in the application;;ALEXANDRE A. BARROS ET AL: ""Bioresorbable ureteral stents from natural origin polymers"", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART B: APPLIED BIOMATERIALS, vol. 103, no. 3, 26 June 2014 (2014-06-26) , pages 608-617, XP55223832, US ISSN: 1552-4973, DOI: 10.1002/jbm.b.33237 cited in the application;;DIRK LANGE ET AL: ""Ureteral stent-associated complications?where we are and where we are going"", NATURE REVIEWS. UROLOGY, vol. 12, no. 1, 23 December 2014 (2014-12-23), pages 17-25, XP55383632, US ISSN: 1759-4812, DOI: 10.1038/nrurol.2014.340",ACTIVE
374,EP,A1,EP 3426314 A1,058-328-798-888-938,2019-01-16,2019,EP 17716635 A,2017-03-13,PT 10922916 A;;IB 2017051448 W,2016-03-11,"BIODEGRADABLE URETERAL STENTS, METHODS AND USES THEREOF",,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEER (2019-04-24),https://lens.org/058-328-798-888-938,Patent Application,yes,0,0,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/04;;A61L31/10;;A61L31/16;;A61L31/18,,0,0,,,,ACTIVE
375,KR,A,KR 20220044220 A,111-769-741-740-899,2022-04-06,2022,KR 20227009623 A,2017-03-13,PT 10922916 A;;KR 20187022321 A;;IB 2017051448 W,2016-03-11,BIODEGRADABLE URETERAL STENTS METHODS AND USES THEREOF,"생분해성 요도 스텐트, 방법 및 이의 용도 본 발명은 항암약물을 포함하는 생분해성 요도 스텐트에 관한 것이고, 또한 채널, 즉 포유 동물의 요관, 예를 들어 요로 결석, 종양 형성 또는 수술에 의해 막힌 요관의 개방성을 보장하기 위해 사용될 수 있는 의약용 조성물에 관한 것이다. 본 발명에 개시된 생분해성 요도 스텐트(BUS)는 예기치 않게 항암약물의 적절한 방출을 허용하여 치료 기간을 연장시키고 치료의 효능을 증가시킨다.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONCALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTONIO;;RODRIGUES DE LIMA ESTEVAO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRE,,https://lens.org/111-769-741-740-899,Patent Application,no,0,0,10,10,0,A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/16;;A61L31/18;;C08L83/06;;A61L2300/416;;A61P13/00;;A61P35/00;;A61P43/00;;A61P13/00;;A61P35/00;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L31/18;;C08L83/06;;A61F2002/048;;A61F2250/0068;;A61L2300/416;;A61F2/04;;A61F2002/048;;A61K31/337;;A61K31/704;;A61K31/7068;;A61K47/36;;A61K47/42;;A61L31/041;;A61L31/148;;A61L31/16;;A61L31/18;;A61L2300/416,A61L31/16;;A61F2/04;;A61K31/337;;A61K47/36;;A61K47/42;;A61L31/04;;A61L31/10;;A61L31/14;;A61L31/18;;A61P35/00;;C08L83/06,,0,0,,,,ACTIVE
376,US,B2,US 8106250 B2,196-447-949-073-855,2012-01-31,2012,US 51037109 A,2009-07-28,BR PI0802431 A,2008-07-28,Process for removing silicon compounds from hydrocarbon streams,"The present invention relates to a process for removing organic silicon compounds from hydrocarbon streams by contact with an adsorbent and hydrogen. The adsorbent is composed of lamellar double hydroxides and group VI-B or group VIII hydrogenating metal. More specifically, the process of the present invention involves a stage of activation for formation of the lamellar double hydroxide, and maintaining the phase of lamellar double hydroxide by adding water.",DE ALMEIDA RAFAEL MENEGASSI;;RABELLO CARLOS RENE KLOTZ;;DUARTE MARCUS VINICIUS EIFFLE;;MONTEIRO DE SOUZA GUILHERME LUIS;;LESLIE LEGAL REPRESENTATIVE JOYCE;;HU XIAONDONG;;PETROLEO BRASILEIRO SA,DE ALMEIDA RAFAEL MENEGASSI;;RABELLO CARLOS RENE KLOTZ;;DUARTE MARCUS VINICIUS EIFFLE;;MONTEIRO DE SOUZA GUILHERME LUIS;;LESLIE LEGAL REPRESENTATIVE JOYCE;;HU XIAONDONG,PETROLEO BRASILEIRO S.A.-PETROBRAS (2009-05-12),https://lens.org/196-447-949-073-855,Granted Patent,yes,12,9,9,9,0,C10G25/003;;C10G25/003;;C10G25/12;;C10G25/12;;C10G2300/201;;C10G2300/201;;C10G2300/4018;;C10G2300/4018,C07C7/12,585/820;;585/823;;208/299,2,2,048-039-448-654-302;;122-436-611-041-794,10.1006/jcat.1993.1252;;10.1016/s0009-2509(02)00185-9,"Kellberg, Lars et al., ""Deactivation of HDT Catalysts by Formation of Silica Gels from Silicone Oil. Characterization of Spent Catalysts from HDT of Coker Naphtha Using 29Si and 13C CP/MAS NMR"", Journal of Catalysis 143, (1993), pp. 45-51.;;Yang, Weishen et al, ""A Study by in Situ Techniques of the Thermal Evolution of the Structure of a Mg-A1-CO3 Layered Double Hydroxide"", Chemical Engineering Science 57, (2002), pp. 2945-2953.",ACTIVE
377,EP,A2,EP 0588750 A2,024-964-715-007-773,1994-03-23,1994,EP 93500120 A,1993-08-05,CU 1992089 A,1992-08-05,"Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv.","The present invention provides recombinant polypeptides bearing selected epitopes from Human Immunodeficiency Virus (HIV) isolates. The technical aim is to design and obtain, by means of chemical synthesis, genes encoding for a polypeptide composed not only by different HIV epitopes but also including epitopes corresponding to different HIV isolates. Said polypeptides correspond to the general formulae:
  Where:
 I. X1 to Xn represent fragments or viral proteins capable of inducing neutralizing antibodies or peptidic fragments capable of stimulating the proliferation and activation of helper T lymphocytes. II. L represents spacer sequence or ""linkers"" located between two X regions. Said polypeptides are capable of inducing neutralizing antibodies against HIV. Said polypeptides or antibodies generated against it could be useful for the diagnosis, treatment or prevention of AIDS.",CIGB,DUARTE CANO CARLOS A;;MENENDEZ ALARCON ALFREDO;;MONTERO RAMOS MARINIEVE;;PADRON PALOMARES GABRIEL RAMON;;HERRERA MATINEZ LUIS SATURNINO;;RODRIGUEZ ORTA MARIA DEL CARME,,https://lens.org/024-964-715-007-773,Patent Application,yes,0,1,2,2,12,A61K39/00;;C07K14/005;;C07K16/1063;;C12N2740/16122,A61K39/00;;C07K14/16;;C07K16/10;;C12N15/49;;C12P21/08,,0,0,,,,DISCONTINUED
378,DK,T3,DK 3293429 T3,109-446-888-387-964,2019-09-09,2019,DK 16306137 T,2016-09-09,EP 16306137 A,2016-09-09,Deflektor beregnet til at føre en ledning og tilhørende føringsanordning,,TECHNIP FRANCE,MOZA JUCIMAR COELHO;;DUARTE PAULA;;GIL PAULO-WEBBER;;FERREIRA LUIS PAULO;;SANTOS CARLOS-FILIPE;;LUCENA LEONARDO-ALEXANDRE;;NASCIMENTO CAROLINA-PAIVA;;CORREA JOSÉ-ROBERTO,,https://lens.org/109-446-888-387-964,Granted Patent,no,0,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235;;H02G1/10;;H02G9/02,,0,0,,,,ACTIVE
379,EP,A3,EP 0588750 A3,109-507-776-287-56X,1995-01-11,1995,EP 93500120 A,1993-08-05,CU 1992089 A,1992-08-05,"Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv.","The present invention provides recombinant polypeptides bearing selected epitopes from Human Immunodeficiency Virus (HIV) isolates. The technical aim is to design and obtain, by means of chemical synthesis, genes encoding for a polypeptide composed not only by different HIV epitopes but also including epitopes corresponding to different HIV isolates. Said polypeptides correspond to the general formulae:
  Where:
 I. X1 to Xn represent fragments or viral proteins capable of inducing neutralizing antibodies or peptidic fragments capable of stimulating the proliferation and activation of helper T lymphocytes. II. L represents spacer sequence or ""linkers"" located between two X regions. Said polypeptides are capable of inducing neutralizing antibodies against HIV. Said polypeptides or antibodies generated against it could be useful for the diagnosis, treatment or prevention of AIDS.",CIGB,DUARTE CANO CARLOS A;;MENENDEZ ALARCON ALFREDO;;MONTERO RAMOS MARINIEVE;;PADRON PALOMARES GABRIEL RAMON;;HERRERA MATINEZ LUIS SATURNINO;;RODRIGUEZ ORTA MARIA DEL CARME,,https://lens.org/109-507-776-287-56X,Search Report,yes,4,0,2,2,0,A61K39/00;;C07K14/005;;C07K16/1063;;C12N2740/16122,A61K39/00;;C07K14/16;;C07K16/10;;C12N15/49;;C12P21/08,,2,2,035-548-856-280-091;;042-315-495-612-965,pmc53003;;10.1073/pnas.88.23.10726;;1961739;;7517147;;10.1089/aid.1994.10.235,"OHNO ET AL.: ""A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 88, December 1991 (1991-12-01), WASHINGTON US, pages 10726 - 10729;;DUARTE ET AL.: ""Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop"", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 10, no. 3, March 1994 (1994-03-01), pages 235 - 243",DISCONTINUED
380,WO,A1,WO 2022/187977 A1,095-457-147-258-919,2022-09-15,2022,CL 2021050014 W,2021-03-11,CL 2021050014 W,2021-03-11,PAYMENT CARD WITH BIOCIDAL PROPERTIES FOR MONETARY TRANSACTIONS,"The invention relates to a payment card with biocidal properties for monetary transactions, which is formed by an arrangement of consecutive layers comprising: a polymeric base layer of polyvinyl chloride; a layer of screen-printed varnish including copper nanoparticles; and a superimposed layer of a plastic film. The invention also relates to the method for manufacturing the payment card with biocidal properties.",ARCHIVERT S A,GUZMÁN AREVALO RUBÉN ESTEBAN;;ASTORGA CHAVARRIGA RODRIGO EFRAÍN;;VERA PÉREZ LUIS GUSTAVO;;DUARTE BOBADILLA GENESIS CELESTE;;ARENDS NELSON RAFAEL;;INZULZA LOYOLA CRISTIAN ALFREDO,,https://lens.org/095-457-147-258-919,Patent Application,yes,9,0,1,1,0,Y02A50/30;;A01N59/20;;B32B27/30;;B42D25/20;;B82Y30/00;;C09D5/14;;G06K19/02,G06K19/02;;A01N59/20;;B32B27/30;;B42D25/20;;B82Y30/00;;C09D5/14,,0,0,,,,PENDING
381,PT,A,PT 103326 A,175-612-942-061-928,2007-01-31,2007,PT 10332605 A,2005-07-27,PT 10332605 A,2005-07-27,MÉTODO PARA OBTENÇÃO DE UM CONCENTRADO NATURAL RICO EM HIDROXITIROSOL A PARTIR DE RESÍDUOS DA PRODUÇÃO DE AZEITE UTILIZANDO TECNOLOGIAS LIMPAS,"ESTA INVENÇÃO DESCREVE UM MÉTODO NO ÂMBITO DAS TECNOLOGIAS LIMPAS PARA A OBTENÇÃO DE UM CONCENTRADO NATURAL RICO EM HIDROXITIROSOL A PARTIR DE RESÍDUOS DERIVADOS DA PRODUÇÃO DE AZEITE. O PROCESSO DESENVOLVIDO CONSISTE NA UTILIZAÇÃO COMBINADA OU EM SEPARADO DE TECNOLOGIA DE MEMBRANAS E UTILIZAÇÃO DE FLUIDOS SUPERCRÍTICOS. O CONCENTRADO NATURAL OBTIDO POR ESTE MÉTODO APRESENTA PROPRIEDADES ANTIOXIDANTES E ANTI-MICROBIANAS COM POTENCIAL APLICAÇÃO NAS INDÚSTRIAS ALIMENTAR, COSMÉTICA E FARMACÊUTICA. O CONCENTRADO PODE SER APRESENTADO SOB A FORMA DE SÓLIDO, SOLUÇÃO AQUOSA, EMULSÃO OU NANOPARTÍCULAS DE BASE LIPÍDICA.",INST DE BIOLOG EX E TECNOLOGIC,PONTE MANUEL LUIS DE MAGALHAES NUNES DA;;DUARTE CATARINA MARIA MARTINS;;CRESPO JOAO PAULO SEREJO GOULAO;;VELIZAROV SVETLOZAR GUEORGUIEV;;MATIAS ANA ALEXANDRA FIGUEREDO;;SANTOS JOSE LUIS CARDADOR DOS;;NUNES ANA VITAL MORGADO MARQUES,,https://lens.org/175-612-942-061-928,Patent Application,no,0,1,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C37/68;;A61K36/63;;A61P31/00;;A61P33/00;;C02F1/44;;C02F1/58;;C02F103/32,,0,0,,,,INACTIVE
382,RU,C2,RU 2494713 C2,039-764-429-868-271,2013-10-10,2013,RU 2011108557 A,2009-08-05,US 18593408 A;;BR 2009000232 W,2008-08-05,"METHOD OF MANUFACTURING ABSORBING CORE, WHICH HAS MULTITUDE OF FIRST AREAS AND SECOND AREA, SURROUNDING EACH OF FIRST AREAS","FIELD: medicine.SUBSTANCE: invention relates to hygienic absorbing products and, in particular to sanitary absorbing towels, which possess improved characteristics of air-permeability, temperature and moisture control, and it also relates to method of manufacturing absorbing core for application in said products. Method of manufacturing structure of absorbing core of hygienic product includes the following stages: providing fibrous cellulose; support of fibrous cellulose in chamber; installation of mould into rotating forming drum, with mould having first porous part and centrally located non-porous part; rotation of mould on rotating forming drum until mould comes into interaction with chamber; pulling fibrous cellulose into mould in such a way as to form core, which has multitude of first areas and second area, with each of said first areas being located at a distance from other first areas, and each of first areas being completely surrounded with second area; pushing out core structure from mould; and transfer of core structure through calendar roller in order to compress core structure until multitude of first areas and second area acquire similar thickness.EFFECT: improvement of characteristics of air-permeability, temperature and moisture control.6 cl, 12 dwg",DZHONSON EHND DZHONSON IND LTDA,DE KARVAL JU ANTON JU KARLOS RIBEJRU;;DUARTE IVAIR LUIS;;SALLES MARIJA MARSIJA R KAL DAS;;FAZHOLLI MARSIJA EHLENA TEJSHEJRA;;RIMOLI FRANSISKU ANTON JU,,https://lens.org/039-764-429-868-271,Granted Patent,no,6,2,15,15,0,A61F13/15658;;A61F13/15658;;A61F13/15642;;A61F13/15642;;A61F13/532;;A61F13/532,A61F13/15,,0,0,,,,INACTIVE
383,WO,A8,WO 2016/195521 A8,093-243-987-139-721,2018-02-08,2018,PT 2016050011 W,2016-05-27,PT 10851715 A,2015-05-29,ASSEMBLY AND PROCESS FOR ORGANISING STACKS OF CORK STOPPERS AND MACHINE COMPRISING SAID ASSEMBLY,"The present invention relates to an assembly (1) for organising stacks of cork stoppers and a process for organising stacks of cork stoppers carried out by said assembly (1). The invention further relates to a machine comprising said assembly (1) for organising stacks of cork stoppers. The stacks of cork stoppers are disposed in an organised way to facilitate and optimize their packaging, reducing the packaging volume and facilitating their transport. The present invention applies to field of cork industry and cork stopper production.",AMORIM CORK RES LDA,ALMEIDA E SOUSA ANTÓNIO GIL DA COSTA;;LEITÃO LUÍS FILIPE CAMPOS;;DA SILVA LUIS FILIPE PEIXOTO MACHADO;;DUARTE PEDRO NUNO ESTEVES;;RIBEIRO REINALDO LEMOS,,https://lens.org/093-243-987-139-721,Amended Application,yes,0,0,8,8,0,B65B5/105;;B65B19/00;;B27J5/00;;B65B5/06;;B65B5/101;;B65B5/106;;B65B5/108;;B65B25/00;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/54,B65B5/10;;B27J5/00;;B65B25/02;;B65B35/38;;B65B35/40;;B65B35/52;;B65B35/54,,0,0,,,,PENDING
384,WO,A1,WO 2016/195521 A1,072-619-858-504-471,2016-12-08,2016,PT 2016050011 W,2016-05-27,PT 10851715 A,2015-05-29,ASSEMBLY AND PROCESS FOR ORGANISING STACKS OF CORK STOPPERS AND MACHINE COMPRISING SAID ASSEMBLY,"The present invention relates to an assembly (1) for organising stacks of cork stoppers and a process for organising stacks of cork stoppers carried out by said assembly (1). The invention further relates to a machine comprising said assembly (1) for organising stacks of cork stoppers. The stacks of cork stoppers are disposed in an organised way to facilitate and optimize their packaging, reducing the packaging volume and facilitating their transport. The present invention applies to field of cork industry and cork stopper production.",AMORIM CORK RES LDA,ALMEIDA E SOUSA ANTÓNIO GIL DA COSTA;;LEITÃO LUÍS FILIPE CAMPOS;;DA SILVA LUIS FILIPE PEIXOTO MACHADO;;DUARTE PEDRO NUNO ESTEVES;;RIBEIRO REINALDO LEMOS,,https://lens.org/072-619-858-504-471,Patent Application,yes,7,1,8,8,0,B65B25/00;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/54;;B65B5/101;;B65B5/105;;B65B5/106;;B65B5/108;;B27J5/00;;B65B5/06;;B65B19/00,B65B5/10;;B27J5/00;;B65B25/02;;B65B35/38;;B65B35/40;;B65B35/52;;B65B35/54,,0,0,,,,PENDING
385,ES,T3,ES 2741224 T3,047-147-019-337-36X,2020-02-10,2020,ES 16732008 T,2016-05-27,PT 10851715 A;;PT 2016050011 W,2015-05-29,Conjunto y proceso para organizar pilas de tapones de corcho y máquina que comprende dicho conjunto,"Un conjunto (1) para organizar pilas de tapones de corcho, que comprende: · una plataforma (2) para organizar pilas de tapones de corcho que comprende una base (3) que define un plano (P), comprendiendo la plataforma (2) una zona (4) de recepción para recibir pilas de tapones de corcho, una zona de transporte (5) para transportar pilas de tapones de corcho y una zona de envasado (6) para envasar pilas de tapones de corcho; · un mecanismo (7) para recibir y posicionar pilas de tapones de corcho, comprendiendo el mecanismo (7): un órgano (8) para recibir y transportar pilas de tapones de corcho, comprendiendo el órgano (8) una primera placa de recepción (9) para recibir pilas de tapones de corcho, siendo móvil la primera placa (9) con respecto al plano (P), una segunda placa (11) de recepción para recibir pilas de tapones de corcho, siendo móvil la segunda placa (11) con respecto al plano (P), un órgano (12) de retención para retener pilas de tapones de corcho, comprendiendo el órgano (12) un elemento (13) de retención y un prensador (14) que son ambos móviles perpendicularmente al plano (P) y están dispuestos para funcionar en la zona de envasado (6); · un ribete (15) que comprende una pared (16) para el alineamiento de pilas de tapones de corcho, siendo móvil el ribete (15) paralelo con respecto al plano (P) y estando dispuesto sobre la plataforma (2) y alrededor del mecanismo (7) de recepción y posicionamiento; en donde las placas (9, 11) tienen, respectivamente, guías (1709, 1711) para recibir y almacenar pilas de tapones de corcho; y la primera placa (9) para recibir pilas de tapones de corcho es paralela con respecto a la pared (16) para el alineamiento de pilas de tapones de corcho de dicho ribete (15).",AMORIM CORK RES LDA,ALMEIDA E SOUSA ANTÓNIO GIL DA COSTA;;LEITÃO LUÍS FILIPE CAMPOS;;DA SILVA LUIS FILIPE PEIXOTO MACHADO;;DUARTE PEDRO NUNO ESTEVES;;RIBEIRO REINALDO LEMOS,,https://lens.org/047-147-019-337-36X,Granted Patent,no,0,0,8,8,0,B65B5/105;;B65B19/00;;B27J5/00;;B65B5/06;;B65B5/101;;B65B5/106;;B65B5/108;;B65B25/00;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/54,B65B5/10;;B27J5/00;;B65B25/00;;B65B25/02;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/52;;B65B35/54,,0,0,,,,ACTIVE
386,EP,A1,EP 3305669 A1,108-132-450-521-235,2018-04-11,2018,EP 16732008 A,2016-05-27,PT 10851715 A;;PT 2016050011 W,2015-05-29,ASSEMBLY AND PROCESS FOR ORGANISING STACKS OF CORK STOPPERS AND MACHINE COMPRISING SAID ASSEMBLY,"The present invention relates to an assembly (1) for organising stacks of cork stoppers and a process for organising stacks of cork stoppers carried out by said assembly (1). The invention further relates to a machine comprising said assembly (1) for organising stacks of cork stoppers. The stacks of cork stoppers are disposed in an organised way to facilitate and optimize their packaging, reducing the packaging volume and facilitating their transport. The present invention applies to field of cork industry and cork stopper production.",AMORIM CORK RES LDA,ALMEIDA E SOUSA ANTÓNIO GIL DA COSTA;;LEITÃO LUÍS FILIPE CAMPOS;;DA SILVA LUIS FILIPE PEIXOTO MACHADO;;DUARTE PEDRO NUNO ESTEVES;;RIBEIRO REINALDO LEMOS,,https://lens.org/108-132-450-521-235,Patent Application,yes,0,0,8,8,0,B65B5/105;;B65B19/00;;B27J5/00;;B65B5/06;;B65B5/101;;B65B5/106;;B65B5/108;;B65B25/00;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/54,B65B5/10;;B27J5/00;;B65B25/00;;B65B25/02;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/52;;B65B35/54,,1,0,,,See references of WO 2016195521A1,ACTIVE
387,PT,T,PT 3305669 T,100-796-574-481-969,2019-08-23,2019,PT 16732008 T,2016-05-27,PT 10851715 A;;PT 2016050011 W,2015-05-29,ASSEMBLY AND PROCESS FOR ORGANISING STACKS OF CORK STOPPERS AND MACHINE COMPRISING SAID ASSEMBLY,,AMORIM CORK RES LDA,LUÍS FILIPE CAMPOS LEITÃO;;ANTÓNIO GIL DA COSTA ALMEIDA E SOUSA;;REINALDO LEMOS RIBEIRO;;LUIS FILIPE PEIXOTO MACHADO DA SILVA;;PEDRO NUNO ESTEVES DUARTE,,https://lens.org/100-796-574-481-969,Patent Application,no,0,0,8,8,0,B65B5/105;;B65B19/00;;B27J5/00;;B65B5/06;;B65B5/101;;B65B5/106;;B65B5/108;;B65B25/00;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/54,B65B5/10;;B27J5/00;;B65B25/00;;B65B25/02;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/52;;B65B35/54,,0,0,,,,PENDING
388,EP,B1,EP 3305669 B1,125-341-723-340-809,2019-05-08,2019,EP 16732008 A,2016-05-27,PT 10851715 A;;PT 2016050011 W,2015-05-29,ASSEMBLY AND PROCESS FOR ORGANISING STACKS OF CORK STOPPERS AND MACHINE COMPRISING SAID ASSEMBLY,,AMORIM CORK RES LDA,ALMEIDA E SOUSA ANTÓNIO GIL DA COSTA;;LEITÃO LUÍS FILIPE CAMPOS;;DA SILVA LUIS FILIPE PEIXOTO MACHADO;;DUARTE PEDRO NUNO ESTEVES;;RIBEIRO REINALDO LEMOS,,https://lens.org/125-341-723-340-809,Granted Patent,yes,7,0,8,8,0,B65B25/00;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/54;;B65B5/101;;B65B5/105;;B65B5/106;;B65B5/108;;B27J5/00;;B65B5/06;;B65B19/00,B65B5/10;;B27J5/00;;B65B25/00;;B65B25/02;;B65B35/38;;B65B35/40;;B65B35/50;;B65B35/52;;B65B35/54,,0,0,,,,ACTIVE
389,CO,A1,CO 2018004242 A1,162-144-352-242-538,2018-10-22,2018,CO 2018004242 A,2018-04-20,CO 2018004242 A,2018-04-20,Banco diagnóstico de pruebas sistema de luces de aeronaves de ala fija y ala rotaroria,"La presente invención se relaciona con un banco para pruebas y diagnóstico del sistema de luces de navegación de aeronaves de ala rotatoria y ala fija, el cual permite llevar a cabo una serie de pruebas de chequeo operacional de los componentes de dicho sistema en aeronaves de ala rotatoria (sin limitación), en donde el banco de pruebas y diagnósUco se basa en un módulo de operación, control y monitoreo, dos soportes para acoplar la luz de búsqueda, la luz de aterrizaje y dos cajas polarizadas para alojar las luces anticolisión, minimizando el haz de luz que emiten durante el chuequeo operacional, en donde dichos elementos interactúan entre si para poder determinar si alguna parte o componente del sistema de luces de navegación de la aeronave funciona correctamente o si por el contrario, presenta algún inconveniente y así se pueden tomar medidas en fierra que facilitan la capacidad de vuelo y además, ayudan a mantener la integridad de la aeronave en vuelo y de sus tripulantes.",MINISTERIO DE DEFENSA EJERCITO NAC,FRANCO GARCÍA GUSTAVO ALFREDO;;MORA GONZÁLEZ YONNY ALEXANDER;;ALTAMIRANDA RAMOS LUIS ENARIO;;PEÑA CALLE CESAR AUGUSTO;;CUESTA DÍAZ JULIO ANDRÉS;;DUARTE FERREIRA ARIEL FERNANDO,,https://lens.org/162-144-352-242-538,Patent Application,no,0,0,1,1,0,,G01M9/08;;G01L5/00;;G01M99/00,,0,0,,,,PENDING
390,WO,A1,WO 2009/096801 A1,188-343-429-005-289,2009-08-06,2009,PT 2009000007 W,2009-01-30,PT 10395308 A;;PT 10415908 A,2008-02-01,PLASTIC DEFORMATION TECHNOLOGICAL PROCESS FOR PRODUCTION OF THIN WALL REVOLUTION SHELLS FROM TUBULAR BILLETS,"This invention refers to a process of plastic deformation for production of thin wall revolution shells from tubular billets. The process consists in end-forming a hollow circular section billet, which can be composed of a multi- layered assembly, by using sharp edge internal domed shaped molds (1) that are guided externally by a constraining sleeve (3).This mold-sleeve tool can be assembled in a press in order to generate the pressure forces necessary for the forming process. The plastic deformation can result in thin walled spheres or cylinders with domed ends. The resultant revolution shells have two opposite (polar) circular openings. Both the shell's length as the polar hole diameter is mainly determined by the billet's initial dimensions and mold (1) domed geometry. An innovative flexible inner mandrel may be introduced to considerably improve overall shell characteristics, allowing reduction of shell polar opening diameter, giving control of along-meridian thickness, solving typical thin wall forming problems such as buckling, wrinkling and ruptures and improve both outer and inner surface quality. This mandrel can be discarded and/or recycled after forming. This invention enables a low-cost and high-rate process for production of structural revolution shells capable of being used as high-pressure vessels.",OMNIDEA LDA;;MENDONCA ALVES LUIS MANUEL;;FIRME MARTINS PAULO ANTONIO;;DA COSTA DUARTE PARDAL TIAGO;;CORREIRA DE ALMEIDA PAULO JORGE;;PEREIRA DOS ANJOS VALVERDE NUNO MIGUEL,MENDONCA ALVES LUIS MANUEL;;FIRME MARTINS PAULO ANTONIO;;DA COSTA DUARTE PARDAL TIAGO;;CORREIRA DE ALMEIDA PAULO JORGE;;PEREIRA DOS ANJOS VALVERDE NUNO MIGUEL,,https://lens.org/188-343-429-005-289,Patent Application,yes,18,0,4,6,0,B21D51/08;;B21D51/24;;Y10T428/24008;;Y10T428/24008;;B21D51/24;;B21D51/08,B21D51/24;;B21D51/08,,0,0,,,,PENDING
391,BR,A2,BR 102017011993 A2,057-126-157-047-141,2018-12-26,2018,BR 102017011993 A,2017-06-06,BR 102017011993 A,2017-06-06,conjunto estrutural para sustentação de um trocador de calor para veículos e veículo de uso rural ou na construção civil,"conjunto estrutural para sustentação de um trocador de calor para veículos e veículo de uso rural ou na construção civil. a presente invenção refere-se a um conjunto estrutural para sustentação de um trocador de calor, que pode ser a unidade condensadora, o radiador, ou o intercooler de um veículo e também se refere ao veículo contendo esse conjunto estrutural, os quais compreendem aspectos técnicos e construtivos capazes de melhorar os níveis de ventilação dos sistemas de arrefecimento, mas também simplificar os processos de limpeza e manutenção dos componentes que se encontram atrás dos trocadores de calor, por exemplo, da unidade condensadora. mais particularmente, o conjunto estrutural, segundo a presente invenção, compreende uma armação basculante (10), na qual o dito trocador de calor é fixado em uma condição que permita o basculamento, ao menos parcial, do referido conjunto.",CNH IND BRASIL LTDA,DIEGO DOIN HOEPFNER;;LARISSA LOPES DA SILVA CANDEO;;MÁRLON BASSETTO;;OTACILIO CARDOSO DUARTE FILHO;;RAFAEL DE PAULA CHAVES;;RODOLFO LOPES PEREIRA;;VINICIUS LUIS GAMA,,https://lens.org/057-126-157-047-141,Patent Application,no,0,0,1,1,0,,F24F13/14;;F24F13/32,,0,0,,,,PENDING
392,US,A1,US 2021/0007779 A1,096-349-813-454-881,2021-01-14,2021,US 201916968767 A,2019-02-11,PT 11056318 A;;IB 2019051083 W,2018-02-09,MEDICAL DEVICE FOR THE DELIVERY OF THERAPEUTIC FORMULATIONS AND METHODS OF USE THEREOF,"An arthroscopic surgery device for delivering a therapeutic formulation into a cartilage of an articular joint, wherein the device comprises: a flexible tubular delivery arm, comprising one or more internal channels for carrying the therapeutic formulation; a flexible external sleeve enveloping the delivery arm lengthwise; a pliable cup attached to an end of the delivery arm, for covering a cartilage part where the therapeutic formulation is to be delivered, arranged such that by outwards axial displacement of the delivery arm in respect to the external sleeve, the cup moves from inside to outside of the external sleeve, expanding the cup. The device may comprise a flexible internal sleeve between the delivery arm and the external sleeve, such that the flexible internal sleeve envelops the delivery arm lengthwise. The arthroscopic surgery device may be also used for extracting fluid from an articular cavity.",STEMMATTERS BIOTECNOLOGIA E MEDICINA REGENERATIVA S A,VILELA GOMES CARLOS ALBERTO;;ROMERO AMANDI DE SOUSA RUI PEDRO;;CORREIA CRISTINA;;GONÇALVES DOS REIS RUI LUIS;;COELHO DO SAMEIRO ESPREGUEIRA MENDE JOÄO DUARTE,STEMMATTERS BIOTECNOLOGIA E MEDICINA REGENERATIVA S.A (2020-07-10),https://lens.org/096-349-813-454-881,Patent Application,yes,8,0,5,5,0,A61B17/3421;;A61B17/3472;;A61B17/3478;;A61B2017/3445;;A61B2017/3484;;A61B17/3421;;A61B17/3472;;A61B17/3478;;A61B18/18;;A61B2017/3484;;A61B2018/1807;;A61B2217/005;;A61B2217/007;;A61B2560/04,A61B17/34;;A61B18/18,,0,0,,,,PENDING
393,US,A1,US 2010/0310815 A1,135-261-900-927-428,2010-12-09,2010,US 86565609 A,2009-01-30,PT 10395308 A;;PT 10415908 A;;PT 2009000007 W,2008-02-01,PLASTIC DEFORMATION TECHNOLOGICAL PROCESS FOR PRODUCTION OF THIN WALL REVOLUTION SHELLS FROM TUBULAR BILLETS,"This invention refers to a process of plastic deformation for production of thin wall revolution shells from tubular billets. The process consists in end-forming a hollow circular section billet, which can be composed of a multi- layered assembly, by using sharp edge internal domed shaped molds ( 1 ) that are guided externally by a constraining sleeve ( 3 ). This mold-sleeve tool can be assembled in a press in order to generate the pressure forces necessary for the forming process. The plastic deformation can result in thin walled spheres or cylinders with domed ends. The resultant revolution shells have two opposite (polar) circular openings. Both the shell's length as the polar hole diameter is mainly determined by the billet's initial dimensions and mold ( 1 ) domed geometry. An innovative flexible inner mandrel may be introduced to considerably improve overall shell characteristics, allowing reduction of shell polar opening diameter, giving control of along-meridian thickness, solving typical thin wall forming problems such as buckling, wrinkling and ruptures and improve both outer and inner surface quality. This mandrel can be discarded and/or recycled after forming. This invention enables a low-cost and high-rate process for production of structural revolution shells capable of being used as high-pressure vessels.",OMNIDEA LDA,MENDONCA ALVES LUIS MANUEL;;FIRME MARTINS PAULO ANTONIO;;DA COSTAL DUARTE PARDAL TIAGO;;CORREIRA DE ALMEIDA PAULO JORGE;;PEREIRA DOS ANJOS VALVERDE NUNO MIGUEL,,https://lens.org/135-261-900-927-428,Patent Application,yes,5,15,4,6,0,B21D51/08;;B21D51/24;;Y10T428/24008;;Y10T428/24008;;B21D51/24;;B21D51/08,B21D51/08;;B21D51/24;;B32B3/06,428/99;;72/379.4,0,0,,,,DISCONTINUED
394,EP,A1,EP 3135835 A1,024-956-607-923-715,2017-03-01,2017,EP 16177024 A,2016-06-29,PT 10862215 A,2015-06-30,ANCHORING CONNECTOR AND METHODS FOR MANUFACTURING THEREOF,"The present disclosure concerns an anchoring connector for interconnecting two solid bodies, namely concrete layers from different concreting. The connector disclosed herein comprises a tubular body with a front part for inserting into the first solid body and a rear part for attaching the second solid body to the first solid body, and a plurality of anchoring elements for anchoring the connector to the two solid bodies, wherein the anchoring elements are distributed along the entire tubular body of the connector, wherein the anchoring elements distributed on the front part of the tubular body have an anchoring contrary to the front-rear movement of the connector and, the anchoring elements distributed on the rear part of the tubular body have an anchoring contrary to the rear-front movement of the connector.
",ETMA - EMPRESA TECNICA DE METALURGIA S A,RENDEIRO CORREIA DE SOUSA JOÃO PEDRO;;PINTO DE QUEIRÓS LUÍS MIGUEL;;JÚLIO EDUARDO;;COSTA NEVES LUIS;;RAPOSO JOSÉ MARIA;;MARTINS JOÃO PAULO;;SANTOS DUARTE GONÇALO,,https://lens.org/024-956-607-923-715,Patent Application,yes,2,0,1,1,0,E04B1/483;;E04C2002/047;;F16B13/02;;F16B13/025,E04B1/48;;E04C2/04;;F16B13/00,,0,0,,,,DISCONTINUED
395,EP,A1,EP 3325883 A1,008-109-369-125-613,2018-05-30,2018,EP 16741000 A,2016-07-18,PT 2015108703 A;;EP 2016067007 W,2015-07-17,HEATER APPLIANCE AND METHOD FOR OPERATING A HEATER APPLIANCE,,BOSCH TERMOTECNOLOGIA SA,OLIVEIRA SIMOES MAURO ANDRÉ;;VIEIRA RICARDO JORGE DE SOUSA;;MARQUES MARCO;;PACHECO MONTEIRO LUIS MIGUEL;;SALUSTIO SERGIO;;FERNANDES GARCIA LIMA DUARTE NUNO;;PEREIRA JOEL FILIPE,,https://lens.org/008-109-369-125-613,Patent Application,yes,0,0,1,1,0,F23N3/002;;F23N3/082;;F23N2225/16;;F23N2225/20;;F23N2225/21;;F23N2241/04,F23N3/00;;F23N3/08,,1,0,,,See references of WO 2017013048A1,DISCONTINUED
396,US,B2,US 10634346 B2,062-300-310-976-10X,2020-04-28,2020,US 201615745159 A,2016-07-18,PT 10870315 A;;EP 2016067007 W,2015-07-17,Heater device and method for operating a heater device,"A heater device including at least one control and/or regulating unit, which is provided to set an air ratio of a combustion process to a setpoint air ratio. It is provided that the control and/or regulating unit is provided to ascertain a power correction factor in at least one operating state and take it into consideration in the setting of the air ratio.",BOSCH TERMOTECNOLOGIA SA,FERNANDES GARCIA LIMA DUARTE NUNO;;PEREIRA JOEL FILIPE;;PACHECO MONTEIRO LUIS MIGUEL;;OLIVEIRA SIMOES MAURO ANDRÉ;;VIEIRA RICARDO JORGE DE SOUSA;;SALUSTIO SERGIO;;MARQUES MARCO,BOSCH TERMOTECNOLOGIA S.A (2018-02-09),https://lens.org/062-300-310-976-10X,Granted Patent,yes,5,0,5,5,0,F23N1/022;;F23N3/082;;F23N3/082;;F23N3/002;;F23N3/002;;F23N5/003;;F23N2225/16;;F23N2225/16;;F23N2225/20;;F23N2225/20;;F23N2225/21;;F23N2225/21;;F23N2241/04;;F23N2241/04,F23N3/08;;F23N3/00;;F23N5/00,,1,0,,,"International Search Report dated Nov. 7, 2016, of the corresponding International Application PCT/EP2016/067007 filed Jul. 18, 2016.",ACTIVE
397,WO,A1,WO 2017/013048 A1,151-831-958-832-829,2017-01-26,2017,EP 2016067007 W,2016-07-18,PT 10870315 A,2015-07-17,HEATER APPLIANCE AND METHOD FOR OPERATING A HEATER APPLIANCE,"The invention relates to a heater appliance having at least one control unit and/or regulating unit (10), which is provided in order to set an air/fuel ratio (λ c ) of a combustion system to a desired air/fuel ratio (λ d ). According to the invention the control unit and/or regulating unit (10) is provided, in at least one operational state, to determine an output correction factor (C F ) and to take said factor into consideration when setting the air/fuel ratio (λ c ).",BOSCH TERMOTECNOLOGIA SA,OLIVEIRA SIMOES MAURO ANDRÉ;;VIEIRA RICARDO JORGE DE SOUSA;;MARQUES MARCO;;PACHECO MONTEIRO LUIS MIGUEL;;SALUSTIO SERGIO;;FERNANDES GARCIA LIMA DUARTE NUNO;;PEREIRA JOEL FILIPE,,https://lens.org/151-831-958-832-829,Patent Application,yes,4,0,5,5,0,F23N1/022;;F23N3/082;;F23N3/082;;F23N3/002;;F23N3/002;;F23N5/003;;F23N2225/16;;F23N2225/16;;F23N2225/20;;F23N2225/20;;F23N2225/21;;F23N2225/21;;F23N2241/04;;F23N2241/04,F23N3/00;;F23N3/08,,0,0,,,,PENDING
398,PT,A,PT 106220 A,114-532-773-434-750,2013-09-23,2013,PT 10622012 A,2012-03-21,PT 10622012 A,2012-03-21,MÉTODO DE PREPARAÇÃO DE ESTRUTURAS TRIDIMENSIONAIS À BASE DE LISADOS DE PLAQUETAS PROCESSADOS POR TECNOLOGIA SUPERCRÍTICA,"ESTA INVENÇÃO DESCREVE UM MÉTODO DE PREPARAÇÃO DE UMA MATRIZ TRIDIMENSIONAL À BASE DE LISADOS DE PLAQUETAS PROCESSADOS POR TECNOLOGIA SUPERCRITICA COM POTENCIAL APLICAÇÃO NA REGENERAÇÃO DE TECIDOS MOLES, NA REGENERAÇÃO DE TECIDOS DUROS, COMO RESERVATÓRIOS DE LIBERTAÇÃO CONTROLADA E AGENTES BIOACTIVOS E/OU ENCHIMENTOS, NO SENTIDO DE FORNECER UMA ESTRUTURA POROSA E INTERCONECTADA, DE SUPORTE AO CRESCIMENTO DE CÉLULAS E/OU FAZER A LIBERTAÇÃO CONTROLADA DE UMA(S) PROTEÍNA E/OU FACTOR(ES) DE CRESCIMENTO E/OU DE UM ADITIVO BIOACTIVO E/OU INDUZIR A MINERALIZAÇÃO DA MATRIZ. EM PARTICULAR, ESTA INVENÇÃO RELATA UM PROCESSO UNITÁRIO PARA PROMOVER A PRECIPITAÇÃO POR INVERSÃO DE FASES DE UMA MATRIZ À BASE DE LISADOS DE PLAQUETAS AO MESMO TEMPO QUE A ESTRUTURA É RETICULADA, UTILIZANDO UMA TECNOLOGIA LIMPA, NOMEADAMENTE, ATRAVÉS DO USO DE FLUIDOS COMPRIMIDOS.",ASS FOR THE ADVANCEMENT OF TISSUE ENGINEERING CELL BASED TECHNOLOGIES & THERAPIES A4TEC ASSOCIACAO,GOMES MARIA MANUELA ESTIMA;;MANO JOAO FILIPE COLARDELLE DA LUZ;;DUARTE ANA RITA CRUZ;;REIS RUI LUIS GONCALVES DOS;;SANTO VITOR SERGIO SOARES DO ESPIRITO,,https://lens.org/114-532-773-434-750,Patent Application,no,0,0,1,1,0,,A61L27/56;;C12N5/078,,0,0,,,,DISCONTINUED
399,US,A1,US 2018/0209648 A1,080-496-529-721-718,2018-07-26,2018,US 201615745159 A,2016-07-18,PT 10870315 A;;EP 2016067007 W,2015-07-17,HEATER DEVICE AND METHOD FOR OPERATING A HEATER DEVICE,"A heater device including at least one control and/or regulating unit, which is provided to set an air ratio of a combustion process to a setpoint air ratio. It is provided that the control and/or regulating unit is provided to ascertain a power correction factor in at least one operating state and take it into consideration in the setting of the air ratio.",BOSCH TERMOTECNOLOGIA SA,FERNANDES GARCIA LIMA DUARTE NUNO;;PEREIRA JOEL FILIPE;;PACHECO MONTEIRO LUIS MIGUEL;;OLIVEIRA SIMOES MAURO ANDRÉ;;VIEIRA RICARDO JORGE DE SOUSA;;SALUSTIO SERGIO;;MARQUES MARCO,BOSCH TERMOTECNOLOGIA S.A (2018-02-09),https://lens.org/080-496-529-721-718,Patent Application,yes,0,0,5,5,0,F23N1/022;;F23N3/082;;F23N3/082;;F23N3/002;;F23N3/002;;F23N5/003;;F23N2225/16;;F23N2225/16;;F23N2225/20;;F23N2225/20;;F23N2225/21;;F23N2225/21;;F23N2241/04;;F23N2241/04,F23N3/08;;F23N5/00,,0,0,,,,ACTIVE
400,WO,A2,WO 2009/022929 A2,049-515-983-800-472,2009-02-19,2009,PT 2008000031 W,2008-08-13,PT 10380707 A,2007-08-13,FULLY AUTONOMOUS OR REMOTELY OPERATED GOLF BALL PICKING SYSTEM,"The present invention regards a motorised system with electric traction with computer vision for outdoor environments, which can interact with the surrounding environment in an autonomous way or remotely operated. This vehicle tows a trailer that permits, amongst other functions, to perform golf balls picking. The totally autonomous golf picking system comprises : a base (1) with, at least, two linked wheels, each driven by an independent motor; a vision system (8) with a variable amount of video cameras; a set of sensors - humidity, accelerometer, compass, coders, temperature, ultrasounds, GPS, that allow the path optimisation of the system; an image acquisition and processing system; a continuous processing unit of sensor data and motor control; a trailer with a mechanical device for picking the balls (3) and a ball container (2) with an automatic opening system (4) to an unloading dock; and a unit of rechargeable batteries through external terminals.",UNIV DO MINHO;;MACEDO RIBEIRO ANTONIO FERNAND;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXA;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIAN,MACEDO RIBEIRO ANTONIO FERNANDO;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXANDRE;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIANA,,https://lens.org/049-515-983-800-472,Patent Application,yes,0,12,5,5,0,G05D1/0225;;G05D1/0246;;G05D1/0259;;G05D1/027;;G05D1/0278;;G05D1/028;;A63B47/021;;A63B2047/022;;G05D1/0246;;G05D1/027;;G05D1/028;;G05D1/0278;;G05D1/0259;;G05D1/0225;;A63B47/021;;A63B2047/022,A63B47/02;;G05D1/02,,0,0,,,,PENDING
401,EP,A2,EP 2178604 A2,124-146-884-177-256,2010-04-28,2010,EP 08793976 A,2008-08-13,PT 2008000031 W;;PT 10380707 A,2007-08-13,FULLY AUTONOMOUS OR REMOTELY OPERATED GOLF BALL PICKING SYSTEM,,UNIV DO MINHO,MACEDO RIBEIRO ANTONIO FERNAND;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXANDRE;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIANA,,https://lens.org/124-146-884-177-256,Patent Application,yes,0,0,5,5,0,G05D1/0225;;G05D1/0246;;G05D1/0259;;G05D1/027;;G05D1/0278;;G05D1/028;;A63B47/021;;A63B2047/022;;G05D1/0246;;G05D1/027;;G05D1/028;;G05D1/0278;;G05D1/0259;;G05D1/0225;;A63B47/021;;A63B2047/022,A63B47/02;;G05D1/02,,0,0,,,,DISCONTINUED
402,PT,A,PT 103807 A,035-757-727-929-908,2009-01-13,2009,PT 10380707 A,2007-08-13,PT 10380707 A,2007-08-13,SISTEMA DE RECOLHA DE BOLAS DE GOLF TOTALMENTE AUTÓNOMO OU REMOTAMENTE OPERADO,"A PRESENTE INVENÇÃO DIZ RESPEITO A UM SISTEMA MOTORIZADO COM TRACÇÃO ELÉCTRICA COM VISÃO POR COMPUTADOR PARA AMBIENTES EXTERIORES, O QUAL PODE ACTUAR COM O MEIO ENVOLVENTE AUTONOMAMENTE OU TELE-OPERADO. ESTE VEÍCULO TEM ACOPLADO UM REBOQUE QUE LHE PERMITE, ENTRE OUTRAS FUNÇÕES, REALIZAR A RECOLHA DAS BOLAS DE GOLFE. O SISTEMA DE RECOLHA DE BOLAS DE GOLFE TOTALMENTE AUTÓNOMO COMPREENDE: UMA BASE (1) COM, PELO MENOS, DUAS RODAS ACOPLADAS, SENDO CADA RODA MOVIDA POR UM MOTOR INDEPENDENTE; UM SISTEMA DE VISÃO (8) COM UM NÚMERO VARIÁVEL DE CÂMARAS; UM CONJUNTO DE SENSORES - HUMIDADE, ACELERÓMETRO, BÚSSOLA, ENCODERS, TEMPERATURA, ULTRA-SONS, GPS, QUE PERMITEM OPTIMIZAR O TRAJECTO DO SISTEMA; UMA UNIDADE DE PROCESSAMENTO PARA AQUISIÇÃO E PROCESSAMENTO DE IMAGEM; UMA UNIDADE DE PROCESSAMENTO CONTÍNUO DE DADOS DOS SENSORES E CONTROLO DOS MOTORES; UM ATRELADO COM DISPOSITIVO MECÂNICO DE RECOLHA DE BOLAS (3) E DEPÓSITO DE BOLAS (2) COM SISTEMA DE ABERTURA AUTOMÁTICA (4) PARA UM CAIS DE DESCARGA (14); E UMA UNIDADE DE BATERIAS RECARREGÁVEIS ATRAVÉS DE PÓLOS EXTERNOS.",UNIV DO MINHO,MACEDO RIBEIRO ANTONIO FERNANDO;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXANDRE;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIANA,,https://lens.org/035-757-727-929-908,Patent Application,no,0,0,5,5,0,G05D1/0225;;G05D1/0246;;G05D1/0259;;G05D1/027;;G05D1/0278;;G05D1/028;;A63B47/021;;A63B2047/022;;G05D1/0246;;G05D1/027;;G05D1/028;;G05D1/0278;;G05D1/0259;;G05D1/0225;;A63B47/021;;A63B2047/022,A63B69/36;;A63B47/02,,0,0,,,,DISCONTINUED
403,US,A1,US 2010/0250024 A1,078-551-274-114-939,2010-09-30,2010,US 67376908 A,2008-08-13,PT 10380707 A;;PT 2008000031 W,2007-08-13,FULLY AUTONOMOUS OR REMOTELY OPERATED GOLF BALL PICKING SYSTEM,"The present invention regards a motorised system with electric traction with computer vision for outdoor environments, which can interact with the surrounding environment in an autonomous way or remotely operated. This vehicle tows a trailer that permits, amongst other functions, to perform golf balls picking.",MACEDO RIBEIRO ANTONIO FERNANDO;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXANDRE;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIANA,MACEDO RIBEIRO ANTONIO FERNANDO;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXANDRE;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIANA,UNIVERSIDADE DO MINHO (2010-03-31),https://lens.org/078-551-274-114-939,Patent Application,yes,6,40,5,5,0,G05D1/0225;;G05D1/0246;;G05D1/0259;;G05D1/027;;G05D1/0278;;G05D1/028;;A63B47/021;;A63B2047/022;;G05D1/0246;;G05D1/027;;G05D1/028;;G05D1/0278;;G05D1/0259;;G05D1/0225;;A63B47/021;;A63B2047/022,G01S1/08;;A63B47/02;;G05D1/02,701/2;;701/22;;342/386,0,0,,,,DISCONTINUED
404,WO,A3,WO 2009/022929 A3,050-812-271-789-152,2009-07-30,2009,PT 2008000031 W,2008-08-13,PT 10380707 A,2007-08-13,FULLY AUTONOMOUS OR REMOTELY OPERATED GOLF BALL PICKING SYSTEM,"The present invention regards a motorised system with electric traction with computer vision for outdoor environments, which can interact with the surrounding environment in an autonomous way or remotely operated. This vehicle tows a trailer that permits, amongst other functions, to perform golf balls picking. The totally autonomous golf picking system comprises : a base (1) with, at least, two linked wheels, each driven by an independent motor; a vision system (8) with a variable amount of video cameras; a set of sensors - humidity, accelerometer, compass, coders, temperature, ultrasounds, GPS, that allow the path optimisation of the system; an image acquisition and processing system; a continuous processing unit of sensor data and motor control; a trailer with a mechanical device for picking the balls (3) and a ball container (2) with an automatic opening system (4) to an unloading dock; and a unit of rechargeable batteries through external terminals.",UNIV DO MINHO;;MACEDO RIBEIRO ANTONIO FERNAND;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXA;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIAN,MACEDO RIBEIRO ANTONIO FERNANDO;;DUARTE OLIVEIRA E SILVA CARLOS;;CORREIA MOUTINHO IVO MAURO;;DA COSTA E SILVA PEDRO LUIS;;COSTA PACHECO LUIS FERNANDO;;COSTA DE OLIVEIRA SERGIO ALEXANDRE;;BARBOSA OLIVEIRA ANDRE JOAQUIM;;CARDOSO COSTA HELOISA CRISTIANA,,https://lens.org/050-812-271-789-152,Search Report,yes,4,0,5,5,0,G05D1/0225;;G05D1/0246;;G05D1/0259;;G05D1/027;;G05D1/0278;;G05D1/028;;A63B47/021;;A63B2047/022;;G05D1/0246;;G05D1/027;;G05D1/028;;G05D1/0278;;G05D1/0259;;G05D1/0225;;A63B47/021;;A63B2047/022,A63B47/02;;G05D1/02,,0,0,,,,PENDING
405,CA,C,CA 2682453 C,087-041-046-598-675,2016-07-12,2016,CA 2682453 A,2008-03-31,ES 200700835 A;;ES 2008000191 W,2007-03-29,METHOD FOR OBTAINING THREE-DIMENSIONAL STRUCTURES FOR TISSUE ENGINEERING,Method for obtaining three-dimensional structures for tissue engineering is provided. The method includes mixing a source of albumin and a cross-linking agent and introducing the resultant mixture in a mold with the shape of the solid structure; freezing the solid structure; lyophilizing the solid structure; and then progressive rehydrating the solid structure by means of successive immersion in alcohols of decreasing strength. Ex-vivo method for regenerating a tissue with the three-dimensional structure is also provided. The ex-vivo method includes seeding cells in the three-dimensional structure and incubating the cells in a culture medium inside an oven or bioreactor.,CENTRO COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS;;CENTRO DE INVESTIG ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,,https://lens.org/087-041-046-598-675,Granted Patent,no,0,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/58,,0,0,,,,INACTIVE
406,ES,T3,ES 2565856 T3,084-860-593-735-253,2016-04-07,2016,ES 08750425 T,2008-03-31,ES 200700835 A;;ES 2008000191 W,2007-03-29,Procedimiento de preparación de estructuras tridimensionales para ingeniería tisular,La presente invención pertenece al campo de la ingeniería tisularconcretamente se refiere a un método para obtener estructuras tridimensionales para ingeniería tisular y a las estructuras obtenidas por dicho procedimiento. La invención también se refiere a unmétodo ex vivo para regenerar un tejido usando las estructuras tridimensionales de la invención y al uso de las estructuras así tratadas para su transplante a la zona a regenerar del paciente.,CENTRO COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS;;CENTRO DE INVESTIG ENERGÉTICAS MEDIOAMBIENTALES Y TECNOLÓGICAS,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERÓNICA;;JORCANO NOVAL JOSÉ LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,,https://lens.org/084-860-593-735-253,Granted Patent,no,0,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/38;;A61L27/58;;A61L27/60,,0,0,,,,ACTIVE
407,US,A1,US 2010/0040665 A1,108-269-814-202-719,2010-02-18,2010,US 59390908 A,2008-03-31,ES 200700835 A;;ES 2008000191 W,2007-03-29,METHOD FOR OBTAINING THREE-DIMENSIONAL STRUCTURES FOR TISSUE ENGINEERING,The present invention belongs to the field of tissue engineering and specifically relates to a method for obtaining three-dimensional structures for tissue engineering and to the structures obtained by said method. The invention also relates to an ex vivo method for regenerating a tissue using the three-dimensional structures of the invention and to the use of the structures thus treated for their transplanting to the area to be regenerated of the patient.,CT COMUNITARIO DE SANGRE Y TEJ,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,CENTRO COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS (2009-09-10);;CENTRO DE INVESTIGACIONES ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS (2009-09-10),https://lens.org/108-269-814-202-719,Patent Application,yes,3,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61F2/00;;A61L27/22;;C07K1/00;;C12N11/02,424/423;;435/177;;424/93.7;;530/362;;435/371,4,3,012-171-905-488-277;;016-546-628-170-220;;039-423-282-300-95X,10.1016/s0142-9612(99)00011-3;;10382829;;14615173;;10.1016/s0142-9612(03)00630-6;;10.1016/j.cep.2006.09.003,English translation of Zimmerman et al. (DE 35 17 456 (1986)).;;Madihally et al. (Biomaterials 20 (1999) 1133-1142).;;O'Brien et al. (Biomaterials 25 (2004) 1077-1086.;;Hottot et . (Chemical Engineering and Processing 46 (2007) 666-674).,DISCONTINUED
408,DK,T3,DK 2145635 T3,155-131-711-000-076,2016-03-14,2016,DK 08750425 T,2008-03-31,ES 200700835 A;;ES 2008000191 W,2007-03-29,Fremgangsmåde til fremstilling af tredimensionelle strukturer til vævs(re)etablering,,CT COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS;;CT DE INVESTIGACIONES ENERGÉTICAS MEDIOAMBIENTALES Y TECNOLÓGICAS,JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA;;MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA,,https://lens.org/155-131-711-000-076,Granted Patent,no,0,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/38;;A61L27/58;;A61L27/60,,0,0,,,,ACTIVE
409,EP,A4,EP 2145635 A4,071-717-880-560-712,2010-04-07,2010,EP 08750425 A,2008-03-31,ES 2008000191 W;;ES 200700835 A,2007-03-29,METHOD FOR PREPARING THREE-DIMENSIONAL STRUCTURES FOR TISSUE ENGINEERING,,CT COMUNITARIO DE SANGRE Y TEJ;;CT INVESTIG ENERGETICAS CIEMAT,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,,https://lens.org/071-717-880-560-712,Search Report,no,4,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/38;;A61L27/58;;A61L27/60,,1,0,,,See also references of WO 2008119855A1,ACTIVE
410,PT,A,PT 109580 A,182-704-376-368-07X,2018-02-12,2018,PT 10958016 A,2016-08-11,PT 10958016 A,2016-08-11,SISTEMA PARA COMUNICAÇÃO E SINALIZAÇÃO DO ESTADOS DE ELEMENTOS DE EQUIPAS DE SALVAMENTO,"A PRESENTE INVENÇÃO FOI DESENVOLVIDA NA ÁREA DE ELETRÓNICA E TELECOMUNICAÇÕES E É PARA SER USADA PARA INDICAR O ESTADO DO PESSOAL DE EQUIPAS DE BUSCA E SALVAMENTO E BOMBEIROS. O ESTADO DO UTILIZADOR ALTERNA ENTRE OS ESTADOS: SALVO, BUSCA E AJUDA. ESTE INVENTO É UM SISTEMA MODULAR COMPOSTO POR TRÊS TIPOS DE UNIDADES, NOMEADAMENTE, SINALIZADOR MÓVEL, CARREGADOR SEM FIOS, E ESTAÇÃO BASE. OS SINALIZADORES MÓVEIS PODEM SER INCORPORADOS NOS CINTOS, COLETES OU GARRAFAS DE OXIGÉNIO DOS BOMBEIROS. ELES RECEBEM A INDICAÇÃO DO ESTADO DO UTILIZADOR POR MEIO DE UM BOTÃO, E TRANSMITEM-NO PARA A ESTAÇÃO BASE. O SINALIZADOR MÓVEL TAMBÉM EMITE UM ALERTA VISUAL DE ACORDO COM O ESTADO. ESTA UNIDADE CONTÉM AINDA UM MÓDULO UM SENSOR DE CONDIÇÕES AMBIENTAIS PARA ALERTAR CONDIÇÕES ADVERSAS. A ESTAÇÃO BASE RECEBE INFORMAÇÃO DOS SINALIZADORES MÓVEIS VIA RÁDIO-FREQUÊNCIA, E APRESENTA A INFORMAÇÃO CORRESPONDENTE NUM ECRÃ. TODAS AS UNIDADES SÃO ALOJADAS EM CAIXAS ESTANQUES.",RUI ANTONIO POLICARPO DUARTE;;HUGO RIBEIRO DA SILVA PUGSLEY;;MARCO ANDRE SILVA DO CARMO;;BRUNO FILIPE CAIADO MARTINS;;ANTONIO MANUEL SALVADOR ALMEIDA;;LUIS MANUEL PEREIRA GALHOZ,RUI ANTÓNIO POLICARPO DUARTE;;HUGO RIBEIRO DA SILVA PUGSLEY;;MARCO ANDRÉ SILVA DO CARMO;;BRUNO FILIPE CAIADO MARTINS;;ANTÓNIO MANUEL SALVADOR ALMEIDA;;LUIS MANUEL PEREIRA GALHOZ,,https://lens.org/182-704-376-368-07X,Patent Application,no,5,0,1,1,0,G08B25/014;;G08B25/016;;G08B25/10,G08B25/01;;G08B25/10,,0,0,,,,PENDING
411,EP,B1,EP 2145635 B1,001-009-681-649-312,2015-12-09,2015,EP 08750425 A,2008-03-31,ES 2008000191 W;;ES 200700835 A,2007-03-29,METHOD FOR PREPARING THREE-DIMENSIONAL STRUCTURES FOR TISSUE ENGINEERING,,CT COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS;;CT DE INVESTIGACIONES ENERGÉTICAS MEDIOAMBIENTALES Y TECNOLÓGICAS,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,,https://lens.org/001-009-681-649-312,Granted Patent,yes,6,2,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/38;;A61L27/58;;A61L27/60,,2,0,,,"YOUNG S. ET AL.: 'Gelatin as a delivery vehicle for the controlled release of bioactive molecules' JOURNAL OF CONTROLLED RELEASE vol. 109, no. 1-3, 2005, pages 256 - 274, XP005196220;;MA L. ET AL.: 'Collagen/chitosan porous scaffolds with improved biostability for skin tissue engineering' BIOMATERIALS vol. 24, no. 26, 01 November 2003, pages 4833 - 4841, XP004460200",ACTIVE
412,EP,A1,EP 2145635 A1,168-285-169-424-680,2010-01-20,2010,EP 08750425 A,2008-03-31,ES 2008000191 W;;ES 200700835 A,2007-03-29,METHOD FOR PREPARING THREE-DIMENSIONAL STRUCTURES FOR TISSUE ENGINEERING,The present invention belongs to the field of tissue engineering and specifically relates to a method for obtaining three-dimensional structures for tissue engineering and to the structures obtained by said method. The invention also relates to an ex vivo method for regenerating a tissue using the three-dimensional structures of the invention and to the use of the structures thus treated for their transplanting to the area to be regenerated of the patient.,CT COMUNITARIO DE SANGRE Y TEJ;;CT INVESTIG ENERGETICAS CIEMAT,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,,https://lens.org/168-285-169-424-680,Patent Application,yes,0,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/38;;A61L27/58;;A61L27/60,,0,0,,,,ACTIVE
413,WO,A1,WO 2008/119855 A1,104-725-072-278-343,2008-10-09,2008,ES 2008000191 W,2008-03-31,ES 200700835 A,2007-03-29,METHOD FOR PREPARING THREE-DIMENSIONAL STRUCTURES FOR TISSUE ENGINEERING,The present invention belongs to the field of tissue engineering and concerns specifically a method for preparing three-dimensional structures for tissue engineering and the structures obtained by said method. The invention also concerns an ex vivo method for regenerating a tissue using the three-dimensional structures of the invention and use of the structures treated in this way for transplanting to the zone for regeneration of the patient.,CT COMUNITARIO DE SANGRE Y TEJ;;CT INVESTIG ENERGETICAS CIEMAT;;MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;JORCANO NOVAL JOSE LUIS;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;DUARTE GONZALEZ BLANCA;;HOLGUIN FERNANDEZ ALMUDENA,,https://lens.org/104-725-072-278-343,Patent Application,yes,5,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/58,,11,6,118-015-827-905-678;;088-618-458-776-183;;135-510-931-727-765;;042-161-768-458-205;;043-364-646-491-169;;048-963-663-479-23X,16266768;;10.1016/j.jconrel.2005.09.023;;14530080;;10.1016/s0142-9612(03)00374-0;;10.1111/j.1749-6632.2002.tb03056.x;;12081872;;15348059;;10.1023/a:1008997311364;;10721748;;10.1016/s0142-9612(99)00241-0;;9882060;;10.1016/s0305-4179(98)00107-7,"YOUNG S. ET AL.: ""Gelatin as a delivery vehicle for the controlled release of bioactive molecules"", JOURNAL OF CONTROLLED RELEASE, vol. 109, no. 1-3, 2005, pages 256 - 274, XP005196220;;MA L. ET AL.: ""Collagen/chitosan porous scaffolds with improved biostability for skin tissue engineering"", BIOMATERIALS, vol. 24, no. 26, 1 November 2003 (2003-11-01), pages 4833 - 4841, XP004460200;;See also references of EP 2145635A4;;GRIFFITH L, ANN N. Y. ACAD SCI, vol. 961, 2002, pages 83 - 95;;KULKARNY ET AL., ARCH SURG, vol. 93, 1993, pages 839 - 843;;ITAY S ET AL., CLIN ORTHOP, vol. 220, 1987, pages 234 - 300;;PRASITSILP ET AL., J MAT SCI: MAT IN MED, vol. 11, 2000, pages 773 - 778;;FRAGONAS ET AL., BIOMATERIALS, vol. 21, 2000, pages 795 - 801;;MARAGUCHI ET AL., PLAST RECONSTR SURG, vol. 93, 1994, pages 537 - 544;;GUREVITCH O. ET AL., TISSUE ENGINEERING, vol. 8, 2002, pages 661 - 672;;MEANA ET AL., BURNS, 1998, pages 621 - 630",PENDING
414,CA,A1,CA 2682453 A1,145-902-025-870-063,2008-10-09,2008,CA 2682453 A,2008-03-31,ES 200700835 A;;ES 2008000191 W,2007-03-29,METHOD FOR OBTAINING THREE-DIMENSIONAL STRUCTURES FOR TISSUEENGINEERING,The present invention belongs to the field of tissue engineering and conc erns specifically a method for preparing three-dimensional structures for ti ssue engineering and the structures obtained by said method. The invention a lso concerns an ex vivo method for regenerating a tissue using the three-dim ensional structures of the invention and use of the structures treated in th is way for transplanting to the zone for regeneration of the patient.,CT INVESTIG ENERGETICAS CIEMAT;;CT COMUNITARIO DE SANGRE Y TEJ,MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GARCIA DIAZ VERONICA;;DUARTE GONZALEZ BLANCA;;DEL RIO NECHAEVSKY MARCELA;;LARCHER LAGUZZI FERNANDO;;HOLGUIN FERNANDEZ ALMUDENA;;JORCANO NOVAL JOSE LUIS,,https://lens.org/145-902-025-870-063,Patent Application,no,0,0,13,13,0,A61L27/227;;A61L27/58;;A61L27/60;;A61L27/60;;A61L27/227;;A61L27/227;;A61L27/38;;A61L27/38,A61L27/22;;A61L27/58,,0,0,,,,INACTIVE
415,EP,A1,EP 3294361 A1,088-949-663-863-004,2018-03-21,2018,EP 16726187 A,2016-05-17,IB 2016052875 W;;PT 10847615 A;;EP 15169249 A;;PT 10912216 A,2015-05-14,"AN URETERAL STENT, METHODS AND USES THEREOF",,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRE;;NUNES CORREIA PINTO JORGE MANUEL,,https://lens.org/088-949-663-863-004,Patent Application,yes,0,0,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/04;;A61L31/10;;A61L31/14,,0,0,,,,ACTIVE
416,WO,A1,WO 2016/181371 A1,060-206-716-085-506,2016-11-17,2016,IB 2016052875 W,2016-05-17,IB 2016052875 W;;PT 10847615 A;;EP 15169249 A;;PT 10912216 A,2015-05-14,"AN URETERAL STENT, METHODS AND USES THEREOF","The present disclosure relates to ureteral stents, in particular a composition for ureteral stents that are used to ensure patency of a channel, namely the ureter which may be compromised, for example, by a urinary stone, neoplasia or a surgical procedure The solution now disclosed relates to a composition for biodegradable stents, in particular to ureteral stents and method for obtain such stents. This disclosure overcomes the problems encountered in the available stents, in particular, ureteral stents, as it namely: avoids the need for a second surgery for stent removal; decreases the morbidity in patients submitted to a surgical procedure; decreases or eliminates the risk of infection after the implantation of the ureteral stent.",ASS FOR THE ADVANCEMENT OF TISSUE ENG AND CELL BASED TECH AND THERAPIES - A4TEC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ;;NUNES CORREIA PINTO JORGE MANUEL,,https://lens.org/060-206-716-085-506,Patent Application,yes,3,1,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/04;;A61L31/10;;A61L31/14,,30,29,001-591-775-469-466;;001-591-775-469-466;;066-724-404-458-295;;016-497-913-211-484;;006-555-449-698-312;;002-769-425-721-168;;022-580-772-722-989;;054-462-155-361-157;;023-169-109-811-797;;069-785-071-160-869;;025-717-303-945-868;;043-184-905-499-416;;024-270-471-124-722;;026-392-013-964-626;;052-367-809-883-512;;087-415-510-107-31X;;061-822-657-398-275;;001-591-775-469-466;;003-658-166-774-103;;091-271-387-131-051;;027-125-789-019-429;;070-600-440-407-639;;016-132-088-036-724;;036-677-083-255-931;;068-127-580-059-282;;054-324-477-746-361;;110-743-298-333-604;;132-457-361-658-665;;012-720-051-696-302,10.1002/jbm.b.33237;;24965000;;10.1002/jbm.b.33237;;24965000;;10.1038/nrurol.2014.340;;25534997;;10.1111/j.1464-410x.2011.10903.x;;22313688;;10.1016/j.juro.2009.11.035;;20092835;;10.1016/j.eururo.2006.05.054;;16814926;;10.1016/s0022-5347(05)65128-2;;11956478;;10.1097/00005392-200205000-00071;;10.1177/1756287210370699;;pmc3126070;;21789086;;10.1089/end.2009.0516;;20073560;;10.1016/j.juro.2009.09.073;;20022028;;12803989;;10.1089/089277903321618734;;10.1089/end.1999.13.107;;10213104;;18186698;;10.1089/end.2005.0085;;10.1097/00005392-200010000-00074;;10992415;;10.1016/s0022-5347(05)67199-6;;12184080;;10.1089/089277902760102785;;10.3109/00365599.2010.544673;;21222571;;24997428;;10.1016/j.jmbbm.2014.06.004;;10.1002/jbm.b.33237;;24965000;;10.1046/j.1464-410x.1997.00484.x;;9439407;;10.1007/s10856-011-4285-8;;21437640;;18571311;;10.1016/j.eururo.2008.06.010;;12686808;;10.1097/01.ju.0000055600.18515.a1;;10.1016/j.supflu.2013.01.004;;15360280;;10.1021/bm049879r;;10.1016/s1389-1723(00)87103-0;;16232687;;21436510;;10.1088/1748-6041/6/2/025010;;10.1016/j.ijbiomac.2005.03.012;;15896839;;10.1002/mabi.200600069;;16881042;;24147536;;10.1111/iju.12297,"ALEXANDRE A. BARROS ET AL: ""Bioresorbable ureteral stents from natural origin polymers"", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART B: APPLIED BIOMATERIALS, vol. 103, no. 3, 26 June 2014 (2014-06-26), US, pages 608 - 617, XP055223832, ISSN: 1552-4973, DOI: 10.1002/jbm.b.33237;;BARROS AA; RITA A; DUARTE C; PIRES RA; SAMPAIO-MARQUES B; LUDOVICO P; LIMA E; MANO JF; REIS RL: ""Bioresorbable ureteral stents from natural origin polymers"", J BIOMED MATER RES, vol. 103B, 2015, pages 608 - 617, XP055223832, DOI: doi:10.1002/jbm.b.33237;;D. LANGE; S. BIDNUR; N. HOAG; B.H. CHEW: ""Ureteral stent-associated complications[mdash]where we are and where we are going"", NAT REV UROL, vol. 12, 2015, pages 17 - 25;;C.E. MENDEZ-PROBST; L.W. GONEAU; K.W. MACDONALD; L. NOTT; S. SENEY; C.N. ELWOOD ET AL.: ""The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial"", BJU INT., vol. 110, 2012, pages 749 - 754;;A.E. KRAMBECK; R.S. WALSH; J.D. DENSTEDT; G.M. PREMINGER; J. LI; J.C. EVANS ET AL.: ""A Novel Drug Eluting Ureteral Stent: A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of a Ketorolac Loaded Ureteral Stent"", J. UROL., vol. 183, 2010, pages 1037 - 1043, XP026938397, DOI: doi:10.1016/j.juro.2009.11.035;;E.N. LIATSIKOS; D. KARNABATIDIS; G.C. KAGADIS; K. ROKKAS; C. CONSTANTINIDES; N. CHRISTEAS ET AL.: ""Application of paclitaxel-eluting metal mesh stents within the pig ureter: An experimental study"", EUR. UROL., vol. 51, 2007, pages 217 - 223, XP029875865, DOI: doi:10.1016/j.eururo.2006.05.054;;E.O. OLWENY; J. LANDMAN; C. ANDREONI; W. COLLYER; K. KERBL; M. ONCIU ET AL.: ""Evaluation of the use of a biodegradable ureteral stent after retrograde endopyelotomy in a porcine model"", J. UROL., vol. 167, 2002, pages 2198 - 2202, XP005542855, DOI: doi:10.1016/S0022-5347(05)65128-2;;A. AL-AOWN; I. KYRIAZIS; P. KALLIDONIS; P. KRANIOTIS; C. RIGOPOULOS; D. KARNABATIDIS ET AL.: ""Ureteral stents: new ideas, new designs"", THER ADV UROL., vol. 2, 2010, pages 85 - 92;;N. VENKATESAN; S. SHROFF; K. JAYACHANDRAN; M. DOBLE: ""Polymers as Ureteral Stents"", J. ENDOUROL, vol. 24, 2010, pages 191 - 198;;B.H. CHEW; D. LANGE; R.F. PATERSON; K. HENDLIN; M. MONGA; K.W. CLINKSCALES ET AL.: ""Next Generation Biodegradable Ureteral Stent in a Yucatan Pig Model"", J. UROL., vol. 183, 2010, pages 765 - 771, XP026833127;;J.E. LINGEMAN; D.A. SCHULSINGER; R.L. KUO: ""Phase I trial of a temporary ureteral drainage stent"", J. ENDOUROL., vol. 17, 2003, pages 169 - 171;;J. LUMIAHO; A. HEINO; V. TUNNINEN; M. ALA-OPAS; M. TALJA; T. VALIMAA ET AL.: ""New bioabsorbable polylactide ureteral stent in the treatment of ureteral lesions: An experimental study"", J. ENDOUROL., vol. 13, 1999, pages 107 - 112;;J. LUMIAHO; A. HEINO; T. KAUPPINEN; M. TALJA; E. ALHAVA; T. VALIMAA ET AL.: ""Drainage and antireflux characteristics of a biodegradable self-reinforced, self-expanding X-ray-positive ploy-L,D-lactide spiral partial Ureteral stent: An experimental study"", J. ENDOUROL., vol. 21, 2007, pages 1559 - 1564;;J. LUMIAHO; A. HEINO; T. PIETILAINEN; M. ALA-OPAS; M. TALJA; T. VALIMAA ET AL.: ""The morphological, in situ effects of a self-reinforced bioabsorbable polylactide (SR-PLA 96) ureteric stent; An experimental study"", J. UROL., vol. 164, 2000, pages 1360 - 1363, XP005553803, DOI: doi:10.1016/S0022-5347(05)67199-6;;M. TALJA; M. MULTANEN; T. VALIMAA; P. TORMALA: ""Bioabsorbable SR-PLGA horn stent after antegrade endopyelotomy: A case report"", J. ENDOUROL., vol. 16, 2002, pages 299 - 302;;J. LUMIAHO; A. HEINO; S. AALTOMAA; T. VALIMAA; M. TALJA: ""A short biodegradable helical spiral ureteric stent provides better antireflux and drainage properties than a double-J stent"", SCAND. J. UROL. NEPHROL., vol. 45, 2011, pages 129 - 133;;T. ZOU; L. WANG; W.C. LI; W.Z. WANG; F. CHEN; M.W. KING: ""A resorbable bicomponent braided ureteral stent with improved mechanical performance"", J. MECH. BEHAV. BIOMED. MATER., vol. 38, 2014, pages 17 - 25, XP029016602, DOI: doi:10.1016/j.jmbbm.2014.06.004;;A.A. BARROS; A. RITA; C. DUARTE; R.A. PIRES; B. SAMPAIO-MARQUES; P. LUDOVICO ET AL.: ""Bioresorbable ureteral stents from natural origin polymers"", J. BIOMED. MATER. RES. PART B APPL. BIOMATER., vol. 103, 2015, pages 608 - 617, XP055223832, DOI: doi:10.1002/jbm.b.33237;;R.W. SCHLICK; K. PLANZ: ""Potentially useful materials for biodegradable ureteric stents"", BR. J. UROL., vol. 80, 1997, pages 908 - 910;;A. KHANDWEKAR; M. DOBLE: ""Physicochemical characterisation and biological evaluation of polyvinylpyrrolidone-iodine engineered polyurethane"", J. MATER. SCI. MATER. MED., vol. 22, 2011, pages 1231 - 1246, XP019910198, DOI: doi:10.1007/s10856-011-4285-8;;""Biological Evaluation of Medical Devices"", TEST FOR CYTOTOXICITY IN VITRO METHODS: 8.2 TEST ON EXTRACTS., 1992;;E. LIMA; C. ROLANDA; L. OSORIO; J.M. PEGO; D. SILVA; T. HENRIQUES-COELHO ET AL.: ""Endoscopic closure of transmural bladder wall perforations."", EUR. UROL, vol. 56, 2009, pages 151 - 7;;J.E. LINGEMAN; G.M. PREMINGER; Y. BERGER; J.D. DENSTEDT; L. GOLDSTONE; J.W. SEGURA ET AL.: ""Use of a temporary ureteral drainage stent after uncomplicated ureteroscopy: Results from a phase II clinical trial"", J. UROL., vol. 169, 2003, pages 1682 - 1688, XP005535874, DOI: doi:10.1097/01.ju.0000055600.18515.a1;;A.R.C. DUARTE; V.E. SANTO; A. ALVES; S.S. SILVA; J. MOREIRA-SILVA; T.H. SILVA ET AL.: ""Unleashing the Potential of Supercritical Fluids for Polymer Processing in Tissue Engineering and Regenerative Medicine"", J. SUPERCRIT. FLUIDS., 2013;;H.J. KONG; D. KAIGLER; K. KIM; D.J. MOONEY: ""Controlling Rigidity and Degradation of Alginate Hydrogels via Molecular Weight Distribution"", BIOMACROMOLECULES, vol. 5, 2004, pages 1720 - 1727;;A. BLANDINO; M. MACIAS; D. CANTERO: ""Formation of calcium alginate gel capsules: Influence of sodium alginate and CaCI2 concentration on gelation kinetics"", J. BIOSCI. BIOENG., vol. 88, 1999, pages 686 - 689;;A. JEJURIKAR; G. LAWRIE; D. MARTIN; L. GRONDAHL: ""A novel strategy for preparing mechanically robust ionically cross-linked alginate hydrogels"", BIOMED MATER., vol. 6, 2011;;B. MOHANTY; H.B. BOHIDAR: ""Microscopic structure of gelatin coacervates"", INT. J. BIOL. MACROMOL, vol. 36, 2005, pages 39 - 46, XP025279348, DOI: doi:10.1016/j.ijbiomac.2005.03.012;;A.D. AUGST; H.J. KONG; D.J. MOONEY: ""Alginate Hydrogels as Biomaterials"", MACROMOL. BIOSCI., vol. 6, 2006, pages 623 - 633, XP055096869, DOI: doi:10.1002/mabi.200600069;;M.Q. ZHANG; T. ZOU; Y.C. HUANG; Y.F. SHANG; G.G. YANG; W.Z. WANG ET AL.: ""Braided thin-walled biodegradable ureteral stent: Preliminary evaluation in a canine model"", INT. J. UROL., vol. 21, 2014, pages 401 - 407",PENDING
417,WO,A1,WO 2023/203509 A1,115-284-607-336-350,2023-10-26,2023,IB 2023054014 W,2023-04-19,PT 11791522 A,2022-04-19,IMAGE DATA COMPRESSION METHOD AND DEVICE USING SEGMENTATION AND CLASSIFICATION,"Device and method for image data compression using segmentation and classification, the method comprising the steps of: identifying regions in a received image comprised of image pixels; segmenting the image pixels into segmented regions, each segmented region corresponding to an identified region, and into an image background comprised of image pixels, if existing, not belonging to any of the identified regions; determining a class for each segmented image region from a plurality of predetermined image classification classes; applying an image learning-based encoder to each segmented image region, according to the determined class of each segmented image region, wherein a specific image learning- based encoder has been preselected for each of the image classification classes from a library of image learning-based encoders; outputting the encoded segmented image regions.",INST DE TELECOMUNICACOES;;INST POLITECNICO DE LEIRIA;;UNIV AVEIRO,AMADO DE ASSUNÇÃO PEDRO ANTÓNIO;;MACIEL DE FARIA SÉRGIO MANUEL;;DE OLIVEIRA PEGADO DE NORONHA E TÁVORA LUIS MIGUEL;;NUNES NAVARRO RODRIGUES ANTÓNIO JOSÉ;;DUARTE ANTÓNIO RÚBEN,,https://lens.org/115-284-607-336-350,Patent Application,yes,7,0,1,1,0,G06V10/82;;G06V10/95;;G06V20/70;;H04N19/20,G06V10/82;;G06V10/94;;G06V20/70;;H04N19/25,,14,8,044-803-710-352-701;;169-289-137-122-973;;021-950-408-008-307;;043-676-088-077-897;;189-434-051-185-723;;102-044-432-780-139;;167-250-740-041-739;;121-131-412-484-070,10.1109/iv47402.2020.9304779;;10.23919/jcin.2021.9663101;;10.1109/tcsvt.2020.2995955;;10.1109/pcs.2018.8456308;;32857694;;10.1109/dcc50243.2021.00024;;10.1007/s00371-021-02286-0;;10.1109/cvpr42600.2020.00796,"LOHDEFINK JONAS ET AL: ""Focussing Learned Image Compression to Semantic Classes for V2X Applications"", 2020 IEEE INTELLIGENT VEHICLES SYMPOSIUM (IV), IEEE, 19 October 2020 (2020-10-19), pages 1641 - 1648, XP033872794, DOI: 10.1109/IV47402.2020.9304779;;LAN QIAO ET AL: ""What Is Semantic Communication? A View on Conveying Meaning in the Era of Machine Intelligence"", JOURNAL OF COMMUNICATIONS AND INFORMATION NETWORKS, 24 December 2021 (2021-12-24), pages 336 - 371, XP093061437, Retrieved from the Internet <URL:https://ieeexplore.ieee.org/ielx7/8892389/9663097/09663101.pdf?tp=&arnumber=9663101&isnumber=9663097&ref=aHR0cHM6Ly9pZWVleHBsb3JlLmllZWUub3JnL2Fic3RyYWN0L2RvY3VtZW50Lzk2NjMxMDE=> [retrieved on 20230705];;S. LIUW.-H. PENGL. YU: ""Guest editorial introduction to special section on learning-based image and video compression"", IEEE TRANSACTIONS ON CIRCUITS AND SYSTEMS FOR VIDEO TECHNOLOGY, vol. 30, no. 7, 2020, pages 1785 - 1788, XP011796772, DOI: 10.1109/TCSVT.2020.2995955;;Z. CHENGH. SUNM. TAKEUCHIJ. KATTO: ""Deep convolutional autoencoder-based lossy image compression"", 2018 PICTURE CODING SYMPOSIUM (PCS, 2018, pages 253 - 257;;J. BALLEV. LAPARRAE. SIMONCELLI: ""End-to-end optimized image compression"", 5TH INTERNATIONAL CONFERENCE ON LEARNING REPRESENTATIONS, TOULON, FRANCE, April 2017 (2017-04-01);;J. BALLED. MINNENS. SINGHS. J. HWANGN. JOHNSTON: ""Variational image compression with a scale hyperprior"", 6TH INTERNATIONAL CONFERENCE ON LEARNING REPRESENTATIONS, VANCOUVER, CANADA, April 2018 (2018-04-01);;L. DUANJ. LIUW. YANGT. HUANGW. GAO: ""Video coding for machines: A paradigm of collaborative compression and intelligent analytics"", IEEE TRANSACTIONS ON IMAGE PROCESSING, vol. 29, 2020, pages 8680 - 8695;;L. D. CHAMAINF. RACAPEJ. BEGAINTA. PUSHPARAJAS. FELTMAN: ""End-to-end optimized image compression for machines, a study"", 2021 DATA COMPRESSION CONFERENCE (DCC, 2021, pages 163 - 172;;R. KALSOTRAS. ARORA: ""Background subtraction for moving object detection: explorations of recent developments and challenges"", THE VISUAL COMPUTER - INTERNATIONAL JOURNAL OF COMPUTER GRAPHICS, 2021;;Z. CHENGH. SUNM. TAKEUCHIJ. KATTO: ""Learned image compression with discretized gaussian mixture likelihoods and attention modules"", PROC. IEEE/CVF CONFERENCE ON COMPUTER VISION PATTERN RECOGNITION, March 2020 (2020-03-01), pages 7936 - 7945;;D. MINNENJ. BALLEG. TODERICI: ""Joint autoregressive and hierarchical priors for learned image compression"", ADVANCES IN NEURAL INFORMATION PROCESSING SYSTEMS, 2018, pages 10794 - 10803;;Y. WUA. KIRILLOVF. MASSAW.-Y. LOR. GIRSHICK, DETECTRON, vol. 2, 2019;;J. BEGAINTF. RACAPES. FELTMANA. PUSHPARAJA: ""Compressai: a pytorch library and evaluation platform for end-to-end compression research"", COMPRESSAL: A PYTORCH LIBRARY AND EVALUATION PLATFORM FOR END-TO-END COMPRESSION RESEARCH, 2020;;T. XUEB. CHENJ. WUD. WEIW. T. FREEMAN: ""Video enhancement with task-oriented flow"", INTERNATIONAL JOURNAL OF COMPUTER VISION (IJCV, November 2019 (2019-11-01), pages 1106 - 1125",PENDING
418,US,B2,US 9492466 B2,146-570-997-654-785,2016-11-15,2016,US 201313826951 A,2013-03-14,US 201313826951 A;;US 201261659700 P,2012-06-14,Beta-hydroxy-gamma-aminophosphonates for treating immune disorders,"The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a β-hydroxy-γ-aminophosphonate or β-amino-γ-aminophosphonate.",NUCITEC SA DE CV,DE LA CRUZ CORDERO RICARDO ABRAHAM;;ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL;;ORDÓÑEZ PALACIOS JOSÉ MARIO;;REYES ESPARZA JORGE ALBERTO;;DE LOURDES RODRIGUEZ FRAGOSO MARIA,NUCITEC S.A. DE C.V (2013-04-08),https://lens.org/146-570-997-654-785,Granted Patent,yes,7,0,3,3,0,A61K31/662;;A61K31/662;;A61K45/06;;A61K45/06;;C07F9/3808;;C07F9/3808;;C07F9/3834;;C07F9/4006;;C07F9/4006,A61K31/662;;A61K45/06;;C07F9/38;;C07F9/40,,88,85,001-881-714-575-017;;027-811-946-271-194;;033-701-088-111-046;;064-005-906-277-204;;093-001-762-848-963;;031-918-874-072-771;;024-336-398-005-522;;018-321-853-529-039;;010-865-109-364-023;;047-812-275-884-781;;058-625-810-449-892;;043-054-081-891-005;;014-814-714-007-556;;091-458-861-956-705;;043-497-532-933-036;;068-357-471-893-853;;059-565-132-013-225;;028-331-568-349-508;;037-530-601-279-096;;067-559-720-114-961;;013-905-959-066-359;;022-652-982-425-675;;038-107-395-525-628;;006-916-913-621-636;;080-113-319-705-575;;083-524-738-064-78X;;051-851-554-796-983;;052-265-693-042-908;;046-992-845-049-441;;001-011-926-666-19X;;067-128-008-713-333;;042-707-152-982-721;;122-809-691-712-808;;106-050-274-424-345;;012-711-146-945-354;;117-217-326-016-281;;036-451-301-485-70X;;019-051-551-046-786;;087-584-278-992-154;;033-314-198-655-378;;056-884-862-136-744;;062-711-051-703-25X;;062-734-430-488-811;;054-730-552-904-467;;012-824-388-941-525;;101-399-753-456-811;;160-844-038-790-741;;053-281-636-765-882;;096-280-265-066-972;;037-075-661-995-228;;014-650-981-990-331;;018-685-440-192-770;;133-144-046-963-060;;035-158-148-481-657;;051-360-453-266-573;;032-231-805-935-110;;129-323-939-734-90X;;022-360-846-272-032;;074-018-237-029-54X;;047-873-366-537-768;;102-585-704-514-582;;081-566-653-717-676;;021-664-040-654-521;;072-128-344-560-453;;026-677-445-792-142;;023-949-272-702-475;;033-609-340-821-073;;008-828-971-692-080;;028-360-174-363-780;;115-613-908-303-581;;052-765-232-998-879;;048-793-450-973-294;;023-402-389-311-786;;013-200-131-164-434;;074-332-351-527-011;;144-772-027-009-809;;136-820-822-174-348;;036-201-107-307-430;;064-860-859-337-450;;005-968-867-921-803;;111-684-429-258-704;;007-779-807-314-526;;122-642-962-755-307;;029-348-025-272-230;;053-586-658-693-215,10.3998/ark.5550190.0006.623;;9486313;;10.1152/ajpregu.1998.274.2.r524;;10.2337/diacare.15.6.773;;1600836;;21709430;;10.1159/000328772;;12398518;;10.1021/jo020330x;;10.1016/j.tetasy.2006.12.001;;10.1039/b307638p;;14599018;;10.1002/1099-0690(200208)2002:16<2758::aid-ejoc2758>3.0.co;2-q;;10.1016/j.tet.2005.09.126;;10.1002/art.22692;;17530650;;10.1016/j.febslet.2011.04.034;;21515267;;2525437;;pmc1541735;;18240217;;10.1002/art.23045;;19479864;;10.1002/art.24576;;10.1002/clc.4960120106;;2912606;;9079408;;10.1093/humupd/2.2.118;;pmc4132586;;22705915;;10.1038/cmi.2012.15;;20644119;;10.1182/blood-2010-03-276162;;15762980;;pmc555850;;10.1186/1740-2557-2-1;;304778;;pmc1541167;;17977483;;10.4049/jimmunol.166.4.2878;;11160357;;14511932;;10.1016/s0140-6736(03)14368-1;;pmc1041377;;2964862;;10.1136/bjo.72.2.83;;10.1016/s0002-9440(10)63481-5;;14507631;;pmc1868314;;pmc193730;;12932293;;10.1186/ar793;;10.1086/322644;;11528573;;19752224;;10.4049/jimmunol.0803688;;23282416;;10.1097/wox.0b013e3181d675f8;;pmc3651146;;10.1111/j.1365-2249.2010.04143.x;;pmc2990924;;20682002;;10.1111/j.1365-2249.1992.tb03073.x;;1572092;;pmc1554305;;16761672;;10.4049/jimmunol.170.5.2719;;12594302;;10.1155/2013/764290;;pmc3852314;;24347833;;23871638;;10.1016/j.jaut.2013.06.004;;pmc2647597;;10.1513/pats.200606-130ms;;17684290;;9808568;;10.1182/blood.v92.10.3737;;1705662;;10.1056/nejm199103283241303;;10.1016/s1074-7613(00)80121-1;;10549628;;10.5772/20005;;10.5772/23899;;10.7326/0003-4819-140-2-200401200-00013;;10.7326/0003-4819-140-1-200401060-00010;;14706971;;pmc3693555;;23814683;;10.4172/2155-9899.s1-009;;1711833;;10.1136/ard.50.6.354;;pmc1004435;;10.1007/s11894-004-0053-y;;15341713;;10.1007/s00415-007-1003-z;;18094948;;10.1007/s12016-007-0030-y;;10.1136/jnnp.42.8.734;;490180;;pmc490307;;pmc1577135;;3156702;;pmc3305810;;10.1002/ana.21379;;18496841;;10.1093/humrep/16.6.1278;;11387306;;10.1590/s0365-05962006000300010;;15177771;;10.1016/j.clineuro.2004.02.018;;12656657;;10.1530/eje.0.1480383;;pmc442543;;10.1172/jci113401;;2449461;;10.1016/0002-9343(88)90058-7;;2966579;;pmc1001796;;10.1136/ard.44.12.852;;3909972;;21832158;;pmc3304102;;10.4049/jimmunol.1004019;;10.1097/01.mp.0000062995.72390.14;;12692198;;10.1136/thx.39.2.143;;6230751;;pmc459742;;10.1136/gut.18.6.472;;pmc1411515;;326639;;10.1186/ar386;;pmc64855;;11879540;;10.1016/s2255-5021(13)70010-5;;23588520;;6611346;;10.1007/bf00915293;;pmc3095831;;10837052;;10.1146/annurev.immunol.18.1.53;;18425726;;10.1002/eji.200838371;;10.1111/j.1432-2277.2005.00245.x;;16441359;;pmc3182565;;10.1155/2012/808724;;21969839;;21821914;;pmc3163963;;10.1172/jci57379;;10.1681/asn.2005091013;;16624930;;9824394;;10.1046/j.1365-2222.1998.00397.x;;10369864;;10.1093/hmg/8.7.1195;;9046059;;pmc1382398;;7883211;;10.1136/gut.36.2.171;;1055404;;pmc432520;;10.1073/pnas.72.4.1301;;10.1128/jvi.77.24.13323-13334.2003;;14645588;;pmc296062;;pmc2875650;;10.1186/ar2923;;20236453;;10415075;;21169553;;10.4049/jimmunol.1001597;;pmc4975520;;pmc1782226;;16476048;;10.1111/j.1365-2567.2005.02317.x;;10.4161/oxim.2.2.8177;;20357928;;pmc2763248;;10.1016/s0300-483x(03)00050-7;;12699906;;14571743;;22698429;;pmc3423512;;10.1016/j.jss.2012.05.053;;23049215;;pmc3460333;;10.3748/wjg.v18.i36.5065,"""Autoimmune Diseases"" from the Health Central Network. (20009).;;De la Cruz-Cordero, R. et al., ""Preparation of phosphostatine and phosphoepistatine from L-leucine via high diastereoselective reduction of 3-amino-2-ketophosphonates,"" ARKIVOC (vi):277-286, ARKAT USA, Inc. (2005).;;Deems, R.O. et al., ""Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys,"" Am. J Physiol. Regul. Integr. Comp. Physiol. 274:R524-R528, American Physiological Society (1998).;;Foley, J.E., ""Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus,"" Diabetes Care 15:773-784, American Diabetes Association (1992).;;Gómez-Solís, A. et al., ""Efficacy and Safety of Two Analogs of L-Carnitine on Rats Made Insulin Resistant by a High-Fructose Diet,"" Pharmacol. 88:1-8, S. Karger AG, Basel (2011).;;Mikolajczyk, M. et al., ""Chemoenzymatic Synthesis of Phosphocarnitine Enantiomers,"" J. Org. Chem. 67:7872-7875, American Chemical Society (2002).;;Ordóñez, M. and Cativiela, C., ""Stereoselective synthesis of gamma-amino acids,"" Tetrahedron Asymmetry 18:3-99, Elsevier Ltd. (2007).;;Stahl, R.H. and Wermuth, C.G., Eds., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, pp. 1-7, 84, 161-173, 214-215, 310-311, Wiley-VCH (2002).;;Wang, K. et al., ""Enzymatic synthesis of phosphocarnitine, phosphogabob and fosfomycin,"" Org. Biomol. Chem. 1: 3564-3569, The Royal Society of Chemistry (2003).;;Wróblewski, A.E. and Halajewska-Wosik, A., ""An Efficient Synthesis of Enantiomeric (S)-Phosphocarnitine,"" Eur. J. Org. Chem. 16: 2758-2763, Wiley-VCH Verlag GmbH, Weinheim (2002).;;Yamagishi, T. et al., ""Asymmetric synthesis of phosphonic acid analogues for acylcarnitine,"" Tetrahedron 62:54-65, Elsevier Ltd. (2006).;;Office Action mailed Oct. 25, 2011, in U.S. Appl. No. 12/575,856, filed Oct. 8, 2009 (now U.S. Pat. No. 8,536,362 B2), inventors: De La Cruz Cordero et al., U.S. Patent and Trademark Office, Alexandria, VA.;;Abdulahad, W.H. et al., ""Functional Defect of Circulating Regulatory CD4+ T Cells in Patients With Wegener's Granulomatosis in Remission,"" Arthritis & Rheumatism 56:2080-2091, American College of Rheumatology (2007).;;Alzabin, S. and Williams, R.O., ""Effector T cells in rheumatoid arthritis: Lessons from animal models,"" FEBS Lett. 585:3649-3659, Elsevier B.V. (2011).;;Barnett, A.J. et al., ""T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis),"" Clin. Exp. Immunol. 76:24-29, Blackwell Scientific Publications (1989).;;Bennett, J.C., ""The Role of T Lymphocytes in Rheumatoid Arthritis and Other Autoimmune Diseases,"" Arthritis Rheum. 58:S53-S57, American College of Rheumatology (2008).;;Berden, A.E. et al., ""Cellular Immunity in Wegener's Granulomatosis,"" Arthritis Rheum. 60:1578-1587, American College of Rheumatology (2009).;;Bhatia, R. et al., ""Lymphocyte Subsets in Acute Rheumatic Fever and Rheumatic Heart Disease,"" Clin. Cardiol. 12:34-38, John Wiley & Sons, Inc. (1989).;;Bulletti, C. et al., ""Reproductive failure due to spontaneous abortion and recurrent miscarriage,"" Hum. Reprod. Update 2:118-136, European Society for Human Reproduction and Embryology (1996).;;Cai, Y. et al., ""New insights of T cells in the pathogenesis of psoriasis,"" Cell. Mol. Immunol. 9:302-309, CSI and USTC (2012).;;Chadebech, P. et al., ""IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and FcalphaRI,"" Blood 116:4141-4147, The American Society of Hematology (2010).;;Chistiakov, D.A., ""Immunogenetics of Hashimoto's thyroiditis,"" J. Autoimmune Dis. 2:21 pages, BioMed Central Ltd. (2005).;;Colombo, M. et al., ""T and B lymphocytes in patients with chronic active hepatitis (CAH),"" Clin. Exp. Immunol. 30:4-9, Blackwell Scientific Publications (1977).;;Cope, A.P. et al., ""The central role of T cells in rheumatoid arthritis,"" Clin. Exp. Rheumatol. 25(Suppl. 46):S-4-S11, Clinical and Experimental Rheumatology (2007).;;Costello, P.J. et al., ""Psoriatic Arthritis Joint Fluids Are Characterized by CD8 and CD4 T Cell Clonal Expansions that Appear Antigen Driven,"" J. Immunol. 166:2878-2886, The American Association of Immunologists (2001).;;Dalakas, M.C. and Hohlfeld, R., ""Polymyositis and dermatomyositis,"" The Lancet 362:971-982, Lancet Publishing Group (2003).;;Deschènes, J. et al., ""Activated T lymphocytes in uveitis,"" Br. J. Ophthalmol. 72:83-87, BMJ Pub. Group (1988).;;Dornmair, K. et al., ""T-Cell-Mediated Autoimmunity: Novel Techniques to Characterize Autoreactive T-Cell Receptors,"" Am. J. Pathol. 163:1215-1226, American Society for Investigative Pathology (2003).;;Duftner, C. et al., ""Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis,"" Arthritis Res. Ther. 5:R292-R300, BioMed Central Ltd. (2003).;;Dworkin, M.S. et al., ""Reactive Arthritis and Reiter's Syndrome Following an Outbreak of Gastroenteritis Caused by Salmonella enteritidis,"" Clin. Infect. Dis. 33:1010-1014, Infectious Diseases Society of America (2001).;;Fasth, A.E.R. et al., ""T Cell Infiltrates in the Muscles of Patients with Dermatomyositis and Polymyositis Are Dominated by CD28null T Cells,"" J. Immunol. 183:4792-4799, The American Association of Immunologists, Inc. (2009).;;Ferran, M.F. and Santamaria-Babi, L.F., ""Pathological Mechanisms of Skin Homing T Cells in Atopic Dermatitis,"" WAO Journal 3:44-47, World Allergy Organization (2010).;;Fletcher, J.M. et al., ""T cells in multiple sclerosis and experimental autoimmune encephalomyelitis,"" Clin. Exp. Immunol. 162:1-11, Br. Society for Immunology (2010).;;Freeman, M. and Weetman, A.P., ""T and B cell reactivity to adrenal antigens in autoimmune Addison's disease,"" Clin. Exp. Immunol. 88:275-279, Br. Society for Immunology (1992).;;Ghaly, N.R. et al., ""Role of mast cells and T-lymphocytes in pemphigus vulgaris: significance of CD44 and the c-kit gene product (CD117)"" Eastern Mediterranean Health Journal 11:1009-1017, Eastern Mediterranean Regional Office of the World Health Organization (2005).;;Gianfrani, C. et al., ""Celiac Disease Association with CD8+ T Cell Responses: Identification of a Novel Gliadin-Derived HLA-A2-Restricted Epitope,"" J. Immunol. 170:2719-2726, The American Association of Immunologists (2003).;;Giurdanella, F. et al., ""A Possible Role for CD8+ T Lymphocytes in the Cell-Mediated Pathogenesis of Pemphigus Vulgaris,"" Mediators of Inflamm. 2013:1-35, Hindawi Publishing Corporation (2013).;;Gravano, D.M. and Hoyer, K.K., ""Promotion and prevention of autoimmune disease by CD8+ T cells,"" J. Autoimmun. 2013:1-12, Elsevier Ltd. (2013).;;Grunewald, J. and Eklund, A., ""Role of CD4+ T Cells in Sarcoidosis,"" Proc. Am. Thorac. Soc. 4:461-464, American Thoracic Society (2007).;;Grunewald, J. et al., ""T-Cell Expansions With Conserved T-Cell Receptor beta Chain Motifs in the Peripheral Blood of HLA-DRB1*0401 Positive Patients With Necrotizing Vasculitis,"" Blood 92:3737-3744, The American Society of Hemotology (1998).;;Hohlfeld, R. et al., ""Polymyositis Mediated by T Lymphocytes That Express the gamma/deltaReceptor,"" N. Engl. J. Med. 324:877-881, Massachusetts Medical Society (1991).;;Homann, D. et al., ""Autoreactive CD4+ T Cells Protect from Autoimmune Diabetes via Bystander Suppression Using the IL-4/Stat6 Pathway,"" Immunity 11:463-472, Cell Press (1999).;;Iwona, B.-S., ""Graves' Disease-The Interaction of Lymphocytes and Thyroid Cells,"" in Autoimmune Disorders-Pathogenetic Aspects, Mavragani, C.P., ed., Ch. 12, pp. 229-240, InTech (2011).;;Iwona, B.-S., ""Hashimoto's Thyroiditis-Interactions of Lymphocytes, Thyroid Cells and Fibroblasts,"" in Autoimmune Disorders-Pathogenetic Aspects, Mavragani, C.P., ed., Ch. 13, pp. 241-254, InTech (2011).;;Jimemez, S.A. and Derk, C.T., ""Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis,"" Ann. Intern. Med. 140:37-50, American College of Physicians (2004).;;Jin, J.-O. and Yu, Q., ""T Cell-Associated Cytokines in the Pathogenesis of Sjögren's Syndrome,"" J. Clin. Cell. Immunol. S!(9):1-14, OMICS Publishing Group (2013).;;Kahan, A. et al., ""Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies,"" Ann. Rheum. Dis. 50:354-358, BMJ Pub. Group (1991).;;Kalha, I. and Sellin, J.H., ""Common Variable Immunodeficiency and the Gastrointestinal Tract,"" Curr. Gastroenterol. Rep. 6:377-383, Current Science Inc. (2004).;;Kasper, L.H. et al., ""Regulatory mechanisms of the immune system in multiple sclerosis. T regulatory cells: turned on to turn off,"" J. Neurol. 254(Suppl 1):1/10-1/14, Springer-Verlag (2007).;;Kasperkiewicz, M. and Zillikens, D., ""The Pathophysiology of Bullous Pemphigoid,"" Clinic. Rev. Allerg. Immunol. 33:67-77, Humana Press Inc. (2007).;;Kawanami, S. et al., ""Lymphocyte function in myasthenia gravis,"" J. Neurol. Neurosurg. Psychiatr. 42:734-740, BMJ Pub. Group (1979).;;Kennedy, R. et al., ""Activated T cells in Graves' disease before treatment,"" Clin. Exp. Immunol. 59:377-382, Blackwell Scientific Publications (1985).;;Kivisäkk, P. et al., ""Localizing CNS immune surveillance: Meningeal APCs activate T cells curing EAE,"" Ann. Neurol. 65:457-469, Wiley-Liss (2009).;;Kotlan, B. et al., ""High anti-paternal cytotoxic T-lymphocyte precursor frequencies in women with unexplained recurrent spontaneous abortions,"" Hum. Reprod. 16:1278-1285, European Society of Human Reproduction and Embryology (2001).;;Lima, H.C., ""Role of regulatory T cells in the development of skin diseases,"" An. Bras. Dermatol. 81:269-281, Anais Brasileiros de Dermatologia (2006).;;Markovic-Plese, S. et al., ""The initiation of the autoimmune response in multiple sclerosis,"" Clin. Neurol. Neurosurg. 2004:1-5, Elsevier B.V. (2004).;;Mazziotti, G. et al., ""Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis,"" Eur. J. Endocrinol. 148:383-388, Society of the European Journal of Endocrinology (2003).;;Melms, A. et al., ""Thymus in Myasthenia Gravis: Isolation of T-Lymphocyte Lines Specific for the Nicotinic Acetylcholine Receptor from Thymuses of Myasthenic Patients,"" J. Clin. Invest. 81:902-908, The American Society for Clinical Investigation, Inc. (1988).;;Morimoto, C. et al., ""Abnormalities in CD4+ T-Lymphocyte Subsets in Inflammatory Rheumatic Diseases,"" Am. J. Med. 84:817-825, Excerpta Medica, New York (1988).;;Nordström, D. et al., ""Synovial fluid cells in Reiter's syndrome,"" Ann. Rheum. Dis. 44:852-856, BMJ Pub. Group (1985).;;Oh, H.-M. et al., ""Autoreactive Memory CD4+ T Lymphocytes That Mediate Chronic Uveitis Reside in the Bone Marrow through STAT3-Dependent Mechanisms,"" J. Immunol. 187:3338-3346, The American Association of Immunologists, Inc. (2011).;;Owen, D.A., ""Gastritis and Carditis,"" Modern Pathol. 16:325-341, The United States and Canadian Academy of Pathology, Inc. (2003).;;Rossi, G.A. et al., ""Pulmonary sarcoidosis: excess of helper T lymphocytes and T cell subset imbalance at sites of disease activity,"" Thorax 39:143-149, British Medical Association (1984).;;Sanchez-Tapias, J. et al., ""Lymphocyte populations in liver biopsy specimens from patients with chronic liver disease,"" Gut 18:472-475, BMJ Pub. Group (1977).;;Schirmer, M. et al., ""Circulating cytotoxic CD8+ CD28- T cells in ankylosing spondylitis,"" Arthritis Res. 4:71-76, BioMed Central Ltd. (2002).;;Shinjo, S.K. et al., ""Dermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics),"" Rev. Bras. Reumatol. 53:101-110, Elsevier Editora Ltda. (2013).;;Si, L. et al., ""T-Lymphocytes Subsets in Liver Tissues of Patients with Primary Biliary Cirrhosis (PBC), Patients with Primary Sclerosing Cholangitis (PSC) and Normal Controls,"" J. Clin. Immunol. 4:262-272, Plenum Publishing Corporation (1984).;;Sollid, L.M., ""Molecular Basis of Celiac Disease,"" Annu. Rev. Immunol. 18:53-81, Annual Reviews, Inc. (2000).;;Stinissen, P. and Hellings, N., ""Activation of myelin reactive T cells in multiple sclerosis: A possible role for T cell degeneracy?,"" Eur. J. Immunol. 38:1190-1193, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim (2008).;;Sun, Q. et al., ""An aggressive systematic strategy for acute respiratory distress syndrome caused by severe pneumonia after renal transplantation,"" Transpl. Int. 19:110-116, European Society for Organ Transplantation (2006).;;Szalay, B. et al., ""Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy,"" Clin. Dev. Immunol. 2012:1-8, Hindawi Publishing Corporation (2012).;;Takahashi, H. et al., ""Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice,"" J. Clin. Invest. 121:3677-3688, American Society for Clinical Investigation (2011).;;Tipping, P.G. and Holdsworth, S.R., ""T Cells in Crescentic Glomerulonephritis,"" J. Am. Soc. Nephrol. 17:1253-1263, American Society of Nephrology (2006).;;Torres, M.J. et al., ""Circulating CLA+ lymphocytes from children with atopic dermatitis contain an increased percentage of cells bearing staphylococcal-related T-cell receptor variable segments,"" Clin. Exp. Allergy 28:1264-1272, Blackwell Science Ltd. (1998).;;Vaidya, B. et al., ""The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus,"" Hum. Mol. Genet. 8:1195-1199, Oxford University Press (1999).;;Van Alderwegen, I.E. et al., ""T cell subsets in immunologically-mediated glomerulonephritis,"" Histol. Histopathol. 12:241-250, Histology and Histopathology, Spain (1997).;;Vargas, J.A. et al., ""Functional defect of T cells in autoimmune gastritis,"" Gut 36:171-175, British Medical Association (1995).;;Wands, J.R. and Isselbacher, K.J., ""Lymphocyte Cytotoxicity to Autologous Liver Cells in Chronic Active Hepatitis,"" Proc. Natl. Acad. Sci. USA 72:1301-1303, National Academy of Sciences (1975).;;Wang, Y. et al., ""CD8+ T Cells Mediate Recovery and Immunopathology in West Nile Virus Encephalitis,"" J. Virol. 77:13323-13334, American Society for Microbiology (2003).;;Wilde, B. et al., ""T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?,"" Arthritis Res. Ther. 12:1-9, BioMed Central Ltd. (2010).;;Wong, H.K. et al., ""Abnormal NJ-kappaB Activity in T Lymphocytes from Patients with Systemic Lupus Eythematosus Is Associated with Decreased p65-RelA Protein Expression,"" J. Immunol. 163:1682-1689,The American Association of Immunologists (1999).;;Yang, G.-X. et al., ""CD8 T Cells Mediate Directed Biliary Ductule Damage in Nonobese Diabetic Autoimmune Biliary Disease,"" J. Immunol. 186:1259-1267, The American Association of Immunologists, Inc. (2011).;;Dejaco, C. et al., ""Imbalance of regulatory T cells in human autoimmune diseases,"" Immunology 117:289-300, Blackwell Publishing Ltd. (2005).;;Abd-Allah, A.R.A. et al., ""Pro-inflammatory and oxidative stress pathways which compromise sperm motility and survival may be altered by L-carnitine,"" Oxid. Med. Cell. Longev.2:73-81, Landes Bioscience (2009).;;Arafa, H.M.M. et al., ""Immunomodulatory effects of L-carnitine and q10 in mouse spleen exposed to low-frequency high-intensity magnetic field,"" Toxicology 187:171-181, Elsevier Science Ltd. (2003).;;Gasbarrini, G. et al., ""Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report,"" Hepatogastroenterology 50:1385-1389, H.G.E. Update Medical Publishing, Athens (2003).;;Idrovo, J.-P. et al., ""Stimulation of Carnitine Palmitoyltransferase 1 Improves Renal Function and Attenuates Tissue Damage after Ischemia/Reperfusion,"" J. Surg. Res. 177:157-164, Elsevier Inc. (2012).;;Merra, G. et al., ""Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases,"" World J. Gastroenterol. 18:5065-5071, Baishideng Publishing Group (2012).",INACTIVE
419,US,B2,US 11000633 B2,170-516-140-441-791,2021-05-11,2021,US 201615574046 A,2016-05-17,PT 10847615 A;;EP 15169249 A;;PT 10912216 A;;IB 2016052875 W,2015-05-14,"Ureteral stent, methods and uses thereof","Stents and methods for producing stents are provided. The stent includes a polymeric substrate comprised of 10-50% (w/w) of alginate and 45-85% (w/w) of gelatine and further includes a polymeric biodegradable resin for coating said polymeric substrate. The stent can also include a contrast agent. The stent can further include a crosslinking agent. The method for producing the stent includes dissolving the alginate and gelatine in water and stirring to obtain a polymeric substrate. The method also includes adding a crosslinking agent to the substrate, injecting the substrate into a mold to obtain the stent, placing the stent in a first alcohol solution, and placing the stent in a crosslinking agent solution. The method further includes placing the stent in a second alcohol solution, and a series of interchanging drying and immersing steps.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH AND THERAPIES—A4TEC;;ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENG,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ;;NUNES CORREIA PINTO JORGE MANUEL,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES AND THERAPIES - A4TEC (2017-11-07),https://lens.org/170-516-140-441-791,Granted Patent,yes,6,1,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/04;;A61F2/04;;A61L31/10;;A61L31/14;;A61L31/16;;B29C45/00;;B29C71/00;;B29L31/00,,30,28,069-412-240-548-046;;054-462-155-361-157;;132-457-361-658-665;;001-591-775-469-466;;068-127-580-059-282;;069-785-071-160-869;;016-132-088-036-724;;054-324-477-746-361;;091-271-387-131-051;;006-555-449-698-312;;066-724-404-458-295;;002-769-425-721-168;;027-125-789-019-429;;025-717-303-945-868;;070-600-440-407-639;;087-415-510-107-31X;;024-270-471-124-722;;043-184-905-499-416;;026-392-013-964-626;;016-497-913-211-484;;110-743-298-333-604;;022-580-772-722-989;;003-658-166-774-103;;052-367-809-883-512;;023-169-109-811-797;;012-720-051-696-302;;061-822-657-398-275;;036-677-083-255-931,10.1002/app.21610;;10.1177/1756287210370699;;pmc3126070;;21789086;;10.1002/mabi.200600069;;16881042;;10.1002/jbm.b.33237;;24965000;;10.1016/s1389-1723(00)87103-0;;16232687;;10.1016/j.juro.2009.09.073;;20022028;;10.1016/j.supflu.2013.01.004;;21436510;;10.1088/1748-6041/6/2/025010;;10.1007/s10856-011-4285-8;;21437640;;10.1016/j.juro.2009.11.035;;20092835;;10.1038/nrurol.2014.340;;25534997;;10.1016/j.eururo.2006.05.054;;16814926;;18571311;;10.1016/j.eururo.2008.06.010;;12803989;;10.1089/089277903321618734;;12686808;;10.1097/01.ju.0000055600.18515.a1;;10.3109/00365599.2010.544673;;21222571;;18186698;;10.1089/end.2005.0085;;10.1089/end.1999.13.107;;10213104;;10.1097/00005392-200010000-00074;;10992415;;10.1016/s0022-5347(05)67199-6;;10.1111/j.1464-410x.2011.10903.x;;22313688;;10.1016/j.ijbiomac.2005.03.012;;15896839;;10.1016/s0022-5347(05)65128-2;;11956478;;10.1097/00005392-200205000-00071;;10.1046/j.1464-410x.1997.00484.x;;9439407;;12184080;;10.1089/089277902760102785;;10.1089/end.2009.0516;;20073560;;24147536;;10.1111/iju.12297;;24997428;;10.1016/j.jmbbm.2014.06.004;;15360280;;10.1021/bm049879r,"Barros, Alexandre A., et al. “Tailor made degradable ureteral stents from natural origin polysaccharides.” Tenth Conference on Supercritical Fluids and Their Applications. University of Salerno, 2013.;;Fan, Lihong, et al. “Preparation and characterization of alginate/gelatin blend fibers.” Journal of Applied Polymer Science 96.5 (2005): 1625-1629.;;Al-Aown et al. “Ureteral stents: new ideas, new designs.” Therapeutic Advances in Urology 2.2 (2010): 85-92.;;Association for the Advancement of Medical Instrumentation. “Biological Evaluation of Medical Devices—Part 5: Tests for In Vitro Cytotoxicity” AAMI, 2009. 13 pages.;;Augst et al. “Alginate hydrogels as biomaterials.” Macromolecular Bioscience 6.8 (2006): 623-633.;;Barros et al. “Bioresorbable ureteral stents from natural origin polymers.” Journal of Biomedical Materials Research Part B: Applied Biomaterials 103.3 (2015): 608-617.;;Blandino et al. “Formation of calcium alginate gel capsules: influence of sodium alginate and CaCl 2 concentration on gelation kinetics.” Journal of Bioscience and Bioengineering 88.6 (1999): 686-689.;;Chew et al. “Next generation biodegradable ureteral stent in a yucatan pig model.” The Journal of Urology 183.2 (2010): 765-771.;;Duarte et al. “Unleashing the potential of supercritical fluids for polymer processing in tissue engineering and regenerative medicine.” The Journal of Supercritical Fluids 79 (2013): 177-185.;;Jejurikar et al. “A novel strategy for preparing mechanically robust ionically cross-linked alginate hydrogels.” Biomedical Materials 6.2 (2011): 025010.;;ANAND P. KHANDWEKAR; MUKESH DOBLE: ""Physicochemical characterisation and biological evaluation of polyvinylpyrrolidone-iodine engineered polyurethane (Tecoflex)"", JOURNAL OF MATERIALS SCIENCE: MATERIALS IN MEDICINE, KLUWER ACADEMIC PUBLISHERS, BO, vol. 22, no. 5, 25 March 2011 (2011-03-25), Bo, pages 1231 - 1246, XP019910198, ISSN: 1573-4838, DOI: 10.1007/s10856-011-4285-8;;Krambeck et al. “A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent.” The Journal of Urology 183.3 (2010): 1037-1043.;;Lange et al. “Ureteral stent-associated complications—Where we are and where we are going.” Nature Reviews Urology 12.1 (2015): 17-25.;;Liatsikos et al. “Application of paclitaxel-eluting metal mesh stents within the pig ureter: an experimental study.” European Urology 51.1 (2007): 217-223.;;Lima et al. “Endoscopic closure of transmural bladder wall perforations.” European Urology 56.1 (2009): 151-158.;;Lingeman et al. “Phase I trial of a temporary ureteral drainage stent.” Journal of Endourology 17.3 (2003): 169-171.;;Lingeman et al. “Use of a temporary ureteral drainage stent after uncomplicated ureteroscopy: results from a phase II clinical trial.” The Journal of Urology 169.5 (2003): 1682-1688.;;Lumiaho et al. “A short biodegradable helical spiral ureteric stent provides better antireflux and drainage properties than a double-J stent.” Scandinavian Journal of Urology and Nephrology 45.2 (2011): 129-133.;;Lumiaho et al. “Drainage and antireflux characteristics of a biodegradable self-reinforced, self-expanding X-ray-positive poly-L, D-lactide spiral partial ureteral stent: an experimental study.” Journal of Endourology 21.12 (2007): 1559-1564.;;Lumiaho et al. “New bioabsorbable polylactide ureteral stent in the treatment of ureteral lesions: an experimental study.” Journal of endourology 13.2 (1999): 107-112.;;Lumiaho et al. “The morphological, in situ effects of a self-reinforced bioabsorbable polylactide (SR-PLA 96) ureteric stent; an experimental study.” The Journal of Urology 164.4 (2000): 1360-1363.;;Mendez-Probst et al. “The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial.” BJU international 110.5 (2012): 749-754.;;Mohanty et al. “Microscopic structure of gelatin coacervates.” International Journal of Biological Macromolecules 36.1 (2005): 39-46.;;Olweny et al. “Evaluation of the use of a biodegradable ureteral stent after retrograde endopyelotomy in a porcine model.” The Journal of Urology 167.5 (2002): 2198-2202.;;Schlick et al. “Potentially useful materials for biodegradable ureteric stents.” BJU International 80.6 (1997): 908-910.;;Taljia et al. “Bioabsorbable SR-PLGA horn stent after antegrade endopyelotomy: a case report.” Journal of Endourology 16.5 (2002): 299-302.;;Venkatesan et al. “Polymers as ureteral stents.” Journal of endourology 24.2 (2010): 191-198.;;Zhang et al. “Braided thin-walled biodegradable ureteral stent: Preliminary evaluation in a canine model.” International Journal of Urology 21.4 (2014): 401-407.;;Zou et al. “A resorbable bicomponent braided ureteral stent with improved mechanical performance.” Journal of the Mechanical Behavior of Biomedical Materials 38 (2014): 17-25.;;Kong et al. “Controlling rigidity and degradation of alginate hydrogels via molecular weight distribution.” Biomacromolecules 5.5 (2004): 1720-1727.",ACTIVE
420,US,B1,US 10706195 B1,071-488-711-451-025,2020-07-07,2020,US 201815989469 A,2018-05-25,US 201815989469 A,2018-05-25,"System, method, and computer program product for over-constraint/deadcode detection in a formal verification","The present disclosure relates to a method for use in the formal verification of an electronic circuit. Embodiments may include receiving, using a processor, a portion of an electronic circuit design and analyzing a syntactic structure of a string associated with the electronic circuit design. Embodiments may also include generating a parse tree, based upon, at least in part, the analysis and traversing the parse tree to identify one or more conditional nodes. Embodiments may further include generating a new node for each of the one or more conditional nodes and displaying, at a graphical user interface, a check, at least one of the one or more conditional nodes or the new node prior to performing either register-transfer-level RTL synthesis or final synthesis.",CADENCE DESIGN SYSTEMS INC,REZENDE BARBOSA LUIS HUMBERTO;;DOS SANTOS PEREIRA RAQUEL LARA;;FURTADO CAIO ALVES;;DIAS VITORINO BRENO AUGUSTO;;CREPALDE MIRLAINE APARECIDA;;DA SILVA MANTINI VIANA RODRIGO;;PRATES LUCAS DUARTE,CADENCE DESIGN SYSTEMS INC (2018-05-23),https://lens.org/071-488-711-451-025,Granted Patent,yes,19,2,1,1,0,G06F30/3323;;G06F30/3323;;G06F30/30;;G06F30/31;;G06F30/337;;G06F30/367;;G06F30/373;;G06F30/398;;G06F2111/04,G06F30/30;;G06F30/31;;G06F30/3323;;G06F30/337;;G06F30/367;;G06F30/373;;G06F30/398,,0,0,,,,ACTIVE
421,CN,A,CN 113318278 A,074-978-560-955-883,2021-08-31,2021,CN 202110698734 A,2016-05-17,EP 15169249 A;;PT 10847615 A;;PT 10912216 A;;CN 201680040009 A,2015-05-14,"An ureteral stent, methods and uses thereof","The invention relates to an ureteral stent, methods and uses thereof. The present disclosure relates to ureteral stents, in particular a composition for ureteral stents that are used to ensure patency of a channel, namely the ureter which may be compromised, for example, by a urinary stone, neoplasia or a surgical procedure The solution now disclosed relates to a composition for biodegradable stents, in particular to ureteral stents and method for obtain such stents. This disclosure overcomes the problems encountered in the available stents, in particular, ureteral stents, as it namely: avoids the need for a second surgery for stent removal; decreases the morbidity in patients submitted to a surgical procedure; decreases or eliminates the risk of infection after the implantation of the ureteral stent.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH AND THERAPIES A4TEC,GONCALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTONIO;;RODRIGUES DE LIMA ESTEVAO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRE;;NUNES CORREIA PINTO JORGE MANUEL,,https://lens.org/074-978-560-955-883,Patent Application,no,4,0,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/04;;A61F2/04;;A61L31/10;;A61L31/14;;A61L31/16;;A61L31/18,,2,0,,,"ALEXANDRE A. BARROS等: ""Bioresorbable ureteral stents from natural origin polymers"", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH B: APPLIED BIOMATERIALS》;;LIHONG FAN等: ""Preparation and Characterization of Alginate/Gelatin Blend Fibers"", 《JOURNAL OF APPLIED POLYMER SCIENCE》",DISCONTINUED
422,US,A1,US 2018/0296734 A1,122-466-858-741-618,2018-10-18,2018,US 201615574046 A,2016-05-17,PT 10847615 A;;EP 15169249 A;;PT 10912216 A;;IB 2016052875 W,2015-05-14,"AN URETERAL STENT, METHODS AND USES THEREOF","Stents and methods for producing stents are provided. The stent includes a polymeric substrate comprised of 10-50% (w/w) of alginate and 45-85% (w/w) of gelatine and further includes a polymeric biodegradable resin for coating said polymeric substrate. The stent can also include a contrast agent. The stent can further include a crosslinking agent. The method for producing the stent includes dissolving the alginate and gelatine in water and stirring to obtain a polymeric substrate. The method also includes adding a crosslinking agent to the substrate, injecting the substrate into a mold to obtain the stent, placing the stent in a first alcohol solution, and placing the stent in a crosslinking agent solution. The method further includes placing the stent in a second alcohol solution, and a series of interchanging drying and immersing steps.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEE RINGANDCELL BASED TECH AND THERAPIES A4TEC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ;;NUNES CORREIA PINTO JORGE MANUEL,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES AND THERAPIES - A4TEC (2017-11-07),https://lens.org/122-466-858-741-618,Patent Application,yes,0,2,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/10;;A61L31/04;;A61L31/14;;A61L31/16;;B29C45/00;;B29C71/00,,0,0,,,,ACTIVE
423,KR,A,KR 20180020958 A,081-445-002-439-675,2018-02-28,2018,KR 20177032502 A,2016-05-17,PT 10847615 A;;EP 15169249 A;;PT 10912216 A;;IB 2016052875 W,2015-05-14,"요관 스텐트와 그의 제조방법, 및 그의 용도","본 발명은 요관 스텐트, 특히 예를 들어 요석, 신생물 또는 외과 시술에 의해 손상되었을 수 있는 통로, 즉 요관의 개통성을 보장하기 위해 사용되는 요관 스텐트를 위한 조성물에 관한 것이다. 본 발명은 생분해성 스텐트, 특히 요관 스텐트를 위한 조성물 및 그러한 스텐트를 제작하기 위한 방법에 관련된 것이다. 본 발명은 종래의 스텐트, 특히 요관 스텐가 직면한 문제들을 다음과 같이 극복한다: 스텐트 제거를 위한 2차적인 시술 방지; 외과 시술을 받는 환자의 이환율 감소; 요관 스텐트의 삽입 이후 감염 위험요소를 감소시키거나 또는 제거.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONCALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTONIO;;RODRIGUES DE LIMA ESTEVAO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRE;;NUNES CORREIA PINTO JORGE MANUEL,,https://lens.org/081-445-002-439-675,Patent Application,no,1,0,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/04;;A61L31/10;;A61L31/14;;A61L31/16,,0,0,,,,ACTIVE
424,EP,B1,EP 3294361 B1,100-087-779-600-800,2020-05-20,2020,EP 16726187 A,2016-05-17,IB 2016052875 W;;PT 10847615 A;;EP 15169249 A;;PT 10912216 A,2015-05-14,"AN URETERAL STENT, METHODS AND USES THEREOF",,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ;;NUNES CORREIA PINTO JORGE MANUEL,,https://lens.org/100-087-779-600-800,Granted Patent,yes,3,0,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/04;;A61L31/10;;A61L31/14,,1,0,,,"ALEXANDRE A. BARROS ET AL: ""Bioresorbable ureteral stents from natural origin polymers"", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART B: APPLIED BIOMATERIALS, vol. 103, no. 3, 26 June 2014 (2014-06-26) , pages 608-617, XP055223832, US ISSN: 1552-4973, DOI: 10.1002/jbm.b.33237",ACTIVE
425,CN,A,CN 107847646 A,151-231-846-757-845,2018-03-27,2018,CN 201680040009 A,2016-05-17,EP 15169249 A;;PT 10847615 A;;PT 10912216 A;;IB 2016052875 W,2015-05-14,"An ureteral stent, methods and uses thereof","The present disclosure relates to ureteral stents, in particular a composition for ureteral stents that are used to ensure patency of a channel, namely the ureter which may be compromised, for example, by a urinary stone, neoplasia or a surgical procedure The solution now disclosed relates to a composition for biodegradable stents, in particular to ureteral stents and method for obtain such stents. This disclosure overcomes the problems encountered in the available stents, in particular, ureteral stents, as it namely: avoids the need for a second surgery for stent removal; decreases the morbidity in patients submitted to a surgical procedure; decreases or eliminates the risk of infection after the implantation of the ureteral stent.",ASS FOR THE ADVANCEMENT OF TISSUE ENG AND CELL BASED TECH AND THERAPIES A4TEC,GONCALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTONIO;;RODRIGUES DE LIMA ESTEVAO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRE;;NUNES CORREIA PINTO JORGE MANUEL,,https://lens.org/151-231-846-757-845,Patent Application,no,5,0,12,13,0,A61L31/041;;A61L31/18;;A61L31/10;;A61L31/16;;A61L31/148;;A61F2/04;;A61L2300/404;;A61L2300/416;;A61L2300/408;;A61L2430/22;;A61L2300/41;;A61F2250/0067;;A61F2002/048;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L2430/22;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61L31/041;;A61L31/042;;A61L31/045;;A61L31/10;;A61L31/148;;A61L31/16;;A61L2300/408;;A61L2300/404;;A61L2300/416;;A61L2300/41;;A61L2430/22;;A61L31/10;;A61L31/148;;A61L2430/22;;A61L31/045;;A61L31/042;;A61F2/04;;A61F2002/048;;A61F2240/001;;A61F2250/0067;;A61F2250/0096;;A61L31/041;;A61L31/16;;B29C45/0001;;B29C71/0009;;B29K2089/00;;B29L2031/753,A61L31/04;;A61L31/10;;A61L31/14,,4,0,,,"ALEXANDRE A. BARROS 等: ""Tailor made degradable ureteral stents from natural origin polysaccharides"", 《TENTH CONFERENCE ON SUPERCRITICAL FLUIDS AND THEIR APPLICATIONS》;;LIHONG FAN 等: ""Preparation and Characterization of Alginate/Gelatin Blend Fibers"", 《JOURNAL OF APPLIED POLYMER SCIENCE》;;夏扬: ""海藻酸钠-明胶共混体系为载体的可注射式组织工程骨的研究"", 《中国博士学位论文全文数据库 医药卫生科技辑》;;ALEXANDRE A. BARROS 等: ""Bioresorbable ureteral stents from natural origin polymers"", 《SOCIETY FOR BIOMATERIALS》",DISCONTINUED
426,DE,D1,DE 602004017043 D1,132-955-126-510-144,2008-11-20,2008,DE 602004017043 T,2004-10-28,PT 10303403 A;;PT 2004000026 W,2003-10-28,MEHRACHSIGE UNIVERSALTESTMASCHINE,"The invention concerns a multiaxial universal testing machine, which allows evaluating the mechanical behavior and performance of materials with planar structures, such as fabrics, composites and laminates. The machine comprises 4 horizontal axes, each one with 2 arms, resulting in a final arrangement of 8 gripping jaws at 45°, displaceable along slide rails and moved by the action of 8 independent motors. The connection between a gripping jaw and its respective motor is assured by a linear actuator. The test specimen is fixed by the gripping jaws and can be subject to tensile, compression and fatigue testing, making possible the analysis of the materials behavior under simultaneous multi-directional loads.",UNIV DO MINHO,MONTEIRO JO O LUIS;;DA ROCHA ANA MARIA;;LIMA MARIO FILIPE;;MARTINS JULIO MANUEL DE SO;;ARA JO MARIO DUARTE DE;;COUTO CARLOS ALBERTO;;MENDES FERNANDO JORGE,,https://lens.org/132-955-126-510-144,Granted Patent,no,0,0,10,10,0,G01N3/08;;G01N2203/0016;;G01N2203/0073;;G01N2203/0085;;G01N2203/025;;G01N2203/0254;;G01N2203/0278;;G01N2203/0282;;G01N3/08;;G01N2203/0282;;G01N2203/0016;;G01N2203/0278;;G01N2203/0073;;G01N2203/0254;;G01N2203/0085;;G01N2203/025,G01N3/08;;G01N3/00;;G01N3/02,,0,0,,,,INACTIVE
427,WO,A1,WO 2012/044189 A1,095-108-958-901-757,2012-04-05,2012,PT 2011000033 W,2011-09-26,PT 10531510 A,2010-09-29,"A NEW HYDRATED CRYSTALLINE FORM OF PERINDOPRIL ERBUMINE, METHODS FOR ITS PREPARATION AND ITS USE IN PHARMACEUTICAL PREPARATIONS","The object of this invention is a new hydrated form of perindopril erbumine (I) characterized by different techniques, including powder and single crystal X-ray diffraction, being useful in the preparation of pharmaceutical compounds. This new form may be obtained by crystallization from an alcoholic solution or directly by grinding of other crystalline forms. All the synthetic pathways described lead to new form starting from any of the perindopril erbumine polymorphic forms.",INST SUPERIOR TECNICO;;DUARTE MARIA TERESA NOGUEIRA LEAL DA SILVA;;ANDRE VANIA MAFALDA DE OLIVEIRA;;SILVA LUIS MANUEL CUNHA;;SANTOS PEDRO PAULO DE LACERDA E OLIVEIRA;;EMPIS JOSE MANUEL ABECASSIS,DUARTE MARIA TERESA NOGUEIRA LEAL DA SILVA;;ANDRE VANIA MAFALDA DE OLIVEIRA;;SILVA LUIS MANUEL CUNHA;;SANTOS PEDRO PAULO DE LACERDA E OLIVEIRA;;EMPIS JOSE MANUEL ABECASSIS,,https://lens.org/095-108-958-901-757,Patent Application,yes,26,1,4,4,0,A61P9/00;;A61P9/12;;C07D209/42,C07D209/42;;A61K31/405;;A61P9/12,,0,0,,,,PENDING
428,ES,T3,ES 2812678 T3,134-722-591-163-411,2021-03-17,2021,ES 16726187 T,2016-05-17,PT 2015108476 A;;EP 15169249 A;;PT 2016109122 A;;IB 2016052875 W,2015-05-14,"Stent uretral, métodos y usos del mismo",Stent que comprende un sustrato polimérico en la que el sustrato polimérico comprende un 10-50% (p/p) de alginato y un 45-85% (p/p) de gelatina; y una resina biodegradable polimérica para recubrir dicho sustrato polimérico.,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONSALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;RODRIGUES DE LIMA ESTÊVÃO AUGUSTO;;RIBEIRO OLIVEIRA CARLOS ANDRÉ;;NUNES CORREIA PINTO JORGE MANUEL,,https://lens.org/134-722-591-163-411,Granted Patent,no,0,0,1,13,0,,A61L31/04;;A61L31/10;;A61L31/14,,0,0,,,,ACTIVE
429,US,A1,US 2022/0372043 A1,053-230-074-762-101,2022-11-24,2022,US 202017618971 A,2020-06-15,PT 11558119 A;;IB 2020055584 W,2019-06-14,"SMALL CATIONIC ORTHO-5,15-DI-HETEROARYL-PORPHYRINS DERIVATIVES AND THEIR APPLICATIONS IN PHOTOINACTIVATION OF MICROORGANISMS","The present invention relates to small cationic ortho-5,15-di-heteroaryl porphyrin derivatives, in particular porphyrins, chlorins or bacteriochlorin of formula (I) or pharmaceutically acceptable salts thereof. This invention also relates to the use of the above-mentioned cationic ortho-5,10-di-heteroaryl porphyrin derivatives of Formula (I) or a pharmaceutically acceptable salts thereof, in photodynamic inactivation of microorganisms, where the referred derivatives are able to treat the same in the presence of an adequate light. The present invention also describes pharmaceutical compositions comprising one or more of the cationic ortho-5,10-di-heteroaryl porphyrin derivatives, in particular prophyrins, chlorins or bacteriochlorins of Formula (I), or pharmaceutically acceptable salts thereof, for the treatment of bacterial and/or fungi and/or yeasts and/or viral infections, in humans or animals.",UNIV DE COIMBRA,MIGUÉNS PEREIRA MARIA;;DUARTE JORGE DA SILVA GABRIELA CONCEIÇÅO;;DA SILVA ARNAUT MOREIRA LUIS GUILERNE;;DOS SANTOS VINAGREIRO CAROLINA;;BLANCO KATE CRISTINA;;SALVADOR BAGNATO VANDERIEI;;MAYUMI INADA NATALIA,UNIVERSIDADE DE COIMBRA (2021-12-13),https://lens.org/053-230-074-762-101,Patent Application,yes,0,0,7,7,0,C09B47/00;;A61P31/04;;A61K31/555;;A61K41/0057;;A61K45/06;;C07D487/22,C07D487/22;;A61K31/555;;A61K41/00;;A61K45/06;;A61P31/04,,0,0,,,,PENDING
430,WO,A1,WO 2015/173206 A1,172-242-494-637-289,2015-11-19,2015,EP 2015060395 W,2015-05-11,ES 201430701 A,2014-05-13,"ARTIFICIAL DERMIS, ARTIFICIAL SKIN, METHODS FOR THEIR PREPARATION AND THEIR USES","The present invention relates to an artificial dermis comprising a first gel layer of clotted blood plasma comprising platelets and dermal cells, and a second gel layer of clotted blood plasma comprising platelets and dermal cells, and a polymer net situated between the first and the second gel layers. The invention also relates to an artificial skin comprising said artificial dermis with at least a layer of epithelial cells. The invention discloses methods for the preparation of the artificial dermis and the artificial skin, as well as their uses in the preparation of a medicament, in particular for the treatment of re-epithelialization of a patient in need thereof.",FUNDACION TEKNIKER;;CT DE INVESTIGACIONES ENERGÉTICAS MEDIOAMBIENTALES Y TECNOLÓGICAS CIEMAT;;CT COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS CCST,MERINO ÁLVAREZ SANTOS;;RETOLAZA MUÑOA ARITZ;;AZCÁRATE LETURIA SABINO;;JORCANO NOVAL JOSÉ LUIS;;HOLGUÍN FERNÁNDEZ ALMUDENA;;DUARTE GONZÁLEZ BLANCA;;MEANA INFIESTA ÁLVARO;;GARCÍA PÉREZ EVA;;GÓMEZ LLAMES SARA,,https://lens.org/172-242-494-637-289,Patent Application,yes,2,2,3,3,0,A61L27/60;;A61L27/60;;A61L27/3813;;C12N5/0625,A61L27/60,,0,0,,,,PENDING
431,EP,B1,EP 3293429 B1,008-450-399-607-209,2019-06-26,2019,EP 16306137 A,2016-09-09,EP 16306137 A,2016-09-09,DEFLECTOR INTENDED TO GUIDE A LINE AND RELATED GUIDING ASSEMBLY,,TECHNIP FRANCE,LOPES DE CASTRO MÁRIO AUGUSTO;;MOZA JUCIMAR COELHO;;LUCENA LEONARDO-ALEXANDRE;;NASCIMENTO CAROLINA-PAIVA;;CORREA JOSÉ-ROBERTO;;DUARTE PAULA;;GIL PAULO-WEBBER;;FERREIRA LUIS PAULO;;SANTOS CARLOS-FILIPE,,https://lens.org/008-450-399-607-209,Granted Patent,yes,4,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235;;H02G1/10;;H02G9/02,,0,0,,,,ACTIVE
432,PT,A,PT 105977 A,044-443-409-032-753,2013-04-30,2013,PT 10597711 A,2011-10-30,PT 10597711 A,2011-10-30,MÉTODO PARA A PRODUÇÃO DE UMA PREPARAÇÃO ENZIMÁTICA COM ACTIVIDADE DE SUPERÓXIDO DISMUTASE,"A PRESENTE INVENÇÃO DIZ RESPEITO A UM NOVO MÉTODO PARA PRODUÇÃO DE UMA PREPARAÇÃO ENZIMÁTICA COM ATIVIDADE DE SUPERÓXIDO DISMUTASE CARACTERIZADO POR UTILIZAR COMO MATÉRIA-PRIMA SOLUÇÕES AQUOSAS DE XILOSE E QUE PODEM TAMBÉM CONTER OUTRAS PENTOSES OU HEXOSES, TAIS COMO GLUCOSE, BEM COMO OUTROS COMPOSTOS. A SOLUÇÃO CONTENDO XILOSE E OUTRAS PENTOSE E/OU HEXOSES É FERMENTADA A BIOMASSA COM UMA ESTIRPE DE LEVEDURA CAPAZ DE ASSIMILAR PENTOSES E/OU HEXOSES. AS CÉLULAS DE LEVEDURA SÃO REMOVIDAS DA SOLUÇÃO POR FILTRAÇÃO, CENTRIFUGAÇÃO OU OUTROS PROCEDIMENTOS ADEQUADOS E LISADAS. TÉCNICAS DE SEPARAÇÃO SUBSEQUENTES PRODUZEM UMA FRAÇÃO OU FRAÇÕES QUE APRESENTAM ALTO TEOR PROTEICO E ATIVIDADE DE SUPERÓXIDO DISMUTASE A PARTIR DAS QUAIS SE PODE RECUPERAR UM EXTRATO PROTEICO COM ATIVIDADE DE SUPERÓXIDO DISMUTASE COM APLICAÇÕES EM MEDICINA, E NAS INDÚSTRIAS ALIMENTAR, NUTRACÊUTICA, FARMACÊUTICA, QUÍMICA E DAS BIORREFINARIAS",UNIV LISBOA;;NAC DE EN E GEOL LAB,DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;AMARO FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES;;LOPES SONIA CRISTINA PARDAL;;CORVO MARIA LUISA TEIXEIRA DE AZEVEDO RODRIGUES;;GIRIO FRANCISCO MANUEL FERREIRA,,https://lens.org/044-443-409-032-753,Patent Application,no,0,0,1,1,0,,C12P21/02;;C12N9/02,,0,0,,,,DISCONTINUED
433,ES,B1,ES 2551143 B1,169-039-846-301-585,2016-07-01,2016,ES 201430701 A,2014-05-13,ES 201430701 A,2014-05-13,"Dermis artificial, piel artificial, métodos para su preparación y sus usos",,FUNDACIÓN TEKNIKER;;CENTRO DE INVESTIG ENERGÉTICAS MEDIOAMBIENTALES Y TECNOLÓGICAS (CIEMAT);;CENTRO COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS (CCST),MERINO ALVAREZ SANTOS;;RETOLAZA MUNOA ARITZ;;AZCARATE LETURIA SABINO;;JORCANO NOVAL JOSÉ LUIS;;HOLGUIN FERNANDEZ ALMUDENA;;DUARTE GONZALEZ BLANCA;;MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GOMEZ LLAMES SARA,,https://lens.org/169-039-846-301-585,Granted Patent,no,0,0,3,3,0,A61L27/60;;A61L27/60;;A61L27/3813;;C12N5/0625,A61L27/60;;A61L27/38;;C12N5/071,,0,0,,,,INACTIVE
434,US,B2,US 10711918 B2,106-330-668-429-022,2020-07-14,2020,US 201716331550 A,2017-09-08,EP 16306137 A;;EP 2017072611 W,2016-09-09,Deflector intended to guide a line and related guiding assembly,"A deflector ( 38 ) including: a support ( 70 ); an intermediate member ( 72 ), pivotally mounted in the support ( 70 ) around a first rotation axis (B-B′); at least a secondary pivoting member ( 74 ), pivotally connected to the intermediate member ( 72 ) around a second rotation axis (C-C′) parallel to the first rotation axis (B-B′); for each secondary pivoting member ( 74 ), at least a pair of rotating members ( 76 ). Each rotating member ( 76 ) is connected to the secondary pivoting member ( 74 ). The deflector ( 38 ) including: a guiding mechanism, for guiding each rotating member ( 76 ) in translation with regard to the support ( 70 ) along a translation axis (D-D′) non parallel to the first rotation axis (B-B′); a connecting member ( 78 ), pivotally mounted to the secondary pivoting member ( 74 ). The rotating member ( 76 ) is rotatably mounted on the connecting member ( 78 ) around a rotating member rotation axis (E-E′).",TECHNIP FRANCE,LOPES DE CASTRO MÁRIO AUGUSTO;;MOZA JUCIMAR COELHO;;LUCENA LEONARDO-ALEXANDRE;;NASCIMENTO CAROLINA-PAIVA;;CORREA JOSÉ-ROBERTO;;DUARTE PAULA;;GIL PAULO-WEBBER;;FERREIRA LUIS PAULO;;SANTOS CARLOS-FILIPE,TECHNIP FRANCE (2019-03-07),https://lens.org/106-330-668-429-022,Granted Patent,yes,11,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235;;H02G1/10;;H02G9/02,,3,0,,,"International Search Report dated Nov. 20, 2017 in corresponding PCT International Application No. PCT/EP2017/072611.;;Written Opinion dated Nov. 20, 2017 in corresponding PCT International Application No. PCT/EP2017/072611.;;Extended European Search Report dated Mar. 2, 2017 in corresponding European Patent Application No. 16306137.7.",ACTIVE
435,WO,A1,WO 2020/174340 A1,138-604-952-270-692,2020-09-03,2020,IB 2020051486 W,2020-02-21,PT 11534119 A,2019-02-25,EUTECTIC MENTHOL-FATTY ACID COMBINATIONS FOR WOUND HEALING,"The present disclosure relates to a eutectic composition comprising menthol and a saturated fatty acid as a THEDES (therapeutic deep eutectic system), for use in medicine. The present disclosure further relates to the eutectic composition of menthol-fatty acids for use in therapeutic purposes such as for wound treatment, and/or for the treatment or prevention of microbial infection. The use of the eutectic composition as an enhancer of wound healing and as a drug resistance preventer/prophylactic agent is also encompassed.",UNIV NOVA DE LISBOA;;ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC;;NOVA ID FCT ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCT,MARQUES DA SILVA JOANA MARIA;;VELHINHO PEREIRA CAROLINA;;MANO MARIA FRANCISCA;;GONÇALVES REIS RUI LUIS;;DE ALMEIDA PAIVA ALEXANDRE BABO;;FIGUEIREDO MATIAS ANA ALEXANDRA;;CRUZ DUARTE ANA RITA,,https://lens.org/138-604-952-270-692,Patent Application,yes,7,2,1,1,0,A61K31/045;;A61K31/20;;A61P31/04;;A61P43/00;;A61K9/0014;;A61K9/06;;A61K47/14;;Y02A50/30,A61K31/045;;A61K9/00;;A61K31/20;;A61P31/04;;A61P43/00,,8,7,145-881-610-998-834;;039-242-892-567-560;;086-399-422-379-848;;001-586-992-730-214;;145-881-610-998-834;;005-788-713-683-269;;013-169-849-154-611,10.1021/acssuschemeng.5b00532;;pmc6993812;;10.1021/acsabm.9b00598;;32030369;;31624310;;10.1038/s41598-019-51472-7;;pmc6797721;;10.1021/sc500096j;;10.1021/acssuschemeng.5b00532;;9889172;;19956944;;10.1007/s00253-009-2355-3,"BERNARDO D RIBEIRO ET AL: ""Menthol-based Eutectic Mixtures: Hydrophobic Low Viscosity Solvents"", vol. 3, no. 10, 1 January 2015 (2015-01-01), pages 2469 - 2477, XP009518493, ISSN: 2168-0485, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acssuschemeng.5b00532> [retrieved on 20200518], DOI: 10.1021/ACSSUSCHEMENG.5B00532;;JOANA M. SILVA ET AL: ""Therapeutic Role of Deep Eutectic Solvents Based on Menthol and Saturated Fatty Acids on Wound Healing"", ACS APPLIED BIO MATERIALS, vol. 2, no. 10, 26 August 2019 (2019-08-26), pages 4346 - 4355, XP055696299, ISSN: 2576-6422, DOI: 10.1021/acsabm.9b00598;;CAROLINA V. PEREIRA ET AL: ""Unveil the Anticancer Potential of Limomene Based Therapeutic Deep Eutectic Solvents"", SCIENTIFIC REPORTS, vol. 9, no. 1, 17 October 2019 (2019-10-17), pages 14926, XP055696305, DOI: 10.1038/s41598-019-51472-7;;A. PAIVAR. CRAVEIROI. AROSOM. MARTINSR.L. REISA.R.C. DUARTE: ""Natural deep eutectic solvents-solvents for the 21st century"", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, vol. 2, no. 5, 2014, pages 1063 - 1071, XP055236257, DOI: 10.1021/sc500096j;;M.A.R. MARTINSE.A. CRESPOP.V. PONTESL.P. SILVAM. BULOWG.J. MAXIMOE.A.C. BATISTAC. HELDS.P. PINHOJ.A. COUTINHO: ""Tunable hydrophobic eutectic solvents based on terpenes and monocarboxylic acids"", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, 2018;;B.D. RIBEIROC. FLORINDOL.C. IFFM.A. COELHOI.M. MARRUCHO: ""Menthol-based eutectic mixtures: hydrophobic low viscosity solvents"", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, vol. 3, no. 10, 2015, pages 2469 - 2477, XP009518493, DOI: 10.1021/acssuschemeng.5b00532;;U. JUERGENSM. STOBERH. VETTER: ""The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases"", EUROPEAN JOURNAL OF MEDICAL RESEARCH, vol. 3, no. 12, 1998, pages 539 - 545, XP002137998;;A.P. DESBOISV.J. SMITH: ""Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential"", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 85, no. 6, 2010, pages 1629 - 1642, XP019778619",PENDING
436,MX,A,MX 2013006633 A,067-938-783-918-318,2014-04-28,2014,MX 2013006633 A,2013-06-12,US 201261659700 P;;US 201313826951 A,2012-06-14,BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES FOR TREATING IMMUNE DISORDERS.,"The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a ?-hydroxy-?-aminophosphonate or ?-amino-?-aminophosphonate.",NUCITEC SA DE CV,LORIA JORGE LUIS ROSADO;;VÁZQUEZ MIGUEL ÁNGEL DUARTE;;ESPARZA JORGE ALBERTO REYES;;FRAGOSO MARÍA DE LOURDES RODRÍGUEZ;;CORDERO RICARDO ABRAHAM DE LA CRUZ;;PALACIOS JOSÉ MARIO ORDO EZ,,https://lens.org/067-938-783-918-318,Patent Application,no,0,0,3,3,0,A61K31/662;;A61K31/662;;A61K45/06;;A61K45/06;;C07F9/3808;;C07F9/3808;;C07F9/3834;;C07F9/4006;;C07F9/4006,A61K38/43;;A61K31/662;;A61K38/00;;A61K38/04;;A61K45/06;;C07F9/38,,0,0,,,,PENDING
437,US,A1,US 2019/0211946 A1,065-638-127-871-454,2019-07-11,2019,US 201716331550 A,2017-09-08,EP 16306137 A;;EP 2017072611 W,2016-09-09,DEFLECTOR INTENDED TO GUIDE A LINE AND RELATED GUIDING ASSEMBLY,"A deflector ( 38 ) including: a support ( 70 ); an intermediate member ( 72 ), pivotally mounted in the support ( 70 ) around a first rotation axis (B-B′); at least a secondary pivoting member ( 74 ), pivotally connected to the intermediate member ( 72 ) around a second rotation axis (C-C′) parallel to the first rotation axis (B-B′); for each secondary pivoting member ( 74 ), at least a pair of rotating members ( 76 ). Each rotating member ( 76 ) is connected to the secondary pivoting member ( 74 ). The deflector ( 38 ) including: a guiding mechanism, for guiding each rotating member ( 76 ) in translation with regard to the support ( 70 ) along a translation axis (D-D′) non parallel to the first rotation axis (B-B′); a connecting member ( 78 ), pivotally mounted to the secondary pivoting member ( 74 ). The rotating member ( 76 ) is rotatably mounted on the connecting member ( 78 ) around a rotating member rotation axis (E-E′).",TECHNIP FRANCE,LOPES DE CASTRO MÁRIO AUGUSTO;;MOZA JUCIMAR COELHO;;LUCENA LEONARDO-ALEXANDRE;;NASCIMENTO CAROLINA-PAIVA;;CORREA JOSÉ-ROBERTO;;DUARTE PAULA;;GIL PAULO-WEBBER;;FERREIRA LUIS PAULO;;SANTOS CARLOS-FILIPE,TECHNIP FRANCE (2019-03-07),https://lens.org/065-638-127-871-454,Patent Application,yes,0,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235,,0,0,,,,ACTIVE
438,EP,A2,EP 1910257 A2,134-273-612-409-978,2008-04-16,2008,EP 06780204 A,2006-07-25,IB 2006052552 W;;PT 10332605 A,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,,DE MAGALHAES NUNESDA PONTE MAN;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,DE MAGALHAES NUNESDA PONTE MAN;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,"ZEYTON NUTRACEUTICALS, LDA, PT (2015-01-07);;ZEYTON NUTRACEUTICALS, LDA. (2014-06-11)",https://lens.org/134-273-612-409-978,Patent Application,yes,0,1,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,A61Q19/00;;A23L1/30;;A61K8/34;;A61K8/97;;A61Q17/00;;C07C37/00;;C07C39/11,,0,0,,,,ACTIVE
439,CO,A1,CO 2018004239 A1,127-891-466-682-152,2019-10-21,2019,CO 2018004239 A,2018-04-20,CO 2018004239 A,2018-04-20,Banco diagnostico de pruebas sistema apu de aeronaves de ala fija y ala rotatoria,"La presente invención hace referencia un banca para diagnóstico y pruebas de la unidad de potencia auxiliar (APU por sus siglas en inglés), el cual permite llevar a cabo una serie de pruebas de chequeo operacional de los componentes de dicho sistema en aeronaves de ala rotatoria y ala fija (sin limitación), en donde el banco de diagnóstico y pruebas se compone de un módulo de operación, control y monitoreo, una pantalla táctil donde se muestra la interfaz gráfica para el funcionamiento del banco, y un panel de control análogo que cuenta con interruptores de control e indicadores para el funcionamiento del mismo.",MINISTERIO DE DEFENSA EJERCITO NAC,FRANCO GARCÍA GUSTAVO ALFREDO;;MORA GONZÁLEZ YONNY ALEXANDER;;ALTAMIRANDA RAMOS LUIS ENARIO;;PEÑA CALLE CESAR AUGUSTO;;CUESTA DÍAZ JULIO ANDRÉS;;DUARTE FERREIRA ARIEL FERNANDO;;CUADROS ANTOLÍNEZ RUBÉN DARÍO,,https://lens.org/127-891-466-682-152,Patent Application,no,0,0,1,1,0,,G01M99/00,,0,0,,,,PENDING
440,WO,A1,WO 2018/046675 A1,145-628-912-333-185,2018-03-15,2018,EP 2017072611 W,2017-09-08,EP 16306137 A,2016-09-09,DEFLECTOR INTENDED TO GUIDE A LINE AND RELATED GUIDING ASSEMBLY,"The deflector (38) comprises: - a support (70); - an intermediate member (72), pivotally mounted in the support (70) around a first rotation axis (B-B'); - at least a secondary pivoting member (74), pivotally connected to the intermediate member (72) around a second rotation axis (C-C') parallel to the first rotation axis (B-B'); - for each secondary pivoting member (74), at least a pair of rotating members (76). Each rotating member (76) is connected to the secondary pivoting member (74). The deflector (38) comprises: - a guiding mechanism, for guiding each rotating member (76) in translation with regard to the support (70) along a translation axis (D-D') non parallel to the first rotation axis (B-B'); - a connecting member (78), pivotally mounted to the secondary pivoting member (74). The rotating member (76) is rotatably mounted on the connecting member (78) around a rotating member rotation axis (E-E').",TECHNIP FRANCE,LOPES DE CASTRO MÁRIO AUGUSTO;;MOZA JUCIMAR COELHO;;LUCENA LEONARDO-ALEXANDRE;;NASCIMENTO CAROLINA-PAIVA;;CORREA JOSÉ-ROBERTO;;DUARTE PAULA;;GIL PAULO-WEBBER;;FERREIRA LUIS PAULO;;SANTOS CARLOS-FILIPE,,https://lens.org/145-628-912-333-185,Patent Application,yes,5,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235;;H02G1/10;;H02G9/02,,0,0,,,,PENDING
441,CA,A1,CA 3143430 A1,018-789-819-138-361,2020-12-17,2020,CA 3143430 A,2020-06-15,PT 11558119 A;;IB 2020055584 W,2019-06-14,"SMALL CATIONIC ORTHO-5,15-DI-HETEROARYL-PORPHYRINS DERIVATIVES AND THEIR APPLICATIONS IN PHOTOINACTIVATION OF MICROORGANISMS","The present invention relates to small cationic ortho-5,15-di-heteroaryl porphyrin derivatives, in particular porphyrins, chlorins or bacteriochlorin of formula (I).or pharmaceutically acceptable salts thereof. This invention also relates to the use of the above-mentioned cationic ortho-5,10-di-heteroaryl porphyrin derivatives of Formula (I) or a pharmaceutically acceptable salts thereof, in photodynamic inactivation of microorganisms, where the referred derivatives are able to treat the same in the presence of an adequate light. The present invention also describes pharmaceutical compositions comprising one or more of the cationic ortho-5,10-di-heteroaryl porphyrin derivatives, in particular prophyrins, chlorins or bacteriochlorins of Formula (I), or pharmaceutically acceptable salts thereof, for the treatment of bacterial and/or fungi and/or yeasts and/or viral infections, in humans or animals.",UNIV DE COIMBRA,MIGUENS PEREIRA MARIA;;DUARTE JORGE DA SILVA GABRIELA CONCEICAO;;DA SILVA ARNAUT MOREIRA LUIS GUILERME;;DOS SANTOS VINAGREIRO CAROLINA;;BLANCO KATE CRISTINA;;SALVADOR BAGNATO VANDERLEI;;MAYUMI INADA NATALIA,,https://lens.org/018-789-819-138-361,Patent Application,no,0,0,7,7,0,C09B47/00;;A61P31/04;;A61K31/555;;A61K41/0057;;A61K45/06;;C07D487/22,,,0,0,,,,PENDING
442,ES,A1,ES 2551143 A1,097-602-667-534-834,2015-11-16,2015,ES 201430701 A,2014-05-13,ES 201430701 A,2014-05-13,"Artificial dermis, artificial skin, methods for its preparation and its uses (Machine-translation by Google Translate, not legally binding)","Artificial dermis, artificial skin, methods for its preparation and its uses. The present invention relates to an artificial dermis comprising a first layer of coagulated blood plasma gel comprising platelets and dermal cells, and a second gel layer of coagulated blood plasma comprising platelets and dermal cells, and a network of located polymer between the first and second gel layers. The invention also relates to an artificial skin comprising said artificial dermis with at least one layer of epithelial cells. The invention discloses methods for the preparation of the artificial dermis and artificial skin, as well as its uses in the preparation of a medicament, in particular for the treatment of reepithelialization of a patient in need thereof. (Machine-translation by Google Translate, not legally binding)",FUNDACIÓN TEKNIKER;;CT DE INVESTIGACIONES ENERGÉTICAS MEDIOAMBIENTALES Y TECNOLÓGICAS CIEMAT;;CT COMUNITARIO DE SANGRE Y TEJIDOS DE ASTURIAS CCST,MERINO ALVAREZ SANTOS;;RETOLAZA MUNOA ARITZ;;AZCARATE LETURIA SABINO;;JORCANO NOVAL JOSÉ LUIS;;HOLGUIN FERNANDEZ ALMUDENA;;DUARTE GONZALEZ BLANCA;;MEANA INFIESTA ALVARO;;GARCIA PEREZ EVA;;GOMEZ LLAMES SARA,,https://lens.org/097-602-667-534-834,Patent Application,no,3,0,3,3,0,A61L27/60;;A61L27/60;;A61L27/3813;;C12N5/0625,A61L27/60;;A61L27/38;;C12N5/071,,3,2,041-188-191-068-619;;071-766-441-062-616,10.1016/j.ijporl.2011.03.012;;21481479;;20022702;;10.1016/j.burns.2009.08.016,"RUSZYMAH B H I et al. Formation of tissue engineered composite construct of cartilage and skin using high density polyethylene as inner scaffold in the shape of human helix. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 20110315 ELSEVIER, AMSTERDAM, NL 15/03/2011 VOL: 75 No: 6 Pags: 805 - 810 ISSN 0165-5876 Doi: doi:10.1016/j.ijporl.2011.03.012. Ver todo el documento, especialmente el apartado 2.2 de ""Materiales y métodos"".;;STEFANO N., et al. Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Journal of Clinical Rehabilitative Tissue Engineering Research, 20091119 19/11/2009 VOL: 13 No: 47 Pags: 9211 - 9216 ISSN 1673-8225 Doi: doi:10.3969/j.issn.1673-8225.2009.47.001. Ver todo el documento.;;BÖTTCHER-HABERZETH S., et al. Tissue engineering of skin. Burns : journal of the International Society for Burn Injuries Netherlands Jun 2010 VOL: 36 No: 4 Pags: 450 - 460 ISSN 1879-1409 (Electrónico) Doi: doi:10.1016/j.burns.2009.08.016 pubmed:20022702. Ver todo el documento.",INACTIVE
443,US,A1,US 2014/0107079 A1,114-456-733-124-959,2014-04-17,2014,US 201313826951 A,2013-03-14,US 201313826951 A;;US 201261659700 P,2012-06-14,Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders,"The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a β-hydroxy-γ-aminophosphonate or β-amino-γ-aminophosphonate.",NUCITEC SA DE CV;;NUCITES S A DE C V,DE LA CRUZ CORDERO RICARDO ABRAHAM;;ROSADO LORIA JORGE LUIS;;DUARTE VAZQUEZ MIGUEL ANGEL;;ORDÓ EZ PALACIOS JOSÉ MARIO;;REYES ESPARZA JORGE ALBERTO;;DE LOURDES RODRIGUEZ FRAGOSO MARIA,NUCITEC S.A. DE C.V (2013-04-08),https://lens.org/114-456-733-124-959,Patent Application,yes,1,0,3,3,0,A61K31/662;;A61K31/662;;A61K45/06;;A61K45/06;;C07F9/3808;;C07F9/3808;;C07F9/3834;;C07F9/4006;;C07F9/4006,A61K31/662;;A61K45/06;;C07F9/38,514/119;;514/114,1,0,,,"""Autoimmune Diseases"" from the Health Central Network. (20009)",INACTIVE
444,EP,A1,EP 3293429 A1,130-814-018-563-538,2018-03-14,2018,EP 16306137 A,2016-09-09,EP 16306137 A,2016-09-09,DEFLECTOR INTENDED TO GUIDE A LINE AND RELATED GUIDING ASSEMBLY,"The deflector (38) comprises: 
- a support (70); 
- an intermediate member (72), pivotally mounted in the support (70) around a first rotation axis (B-B'); 
- at least a secondary pivoting member (74), pivotally connected to the intermediate member (72) around a second rotation axis (C-C') parallel to the first rotation axis (B-B'); 
- for each secondary pivoting member (74), at least a pair of rotating members (76). Each rotating member (76) is connected to the secondary pivoting member (74). The deflector (38) comprises: 
- a guiding mechanism, for guiding each rotating member (76) in translation with regard to the support (70) along a translation axis (D-D') non parallel to the first rotation axis (B-B'); 
- a connecting member (78), pivotally mounted to the secondary pivoting member (74). The rotating member (76) is rotatably mounted on the connecting member (78) around a rotating member rotation axis (E-E').
",TECHNIP FRANCE,LOPES DE CASTRO MÁRIO AUGUSTO;;MOZA JUCIMAR COELHO;;LUCENA LEONARDO ALEXANDRE;;NASCIMENTO CAROLINA PAIVA;;CORREA JOSE ROBERTO;;DUARTE PAULA;;GIL PAULO WEBBER;;FERREIRA LUIS PAULO;;SANTOS CARLOS FILIPE,,https://lens.org/130-814-018-563-538,Patent Application,yes,5,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235;;H02G1/10;;H02G9/02,,0,0,,,,ACTIVE
445,EP,A1,EP 3403502 A1,092-981-648-016-792,2018-11-21,2018,EP 17179887 A,2017-07-05,PT 11008017 A,2017-05-17,"CRYOPROTECTANT AND/OR CRYOPRESERVANT COMPOSITION, METHODS AND USES THEREOF","The present disclosure relates to cryoprotectant and/or cryopreservant composition, methods and uses thereof. This composition may be used in the preservation and/or protection of cell, organism and/or tissue.",ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH,CRUZ DUARTE ANA RITA;;BABO DE ALMEIDA PAIVA ALEXANDRE;;GONÇALVES DOS REIS RUI LUIS;;PAIVA CRAVEIRO RITA PAULA;;MARQUES DA SILVA JOANA MARIA;;BAPTISTA DE CASTRO VANIA ISABEL,,https://lens.org/092-981-648-016-792,Patent Application,yes,4,1,9,9,0,A01N1/0221;;A01N1/0221;;A01N1/0221;;A01N1/0221,A01N1/02,,28,26,109-755-476-339-308;;025-982-349-849-633;;101-129-911-638-70X;;026-765-561-876-431;;081-771-926-748-594;;021-749-030-810-140;;134-298-274-168-964;;018-900-232-222-428;;089-392-880-748-986;;110-212-918-800-603;;003-930-415-756-96X;;072-862-228-791-621;;022-882-925-269-438;;060-991-216-853-595;;019-283-437-855-777;;070-036-296-175-399;;134-216-097-832-104;;068-685-821-892-619;;006-924-578-850-908;;003-913-255-955-788;;010-176-685-975-187;;116-423-011-346-332;;075-075-320-895-788;;117-021-316-525-520;;050-271-230-242-338;;009-776-931-439-683,12818211;;10.1016/s0011-2240(03)00046-4;;8745321;;10.1016/0142-9612(96)85562-1;;10.1007/s11596-016-1559-x;;27072955;;26541066;;pmc4775837;;10.1016/j.bpj.2015.09.029;;pmc2781091;;20046674;;10.4161/org.5.3.9583;;10.1201/9781482278637;;10.1242/jeb.020701;;19112150;;10.1007/bf00239062;;10.1078/0044-5231-00068;;10.1002/jez.1402580305;;18070104;;10.1111/j.1742-4658.2007.06198.x;;10.1016/j.jinsphys.2011.03.011;;21420974;;10.1016/0022-1910(94)00124-y;;10.1016/j.jinsphys.2007.06.012;;17662301;;10.3354/cr005061;;23613923;;pmc3629207;;10.1371/journal.pone.0061745;;17331186;;10.1111/j.1742-4658.2007.05723.x;;10.1016/0022-1910(76)90014-7;;10.1016/s1226-8615(08)60130-2;;17481650;;10.1016/j.jinsphys.2007.02.009;;20086136;;10.1242/jeb.035758;;10.1104/pp.111.178426;;21677097;;pmc3149944;;10.1002/chin.201424290;;24188074;;10.1021/np400051w;;10.1002/anie.201207548;;23401138;;10.1016/j.biochi.2015.09.019;;26391220,"HUB, Z., PROTECTANTS USED IN THE CRYOPRESERVATION OF MICROORGANISMS Q., vol. 46, 2003, pages 205 - 229;;KARLSSON, J. O. M.; TONER, M.: ""Long-term storage of tissues by cryopreservation: Critical issues."", BIOMATERIALS, vol. 17, no. 3, 1996, pages 243 - 256;;LIU, D.; PAN, F., ADVANCES IN CRYOPRESERVATION OF ORGANS, vol. 36, no. 2, 2016, pages 153 - 161;;""Basic principles of cryopreservation."", CRYOCONSERVATION ANIM. GENET. RESOUR., 2012, pages 85 - 94;;SEGALL, P. E.: ""Med. Phys"", vol. 9, 1982, article ""Low Temperature Preservation in Medicine and Biology"", pages: 19 - 44;;HUEBINGER, J.; HAN, H. M.; HOFNAGEL, O.; VETTER, I. R.; BASTIAENS, P. I. H.; GRABENBAUER, M.: ""Direct Measurement of Water States in Cryopreserved Cells Reveals Tolerance toward Ice Crystallization."", BIOPHYS. J., vol. 110, no. 4, 2016, pages 840 - 849;;BAKHACH, J.: ""The cryopreservation of composite tissues: Principles and recent advancement on cryopreservation of different type of tissues."", ORGANOGENESIS, vol. 5, no. 3, 2009, pages 119 - 126;;JOHN M. KIMBLE: ""Global Climate Change and Cold Regions Ecosystems"", 2000, CRC PRESS;;WALTERS, K. R.; SFORMO, T.; BARNES, B. M.; DUMAN, J. G.: ""Freeze tolerance in an arctic Alaska stonefly"", J. EXP. BIOL., vol. 212, 2009, pages 305 - 312;;SØMME, L.; MEIER, T.: ""Cold tolerance in Tardigrada from Dronning Maud Land, Antarctica"", POLAR BIOL, vol. 15, no. 3, 1995, pages 221 - 224;;RIGHT, J. C. W., CRYPTOBIOSIS 300 YEARS ON FROM VAN LEUWENHOEK : WHAT HAVE WE LEARNED ABOUT TARDIGRADES ?, vol. 240, August 2000 (2000-08-01), pages 563 - 582;;WESTH, P.; RAMLOV, H.: ""Trehalose accumulation in the tardigrade Adorybiotus coronifer during anhydrobiosis"", JOURNAL OF EXPERIMENTAL ZOOLOGY., 1991, pages 303 - 311;;HENGHERR, S.; HEYER, A. G.; KOHLER, H. R.; SCHILL, R. O.: ""Trehalose and anhydrobiosis in tardigrades - Evidence for divergence in responses to dehydration"", FEBS J., vol. 275, no. 2, 2008, pages 281 - 288;;KOSTAL, V.; DOLEZAL, P.; ROZSYPAL, J.; MORAVCOVA, M.; ZAHRADNICKOVA, H.; SIMEK, P.: ""Physiological and biochemical analysis of overwintering and cold tolerance in two Central European populations of the spruce bark beetle, Ips typographus"", J. INSECT PHYSIOL., vol. 57, no. 8, 2011, pages 1136 - 1146;;KOSTAL, V.; SIMEK, P.: ""Dynamics of cold hardiness, supercooling and cryoprotectants in diapausing and non-diapausing pupae of the cabbage root fly, Delia radicum L"", J. INSECT PHYSIOL., vol. 41, no. 7, 1995, pages 627 - 634;;OVERGAARD, J.; MALMENDAL, A.; S RENSEN, J. G.; BUNDY, J. G.; LOESCHCKE, V.; NIELSEN, N. C.; HOLMSTRUP, M.: ""Metabolomic profiling of rapid cold hardening and cold shock in Drosophila melanogaster"", J. INSECT PHYSIOL., vol. 53, no. 12, 2007, pages 1218 - 1232;;LEE, R.; DOMMEL, R.; JOPLIN, K.; DENLINGER, D.: ""Cryobiology of the freeze-tolerant gall fly Eurosta solidaginis: overwintering energetics and heat shock proteins"", CLIM. RES, vol. 5, 1995, pages 61 - 67;;ROZSYPAL, J.; KOSTAL, V.; ZAHRADNICKOVA, H.; SIMEK, P.: ""Overwintering Strategy and Mechanisms of Cold Tolerance in the Codling Moth (Cydia pomonella)."", PLOS ONE, vol. 8, no. 4, 2013;;LALOUETTE, L.; KOSTAL, V.; COLINET, H.; GAGNEUL, D.; RENAULT, D.: ""Cold exposure and associated metabolic changes in adult tropical beetles exposed to fluctuating thermal regimes"", FEBS J., vol. 274, no. 7, 2007, pages 1759 - 1767;;MORRISSEY, R. E.; BAUST, J. G.: ""The ontogeny of cold tolerance in the gall fly, Eurosta solidagensis."", J. INSECT PHYSIOL., vol. 22, no. 3, 1976, pages 431 - 437;;LEE, K. Y.; CHANG, Y. D.; KIM, Y. G.: ""Trehalose, a Major Sugar Cryoprotectant of the Overwintering Rice Water Weevil, Lissorhoptrus oryzophilus (Coleoptera: Curculionidae"", J. ASIA. PAC. ENTOMOL., vol. 5, no. 1, 2002, pages 35 - 41;;KOSTAL, V.; ZAHRADNICKOVA, H.; SIMEK, P.; ZELENY, J.: ""Multiple component system of sugars and polyols in the overwintering spruce bark beetle, Ips typographus."", J. INSECT PHYSIOL., vol. 53, no. 6, 2007, pages 580 - 586;;SFORMO, T.; WALTERS, K.; JEANNET, K.; WOWK, B.; FAHY, G. M.; BARNES, B. M.; DUMAN, J. G.: ""Deep supercooling, vitrification and limited survival to -lOOoC in the Alaskan beetle Cucujus clavipes puniceus (Coleoptera: Cucujidae)."", J. EXP. BIOL., vol. 213, 2010, pages 502 - 509;;CHOI, Y. H.; VAN SPRONSEN, J.; DAI, Y.; VERBERNE, M.; HOLLMANN, F.; ARENDS, I. W. C. E.; WITKAMP, G.-J.; VERPOORTE, R.: ""Are natural deep eutectic solvents the missing link in understanding cellular metabolism and physiology?"", PLANT PHYSIOL., vol. 156, no. 4, 2011, pages 1701 - 1705;;PAIVA, A.; CRAVEIRO, R.; AROSO, I.; MARTINS, M.; REIS, R. L.; DUARTE, A. R. C.; PAIVA, ALEXANDRE; CRAVEIRO, RITA; AROSO, IVO; MART: ""Natural Deep Eutectic Solvents - Solvents for the 21st century. Sustain"", CHEM. ENG., 2014;;DAI, Y.; VAN SPRONSEN, J.; WITKAMP, G.-J.; VERPOORTE, R.; CHOI, Y. H.: ""Ionic liquids and deep eutectic solvents in natural products research: mixtures of solids as extraction solvents"", J. NAT. PROD., vol. 76, no. 11, 2013, pages 2162 - 2173;;FRANCISCO, M.; VAN DEN BRUINHORST, A.; KROON, M. C.: ""Low-transition-temperature mixtures (LTTMs): a new generation of designer solvents"", ANGEW. CHEM. INT. ED. ENGL., vol. 52, no. 11, 2013, pages 3074 - 3085;;DURAND, E.; LECOMTE, J.; VILLENEUVE, P.: ""From green chemistry to nature: The versatile role of low transition temperature mixtures"", BIOCHIMIE, vol. 120, 2016, pages 119 - 123",DISCONTINUED
446,BR,A2,BR 112019004721 A2,046-442-429-633-052,2019-06-18,2019,BR 112019004721 A,2017-09-08,EP 2017072611 W;;EP 16306137 A,2016-09-09,defletor e conjunto de direção de linha,"""defletor e conjunto de direção de linha"" o defletor (38) compreende: - um suporte (70); - um elemento intermediário (72), montado de modo articulado no suporte (70) em torno de um primeiro eixo de rotação (b-b'); - pelo menos um elemento de articulação secundário (74), conectado de modo articulado ao elemento intermediário (72) em torno de um segundo eixo de rotação (c-c') paralelo ao primeiro eixo de rotação (b-b'); - para cada elemento de articulação secundário (74), pelo menos um par de elementos rotativos (76). cada elemento rotativo (76) é conectado ao elemento de articulação secundário (74). 0 defletor (38) compreende: - um mecanismo de direção, para guiar cada elemento rotativo (76) em translação em relação ao suporte (70) ao longo de um eixo de transiação (d-d') não paralelo ao primeiro eixo de rotação (b-b'); - um elemento de ligação (78), montado de modo articulado no elemento de articulação secundário (74). 0 elemento rotativo (76) é montado de modo giratório no elemento de ligação (78) em torno de um eixo de rotação de elemento rotativo (e-e').",TECHNIP FRANCE,CARLOS-FILIPE SANTOS;;CAROLINA-PAIVA NASCIMENTO;;JOSÉ-ROBERTO CORREA;;JUCIMAR COELHO MOZA;;LEONARDO-ALEXANDRE LUCENA;;LUIS PAULO FERREIRA;;MÁRIO AUGUSTO LOPES DE CASTRO;;PAULA DUARTE;;PAULO-WEBBER GIL,TECHNIP N-POWER (FR) (2021-05-11),https://lens.org/046-442-429-633-052,Patent Application,no,0,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235;;H02G1/10;;H02G9/02,,0,0,,,,ACTIVE
447,BR,B1,BR 112019004721 B1,143-821-404-494-793,2022-11-29,2022,BR 112019004721 A,2017-09-08,EP 2017072611 W;;EP 16306137 A,2016-09-09,DEFLETOR E CONJUNTO DE DIREÇÃO DE LINHA,"""DEFLETOR E CONJUNTO DE DIREÇÃO DE LINHA"" O defletor (38) compreende: - um suporte (70); - um elemento intermediário (72), montado de modo articulado no suporte (70) em torno de um primeiro eixo de rotação (B-B'); - pelo menos um elemento de articulação secundário (74), conectado de modo articulado ao elemento intermediário (72) em torno de um segundo eixo de rotação (C-C') paralelo ao primeiro eixo de rotação (B-B'); - para cada elemento de articulação secundário (74), pelo menos um par de elementos rotativos (76). Cada elemento rotativo (76) é conectado ao elemento de articulação secundário (74). 0 defletor (38) compreende: - um mecanismo de direção, para guiar cada elemento rotativo (76) em translação em relação ao suporte (70) ao longo de um eixo de transiação (D-D') não paralelo ao primeiro eixo de rotação (B-B'); - um elemento de ligação (78), montado de modo articulado no elemento de articulação secundário (74). 0 elemento rotativo (76) é montado de modo giratório no elemento de ligação (78) em torno de um eixo de rotação de elemento rotativo (E-E').",TECHNIP FRANCE;;TECHNIP N POWER,MÁRIO AUGUSTO LOPES DE CASTRO;;CARLOS-FILIPE SANTOS;;CAROLINA-PAIVA NASCIMENTO;;JOSÉ-ROBERTO CORREA;;JUCIMAR COELHO MOZA;;LEONARDO-ALEXANDRE LUCENA;;LUIS PAULO FERREIRA;;PAULA DUARTE;;PAULO-WEBBER GIL,TECHNIP N-POWER (FR) (2021-05-11),https://lens.org/143-821-404-494-793,Granted Patent,no,0,0,8,8,0,H02G1/10;;H02G9/02;;F16L1/235;;H02G9/02;;H02G1/10;;F16L1/235,F16L1/235;;H02G1/10;;H02G9/02,,0,0,,,,ACTIVE
448,WO,A1,WO 2020/188547 A1,159-101-550-203-654,2020-09-24,2020,IB 2020052708 W,2020-03-23,PT 11538319 A,2019-03-21,"TERPENE BASED THERAPEUTIC DEEP EUTECTIC SYSTEM, METHOD OF OBTAINING AND USES THEREOF","The present disclosure describes a eutectic composition for use in the treatment of cancer comprising a nonsteroidal anti-inflammatory drug and a terpene, preferably ibuprofen and limonene.",UNIV NOVA DE LISBOA;;ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC;;NOVA ID FCT – ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCT,MARQUES DA SILVA JOANA MARIA;;VELHINHO PEREIRA CAROLINA;;AMARO RODRIGUES LILIANA ANDREIA;;GONÇALVES REIS RUI LUIS;;DE ALMEIDA PAIVA ALEXANDRE BABO;;FIGUEIREDO MATIAS ANA ALEXANDRA;;CRUZ DUARTE ANA RITA,,https://lens.org/159-101-550-203-654,Patent Application,yes,9,0,3,3,0,A61K31/616;;A61K31/192;;A61K31/045;;A61K31/015;;A61K31/05;;A61K31/01;;A61K31/11;;A61P35/00;;A61K31/015;;A61K31/045;;A61K31/192,A61K31/01;;A61K31/015;;A61K31/045;;A61K31/05;;A61K31/11;;A61K31/192;;A61K31/616;;A61P35/00,,1,1,002-315-076-248-678,10.1080/10717540601036872;;17613016,"N. GONZALEZH. SUMANO, DESIGN OF TWO LIQUID IBUPROFEN-POLOXAMER-LIMONENE OR MENTHOL PREPARATIONS FOR DERMAL ADMINISTRATION",PENDING
449,US,A1,US 2008/0179246 A1,057-370-740-652-968,2008-07-31,2008,US 2096008 A,2008-01-28,PT 10332605 A;;IB 2006052552 W,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,"The present invention relates to a process of obtaining a natural, bioactive concentrate, rich on hydroxytyrosol, from olive tree residues and subproducts using clean technologies. These technologies comprise supercritical fluid extraction, nanofiltration and reverse osmosis which are used individually or in an integrated mode. The natural extract comprises a minimum concentration of 15% (mass fraction) in hydroxytirosol and a maximum concentration of 98% (mass fraction) in this compound. The hydroxytyrosol-rich concentrate exhibits anti-oxidant, anti-microbial, anti-inflammatory and anti-carcinogenic activities, which are superior to the activities observed for isolated hydroxytyrosol in equivalent concentration. The hydroxytyrosol-rich concentrate can be prepared in the form of solid particles, as an aqueous solution, in an emulsion or as lipidic based nanoparticles. Industrial application comprises the food, pharmaceutical and cosmetics industries.",DE MAGALHAES NUNES DA PONTE MA;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,DE MAGALHAES NUNES DA PONTE MA;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,,https://lens.org/057-370-740-652-968,Patent Application,yes,1,7,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,B01D11/04;;A61K31/353;;A61P29/00;;A61P31/00;;A61P35/00;;B01D61/02,210/637;;514/456;;210/652,0,0,,,,ACTIVE
450,CU,A1,CU 23011 A1,175-532-565-357-052,2004-12-17,2004,CU 20000242 A,2000-11-03,CU 20000242 A,2000-11-03,MÉTODO DE OBTENCIÓN DE ESTRUCTURAS ANTIGÉNICAS QUEMÉTODO DE OBTENCIÓN DE ESTRUCTURAS ANTIGÉNICAS QUE POTENCIAN LA REACTIVIDAD CRUZADA ESPECÍFICA Y SU POTENCIAN LA REACTIVIDAD CRUZADA ESPECÍFICA Y SU USO EN FORMULACIONES USO EN FORMULACIONES,"La presente invención se relaciona con el método pLa presente invención se relaciona con el método para la obtención de estructuras antigiénicas de alara la obtención de estructuras antigiénicas de alta reactividad cruzada, capaces de potenciar la reta reactividad cruzada, capaces de potenciar la respuesta inmune a antíjenos peptídios administradosspuesta inmune a antíjenos peptídios administrados par vía sistémica y/o mucosal, generando potentes par vía sistémica y/o mucosal, generando potentes respuestas inmunes así coma estructuras químicas respuestas inmunes así coma estructuras químicas resultantes de la aplicación de este método, formuresultantes de la aplicación de este método, formulaciones obtenidas a partir de dichas estructuras laciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtenciy uso de las mismas. El método describe la obtención de nuevas estructuras dendriméricas. Partiendo ón de nuevas estructuras dendriméricas. Partiendo de la selección y síntesis de dendrímeros, que posde la selección y síntesis de dendrímeros, que posteriormente son acoplados a moléculas portadoras. teriormente son acoplados a moléculas portadoras. Las estructuras resultantes pueden utilizarse convLas estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulación donde enientemente adyuvadas o en una formulación donde pueden introducirse varios antígenos de este tipo,pueden introducirse varios antígenos de este tipo, encontrándose un efecto sinérgico entre estos com encontrándose un efecto sinérgico entre estos componentes con respecto a la reactividad cruzada y lponentes con respecto a la reactividad cruzada y la inmunogenicidad de la respuesta obtenida. Ademása inmunogenicidad de la respuesta obtenida. Además la preparación puede contener, estabilizadores y la preparación puede contener, estabilizadores y preservos. Las estructuras antigénicas resultantespreservos. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como son aplicables en la industria farmacéutica como formulaciones vacúnales tanto para uso humano comoformulaciones vacúnales tanto para uso humano como veterinario y coma parte de sistemas de diagnósti veterinario y coma parte de sistemas de diagnóstico. co.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS DUARTE CANO CARLOS;;IGLESIAS PEREZ ENRIQUE IGLESIAS PEREZ ENRIQUE;;CRUZ RICONDO LUIS JAVIER CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR AGUILAR RUBIDO JULIO CE;;GARAY PEREZ HILDA ELISA GARAY PEREZ HILDA ELISA;;REYES ACOSTA OSVALDO REYES ACOSTA OSVALDO;;GUILLEN NIETO GERARDO ENRIQUE GUILLEN NIETO GERARD;;MUZIO GONZALEZ VERENA LUCILA MUZIO GONZALEZ VERENA;;PENTON ARIAS EDUARDO PENTON ARIAS EDUARDO,,https://lens.org/175-532-565-357-052,Limited Patent,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K31/74;;A61K31/785;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K39/39;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
451,WO,A3,WO 2007/013032 A3,041-883-545-225-373,2007-05-31,2007,IB 2006052552 W,2006-07-25,PT 10332605 A,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,"The present invention relates to a process of obtaining a natural, bioactive concentrate, rich on hydroxytyrosol, from olive tree residues and subproducts using clean technologies. These technologies comprise supercritical fluid extraction, nanofiltration and reverse osmosis which are used individually or in an integrated mode. The natural extract comprises a minimum concentration of 15% (mass fraction) in hydroxytirosol and a maximum concentration of 98% (mass fraction) in this compound. The hydroxytyrosol-rich concentrate exhibits anti-oxidant, anti-microbial, anti-inflammatory and anti-carcinogenic activities, which are superior to the activities observed for isolated hydroxytyrosol in equivalent concentration. The hydroxytyrosol-rich concentrate can be prepared in the form of solid particles, as an aqueous solution, in an emulsion or as lipidic based nanoparticles. Industrial application comprises the food, pharmaceutical and cosmetics industries.",DE MAGALHAES NUNES DA PONTE MA;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,DE MAGALHAES NUNES DA PONTE MA;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,,https://lens.org/041-883-545-225-373,Search Report,yes,3,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C39/11;;A23L1/30;;A61K8/34;;A61K31/05;;A61Q19/02;;C07C37/00;;C07C37/68,,1,0,,,"SKALTSOUNIS L ET AL: ""MINOS PROJECT Process development for an integrated olive mill waste management recovering natural antioxidants and producing organic fertilizer"", INTERNET CITATION, April 2004 (2004-04-01), XP002354663, Retrieved from the Internet <URL:http://www.pharm.uoa.gr/minos/manualeng.pdf> [retrieved on 20051116]",PENDING
452,WO,A2,WO 2007/013032 A2,114-748-702-320-142,2007-02-01,2007,IB 2006052552 W,2006-07-25,PT 10332605 A,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,"The present invention relates to a process of obtaining a natural, bioactive concentrate, rich on hydroxytyrosol, from olive tree residues and subproducts using clean technologies. These technologies comprise supercritical fluid extraction, nanofiltration and reverse osmosis which are used individually or in an integrated mode. The natural extract comprises a minimum concentration of 15% (mass fraction) in hydroxytirosol and a maximum concentration of 98% (mass fraction) in this compound. The hydroxytyrosol-rich concentrate exhibits anti-oxidant, anti-microbial, anti-inflammatory and anti-carcinogenic activities, which are superior to the activities observed for isolated hydroxytyrosol in equivalent concentration. The hydroxytyrosol-rich concentrate can be prepared in the form of solid particles, as an aqueous solution, in an emulsion or as lipidic based nanoparticles. Industrial application comprises the food, pharmaceutical and cosmetics industries.",DE MAGALHAES NUNES DA PONTE MA;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,DE MAGALHAES NUNES DA PONTE MA;;CARDADOR DOS SANTOS JOSE LUIS;;FIGUEIREDO MATIAS ANA ALEXANDR;;MORGADO MARQUES NUNES ANA VITA;;MARTINS DUARTE CATARINA MARIA;;SEREJO GOULAO CRESPO JOAO PAUL,,https://lens.org/114-748-702-320-142,Patent Application,yes,0,17,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C39/11;;A23L1/30;;A61K8/34;;A61K31/05;;A61Q19/02;;C07C37/00;;C07C37/68,,0,0,,,,PENDING
453,CA,A1,CA 2617002 A1,057-519-819-665-983,2007-02-01,2007,CA 2617002 A,2006-07-25,PT 10332605 A;;IB 2006052552 W,2005-07-27,METHOD OF OBTAINING A NATURAL HYDROXYTYROSOL-RICH CONCENTRATE FROM OLIVE TREE RESIDUES AND SUBPRODUCTS USING CLEAN TECHNOLOGIES,,CARDADOR DOS SANTOS JOSE LUIS;;DE MAGALHAES NUNES DA PONTE MA;;FIGUEIREDO MATIAS ANA ALEXANDR;;SEREJO GOULAO CRESPO JOAO PAUL;;MARTINS DUARTE CATARINA MARIA;;MORGADO MARQUES NUNES ANA VITA,CARDADOR DOS SANTOS JOSE LUIS;;DE MAGALHAES NUNES DA PONTE MA;;FIGUEIREDO MATIAS ANA ALEXANDR;;SEREJO GOULAO CRESPO JOAO PAUL;;MARTINS DUARTE CATARINA MARIA;;MORGADO MARQUES NUNES ANA VITA,,https://lens.org/057-519-819-665-983,Patent Application,no,0,0,20,20,0,A61K8/97;;A23L33/105;;A61K8/347;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A61K2800/522;;A61K8/347;;A61K2800/522;;A61Q17/005;;A61Q19/00;;C07C37/004;;C07C39/11;;A23L33/105;;A61K8/9789;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;A61P39/06;;Y02P20/54;;C11B1/06;;C11B5/0035;;A23V2002/00;;C07C39/11;;A23L33/105;;A61K8/347;;A61Q17/005;;C07C37/004;;A61K2800/522;;A61Q19/00;;A61K8/9789;;Y02P20/54,C07C39/11;;A23L1/30;;A61K8/34;;A61K31/05;;A61Q19/02;;C07C37/00;;C07C37/68,,0,0,,,,ACTIVE
454,RU,C2,RU 2577489 C2,192-952-987-544-840,2016-03-20,2016,RU 2011133816 A,2011-08-11,US 85518310 A,2010-08-12,DEVICE FOR FABRICATION OF FORMED FIBROUS ARTICLE WITH 3D OUTLINE,"FIELD: process engineering.SUBSTANCE: claimed device comprises the calendar composed by the first and second rollers. The second roller includes the recess for forming of fibrous article with 3D outline. This device comprises also the embossing calendar including the first and second rollers. The first and second rollers are configured and arranged to fed the fibrous article in between the first and second rollers without the application of a bearing ply. The calendar second roller comprises the vacuum drum while the second roller comprises the opposite calendar shaft.EFFECT: perfected method.22 cl, 26 dwg, 1 tbl",DZHONSON END DZHONSON DU BRAZIL IND E KOMERSIU DI PRODUTUS PARA SAUDI LTDA,ALKMIN MARKO ANTONIO;;KAU ZHOZE FRANSISKO;;KOTINJU ZHOZE MANUEL SOARES;;DUARTE IVAIR LUIS;;FARIJA REJNALDO LORENSO;;ERNANDES FRANSISKU KH V;;RIMOLI FRANSISKU ANTONJU;;NETO FRANSISKO SAVASTANO;;JAMASITA ALESANDRE TEJSEJRA,,https://lens.org/192-952-987-544-840,Granted Patent,no,0,1,13,40,0,A61F13/15731;;A61F13/15731;;A61F13/47218;;A61F13/47218,D04H1/54,,0,0,,,,ACTIVE
455,US,A1,US 2022/0142957 A1,140-378-721-084-760,2022-05-12,2022,US 202017441642 A,2020-03-23,PT 11538319 A;;IB 2020052708 W,2019-03-21,"TERPENE BASED THERAPEUTIC DEEP EUTECTIC SYSTEM, METHOD OF OBTAINING AND USES THEREOF","The present disclosure describes a eutectic composition for use in the treatment of cancer comprising a nonsteroidal anti-inflammatory drug and a terpene, preferably ibuprofen and limonene.",UNIV NOVA DE LISBOA;;ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC;;NOVA ID FCT ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCT,MARQUES DA SILVA JOANA MARIA;;VELHINHO PEREIRA CAROLINA;;AMARO RODRIGUES LILIANA ANDREIA;;GONÇALVES REIS RUI LUIS;;DE ALMEIDA PAIVA ALEXANDRE BABO;;FIGUEIREDO MATIAS ANA ALEXANDRA;;CRUZ DUARTE ANA RITA,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES & THERAPIES A4TEC - ASSOCIAÇÃO (2021-09-17);;NOVA.ID.FCT - ASSOCIAÇÃO PARA A INOVAÇÃO E DESENVOLVIMENTO DA FCT (2021-09-16);;UNIVERSIDADE NOVA DE LISBOA (2021-09-15),https://lens.org/140-378-721-084-760,Patent Application,yes,0,0,3,3,0,A61K31/616;;A61K31/192;;A61K31/045;;A61K31/015;;A61K31/05;;A61K31/01;;A61K31/11;;A61P35/00;;A61K31/015;;A61K31/045;;A61K31/192,A61K31/015;;A61K31/192;;A61K31/045,,0,0,,,,PENDING
456,EP,A1,EP 3941447 A1,173-634-605-233-156,2022-01-26,2022,EP 20720932 A,2020-03-23,PT 11538319 A;;IB 2020052708 W,2019-03-21,"TERPENE BASED THERAPEUTIC DEEP EUTECTIC SYSTEM, METHOD OF OBTAINING AND USES THEREOF",,UNIV NOVA DE LISBOA;;ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC;;NOVA ID FCT ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCT,MARQUES DA SILVA JOANA MARIA;;VELHINHO PEREIRA CAROLINA;;AMARO RODRIGUES LILIANA ANDREIA;;GONÇALVES REIS RUI LUIS;;DE ALMEIDA PAIVA ALEXANDRE BABO;;FIGUEIREDO MATIAS ANA ALEXANDRA;;CRUZ DUARTE ANA RITA,,https://lens.org/173-634-605-233-156,Patent Application,yes,0,0,3,3,0,A61K31/616;;A61K31/192;;A61K31/045;;A61K31/015;;A61K31/05;;A61K31/01;;A61K31/11;;A61P35/00;;A61K31/015;;A61K31/045;;A61K31/192,A61K31/01;;A61K31/015;;A61K31/045;;A61K31/05;;A61K31/11;;A61K31/192;;A61K31/616;;A61P35/00,,0,0,,,,PENDING
457,MX,A,MX PA03003849 A,022-412-523-911-428,2004-10-15,2004,MX PA03003849 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY.,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/022-412-523-911-428,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,DISCONTINUED
458,WO,A2,WO 2002/036160 A2,035-295-181-352-524,2002-05-10,2002,CU 0100007 W,2001-11-01,CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH;;CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/035-295-181-352-524,Patent Application,yes,0,0,21,21,59,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,PENDING
459,ZA,B,ZA 200205236 B,161-223-681-917-558,2003-09-29,2003,ZA 200205236 A,2002-06-28,CU 20000242 A,2000-11-03,Method for obtaining antigenic structures enhancing specific cross reactivity.,,CT INGENIERIA GENETICA BIOTECH,RICONDO LUIS JAVIER CRUZ;;PEREZ ENRIQUE IGESIAS;;PEREZ HILDA ELISA GARAY;;NIETO GERARDO ENRIQUE GUILLEN;;ARIAS EDUARDO PENTON;;RUBIDO AGUILAR;;OSVALDO JULIO CESAR REYES ACOS;;BONZALEZ VERENA LUCILA MUZIO;;CANO CARLOS DUARTE,,https://lens.org/161-223-681-917-558,Granted Patent,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
460,PT,B,PT 108703 B,109-504-606-990-347,2021-03-15,2021,PT 10870315 A,2015-07-17,PT 10870315 A,2015-07-17,DISPOSITIVO PARA APARELHOS DE AQUECIMENTO E PROCESSO PARA A OPERAÇÃO DE UM DISPOSITIVO PARA APARELHOS DE AQUECIMENTO,"A PRESENTE INVENÇÃO DIVULGA UM DISPOSITIVO PARA APARELHOS DE AQUECIMENTO COMPREENDENDO PELO MENOS UMA UNIDADE DE CONTROLO E/OU DE REGULAÇÃO, A QUAL ESTÁ PREVISTA PARA AJUSTAR UMA RAZÃO AR/COMBUSTÍVEL (¿C) DE UMA COMBUSTÃO A UMA RAZÃO AR/COMBUSTÍVEL DE REFERÊNCIA (¿D).A UNIDADE DE CONTROLO E/OU DE REGULAÇÃO ESTÁ PREVISTA PARA, EM PELO MENOS UM ESTADO OPERACIONAL, CALCULAR UM FATOR DE CORREÇÃO DA POTÊNCIA (CF) E PARA CONSIDERÁ-LO DURANTE O AJUSTE DA RAZÃO AR/COMBUSTÍVEL (¿C).",BOSCH TERMOTECNOLOGIA SA,LUIS MIGUEL PACHECO MONTEIRO;;RICARDO JORGE DE SOUSA VIEIRA;;MARCO PAULO ROSA DE LIMA VILAÇA MARQUES;;SÉRGIO VARO OLIVEIRA SALUSTIO;;JOEL FILIPE PEREIRA;;MAURO ANDRÉ OLIVEIRA SIMÕES;;DUARTE NUNO FERNANDES GARCIA LIMA,,https://lens.org/109-504-606-990-347,Granted Patent,no,0,0,5,5,0,F23N1/022;;F23N3/082;;F23N3/082;;F23N3/002;;F23N3/002;;F23N5/003;;F23N2225/16;;F23N2225/16;;F23N2225/20;;F23N2225/20;;F23N2225/21;;F23N2225/21;;F23N2241/04;;F23N2241/04,F23N1/02,,0,0,,,,ACTIVE
461,CN,A,CN 1446094 A,156-361-019-338-687,2003-10-01,2003,CN 01803978 A,2001-11-01,CU 20000242 A,2000-11-03,Method for obtaining antigenic structures enhancing specific cross reactivity,,CENTO DE INGENIERIA GENETICA Y,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/156-361-019-338-687,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
462,WO,A3,WO 2002/036160 A3,056-616-434-795-590,2003-05-30,2003,CU 0100007 W,2001-11-01,CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH;;CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/056-616-434-795-590,Search Report,yes,1,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,2,1,015-688-221-013-431,10.1159/000024268;;10592465,"NAKANO ET AL.: ""Antigen-specific, Ig E-selective unresponsiveness induced by antigen-liposome conjugates"", INT. ARCH. ALLERGY IMMUNOL., vol. 120, no. 3, November 1999 (1999-11-01), XP002209693;;See also references of EP 1334727A2",PENDING
463,BR,A,BR 0107424 A,181-093-619-939-097,2002-10-15,2002,BR 0107424 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,"Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma","""MéTODO PARA OBTENçãO DE ESTRUTURAS ANTIGêNICAS, ESTRUTURA ANTIGêNICA, USO DA MESMA, FORMULAçãO DE VACINA, E, USO DA MESMA"". A presente invenção está relacionada com um método para se obter estruturas antigênicas com alta reatividade cruzada, capazes de intensificar a resposta imune a antígenos peptídicos sistêmica e/ou mucosicamente administrados, e às estruturas químicas obtidas com dito método e as formulações obtidas a partir de ditas estruturas e seus usos. O método descreve a obtenção de novas estruturas dendriméricas a partir da seleção e síntese de dendrímeros, que são ligados subseq³entemente a moléculas portadoras. As estruturas resultantes podem ser usadas convenientemente adjuvadas ou em uma formulação na qual diversos antígenos deste tipo podem ser introduzidos, um efeito sinergístico acontecendo entre esses componentes em relação à reatividade cruzada e à imunogenicidade da resposta obtida. A preparação pode também conter estabilizadores e agentes conservantes. As estruturas antigênicas resultantes podem ser usadas na indústria farmacêutica como formulações de vacina para uso em seres humanos e animais e como parte de sistemas de diagnóstico.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/181-093-619-939-097,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,DISCONTINUED
464,CA,A1,CA 2427539 A1,065-872-809-077-712,2003-05-01,2003,CA 2427539 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFICCROSS REACTIVITY,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH,REYES ACOSTA OSVALDO;;IGLESIAS PEREZ ENRIQUE;;GARAY PEREZ HILDA ELISA;;AGUILAR RUBIDO JULIO CESAR;;PENTON ARIAS EDUARDO;;CRUZ RICONDO LUIS JAVIER;;GUILLEN NIETO GERARDO ENRIQUE;;MUZIO GONZALEZ VERENA LUCILA;;DUARTE CANO CARLOS,,https://lens.org/065-872-809-077-712,Patent Application,no,0,0,21,21,59,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,DISCONTINUED
465,EA,B1,EA 005313 B1,165-878-006-875-190,2004-12-30,2004,EA 200300535 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"1. Method for obtaining antigenic structures able to enhance the specific cross reactivity comprising the steps: A) selection of the epitope of interest; B) obtaining of dendrimeric structures with the epitopes selected in (A), using a method of synthesis selected from the following group: 1) synthesis on a nucleus of aspartic acid or lysine; 2) synthesis on a nucleus of organic molecules and 3) direct coupling of peptides on a dendrimeric nucleus, the B and T-cell epitopes can be mixed on the same nucleus; C) conjugation of one or various dendrimeric structures obtained in (B), to one or various carrier molecules using a method of coupling selected from the group consisting in: 1) conjugation using glutaraldehyde, 2) using succinic anhydride, 3) using the ester of the beta -maleimidopropionic-N-hidroxisucci-nimidic acid (MPS), and 4) any method avoiding the use of spacer agents with aromatic side chains; D) mixture of conjugates obtained in the step (C) including the addition of the CD4-binding peptide or a conjugate containing it; and E) adjuvation of the resulting formulation in alum or a any other convenient adjuvant. 2. Method according to claim 1, wherein peptides contained in the structures obtained from step (B) belong to regions from the Human Immunodeficiency virus type 1 or 2. 3. Method according to claim 2, wherein peptides contained in the structures obtained from the step (B) belong to variable regions from the Human Immunodeficiency virus type 1 or 2. 4. Method according to claim 3, wherein peptides contained in the structures obtained from the step (B) belong to the third variable region (V3) from the Human Immunodeficiency Virus 1 or 2. 5. Method for according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to the Hepatitis B Virus. 6. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to the Hepatitis C Virus. 7. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to Dengue Virus. 8. Method according to claim 1, wherein the oligomers contained in the structures obtained from the step (B) belong to polysaccharidic regions from Neisseria meningitidis. 9. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) are mimetic peptides of antigenic polyssacharides. 10. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to antigenic regions from a microorganism or a pathogen. 11. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to self-antigens. 12. Method according to claim 11, wherein peptides contained in the structures obtained from the step (B) belong to the Gonadotropine Releasing Hormone. 13. Method according to claim 1, wherein the carrier molecule from the step (C) is the Hepatitis B surface antigen, HBsAg. 14. Method according to claim 1, wherein the carrier molecule from the step (C) is the p64K protein from Neisseria meningitidis. 15. Method according to claim 1, wherein the carrier molecule from the step (C) is the core protein from the Human Inmunodeficiency Virus. 16. Method according to claim 1, wherein the-carrier molecule from the step (C) is the hepatitis b core antigen or the Hepatitis C core antigen. 17. Method according to claim 1, wherein the carrier molecule from the step (C) is a polysaccharide. 18. Method according to claim 17, wherein the carrier molecule from the step (C) is a dextran. 19. Method according to claim 1, wherein the carrier molecule and the dendrimeric structure from the step (C) are coupled covalently, electrostatically or by hydrophobicity. 20. Antigenic structure able to enhance the specific cross reactivity comprising dendrimeric antigenic epitopes coupled to carrier proteins. 21. Antigenic structure according to claim 20 wherein the epitopes from the dendrimeric region have peptidic or oligosaccharidic nature. 22. Antigenic structure according to claim 21 wherein the epitopes of peptidic nature are peptidic consensus of variable regions selected from subtypes, subgroups, serotypes or other kind of associations. 23. Antigenic structure according to claim 21 wherein the epitopes of peptidic nature are peptidic libraries from peptidic sequences selected from microorganisms or mimetic peptides. 24. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to the Human Immunodeficiency Virus 1 or 2. 25. Antigenic structure according to claims 24 wherein the epitopes from the dendrimeric peptidic regions belong to variable regions from the Human Immunodeficiency Virus 1 or 2. 26. Antigenic structure according to claim 25 wherein the epitopes from the dendrimeric peptidic regions belong to the V3 variable region from the Human Immunodeficiency Virus 1 or 2. 27. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to regions from the Hepatitis B Virus. 28. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to regions from the Hepatitis C Virus. 29. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to regions from Dengue Virus. 30. Antigenic structure according to claim 21 wherein the epitopes from the dendrimeric peptidic regions belong to polysaccharidic antigens from Neisseria meningitidis. 31. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions are mimetic peptides from polysaccharidic or proteic antigens. 32. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to microorganisms or pathogens. 33. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to self-antigens. 34. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to the Gonadotropine Releasing Hormone. 35. Antigenic structure according to claim 20 wherein the carrier molecule is the Hepatitis B Surface Antigen, HBsAg. 36. Antigenic structure according to claim 20 wherein the carrier molecule is the p64K protein from Neisseria meningitidis. 37. Antigenic structure according to claim 20 wherein the carrier molecule is the HIV nucleocapside antigen. 38. Antigenic structure according to claim 20 wherein the carrier molecule is the HBV nucleocapside antigen (HBcAg). 39. Antigenic structure according to claim 20 wherein the carrier molecule is a polysaccharide. 40. Antigenic structure according to claim 39 wherein the carrier molecule is a dextran. 41. Use of the antigenic structure according to claims 20 to 40 in a diagnostic system. 42. Use of the antigenic structure according to claims 20 to 40 in preventive and therapeutic vaccines. 43. Vaccine formulation comprising the antigenic structure of claims 20 to 40 adsorbed or adjuvated conveniently. 44. Vaccine formulation according to claim 43 for systemic or mucosal use. 45. Use of vaccine formulations of claims 43 and 44 to prevent infectious diseases, autoimmunity or cancer. 46. Use of vaccine formulations of claims 43 and 44 to treat infectious diseases, autoimmunity or cancer.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/165-878-006-875-190,Granted Patent,no,0,1,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
466,HK,A1,HK 1058154 A1,185-574-033-309-648,2004-05-07,2004,HK 04101011 A,2004-02-13,CU 0100007 W;;CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,,CT INGENIERIA GENETICA BIOTECH,RICONDO LUIS JAVIER CRUZ;;RUBIDO JULIO CESAR AGUILAR;;PEREZ ENRIQUE IGLESIAS;;ACOSTA OSVALDO REYES;;PEREZ HILDA ELISA GARAY;;GONZALEZ VERENA LUCILA MUZIO;;NIETO GERARDO ENRIQUE GUILLEN;;CANO CARLOS DUARTE;;ARIAS EDUARDO PENTON,,https://lens.org/185-574-033-309-648,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P/;;A61P31/00;;A61P31/18;;A61P35/00;;C07K/;;C07K7/08;;C07K14/00;;C07K14/16;;C08G/;;C08G83/00,,0,0,,,,DISCONTINUED
467,AR,A1,AR 031182 A1,019-950-212-914-592,2003-09-10,2003,AR P010105120 A,2001-11-01,CU 20000242 A,2000-11-03,METODO DE OBTENCION DE ESTRUCTURAS ANTIGENICAS QUE POTENCIAN LA REACTIVIDAD CRUZADA ESPECIFICA Y SU USO EN FORMULACIONES,"La presente se relaciona con el método para la obtencion de estructuras antigénicas de alta reactividad cruzada, capaces de potenciar la respuesta inmune a antígenos peptídicos administrados por vía sistémica y/o mucosal, generando potentes respuestas inmunes así como estructuras químicas resultantes de la aplicacion de este método, formulaciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtencion de nuevas estructuras dendriméricas. Partiendo de la seleccion y síntesis de dendrímeros, que posteriormente son acoplados a moléculas portadoras. Las estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulacion donde pueden introducirse varios antígenos de este tipo, encontrándose un efecto sinérgico entre estos componentes con respecto a la reactividad cruzada y la inmunogenicidad de la respuesta obtenida. Además, la preparacion puede contener, estabilizadores y preservativos. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como formulaciones vacunales tanto para uso humano como veterinario y como parte de sistemas de diagnostico.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/019-950-212-914-592,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,PENDING
468,AU,B2,AU 2002/214938 B2,080-419-429-201-37X,2006-04-13,2006,AU 2002/214938 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,Method for obtaining antigenic structures enhancing specific cross reactivity,,CT INGENIERIA GENETICA BIOTECNOLOGIA,CANO CARLOS DUARTE;;PEREZ ENRIQUE IGLESIAS;;PEREZ HILDA ELISA GARAY;;NIETO GERARDO ENRIQUE GUILLEN;;RICONDO LUIS JAVIER CRUZ;;ARIAS EDUARDO PENTON;;ACOSTA OSVALDO REYES;;RUBIDO JULIO CESAR AGUILAR;;GONZALEZ VERENA LUCILA MUZIO,,https://lens.org/080-419-429-201-37X,Granted Patent,no,1,1,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,A61K39/12;;C12P21/02;;A61K/;;A61K39/00;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
469,AU,A,AU 2002/014938 A,082-742-286-151-32X,2002-05-15,2002,AU 2002/014938 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,Method for obtaining antigenic structures enhancing specific cross reactivity,,CT INGENIERIA GENETICA BIOTECH,RICONDO LUIS JAVIER CRUZ;;RUBIDO JULIO CESAR AGUILAR;;PEREZ ENRIQUE IGLESIAS;;ACOSTA OSVALDO REYES;;PEREZ HILDA ELISA GARAY;;GONZALEZ VERENA LUCILA MUZIO;;NIETO GERARDO ENRIQUE GUILLEN;;CANO CARLOS DUARTE;;ARIAS EDUARDO PENTON,,https://lens.org/082-742-286-151-32X,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,PENDING
470,PT,A,PT 108703 A,106-582-482-591-903,2017-01-17,2017,PT 10870315 A,2015-07-17,PT 10870315 A,2015-07-17,DISPOSITIVO PARA APARELHOS DE AQUECIMENTO E PROCESSO PARA A OPERAÇÃO DE UM DISPOSITIVO PARA APARELHOS DE AQUECIMENTO,"A PRESENTE INVENÇÃO DIVULGA UM DISPOSITIVO PARA APARELHOS DE AQUECIMENTO COMPREENDENDO PELO MENOS UMA UNIDADE DE CONTROLO E/OU DE REGULAÇÃO, A QUAL ESTÁ PREVISTA PARA AJUSTAR UMA RAZÃO AR/COMBUSTÍVEL (¿C) DE UMA COMBUSTÃO A UMA RAZÃO AR/COMBUSTÍVEL DE REFERÊNCIA (¿D).A UNIDADE DE CONTROLO E/OU DE REGULAÇÃO ESTÁ PREVISTA PARA, EM PELO MENOS UM ESTADO OPERACIONAL, CALCULAR UM FATOR DE CORREÇÃO DA POTÊNCIA (CF) E PARA CONSIDERÁ-LO DURANTE O AJUSTE DA RAZÃO AR/COMBUSTÍVEL (¿C).",BOSCH TERMOTECNOLOGIA SA,LUIS MIGUEL PACHECO MONTEIRO;;RICARDO JORGE DE SOUSA VIEIRA;;MARCO PAULO ROSA DE LIMA VILAÇA MARQUES;;SÉRGIO VARO OLIVEIRA SALUSTIO;;JOEL FILIPE PEREIRA;;MAURO ANDRÉ OLIVEIRA SIMÕES;;DUARTE NUNO FERNANDES GARCIA LIMA,,https://lens.org/106-582-482-591-903,Patent Application,no,0,0,5,5,0,F23N1/022;;F23N3/082;;F23N3/082;;F23N3/002;;F23N3/002;;F23N5/003;;F23N2225/16;;F23N2225/16;;F23N2225/20;;F23N2225/20;;F23N2225/21;;F23N2225/21;;F23N2241/04;;F23N2241/04,F23N1/02,,0,0,,,,ACTIVE
471,CO,A1,CO 2020006806 A1,108-044-549-687-817,2020-11-30,2020,CO 2020006806 A,2020-05-31,CO 2020006806 A,2020-05-31,Equipo fijo y movil para la medición de degradación mecánica de soluciones poliméricas a través de válvulas reguladoras y controladoras de flujo en pozos inyectores,La presente invención se refiere a un equipo fijo que mide la degradación mecánica de las soluciones poliméricas utilizadas en procesos de recobro mejorado de crudo a través de válvulas reguladoras y controladoras de flujo. El equipo fijo comprende una serie de componentes e instrumentación que permiten cuantificar experimentalmente la pérdida de viscosidad de soluciones poliméricas sintéticas o naturales usadas en procesos de recobro mejorado al fluir a través de restricciones presentes en válvulas reguladoras de flujo. Los resultados obtenidos ayudan a determinar el comportamiento reológico del fluido en válvulas reguladoras de flujo con el objetivo de determinar las capacidades de operación de las válvulas y diseñar redes de distribución de polímero que conlleven a un factor de recobro de crudo eficiente en procesos de inyección de polímeros.,ECOPETROL SA,GARCIA DUARTE HUGO ALEJANDRO;;MAYA TORO GUSTAVO ADOLFO;;CASTRO GARCIA RUBEN HERNAN;;JIMENEZ DIAZ ROBINSON;;QUINTERO PEREZ HENDERSON IVAN;;HERRERA QUINTERO JULIA JINETH;;GUTIERREZ BENAVIDEZ MAURICIO;;PEREZ ROJAS EDUAR ERNESTO;;MALDONADO MANRIQUE LAURA YEDXENIA;;GOMEZ VERGEL JOSE LUIS;;MANRIQUE VENTURA EDUARDO JOSE;;PRADA NIÑO LUIS CARLOS,,https://lens.org/108-044-549-687-817,Patent Application,no,0,0,1,1,0,,E21B34/00;;E21B43/00,,0,0,,,,PENDING
472,PT,A,PT 117291 A,136-125-064-388-579,2022-12-19,2022,PT 11729121 A,2021-06-17,PT 11729121 A,2021-06-17,VISEIRA DE PROTEÇÃO INDIVIDUAL VENTILADA,"A PRESENTE INVENÇÃO REFERE-SE A UM EQUIPAMENTO DE PROTEÇÃO INDIVIDUAL, NOMEADAMENTE A UMA VISEIRA DE PROTEÇÃO INDIVIDUAL PARA USO EM MÁS ATMOSFERAS. ESTE EQUIPAMENTO COMPREENDE UM CHASSI PRINCIPAL (1) QUE INCORPORA TODOS OS COMPONENTES ELETRÓNICOS NECESSÁRIOS PARA O CORRETO FUNCIONAMENTO DA INVENÇÃO. ESTES COMPONENTES ELETRÓNICOS GARANTEM O DESEMBACIAMENTO DE UMA VISEIRA (8) DE PROTEÇÃO E AUMENTA O CONFORTO QUANDO É USADA EM SIMULTÂNEO COM UMA MÁSCARA DE PROTEÇÃO INDIVIDUAL DEVIDO À REFRIGERAÇÃO GERADA PELO VENTILADOR. O AR VENTILADO, QUE É FILTRADO, GARANTE A SEGURANÇA DO UTILIZADOR. O CHASSI PRINCIPAL (1) APRESENTA ACOPLADO UMA TAMPA (2) QUE PROTEGE OS COMPONENTES ELETRÓNICOS, UM DIFUSOR DE AR (3), UM CHASSI DO FILTRO (4) PARA COLOCAÇÃO DE UM FILTRO DE PARTÍCULAS (5) E UM ELÁSTICO (7) FIXO POR COMPONENTES DE FIXAÇÃO DO ELÁSTICO (6).",INST POLITECNICO DE COIMBRA,FERNANDO DOMINGUES MOITA;;MARCO JOSÉ DA SILVA;;NUNO ANTÓNIO SIMÃO DA CRUZ;;LUIS MANUEL FERREIRA ROSEIRO;;NUNO FILIPE JORGE LAVADO;;DIOGO MOREIRA FERNANDES;;JOÃO MIGUEL ANTUNES SOBRAL;;BRUNO GONÇALO DUARTE GLÓRIA PAIS MARTINS,,https://lens.org/136-125-064-388-579,Patent Application,no,0,0,1,1,0,A41D13/1184,A41D13/11,,0,0,,,,PENDING
473,CO,U1,CO 2018013589 U1,125-267-196-258-092,2019-02-08,2019,CO 2018013589 U,2018-12-14,CO 2018013589 U,2018-12-14,Banco de diagnostico y pruebas para panel de relevos,"La presente invención relaciona un banco de diagnóstico y pruebas para paneles de relevos de una aeronave que consta de una fuente de potencia (170); una UPS (140); un conjunto de CPU/controlador (150); una fuente de suministro de corriente continua (160); módulo para evaluar el panel de relevos izquierdo (111) que incorpora interruptores de control, indicadores y puntos de prueba para el chequeo operacional del panel izquierdo; módulo que evalúa paneles izquierdo y derecho integrados (110) que tiene una interfaz para control y monitoreo del banco, arnés eléctrico que permite la interacción entre los componentes a evaluar y el banco de pruebas; módulo para evaluar el panel de relevos derecho (112) que incorpora interruptores de control, indicadores y puntos de prueba para el chequeo operacional del panel derecho.",MINISTERIO DE DEFENSA EJERCITO NAC,FRANCO GARCÍA GUSTAVO ALFREDO;;PEÑA CALLE CESAR AUGUSTO;;CUESTA DÍAZ JULIO ANDRÉS;;DUARTE FERREIRA ARIEL FERNANDO;;CUADROS ANTOLÍNEZ RUBÉN DARÍO;;MORA GONZALEZ YONNY ALEXANDER;;ALTAMIRANDA RAMOS LUIS ENAIRO;;GUISADO SEPÚLVEDA WALTER DE JESÚS,,https://lens.org/125-267-196-258-092,Unknown,no,0,0,1,1,0,,G01R31/327,,0,0,,,,PENDING
474,WO,A1,WO 2012/140629 A1,064-192-863-817-114,2012-10-18,2012,IB 2012051880 W,2012-04-16,PT 10563011 A,2011-04-15,POLYMER-BASED ELECTRODE FOR BIO-SIGNAL RECORDING,"A novel polymer-based pasteless electrode suitable for electroencephalogram (EEG) recording is described. This electrode is suitable for use in medicine, in particular for bio-signal recording, in particular for use in electroencephalogram (EEG), electrocardiogram (ECG) or electromyogram (EMG). The electrode is between the classic ""wet"" and ""dry"" electrodes. A localized skin hydration effect at the electrode/scalp contact point is achieved by the release of a small amount of a hydrating agent from a reservoir on the electrode itself, triggered by the electrode/scalp coupling pressure. The electrode functionality comprises polymer mechanical properties and the design of the electrode reservoir, whose volume decreases upon the application of the specified pressure. The electrode comprises a polymeric flexible body (1), a reservoir (2), within said body (1), and at least one orifice (3) in said reservoir (2), and a coating of conductive film on whole or part of the electrode body (1).",UNIV DO PORTO;;UNIV DE COIMBRA;;UNIV DO MINHO;;MAGALHAES DUQUE DA FONSECA JOSE CARLOS;;DE AMORIM NOVAIS DA COSTA NOBREGA JOAO MIGUEL;;ALVES MACHADO NOBREGA ANA VERA;;VILELA VAZ JOSE FILIPE;;FIGUEIREDO OLIVEIRA DUARTE LUIS MIGUEL;;MACEDO DA MOTA ARMANDO RAFAEL,MAGALHAES DUQUE DA FONSECA JOSE CARLOS;;DE AMORIM NOVAIS DA COSTA NOBREGA JOAO MIGUEL;;ALVES MACHADO NOBREGA ANA VERA;;VILELA VAZ JOSE FILIPE;;FIGUEIREDO OLIVEIRA DUARTE LUIS MIGUEL;;MACEDO DA MOTA ARMANDO RAFAEL,,https://lens.org/064-192-863-817-114,Patent Application,yes,10,17,1,1,0,A61B5/6803;;A61B5/681;;A61B2562/0217;;A61B2562/0215;;A61B5/252;;A61B5/25;;A61B5/291;;A61B5/296;;A61B2562/0217;;A61B2562/0215;;A61B5/25,A61B5/296,,9,6,122-005-533-389-175;;074-939-973-087-250;;130-122-436-449-722;;022-984-871-022-217;;064-628-879-866-003;;136-285-449-651-844,12046705;;10.1109/tbme.2002.1001974;;10.1016/j.sna.2008.03.007;;10.1109/tbme.1973.324197;;4708767;;10.1016/0013-4694(94)90053-1;;7514984;;17260869;;10.1109/tbme.2006.884649;;10847194;;10.1088/0967-3334/21/2/307,"M. TEPLAN: ""Fundamentals of EEG measurement"", MEASUREMENT SCIENCE REVIEW, vol. 2, no. 2, 2002;;E.MCADAMS: ""Encyclopedia of Medical Devices and Instrumentation"", 1988, WILEY, article ""Bioelectrodes"", pages: 120 - 166;;P.GRISS; H.K. TOLVANEN-LAAKSO; P.MERILAINEN; G.STEMME: ""Characterization of Micromachined Spiked Biopotential Electrodes"", IEEE TRANSS. BIOM. ENG, vol. 49, no. 6, 2002, XP002297850, DOI: doi:10.1109/TBME.2002.1001974;;G.RUFFINI; S.DUNNE; L.FUENTEMILLA; C.GRAU; E.FARRES; J. MARCO-PALLARES; P.WATTS; S. SILVA: ""First human trials of a dry electrophysiology sensor using a carbon nanotube array interface"", SENSORS AND ACTUATORS A, vol. 144, no. 2, 2008, pages 275 - 279, XP022664305, DOI: doi:10.1016/j.sna.2008.03.007;;W.H.KO; J.HYNECEK: ""Biomedical electrode technology"", 1974, ACADEMIC PRESS, article ""Dry electrodes and electrode amplifiers"", pages: 169 - 181;;MATSUO, T.; IINUMA, K.; ESASHI, M.: ""IEEE Transations on Biomedical Eng."", 1973, article ""A Barium- titanate-ceramics capacitive type EEG electrode"", pages: 299 - 301;;TAHERI, B.A.; KNIGHT, R.T.; SMITH, R.L.: ""A dry electrode for EEG recording"", ELECTROENCEPHALOGRAPHY AND CLIN. NEUROPHYSIOL., vol. 90, 1994, pages 376 - 383, XP024296251, DOI: doi:10.1016/0013-4694(94)90053-1;;C.FONSECA; J.P.SILVA CUNHA; R.E.MARTINS; VM FERREIRA; J.P.MARQUES DE SÁ; M.A.BARBOSA; A.MARTINS SILVA: ""A novel dry active electrode for EEG recording"", IEEE TRANS. BIOMED. ENG., vol. 54, no. 1, 2007, pages 162 - 165, XP011152295, DOI: doi:10.1109/TBME.2006.884649;;A.SEARLE; L.KIRKUP: ""A Direct Comparison of Wet, Dry and Insulating Bioelectric Recording Electrodes"", PHYSIOL. MEAS., vol. 22, 2000, pages 71 - 83",PENDING
475,BR,A2,BR PI1012429 A2,189-626-762-937-342,2016-08-09,2016,BR PI1012429 A,2010-09-29,BR PI1012429 A,2010-09-29,"processo de produção, uso e composição farmacêutica compreendendo compostos obtidos a partir de cera de carnaúba","proesso de produção, uso e composição farmacêutica compreendendo compostos obtidos a partir de cera de carnaúba. a presente invenção refere-se a certos novos derivados isolados da cera de carnaúba, a processos para preparar tais compostos e a utilidade da fração isolada da cera da carnaúba (pco-c) em produtos farmacêuticos, especialmente para o tratamento de diabetes e dislipidemias e a composição farmacêuticas contendo compostos obtidos a partir da cera de carnaúba. em espcial, a atividade da fração isolada da cera da carnaúba se deve a presença de substâncias classificadas quimicamente como ésteres do acido cinâmico.",BANCO DO NORDESTE DO BRASIL S A;;FUNDAÇÃO UNIVERSIDADE ESTADUAL DO CEARÁ;;UNIV FED DO CEARA,ARRUDA ANTÔNIO CARLOS VASCONCELOS JR;;ALVES CARLUCIO ROBERTO;;MENDES FRANCISCA NOÉLIA PEREIRA;;VIEIRA ICARO GUSMÃO PINTO;;ALMEIDA LIA MAGALHÃES DE;;DUARTE LUIS SÉRGIO FONTELES;;QUEIROZ MARIA GORETTI RODRIGUES DE;;GUEDES MARIA IZABEL FLORINDO,,https://lens.org/189-626-762-937-342,Patent Application,no,0,0,1,1,0,,C07C15/04;;A61K31/216;;A61P3/00;;A61P3/06;;A61P3/08;;C07C37/68;;C07C39/19;;C07C51/42,,0,0,,,,DISCONTINUED
476,CO,U1,CO 2018013591 U1,158-350-304-825-627,2019-02-08,2019,CO 2018013591 U,2018-12-14,CO 2018013591 U,2018-12-14,Banco de diagnóstico y pruebas para radar y/o altímetro,"Banco de diagnóstico y pruebas para radar yio altímetro que consta de una fuente (le potencia, una UPS, una unidad central de procesamiento (CPU), una inierfaz para control y monitoreo del equipo, fuentes de suministro de corriente continua, un regulador de voltaje de corriente continua, y un emulador de radar / altimetría para ci monitoreo y simulación de los componentes.",MINISTERIO DE DEFENSA EJERCITO NAC,FRANCO GARCÍA GUSTAVO ALFREDO;;PEÑA CALLE CESAR AUGUSTO;;CUESTA DÍAZ JULIO ANDRÉS;;DUARTE FERREIRA ARIEL FERNANDO;;CUADROS ANTOLÍNEZ RUBÉN DARÍO;;MORA GONZALEZ YONNY ALEXANDER;;ALTAMIRANDA RAMOS LUIS ENAIRO;;GUISADO SEPÚLVEDA WALTER DE JESÚS,,https://lens.org/158-350-304-825-627,Unknown,no,0,0,1,1,0,,G01S7/497;;G01S7/42;;G01S7/484;;G01S7/486;;G01S13/00,,0,0,,,,PENDING
477,PT,A,PT 103034 A,033-961-942-704-897,2005-04-29,2005,PT 10303403 A,2003-10-28,PT 10303403 A,2003-10-28,MAQUINA UNIVERSAL DE ENSAIOS MULTIAXIAIS,"The invention concerns a multiaxial universal testing machine, which allows evaluating the mechanical behavior and performance of materials with planar structures, such as fabrics, composites and laminates. The machine comprises 4 horizontal axes, each one with 2 arms, resulting in a final arrangement of 8 gripping jaws at 45°, displaceable along slide rails and moved by the action of 8 independent motors. The connection between a gripping jaw and its respective motor is assured by a linear actuator. The test specimen is fixed by the gripping jaws and can be subject to tensile, compression and fatigue testing, making possible the analysis of the materials behavior under simultaneous multi-directional loads.",UNIV DO MINHO;;INST DE DESENVOLVIMENTO E INOV,MONTEIRO JOAO LUIS MARQUES PER;;ROCHA ANA MARIA MOREIRA FERREI;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARAUJO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,,https://lens.org/033-961-942-704-897,Patent Application,no,0,0,10,10,0,G01N3/08;;G01N2203/0016;;G01N2203/0073;;G01N2203/0085;;G01N2203/025;;G01N2203/0254;;G01N2203/0278;;G01N2203/0282;;G01N3/08;;G01N2203/0282;;G01N2203/0016;;G01N2203/0278;;G01N2203/0073;;G01N2203/0254;;G01N2203/0085;;G01N2203/025,G01N3/00;;G01N3/02;;G01N3/08,,0,0,,,,DISCONTINUED
478,CO,U1,CO 2018013587 U1,014-704-639-992-535,2019-02-08,2019,CO 2018013587 U,2018-12-14,CO 2018013587 U,2018-12-14,Banco de diagnóstico y pruebas para sistemas de comunicación de aeronaves,"Banco de diagnóstico y priLebas para sistemas de intercomunicación de aeronaves (100) que consta de una fuente de potencia, una UPS (130), una unidad de control de pruebas (120), una interfaz para control y monitoreo del equipo (110), fuentes de suministro de corriente continua (140) y un regulador de voltaje de corriente continua.",MINISTERIO DE DEFENSA EJERCITO NAC,FRANCO GARCÍA GUSTAVO ALFREDO;;PEÑA CALLE CESAR AUGUSTO;;CUESTA DÍAZ JULIO ANDRÉS;;DUARTE FERREIRA ARIEL FERNANDO;;CUADROS ANTOLÍNEZ RUBÉN DARÍO;;MORA GONZALEZ YONNY ALEXANDER;;ALTAMIRANDA RAMOS LUIS ENAIRO;;GUISADO SEPÚLVEDA WALTER DE JESÚS,,https://lens.org/014-704-639-992-535,Unknown,no,0,0,1,1,0,,H04B7/185;;G01S5/02;;H04B7/005;;H04B17/11;;H04B17/21,,0,0,,,,PENDING
479,WO,A3,WO 2005/040765 A3,001-828-119-300-77X,2005-08-04,2005,PT 2004000026 W,2004-10-28,PT 10303403 A,2003-10-28,MULTIAXIAL UNIVERSAL TESTING MACHINE,"The invention concerns a multiaxial universal testing machine, which allows evaluating the mechanical behaviour and performance of materials with planar structures, such as fabrics, composites and laminates. The machine comprises 4 horizontal axes at 45&deg;, with 8 gripping jaws displaceable along slide rails and moved by the action of 8 independent motors. The connection between a gripping jaw and its respective motor is assured by a linear actuator. The test specimen is fixed by the gripping jaws and can be subject to tensile, compression and fatigue testing, making possible the analysis of the materials behaviour under simultaneous multi-directional loads.",UNIV DO MINHO;;MONTEIRO JOAO LUIS MARQUES PER;;DA ROCHA ANA MARIA MOREIRA FER;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARAUJO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,MONTEIRO JOAO LUIS MARQUES PER;;DA ROCHA ANA MARIA MOREIRA FER;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARAUJO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,,https://lens.org/001-828-119-300-77X,Search Report,yes,2,2,10,10,0,G01N3/08;;G01N2203/0016;;G01N2203/0073;;G01N2203/0085;;G01N2203/025;;G01N2203/0254;;G01N2203/0278;;G01N2203/0282;;G01N3/08;;G01N2203/0282;;G01N2203/0016;;G01N2203/0278;;G01N2203/0073;;G01N2203/0254;;G01N2203/0085;;G01N2203/025,G01N3/00;;G01N3/02;;G01N3/08,,3,1,023-038-164-047-453,10.1007/bf02328435,"BOEHLER J P ET AL: ""A NEW DIRECT BIAXIAL TESTING MACHINE FRO ANISOTROPIC MATERIALS"", 1 March 1994, EXPERIMENTAL MECHANICS, SOCIETY FOR EXPERIMENTAL STRESS ANALYSIS,, US, PAGE(S) 1-9, ISSN: 0014-4851, XP000574645;;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 02 29 February 2000 (2000-02-29);;URUMOV G T: ""A MACHINE FOR TESTING SHEET SPECIMENS FOR FATIGUE UNDER TWO- FREQUENCY LOADING CONDITIONS"", October 1997, INDUSTRIAL LABORATORY, CONSULTANTS BUREAU. NEW YORK, US, PAGE(S) 620-622, ISSN: 0019-8447, XP000777371",PENDING
480,BR,A2,BR 102018076054 A2,111-817-243-436-281,2020-06-23,2020,BR 102018076054 A,2018-12-14,BR 102018076054 A,2018-12-14,modelo de treinamento de retalho em face de silicone,"modelo de treinamento de retalho em face de silicone. para melhorias das habilidades médico-cirúrgicas em retalhos de face, quer seja a nível de primeiro contato para acadêmicos, quer seja como treinamento para médicos residentes, por meio de modelo experimental em face siliconada simulando pele, tecido celular subcutâneo e músculo. o modelo sugere sanar lacunas tanto na educação médica da formação acadêmica brasileira quanto o aperfeiçoamento de técnicas de reconstrução de face em virtude de tumores ou traumas. o material confeccionou resistência e elasticidade necessárias e satisfatórios para as rotações técnicas dos retalhos na pele, desenvolvendo a habilidade de destreza e sensação de espessura da pele e estruturas ósseas, diferindo dos usuais modelos de sutura por matéria e finalidade.",UNIV DO ESTADO DO PARA,AMÁLIA COSTA COIMBRA;;HÍCARO DONATO GRANHEN;;LIZANDRA LUJAN DELPUPO TRIVILIN;;LUCIANO GOMES MOURA;;LUIS FERNANDO FREITAS DE SOUSA;;RAFAEL DE AZEVEDO SILVA;;SAMARA NAZARÉ DOS SANTOS COSTA;;SÉRGIO CUNHA TRINDADE JÚNIOR;;TIAGO BRAGA DUARTE,,https://lens.org/111-817-243-436-281,Patent Application,no,0,0,1,1,0,,G09B23/28;;G09B23/30,,0,0,,,,DISCONTINUED
481,CN,A,CN 114901288 A,195-286-586-485-306,2022-08-12,2022,CN 202080090663 A,2020-12-18,CU 20190115 A;;CU 2020050009 W,2019-12-26,Application of benzodiazepine derivative and method for treating traumatic brain injury,"The invention aims to protect a new application of a benzodiazepine derivative JM-20 in treatment and recovery of traumatic brain injury (TBI) and related symptoms thereof. In addition, it provides a method of treating TBI-induced brain injury.",CENTRE FOR DRUG RES,BELLA FUERTADO ANA BEATRIZ;;ALVISI CORTES ANTONIO;;FALINA GONCALVES DANIEL;;DUARTE HARTMANN DANIEL;;CASSOL GENEVI ¨ ¨ VE;;FREIRE ROJES LUIS FERNANDO;;ANDUNES SOARES FRANCISCO ALEJANDRO;;NUNES FIGUEIREDO YOLANDA;;MONDELO RODRIGUEZ ANTONIO;;PADRON YAQUIS ALEJANDRO SAUL,,https://lens.org/195-286-586-485-306,Patent Application,no,0,0,8,8,0,A61K31/5513;;A61P25/28;;A61P25/28;;A61K31/5513,A61K31/5513;;A61P25/28,,0,0,,,,DISCONTINUED
482,US,B2,US 7509882 B2,138-772-832-067-182,2009-03-31,2009,US 57586704 A,2004-10-28,PT 10303403 A;;PT 2004000026 W,2003-10-28,Multiaxial universal testing machine,"The invention concerns a multiaxial universal testing machine, which allows evaluating the mechanical behavior and performance of materials with planar structures, such as fabrics, composites and laminates. The machine comprises 4 horizontal axes, each one with 2 arms, resulting in a final arrangement of 8 gripping jaws at 45°, displaceable along slide rails and moved by the action of 8 independent motors. The connection between a gripping jaw and its respective motor is assured by a linear actuator. The test specimen is fixed by the gripping jaws and can be subject to tensile, compression and fatigue testing, making possible the analysis of the materials behavior under simultaneous multi-directional loads.",UNIV DO MINHO,MONTEIRO JOAO LUIS MARQUES PEREIRA;;DA ROCHA ANA MARIA MOREIRA FERREIRA;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARAUJO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,UNIVERSIDADE DO MINHO (2007-05-14),https://lens.org/138-772-832-067-182,Granted Patent,yes,4,19,10,10,0,G01N3/08;;G01N2203/0016;;G01N2203/0073;;G01N2203/0085;;G01N2203/025;;G01N2203/0254;;G01N2203/0278;;G01N2203/0282;;G01N3/08;;G01N2203/0282;;G01N2203/0016;;G01N2203/0278;;G01N2203/0073;;G01N2203/0254;;G01N2203/0085;;G01N2203/025,G01D7/00;;G01N3/00;;G01N3/02;;G01N3/08,73/862.046,2,1,023-038-164-047-453,10.1007/bf02328435,"G. T. Urumov, ""A Machine for Testing Sheet Specimens for Fatigue Under Two-Frequency Loading Conditions"", Industrial Laboratory (Diagnostics of Material), vol. 63, No. 10, Oct. 1997, pp. 620-622.;;J. P. Boehler, et al, ""A New Direct Biaxial Testing Machine for Anisotropic Materials"", Experimental Mechanics, Society for Experimental Stress Analysis, US, Mar. 1, 1994, pp. 1-9, XP000574645, ISSN: 0014-4851.",INACTIVE
483,BR,A,BR 8801936 A,175-089-158-023-000,1989-11-14,1989,BR 8801936 A,1988-04-22,BR 8801936 A,1988-04-22,ESCALA DE MEDICAO DA EXPANSAO DE TOPO DE LINGOTE DE ACO SEMI ACALMADO,,TUBARAO SIDERURGICA,SOARES CARLOS EDUARDO DA S;;ABREU EVANDRO MORAES;;JESUS LUIZ CARLOS DE;;COSTA MARCO TULIO DA SILVA;;MANTOVANI JOSE VALDERIO;;AMARAL LUIZ CARLOS DO;;DUARTE RODINEY OLIVEIRA;;SANTANA ZILMAR LUIS;;NOVAES CARLOS VESLEY VALVERDE,,https://lens.org/175-089-158-023-000,Patent Application,no,0,0,1,1,0,,B22D2/00,,0,0,,,,DISCONTINUED
484,MY,A,MY 137709 A,158-713-504-253-336,2009-02-27,2009,MY PI20015012 A,2001-10-30,CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES OF HIGH CROSS REACTIVITY AND THEIR USE IN FORMULATIONS,"THE PRESENT INVENTION IS RELATED TO A METHOD FOR OBTAINING NEW ANTIGENIC STRUCTURES, ABLE TO ENHANCE THE IMMUNE RESPONSE TO PEPTIDIC ANTIGENS ADMINISTERED SYSTEMICALLY AND/OR MUCOSALLY, GENERATING STRONG IMMUNE RESPONSES AS WELL AS CHEMICAL STRUCTURES RESULTING FROM THE APPLICATION OF THE METHOD, FORMULATIONS OBTAINED AND THEIR USES. @THE METHOD DESCRIBED IN THE PRESENT INVENTION ENABLES THE OBTENTION OF NEW ANTIGENIC STRUCTURES. STARTING FROM THE SELECTION AND SYNTHESIS OF DENDRIMERS, THEY ARE COUPLED TO CARRIER. THE RESULTING STRUCTURES CAN BE USED ADJUVATED CONVENIENTLY OR IN A FORMULATION OF VARIOUS ANTIGENS. A SYNERGISTIC EFFECT CAN BE FOUND IN THE CROSSREACTIVITY AND IMMUNOGENICITY. FUTHERMORE, THE FORMULATIONS CAN CONTAIN STABILIZERS AND PRESERVES. @THE ANTIGENIC STRUCTURES OF THE PRESENT INVENTION CAN BE USED IN THE PHARMACEUTICAL INDUSTRY AS VACCINE FORMULATIONS TO PREVENT OR TO TREAT DISEASES IN HUMANS AND ANIMALS, AS WELL AS IN THE DEVELOPMENT OF DIAGNOSTIC SYSTEMS.",CT INGENIERIA GENETICA BIOTECH,JAVIER CRUZ RICONDO LUIS;;AGUILAR RUBIDO JULIO CESAR;;ENRIQUE IGLESIAS PEREZ;;OSVALDO REYES ACOSTA;;ELISA GARAY PEREZ HILDA;;LUCILA MUZIO GONZALEZ VERENA;;ENRIQUE GUILL XC N NIETO GERARDO;;CARLOS DUARTE CANO;;EDUARDO PENTON ARIAS,,https://lens.org/158-713-504-253-336,Granted Patent,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
485,WO,A2,WO 2005/040765 A2,151-394-903-529-299,2005-05-06,2005,PT 2004000026 W,2004-10-28,PT 10303403 A,2003-10-28,MULTIAXIAL UNIVERSAL TESTING MACHINE,"The invention concerns a multiaxial universal testing machine, which allows evaluating the mechanical behaviour and performance of materials with planar structures, such as fabrics, composites and laminates. The machine comprises 4 horizontal axes at 45&deg;, with 8 gripping jaws displaceable along slide rails and moved by the action of 8 independent motors. The connection between a gripping jaw and its respective motor is assured by a linear actuator. The test specimen is fixed by the gripping jaws and can be subject to tensile, compression and fatigue testing, making possible the analysis of the materials behaviour under simultaneous multi-directional loads.",UNIV DO MINHO;;MONTEIRO JOAO LUIS MARQUES PER;;DA ROCHA ANA MARIA MOREIRA FER;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARAUJO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,MONTEIRO JOAO LUIS MARQUES PER;;DA ROCHA ANA MARIA MOREIRA FER;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARAUJO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,,https://lens.org/151-394-903-529-299,Patent Application,yes,0,12,10,10,0,G01N3/08;;G01N2203/0016;;G01N2203/0073;;G01N2203/0085;;G01N2203/025;;G01N2203/0254;;G01N2203/0278;;G01N2203/0282;;G01N3/08;;G01N2203/0282;;G01N2203/0016;;G01N2203/0278;;G01N2203/0073;;G01N2203/0254;;G01N2203/0085;;G01N2203/025,G01N3/00;;G01N3/02;;G01N3/08,,0,0,,,,PENDING
486,MX,A,MX 9707071 A,087-820-041-678-863,1997-11-29,1997,MX 9707071 A,1997-01-17,CU 9700001 W;;CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS.,"The present invention relates to biotechnology and genetic engineering, particularly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an oppropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 aminoacids of the antigen P64k of Neisseria meningitidis B:4 :P1.15. In particular, use is made of a recombinant plasmide containing said sequence, under the control of the triptophane promotor of E. coli and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.",CT INGENIERIA GENETICA BIOTECH,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGU RICARDO DE LA CARIDAD;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL,,https://lens.org/087-820-041-678-863,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
487,RU,C2,RU 2604851 C2,018-089-813-091-817,2016-12-10,2016,RU 2011133830 A,2011-08-11,US 85517510 A,2010-08-12,METHOD OF FORMING FIBROUS PRODUCT,"FIELD: hygiene.SUBSTANCE: present invention relates to method and device for forming fibrous product, involving following steps: 1) passage of formed fibrous product through calender, comprising vacuum drum and opposite calender shaft, on surface of which, at least one groove is located, configuration of which allows to give volumetric contour to formed fibrous product; 2) embossing calendering of fibrous product in embossing calender between first and second rollers without use of bearing layer. Thus produced fibrous product can be used as layer of absorbent core of disposable hygienic products, such as sanitary napkins, daily linings, diapers, etc. Present invention also relates to disposable hygienic products, base for making of which is formed fibrous product, made in compliance with principles of present invention.EFFECT: use of bearing layer complicates production of products, and if bearing layer must be added to end product, it may cause increase of cost of end product and(or) negatively affect hygroscopic properties of product, therefore method and device for forming fibrous product allows to avoid above disadvantages.18 cl, 26 dwg, 1 tbl, 4 ex",DZHONSON END DZHONSON DU BRAZIL IND E KOMERSIU DI PRODUTUS PARA SAUDI LTDA,ALKMIN MARKO ANTONIO;;BARBOSA LIVEJA FUDZITA;;KAU ZHOZE FRANSISKO;;KOTINO ZHOZE MANUEL SOARES;;DUARTE IVAIR LUIS;;FARIJA REJNALDO LORENSO;;ERNANDES FRANSISKU KH V;;MARTINES MANUELA LEONEL;;RIMOLI FRANSISKU ANTONJU;;NETO FRANSISKO SAVASTANO;;JAMASITA ALESANDRE TEJSEJRA,,https://lens.org/018-089-813-091-817,Granted Patent,no,0,0,25,40,0,A61F13/15626;;A61F13/15626;;A61F13/15658;;A61F13/00;;A61F13/47218;;A61F13/533;;D06C15/00;;Y10T428/24488;;Y10T428/24488;;Y10T428/24562;;Y10T428/24562,D06C15/00;;A61F13/15,,0,0,,,,ACTIVE
488,RU,C2,RU 2636299 C2,102-167-275-804-028,2017-11-21,2017,RU 2011134508 A,2011-08-17,US 85517510 A;;US 85861910 A,2010-08-12,ABSORBENT PRODUCT INCLUDING FORMED FIBRE PRODUCTS,"FIELD: items for personal use.SUBSTANCE: invention generally relates to a method and device for manufacture of a formed fibre product and, in particular, to a method and device for manufacture of a formed fibre products that can used as an absorbent core of disposable hygiene products, such as sanitary towels, daily gaskets, diapers, etc. This invention also relates to disposable hygienic products with core represented by a formed fibre moulds product in accordance with the principles of this invention.EFFECT: improved product absorbency.11 cl, 26 dwg",DZHONSON END DZHONSON DU BRAZIL IND E KOMERSIU DI PRODUTUS PARA SAUDI LTDA,ALKMIN MARKO ANTONIO;;BARBOSA LIVEYA FUDZITA;;KAU ZHOZE FRANSISKO;;KOTINO ZHOZE MANUEL SOARES;;DUARTE IVAIR LUIS;;FARIYA REJNALDO LORENSO;;ERNANDES FRANSISKU KH V;;MARTINES MANUELA LEONEL;;RIMOLI FRANSISKU ANTONYU;;NETO FRANSISKO SAVASTANO;;YAMASITA ALESANDRE TEJSEJRA,,https://lens.org/102-167-275-804-028,Granted Patent,no,5,0,25,40,0,A61F13/15626;;A61F13/15626;;A61F13/15658;;A61F13/00;;A61F13/47218;;A61F13/533;;D06C15/00;;Y10T428/24488;;Y10T428/24488;;Y10T428/24562;;Y10T428/24562,A61F13/47;;A61F13/513,,0,0,,,,ACTIVE
489,WO,A1,WO 2015/151030 A1,058-058-473-845-748,2015-10-08,2015,IB 2015052370 W,2015-03-31,PT 10755114 A,2014-03-31,METHOD TO OBTAIN COLLAGEN/GELATIN FROM MARINE SPONGES,"The present disclosure relates to a method to obtain collagen/gelatin from marine sponges based on water acidified with carbon dioxide for the isolation and/or purification of soluble compounds, in particular a method for obtaining collagen/gelatin from a marine sponge comprising the extraction of the collagen/gelatin from said sponge using water acidified with carbon dioxide and using high pressure. The present disclosure has a surprisingly high collagen extraction yield.",ASS FOR THE ADVANCEMENT OF TISSUE ENGINEERING CELL BASED TECHNOLOGIES & THERAPIES A4TEC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;COLARDELLE DA LUZ MANO JOÃO FILIPE;;QUINTEIROS LOPES HENRIQUES DA SILVA TIAGO JOSÉ;;DE ASCENSÃO AROSO IVO MANUEL;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;FERNANDES DA SILVA JOÃO CARLOS,,https://lens.org/058-058-473-845-748,Patent Application,yes,1,0,3,3,0,A23J1/04;;C07K14/78;;A23V2002/00;;C07K14/43595,C07K14/78;;A23J1/04,,15,8,070-064-147-251-317;;042-009-991-535-668;;042-292-530-976-870;;001-652-924-912-262;;070-064-147-251-317;;032-582-093-090-651;;116-566-483-555-798;;001-679-206-236-992,10.1016/s0939-6411(01)00192-8;;11777758;;10.1016/j.foodhyd.2004.12.011;;10.1021/sc500621z;;pmc3131555;;10.3390/md9060967;;21747742;;10.1016/s0939-6411(01)00192-8;;11777758;;10.1021/ja01878a010;;10.1007/s10126-011-9415-2;;22072047;;21501629;;10.1016/j.ijbiomac.2011.03.019,"SWATSCHEK D ET AL: ""Marine sponge collagen: isolation, characterization and effects on the skin parameters surface-pH, moisture and sebum"", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 53, no. 1, 1 January 2002 (2002-01-01), pages 107 - 113, XP004331337, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(01)00192-8;;GOMEZ-GUILLEN M C ET AL: ""Extraction of gelatin from fish skins by high pressure treatment"", FOOD HYDROCOLLOIDS, ELSEVIER BV, NL, vol. 19, no. 5, 1 September 2005 (2005-09-01), pages 923 - 928, XP027795244, ISSN: 0268-005X, [retrieved on 20050901];;ANA RITA ET AL: ""Green solvents extraction of sponge-origin collagen/gelatin for biomedical applications"", 2014 ANNUAL MEETING & EXPOSITION, SOCIETY FOR BIOMATERIALS, 16 April 2014 (2014-04-16), XP055199286;;J C SILVA ET AL: ""Collagen/gelatin extraction from marine sponges -­- a green technology approach"", TERM STEM 2014, 23 October 2014 (2014-10-23), XP055197846, Retrieved from the Internet <URL:http://www.researchgate.net/profile/Joao_Silva61/publication/275893798_Collagengelatin_extraction_from_marine_sponges_-_a_green_technology_approach/links/5549803f0cf2ebfd8e3b0785.pdf?disableCoverPage=true> [retrieved on 20150623];;J C SILVA ET AL: ""MARINE SPONGES - AN ALTERNATIVE COLLAGEN/GELATIN SOURCE FOR BIOMEDICAL APPLICATIONS"", BIOMACROMOLECULES EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS TISSUE ENGINEERING PART C METHODS, 1 November 2014 (2014-11-01), pages 3452 - 3457, XP055197843, Retrieved from the Internet <URL:http://www.3bs.uminho.pt/system/files/biblio/18294-Abstract_ICVS_3BsMeeting_Joao Silva.pdf> [retrieved on 20150623];;ALEXANDRE A. BARROS ET AL: ""Water and Carbon Dioxide: Green Solvents for the Extraction of Collagen/Gelatin from Marine Sponges"", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, vol. 3, no. 2, 2 February 2015 (2015-02-02), US, pages 254 - 260, XP055197933, ISSN: 2168-0485, DOI: 10.1021/sc500621z;;SOUROUR ADDAD ET AL: ""Isolation, Characterization and Biological Evaluation of Jellyfish Collagen for Use in Biomedical Applications"", MARINE DRUGS, vol. 9, no. 12, 7 December 2011 (2011-12-07), pages 967 - 983, XP055197859, ISSN: 1660-3397, DOI: 10.3390/md9060967;;Z. ZHANG ET AL: ""PHYSICOCHEMICAL PROPERTIES OF COLLAGEN, GELATIN AND COLLAGEN HYDROLYSATE DERIVED FROM BOVINE LIMED SPLIT WASTES"", JOURNAL OF THE SOCIETY OF LEATHER TECHNOLOGISTS AND CHEMISTS, vol. 90, 1 January 2005 (2005-01-01), pages 23 - 28, XP055197642;;S WATSCHEK, D.; SCHATTON, W.; KELLERMANN, J.; KREUTER, J. R., EUR. J.PHARM. BIOPHARM., vol. 53, 2002, pages 107 - 113;;ZHANG, Z. K.; LI, G. Y.; SHI, B. J., SOC. LEATHER TECHNOL. CHEM., vol. 90, 2006, pages 23 - 28;;HIGHBERGER, J. H., J. AM. CHEM. SOC., vol. 61, 1939, pages 2302 - 2303;;POZZOLINI, M.; BRUZZONE, F.; BERILLI, V.; MUSSINO, F.; CERRANO, C.; BENATTI, U.; GIOVINE, M., MAR. BIOTECHNOL., vol. 14, 2012, pages 281 - 293;;ETHERINGTON, D. J., ANN. RHEUM. DIS., vol. 36, 1977, pages 14 - 17;;SWATSCHEK, D.; SCHATTON, W.; KELLERMANN, J.; KREUTER, J. R., EUR. J. PHARM. BIOPHARM., vol. 53, 2002, pages 107 - 113;;PALLELA, R.; BOJJA, S.; JANAPALA, V. R., INT. J. BIOL. MACROMOL., vol. 49, 2011, pages 85 - 92",PENDING
490,EP,B1,EP 1685382 B1,173-738-905-513-260,2008-10-08,2008,EP 04775192 A,2004-10-28,PT 2004000026 W;;PT 10303403 A,2003-10-28,MULTIAXIAL UNIVERSAL TESTING MACHINE,"The invention concerns a multiaxial universal testing machine, which allows evaluating the mechanical behavior and performance of materials with planar structures, such as fabrics, composites and laminates. The machine comprises 4 horizontal axes, each one with 2 arms, resulting in a final arrangement of 8 gripping jaws at 45°, displaceable along slide rails and moved by the action of 8 independent motors. The connection between a gripping jaw and its respective motor is assured by a linear actuator. The test specimen is fixed by the gripping jaws and can be subject to tensile, compression and fatigue testing, making possible the analysis of the materials behavior under simultaneous multi-directional loads.",UNIV DO MINHO,MONTEIRO JO O LUIS MARQUES PER;;DA ROCHA ANA MARIA MOREIRA FER;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARA JO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,,https://lens.org/173-738-905-513-260,Granted Patent,yes,2,0,10,10,0,G01N3/08;;G01N2203/0016;;G01N2203/0073;;G01N2203/0085;;G01N2203/025;;G01N2203/0254;;G01N2203/0278;;G01N2203/0282;;G01N3/08;;G01N2203/0282;;G01N2203/0016;;G01N2203/0278;;G01N2203/0073;;G01N2203/0254;;G01N2203/0085;;G01N2203/025,G01N3/08;;G01N3/00;;G01N3/02,,3,0,,,"BOEHLER J P ET AL: ""A NEW DIRECT BIAXIAL TESTING MACHINE FRO ANISOTROPIC MATERIALS"" 1 March 1994 (1994-03-01), EXPERIMENTAL MECHANICS, SOCIETY FOR EXPERIMENTAL STRESS ANALYSIS,, US, PAGE(S) 1-9 , XP000574645 ISSN: 0014-4851 the whole document;;PATENT ABSTRACTS OF JAPAN vol. 2000, no. 02, 29 February 2000 (2000-02-29) & JP 11 327286 A (MURATA MACH LTD), 26 November 1999 (1999-11-26);;URUMOV G T: ""A MACHINE FOR TESTING SHEET SPECIMENS FOR FATIGUE UNDER TWO- FREQUENCY LOADING CONDITIONS"" October 1997 (1997-10), INDUSTRIAL LABORATORY, CONSULTANTS BUREAU. NEW YORK, US, PAGE(S) 620-622 , XP000777371 ISSN: 0019-8447 page 1 - page 2; figure 1",ACTIVE
491,EP,B1,EP 3126382 B1,157-143-138-247-631,2019-06-12,2019,EP 15722255 A,2015-03-31,PT 10755114 A;;IB 2015052370 W,2014-03-31,METHOD TO OBTAIN COLLAGEN/GELATIN FROM MARINE SPONGES,,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECH & THERAPIES A4TEC ASSOCIAC,GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;COLARDELLE DA LUZ MANO JOÃO FILIPE;;QUINTEIROS LOPES HENRIQUES DA SILVA TIAGO JOSÉ;;DE ASCENSÃO AROSO IVO MANUEL;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;FERNANDES DA SILVA JOÃO CARLOS,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEER (2019-04-03),https://lens.org/157-143-138-247-631,Granted Patent,yes,1,0,3,3,0,A23J1/04;;C07K14/78;;A23V2002/00;;C07K14/43595,C07K14/435;;A23J1/04;;C07K14/78,,8,0,,,"SWATSCHEK D ET AL: ""Marine sponge collagen: isolation, characterization and effects on the skin parameters surface-pH, moisture and sebum"", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 53, no. 1, 1 January 2002 (2002-01-01), pages 107-113, XP004331337, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(01)00192-8;;GOMEZ-GUILLEN M C ET AL: ""Extraction of gelatin from fish skins by high pressure treatment"", FOOD HYDROCOLLOIDS, ELSEVIER BV, NL, vol. 19, no. 5, 1 September 2005 (2005-09-01), pages 923-928, XP027795244, ISSN: 0268-005X [retrieved on 2005-09-01];;ANA RITA ET AL: ""Green solvents extraction of sponge-origin collagen/gelatin for biomedical applications"", 2014 ANNUAL MEETING & EXPOSITION, SOCIETY FOR BIOMATERIALS, 16 April 2014 (2014-04-16), XP055199286,;;J C Silva ET AL: ""Collagen/gelatin extraction from marine sponges --- a green technology approach"", Term Stem 2014, 23 October 2014 (2014-10-23), XP55197846, Retrieved from the Internet: URL:http://www.researchgate.net/profile/Jo ao_Silva61/publication/275893798_Collageng elatin_extraction_from_marine_sponges_-_a_ green_technology_approach/links/5549803f0c f2ebfd8e3b0785.pdf?disableCoverPage=true [retrieved on 2015-06-23];;J C Silva ET AL: ""MARINE SPONGES - AN ALTERNATIVE COLLAGEN/GELATIN SOURCE FOR BIOMEDICAL APPLICATIONS"", Biomacromolecules European Journal of Pharmaceutics and Biopharmaceutics Tissue Engineering Part C Methods, 1 November 2014 (2014-11-01), pages 3452-3457, XP55197843, Retrieved from the Internet: URL:http://www.3bs.uminho.pt/system/files/ biblio/18294-Abstract_ICVS_3BsMeeting_Joao Silva.pdf [retrieved on 2015-06-23];;ALEXANDRE A. BARROS ET AL: ""Water and Carbon Dioxide: Green Solvents for the Extraction of Collagen/Gelatin from Marine Sponges"", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, vol. 3, no. 2, 2 February 2015 (2015-02-02), pages 254-260, XP055197933, US ISSN: 2168-0485, DOI: 10.1021/sc500621z;;SOUROUR ADDAD ET AL: ""Isolation, Characterization and Biological Evaluation of Jellyfish Collagen for Use in Biomedical Applications"", MARINE DRUGS, vol. 9, no. 12, 7 December 2011 (2011-12-07), pages 967-983, XP55197859, ISSN: 1660-3397, DOI: 10.3390/md9060967;;Z. ZHANG ET AL: ""PHYSICOCHEMICAL PROPERTIES OF COLLAGEN, GELATIN AND COLLAGEN HYDROLYSATE DERIVED FROM BOVINE LIMED SPLIT WASTES"", JOURNAL OF THE SOCIETY OF LEATHER TECHNOLOGISTS AND CHEMISTS, vol. 90, 1 January 2005 (2005-01-01), pages 23-28, XP055197642,",ACTIVE
492,EP,A2,EP 1685382 A2,073-525-542-962-328,2006-08-02,2006,EP 04775192 A,2004-10-28,PT 2004000026 W;;PT 10303403 A,2003-10-28,MULTIAXIAL UNIVERSAL TESTING MACHINE,"The invention concerns a multiaxial universal testing machine, which allows evaluating the mechanical behavior and performance of materials with planar structures, such as fabrics, composites and laminates. The machine comprises 4 horizontal axes, each one with 2 arms, resulting in a final arrangement of 8 gripping jaws at 45°, displaceable along slide rails and moved by the action of 8 independent motors. The connection between a gripping jaw and its respective motor is assured by a linear actuator. The test specimen is fixed by the gripping jaws and can be subject to tensile, compression and fatigue testing, making possible the analysis of the materials behavior under simultaneous multi-directional loads.",UNIV DO MINHO,MONTEIRO JO O LUIS MARQUES PER;;DA ROCHA ANA MARIA MOREIRA FER;;LIMA MARIO FILIPE ARAUJO GONCA;;MARTINS JULIO MANUEL DE SOUSA;;ARA JO MARIO DUARTE DE;;COUTO CARLOS ALBERTO CARIDADE;;MENDES FERNANDO JORGE DE CASTR,,https://lens.org/073-525-542-962-328,Patent Application,yes,0,0,10,10,0,G01N3/08;;G01N2203/0016;;G01N2203/0073;;G01N2203/0085;;G01N2203/025;;G01N2203/0254;;G01N2203/0278;;G01N2203/0282;;G01N3/08;;G01N2203/0282;;G01N2203/0016;;G01N2203/0278;;G01N2203/0073;;G01N2203/0254;;G01N2203/0085;;G01N2203/025,G01N3/08;;G01N3/00;;G01N3/02,,0,0,,,,ACTIVE
493,EP,A2,EP 1334727 A2,054-611-976-348-124,2003-08-13,2003,EP 01983427 A,2001-11-01,CU 0100007 W;;CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"The present invention is related to a method for obtaining antigenic structures with high cross reactivity, able to enhance the immune response to peptidic antigens administered systemically and/or mucosally, as well as with the chemical structures obtained from this method, and with formulations obtained and their uses. The method described in the present invention enables the obtaining of new antigenic structures, starting from the selection and synthesis of dendrimers, which are coupled to carrier molecules. The resulting structures can be used adjuvated conveniently or in a formulation of various antigens. A synergistic effect can be found in the cross reactivity and immunogenicity. Furthermore, the formulations may contain stabilizers and preserves. The antigenic structures of the present invention can be used in the pharmaceutical industry as vaccine formulations to prevent or to treat diseases in humans and animals, as well as in the development of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY P REZ HILDA ELISA;;MUZIO GONZ LEZ VERENA LUCILA;;GUILL N NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENT N ARIAS EDUARDO,,https://lens.org/054-611-976-348-124,Patent Application,yes,1,1,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,6,4,170-782-665-410-754;;011-325-090-999-852;;022-217-950-107-369;;030-969-890-444-663,10.1002/(sici)1099-1387(200005)6:5<217::aid-psc242>3.0.co;2-u;;10.1002/(sici)1099-1387(200005)6:5<217::aid-psc242>3.3.co;2-l;;10823490;;10.1016/0264-410x(95)00072-9;;8578819;;10596755;;10.1016/s1050-3862(99)00019-4;;1925584;;10.1126/science.1925584;;10.1126/science.254.5029.285,"CRUZ L.J.: ""Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice."", J PEPT SCI., vol. 6, no. 5, May 2000 (2000-05-01), pages 217-24;;RAJADHYAKSHA M. ET AL: ""Immunological evaluation of three generations of anti-idiotype vaccine: study of B and T cell responses following priming with anti-idiotype, anti-idiotype peptide and its MAP structure."", VACCINE, vol. 13, no. 15, 1 January 1995 (1995-01-01), BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, pages 1421 - 1426, XP004057451;;CANO C.A.: ""The multi-epitope polypeptide approach in HIV-1 vaccine development"", GENETC ANALYSIS: BIOMOLECULAR ENGINEERING, vol. 15, no. 3-5, November 1999 (1999-11-01), pages 149-153, XP009079077, DOI: doi:10.1016/S1050-3862(99)00019-4;;WANG C.Y. ET AL: ""Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen"", SCIENCE, vol. 254, no. 285, 1991, pages 285-254;;""Trilateral Project B3b: Mutual understanding in search and examination - Report on Comparative study on biotechnology patent practices; Theme: Comparative study on ?reach-through claims?"", SAN FRANCISCO, CALIFORNIA; NOVEMBER 5-9, 2001, 5 November 2001 (2001-11-05), Retrieved from the Internet <URL:http://www.trilateral.net/projects/biotechnology/reach_through_claims/B3b_reachthrough_text.pdf>;;See also references of WO 0236160A3",DISCONTINUED
494,EP,A1,EP 3126382 A1,021-663-044-327-507,2017-02-08,2017,EP 15722255 A,2015-03-31,PT 10755114 A;;IB 2015052370 W,2014-03-31,METHOD TO OBTAIN COLLAGEN/GELATIN FROM MARINE SPONGES,,ASS FOR THE ADVANCEMENT OF TISSUE ENG AND CELL BASED TECH & THERAPIES (A4TEC),GONÇALVES DOS REIS RUI LUIS;;CRUZ DUARTE ANA RITA;;COLARDELLE DA LUZ MANO JOÃO FILIPE;;QUINTEIROS LOPES HENRIQUES DA SILVA TIAGO JOSÉ;;DE ASCENSÃO AROSO IVO MANUEL;;ANTUNES BARROS ALEXANDRE ANTÓNIO;;FERNANDES DA SILVA JOÃO CARLOS,ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEER (2019-04-03),https://lens.org/021-663-044-327-507,Patent Application,yes,0,1,3,3,0,A23J1/04;;C07K14/78;;A23V2002/00;;C07K14/43595,C07K14/78;;A23J1/04,,0,0,,,,ACTIVE
495,DK,T3,DK 0816506 T3,111-972-502-386-136,2001-05-21,2001,DK 97901516 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,System til ekspression af heterologe antigener som fusionsproteiner,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO AVENID;;MARTIN DUNN ALEJANDRO MIGUEL A,,https://lens.org/111-972-502-386-136,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
496,BR,B1,BR 9704641 B1,180-408-257-424-818,2010-03-09,2010,BR 9704641 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,"proteìna de fusão, vetor de expressão de proteìnas de fusão em e. coli, cepa recombinante e composição de vacina.",,,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGUEZ RICARDO DE LA CARIDAD;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN;;VAZQUEZ DIOGENES QUITANA,,https://lens.org/180-408-257-424-818,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,C12N15/62;;G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
497,CZ,A3,CZ 291097 A3,126-713-633-234-042,1998-11-11,1998,CZ 291097 A,1997-01-17,CU 1996010 A,1996-01-17,EXPRESSION SYSTEM OF HETEROLOGOUS PROTEINS AS FUSED PROTEINS,,CIGB,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGUEZ RICARDO DE LA;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/126-713-633-234-042,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,PENDING
498,AU,B2,AU 722317 B2,121-149-587-457-467,2000-07-27,2000,AU 1997/015396 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,System for the expression of heterologous antigens as fusion proteins,,CIGB,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGEZ RICARDO DE LA CARIDAD;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN,,https://lens.org/121-149-587-457-467,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
499,CA,A1,CA 2214840 A1,175-579-576-980-403,1997-07-24,1997,CA 2214840 A,1997-01-17,CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"The present invention relates to biotechnology and genetic engineering, particul arly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterotogous prot eins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in a oppropriate fo rm for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence de rived from the first 47 aminoacids of the antigen P64k of Neisseria meningitidis B:4 :P1.15. In particular, use is made of a recombinant p lasmide containing said sequence, under the control of the triptophane promotor of E. coli and of the terminator of the transcription of th e phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The proce ss of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and i n any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.",CIGB,NAZABAL GALVEZ CONSUELO;;QUINTANA VAZQUEZ DIOGENES;;CARPIO MUNOZ EMILIO LUIS;;MARTIN DUNN ALEJANDRO MIGUEL;;LEAL ANGULO MARIA DE JESUS;;GOMEZ RODRIGUEZ CARMEN ELENA;;DUARTE CANO CARLOS ANTONIO;;ALVAREZ ACOSTA ANABEL;;SILVA RODRIGUEZ RICARDO DE LA;;GUILLEN NIETO GERARDO ENRIQUE,,https://lens.org/175-579-576-980-403,Patent Application,no,0,0,33,33,21,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,DISCONTINUED
500,EP,A4,EP 4078560 A4,157-079-394-977-146,2024-01-10,2024,EP 20903355 A,2020-12-16,US 201962949919 P;;BR 2020050551 W,2019-12-18,FLIGHT SIMULATOR WITH A VISUAL SYSTEM INTEGRATED IN A ROBOTIC MANIPULATOR,,EMBRAER SA;;ITA INST TECNOLOGICO DE AERONAUTICA,ALVES JR MARCO ANTONIO DE OLIVEIRA;;SILVA EDMAR THOMAZ DA;;PENNA SERGIO DUARTE;;TRABASSO LUIS GONZAGA;;VILLANI EMILIA;;ROCHA ALFREDO;;EGUTI CARLOS CESAR A;;OLIVEIRA WESLEY RODRIGUES DE;;CUNHA LARA JUNIOR WILSON DA;;NATAL GUILHERME SARTORI;;RODAMILANS GUILHERME BOULHOSA,,https://lens.org/157-079-394-977-146,Search Report,no,0,0,7,7,0,G09B9/12;;G09B9/326;;B25J11/00;;G09B9/12;;B25J11/00;;B25J13/065;;G09B9/326,G09B9/32;;B25J11/00;;G02B27/01;;G03B21/60;;G09B9/12,,1,1,072-726-723-587-381,10.1007/978-3-319-46792-4_16,"ANDRÉ VINÍCIUS SANTOS SILVA ET AL: ""Robot Based Flight Simulator Development Project"", 1 January 2017, THE LEAN PRODUCT DESIGN AND DEVELOPMENT JOURNEY, SPRINGER INTERNATIONAL PUBLISHING, PAGE(S) 257 - 279, ISBN: 978-3-319-46791-7, XP009537605",PENDING
501,WO,A1,WO 2021/119788 A1,089-595-691-562-576,2021-06-24,2021,BR 2020050551 W,2020-12-16,US 201962949919 P,2019-12-18,FLIGHT SIMULATOR WITH A VISUAL SYSTEM INTEGRATED IN A ROBOTIC MANIPULATOR,"One example non-limiting example provides a full representative part 25 commercial aircraft flight deck with a visual system integrated with a robotic manipulator to provide an immersive simulation environment for training and research purposes. Such technology provides an architecture that provides visual blending-warp adjustment along with visual system integration, including for example Spherical screen design, Structural design and Projectors allocation.",EMBRAER SA;;ITA INST TECNOLOGICO DE AERONAUTICA,ALVES JR MARCO ANTONIO DE OLIVEIRA;;SILVA EDMAR THOMAZ DA;;PENNA SERGIO DUARTE;;TRABASSO LUIS GONZAGA;;VILLANI EMILIA;;ROCHA ALFREDO;;EGUTI CARLOS CESAR A;;OLIVEIRA WESLEY RODRIGUES DE;;CUNHA LARA JUNIOR WILSON DA;;NATAL GUILHERME SARTORI;;RODAMILANS GUILHERME BOULHOSA,,https://lens.org/089-595-691-562-576,Patent Application,yes,3,0,7,7,0,G09B9/12;;G09B9/326;;B25J11/00;;G09B9/12;;B25J11/00;;B25J13/065;;G09B9/326,G09B9/12;;G02B27/01;;G03B21/60;;G09B9/32,,4,2,072-726-723-587-381;;026-649-326-950-162,10.1007/978-3-319-46792-4_16;;10.5626/jcse.2013.7.2.122,"PESSÃ´A MARCUS VINICIUS PEREIRA, TRABASSO LUÃ¬S: ""Robot Based Flight Simulator Development Project"", 1 January 2017 (2017-01-01), pages 257 - 279, XP009537605, ISBN: 9783319467917, DOI: 10.1007/978-3-319-46792-4_16;;""German researchers claim first: Robotic Flight Simulator"", 3 April 2013 (2013-04-03), XP055836352, Retrieved from the Internet <URL:https://www.aopa.org/news-and-media/all-news/2013/april/03/german-researchers-claim-first-robotic-flight-simulator> [retrieved on 20210310];;NIEUWENHUIZEN, FRANK ET AL.: ""The MPI CyberMotion Simulator: A Novel Research Platform to Investigate Human Control Behavior"", JOURNAL OF COMPUTING SCIENCE AND ENGINEERING, vol. 7, 2013, XP055836356, DOI: 10.5626/JCSE. 2013.7.2 .122;;See also references of EP 4078560A4",PENDING
502,EP,A1,EP 4078560 A1,157-187-335-834-688,2022-10-26,2022,EP 20903355 A,2020-12-16,US 201962949919 P;;BR 2020050551 W,2019-12-18,FLIGHT SIMULATOR WITH A VISUAL SYSTEM INTEGRATED IN A ROBOTIC MANIPULATOR,,EMBRAER SA;;ITA INST TECNOLOGICO DE AERONAUTICA,ALVES JR MARCO ANTONIO DE OLIVEIRA;;SILVA EDMAR THOMAZ DA;;PENNA SERGIO DUARTE;;TRABASSO LUIS GONZAGA;;VILLANI EMILIA;;ROCHA ALFREDO;;EGUTI CARLOS CESAR A;;OLIVEIRA WESLEY RODRIGUES DE;;CUNHA LARA JUNIOR WILSON DA;;NATAL GUILHERME SARTORI;;RODAMILANS GUILHERME BOULHOSA,,https://lens.org/157-187-335-834-688,Patent Application,yes,0,0,7,7,0,G09B9/12;;G09B9/326;;B25J11/00;;G09B9/12;;B25J11/00;;B25J13/065;;G09B9/326,G09B9/12;;G02B27/01;;G03B21/60;;G09B9/32,,0,0,,,,PENDING
503,PT,E,PT 816506 E,052-627-629-662-956,2001-06-29,2001,PT 97901516 T,1997-01-17,CU 1996010 A,1996-01-17,SISTEMA PARA A EXPRESSAO DE ANTIGENIOS HETEROLOGOS COMO PROTEINAS DE FUSAO,,CT INGENIERIA GENETICA BIOTECH,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGUEZ RICARDO DE LA CARIDA;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN,,https://lens.org/052-627-629-662-956,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
504,CA,A1,CA 3165231 A1,130-163-246-275-179,2021-06-24,2021,CA 3165231 A,2020-12-16,US 201962949919 P;;BR 2020050551 W,2019-12-18,FLIGHT SIMULATOR WITH A VISUAL SYSTEM INTEGRATED IN A ROBOTIC MANIPULATOR,"One example non-limiting example provides a full representative part 25 commercial aircraft flight deck with a visual system integrated with a robotic manipulator to provide an immersive simulation environment for training and research purposes. Such technology provides an architecture that provides visual blending-warp adjustment along with visual system integration, including for example Spherical screen design, Structural design and Projectors allocation.",EMBRAER SA;;ITA INST TECNOLOGICO DE AERONAUTICA,ALVES JR MARCO ANTONIO DE OLIVEIRA;;SILVA EDMAR THOMAZ DA;;PENNA SERGIO DUARTE;;TRABASSO LUIS GONZAGA;;VILLANI EMILIA;;ROCHA ALFREDO;;EGUTI CARLOS CESAR A;;OLIVEIRA WESLEY RODRIGUES DE;;CUNHA LARA JUNIOR WILSON DA;;NATAL GUILHERME SARTORI;;RODAMILANS GUILHERME BOULHOSA,,https://lens.org/130-163-246-275-179,Patent Application,no,0,0,7,7,0,G09B9/12;;G09B9/326;;B25J11/00;;G09B9/12;;B25J11/00;;B25J13/065;;G09B9/326,G09B9/12;;G02B27/01;;G03B21/60;;G09B9/32,,0,0,,,,PENDING
505,BR,A,BR 9704641 A,195-541-948-950-822,1998-06-09,1998,BR 9704641 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,Sistema de expressão de antígenos heterólogos como proteínas de fusão,,INGENIERIA GENETIC Y BIOTECNOL,MARTIN DUNN ALEJANDRO MIGUEL;;LEAL ANGULO MARIA DE JESUS;;NAZABAL GALVEZ CONSUELO;;QUITANA VAZQUEZ DIOGENES;;SILVA RODRIGUEZ RICARDO DE LA;;DUARTE CANO CARLOS ANTONIO;;GOMEZ RODRIGUEZ CARMEN ELENA;;CARPIO MUNOZ EMILIO LUIS;;ALVAREZ ACOSTA ANABEL;;GUILLEN NIETO GERARDO ENRIQUE,,https://lens.org/195-541-948-950-822,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
506,EA,B1,EA 000307 B1,079-432-573-661-769,1999-04-29,1999,EA 199700244 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"1. Fusion protein, containing peptide stabilizer representing a modified N-terminal part of 47 aminoacids of the antigen P64K of Neisseria meningitidis B:4:P1.15 having structure 2. Fusion protein according to Claim 1, characterized in that heterologous protein is a protein of external membrane of Neisseria meningitidis. 3. Fusion protein according to Claim 2, characterized in that the protein of external membrane of Neisseria meningitidis is a protein PorA or Opc(5c) of Neisseria meningitidis. 4. Fusion protein according to Claim 1, characterized in that heterologous protein is a multiepitopic polypeptide, including various copies of the central part of the variable region 3 (v3) gp 120 VIH-1. 5. Fusion protein according to Claim 1, characterized in that the multiepitopic polypeptide is a polypeptide TAB 4 or TAB 9. 6. Vector of expression of fusion protein according to Claim 1 in E. Coli, continuing the sequence of sensing, comprising the following constructive elements: - sequence of nucleotides, coding peptide-stabilizer representing a modified N-terminal part of 47 aminoacids of the antigen P64K of Neisseria meningitidis B:4:P1.15 having structure: and being under the control of the triptophane promotor of E. coli - sites of restrictions Xbal, EcoRVand BamHl localized after the sequence of nucleotides, coding peptide-stabilizer; - DNA fragment, coding heterologous protein or polypeptide built-in by said sites; - the terminator of the transcription of the phage T4, arranged behind the DNA fragment, coding for heterologous protein or polypeptide; - gen of resistance against ampicillin as a selective marker gen. 7. Vector of expression according to Claim 6, characterized in that DNA fragment codes for protein of external membrane of Neisseria meningitidis. 8. Vector of expression according to Claim 6, characterized in that DNA fragment codes for heterologous polypeptide, which is multiepitopic polypeptide, including various copies of the central part of the variable region 3 (v3) of protein gp 120 VIH-1 9. Vector of expression according to Claim 7, characterized in that represents vector pM-80. 10. Vector of expression according to Claim 7, characterized in that represents vector pM-82. 11. Vector of expression according to Claim 7, characterized in that represents vector pTAB9. 12. Recombinant plasmide of Escherichia coli transformed by vector of expression according to any of 6-11 Claims and used to prepare fusion protein according to any of 1-5 Claims. 13. Vaccine preparation, characterized in that constituting fusion protein according to 1-5 Claims and appropriate adjuvant.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUEOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/079-432-573-661-769,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;G01N33/569;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
507,WO,A1,WO 1997/026359 A1,161-671-325-238-494,1997-07-24,1997,CU 9700001 W,1997-01-17,CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"The present invention relates to biotechnology and genetic engineering, particularly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an oppropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 aminoacids of the antigen P64k of Neisseria meningitidis B:4 :P1.15. In particular, use is made of a recombinant plasmide containing said sequence, under the control of the triptophane promotor of E. coli and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.",CIGB;;DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/161-671-325-238-494,Patent Application,yes,2,19,33,33,21,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;G01N33/569;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,2,1,048-786-274-866-581,7567952;;10.1002/prot.340210404,"GERARDO GUILLÉN ET AL.: ""Cloning, expression and characterization of the P64k outer membrane protein from N. meningitidis"", BIOTECNOLOGÍA APLICADA, vol. 12, no. 2, 1995, pages 72, XP000671542;;BRINGAS R ET AL: ""A Lipoamide Dehydrogenase From Neisseria meningitidis has a Lipoyl Domain."", PROTEINS STRUCTURE FUNCTION AND GENETICS 21 (4). 1995. 303-306. ISSN: 0887-3585, XP000671539",PATENTED
508,AU,A,AU 1997/015396 A,004-643-422-668-700,1997-08-11,1997,AU 1997/015396 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,System for the expression of heterologous antigens as fusion proteins,,CT INGENIERIA GENETICA BIOTECNOLOGIA,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/004-643-422-668-700,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
509,AT,T1,AT E198491 T1,105-780-084-003-10X,2001-01-15,2001,AT 97901516 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/105-780-084-003-10X,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,DISCONTINUED
510,EP,A1,EP 0816506 A1,141-293-689-327-374,1998-01-07,1998,EP 97901516 A,1997-01-17,CU 9700001 W;;CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"The present invention relates to biotechnology and genetic engineering, particularly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in  Escherichia coli  of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 aminoacids of the antigen P64k of  Neisseria meningitidis  B:4 :P1.15. In particular, use is made of a recombinant plasmide containing said sequence, under the control of the triptophane promotor of  E. coli  and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in  E. coli .",CIGB,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/141-293-689-327-374,Patent Application,yes,0,2,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
511,DE,D1,DE 69703813 D1,161-204-541-501-987,2001-02-08,2001,DE 69703813 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIETAGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JES S;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/161-204-541-501-987,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
512,HU,A2,HU P9800730 A2,033-218-478-771-066,1998-07-28,1998,HU P9800730 A,1997-01-17,CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"A találmány tárgya heterőlóg prőteinek mikrőbiális gazdasejtekbentörténő expresszáltatása, rekőmbináns DNS technőlógia alkalmazásával.A találmány szerint a heterőlóg pőlipeptideket bakteriálispőlipeptidekkel fűziőnálva expreszálják.A találmány tárgyát közelebbről a Neisseria meningitidis B:4:P1.15P64K-antigénjének első 47 aminősavából származtatőtt stabilizátőrpeptidet tartalmazó fúziós prőteinek képezik, tővábbá eljárásőkheterőlóg prőteinek fúziós fehérjeként történő előállítására, atalálmány szerinti fúziós prőteinek alkalmazásával.A találmány szerinti megőldás alkalmas heterőlóg prőteinek mikrőbiálisgazdasejtekben történő expresszáltatására.ŕ",CIGB,ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;DUARTE CANO CARLOS ANTONIO;;GOMEZ RODRIGUEZ CARMEN ELENA;;GUILLEN NIETO GERARDO ENRIQUE;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL;;NAZABAL GALVEZ CONSUELO;;QUINTANA VAZQUEZ DIOGENES;;SILVA RODRIGEZ RICARDO DE LA C,,https://lens.org/033-218-478-771-066,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,PENDING
513,GR,T3,GR 3035690 T3,105-987-702-883-529,2001-07-31,2001,GR 20010400539 T,2001-04-02,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/105-987-702-883-529,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
514,EP,B1,EP 0816506 B1,182-455-858-668-353,2001-01-03,2001,EP 97901516 A,1997-01-17,CU 9700001 W;;CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/182-455-858-668-353,Granted Patent,yes,2,1,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,2,0,,,"BIOTECNOLOG A APLICADA, vol. 12, no. 2, 1995, page 72 XP000671542 GERARDO GUILL N ET AL.: ""Cloning, expression and characterization of the P64k outer membrane protein from N. meningitidis"";;PROTEINS STRUCTURE FUNCTION AND GENETICS 21 (4). 1995. 303-306. ISSN: 0887-3585, XP000671539 BRINGAS R ET AL: ""A Lipoamide Dehydrogenase From Neisseria meningitidis has a Lipoyl Domain.""",EXPIRED
515,DE,T2,DE 69703813 T2,163-736-671-349-346,2001-08-09,2001,DE 69703813 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIETAGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JES S;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/163-736-671-349-346,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
516,WO,A1,WO 2005/037311 A1,091-645-384-180-070,2005-04-28,2005,CU 2004000011 W,2004-10-20,CU 20030240 A,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,"The invention relates to therapeutic vaccines against pathogens which cause chronic diseases. More specifically, the invention relates to the use of the hepatitis B virus surface antigen (HBsAg) which is produced by recombinant means from Pichia pastoris, by way of a main component, in order to obtain pharmaceutical compositions for therapeutic purposes. The inventive compositions can comprise a combination of the hepatitis B antigen and other coadministered antigens. The aforementioned formulations can generate a strong lymphoproliferative response and cytotoxic T lymphocytes, as well as a significant specific antibody response. In this way, said formulations are very effective for the treatment of the above-mentioned diseases in humans.",CT INGENIERIA GENETICA BIOTECH;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOVAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOVAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/091-645-384-180-070,Patent Application,yes,6,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,10,10,014-680-069-455-653;;015-857-934-045-841;;057-206-031-740-178;;041-510-512-838-745;;055-008-872-424-17X;;028-251-769-423-217;;049-909-210-178-361;;088-072-146-165-824;;014-680-069-455-653;;051-433-308-735-163,12794712;;10.1002/jmv.10425;;10.1016/s0168-1656(99)00201-1;;10682276;;10.1016/s0264-410x(02)00393-6;;12477434;;7678639;;10.1002/jmv.1890390113;;10.1016/s0140-6736(94)91384-6;;7914291;;7791465;;10.1016/s0140-6736(95)91126-x;;9658616;;10.1016/s0168-8278(01)00028-9;;11451177;;12794712;;10.1002/jmv.10425;;11237755;;10.1006/bbrc.2001.4449,"VANLANDSCHOOT PETER ET AL: ""Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity."", JOURNAL OF MEDICAL VIROLOGY, vol. 70, no. 4, August 2003 (2003-08-01), pages 513 - 519, XP002316328, ISSN: 0146-6615;;HARDY E ET AL: ""Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris"", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 77, no. 2-3, February 2000 (2000-02-01), pages 157 - 167, XP004185816, ISSN: 0168-1656;;MICHEL M-L: ""Towards immunotherapy for chronic hepatitis B virus infections"", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, 19 December 2002 (2002-12-19), pages A83 - A88, XP004397477, ISSN: 0264-410X;;MANCINI M ET AL.: ""Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg transgenic mice: a possible way of circumventing ''nonresponse'' to HBsAg"", J MED VIROL., vol. 39, 1993, pages 67 - 74;;POL S ET AL., LANCET, 1994, pages 342;;WEN Y-M ET AL., LANCET, vol. 345, 1995, pages 1575 - 1576;;POL S ET AL., ACTA GASTROENTEROLOGICA BELGICA, vol. 61, 1998, pages 228 - 33;;POL S ET AL., J HEPATOL, vol. 34, 2001, pages 917 - 21;;VALANDSCHOOT P ET AL., J. MED VIROL, vol. 70, 2003, pages 513 - 519;;LORENZO LJ ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 281, no. 4, 2001, pages 962 - 965",PENDING
517,KR,A,KR 20060117920 A,154-730-722-939-810,2006-11-17,2006,KR 20067008110 A,2006-04-27,CU 20030240 A,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,"The invention relates to therapeutic vaccines against pathogens which cause chronic diseases. More specifically, the invention relates to the use of the hepatitis B virus surface antigen (HBsAg) which is produced by recombinant means from Pichia pastoris, by way of a main component, in order to obtain pharmaceutical compositions for therapeutic purposes. The inventive compositions can comprise a combination of the hepatitis B antigen and other coadministered antigens. The aforementioned formulations can generate a strong lymphoproliferative response and cytotoxic T lymphocytes, as well as a significant specific antibody response. In this way, said formulations are very effective for the treatment of the above-mentioned diseases in humans.",CT INGENIERIA GENETICA BIOTECH,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/154-730-722-939-810,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/12;;A61K39/21;;A61K39/29;;A61K39/295;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
518,CU,A1,CU 23405 A1,175-359-440-521-22X,2009-08-04,2009,CU 20030240 A,2003-10-20,CU 20030240 A,2003-10-20,COMPOSICIONES FARMACÉUTICAS PARA USO TERAPÉUTICO,"Vacunas terapéuticas contra patógenos que causan enfermedades crónicas. Uso del antígeno de la superficie del virus de la hepatitis B (HbsAg), producido por vía recombinante a partir de Pichia pastoris, como componente principal, para la obtención de composiciones farmacéuticas con fines terapéuticos. Las mismas pueden comprender la combinación del antígeno de hepatitis b con otros antigenos coadministrados. Estas formulaciones son capaces de generar una potente respuesta linfoproliferativa y de linfocitos T citotóxicos, además de una considerable respuesta de anticuerpos específicos, lo que las hace muy efectivas para el tratamiento de estas enfermedades en humanos.",CT INGENIERIA GENETICA BIOTECH,VANLANDSHOOT PETER;;DUARTE CANO CARLOS;;ALVAREZ OBREGON JULIO CESAR;;UBIETA GOMEZ RAIMUNDO;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;ACOSTA RIVERO NELSON;;DUENAS CARRERA SANTIAGO;;IGLESIAS PEREZ ENRIQUE;;AGUILAR RUBIDO JULIO CESAR;;GUILLEN NIETO GERARDO ENRIQUE;;MUZIO GONZALEZ VERENA LUCILA;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/175-359-440-521-22X,Limited Patent,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,EXPIRED
519,CA,A1,CA 2542680 A1,155-405-937-728-815,2005-04-28,2005,CA 2542680 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,,CT INGENIERIA GENETICA BIOTECH,ACOSTA RIVERO NELSON;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;GARCIA GONZALEZ DAYMIR;;AGUILAR RUBIDO JULIO CESAR;;UBIETA GOMEZ RAIMUNDO;;HERRERA MARTINEZ LUIS SATURNIN;;LOVAINA MATO YADIRA;;IGLESIAS PEREZ ENRIQUE;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;DUENAS CARRERA SANTIAGO;;ALVAREZ OBREGON JULIO CESAR,,https://lens.org/155-405-937-728-815,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/39;;A61K39/21;;A61K39/29;;A61K39/295;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
520,AU,B2,AU 2004/281098 B2,020-963-463-706-112,2009-06-25,2009,AU 2004/281098 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,Pharmaceutical compositions for therapeutic use,,CT INGENIERIA GENETICA BIOTECNOLOGIA,PEREZ ENRIQUE IGLESIAS;;MARTINEZ LUIS SATURNINO HERRERA;;CARRERA SANTIAGO DUENAS;;RIVERO NELSON ACOSTA;;CANO CARLOS DUARTE;;MATO YADIRA LOBAINA;;VANLANDSHOOT PETER;;NIETO GERARDO ENRIQUE GUILLEN;;GOMEZ RAIMUNDO UBIETA;;RUBIDO JULIO CESAR AGUILAR;;GONZALEZ VERENA LUCILA MUZIO;;GONZALEZ DAYMIR GARCIA;;OBREGON JULIO CESAR ALVAREZ,,https://lens.org/020-963-463-706-112,Granted Patent,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,INACTIVE
521,BR,A2,BR 102016030110 A2,008-683-823-785-571,2018-07-17,2018,BR 102016030110 A,2016-12-21,BR 102016030110 A,2016-12-21,utilização de um derivado quinolínico como agente terapêutico de doença inflamatória de pele,"utilização de um derivado quinolínico como agente terapêutico de doença inflamatória de pele. a presente invenção refere-se à utilização de um derivado quinolínico como agente terapêutico de doença inflamatória de pele. ainda, esta invenção refere-se ao uso do derivado quinolínico isoladamente ou em combinação com um filme para uso tópico. a eficácia terapêutica in vivo e ex vivo deste tratamento emdoença inflamatória de pele é demonstrada na presente invenção.",UNIV PELOTAS FEDERAL,ANDRÉ RICARDO FAJARDO;;CRISTIANE LUCHESE;;CRISTIANI FOLHARINI BORTOLATTO;;DIEGO DA SILVA ALVES;;EDER JOÃO LENARDÃO;;ETHEL ANTUNES WILHELM;;GABRIELA TEIXEIRA DA SILVA;;GELSON PERIN;;GUILHERME TEIXEIRA VOSS;;LUCIELLI SAVEGNAGO;;LUIS FERNANDO BARBOSA DUARTE;;RAQUEL GUIMARÃES JACOB;;RENATA LEIVAS DE OLIVEIRA;;RICARDO FREDERICO SCHUMACHER,,https://lens.org/008-683-823-785-571,Patent Application,no,0,0,1,1,0,,C07D211/04;;A61K31/438;;A61P17/00;;A61P29/00,,0,0,,,,DISCONTINUED
522,RU,C2,RU 2673217 C2,097-995-108-586-806,2018-11-22,2018,RU 2014139665 A,2014-09-30,US 201361887316 P,2013-10-04,"OVERHEAD STORAGE BIN ASSEMBLIES FOR TRANSPORT VEHICLES, ESPECIALLY AIRCRAFT CABINS","FIELD: aeronautics; aviation; cosmonautics.SUBSTANCE: present invention relates essentially to the interior of vehicles, in particular the interior cabins of aircraft, namely to overhead bin assemblies, which can be used advantageously in vehicle interiors. Overhead bin assembly for transport vehicles is provided with a generally U-shaped bin shell. Pair of separated transverse bin supports define therebetween a bin space along with a bin door for closing the opening. Cantilever hinge may be provided so as to connect the door to the transverse bin support in a cantilever manner. Arcuate recessed wall is formed as an integral extension of the upper wall and is positioned adjacent and closer to the interior of the cabin relative to the upper wall of the bin frame so that the door in its open position enters the recessed wall. Space of the channel, defined between the bin door and the recessed wall, ensures the direction of light from a lighting device to the interior of the bin with the door open.EFFECT: increases the space above the passenger's head.12 cl, 4 dwg",EMBRAER SA,PAULINU AMAURI;;GOMIDI SERZHIU LUIS ABDALLA;;DI ARRUDA GUSTAVU SELOFITI;;FERREJRA NILMAR SEZAR;;RIBEJRU LUSYANU DOS SANTUSH;;DI KAMPUSH DEMETRIU ANDRADI;;MEJRELISH FILYU SERZHIU AUGUSHTU;;DI OLIVEJRA FREDERIKU LARA;;DI ALBUKERKE DUGLAS GONSALVES;;ALBINU ELYU;;STEJN ANDRE DUARTE;;PRISTMAN POL;;MAKINNES DANIEL,,https://lens.org/097-995-108-586-806,Granted Patent,no,5,0,11,11,0,B64D11/003;;B64D11/003;;B64D11/00;;B64D2011/0053,B64D11/00,,0,0,,,,ACTIVE
523,AU,A1,AU 2004/281098 A1,184-464-888-417-085,2005-04-28,2005,AU 2004/281098 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,Pharmaceutical compositions for therapeutic use,,CT INGENIERIA GENETICA BIOTECH,PEREZ ENRIQUE IGLESIAS;;MARTINEZ LUIS SATURNINO HERRER;;CARRERA SANTIAGO DUENAS;;RIVERO NELSON ACOSTA;;CANO CARLOS DUARTE;;MATO YADIRA LOBAINA;;VANLANDSHOOT PETER;;NIETO GERARDO ENRIQUE GUILLEN;;GOMEZ RAIMUNDO UBIETA;;RUBIDO JULIO CESAR AGUILAR;;GONZALEZ VERENA LUCILA MUZIO;;GONZALEZ DAYMIR GARCIA;;OBREGON JULIO CESAR ALVAREZ,,https://lens.org/184-464-888-417-085,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,C12P21/02;;A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02,,0,0,,,,INACTIVE
524,EP,A1,EP 1676587 A1,143-834-628-554-110,2006-07-05,2006,EP 04762299 A,2004-10-20,CU 2004000011 W;;CU 20030240 A,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,"The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in  Picchia pastoris.  The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.",CT INGENIERIA GENETICA BIOTECH,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/143-834-628-554-110,Patent Application,yes,0,2,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
525,ZA,B,ZA 200603126 B,175-842-757-844-473,2007-02-28,2007,ZA 200603126 A,2006-04-19,CU 20030240 A,2003-10-20,Pharmaceutical compositions for therapeutic use,,CT DE INGENIERYA GENUTICA Y BI,CESAR AGUILAR RUBIDO JULIO;;YADIRA LOBAINA MATO;;LUCILA MUZIO GONZSLEZ VERENA;;NELSON ACOSTA RIVERO;;CESAR ALVAREZ OBREGON JULIO;;CARLOS DUARTE CANO;;SATURNINO HERRERA MARTINEZ LUIS;;ENRIQUE IGLESIAS PEREZ;;DAYMIR GARCIA GONZALEZ;;ENRIQUE GUILLUN NIETO GERARDO;;RAIMUNDO UBIETA GOMEZ;;SANTIAGO DUENAS CARRERA;;PETER VANLANDSHOOT,,https://lens.org/175-842-757-844-473,Granted Patent,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K/;;A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,ACTIVE
526,US,A1,US 2007/0275012 A1,020-391-514-208-738,2007-11-29,2007,US 57615804 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,Pharmaceutical Compositions for Therapeutic Use,"The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.",AGUILAR RUBIDO JULIO C;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA L;;GUILLEN NIETO GERARDO E;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO C;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS S,AGUILAR RUBIDO JULIO C;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA L;;GUILLEN NIETO GERARDO E;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO C;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS S,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2006-05-17),https://lens.org/020-391-514-208-738,Patent Application,yes,1,1,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/295;;A61K39/21;;A61K39/29;;A61K39/39;;A61P31/12;;C07K14/02;;C12P21/02,424/202.1,0,0,,,,DISCONTINUED
527,BR,A,BR PI0415654 A,008-206-254-763-898,2006-12-19,2006,BR PI0415654 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,"composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica","""COMPOSIçõES FARMACêUTICAS PARA USO TERAPêUTICO, USO DO ANTìGENO DE SUPERFìCIE DO VìRUS DA HEPATITE B, E, MéTODO PARA O TRATAMENTO DE INFECçõES POR VìRUS DE PROGRESSãO CRÈNICA"". Vacinas terapêuticas contra patógenos que causam doenças crónicas. O uso do antígeno da superfície do vírus da hepatite B (HBsAg), produzido por via recombinante a partir de Pichia pastoris, como componente principal, para a obtenção de composições farmacêuticas com fins terapêuticos. As mesmas podem compreender a combinação do antígeno de hepatite b com outros antígenos co-administrados. Estas formulações são capazes de gerar uma potente resposta linfoproliferativa e de linfócitos T citotóxicos, além de uma considerável resposta de anticorpos específicos, o que as torna muito efetivas para o tratamento destas doenças em humanos.",CT INGENIERIA GENETICA BIOTECH,RUBIDO JULIO CESAR AGUILAR;;PEREZ ENRIQUE IGLESIAS;;MATO YADIRA LOBAINA;;GONZALES DAYMIR GARCIA;;GONZALEZ VERENA LUCILA MUZIO;;NIETO GERARDO ENRIQUE GUILLEN;;RIVERO NELSON ACOSTA;;GOMEZ RAIMUNDO UBIETA;;OBREGON JULIO CESAR ALVAREZ;;CARRERA SANTIAGO DUE AS;;CANO CARLOS DUARTE;;VANLANDSHOOT PETER;;MARTINEZ LUIS SATURNINO HERRER,,https://lens.org/008-206-254-763-898,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
528,PT,A,PT 104631 A,085-335-285-810-822,2010-12-17,2010,PT 10463109 A,2009-06-17,PT 10463109 A,2009-06-17,PRODUTOS NATURAIS ANTIOXIDANTES OBTIDOS POR EXTRACÇÃO SUPERCRÍTICA APLICADA Á FRACÇÃO INSOLÚVEL QUE FICA APÓS A EXTRACÇÃO COM ÁGUA DA POLPA DE ALFARROBA TRITURADA E SEU MÉTODO DE PRODUÇÃO,"A PRESENTE INVENÇÃO DIZ RESPEITO A DOIS PRODUTOS SÓLIDOS DE VALOR ACRESCENTADO, OBTIDOS POR EXTRACÇÃO SUPERCRÍTICA DA FRACÇÃO INSOLÚVEL (RESÍDUO) QUE SE OBTÉM APÓS A EXTRACÇÃO COM ÁGUA DA POLPA DE ALFARROBA TRITURADA, SUBPRODUTO DA INDÚSTRIA DE PROCESSAMENTO DA SEMENTE E SEU MÉTODO DE PRODUÇÃO. UM DOS PRODUTOS, O EXTRACTO, É CARACTERIZADO POR SER RICO EM COMPOSTOS FENÓLICOS ESPECÍFICOS COM PROPRIEDADES BIOACTIVAS. O SÓLIDO REMANESCENTE (SÓLIDO EXTRACTADO) É CARACTERIZADO POR SER RICO EM FIBRAS ALIMENTARES E COMPOSTOS FENÓLICOS, NOMEADAMENTE O ÁCIDO GÁLICO, E POR POSSUIR CARACTERÍSTICAS ORGANOLÉPTICAS E TECNOLÓGICAS MELHORADAS EM RELAÇÃO A PRODUTOS IDÊNTICOS. TANTO O EXTRACTO, COMO O SÓLIDO EXTRACTADO PODEM SER UTILIZADOS EM FORMULAÇÕES INDUSTRIAIS, NOMEADAMENTE PARA AS INDÚSTRIAS ALIMENTAR, FARMACÊUTICA E/OU DE COSMÉTICA.",INST SUPERIOR TECNICO;;LNEG LAB NAC DE EN E GEOL,ESTEVES MARIA PAULA GOMES SEQUEIRA;;GIL MARIA GABRIELA DA SILVA BERNARDO;;AMARO FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES;;GIRIO FRANCISCO MANUEL FERREIRA;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;ROSEIRO MARIA LUISA NUNES OSTRA DE BIVAR WEINHOLTZ;;MOURA PATRICIA MARIA BRITO MADEIRA DA SILVA;;ROQUE RICARDO,,https://lens.org/085-335-285-810-822,Patent Application,no,0,0,2,2,0,,A23L33/21;;A23L29/238,,0,0,,,,ACTIVE
529,CN,A,CN 116964073 A,151-444-133-913-173,2023-10-27,2023,CN 202180086605 A,2021-12-21,CU 20200110 A;;CU 2021050015 W,2020-12-23,Peptides for treating respiratory tract infections of viral origin,"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 20 and an antiviral drug.",CENTRO DE INGENIER ¨ AA GEN ¨,FERN ¨ ¢ NDEZ ORTEGA CARMEN BEGO;;RAMIREZ SAREZ ANA CRISTINA;;CASILLAS CASANOVA DINA;;DUARTE CANO CARLOS ALBERTO;;UBIETA GOMEZ RAFAEL;;GUILLEN NIETO GERARDO ENRIQUE;;CABRALES RIQUE ANTONIO;;ALVAREZ PEREZ KAREN;;PEREIRA GONZALEZ CARLOS LUIS;;FALCONCAMA VIVIANA;;PEREZ RODRIGUEZ SERGIO EDUARDO;;RODRIGUEZ MOLTO MARIA PILAR;;GARAY P ¨,,https://lens.org/151-444-133-913-173,Patent Application,no,0,0,9,9,0,A61K38/10;;C07K14/4741;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/22;;Y02A50/30;;C07K14/001;;A61P31/12;;A61K38/00;;A61K2300/00,C07K7/08;;A61K38/10;;A61P31/14;;A61P31/16;;A61P31/20;;A61P31/22,,0,0,,,,PENDING
530,PT,B,PT 104631 B,179-675-609-503-239,2011-06-22,2011,PT 10463109 A,2009-06-17,PT 10463109 A,2009-06-17,PRODUTOS NATURAIS ANTIOXIDANTES OBTIDOS POR EXTRACÇÃO SUPERCRÍTICA APLICADA Á FRACÇÃO INSOLÚVEL QUE FICA APÓS A EXTRACÇÃO COM ÁGUA DA POLPA DE ALFARROBA TRITURADA E SEU MÉTODO DE PRODUÇÃO,"A PRESENTE INVENÇÃO DIZ RESPEITO A DOIS PRODUTOS SÓLIDOS DE VALOR ACRESCENTADO, OBTIDOS POR EXTRACÇÃO SUPERCRÍTICA DA FRACÇÃO INSOLÚVEL (RESÍDUO) QUE SE OBTÉM APÓS A EXTRACÇÃO COM ÁGUA DA POLPA DE ALFARROBA TRITURADA, SUBPRODUTO DA INDÚSTRIA DE PROCESSAMENTO DA SEMENTE E SEU MÉTODO DE PRODUÇÃO. UM DOS PRODUTOS, O EXTRACTO, É CARACTERIZADO POR SER RICO EM COMPOSTOS FENÓLICOS ESPECÍFICOS COM PROPRIEDADES BIOACTIVAS. O SÓLIDO REMANESCENTE (SÓLIDO EXTRACTADO) É CARACTERIZADO POR SER RICO EM FIBRAS ALIMENTARES E COMPOSTOS FENÓLICOS, NOMEADAMENTE O ÁCIDO GÁLICO, E POR POSSUIR CARACTERÍSTICAS ORGANOLÉPTICAS E TECNOLÓGICAS MELHORADAS EM RELAÇÃO A PRODUTOS IDÊNTICOS. TANTO O EXTRACTO, COMO O SÓLIDO EXTRACTADO PODEM SER UTILIZADOS EM FORMULAÇÕES INDUSTRIAIS, NOMEADAMENTE PARA AS INDÚSTRIAS ALIMENTAR, FARMACÊUTICA E/OU DE COSMÉTICA.",INST SUPERIOR TECNICO;;LNEG LAB NAC DE EN E GEOL,ESTEVES MARIA PAULA GOMES SEQUEIRA;;GIL MARIA GABRIELA DA SILVA BERNARDO;;AMARO FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES;;GIRIO FRANCISCO MANUEL FERREIRA;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;ROSEIRO MARIA LUISA NUNES OSTRA DE BIVAR WEINHOLTZ;;MOURA PATRICIA MARIA BRITO MADEIRA DA SILVA;;ROQUE RICARDO,,https://lens.org/179-675-609-503-239,Granted Patent,no,0,0,2,2,0,,A23L33/21;;A23B7/02;;A23L29/238;;B01D11/02,,0,0,,,,ACTIVE
531,AR,A1,AR 046063 A1,140-975-007-366-141,2005-11-23,2005,AR P040103654 A,2004-10-08,CU 20030240 A,2003-10-20,COMPOSICIONES FARMACEUTICAS PARA USO TERAPEUTICO,"Vacunas terapéuticas contra patógenos que causan enfermedades crónicas. Uso del antígeno de la superficie del virus de la hepatitis B (HBsAg), producido por vía recombinante a partir de Pichia pastoris, como componente principal, para la obtención de composiciones farmacéuticas con fines terapéuticos. Las mismas pueden comprender la combinación del antígeno de hepatitis B con otros antígenos coadministrados. Estas formulaciones son capaces de generar una potente respuesta linfoproliferativa y de linfocitos T citotóxicos, además de una considerable respuesta de anticuerpos específicos, lo que las hace muy efectivas para el tratamiento de estas enfermedades en humanos. Método de tratamiento. Reivindicación 1: Composiciones farmacéuticas para uso terapéutico caracterizadas porque comprenden el antígeno de superficie del Virus de la Hepatitis B producido a partir de levadura por un método de purificación que comprende al menos uno de los pasos siguientes lisado de las células en presencia de un buffer de ruptura que comprende un agente caotrópico; precipitación de contaminantes a pH ácido; sometimiento de la preparación del antígeno a una cromatografía de inmunoafinidad empleando un anticuerpo monoclonal específico para antígeno de superficie del virus de la hepatitis B; y sometimiento del antígeno eluído a un tratamiento térmico a una temperatura entre 30° C y 40° C.",CT INGENIERIA GENETICA BIOTECH,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS A;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS S,,https://lens.org/140-975-007-366-141,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,PENDING
532,US,B2,US 10426098 B2,009-619-182-805-383,2019-10-01,2019,US 201615165825 A,2016-05-26,BR 102015012722 A,2015-06-01,Remote-controlled robotic equipment for tree pruning near energized power lines,"A remote-controlled robotic equipment for tree pruning near energized power lines, which, provides a remote-controlled robotic equipment in its own, specific electromechanical structure coupled to a truck and based on a robotic arm with a stand, a positioner, a handler and an end effector-pruning tool, a collection bin and a tree branch shredder, which are all integrated, for robotized tree pruning near energized power lines, which can conveniently, safely and precisely streamline the procedures adopted in the maintenance of aerial electric power distribution networks, more specifically, tree pruning near urban electric power distribution networks, combined with full ergonomics and no exposure of operators.",LACTEC—INSTITUTO DE TECNOLOGIA PARA O DESENVOLVIMENTO;;FEERGS—FERRAMENTAS E EQUIPAMENTOS ELETRICOS LTDA;;COELBA—COMPANHIA DE ELETRICIDADE DO ESTADO DA BAHIA;;LACTEC—INSTITUTO DE TECNOLOGIA PARA O DESENVOL VIMENTO,XAVIER KÁTIA CILENE FALCÃO;;BONFIM MARIO ANTONIO DUARTE;;ALMEIDA ROBERTO CHAGAS DE;;CERQUEIRA DAILTON PEDREIRA;;REVILLA MARIELLA MENDES;;SIEBERT LUCIANO CAVALCANTE;;COSTA ALEXANDRE ALBARELLO;;YAMAKAWA EDUARDO KAZUMI;;SALAMANCA HENRY LEONARDO LÓPEZ;;KOWALSKI EDEMIR LUIZ;;BIANCHI FILHO JOSÉ FRANCISCO;;SILVA ANDRÉ LUIS MULLER DA;;GAMBOA LUIS RICARDO ALFARO;;RONCOLATTO RONALDO ANTONIO;;TOLEDO LUIZ FELIPE RIBEIRO BARROZO;;GREBOGE THIAGO;;DAHLKE DIOGO BIASUZ;;NORONHA FELIPE ARAÚJO TEIXEIRA,COELBA - COMPANHIA DE ELETRICIDADE DO ESTADO DA BAHIA (2016-05-18);;FEERGS - FERRAMENTAS E EQUIPAMENTOS ELÉTRICOS LTDA (2016-05-18);;LACTEC - INSTITUTO DE TECNOLOGIA PARA O DESENVOLVIMENTO (2016-05-18),https://lens.org/009-619-182-805-383,Granted Patent,yes,4,0,5,5,0,A01G3/086;;B25J9/046;;B25J18/025;;A01G3/08;;B25J11/0055;;A01G3/08;;B25J11/0055;;A01G23/08;;A01G3/086;;B25J9/046;;B25J18/025,A01G23/08;;A01G3/08;;B25J9/04;;B25J11/00;;B25J18/02,,0,0,,,,ACTIVE
533,BR,A2,BR 102015012722 A2,178-621-063-095-551,2017-07-04,2017,BR 102015012722 A,2015-06-01,BR 102015012722 A,2015-06-01,equipamento robotizado telecomandado para poda de árvores junto à rede elétrica energizada,"resumo ""equipamento robotizado telecomandado para poda de árvores junto à rede elétrica energizada"", descreve-se a presente patente de invenção como um equipamento robotizado telecomandado para poda de árvores junto à rede elétrica energizada que, de acordo com as suas características, propicia a formação de um equipamento robotizado telecomandado (1) em estrutura do tipo eletromecânica disposta acoplada sobre um caminhão (2) e baseada em um braço robótico (a) com apoio (3), posicionador (4), manipulador (5) e efetuador final (6) - ferramenta de poda, um coletor (7) e um triturador (8) de resíduos integrados para poda robotizada de árvores junto à rede de energia elétrica energizada, com vistas a possibilitar de forma extremamente prática, segura e precisa uma completa otimização no conjunto de procedimentos destinados a manutenção das redes aéreas de distribuição de energia elétrica, mais especificamente nas podas de árvores adjacentes aos condutores das linhas de distribuição de energia elétrica urbanas energizadas, aliado a completa ergonomia e eliminação da exposição dos técnicos.",FEERGS FERRAMENTAS E EQUIPAMENTOS ELETRICOS LTDA;;INST DE TECNOLOGIA PARA O DESENVOLVIMENTO LACTEC,ALEXANDRE ALBARELLO COSTA;;ANDRÉ LUIS MULLER DA SILVA;;DAILTON PEDREIRA CERQUEIRA;;DIOGO BIASUZ DAHLKE;;EDEMIR LUIZ KOWALSKI;;EDUARDO KAZUMI YAMAKAWA;;FELIPE ARAÚJO TEIXEIRA NORONHA;;HENRY LEONARDO LÓPEZ SALAMANCA;;JOSÉ FRANCISCO BIANCHI FILHO;;KÁTIA CILENE FALCÃO XAVIER;;LUCIANO CAVALCANTE SIEBERT;;LUIS RICARDO ALFARO GAMBOA;;LUIZ FELIPE RIBEIRO BARROZO TOLEDO;;MARIELLA MENDES REVILLA;;MARIO ANTONIO DUARTE BONFIM;;ROBERTO CHAGAS DE ALMEIDA;;RONALDO ANTONIO RONCOLATTO;;THIAGO GREBOGE,INSTITUTO DE TECNOLOGIA PARA O DESENVOLVIMENTO - L (2018-02-06),https://lens.org/178-621-063-095-551,Patent Application,no,0,0,5,5,0,A01G3/086;;B25J9/046;;B25J18/025;;A01G3/08;;B25J11/0055;;A01G3/08;;B25J11/0055;;A01G23/08;;A01G3/086;;B25J9/046;;B25J18/025,B25J9/00;;A01G3/08;;G05D3/00,,0,0,,,,ACTIVE
534,BR,A8,BR 102015012722 A8,010-010-980-376-937,2018-02-06,2018,BR 102015012722 A,2015-06-01,BR 102015012722 A,2015-06-01,EQUIPAMENTO ROBOTIZADO TELECOMANDADO PARA PODA DE ÁRVORES JUNTO À REDE ELÉTRICA ENERGIZADA,"EQUIPAMENTO ROBOTIZADO TELECOMANDADO PARA PODA DE ÁRVORES JUNTO À REDE ELÉTRICA ENERGIZADA, descreve-se a presente patente de invenção como um equipamento robotizado telecomandado para poda de árvores junto à rede elétrica energizada que, de acordo com as suas características, propicia a formação de um equipamento robotizado telecomandado (1) em estrutura do tipo eletromecânica disposta acoplada sobre um caminhão (2) e baseada em um braço robótico (A) com apoio (3), posicionador (4), manipulador (5) e efetuador final (6) - ferramenta de poda, um coletor (7) e um triturador (8) de resíduos integrados para poda robotizada de árvores junto à rede de energia elétrica energizada, com vistas a possibilitar de forma extremamente prática, segura e precisa uma completa otimização no conjunto de procedimentos destinados a manutenção das redes aéreas de distribuição de energia elétrica, mais especificamente nas podas de árvores adjacentes aos condutores das linhas de distribuição de energia elétrica urbanas energizadas, aliado a completa ergonomia e eliminação da exposição dos técnicos.",COELBA COMPANHIA DE ELETRICIDADE DO ESTADO DA BAHIA;;INST DE TECNOLOGIA PARA O DESENVOLVIMENTO LACTEC;;FEERGS FERRAMENTAS E EQUIPAMENTOS ELETRICOS LTDA,KÁTIA CILENE FALCÃO XAVIER;;MARIO ANTONIO DUARTE BONFIM;;ROBERTO CHAGAS DE ALMEIDA;;MARIELLA MENDES REVILLA;;LUCIANO CAVALCANTE SIEBERT;;ALEXANDRE ALBARELLO COSTA;;HENRY LEONARDO LÓPEZ SALAMANCA;;JOSÉ FRANCISCO BIANCHI FILHO;;ANDRÉ LUIS MULLER DA SILVA;;LUIS RICARDO ALFARO GAMBOA;;RONALDO ANTONIO RONCOLATTO;;THIAGO GREBOGE;;DIOGO BIASUZ DAHLKE;;FELIPE ARAÚJO TEIXEIRA NORONHA;;DAILTON PEDREIRA CERQUEIRA;;EDUARDO KAZUMI YAMAKAWA;;EDEMIR LUIZ KOWALSKI;;LUIZ FELIPE RIBEIRO BARROZO TOLEDO,INSTITUTO DE TECNOLOGIA PARA O DESENVOLVIMENTO - L (2018-02-06),https://lens.org/010-010-980-376-937,Patent Application,no,0,0,5,5,0,A01G3/086;;B25J9/046;;B25J18/025;;A01G3/08;;B25J11/0055;;A01G3/08;;B25J11/0055;;A01G23/08;;A01G3/086;;B25J9/046;;B25J18/025,A01G3/08;;B25J9/00;;G05D3/00,,0,0,,,,ACTIVE
535,BR,B1,BR 102015012722 B1,076-811-208-500-28X,2020-12-01,2020,BR 102015012722 A,2015-06-01,BR 102015012722 A,2015-06-01,equipamento robotizado telecomandado para poda de árvores junto à rede elétrica energizada,"equipamento robotizado telecomandado para poda de árvores junto à rede elétrica energizada, descreve-se a presente patente de invenção como um equipamento robotizado telecomandado para poda de árvores junto à rede elétrica energizada que, de acordo com as suas características, propicia a formação de um equipamento robotizado telecomandado (1) em estrutura do tipo eletromecânica disposta acoplada sobre um caminhão (2) e baseada em um braço robótico (a) com apoio (3), posicionador (4), manipulador (5) e efetuador final (6) - ferramenta de poda, um coletor (7) e um triturador (8) de resíduos integrados para poda robotizada de árvores junto à rede de energia elétrica energizada, com vistas a possibilitar de forma extremamente prática, segura e precisa uma completa otimização no conjunto de procedimentos destinados a manutenção das redes aéreas de distribuição de energia elétrica, mais especificamente nas podas de árvores adjacentes aos condutores das linhas de distribuição de energia elétrica urbanas energizadas, aliado a completa ergonomia e eliminação da exposição dos técnicos.",COELBA COMPANHIA DE ELETRICIDADE DO ESTADO DA BAHIA;;FEERGS FERRAMENTAS E EQUIPAMENTOS ELETRICOS LTDA;;INST DE TECNOLOGIA PARA O DESENVOLVIMENTO LACTEC,ALEXANDRE ALBARELLO COSTA;;ANDRÉ LUIS MULLER DA SILVA;;DAILTON PEDREIRA CERQUEIRA;;DIOGO BIASUZ DAHLKE;;EDEMIR LUIZ KOWALSKI;;EDUARDO KAZUMI YAMAKAWA;;FELIPE ARAÚJO TEIXEIRA NORONHA;;HENRY LEONARDO LÓPEZ SALAMANCA;;JOSÉ FRANCISCO BIANCHI FILHO;;KÁTIA CILENE FALCÃO XAVIER;;LUCIANO CAVALCANTE SIEBERT;;LUIS RICARDO ALFARO GAMBOA;;LUIZ FELIPE RIBEIRO BARROZO TOLEDO;;MARIELLA MENDES REVILLA;;MARIO ANTONIO DUARTE BONFIM;;ROBERTO CHAGAS DE ALMEIDA;;RONALDO ANTONIO RONCOLATTO;;THIAGO GREBOGE,INSTITUTO DE TECNOLOGIA PARA O DESENVOLVIMENTO - L (2018-02-06),https://lens.org/076-811-208-500-28X,Granted Patent,no,0,0,5,5,0,A01G3/086;;B25J9/046;;B25J18/025;;A01G3/08;;B25J11/0055;;A01G3/08;;B25J11/0055;;A01G23/08;;A01G3/086;;B25J9/046;;B25J18/025,B25J9/00;;A01G3/08;;G05D3/00,,0,0,,,,ACTIVE
536,US,A1,US 2016/0353669 A1,066-835-649-445-101,2016-12-08,2016,US 201615165825 A,2016-05-26,BR 102015012722 A,2015-06-01,REMOTE-CONTROLLED ROBOTIC EQUIPMENT FOR TREE PRUNING NEAR ENERGIZED POWER LINES,"A remote-controlled robotic equipment for tree pruning near energized power lines, which, provides a remote-controlled robotic equipment in its own, specific electromechanical structure coupled to a truck and based on a robotic arm with a stand, a positioner, a handler and an end effector-pruning tool, a collection bin and a tree branch shredder, which are all integrated, for robotized tree pruning near energized power lines, which can conveniently, safely and precisely streamline the procedures adopted in the maintenance of aerial electric power distribution networks, more specifically, tree pruning near urban electric power distribution networks, combined with full ergonomics and no exposure of operators.",LACTEC - INST DE TECNOLOGIA PARA O DESENVOLVIMENTO,XAVIER KÁTIA CILENE FALCÃO;;BOMFIM MARIO ANTONIO DUARTE;;ALMEIDA ROBERTO CHAGAS DE;;CERQUEIRA DAILTON PEDREIRA;;REVILLA MARIELLA MENDES;;SIEBERT LUCIANO CAVALCANTE;;COSTA ALEXANDRE ALBARELLO;;YAMAKAWA EDUARDO KAZUMI;;SALAMANCA HENRY LEONARDO LÓPEZ;;KOWALSKI EDEMIR LUIZ;;BIANCHI FILHO JOSÉ FRANCISCO;;SILVA ANDRÉ LUIS MULLER DA;;GAMBOA LUIS RICARDO ALFARO;;RONCOLATTO RONALDO ANTONIO;;TOLEDO LUIZ FELIPE RIBEIRO BARROZO;;GREBOGE THIAGO;;DAHLKE DIOGO BIASUZ;;NORONHA FELIPE ARAÚJO TEIXEIRA,COELBA - COMPANHIA DE ELETRICIDADE DO ESTADO DA BAHIA (2016-05-18);;LACTEC - INSTITUTO DE TECNOLOGIA PARA O DESENVOLVIMENTO (2016-05-18);;FEERGS - FERRAMENTAS E EQUIPAMENTOS ELÉTRICOS LTDA (2016-05-18),https://lens.org/066-835-649-445-101,Patent Application,yes,8,6,5,5,0,A01G3/086;;B25J9/046;;B25J18/025;;A01G3/08;;B25J11/0055;;A01G3/08;;B25J11/0055;;A01G23/08;;A01G3/086;;B25J9/046;;B25J18/025,A01G3/08;;B25J11/00;;B60S9/02,,0,0,,,,ACTIVE
537,PT,A,PT 104632 A,126-019-740-824-961,2010-12-17,2010,PT 10463209 A,2009-06-17,PT 10463209 A,2009-06-17,BEBIDA FUNCIONAL NÃO ALCOÓLICA OBTIDA POR FERMENTAÇÃO DO EXTRACTO AQUOSO DA POLPA DE ALFARROBA TRITURADA E PROCESSO PARA A SUA PREPARAÇÃO,"A PRESENTE INVENÇÃO ENQUADRA-SE NA ÁREA DOS ALIMENTOS FUNCIONAIS E REFERE-SE A UMA BEBIDA POLIFUNCIONAL NÃO ALCOÓLICA OBTIDA POR FERMENTAÇÃO DO EXTRACTO AQUOSO DA POLPA DE ALFARROBA TRITURADA, EVENTUALMENTE SUPLEMENTADO COM SORO DE LEITE, POR UM MICRORGANISMO OU UMA MISTURA DE MICRORGANISMOS DE DIFERENTES GÉNEROS QUE COMPREENDEM MAS NÃO SE LIMITAM A LACTOBACILIUS, STREPTOCOCCUS, SACCHAROMYCES, E A UM PROCESSO PARA A SUA PREPARAÇÃO. A BEBIDA DA PRESENTE INVENÇÃO É CARACTERIZADA POR SER NÃO ALCOÓLICA E POR CONTER COMPOSTOS FENÓLICOS, MAIORITARIAMENTE ÁCIDO GÁLICO COM PROPRIEDADES ANTIOXIDANTES, PINITOL E MICRORGANISMOS COM POTENCIAL PROBIÓTICO.",INST SUPERIOR TECNICO;;LNEG LAB NAC DE EN E GEOL,GIL MARIA GABRIELA DA SILVA BERNARDO;;AMARO FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES;;GIRIO FRANCISCO MANUEL FERREIRA;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;ROSEIRO MARIA LUISA NUNES OSTRA DE BIVAR WEINHOLTZ;;MOURA PATRICIA MARIA BRITO MADEIRA DA SILVA;;ESTEVES MARIA PAULA GOMES DA CONCEICAO SEQUEIRA;;PEREIRA JOANA,,https://lens.org/126-019-740-824-961,Patent Application,no,0,0,2,2,0,,A61K31/736;;A61K35/744,,0,0,,,,ACTIVE
538,CU,A1,CU 22559 A1,068-678-622-381-845,1999-05-03,1999,CU 1996010 A,1996-01-17,CU 1996010 A,1996-01-17,SISTEMA DE EXPRESIÓN DE ANTÍGENOS HETEROLOGOS EN E. COLI COMO PROTEÍNAS DE FUSIÓN,"La presente invención está relacionada con la rama de la biotecnología y la ingeniería genética, particularmente con la expresión de proteínas heterólogas en microorganismos mediante su fusión, usando la tecnología del ADN recombinante, a péptidos bacterianos. El objetivo técnico que se persigue con la solución propuesta es el desarrollo de un procedimiento eficaz para la expresión en Escherichia coli de proteínas heterólogas como polipéptidos de fusión con vistas a su obtención con un alto grado de pureza, en cantidades comercialmente útiles, y de forma que permita su inclusión en preparados vacunales destinados al uso en humanos. Para lograr el mismo se emplea esencialmente una secuencia estabilizadora derivada de los primeros 47 aminoácidos del antígeno P64k de Neisseria meningitidis B:4:P1.15. En particular, se usa un plasmidio recombinante conteniendo dicha secuencia bajo el control del promotor triptófano de E. coli y del terminador de la transcripción del fago T4, incluyendo sitios de restricción que permiten la clonación en fase de fragmentos de ADN codificantes para polipéptidos de interés. El procedimiento objeto de la presente invención es aplicable en la industria farmacéutica, para el desarrollo de sistemas de diagnóstico, de preparados vacunales, y en cualquier situación donde sea necesaria la obtención en grandes cantidades de proteínas heterólogas como polipéptidos de fusión en E. coli.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;NAZABAL GALVEZ CONSUELO;;GOMEZ RODRIGUEZ CARMEN ELENA;;CARPIO MUNOZ EMILIO LUIS;;MARTIN DUNN ALEJANDRO MIGUEL;;ALVAREZ ACOSTA ANABEL;;QUINTANA VAZQUEZ DIOGENES;;LEAL ANGULO MARIA DE JESUS;;MONTERO RAMOS MARINIEVE;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;GUILLEN NIETO GERARDO ENRIQUE;;MENENDEZ ALARCON ALFREDO,,https://lens.org/068-678-622-381-845,Limited Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
539,PT,B,PT 104632 B,137-795-661-741-528,2011-10-04,2011,PT 10463209 A,2009-06-17,PT 10463209 A,2009-06-17,BEBIDA FUNCIONAL NÃO ALCOÓLICA OBTIDA POR FERMENTAÇÃO DO EXTRACTO AQUOSO DA POLPA DE ALFARROBA TRITURADA E PROCESSO PARA A SUA PREPARAÇÃO,"A PRESENTE INVENÇÃO ENQUADRA-SE NA ÁREA DOS ALIMENTOS FUNCIONAIS E REFERE-SE A UMA BEBIDA POLIFUNCIONAL NÃO ALCOÓLICA OBTIDA POR FERMENTAÇÃO DO EXTRACTO AQUOSO DA POLPA DE ALFARROBA TRITURADA E SORO DE LEITE, POR UM MICRORGANISMO OU UMA MISTURA DE MICRORGANISMOS DE DIFERENTES GÉNEROS QUE COMPREENDEM MAS NÃO SE LIMITAM A LACTOBACILIUS E STREPTOCOCCUS, E A UM PROCESSO PARA A SUA PREPARAÇÃO. A BEBIDA DA PRESENTE INVENÇÃO É CARACTERIZADA POR SER NÃO ALCOÓLICA E POR CONTER COMPOSTOS FENÓLICOS, MAIORITARIAMENTE ÁCIDO GÁLICO COM PROPRIEDADES ANTIOXIDANTES, PINITOL E MICRORGANISMOS COM POTENCIAL PROBIÓTICO.",INST SUPERIOR TECNICO;;LNEG LAB NAC DE EN E GEOL,GIL MARIA GABRIELA DA SILVA BERNARDO;;AMARO FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES;;GIRIO FRANCISCO MANUEL FERREIRA;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;ROSEIRO MARIA LUISA NUNES OSTRA DE BIVAR WEINHOLTZ;;MOURA PATRICIA MARIA BRITO MADEIRA DA SILVA;;ESTEVES MARIA PAULA GOMES DA CONCEICAO SEQUEIRA;;PEREIRA JOANA,,https://lens.org/137-795-661-741-528,Granted Patent,no,0,0,2,2,0,,A61K31/736;;A61K35/744,,0,0,,,,ACTIVE
540,BR,A2,BR 102017022414 A2,003-190-708-840-865,2019-05-07,2019,BR 102017022414 A,2017-10-18,BR 102017022414 A,2017-10-18,utilização da 7-cloro-4-fenilseleno-quinolina na profilaxia da doença de alzheimer,"a presente invenção refere-se à utilização de um derivado quinolínico, a 7-cloro-4(fenilseleno)quinolina como agente terapêutico da doença de alzheimer. ainda, esta invenção refere-se ao uso do derivado quinolínico isoladamente. a eficácia terapêutica in vivo deste tratamento na doença de alzheimer é demonstrada na presente invenção.",UNIV PELOTAS FEDERAL,ANE GABRIELA VOGT;;ANELISE BARTH;;ANGÉLICA SCHIAVOM DOS REIS;;CAREN ALINE RAMSON DA FONSECA;;CRISTIANE LUCHESE;;DIEGO DA SILVA ALVES;;ETHEL ANTUNES WILHELM;;GUILHERME TEIXEIRA VOSS;;JAINI JANKE PALTIAN;;KARLINE DA COSTA RODRIGUES;;LUIS FERNANDO BARBOSA DUARTE;;MIKAELA PEGLOW PINZ;;RENATA LEIVAS DE OLIVEIRA;;RODRIGO DE ALMEIDA VAUCHER,,https://lens.org/003-190-708-840-865,Patent Application,no,0,0,1,1,0,,C07D215/16;;A61P25/28,,0,0,,,,PENDING
541,PT,A,PT 105978 A,199-666-651-279-497,2013-04-30,2013,PT 10597811 A,2011-10-31,PT 10597811 A,2011-10-31,MÉTODO PARA O ACONDICIONAMENTO E DESTOXIFICAÇÃO DE HIDROLISADOS ÁCIDOS DE MATERIAIS VEGETAIS,"A PRESENTE INVENÇÃO REFERE-SE A UM NOVO MÉTODO PARA O ACONDICIONAMENTO E DESTOXIFICAÇÃO DE HIDROLISADOS ÁCIDOS DE MATERIAIS VEGETAIS COM VISTA À SUA UTILIZAÇÃO COMO SUBSTRATOS FERMENTATIVOS OU COMO FONTES DE COMPOSTOS FENÓLICOS E/OU SACÁRIDOS SIMPLES OU POLIMÉRICOS CARACTERIZADO POR UTILIZAR CARVO ATIVADO COM UM AGENTE ALCALINO, MORMENTE HIDRÓXIDO DE SÓDIO E ESSA ATIVAÇÃO DO CARVÃO SER FEITA SOB CONDIÇÕES DE OPERAÇÃO SUAVES. AO CONTRÁRIO DOS MÉTODOS CORRENTEMENTE UTILIZADOS NA INDÚSTRIA E DESCRITOS NA LITERATURA PARA O ACONDICIONAMENTO E DESTOXIFICAÇÃO DE HIDROLISADOS, QUE IMPLICAM A UTILIZAÇÃO COMBINADA DE VÁRIAS OPERAÇÕES UNITÁRIAS, NA PRESENTE INVENÇÃO O ACONDICIONAMENTO E DESTOXIFICAÇÃO DOS HIDROLISADOS SÃO FEITOS NUM ÚNICO PASSO. MAIS, AO CONTRÁRIO DOS MÉTODOS MAIS COMUNS, OS COMPOSTOS SELETIVAMENTE REMOVIDOS PODEM AINDA SER FACILMENTE RECUPERADOS COM GRANDE PUREZA DURANTE O PROCESSO DE RECICLAGEM DO CARVÃO, TAMBÉM DESCRITO NESTA INVENÇÃO.",NAC DE EN E GEOL LAB,LOURENCO PEDRO MIGUEL LOPES;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;AMARO FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES;;ROSEIRO LUISA BIVAR;;SEARA JOSE MANUEL SALGADO;;SANTANA IVONE MARIA RUIVO TORRADO;;GUERRA VERA LUCIA COSTA;;FERREIRA CATIA RITA PINTO;;FERNANDES TALITA FERREIRA MARQUES DA SILVA;;BRANCO PEDRO MIGUEL SENA DA COSTA,,https://lens.org/199-666-651-279-497,Patent Application,no,0,0,1,1,0,,C07C7/00,,0,0,,,,DISCONTINUED
542,PT,A,PT 105731 A,199-938-729-065-947,2012-11-28,2012,PT 10573111 A,2011-05-28,PT 10573111 A,2011-05-28,"MÉTODO DE OBTENÇÃO DE PRODUTOS NATURAIS ANTIOXIDANTES E ANTIPROLIFERATIVOS, EXTRATO SÓLIDO NATURAL E SÓLIDO REMANESCENTE EXTRACTADO ASSIM OBTIDOS E RESPECTIVA UTILIZAÇÃO","A PRESENTE INVENÇÃO DIZ RESPEITO A DOIS PRODUTOS DE VALOR ACRESCENTADO, OBTIDOS DE RESÍDUOS DE POLPA DE ALFARROBA (POR EXEMPLO, A POLPA DE ALFARROBA TRITURADA, SUBPRODUTO DA INDÚSTRIA DE PROCESSAMENTO DA ALFARROBA), E SEU MÉTODO DE PRODUÇÃO POR EXTRAÇÃO ASSISTIDA POR ULTRA-SONS. UM DOS PRODUTOS, O EXTRATO, É CARACTERIZADO POR SER CONSTITUÍDO POR COMPOSTOS FENÓLICOS ESPECÍFICOS, EM PARTICULAR ÁCIDO GÁLICO E EPIGALOCATEQUINA GALATO, COM PROPRIEDADES BIOACTIVAS. O SÓLIDO REMANESCENTE (SÓLIDO EXTRATADO) É CARACTERIZADO POR SER RICO EM FIBRAS ALIMENTARES E COMPOSTOS FENÓLICOS, E POR POSSUIR CARACTERÍSTICAS TECNOLÓGICAS DISTINTAS EM RELAÇÃO A PRODUTOS IDÊNTICOS. AMBOS OS PRODUTOS PODEM SER UTILIZADOS EM FORMULAÇÕES INDUSTRIAIS, NOMEADAMENTE PARA A INDÚSTRIA ALIMENTAR, FARMACÊUTICA E COSMÉTICA.",NAC DE EN E GEOL I P LAB,RAUTER AMELIA PILAR GRASES SANTOS SILVA;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;MARTINS ALICE ISABEL MENDES;;ROSEIRO LUISA BIVAR;;OLIVEIRA DIANA LUAZI MATOS DE;;ROQUE RICARDO MIGUEL NUNES;;GIL MARIA GABRIELA DA SILVA BERNARDO;;SEPULVEDA CATARINA PIRES;;ALMEIDA JOANA MARGARIDA MARTO SAMPAIO DE;;MEIRELES MARIA MARGARIDA TEIXEIRA DE FARIA,,https://lens.org/199-938-729-065-947,Patent Application,no,0,0,2,2,0,,A61K36/48;;A61K131/00;;B01J19/10,,0,0,,,,ACTIVE
543,WO,A1,WO 2013/095169 A1,024-900-251-029-751,2013-06-27,2013,PT 2012000051 W,2012-12-17,PT 10606311 A,2011-12-19,CRYSTALLINE MINOCYCLINE THERMO-RESISTANT OBTAINED BY RECRYSTALLIZATION WITH CARBON DIOXIDE,"The present invention relates to a novel form of minocycline chlorohydrate characterized in that- it is crystalline and it presents characteristic powder X-ray diffraction pattern and infrared spectrum. This new polymorph constitutes the most stable form of minocycline with a melting point much higher than that of other known crystalline forms of minocycline. The process of production of this new minocycline polymorphic form consists in the dissolution of carbon dioxide in solutions or suspensions of minocycline chlorohydrate with organic solvents, under certain conditions of pressure and temperature. The present invention places minocycline in the restrict group of antibiotics with a melting temperature higher than the sterilization temperature, which enhances new applications and allows the optimization of production at industrial",INST SUPERIOR TECNICO;;UNIV LISBOA,RODRIGUES MIGUEL ANGELO JOAQUIM;;PADRELA LUIS MIGUEL BORGES;;MATOS HENRIQUE ANIBAL SANTOS DE;;AZEVEDO EDMUNDO JOSE SIMOES GOMES DE;;PINHEIRO LIDIA MARIA VELOSO;;BETTENCOURT ANA FRANCISCA CAMPOS SIMAO;;CASTRO MATILDE LUZ SANTOS DUQUE FONSECA E;;ALMEIDA ANTONIO JOSE LEITAO DAS NEVES;;DUARTE MARIA AIDA DA COSTA E SILVA DA CONCEICAO,,https://lens.org/024-900-251-029-751,Patent Application,no,6,2,3,3,0,A61P31/04;;C07C237/26;;C07B2200/13;;C07C2603/46,C07C237/26;;A61K31/65;;A61P31/04,,10,9,026-872-796-351-596;;016-229-324-753-225;;051-681-840-841-045;;098-046-891-145-43X;;071-803-289-359-959;;011-483-768-667-370;;025-311-294-592-481;;154-664-204-596-528;;028-828-134-460-931,pmc2681267;;19053822;;10.1021/ja806629e;;10.1016/0385-6380(87)90067-7;;10.1016/s0142-9612(03)00554-4;;14585704;;19900792;;10.1016/j.ijantimicag.2009.08.020;;19665876;;10.1016/j.ijantimicag.2009.06.021;;17403814;;10.2106/jbjs.e.01070;;10.2106/00004623-200704000-00026;;10.1016/j.supflu.2008.02.018;;10.1021/ie050075h;;10.1016/j.supflu.2008.07.013,"CUIXIANG SUN ET AL: ""A Robust Platform for the Synthesis of New Tetracycline Antibiotics"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, ACS PUBLICATIONS, US, vol. 130, 31 December 2008 (2008-12-31), pages 17913 - 17927, XP002604988, ISSN: 0002-7863, [retrieved on 20081203], DOI: 10.1021/JA806629E;;KAMIHIRA M ET AL: ""Removal of organic solvent from antibiotics with supercritical carbon dioxide"", JOURNAL OF FERMENTATION TECHNOLOGY, ELSEVIER, JP, vol. 65, no. 1, 1 January 1987 (1987-01-01), pages 71 - 75, XP023543271, ISSN: 0385-6380, [retrieved on 19870101], DOI: 10.1016/0385-6380(87)90067-7;;HENDRIKS JGE; VAN HORN JR; VAN DER MEI HC; BUSSCHER, HJ: ""Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection"", BIOMATERIALS, vol. 25, 2004, pages 545 - 556, XP004469649, DOI: doi:10.1016/S0142-9612(03)00554-4;;HUANG V; CHEUNG CM; KAATZ GW; RYBAK MJ: ""Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community associated and multidrug-resistant hospital-associated meticillin- resistant Staphylococcus aureus"", INT J ANTIMICROB AG, vol. 35, 2010, pages 25 - 29;;BISHBURG E; BISHBURG K: ""Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii"", INT J ANTIMICROB AG, vol. 34, 1999, pages 395 - 401, XP026601916, DOI: doi:10.1016/j.ijantimicag.2009.06.021;;CUI Q; MIHALKO WM; SHIELDS JS; RIES M; SALEH KJ: ""Antibiotic-Impregnated Cement Spacers for the Treatment of Infection Associated with Total Hip or Knee Arthroplasty"", J BONE JOINT SURG AM, vol. 89, 2007, pages 871 - 882;;PINHEIRO L; BETTENCOURT A; DUARTE A; BETTENCOURT K; ALMEIDA AJ; CASTRO M; PADRELA L; RODRIGUES MA; MATOS HA: ""The Impact of Supercritical Fluids processing on Minocycline Antibacterial Activity"", PROCEEDINGS OF THE 12TH EUROPEAN MEETING ON SUPERCRITICAL FLUIDS, 2010, pages 6;;TAVARES CARDOSO MA; GERALDES V; CABRAL JMS; PALAVRA AMF: ""Characterization of minocycline powder micronized by a supercritical antisolvent (SAS) process"", J SUPERCRIT FLUID, vol. 46, 2008, pages 71 - 76, XP022688807, DOI: doi:10.1016/j.supflu.2008.02.018;;JUN LI; M. A. RODRIGUES; H. A. MATOS; E. GOMES DE AZEVEDO: ""VLE of Carbon Dioxide/Ethanol/Water: Applications to Volume Expansion Evaluation and Water Removal Efficiency"", IND. ENG. CHEM. RES., vol. 44, 2005, pages 6751 - 6759;;M MUNT6; N. VENTOSA; S. SALA; J. VECIANA: ""Solubility behaviors of ibuprofen and naproxen drugs in liquid ''C02 - organic solvent'' mixtures"", THE JOURNAL OF SUPERCRITICAL FLUIDS, vol. 47, 2008, pages 147 - 153, XP025868918, DOI: doi:10.1016/j.supflu.2008.07.013",PENDING
544,RU,C2,RU 2670187 C2,091-416-346-936-245,2018-10-18,2018,RU 2014139667 A,2014-09-30,US 201361887313 P,2013-10-04,MODULAR PASSENGER SERVICE UNITS AND ASSEMBLIES THEREOF,"FIELD: satisfaction of human vital requirements.SUBSTANCE: present invention relates essentially to passenger service units and their components that can be used in vehicle interiors, especially in the interior cabinets of aircraft. Elongate passenger service unit (PSU) assembly comprised a plurality of modular passenger service units; and a plurality of variable-length modular spacer units. Modular spacer units are positioned between the modular passenger service units in an end-to-end manner. Plurality of modular oxygen emergency components having different longitudinal dimensions contain oxygen emergency systems. Modular component of the emergency oxygen supply is connected in an end-to-end manner with the modular components of passenger service.EFFECT: convenience of PSU layout improves.12 cl, 6 dwg",EMBRAER SA,PAULINU AMAURI;;GOMIDI SERZHIU LUIS ABDALLA;;DI ARRUDA GUSTAVU SELOFITI;;FERREJRA NILMAR SEZAR;;RIBEJRU LUSYANU DOS SANTUSH;;DI KAMPUSH DEMETRIU ANDRADI;;MEJRELISH FILYU SERZHIU AUGUSHTU;;DI OLIVEJRA FREDERIKU LARA;;DI ALBUKERKE DUGLAS GONSALVES;;ALBINU ELYU;;STEJN ANDRE DUARTE;;PRISTMAN POL;;MAKINNES DANIEL;;DA SILVA LUSYANU RIKARDU MAGALYAJNSH;;MASEDU RIKARDU ROZA,,https://lens.org/091-416-346-936-245,Granted Patent,no,4,0,11,11,0,B64D11/00;;B64D2011/0053;;B64D2013/003;;B64D13/00;;B64D2231/025;;B64D11/00;;B64D11/00;;B64D2011/0053;;B64D2013/003;;A62B7/14;;B64D11/0015;;B64D11/003;;B64D13/00;;B64D2011/0038;;B64D2011/0046;;B64D2231/025,B64D11/00,,0,0,,,,ACTIVE
545,PT,A,PT 106063 A,085-688-366-921-94X,2013-06-19,2013,PT 10606311 A,2011-12-19,PT 10606311 A,2011-12-19,MINOCICLINA CRISTALINA TERMORRESISTENTE PRODUZIDA POR RECRISTALIZAÇÃO COM DIÓXIDO DE CARBONO,"A PRESENTE INVENÇÃO REFERE-SE A UMA NOVA FORMA DE CLORIDRATO DE MINOCICLINA, CARACTERIZADA POR SER CRISTALINA APRESENTANDO ESPECTROS CARACTERÍSTICOS DE DIFRACÇÃO DE RAIOS-X E DE ABSORÇÃO DE INFRAVERMELHOS. ESTE NOVO POLIMORFO CONSTITUI A FORMA MAIS ESTÁVEL DESTE ANTIBIÓTICO, APRESENTANDO UMA TEMPERATURA DE FUSÃO MUITO SUPERIOR À DAS OUTRAS FORMAS CONHECIDAS DE MINOCICLINA. O SEU PROCESSO DE PRODUÇÃO CONSISTE NA MISTURA DE DIÓXIDO DE CARBONO COM SOLUÇÕES OU SUSPENSÕES DE CLORIDRATO DE MINOCICLINA EM SOLVENTES ORGÂNICOS, SOB DETERMINADAS CONDIÇÕES DE PRESSÃO E DE TEMPERATURA. A PRESENTE INVENÇÃO COLOCA A MINOCICLINA NO GRUPO RESTRITO DOS ANTIBIÓTICOS COM TEMPERATURA DE FUSÃO SUPERIOR À TEMPERATURA DE ESTERILIZAÇÃO, O QUE PERMITE POTENCIAR NOVAS APLICAÇÕES E OPTIMIZAR A PRODUÇÃO DESTE ANTIBIÓTICO À ESCALA INDUSTRIAL.",UNIV LISBOA;;INST SUPERIOR TECNICO,ALMEIDA ANTONIO JOSE LEITAO DAS NEVES;;RODRIGUES MIGUEL ANGELO JOAQUIM;;MATOS HENRIQUE ANIBAL SANTOS DE;;AZEVEDO EDMUNDO JOSE SIMOES GOMES DE;;PADRELA LUIS MIGUEL BORGES;;PINHEIRO LIDIA MARIA VELOSO;;BETTENCOURT ANA FRANCISCA CAMPOS SIMAO;;CASTRO MATILDE LUZ SANTOS DUQUE FONSECA E;;DUARTE MARIA AIDA DA COSTA E SILVA DA CONCEICAO,"UNIVERSIDADE DE LISBOA, PT (2014-07-29);;FACULDADE DE FARMACIA DA UNIVERSIDADE DE LISBO, PT (2014-08-04);;UNIVERSIDADE DE FARMACIA DA UNIVERSIDADE DE LI, PT (2014-08-04)",https://lens.org/085-688-366-921-94X,Patent Application,no,0,0,3,3,0,A61P31/04;;C07C237/26;;C07B2200/13;;C07C2603/46,C07C237/26,,0,0,,,,ACTIVE
546,PT,B,PT 105731 B,181-274-939-830-544,2013-07-04,2013,PT 10573111 A,2011-05-28,PT 10573111 A,2011-05-28,UTILIZAÇÃO DE PRODUTOS NATURAIS ANTIOXIDANTES E ANTIPROLIFERATIVOS DA BIOMASSA DA ALFARROBA,"A PRESENTE INVENÇÃO DIZ RESPEITO À APLICAÇÃO DE UM EXTRACTO LÍQUIDO CONSTITUÍDO POR PRODUTOS NATURAIS OBTIDO DE RESÍDUOS DE POLPA DE ALFARROBA (POR EXEMPLO, A POLPA DE ALFARROBA TRITURADA, SUBPRODUTO DA INDÚSTRIA DE PROCESSAMENTO DA ALFARROBA), PARA SER UTILIZADO NA PREVENÇÃO / TRATAMENTO DE DOENÇAS PROLIFERATIVAS. O EXTRACTO LÍQUIDO É CARACTERIZADO POR SER SIMULTANEAMENTE ANTIOXIDANTE E ANTIPROLIFERATIVO, CONSTITUÍDO POR COMPOSTOS FENÓLICOS ESPECÍFICOS COM PROPRIEDADES BIOACTIVAS.ESTE EXTRACTO LÍQUIDO PODE SER UTILIZADO EM FORMULAÇÕES INDUSTRIAIS, NOMEADAMENTE PARA A INDÚSTRIA ALIMENTAR, FARMACÊUTICA E COSMÉTICA.",NAC DE EN E GEOL I P LAB,RAUTER AMELIA PILAR GRASES SANTOS SILVA;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;MARTINS ALICE ISABEL MENDES;;ROSEIRO LUISA BIVAR;;OLIVEIRA DIANA LUAZI MATOS DE;;ROQUE RICARDO MIGUEL NUNES;;GIL MARIA GABRIELA DA SILVA BERNARDO;;SEPULVEDA CATARINA PIRES;;ALMEIDA JOANA MARGARIDA MARTO SAMPAIO DE;;MEIRELES MARIA MARGARIDA TEIXEIRA DE FARIA,,https://lens.org/181-274-939-830-544,Granted Patent,no,2,0,2,2,0,,A61K36/48;;A61K131/00;;B01J19/10,,0,0,,,,ACTIVE
547,RU,C2,RU 2362586 C2,080-969-754-956-027,2009-07-27,2009,RU 2006117308 A,2004-10-20,CU 20030240 A,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC APPLICATION,"FIELD: medicine. ^ SUBSTANCE: invention concerns area of medicine and concerns therapeutic and preventive vaccines against hepatitis B and HIV. The essence of the invention: the offered composition includes a superficial antigen of hepatitis B (HBsAg) as the main component, received as a recombinant product of Pichia pastoris and the vaccine antigen representing polypeptide CR3, containing epitopic determinants of a human immunodeficiency virus. The offered composition can be applied at HIV treatment and during too time as a preventive vaccine against the virus of hepatitis B. ^ EFFECT: working out of a composition which can be applied at treatment HIV and during too time as a preventive vaccine against the virus of hepatitis B. ^ 3 cl, 5 dwg, 7 ex",CIGB,AGILAR RUBIDO KHULIO SESAR;;IGLESIAS PERES EHNRIKE;;LOBAJNA MATO JADIRA;;GARSIJA GONSALES DAJMIR;;MUSIO GONSALES VERENA LUSILA;;GIL EN N ETO KHERARDO EHNRIKE;;AKOSTA RIVERO NEL SON;;UB ETA GOMES RAJMUNDO;;AL VARES OBREGON KHULIO SESAR;;DUEHN JAS KARRERA SANT JAGO;;DUARTE KANO KARLOS;;VANLANDSKHOT PETER;;EHRRERA MARTINES LUIS SATURNIN,,https://lens.org/080-969-754-956-027,Granted Patent,no,0,1,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/12;;A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;A61P31/12;;C07K14/02;;C12P21/02,,0,0,,,,ACTIVE
548,PT,A,PT 108193 A,160-098-413-577-968,2016-08-04,2016,PT 10819315 A,2015-02-04,PT 10819315 A,2015-02-04,PROCESSO CONSTRUTIVO DE UM ESTRADO PARA COMBOIOS DE PASSAGEIROS,"O PRESENTE INVENTO INSERE-SE NO CAMPO DA INDÚSTRIA DE CONSTRUÇÃO MECÂNICA, MAIS PRECISAMENTE NO CAMPO DA INDÚSTRIA FERROVIÁRIA E DE SOLDADURA LASER, E DIZ RESPEITO A UM PROCESSO CONSTRUTIVO DE UM ESTRADO EM ALUMÍNIO PARA COMBOIOS DE PASSAGEIROS, COM FABRICO INDEPENDENTE DE COMPONENTES, CARACTERIZADO POR COMPREENDER OS SEGUINTES PASSOS:- REALIZAÇÃO DE CORTES NOS PERFIS EM FORMATO ¿T¿(4);- POSICIONAMENTO E ENCAIXE(3) DOS PERFIS LONGITUDINAIS(1) E TRANSVERSAIS(2) NA ZONA ONDE FOI EFECTUADO O CORTE;-PROCEDIMENTO DE SOLDADURA(8) SEM LIMITAÇÕES DE POSIÇÃO, ENTRE OS PERFIS(1) E (2) E AS PLACAS SUPERIORES(6) E INFERIORES(7).",ALSTOM PORTUGAL S A;;INST SUPERIOR TÉCNICO (DEPARTAMENTO DE ENGENHARIA MECÂNICA);;INST DE SOLDADURA E QUALIDADE,MANUEL JOSÉ MOREIRA DE FREITAS;;PEDRO MIGUEL GUIMARÃES PIRES MOREIRA;;JOAQUIM ALEXANDRE CASQUEIRO VENTURA;;PAULO JORGE MARQUES FERREIRA;;GIAN PAOLO FANTINO;;EDUARDO LOPES BARATA;;VIRGÍNIA ISABEL MONTEIRO NABAIS INFANTE;;LUIS FILIPE GALRÃO DOS REIS;;JOÃO DIAS CARREIRA;;PAULA ALEXANDRA DIAS BRANCO;;PAULO MANUEL SALGADO TAVARES DE CASTRO;;FRANCISCO MANUEL SEQUEIRA RODRIGUES FERREIRA DUARTE,,https://lens.org/160-098-413-577-968,Patent Application,no,0,0,2,2,0,Y02T30/00,B61D17/04,,0,0,,,,ACTIVE
549,CN,A,CN 106573013 A,104-735-094-223-932,2017-04-19,2017,CN 201580038870 A,2015-05-18,GB 201408752 A;;PT 2015000023 W,2014-05-16,Viscosupplement composition comprising ulvan for treating arthritis,"There is described an ulvan containing composition. This composition is a viscosupplement composition and can be used in the treatment or prophylaxis of arthritis. Also described is a method of treating a musculoskeletal disease, such as 5 arthritis, by administering the ulvan containing composition.",STEMMATTERS BIOTECNOLOGIA E MEDICINA REGENERATIVA SA,SOUSA RUI PEDRO ROMERO AMANDI DE;;GERTRUDES ANA CATARINA FREIRE;;CORREIA CRISTINA;;MORAIS ALAIN JOSE DA SILVA;;GONCALVES CRISTIANA DA MOTA MARTINS;;RADHOUANI HAJER;;GOMES CARLOS ALBERTO VILELA;;SANTOS TIRCIA SUSETE XAVIER CARLOS DOS;;OLIVEIRA JOAQUIM MIGUEL ANTUNES CORREIA DE;;ESPREGUEIRA-MENDES JOAO DUARTE COELHO DO SAMEIRO;;REIS RUI LUIS GONCALVES DOS,,https://lens.org/104-735-094-223-932,Patent Application,no,4,0,9,9,0,A61K31/728;;A61K31/737;;A61K45/06;;A61K45/06;;A61K31/728;;A61K31/738;;A61K31/737;;A61P19/00;;A61P19/02;;A61P29/00;;A61P43/00;;A61K31/728;;A61K45/06;;A61K31/738;;A61K9/0019;;A61K31/737,A61K31/737;;A61K31/728;;A61K45/06;;A61P19/00;;A61P19/02;;A61P29/00,,1,0,,,"吴波 主编: ""《显微镜下的微生物世界》"", 30 June 2012, 北方妇女儿童出版社",ACTIVE
550,PT,B,PT 108193 B,167-580-237-173-314,2023-11-08,2023,PT 10819315 A,2015-02-04,PT 10819315 A,2015-02-04,PROCESSO CONSTRUTIVO DE UM ESTRADO PARA COMBOIOS DE PASSAGEIROS,"O PRESENTE INVENTO INSERE-SE NO CAMPO DA INDÚSTRIA DE CONSTRUÇÃO MECÂNICA, MAIS PRECISAMENTE NO CAMPO DA INDÚSTRIA FERROVIÁRIA E DE SOLDADURA LASER, E DIZ RESPEITO A UM PROCESSO CONSTRUTIVO DE UM ESTRADO EM ALUMÍNIO PARA COMBOIOS DE PASSAGEIROS, COM FABRICO INDEPENDENTE DE COMPONENTES, CARACTERIZADO POR COMPREENDER OS SEGUINTES PASSOS:- REALIZAÇÃO DE CORTES NOS PERFIS EM FORMATO ¿T¿(4);- POSICIONAMENTO E ENCAIXE(3) DOS PERFIS LONGITUDINAIS(1) E TRANSVERSAIS(2) NA ZONA ONDE FOI EFECTUADO O CORTE;-PROCEDIMENTO DE SOLDADURA(8) SEM LIMITAÇÕES DE POSIÇÃO, ENTRE OS PERFIS(1) E (2) E AS PLACAS SUPERIORES(6) E INFERIORES(7).",ALSTOM PORTUGAL S A;;INST SUPERIOR TECNICO DEPARTAMENTO DE ENGENHARIA MECANICA;;INST DE SOLDADURA E QUALIDADE,MANUEL JOSÉ MOREIRA DE FREITAS;;PEDRO MIGUEL GUIMARÃES PIRES MOREIRA;;JOAQUIM ALEXANDRE CASQUEIRO VENTURA;;PAULO JORGE MARQUES FERREIRA;;GIAN PAOLO FANTINO;;EDUARDO LOPES BARATA;;VIRGÍNIA ISABEL MONTEIRO NABAIS INFANTE;;LUIS FILIPE GALRÃO DOS REIS;;JOÃO DIAS CARREIRA;;PAULA ALEXANDRA DIAS BRANCO;;PAULO MANUEL SALGADO TAVARES DE CASTRO;;FRANCISCO MANUEL SEQUEIRA RODRIGUES FERREIRA DUARTE,,https://lens.org/167-580-237-173-314,Granted Patent,no,0,0,2,2,0,Y02T30/00,B61D17/04,,0,0,,,,ACTIVE
551,PT,B,PT 104633 B,117-505-333-472-409,2011-06-01,2011,PT 10463309 A,2009-06-17,PT 10463309 A,2009-06-17,PROCESSO PARA PRODUÇÃO DE MANITOL POR FERMENTAÇÃO DE UM EXTRACTO AQUOSO DE POLPA DE ALFARROBA TRITURADA,"A PRESENTE INVENÇÃO DIZ RESPEITO A UM PROCESSO PARA A PRODUÇÃO DE MANITOL POR FERMENTAÇÃO DA FRACÇÃO SOLÚVEL (EXTRACTO AQUOSO) QUE SE OBTÉM APÓS A EXTRACÇÃO COM ÁGUA DA POLPA DE ALFARROBA TRITURADA, SUBPRODUTO DA INDÚSTRIA DE PROCESSAMENTO DA SEMENTE. ESTE PROCESSO É CARACTERIZADO POR UTILIZAR SUPLEMENTOS ESPECÍFICOS DE BAIXO VALOR COMERCIAL QUE COMPREENDEM, MAS NÃO SE LIMITAM A ÁGUA DE MACERAÇÃO DE MILHO, ÁCIDO CÍTRICO E/OU CITRATOS, CARBONATO DE CÁLCIO, EXTRACTO DE LEVEDURA, PEPTONA, E POR ESTAREM ENVOLVIDOS NA FERMENTAÇÃO, BACTÉRIAS DE DIFERENTES GÉNEROS, QUE COMPREENDEM, MAS NÃO SE LIMITAM A LACTOBACILIUS, LEUCONOSTOC OU WEÍSSELA E/OU GÉNEROS DE LEVEDURAS QUE COMPREENDEM, MAS NÃO SE LIMITAM A DEBARYOMYCES, KLUYVEROMYCES, PICHIA, ZIGOSACCHAROMYCES OU CANDIDA. O MANITOL ASSIM PRODUZIDO PODERÁ TER APLICAÇÕES EM MEDICINA E NAS INDÚSTRIAS ALIMENTAR, NUTRACÊUTICA, FARMACÊUTICA E QUÍMICA.",INST SUPERIOR TECNICO;;LNEG LAB NAC DE EN E GEOL,MARIA GABRIELA DA SILVA BERNARDO GIL;;FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES AMARO;;FRANCISCO MANUEL FERREIRA GIRIO;;LUIS JORGE ABREU CHORAO DE QUELHAS DUARTE;;MARIA LUISA NUNES OSTRA DE BIVAR WEINHOLTZ ROSEIRO;;PATRICIA MARIA BRITO MADEIRA DA SILVA MOURA;;MARIA PAULA GOMES DA CONCEICAO SEQUEIRA ESTEVES;;PATRICIA MARIA AZEVEDO MONIZ;;JOANA PATRICIA CAMPOS SILVA PEREIRA,,https://lens.org/117-505-333-472-409,Granted Patent,no,0,0,2,2,0,,C12P7/18,,0,0,,,,ACTIVE
552,PT,A,PT 104633 A,073-595-067-832-72X,2010-12-17,2010,PT 10463309 A,2009-06-17,PT 10463309 A,2009-06-17,PROCESSO PARA PRODUÇÃO DE MANITOL POR FERMENTAÇÃO DE UM EXTRACTO AQUOSO DE POLPA DE ALFARROBA TRITURADA,"A PRESENTE INVENÇÃO DIZ RESPEITO A UM PROCESSO PARA A PRODUÇÃO DE MANITOL POR FERMENTAÇÃO DA FRACÇÃO SOLÚVEL (EXTRACTO AQUOSO) QUE SE OBTÉM APÓS A EXTRACÇÃO COM ÁGUA DA POLPA DE ALFARROBA TRITURADA, SUBPRODUTO DA INDÚSTRIA DE PROCESSAMENTO DA SEMENTE. ESTE PROCESSO É CARACTERIZADO POR UTILIZAR SUPLEMENTOS ESPECÍFICOS DE BAIXO VALOR COMERCIAL QUE COMPREENDEM, MAS NÃO SE LIMITAM A ÁGUA DE MACERAÇÃO DE MILHO, ÁCIDO CÍTRICO E/OU CITRATOS, CARBONATO DE CÁLCIO, EXTRACTO DE LEVEDURA, PEPTONA, E POR ESTAREM ENVOLVIDOS NA FERMENTAÇÃO, BACTÉRIAS DE DIFERENTES GÉNEROS, QUE COMPREENDEM, MAS NÃO SE LIMITAM A LACTOBACILIUS, LEUCONOSTOC OU WEÍSSELA E/OU GÉNEROS DE LEVEDURAS QUE COMPREENDEM, MAS NÃO SE LIMITAM A DEBARYOMYCES, KLUYVEROMYCES, PICHIA, ZIGOSACCHAROMYCES OU CANDIDA. O MANITOL ASSIM PRODUZIDO PODERÁ TER APLICAÇÕES EM MEDICINA E NAS INDÚSTRIAS ALIMENTAR, NUTRACÊUTICA, FARMACÊUTICA E QUÍMICA.",INST SUPERIOR TECNICO;;LNEG LAB NAC DE EN E GEOL,GIL MARIA GABRIELA DA SILVA BERNARDO;;AMARO FLORBELA DE OLIVEIRA CARVALHEIRO ESTEVES;;GIRIO FRANCISCO MANUEL FERREIRA;;DUARTE LUIS JORGE ABREU CHORAO DE QUELHAS;;ROSEIRO MARIA LUISA NUNES OSTRA DE BIVAR WEINHOLTZ;;MOURA PATRICIA MARIA BRITO MADEIRA DA SILVA;;ESTEVES MARIA PAULA GOMES DA CONCEICAO SEQUEIRA;;MONIZ PATRICIA MARIA AZEVEDO;;PEREIRA JOANA PATRICIA CAMPOS SILVA,,https://lens.org/073-595-067-832-72X,Patent Application,no,0,0,2,2,0,,C12P7/18,,0,0,,,,ACTIVE
553,US,A1,US 2024/0062937 A1,165-455-866-462-607,2024-02-22,2024,US 202318354079 A,2023-07-18,BR 102022014328 A,2022-07-20,DEVICE WITH DIAMETERAL MAGNETIC ARRAYS FOR INSTALLATION IN MAGNETIC SUBS FOR THE REMEDIATION AND MITIGATION OF SCALE IN PRODUCTION COLUMNS,"The present invention refers to a device with diametral magnetic arrays for installations in magnetic SUBs, aiming the remediation and mitigation of inorganic and organic scales in production columns. The proposed magnetic device meets several specific criteria based on the magnetohydrodynamic model (MHD). After applying the said device with the proposed magnetic field, an efficiency of the scale inhibition was experimentally observed through laboratory tests, obtained from the values of the masses encrusted in the walls of the experimental bench system in the laboratory, with respect to the application without magnetic field. The device described herein can be installed in any pipeline used to transport fluids, including underwater pipelines for oil wells. These fluids can be oils, lubricants, gases, steams, water, petroleum or liquids in general.",PETROLEO BRASILEIRO SA PETROBRAS;;CENTRO BRASILEIRO DE PESQUISAS FISICAS,SOMMER RUBEM LUIS;;IGNACIO PEREIRA ALEXANDRE ZACARIAS;;GOMES DA SILVA BRUNO;;ALVES DA SILVA DE MEDEIRO CILENE LABRE;;LEIBSOHN MARTINS ANDRE;;DE PAULA SILVA ALEXANDRE MELLO;;DUARTE FERREIRA MARCUS VINICIUS;;LÓPEZ MEZA ELVIS OSWALDO;;SALATIEL DE OLIVEIRA FERNANDO;;LISBOA SANTOS HUGO FRANCISCO;;BARBOSA CASTRO BRUNO;;PINHEIRO SCHLUTER HELGA ELISABETH;;OLIVEIRA DE OLIVEIRA PAULO GUILHERME;;SINNECKER JOÃO PAULO,,https://lens.org/165-455-866-462-607,Patent Application,yes,0,0,2,2,0,H01F7/0294;;E21B37/00;;B03C2201/18;;B03C1/0332;;B03C1/288;;F16L58/00,H01F7/02;;B03C1/033;;B03C1/28;;E21B37/00;;F16L58/00,,0,0,,,,PENDING
554,BR,A2,BR 102022014328 A2,041-664-686-941-613,2024-01-30,2024,BR 102022014328 A,2022-07-20,BR 102022014328 A,2022-07-20,Dispositivo com arranjos magnéticos diametrais para instalação em subs magnéticos visando a remediação e mitigação de incrustações em colunas de produção,"dispositivo com arranjos magnéticos diametrais para instalação em subs magnéticos visando a remediação e mitigação de incrustações em colunas de produção. a presente invenção se refere a um dispositivo com arranjos magnéticos diametrais para instalações em subs magnéticos, visando a remediação e mitigação de incrustações inorgânicas e orgânicas em colunas de produção. o dispositivo magnético proposto atende a diversos critérios específicos baseados no modelo magnéto-hidrodinâmico (mhd). após a aplicação do referido dispositivo com o campo magnético proposto observou-se experimentalmente por meio de ensaios em laboratório uma eficiência de inibição de incrustação, obtido pelos valores das massas incrustadas nas paredes do sistema de bancada experimental do laboratório, com respeito à aplicação sem campo magnético. o dispositivo aqui descrito pode ser instalado em qualquer tubulação utilizada para o transporte de fluidos, incluindo tubulações submarinas de poços de petróleo. estes fluidos podem ser óleos, lubrificantes, gases, vapores, água, petróleo ou líquidos em geral.",CENTRO BRASILEIRO DE PESQUISAS FISICAS;;PETROLEO BRASILEIRO SA PETROBRAS,ALEXANDRE MELLO DE PAULA SILVA;;ALEXANDRE ZACARIAS IGNACIO PEREIRA;;ANDRE LEIBSOHN MARTINS;;BRUNO BARBOSA CASTRO;;BRUNO GOMES DA SILVA;;CILENE LABRE ALVES DA SILVA DE MEDEIRO;;ELVIS OSWALDO LÓPEZ MEZA;;FERNANDO SALATIEL DE OLIVEIRA;;HELGA ELISABETH PINHEIRO SCHLUTER;;HUGO FRANCISCO LISBOA SANTOS;;JOÃO PAULO SINNECKER;;MARCUS VINICIUS DUARTE FERREIRA;;PAULO GUILHERME OLIVEIRA DE OLIVEIRA;;RUBEM LUIS SOMMER,,https://lens.org/041-664-686-941-613,Patent Application,no,0,0,2,2,0,H01F7/0294;;E21B37/00;;B03C2201/18;;B03C1/0332;;B03C1/288;;F16L58/00,E21B37/00;;F16L58/00,,0,0,,,,PENDING
555,BR,A2,BR 102022015592 A2,117-952-083-166-197,2024-02-06,2024,BR 102022015592 A,2022-08-05,BR 102022015592 A,2022-08-05,Dispositivo com arranjos magnéticos diametrais tipo zig-zag para instalação em subs magnéticos visando a remediação e mitigação de incrustações em colunas de produção,"dispositivo com arranjos magnéticos diametrais tipo zig-zag para instalação em subs magnéticos visando a remediação e mitigação de incrustações em colunas de produção. a presente invenção se refere a um dispositivo com arranjos magnéticos diametrais do tipo zig-zag (alternado) para instalações em subs magnéticos, visando a remediação e mitigação de incrustações inorgânicas e orgânicas em colunas de produção. o dispositivo magnético proposto atende a diversos critérios específicos baseados no modelo magnéto-hidrodinâmico (mhd). após a aplicação do referido dispositivo com o campo magnético proposto observou-se experimentalmente por meio de ensaios em laboratório uma eficiência de inibição de incrustação, obtido pelos valores das massas incrustadas nas paredes do sistema de bancada experimental do laboratório, com respeito à aplicação sem campo magnético. o dispositivo aqui descrito pode ser instalado em qualquer tubulação utilizada para o transporte de fluidos, incluindo tubulações submarinas de poços de petróleo. estes fluidos podem ser óleos, lubrificantes, gases, vapores, água, petróleo ou líquidos em geral.",CENTRO BRASILEIRO DE PESQUISAS FISICAS;;PETROLEO BRASILEIRO SA PETROBRAS,ALEXANDRE MELLO DE PAULA SILVA;;ALEXANDRE ZACARIAS IGNACIO PEREIRA;;ANDRE LEIBSOHN MARTINS;;BRUNO BARBOSA CASTRO;;BRUNO GOMES DA SILVA;;CILENE LABRE ALVES DA SILVA DE MEDEIRO;;ELVIS OSWALDO LÓPEZ MEZA;;FERNANDO SALATIEL DE OLIVEIRA;;HELGA ELISABETH PINHEIRO SCHLUTER;;HUGO FRANCISCO LISBOA SANTOS;;JOÃO PAULO SINNECKER;;MARCUS VINICIUS DUARTE FERREIRA;;PAULO GUILHERME OLIVEIRA DE OLIVEIRA;;RUBEM LUIS SOMMER,,https://lens.org/117-952-083-166-197,Patent Application,no,0,0,1,1,0,,B03C1/02;;F16L55/00,,0,0,,,,PENDING
556,CN,U,CN 209120583 U,030-570-679-101-257,2019-07-16,2019,CN 201590001556 U,2015-06-29,IB 2015054879 W;;PT 10859515 A,2015-06-29,A conductive polymer housing for electronic component,"A conductive polymer housing for an electronic component, the device comprises a base shell and a cover shell, the base shell is used for being matched with the cover shell to obtain a closed shell. wherein both shells are an electrically conductive polymer and each shell comprises a plurality of teeth positioned on one or more of the sidewalls of the shell, the teeth are basically coplanar with the side walls in which the teeth are positioned; the teeth include laterally diverging spaces to receive the teeth of the other shell, all of which are integrally formed with the respective shell by injection molding such that when the shell is closed, each tooth is laterally compressed against one or more mating teeth of the other shell.",BOSCH CAR MULTIMEDIA PORTUGAL SA;;UNIV DO MINHO,RICARDO MANUEL DUARTE FREITAS;;RICARDO FIGUEIREDO DE SA;;MARTA VIRGINIA PINTO GOMES;;ANA FILIPA GONCALVES DA COSTA CARNEIRO;;ALEXANDRE MANUEL DA COSTA PITAES;;NUNO MIGUEL PORTELINHA GONCALVES;;AGNIESZKA ELZBIETA ZMIJEWSKA ROCHA;;CARLA ALEXANDRA FARIA LOUREIRO SIMOES;;RICARDO EMANUEL RIBEIRO CAMPOS;;LUIS CARLOS NETO MARTINS;;RUI NUNO FERREIRA PINTO;;PEDRO MIGUEL SOUSA BERNARDO;;CARLOS JORGE MARQUES RIBEIRO;;ANTONIO JOSE VILELA PONTES;;JOSE ERNESTO DO PACO VIANA,,https://lens.org/030-570-679-101-257,Limited Patent,no,0,0,2,2,0,H05K9/0009;;H05K9/0047,H05K9/00,,0,0,,,,ACTIVE
557,WO,A1,WO 2023/002237 A1,196-190-317-908-331,2023-01-26,2023,IB 2021056652 W,2021-07-22,PT 11735721 A,2021-07-21,POLARIMETRIC MULTIFUNCTIONAL LIDAR SENSOR FOR TARGET RECOGNITION,"The present invention describes a polarimetric multifunctional LiDAR system (100) adapted to perform ranging and polarimetric measurements for target recognition in autonomous driving applications. The disclosed system (100) comprises in a single device the capacity of light ranging (LiDAR) and active polarimetry, by measuring partially or totally the Mueller matrix of targets and/or Stokes parameters of light return from targets. By combining polarimetry with Artificial Intelligence, the polarimetric multifunctional LiDAR system (100) is able to add a new functionality that allows for distinguishing targets. In addition, the herein disclosed system is able to determine the location and/or velocity of targets. The herein disclosed system comprises an emission system (11) and a detection system (12), both controlled by a control and data acquisition system (21), and with a data processing system (22) for computing range information and target recognition.",BOSCH CAR MULTIMEDIA PORTUGAL SA;;UNIV DO MINHO,ESTÉVEZ CARIDE IRENE;;PEIXOTO OLIVEIRA FILIPE ANDRÉ;;J NUNES-PEREIRA EDUARDO;;ROMANYSHYN NAZAR;;FERNANDEZ CUNHA NELSSOM;;DE LIMA FERREIRA RODRIGUES MANUEL JOSÉ;;SILVA TELES OLIVEIRA NUNO MIGUEL;;BRAGA FERNANDES PEDRO;;VIANA GOMES JOSÉ CARLOS;;SOARES PEREIRA RUI MIGUEL;;PEREIRA DA CUNHA MARTINS COSTA MANUEL FILIPE;;DA CUNHA PEREIRA MÁRIO RUI;;VITALIEVITCH SMIRNOV GUEORGUI;;FERNANDES REBOUTA LUIS MANUEL;;SILVA DUARTE MOISÉS ALEXANDRE;;IGOREVICH VASILEVSKIY MIKHAIL,,https://lens.org/196-190-317-908-331,Patent Application,yes,6,0,1,1,0,G01S7/499;;G01S17/931;;G01S7/4802,G01S7/48;;G01S7/499;;G01S17/931,,6,5,085-333-047-624-961;;010-411-389-301-660;;130-013-619-140-194;;111-289-420-318-803;;046-190-553-098-431,10.1117/12.922623;;10.1201/b10436;;10.1117/12.2272587;;10.1117/1.oe.59.7.073106;;10.1117/12.2525415,"VAUGHN ISRAEL J ET AL: ""Classification using active polarimetry"", POLARIZATION: MEASUREMENT, ANALYSIS, AND REMOTE SENSING X, SPIE, 1000 20TH ST. BELLINGHAM WA 98225-6705 USA, vol. 8364, no. 1, 11 May 2012 (2012-05-11), pages 1 - 13, XP060012187, DOI: 10.1117/12.922623;;D.H. GOLDSTEIN: ""Polarized light"", 2011, CRC PRESS;;""The Polarization Lidar Technique for Cloud Research: A Review and Current Assessment"", BULLETIN OF THE AMERICAN METEOROLOGICAL SOCIETY, vol. 72, 1991;;ERANDI WIJERATHNACHARLES D. CREUSEREDAVID VOELZJUAN CASTORENA: ""Polarimetric LIDAR with FRI sampling for target characterization"", PROC. SPIE 10407, POLARIZATION SCIENCE AND REMOTE SENSING VIII, 2017, pages 104070R, XP060095614, DOI: 10.1117/12.2272587;;JARROD P. BROWNRODNEY G. ROBERTSDARRELL C. CARDCHRISTIAN L. SALUDEZCHRISTIAN K. KEYSER: ""Hybrid passive polarimetric imager and lidar combination for material classification"", OPTICAL ENGINEERING, vol. 59, no. 7, 2020, pages 073106;;ALI HAIDERSONGXIN TAN: ""Improvement of LiDAR data classification algorithm using the machine learning technique"", PROC. SPIE 11132, POLARIZATION SCIENCE AND REMOTE SENSING IX, 2019, pages 1113215",PENDING
558,WO,A1,WO 2023/047175 A1,177-374-932-399-29X,2023-03-30,2023,IB 2021058850 W,2021-09-28,PT 11747921 A,2021-09-24,ROAD MONITORING WITH POLARIMETRY BY MULTIFUNCTIONAL LIDAR,"The present application describes a polarimetric multifunctional LiDAR system adapted to perform ranging and polarimetric measurements for monitoring the road, by recognizing its type, its condition, uneven pavements, oil or chemical spills, road marking and obstacles or any other foreigner elements on the road, among others, in automotive applications and monitoring stations. By combining polarimetric measurements, i.e., some, or all, Stokes parameters of light return from the road and/or Mueller matrix elements of the illuminated area, with Artificial Intelligence, the polarimetric multifunctional LiDAR system is able to add a new functionality to conventional LiDAR sensors that allows for monitoring the road. The multifunctional LiDAR system comprises an emission system and a detection system, both controlled by a control and data acquisition system, and with a data processing system for computing range information and road monitoring.",BOSCH CAR MULTIMEDIA PORTUGAL SA;;UNIV DO MINHO,ESTÉVEZ CARIDE IRENE;;PEIXOTO OLIVEIRA FILIPE ANDRÉ;;NUNES-PEREIRA EDUARDO J;;ROMANYSHYN NAZAR;;FERNANDEZ CUNHA NELSSOM;;DE LIMA FERREIRA RODRIGUES MANUEL JOSÉ;;SILVA TELES OLIVEIRA NUNO MIGUEL;;SANTOS BRAGA FERNANDES PEDRO FRANCISCO;;VIANA GOMES JOSÉ CARLOS;;SOARES PEREIRA RUI MIGUEL;;PEREIRA DA CUNHA MARTINS COSTA MANUEL FILIPE;;DA CUNHA PEREIRA MÁRIO RUI;;VITALIEVITCH SMIRNOV GUEORGUI;;FERNANDES REBOUTA LUIS MANUEL;;SILVA DUARTE MOISÉS ALEXANDRE;;IGOREVICH VASILEVSKIY MIKHAIL,,https://lens.org/177-374-932-399-29X,Patent Application,yes,3,0,1,1,0,G01S17/931;;G01S17/89;;G01S7/499;;G01S7/4802,G01S7/48;;G01S7/499;;G01S17/89;;G01S17/931,,8,8,053-800-959-348-268;;012-263-170-938-190;;085-643-179-227-136;;082-524-312-809-442;;081-268-468-619-77X;;007-068-007-066-965;;015-808-774-255-522;;010-411-389-301-660,10.5194/jsss-8-57-2019;;10.1016/j.optlaseng.2015.08.002;;10.1016/j.sna.2019.111540;;22614608;;10.1364/ao.51.003036;;pmc6471196;;10.5220/0007572002830288;;10.3390/s19061360;;30893767;;10.1364/ao.38.003937;;18320002;;10.1364/ol.29.002773;;15605501;;10.1201/b10436,"JAKOB DORINGLAKSHAN THARMAKULARAJAHJAKOB HAPPELKARL-LUDWIG KRIEGER: ""A novel approach for road surface wetness detection with planar capacitive sensors"", J. SENS. SENS. SYST., vol. 8, 2019, pages 57 - 66;;JOHAN CASSELGRENSARA ROSENDAHLMIKAEL SJODAHLPATRIKJONSSON: ""Road condition analysis using NIR illumination and compensating for surrounding light"", OPT. LASERS ENG., vol. 77, 2016, pages 175 - 182, XP029309652, DOI: 10.1016/j.optlaseng.2015.08.002;;KANG GUILIN YEJUNFENG GEFAOUZI ALAYA CHEIKHLIZHEN HUANG: ""Road surface condition detection utilizing resonance frequency and optical technologies"", SENSORS ACTUATORS A PHYS., vol. 297, 2019, pages 111540, XP085825709, DOI: 10.1016/j.sna.2019.111540;;JOHAN CASSELGRENMIKAEL SJODAHL: ""Polarization resolved classification of winter road condition in the near-infrared region"", APPLIED OPTICS, vol. 51, 2012, pages 3036 - 3045, XP001575474, DOI: 10.1364/AO.51.003036;;ARMANDO PICCARDILORENZO COLACE: ""Optical Detection of Dangerous Road Conditions"", SENSORS, vol. 19, 2019, pages 1360;;GARETH D. LEWISDAVID L. JORDANP. JOHN ROBERTS: ""Backscattering target detection in a turbid medium by polarization discrimination"", APPL. OPT., vol. 38, 1999, pages 3937 - 3944;;XIAOHUI NIR. R. ALFANO: ""Time-resolved backscattering of circularly and linearly polarized light in a turbid medium"", OPT. LETT., vol. 29, 2004, pages 2773 - 2775;;D.H. GOLDSTEIN: ""Polarized light"", 2011, CRC PRESS",PENDING
559,AU,A,AU 1991/085574 A,041-332-284-062-199,1992-04-30,1992,AU 1991/085574 A,1991-10-03,CU 1990155 A,1990-10-08,METHOD FOR OBTAINING RECOMBINANT SURFACE ANTIGEN OF HEPATITIS B VIRUS (HEP B) OF HIGHER IMMUNOGENIC CAPACITY AND USE THEREOF IN A VACCINE PREPARATION,,CT INGENIERIA GENETICA BIOTECNOLOGIA,GONZALEZ VERENA LUCILA MUCIO;;ARIAS EDUARDO PENTON;;GARCIA MANUEL PALOU;;ESCOBAR GIUVEL FONTIRROCHI;;GALVEZ MARCELO NAZABAL;;GRIEGO MARTA DE JESUS GONZALEZ;;IZNAGA ALEJANDRO BELDARRAIN;;GONZALEZ GUILLERMO JULIO PADRO;;ALVAGE VICTORIA RAMIREZ;;PENA ARNALDO GARCIA;;CRUZ CARLOS ENRIQUE RUIZ;;LOPEZ GLADYS MABEL IZQUIERDO;;MARTINEZ LUIS SATURNINO HERRER;;CANO CAROLS ANTONIO DUARTE;;SUAREZ LILIA LUISA PEREZ;;CABALLERO JOSE GARCIA;;RIVA GUSTAVO ALBERTO DE LA RIV;;LASA ALEXIS S MUSACCHIO,,https://lens.org/041-332-284-062-199,Patent Application,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
560,RU,C1,RU 2128707 C1,139-685-059-624-236,1999-04-10,1999,SU 5010630 A,1992-01-17,SU 5010630 A,1992-01-17,"METHOD OF PREPARING SURFACE ANTIGEN OF HEPATITIS B VIRUS (HBS AG), MONOCLONAL ANTIBODIES CB-HEPI, SURFACE ANTIGEN OF HEPATITIS B VIRUS (HBS AG) AND METHOD OF PREPARING HYBRID CLONE 48/1/574 PRODUCING MONOCLONAL ANTIBODIES CB-HEPI","FIELD: genetic engineering, vaccines against hepatitis B. SUBSTANCE: method of preparing the surface antigen of hepatitis B virus (HBsAg) involves culturing yeast strain Pichia pastoris C226 transformed with recombinant plasmid TAO 906. Cells are analyzed and antigenic fraction is purified successively using monoclonal antibodies CB-HEPI. Antigen is obtained as immunogenic particles (size is 22 nm), molecular mass is 24000 Da of the enhanced homogeneity. Monoclonal antibodies CB-HEPI used for antigen purification by immunoaffinity method are produced by hybrid clone 48/1/574 and belong to isotype Ig G2b or IgM. They recognize continuous epitope on the general antigenic determinant ""a"" of the surface antigen of all subspecies of hepatitis B virus. For preparing hybrid clone mice of the strain Balb/c are immunized with HBsAg, spleen cells are fused with myeloma cells SP2/O/Ag14, hybrid clones are cultured on nutrient media and required clone producing monoclonal antibodies CB-HEPI is selected. EFFECT: improved method of antigen preparing. 5 cl, 10 dwg, 6 ex",CIGB,VERENA LUSILA MUSIO GONSALES;;EHDUARDO PENTON ARIAS;;KH JUVEL FONTIRROCHI EHSKOBAR;;MARSELO NASABAL GAL VES;;MARTA DE GONSALES GR EGO;;ALEKHANDRO BELDARRAIN ISNAGA;;GIL ERMO PADRON GONSALES;;VIKTORIA RAMIRES AL BAKHES;;ARNAL DO GARSIA PEN JA;;KARLOS EHNRIKE RUIS KRUS;;GLADIS MABEL ISK ERDO LOPES;;LUIS EHRRERA MARTINES;;KHOSE GARSIA SUARES;;GUSTAVO DE LJA RIVA DE LJA RIV;;RAMON ALEKSIS SANT JAGO AVILA;;KARLOS DUARTE KANO;;LILIA PERES SUARES,,https://lens.org/139-685-059-624-236,Granted Patent,no,0,1,1,1,0,,C12N15/36;;C07K14/02;;C12N15/51;;C12P21/08,,0,0,,,,EXPIRED
561,DK,T3,DK 0480525 T3,094-706-684-401-600,1999-08-30,1999,DK 91202615 T,1991-10-07,CU 1990155 A,1990-10-08,Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve,,CIGB,MUCIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PARDRON GONZALEZ GUILLERMO JUL;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA CABALLERO JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;MUSACCHIO LASA ALEXIS S;;GARCIA SUAREZ JOSE;;SANTIAGO AVILA RAMON ALEXIS,,https://lens.org/094-706-684-401-600,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
562,EP,A2,EP 0480525 A2,152-252-496-393-541,1992-04-15,1992,EP 91202615 A,1991-10-07,CU 1990155 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation.,"A multi-step process for recovering hepatitis B surface antigen from  Pichia   pastoris  cells containing a gene encoding said hepatitis B surface antigen and having expressed it. The process leads to a high yield of very pure, homogeneous HBsAg in a particulated form having a high immunogenicity, suitable for use in vaccine compositions for treating human beings and for use in diagnostic methods.",CIGB,MUCIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PARDRON GONZALEZ GUILLERMO JUL;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA CABALLERO JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;MUSACCHIO LASA ALEXIS S;;GARCIA SUAREZ JOSE;;SANTIAGO AVILA RAMON ALEXIS,,https://lens.org/152-252-496-393-541,Patent Application,yes,0,9,25,25,4,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
563,EP,B1,EP 0864649 B1,090-687-303-331-017,2006-04-26,2006,EP 98202021 A,1991-10-07,CU 1990155 A;;EP 91202615 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation,,CT INGENIERIA GENETICA BIOTECH,MUZIO GONZALEZ VERENA L;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO,,https://lens.org/090-687-303-331-017,Granted Patent,yes,1,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
564,EP,A3,EP 0480525 A3,176-599-295-153-713,1992-09-30,1992,EP 91202615 A,1991-10-07,CU 1990155 A,1990-10-08,METHOD FOR OBTAINING RECOMBINANT SURFACE ANTIGEN OF HEPATITIS B VIRUS (HEP B) OF HIGHER IMMUNOGENIC CAPACITY AND USE THEREOF IN A VACCINE PREPARATION,"A multi-step process for recovering hepatitis B surface antigen from  Pichia pastoris  cells containing a gene encoding said hepatitis B surface antigen and having expressed it. The process leads to a high yield of very pure, homogeneous HBsAg in a particulated form having a high immunogenicity, suitable for use in vaccine compositions for treating human beings and for use in diagnostic methods.",CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA,"MUCIO GONZALEZ, VERENA LUCILA;;PENTON ARIAS, EDUARDO;;PALOU, GARCIA, MANUEL;;FONTIRROCHI ESCOBAR, GIUVEL;;NAZABAL GALVEZ, MARCELO;;GONZALEZ GRIEGO, MARTA DE JESUS;;BELDARRAIN IZNAGA, ALEJANDRO;;PARDRON GONZALEZ, GUILLERMO JULIO;;RAMIREZ ALBAJES, VICTORIA;;GARCIA PENA, ARNALDO;;RUIZ CRUZ, CARLOS ENRIQUE;;IZQUIERDO LOPEZ, GLADYS MABEL;;HERRERA MARTINEZ, LUIS SATURNINO;;DUARTE CANO, CARLOS ANTONIO;;PEREZ SUAREZ, LILIA LUISA;;GARCIA CABALLERO, JOSE;;DE LA RIVA DE LA RIVA, GUSTAVO, ALBERTO;;MUSACCHIO LASA, ALEXIS S.;;GARCIA SUAREZ, JOSE;;SANTIAGO AVILA, RAMON ALEXIS",,https://lens.org/176-599-295-153-713,Search Report,yes,5,0,25,25,4,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,1,1,066-408-000-402-178,10.1016/0168-1656(88)90064-8,"JOURNAL OF BIOTECHNOLOGY, vol. 8, 1988, pages 1-22; M. KOBAYASHI et al.: ""Recombinant hepatitis B virus surface antigen carrying the pre-S2 region derived from yeast: purification and characterization""",EXPIRED
565,JP,A,JP 2001231582 A,057-022-638-447-65X,2001-08-28,2001,JP 2000392672 A,2000-12-25,CU 1990155 A,1990-10-08,RECOMBINANT SURFACE ANTIGEN OF HEPATITIS B VIRUS HAVING HIGHER IMMUNOGENIC COMPETENCE AND VACCINE COMPOSITION FOR IMMUNIZING AGAINST HEPATITIS B VIRUS,"PROBLEM TO BE SOLVED: To provide an remarkably homogeneous and particulate recombinant surface antigen of hepatitis B virus having higher immunogenic competence and derived from recombinant Pichia pastoris strain C226 [pTAO906], CBS450.90 and a vaccine composition for immunizing against hepatitis B virus, comprising recombinant hepatitis B surface antigen in an amount effective for vaccination, and at least one carrier, diluent or adjuvant suitable for use in a vaccine composition. SOLUTION: This recombinant hepatitis B surface antigen is obtained from recombinant Pichia pastoris strain C226 [pTAO906], CBS 450.90 containing a gene encoding the above hepatitis B surface antigen and having expressed the gene. This vaccine composition for immunizing against hepatitis B virus contains the above surface antigen as an active ingredient.",CT DE INGENIERIA GENETICA & BI,MUCIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;GALVEZ MARCELO NAZABAL;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;GONZALEZ GUILLERMO JULIO PADRO;;ALBAJES VICTORIA RAMIREZ;;GARCIA PENA ARNALDO;;CRUZ CARLOS ENRIQUE RUIZ;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;MEIRELES ROLANDO PAEZ;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;MAYA YAIR QUINONES,,https://lens.org/057-022-638-447-65X,Patent Application,no,0,0,25,25,4,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
566,EP,A3,EP 0864649 A3,021-950-763-056-952,1998-11-11,1998,EP 98202021 A,1991-10-07,CU 1990155 A;;EP 91202615 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation,"A multi-step process for recovering hepatitis B surface antigen from  Pichia pastoris  cells containing a gene encoding said hepatitis B surface antigen and having expressed it. The process leads to a high yield of very pure, homogeneous HBsAg in a particulated form having a high immunogenicity, suitable for use in vaccine compositions for treating human beings and for use in diagnostic methods.",CIGB,MUZIO GONZALEZ VERENA L;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO J;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/021-950-763-056-952,Search Report,yes,1,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
567,DE,D1,DE 69133525 D1,029-436-986-674-052,2006-06-01,2006,DE 69133525 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung,,CT INGENIERIA GENETICA BIOTECH,MUZIO VERENA L;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/029-436-986-674-052,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
568,DE,T8,DE 69133525 T8,131-577-904-794-138,2007-03-08,2007,DE 69133525 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung,,CT INGENIERIA GENETICA BIOTECH,MUZIO GONZALEZ;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/131-577-904-794-138,Amended Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
569,AU,B2,AU 649482 B2,053-590-339-987-592,1994-05-26,1994,AU 1991/085574 A,1991-10-03,CU 1990155 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation,,CIGB,GONZALEZ VERENA L MUCIO;;ARIAS EDUARDO PENTON;;ESCOBAR GIUVEL FONTIRROCHI;;GALVEZ MARCELO NAZABAL;;GRIEGO MARTA DE JESUS GONZALEZ;;IZNAGA ALEJANDRO BELDARRAIN;;GONZALEZ GUILLERMO JULIO PADRO;;ALVAGE VICTORIA RAMIREZ;;PENA ARNALDO GARCIA;;CRUZ CARLOS ENRIQUE RUIZ;;LOPEZ GLADYS MABEL IZQUIERDO;;MARTINEZ LUIS SATURNINO HERRER;;CANO CAROLS ANTONIO DUARTE;;SUAREZ LILIA LUISA PEREZ;;CABALLERO JOSE GARCIA;;RIVA GUSTAVO ALBERTO DE LA RIV;;LASA ALEXIS SANTIAGO MUSACCHIO;;ZORRILLA FILIBERTO R AYON;;MEIRELES ROLANDO PAEZ;;FIERRO ALBERTO AGRAZ;;BETANCOURT RAUL E DIAZ;;MAYA YAIR QUINONES,,https://lens.org/053-590-339-987-592,Granted Patent,no,3,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
570,DE,T2,DE 69133525 T2,102-084-522-412-301,2006-11-23,2006,DE 69133525 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung,,CT INGENIERIA GENETICA BIOTECH,MUZIO VERENA L;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/102-084-522-412-301,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
571,EP,A2,EP 0864649 A2,035-471-096-287-457,1998-09-16,1998,EP 98202021 A,1991-10-07,CU 1990155 A;;EP 91202615 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation,"A multi-step process for recovering hepatitis B surface antigen from  Pichia   pastoris  cells containing a gene encoding said hepatitis B surface antigen and having expressed it. The process leads to a high yield of very pure, homogeneous HBsAg in a particulated form having a high immunogenicity, suitable for use in vaccine compositions for treating human beings and for use in diagnostic methods.",CIGB,MUZIO GONZALEZ VERENA L MUZIO;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;ALBAJES VICTORIA RAMIREZ;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/035-471-096-287-457,Patent Application,yes,0,1,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
572,DK,T3,DK 0864649 T3,056-054-526-484-237,2006-08-28,2006,DK 98202021 T,1991-10-07,CU 1990155 A;;EP 91202615 A,1990-10-08,Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat,,CT INGENIERIA GENETICA BIOTECH,MUZIO GONZALEZ VERENA L;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESU;;GARCIA SUAREZ JOSE SAN REAFAE;;AYON ZORRILLA FILIBERTO ROSEND;;QUINONES MAYA YAIR;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;RAMIREZ ALBAJES VICTORIA,,https://lens.org/056-054-526-484-237,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;C12N15/51;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
573,GR,T3,GR 3029582 T3,054-781-071-751-148,1999-06-30,1999,GR 990400666 T,1999-03-04,CU 1990155 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B),,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/054-781-071-751-148,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
574,DE,D1,DE 69130724 D1,077-105-895-831-782,1999-02-18,1999,DE 69130724 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Gewinnung von rekombinantem Hepatitis B Virus (HEP B) Oberflächeantigen,,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/077-105-895-831-782,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
575,DE,T2,DE 69130724 T2,164-079-995-222-586,1999-06-17,1999,DE 69130724 T,1991-10-07,CU 1990155 A,1990-10-08,Verfahren zur Gewinnung von rekombinantem Hepatitis B Virus (HEP B) Oberflächeantigen,,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/164-079-995-222-586,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
576,EP,B1,EP 0480525 B1,052-642-419-326-095,1999-01-07,1999,EP 91202615 A,1991-10-07,CU 1990155 A,1990-10-08,Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B),,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/052-642-419-326-095,Granted Patent,yes,1,3,25,25,4,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
577,AT,T1,AT E175445 T1,050-639-052-353-600,1999-01-15,1999,AT 91202615 T,1991-10-07,CU 1990155 A,1990-10-08,VERFAHREN ZUR GEWINNUNG VON REKOMBINANTEM HEPATITIS B VIRUS (HEP B) OBERFLÄCHEANTIGEN,,CIGB,MUZIO GONZALEZ VERENA LUCILA;;PENTON ARIAS EDUARDO;;PALOU GARCIA MANUEL;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;ESQUINA ASUNCION;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;GERTRUDIS Y JOSEFINA;;HERRERA MARTINEZ LUIS;;DUARTE CANO CARLOS ANTONIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE SAN RAFAEL;;DE LA RIVA DE LA RIVA GUSTAVO;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORILLA FILIBERTO ROSENDO;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL E;;QUINONES MAYA YAIR,,https://lens.org/050-639-052-353-600,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,DISCONTINUED
578,AT,T1,AT E324451 T1,118-087-160-384-546,2006-05-15,2006,AT 98202021 T,1991-10-07,CU 1990155 A,1990-10-08,VERFAHREN ZUR HERSTELLUNG VON RECOMBINANTEM HEPATITIS B OBERFLÄCHENANTIGEN MIT ERHÖHTER IMMUNOGEN-KAPAZITÄT UND VERWENDUNG IN EINER IMPFSTOFFZUBEREITUNG,,CT INGENIERIA GENETICA BIOTECH,MUZIO GONZALEZ VERENA L;;ENTRE AVE Y NUEVO VEDADO;;PENTON ARIAS EDUARDO;;FONTIRROCHI ESCOBAR GIUVEL;;NAZABAL GALVEZ MARCELO;;GONZALEZ GRIEGO MARTA DE JESUS;;ESQUINA ASUNCION;;BELDARRAIN IZNAGA ALEJANDRO;;PADRON GONZALEZ GUILLERMO JULI;;RAMIREZ ALBAJES VICTORIA;;GARCIA PENA ARNALDO;;RUIZ CRUZ CARLOS ENRIQUE;;IZQUIERDO LOPEZ GLADYS MABEL;;GERTUDIS Y JOSEFINA;;HERRERA MARTINEZ LUIS SATURNIN;;DUARTE CANO CARLOS ANTONIO;;APTO CUBAY SAN IGNACIO;;PEREZ SUAREZ LILIA LUISA;;GARCIA SUAREZ JOSE;;DE LA RIVA DE LA RIVA GUSTAVO;;D STRAMPES Y GOICURIA;;SANTIAGO AVILA RAMON ALEXIS;;AYON ZORRILLA FILIBERTO ROSEND;;PAEZ MEIRELES ROLANDO;;AGRAZ FIERRO ALBERTO;;DIAZ BETANCOURT RAUL ENRIQUE;;QUINONES MAYA YAIR,,https://lens.org/118-087-160-384-546,Granted Patent,no,0,0,25,25,0,A61K39/00;;C07K14/005;;C07K16/082;;C12N15/815;;C12N2730/10122;;A61P1/16;;A61P31/12,A61K39/29;;A61K39/00;;A61K39/395;;A61P1/16;;A61P31/12;;C07K1/22;;C07K14/00;;C07K14/02;;C07K14/10;;C07K14/18;;C07K16/00;;C07K16/08;;C07K16/10;;C12N1/19;;C12N5/12;;C12N15/09;;C12N15/31;;C12N15/51;;C12N15/81;;C12P21/02;;C12P21/08;;C12R1/84,,0,0,,,,EXPIRED
